

**Appendix B: Patient Data Listings of Demographic**

	Page
329 DEP Appendix B.1 Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population . . . . .	2
329 DEP Appendix B.2 Listing of Demographic Data by Treatment Group and Patient Intent-to-Treat Population . . . . .	22
329 DEP Appendix B.3 Listing of K-SADS-L Diagnostic Criteria at Screening Intent-to-Treat Population . . . . .	37
329 DEP Appendix B.4 Listing of C-GAS Scores by Treatment Group Intent-to-Treat Population . . . . .	61
329 DEP Appendix B.5 Listing of Personal History by Treatment Group and Patient Intent-to-Treat Population . . . . .	81
329 DEP Appendix B.6 Listing of Family History - Epidemiologic by Treatment Group and Patient Intent-to-Treat Population . . . . .	123
329 DEP Appendix B.7 Listing of Medical/Surgical History and Physical Examination by Treatment Group and Patient Intent-to-Treat Population . . . . .	279
329 DEP Appendix B.8 Listing of Medical/Surgical History and Physical Examination by Treatment Group and Disease Classification Intent-to-Treat Population . . . . .	319
329 DEP Appendix B.9 Listing of Concomitant Medications by WHO ATC Classification and Generic Term Screening Failures Only . . . . .	354
329 DEP Appendix B.10 Listing of Concomitant Medications by Patient and WHO ATC Classification . . . . .	359
329 DEP Appendix B.11 Listing of Adverse Experiences by ADECS Body System and Preferred Term Screening Failures Only . . . . .	360
329 DEP Appendix B.12 Listing of Adverse Experiences by Patient Screening Failures Only . . . . .	363
329 DEP Appendix B.13 Listing of Prior and Concomitant Medications by WHO ATC Classification and Generic Term and by Treatment Group Intent-to-Treat Population . . . . .	364
329 DEP Appendix B.14 Listing of Prior and Concomitant Medications by Treatment Group and by Patient . . . . .	449
329 DEP Appendix B.15 Listing of Drug Dispensing Data by Treatment Group and Patient Intent-to-Treat Population . . . . .	491
329 DEP Appendix B.16 Listing of Study Medication Data Intent-to-Treat Population . . . . .	566

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.001.00063	Female	14	No	No	48	20	Adverse event, including intercurrent illness	
329.001.00065	Male	14	No	No	14	20	Adverse event, including intercurrent illness	NEEDED PSYCHIATRIC HOSPITALIZATION FOR INCREASED AGGRESSION AGAINST SELF.
329.001.00068	Female	13	Yes	No	72	40	Lack of Efficacy	
329.001.00072	Male	15	No	No	32	20	Other reason	FAMILY WITHDREW CONSENT.SEE MISCELLANEOUS NOTES.
329.001.00121	Male	15	Yes	No	154	30	Lack of Efficacy	
329.001.00205	Male	12	No	No	8	20	Adverse event, including intercurrent illness	MANIA/HYPOMANIA SYMPTOMS
329.001.00206	Male	16	Yes	No	58	30	Lack of Efficacy	
329.002.00055	Male	13	Yes	No	156	20	Lack of Efficacy	RELAPSE IN CONTINUATION PHASE.
329.002.00058	Female	16	Yes	No	119	40	Adverse event, including intercurrent illness	INTENTIONAL OVERDOSE OF TYLENOL ON 1/19/95.
329.002.00099	Male	15	Yes	Yes	255	20		
329.002.00102	Female	16	Yes	Yes	252	20		
329.002.00105	Male	16	No	No	22	20	Protocol violation, including non-compliance	PATIENT RAN AWAY FROM HOME WITHOUT MEDS. WAS OFF MEDS SEVERAL DAYS BEFORE HE RETURNED HOME. UNABLE TO REACH FAMILY TO RETRIEVE MED PAK/DO WK. 32 VISIT. SEE PROGRESS NOTE FROM WEEK 4
329.002.00106	Female	15	No	No	48	40	Other reason	PT D/C ON OWN -- OPPOSITIONAL DEFIANT DISORDER

\* Relative to Start of Study Medication

2

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.002.00242	Female	15	Yes	No	120	40	Protocol violation, including non-compliance	
329.002.00245	Female	14	No	No	18	20	Adverse event, including intercurrent illness	DOWN TITRATED (PER S. FRITSH, M.D.) 3.A.M. DOSES, LEVEL 1.
329.002.00319	Female	16	Yes	Yes	245	20		
329.003.00075	Female	17	Yes	Yes	240	20		
329.003.00077	Male	16	Yes	No	94	30	Lost to follow-up	JAMES DID NOT ARRIVE FOR MONTH 2VISIT, FAMILY DID NOT RESPOND TO ATTEMPTS TO CONTACT THEM.
329.003.00081	Female	12	Yes	No	59	40	Lack of Efficacy	
329.003.00087	Female	14	No	No	4	20	Other reason	VOLUNTARY WITHDRAWAL
329.003.00089	Female	14	Yes	No	60	20	Adverse event, including intercurrent illness	
329.003.00091	Female	16	Yes	Yes	245	20		
329.003.00248	Female	14	Yes	No	63	30	Lack of Efficacy	
329.003.00250	Female	15	Yes	No	75	30	Adverse event, including intercurrent illness	PT TOOK OVERDOSE & WAS HOSPITALIZED
329.003.00292	Male	16	Yes	No	59	20	Lost to follow-up	
329.003.00313	Male	18	No	No	12	20	Adverse event, including intercurrent illness	PT. WAS DROPPED DUE TO HOSPITALIZATION I.E. ADVERSE EXPERIENCE
329.004.00015	Female	16	Yes	No	203	20	Other reason	CONFLICT BETWEEN SCHOOL AND STUDY
329.004.00017	Female	16	Yes	Yes	238	20		

\* Relative to Start of Study Medication

3

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.004.00019	Female	17	No	No	15	20	Lost to follow-up	
329.004.00212	Female	17	No	No	23	20	Protocol violation, including non-compliance	
329.004.00214	Female	15	Yes	No	88	20	Lack of Efficacy	
329.005.00002	Female	14	Yes	No	147	40	Other reason	PT.STOPPED TAKING MEDICATION BECAUSE SHE DIDN'T WANT TO TAKE PILLS ANYMORE
329.005.00004	Male	16	Yes	No	103	30	Other reason	PT. CHOSE TO WITHDRAW.
329.005.00008	Male	12	Yes	No	142	30	Protocol violation, including non-compliance	
329.005.00011	Female	16	Yes	No	156	30	Adverse event, including intercurrent illness	OVERDOSE WITH BAYER EXTRA STRENGTH {INTENTIONAL}
329.005.00109	Female	17	Yes	No	138	20	Protocol violation, including non-compliance	
329.005.00112	Male	13	Yes	No	93	20	Protocol violation, including non-compliance	
329.005.00116	Female	16	Yes	No	155	20	Adverse event, including intercurrent illness	SEVERE POISON IVY-TAKING PREDNISONE
329.005.00119	Female	14	Yes	No	141	30	Protocol violation, including non-compliance	
329.005.00151	Female	14	Yes	Yes	239	20		
329.005.00152	Female	15	No	No	5	20	Adverse event, including intercurrent illness	
329.005.00257	Female	12	Yes	Yes	239	20		
329.005.00258	Female	14	Yes	No	57	30		PT TO HAVE SURGERY UNDER GENERAL ANESTHESIA 6/24/96

\* Relative to Start of Study Medication

4

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.005.00299	Female	12	Yes	No	164	20	Lack of Efficacy	PT. REMOVED AT PARENTS REQUEST. PT HAD AN INC IN AFFECTIVE SYMPTOMS AFTER INITIAL IMPROVEMENT
329.005.00300	Male	12	Yes	No	57	20		
329.005.00333	Female	16	No	No	33	20	Lack of Efficacy	
329.005.00336	Female	14	Yes	No	58	20		MEETS CRITERIA FOR ENTRANCE INTO CONTINUATION PHASE BUT NO MEDS ARE AVAILABLE
329.006.00038	Female	15	No	No	57	20	Adverse event, including intercurrent illness	SEVERAL PERSONAL CRISIS LED PATIENT TO OVERDOSE ON SEVERAL MEDICATIONS INCLUDING STUDY MEDICATIONS ON 12APR95-MOVE TO WITHDRAW.
329.006.00039	Female	15	Yes	No	92	20	Lack of Efficacy	
329.006.00260	Female	17	Yes	No	154	20	Protocol violation, including non-compliance	
329.006.00261	Male	17	Yes	No	155	20	Protocol violation, including non-compliance	
329.007.00140	Male	11	Yes	No	69	20	Other reason	PATIENT WENT TO LIVE WITH HIS FATHER.HIS FATHER IS OPPOSED TO MEDICATION TREATMENT FOR DEPRESSION,FATHER WITHDREW CONSENT.
329.007.00142	Male	15	No	No	48	40	Lack of Efficacy	MOTHER WANTS PATIENT TO BE WITHDRAWN BECAUSE HIS DEPRESSION HAS NOT IMPROVED AT MAXIMUM DOSAGE.
329.007.00145	Male	16	Yes	Yes	226	20		

\* Relative to Start of Study Medication

5

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.007.00265	Female	16	No	No	15	20	Lost to follow-up	NONCOMPLIANCE WITH MAKING STUDY APPOINTMENTS
329.007.00268	Female	13	Yes	Yes	262	20		
329.007.00294	Female	15	No	No	42	20	Lack of Efficacy	
329.007.00309	Female	18	Yes	Yes	255	20		DATE OF DOWN TITRATION VISIT
329.007.00310	Female	16	Yes	Yes	271	20		
329.007.00318	Male	13	No	No	1	20	Lost to follow-up	
329.008.00157	Male	15	Yes	No	174	20	Other reason	PATIENT DROPPED OUT. PT. FELT NO FURTHER NEED FOR MEDICATION BECAUSE HE IS DOING WELL.
329.008.00160	Female	14	Yes	Yes	281	20		
329.008.00188	Female	17	Yes	No	55	40	Protocol violation, including non-compliance	
329.008.00271	Female	13	Yes	Yes	255	20		
329.008.00275	Male	14	Yes	Yes	223	30		
329.009.00130	Male	15	Yes	No	182	20	Protocol violation, including non-compliance	
329.009.00131	Female	16	Yes	No	118	20	Protocol violation, including non-compliance	
329.009.00133	Female	16	No	No	45	40	Lost to follow-up	PT DECIDED TO STOP STUDY HERSELF NOT FOR LACK OF EFFICACY,PT WAS LOST TO FU
329.009.00138	Female	13	No	No	4	20	Other reason	PATIENT WITHDREW CONSENT
329.009.00170	Female	14	Yes	Yes	245	20		

\* Relative to Start of Study Medication

9

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.009.00173	Female	12	Yes	No	100	20	Lack of Efficacy	
329.009.00193	Female	12	Yes	No	71	20	Lack of Efficacy	
329.009.00196	Female	17	Yes	No	70	20	Other reason	PATIENT WITHDREW CONSENT
329.009.00201	Male	14	Yes	No	59	20	Adverse event, including intercurrent illness	PHYSICIAN DISCRETIONS DUE TO IRREGULAR PARANOID BEHAVIOR
329.009.00204	Male	12	Yes	No	211	20	Lost to follow-up	
329.009.00235	Female	12	Yes	No	130	20	Lack of Efficacy	
329.009.00240	Male	14	No	No	51	30	Adverse event, including intercurrent illness	
329.009.00303	Male	17	Yes	Yes	265	20		
329.009.00304	Male	16	Yes	No	210	20	Other reason	PATIENT WITHDREW CONSENT
329.009.00324	Female	13	Yes	No	73	20	Adverse event, including intercurrent illness	RASH DEVELOPED BETWEEN WEEK 7 & 8
329.009.00328	Male	14	No	No	1	20	Other reason	WITHDREW CONSENT
329.009.00329	Male	14	Yes	No	70	30	Lack of Efficacy	
329.010.00182	Male	18	No	No	32	20	Lost to follow-up	
329.010.00278	Female	17	Yes	Yes	240	20		
329.010.00280	Female	13	Yes	No	74	40	Protocol violation, including non-compliance	PT. HAS SOME SYMPTOMS OF CONDUCT DISORDER AND OPPOSITIONAL DEFIANT DISORDER AND REFUSED TO PARTICIPATE FURTHER. PT.'S DEPRESSION DID RESPOND DURING TREATMENT, BUT HER OTHER PROBLEMS SEEMED TO WORSEN.

\* Relative to Start of Study Medication

7

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.011.00283	Male	16	Yes	No	58	20	Protocol violation, including non-compliance	
329.011.00288	Male	15	No	No	43	20	Lack of Efficacy	PATIENT NO LONGER WANTS TO PARTICIPATE IN STUDY.
329.012.00025	Female	14	Yes	No	73	30	Lack of Efficacy	
329.012.00220	Male	15	Yes	No	159	30	Other reason	WITHDREW CONSENT
329.012.00222	Female	15	Yes	No	86	30	Other reason	NON-COMPLIANCE WITHDREW CONSENT
329.012.00226	Male	15	No	No	18	20	Adverse event, including intercurrent illness	
329.012.00228	Female	15	No	No	4	20	Protocol violation, including non-compliance	
329.012.00231	Female	16	Yes	No	165	20	Protocol violation, including non-compliance	

8

\* Relative to Start of Study Medication

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.001.00061	Female	16	No	No	48	200	Adverse event, including intercurrent illness	
329.001.00066	Female	17	No	No	22	100	Adverse event, including intercurrent illness	
329.001.00067	Male	14	No	No	22	100	Adverse event, including intercurrent illness	
329.001.00070	Male	12	No	No	31	150	Adverse event, including intercurrent illness	
329.001.00122	Male	15	Yes	No	182	200	Lack of Efficacy	
329.002.00050	Male	16	No	No	35	150	Adverse event, including intercurrent illness	MULTIPLE SIDE EFFECTS-INCREASED HEART RATE URINARY HESITANCY DIZZINESS
329.002.00056	Female	17	No	No	36	150	Adverse event, including intercurrent illness	INCREASED HEART RATE
329.002.00057	Female	15	Yes	No	129	50	Adverse event, including intercurrent illness	PT. BECAME PREGNANT
329.002.00098	Female	16	Yes	No	73	250	Lack of Efficacy	NOT RESPONDING TO TREATMENT AND DISCOMFORT DUE TO POSSIBLE SIDE EFFECTS.
329.002.00100	Male	15	Yes	No	85	250	Protocol violation, including non-compliance	
329.002.00103	Female	14	Yes	No	128	50	Lack of Efficacy	RELAPSE OF DEPRESSED SYMPTOMS AND SUICIDAL IDEATION.
329.002.00104	Male	13	Yes	Yes	259	50		
329.002.00243	Female	15	No	No	23	150	Adverse event, including intercurrent illness	HIT HEAD DURING A FALL
329.002.00244	Female	17	Yes	No	84	50	Lack of Efficacy	

\* Relative to Start of Study Medication

6

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.002.00321	Male	14	No	No	12	50	Adverse event, including intercurrent illness	PT WAS HOSPITALIZED ON 6-2-96 AT BRADLEY HOSPITAL FOLLOWING ASSAULTIVE BEHAVIOR NO DOWN TITRATION SINCE PT WAS ONLY ON LEVEL 1.
329.002.00322	Male	14	No	No	46	200	Adverse event, including intercurrent illness	ORTHOSTATIC SIDE EFFECTS
329.003.00073	Female	16	No	No	45	250	Adverse event, including intercurrent illness	
329.003.00076	Female	16	Yes	Yes	240	200		
329.003.00079	Female	15	No	No	17	150	Other reason	PATIENT WITHDREW BY OWN VOLITION
329.003.00082	Female	17	No	No	38	250	Lost to follow-up	
329.003.00088	Female	15	No	No	41	200	Adverse event, including intercurrent illness	URINARY RETENTION
329.003.00090	Female	13	Yes	No	69	150	Lack of Efficacy	
329.003.00092	Female	12	Yes	Yes	261	50		
329.003.00093	Female	17	Yes	No	80	300	Protocol violation, including non-compliance	
329.003.00247	Male	16	Yes	No	111	200	Protocol violation, including non-compliance	CHOSE TO LEAVE STUDY EARLY
329.003.00249	Female	17	Yes	No	62	250	Lack of Efficacy	
329.003.00289	Female	16	Yes	Yes	238	50		
329.003.00290	Male	17	No	No	12	100	Adverse event, including intercurrent illness	HIGH BLOOD PRESSURE

\* Relative to Start of Study Medication

10

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.003.00314	Female	15	Yes	No	77	250	Protocol violation, including non-compliance	
329.003.00317	Female	16	Yes	No	70	250	Lack of Efficacy	
329.004.00013	Male	17	Yes	Yes	248	50		
329.004.00014	Male	14	No	No	15	100	Adverse event, including intercurrent illness	
329.004.00211	Female	18	No	No	49	200	Adverse event, including intercurrent illness	DEHYDRATION POST NAUSEA AND VOMITTING/DIARRHEA DUE TO BACTERIA GASTROENTERITIS RESULTED IN SEVERE DEHYDRATION AND MOUTH SORES/CUTS
UNABLE TO								TOLERATE SIDE EFFECTS OF DRY MOUTH.
329.004.00215	Female	14	No	No	40	200	Adverse event, including intercurrent illness	
329.005.00003	Female	13	No	No	15	100	Adverse event, including intercurrent illness	
329.005.00006	Male	17	Yes	No	175	50	Adverse event, including intercurrent illness	
329.005.00007	Female	15	Yes	No	192	250	Adverse event, including intercurrent illness	
329.005.00009	Female	16	Yes	No	73	250	Lack of Efficacy	
329.005.00110	Female	17	No	No	9	100	Adverse event, including intercurrent illness	POSITIVE PREGNANCY TEST
329.005.00113	Female	15	No	No	32	200	Adverse event, including intercurrent illness	
329.005.00117	Female	16	Yes	No	70	200	Lack of Efficacy	

\* Relative to Start of Study Medication

11

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.005.00118	Male	15	No	No	50	250	Protocol violation, including non-compliance	POSITIVE DRUG SCREEN
329.005.00153	Female	18	Yes	Yes	236	50		
329.005.00255	Female	15	Yes	No	71	200	Lack of Efficacy	
329.005.00256	Female	16	Yes	No	135	50	Other reason	PT CHOSING TO WITHDRAW AS SHE WANTS TO BEGIN KNOWN MED THERAPY
329.005.00295	Female	13	Yes	No	69	250	Adverse event, including intercurrent illness	INVESTIGATOR'S DECISION TO DISCONTINUE STUDY BECAUSE PT. THREATENED TO KILL PARENTS.
329.005.00297	Male	18	No	No	26	200	Protocol violation, including non-compliance	
329.005.00332	Male	17	Yes	No	72	250	Lack of Efficacy	
329.005.00335	Female	15	Yes	No	68	150	Lack of Efficacy	
329.006.00040	Female	18	No	No	14	50	Adverse event, including intercurrent illness	FATIGUE,EYE DILATION,MEDICATION REACTION
329.006.00041	Male	18	Yes	Yes	245	50		
329.007.00139	Female	12	No	No	18	100	Adverse event, including intercurrent illness	CHEST PAIN-RESOLVED ON FOLLOW-UP ASSOCIATED WITH SHORTNESS OF BREATH
329.007.00143	Female	13	No	No	23	100	Adverse event, including intercurrent illness	ACNE
329.007.00146	Female	15	Yes	Yes	241	50		
329.007.00269	Male	15	No	No	15	100	Adverse event, including intercurrent illness	TACHYCARDIA,NEGATIVE/LOW T-WAVES

\* Relative to Start of Study Medication

12

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.007.00270	Male	15	No	No	43	200	Adverse event, including intercurrent illness	CHEST PAIN, CHEST TIGHTNESS, SHORTNESS OF BREATH (PAGE 227, SECOND COL.)
329.007.00307	Female	15	No	No	36	200	Adverse event, including intercurrent illness	MORBILLIFORM
329.007.00308	Male	14	No	No	10	50	Protocol violation, including non-compliance	PATIENT RAN AWAY FROM HOME.
329.008.00159	Female	16	Yes	No	134	200	Protocol violation, including non-compliance	PATIENT DROPPED OUT, DUE TO NON COMPLIANCE.
329.008.00161	Male	17	Yes	No	56	200	Lost to follow-up	
329.008.00187	Female	16	Yes	No	73	200	Lack of Efficacy	PATIENT DEMONSTRATED NO SIGNIFICANT IMPROVEMENT.
329.008.00192	Male	13	No	No	38	200	Protocol violation, including non-compliance	
329.008.00272	Male	12	Yes	No	169	200	Protocol violation, including non-compliance	
329.008.00273	Female	12	Yes	No	116	300	Adverse event, including intercurrent illness	
329.009.00127	Female	12	No	No	47	200	Adverse event, including intercurrent illness	NONCOMPLIANT SECONDARY TO NAUSEA
329.009.00132	Male	12	Yes	No	167	50	Lack of Efficacy	
329.009.00134	Female	15	Yes	No	66	150	Adverse event, including intercurrent illness	PATIENT WITHDRAWN FOR TACHYCARDIA&INCREASED QT/QTc
329.009.00137	Male	14	Yes	No	68	150		TEAM FELT THAT DUE TO CONTINUING ADHD SYMPTOMS PATIENT NEEDED TREATMENT WITH STIMULANT

\* Relative to Start of Study Medication

13

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.009.00171	Female	16	No	No	8	50	Adverse event, including intercurrent illness	MACULAR RASH
329.009.00172	Female	13	Yes	Yes	251	50		
329.009.00194	Male	12	Yes	No	184	200	Adverse event, including intercurrent illness	
329.009.00195	Female	14	No	No	36	150	Adverse event, including intercurrent illness	CARDIAC ARRHYTHMIA (PVC'S)
329.009.00199	Female	14	Yes	No	71	200	Protocol violation, including non-compliance	
329.009.00203	Female	12	No	No	33	100	Adverse event, including intercurrent illness	BORDERLINE PROLONGED QT-QTC 1ST DEGREE AV BLOCK
329.009.00236	Female	13	No	No	41	200	Adverse event, including intercurrent illness	
329.009.00239	Female	16	Yes	No	147	200	Protocol violation, including non-compliance	PT. STOPPED MEDS ON OWN.
329.009.00262	Male	13	Yes	No	69	200	Lack of Efficacy	
329.009.00264	Female	14	Yes	No	65	200	Lack of Efficacy	
329.009.00301	Male	17	Yes	No	97	50	Other reason	WITHDREW CONSENT
329.009.00305	Male	14	Yes	Yes	261	50		
329.009.00325	Female	15	Yes	No	124	50	Lack of Efficacy	
329.009.00326	Male	13	Yes	No	115	50	Lack of Efficacy	THIS WAS PATIENTS ACTUD LAST VISIT TO CLINIC PATIENT WAS GIVEN DOWN TITRATION MEDS, FINISHED ON 28 DEC 96 BUT DID NOT RETURN TO CLINIC - MAILED MED PACKET TO US

\* Relative to Start of Study Medication

14

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

-----  
 ----- Treatment Group=IMIPRAMINE -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.010.00279	Female	13	Yes	Yes	246	50		
329.010.00281	Male	13	Yes	No	178	50	Adverse event, including intercurrent illness	
329.011.00163	Female	15	No	No	28	200	Adverse event, including intercurrent illness	WHEN PT.GOT SICK,THEY STOPPED GIVING MED.WITHOUT CONTACTING ANYONE.
329.011.00208	Male	13	Yes	No	79	50	Adverse event, including intercurrent illness	TOXIC IMIPRAMINE LEVEL (592)
329.011.00209	Male	12	Yes	No	100	250	Other reason	PATIENT WITHDREW CONSENT
329.011.00284	Male	17	Yes	No	138	250	Protocol violation, including non-compliance	STOPPED TAKING MEDS. WITHOUT NOTIFICATION OR DOWN TITRATION
329.011.00286	Female	15	Yes	No	209	300	Lost to follow-up	
329.012.00026	Male	14	No	No	8	100	Protocol violation, including non-compliance	
329.012.00219	Male	14	Yes	Yes	233	200		
329.012.00221	Male	17	Yes	No	132	200	Adverse event, including intercurrent illness	MINOR OVERDOSE OF LORAZEPAM AND WITHDREW CONSENT TO STUDY. REFUSED DOWN-TITRATION
329.012.00223	Female	13	No	No	44	150	Lack of Efficacy	PT WISHED TO WITHDRAW FROM THE STUDY TO BE TREATED OPENLY.
329.012.00227	Male	16	Yes	Yes	260	50		
329.012.00230	Male	15	Yes	No	88	50	Other reason	WITHDREW CONSENT.

\* Relative to Start of Study Medication

15

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

-----  
 ----- Treatment Group=PLACEBO -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.001.00062	Female	15	No	No	27	0	Protocol violation, including non-compliance	PATIENT REFUSED FURTHER MEDICATION.
329.001.00064	Male	13	Yes	No	152	0	Lack of Efficacy	
329.001.00069	Male	16	Yes	No	62	0	Lack of Efficacy	NON RESPONDER
329.001.00071	Female	13	Yes	No	71	0	Lack of Efficacy	
329.001.00123	Female	16	No	No	49	0	Lack of Efficacy	
329.001.00207	Male	14	Yes	No	58	0	Lack of Efficacy	NON RESPONDER
329.002.00049	Male	15	Yes	No	74	0	Lack of Efficacy	
329.002.00059	Male	17	Yes	No	73	0	Lack of Efficacy	NON-RESPONSE TO TREATMENT
329.002.00060	Female	14	Yes	No	85	0	Lack of Efficacy	PT.FELT MEDICATION WASN'T WORKING
329.002.00097	Female	13	Yes	Yes	261	0		
329.002.00101	Male	16	Yes	No	106	0	Protocol violation, including non-compliance	MARIJUANA USE WITH POSITIVE URINE SCREEN, SEE LAB PG. ON WEEK 12 AND SEE A.E. PG. 408.
329.002.00107	Female	15	Yes	Yes	258	0		
329.002.00241	Male	15	Yes	No	108	0	Adverse event, including intercurrent illness	PT HOSPITALIZED DUE TO HOMICIDAL / SUICIDAL IDEATION
329.002.00246	Female	17	Yes	No	72	0	Lack of Efficacy	
329.002.00320	Female	13	Yes	No	146	0	Lack of Efficacy	ESCALATING DEPRESSIVE SYMPTOMS
329.002.00323	Female	17	Yes	Yes	227	0		
329.003.00074	Male	13	Yes	Yes	274	0		
329.003.00078	Female	17	Yes	No	64	0	Lack of Efficacy	

\* Relative to Start of Study Medication

16

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.003.00080	Female	16	Yes	No	75	0	Lack of Efficacy	
329.003.00085	Female	17	Yes	No	71	0	Lack of Efficacy	
329.003.00086	Female	14	Yes	Yes	279	0		
329.003.00094	Female	13	Yes	No	73	0	Lack of Efficacy	
329.003.00251	Female	17	No	No	13	0	Lost to follow-up	
329.003.00252	Female	14	Yes	No	70	0	Lack of Efficacy	
329.003.00291	Female	16	Yes	No	120	0	Lost to follow-up	
329.003.00315	Female	16	Yes	No	60	0		PT. DID NOT WANT TO CONTINUE
329.003.00316	Female	16	Yes	No	64	0	Lack of Efficacy	
329.004.00016	Male	17	No	No	38	0	Lack of Efficacy	
329.004.00018	Female	17	Yes	No	73	0	Other reason	PATIENT WANTED TO TERMINATE, DID NOT WISH TO BE ON MEDICATION
329.004.00020	Female	14	No	No	16	0	Protocol violation, including non-compliance	
329.004.00213	Female	15	Yes	Yes	241	0		
329.005.00001	Female	16	Yes	No	70	0	Lack of Efficacy	-MINIMAL IMPROVEMENT OF DEPRESSION SYMPTOMS
329.005.00005	Female	13	No	No	9	0	Adverse event, including intercurrent illness	ELEVATED HEART RATE ON LEVEL ONE
329.005.00010	Female	16	Yes	Yes	255	0		
329.005.00012	Female	14	Yes	No	165	0	Adverse event, including intercurrent illness	RECURRENCE OF OCULAR TAXOPLASMOISIS

\* Relative to Start of Study Medication

17

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.005.00111	Female	16	Yes	No	110	0	Adverse event, including intercurrent illness	
329.005.00114	Male	16	Yes	No	98	0	Lack of Efficacy	DEPRESSIVE SYMPTOMS RETURNED AFTER GIRLFRIEND BROKE UP WITH HIM.RETURN MAJOR DEPRESSIVE DISORDER SYMPTOMS.
329.005.00115	Female	18	Yes	No	75	0	Other reason	PT. REPORTS FEELING BETTER AND DOES NOT WANT TO TAKE MEDICATION ANY LONGER.
329.005.00120	Male	13	Yes	No	58	0	Lack of Efficacy	DIDN'T RETURN TAPER PACK ALTHOUGH MOM REPORTED THAT HE COMPLETED TAPER PACK DURING A PHONE CONVERSATION.THEY THEN MOVED OUT OF STATE.
329.005.00253	Female	16	Yes	No	56	0	Lack of Efficacy	
329.005.00254	Female	16	Yes	Yes	258	0		
329.005.00293	Female	16	Yes	No	57	0		STUDY MEDICATION FOR PHASE II UNAVAILABLE
329.005.00298	Female	13	Yes	Yes	248	0		
329.005.00331	Female	15	Yes	No	57	0		DRUG SUPPLIES NOT AVAILABLE FROM SKB
329.005.00334	Female	13	Yes	No	56	0		LACK OF STUDY MEDICATION AVAILABLE
329.006.00037	Female	17	No	No	25	0	Protocol violation, including non-compliance	LOST INTEREST,PATIENT HAS REFUSED FOLLOW-UP SAFETY EVALUATION AND ASSISTANCE WITH REFERRAL
329.006.00042	Male	18	Yes	Yes	238	0		

\* Relative to Start of Study Medication

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.006.00259	Male	17	Yes	No	71	0	Lack of Efficacy	
329.007.00141	Male	13	No	No	22	0	Adverse event, including intercurrent illness	PHYSICIAN DISCRETION DUE TO COMPARATOR ARM,VIS-A-VIS AE OF CHEST PAIN.
329.007.00144	Female	12	Yes	No	57	0	Lost to follow-up	
329.007.00266	Female	12	Yes	No	71	0		PATIENT MOVING OUT OF STATE FOR SUMMER.
329.007.00267	Male	16	Yes	No	56	0	Protocol violation, including non-compliance	POSITIVE MULTIPLE DRUG SCREENS,MULTIPLES GIVEN PER JIM MCCAFERTY.
329.007.00311	Male	15	Yes	No	204	0	Lack of Efficacy	*DATE OF FOLLOW-UP VISIT AFTER TAPER FINISHED.
329.008.00158	Female	16	Yes	No	106	0	Protocol violation, including non-compliance	PATIENT DROPPED OUT. PT WAS DROPPED BECAUSE OF NON COMPLIANCE.
329.008.00162	Female	16	Yes	Yes	260	0		
329.008.00191	Female	17	Yes	No	134	0	Other reason	MOVED OUT OF STATE
329.009.00128	Male	13	No	No	22	0	Adverse event, including intercurrent illness	RIGHT BBB
329.009.00129	Male	16	No	No	36	0	Lack of Efficacy	PATIENT DOING SOME WHAT WORSE-MOTHER ANXIOUS ABOUT INCREASE DEATH WISHES
329.009.00135	Female	17	No	No	49	0	Lack of Efficacy	
329.009.00136	Female	14	Yes	No	70	0	Lack of Efficacy	
329.009.00169	Male	13	Yes	No	97	0	Adverse event, including intercurrent illness	

\* Relative to Start of Study Medication

Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.009.00174	Female	15	Yes	No	85	0	Lack of Efficacy	PT.HAD RELAPSE-NEEDED TX
329.009.00197	Male	12	Yes	Yes	248	0		
329.009.00198	Female	17	Yes	No	68	0	Lack of Efficacy	
329.009.00200	Female	17	No	No	57	0	Lack of Efficacy	
329.009.00202	Female	15	No	No	36	0	Protocol violation, including non-compliance	PATIENT WAS NON-COMPLIANT DUE TO POSITIVE DRUG SCREEN
329.009.00237	Male	17	No	No	9	0	Protocol violation, including non-compliance	
329.009.00238	Female	16	Yes	No	69	0	Lack of Efficacy	
329.009.00276	Male	13	Yes	No	71	0	Lack of Efficacy	ALTHOUGH IMPROVED REMAINS SYMPTOMATIC
329.009.00302	Male	17	No	No	15	0	Adverse event, including intercurrent illness	PATIENT WAS WITHDRAWN DUE TO MACULOPAPULAR RASH,SINUS BRADYCARDIA WITH ARRHYTHMIA AND JUNCTIONAL ESCAPE PATTERN
329.009.00306	Female	14	Yes	No	70	0	Lack of Efficacy	
329.009.00312	Female	17	Yes	No	78	0	Lack of Efficacy	
329.009.00327	Female	16	No	No	50	0	Lack of Efficacy	
329.009.00330	Male	12	No	No	15	0	Adverse event, including intercurrent illness	
329.010.00183	Male	14	No	No	18	0	Protocol violation, including non-compliance	
329.010.00263	Male	18	Yes	No	72	0		PT. DOES NOT FEEL HE CAN BE COMPLIANT FOR NEXT SIX MONTHS. ALSO DOES NOT WANT TO TAKE THAT MANY PILLS ANYMORE.

\* Relative to Start of Study Medication



Appendix B.1

Listing of Patient Terminations by Treatment Group and Patient Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Sex	Age (Years)	Completed Acute	Completed Cont.	Study Day *	Dose (mg)	Reason for Withdrawal	Comments
329.010.00277	Female	14	Yes	No	113	0	Protocol violation, including non-compliance	
329.010.00282	Female	15	Yes	No	79	0		CONTINUATION PHASE MEDICATION IS NOT AVAILABLE.
329.011.00164	Male	15	No	No	36	0	Protocol violation, including non-compliance	
329.011.00210	Female	14	Yes	No	67	0	Lost to follow-up	
329.011.00285	Male	16	Yes	No	75	0	Lack of Efficacy	
329.011.00287	Female	14	Yes	No	70	0		DID NOT WANT TO CONTINUE
329.012.00027	Male	15	No	No	37	0	Other reason	EARLY WITHDRAWAL-WK 4VISIT PATIENT CHOSE TO WITHDRAW FROM STUDY BECAUSE HE WANTS TO BE TREATED BY PRIMARY THERAPIST AND WANTS TO BE ABLE TO TAKE OTHER MEDICATIONS LIKE LORAZEPAM.
329.012.00217	Female	14	No	No	25	0	Adverse event, including intercurrent illness	ABIVALENCE ABOUT MEDICATION, VIRAL ILLNESS, MEDICATION ON IP'S ADVICE, HOSPITALIZATION TO PSYCHIATRY, AND WANTING TO KNOW WHICH MED SHE WAS ON.
329.012.00218	Female	17	Yes	No	108	0	Other reason	WISHED TO DISCONTINUE STUDY MEDICATION, FEELS SHE CAN DO WELL WITHOUT "PILLS".
329.012.00224	Female	14	Yes	No	167	0	Protocol violation, including non-compliance	
329.012.00225	Male	14	Yes	Yes	258	0		

\* Relative to Start of Study Medication

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Age (Years)	Sex	Race
329.001.00063	14	Female	Caucasian
329.001.00065	14	Male	Caucasian
329.001.00068	13	Female	Caucasian
329.001.00072	15	Male	Caucasian
329.001.00121	15	Male	Caucasian
329.001.00205	12	Male	Caucasian
329.001.00206	16	Male	Caucasian
329.002.00055	13	Male	Caucasian
329.002.00058	16	Female	Caucasian
329.002.00099	15	Male	Caucasian
329.002.00102	16	Female	Caucasian
329.002.00105	16	Male	WHITE/HISPANIC
329.002.00106	15	Female	Caucasian
329.002.00242	15	Female	Caucasian
329.002.00245	14	Female	Caucasian
329.002.00319	16	Female	Caucasian
329.003.00075	17	Female	HISPANIC
329.003.00077	16	Male	HISPANIC
329.003.00081	12	Female	HISPANIC
329.003.00087	14	Female	Caucasian
329.003.00089	14	Female	Caucasian

22

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Age (Years)	Sex	Race
329.003.00091	16	Female	Caucasian
329.003.00248	14	Female	Caucasian
329.003.00250	15	Female	Black
329.003.00292	16	Male	MONGOLOID (KOREAN)
329.003.00313	18	Male	HISPANIC
329.004.00015	16	Female	Caucasian
329.004.00017	16	Female	EAST INDIAN
329.004.00019	17	Female	Caucasian
329.004.00212	17	Female	Caucasian
329.004.00214	15	Female	Caucasian
329.005.00002	14	Female	Caucasian
329.005.00004	16	Male	Caucasian
329.005.00008	12	Male	Caucasian
329.005.00011	16	Female	Caucasian
329.005.00109	17	Female	Black
329.005.00112	13	Male	Caucasian
329.005.00116	16	Female	Caucasian
329.005.00119	14	Female	Caucasian
329.005.00151	14	Female	Caucasian
329.005.00152	15	Female	Caucasian
329.005.00257	12	Female	Caucasian

23

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Age (Years)	Sex	Race
329.005.00258	14	Female	Caucasian
329.005.00299	12	Female	Caucasian
329.005.00300	12	Male	Caucasian
329.005.00333	16	Female	Caucasian
329.005.00336	14	Female	Caucasian
329.006.00038	15	Female	Caucasian
329.006.00039	15	Female	Caucasian
329.006.00260	17	Female	Caucasian
329.006.00261	17	Male	LATINO - MEXICO
329.007.00140	11	Male	Caucasian
329.007.00142	15	Male	Caucasian
329.007.00145	16	Male	Black
329.007.00265	16	Female	HISPANIC
329.007.00268	13	Female	Caucasian
329.007.00294	15	Female	Caucasian
329.007.00309	18	Female	Caucasian
329.007.00310	16	Female	Caucasian
329.007.00318	13	Male	Caucasian
329.008.00157	15	Male	Caucasian
329.008.00160	14	Female	Caucasian
329.008.00188	17	Female	NATIVE AMERICAN

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Age (Years)	Sex	Race
329.008.00271	13	Female	Caucasian
329.008.00275	14	Male	Caucasian
329.009.00130	15	Male	Oriental
329.009.00131	16	Female	Caucasian
329.009.00133	16	Female	Caucasian
329.009.00138	13	Female	Caucasian
329.009.00170	14	Female	Caucasian
329.009.00173	12	Female	Black
329.009.00193	12	Female	Caucasian
329.009.00196	17	Female	Black
329.009.00201	14	Male	Caucasian
329.009.00204	12	Male	Caucasian
329.009.00235	12	Female	Caucasian
329.009.00240	14	Male	Caucasian
329.009.00303	17	Male	Caucasian
329.009.00304	16	Male	Caucasian
329.009.00324	13	Female	Caucasian
329.009.00328	14	Male	Caucasian
329.009.00329	14	Male	Caucasian
329.010.00182	18	Male	Caucasian
329.010.00278	17	Female	Caucasian

25

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

=====  
----- Treatment Group=PAROXETINE -----

Patient ID	Age (Years)	Sex	Race
329.010.00280	13	Female	Caucasian
329.011.00283	16	Male	Caucasian
329.011.00288	15	Male	Caucasian
329.012.00025	14	Female	Caucasian
329.012.00220	15	Male	Caucasian
329.012.00222	15	Female	Caucasian
329.012.00226	15	Male	Caucasian
329.012.00228	15	Female	Caucasian
329.012.00231	16	Female	Caucasian

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Age (Years)	Sex	Race
329.001.00061	16	Female	Caucasian
329.001.00066	17	Female	Caucasian
329.001.00067	14	Male	Caucasian
329.001.00070	12	Male	Caucasian
329.001.00122	15	Male	Caucasian
329.002.00050	16	Male	Caucasian
329.002.00056	17	Female	Caucasian
329.002.00057	15	Female	Caucasian
329.002.00098	16	Female	Caucasian
329.002.00100	15	Male	Caucasian
329.002.00103	14	Female	Caucasian
329.002.00104	13	Male	Caucasian
329.002.00243	15	Female	Caucasian
329.002.00244	17	Female	Caucasian
329.002.00321	14	Male	Caucasian
329.002.00322	14	Male	Caucasian
329.003.00073	16	Female	Caucasian
329.003.00076	16	Female	HISPANIC
329.003.00079	15	Female	Caucasian
329.003.00082	17	Female	HISPANIC
329.003.00088	15	Female	Caucasian

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Age (Years)	Sex	Race
329.003.00090	13	Female	Caucasian
329.003.00092	12	Female	Caucasian
329.003.00093	17	Female	Caucasian
329.003.00247	16	Male	Caucasian
329.003.00249	17	Female	Black
329.003.00289	16	Female	HISPANIC
329.003.00290	17	Male	HISPANIC
329.003.00314	15	Female	Caucasian
329.003.00317	16	Female	Oriental
329.004.00013	17	Male	Caucasian
329.004.00014	14	Male	Caucasian
329.004.00211	18	Female	Caucasian
329.004.00215	14	Female	Oriental
329.005.00003	13	Female	Caucasian
329.005.00006	17	Male	Caucasian
329.005.00007	15	Female	Caucasian
329.005.00009	16	Female	1/2SPANISH 1/2WHITE
329.005.00110	17	Female	Black
329.005.00113	15	Female	Black
329.005.00117	16	Female	Caucasian
329.005.00118	15	Male	Caucasian

28

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Age (Years)	Sex	Race
329.005.00153	18	Female	Caucasian
329.005.00255	15	Female	Caucasian
329.005.00256	16	Female	Caucasian
329.005.00295	13	Female	Caucasian
329.005.00297	18	Male	Caucasian
329.005.00332	17	Male	Caucasian
329.005.00335	15	Female	Caucasian
329.006.00040	18	Female	Caucasian
329.006.00041	18	Male	EGYPTIAN
329.007.00139	12	Female	Caucasian
329.007.00143	13	Female	Caucasian
329.007.00146	15	Female	Caucasian
329.007.00269	15	Male	Caucasian
329.007.00270	15	Male	Caucasian
329.007.00307	15	Female	Caucasian
329.007.00308	14	Male	Caucasian
329.008.00159	16	Female	Caucasian
329.008.00161	17	Male	Caucasian
329.008.00187	16	Female	Caucasian
329.008.00192	13	Male	Caucasian
329.008.00272	12	Male	Caucasian

29

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Age (Years)	Sex	Race
329.008.00273	12	Female	Caucasian
329.009.00127	12	Female	HISPANIC
329.009.00132	12	Male	Caucasian
329.009.00134	15	Female	Caucasian
329.009.00137	14	Male	Caucasian
329.009.00171	16	Female	Caucasian
329.009.00172	13	Female	Caucasian
329.009.00194	12	Male	Caucasian
329.009.00195	14	Female	Caucasian
329.009.00199	14	Female	Caucasian
329.009.00203	12	Female	Caucasian
329.009.00236	13	Female	Caucasian
329.009.00239	16	Female	Caucasian
329.009.00262	13	Male	Caucasian
329.009.00264	14	Female	Caucasian
329.009.00301	17	Male	Caucasian
329.009.00305	14	Male	Caucasian
329.009.00325	15	Female	Caucasian
329.009.00326	13	Male	Caucasian
329.010.00279	13	Female	Caucasian
329.010.00281	13	Male	Caucasian

30

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Age (Years)	Sex	Race
329.011.00163	15	Female	Caucasian
329.011.00208	13	Male	Caucasian
329.011.00209	12	Male	Caucasian
329.011.00284	17	Male	Caucasian
329.011.00286	15	Female	Caucasian
329.012.00026	14	Male	Caucasian
329.012.00219	14	Male	Caucasian
329.012.00221	17	Male	Caucasian
329.012.00223	13	Female	Caucasian
329.012.00227	16	Male	Caucasian
329.012.00230	15	Male	Caucasian

31

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Age (Years)	Sex	Race
329.001.00062	15	Female	Caucasian
329.001.00064	13	Male	Caucasian
329.001.00069	16	Male	Caucasian
329.001.00071	13	Female	Caucasian
329.001.00123	16	Female	Black
329.001.00207	14	Male	Caucasian
329.002.00049	15	Male	Caucasian
329.002.00059	17	Male	Caucasian
329.002.00060	14	Female	Caucasian
329.002.00097	13	Female	Caucasian
329.002.00101	16	Male	Caucasian
329.002.00107	15	Female	Caucasian
329.002.00241	15	Male	PORTUGUESE
329.002.00246	17	Female	Caucasian
329.002.00320	13	Female	Caucasian
329.002.00323	17	Female	Caucasian
329.003.00074	13	Male	COLUMBIAN YUGOSLAVIC
329.003.00078	17	Female	Caucasian
329.003.00080	16	Female	HISPANIC
329.003.00085	17	Female	Caucasian
329.003.00086	14	Female	Caucasian

32

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Age (Years)	Sex	Race
329.003.00094	13	Female	Caucasian
329.003.00251	17	Female	Caucasian
329.003.00252	14	Female	Caucasian
329.003.00291	16	Female	HISPANIC
329.003.00315	16	Female	Caucasian
329.003.00316	16	Female	Caucasian
329.004.00016	17	Male	Caucasian
329.004.00018	17	Female	Caucasian
329.004.00020	14	Female	Caucasian
329.004.00213	15	Female	Caucasian
329.005.00001	16	Female	Caucasian
329.005.00005	13	Female	Caucasian
329.005.00010	16	Female	Caucasian
329.005.00012	14	Female	Caucasian
329.005.00111	16	Female	Caucasian
329.005.00114	16	Male	Caucasian
329.005.00115	18	Female	Caucasian
329.005.00120	13	Male	Caucasian
329.005.00253	16	Female	Caucasian
329.005.00254	16	Female	Caucasian
329.005.00293	16	Female	Caucasian

33

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Age (Years)	Sex	Race
329.005.00298	13	Female	Caucasian
329.005.00331	15	Female	Caucasian
329.005.00334	13	Female	Caucasian
329.006.00037	17	Female	HISPANIC
329.006.00042	18	Male	Caucasian
329.006.00259	17	Male	Caucasian
329.007.00141	13	Male	Caucasian
329.007.00144	12	Female	HISPANIC
329.007.00266	12	Female	Caucasian
329.007.00267	16	Male	Caucasian
329.007.00311	15	Male	Caucasian
329.008.00158	16	Female	Caucasian
329.008.00162	16	Female	Oriental
329.008.00191	17	Female	Caucasian
329.009.00128	13	Male	Caucasian
329.009.00129	16	Male	HISPANIC
329.009.00135	17	Female	Caucasian
329.009.00136	14	Female	Black
329.009.00169	13	Male	HISPANIC
329.009.00174	15	Female	Caucasian
329.009.00197	12	Male	Caucasian

34

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Age (Years)	Sex	Race
329.009.00198	17	Female	HISPANIC
329.009.00200	17	Female	Caucasian
329.009.00202	15	Female	Caucasian
329.009.00237	17	Male	Caucasian
329.009.00238	16	Female	Caucasian
329.009.00276	13	Male	Caucasian
329.009.00302	17	Male	Caucasian
329.009.00306	14	Female	Black
329.009.00312	17	Female	Black
329.009.00327	16	Female	Oriental
329.009.00330	12	Male	Caucasian
329.010.00183	14	Male	Black
329.010.00263	18	Male	Caucasian
329.010.00277	14	Female	Black
329.010.00282	15	Female	Caucasian
329.011.00164	15	Male	Caucasian
329.011.00210	14	Female	Caucasian
329.011.00285	16	Male	Caucasian
329.011.00287	14	Female	Caucasian
329.012.00027	15	Male	Caucasian
329.012.00217	14	Female	Caucasian

35

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.2

Listing of Demographic Data by Treatment Group and Patient  
Intent-to-Treat Population

=====  
----- Treatment Group=PLACEBO -----

Patient ID	Age (Years)	Sex	Race
329.012.00218	17	Female	Caucasian
329.012.00224	14	Female	Caucasian
329.012.00225	14	Male	Caucasian



Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	Disorders: Past or Continuing Episodes																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.001.00063	C																										
329.001.00065	C														C												
329.001.00068	C																										
329.001.00072	C																	C									
329.001.00121	C																	C					P				
329.001.00205	C																										
329.001.00206	C															P											
329.002.00055	B					P	P							P				P									
329.002.00058	C											C		B				C									
329.002.00099	C																										
329.002.00102	C											C															
329.002.00105	C					C									C	C			P	P	P						

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.002.00106	C																										
329.002.00242	C															C											
329.002.00245	C															C											
329.002.00319	C																										
329.003.00075	C										P																
329.003.00077	C																										
329.003.00087	C												C														
329.003.00089	C																										
329.003.00091																											
329.003.00248	C																										
329.003.00250	C																										
329.003.00292	C										C		C														

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	
329.003.00313	C																											
329.004.00015	C																											
329.004.00017	B																											
329.004.00019	C																											
329.004.00212	B					C									P	P												
329.004.00214	C					C					C		C															
329.005.00002	C																											
329.005.00004	C																											
329.005.00008	C																											
329.005.00011	C																											
329.005.00109	C																											
329.005.00112	C																											

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.005.00116	C																										
329.005.00119	C							P											C								
329.005.00151	C																		C								
329.005.00152	C											C															
329.005.00257	C						C												C								
329.005.00258	C																										
329.005.00299	C						C																				
329.005.00300	B																										
329.005.00333	C																										
329.005.00336	B																										
329.006.00038	C																										
329.006.00039	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia,  
 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia),  
 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder,  
 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder,  
 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse,  
 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.006.00260	C																										
329.006.00261	C	C												P							C						
329.007.00140	C																										
329.007.00142	C																										
329.007.00145	C																										
329.007.00265	C																C										
329.007.00268	C																										
329.007.00294	C																										
329.007.00309	C																										P
329.007.00310	C																										C
329.007.00318	C																										C
329.008.00157	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.008.00160	C																										
329.008.00188	C																										
329.008.00271	C					C																					
329.008.00275	C																										
329.009.00130	C											C															
329.009.00131	B											C															
329.009.00133	C																										
329.009.00138	B					P	P					C			P			C					P				
329.009.00170	B					C					C																
329.009.00173	B																										
329.009.00193	B																										
329.009.00196	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.009.00201	C																										
329.009.00204	C											C			C												
329.009.00235	C																		C								
329.009.00240	C																										
329.009.00303	C																										
329.009.00304	B																										
329.009.00324	B																										
329.009.00328	B												C														
329.009.00329	B																										
329.010.00182	C												C			C											
329.010.00278	C																										
329.010.00280	B																										P

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = PAROXETINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.011.00283	C												C			C		C									
329.011.00288	C														C	C		C									
329.012.00025	C																										
329.012.00220	C														C								P				
329.012.00222	C																										
329.012.00226	C																										
329.012.00228	B																										
329.012.00231	B																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia,  
7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia),  
10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder,  
14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder,  
18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse,  
23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder



Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.001.00061	C					C																					
329.001.00066	C																										
329.001.00067	C														C												
329.001.00070	C														C												
329.001.00122	C											C			C				C								
329.002.00050	C																										
329.002.00056	C																										
329.002.00057	B														C	C			C								
329.002.00098	C																				P						
329.002.00100	B															C											
329.002.00103	C																										
329.002.00104	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

45

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.002.00243	C										C			P													
329.002.00244	C																										
329.002.00321	C										C				C	C		C									
329.002.00322	B																	P									
329.003.00073	C																										
329.003.00076	C																										
329.003.00079	C																										
329.003.00082	C																										
329.003.00088	C																										
329.003.00090	C																										
329.003.00092	C																										
329.003.00093	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.003.00247	C																P										
329.003.00249	C										C		C														
329.003.00289	C										C		C														
329.003.00290	C										C																
329.003.00317	C												B														
329.004.00013	C																										
329.004.00014	C						B	C																			
329.004.00211	C																										
329.004.00215	C																										
329.005.00003	C					C			C							P											
329.005.00006	C																										
329.005.00007	C							P					P														

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.005.00009	C																										
329.005.00110	C											C															
329.005.00113	C										C																
329.005.00117	C														C			C									
329.005.00118	C															C											
329.005.00153	C																										
329.005.00255	C														P												
329.005.00256	C					B					C																
329.005.00295	B																										
329.005.00297	C														C												
329.005.00332	C																										
329.005.00335	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.006.00040	C																										
329.006.00041	C																										
329.007.00139	C																										
329.007.00143	C										C												C				
329.007.00146	C																										
329.007.00269	C					P									C												
329.007.00270	C																										
329.007.00307	C																										
329.007.00308	C															C											
329.008.00159	C							P																			
329.008.00161	C																										
329.008.00187	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

---

Treatment = IMIPRAMINE

---

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.008.00192	C							P							C												
329.008.00272	C																		C								
329.008.00273	C											C															
329.009.00127	P							P																			
329.009.00132	C											C			C				C								
329.009.00134	C											C															
329.009.00137	B														C	C											
329.009.00171	B																										
329.009.00172	C																										
329.009.00194	B														C												
329.009.00195	B																										
329.009.00199	B							C																			

---

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia,  
7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia),  
10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder,  
14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder,  
18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse,  
23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.009.00203	C																										
329.009.00236	C																										
329.009.00239	B																										
329.009.00262	B											C															
329.009.00264	B																										
329.009.00301	C																										
329.009.00305	C														C												
329.009.00325	B																			P							
329.009.00326	C																										
329.010.00279	P																										
329.010.00281	P																										
329.011.00163	C					C		C			C		C		C									P			

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

51

CONFIDENTIAL

BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = IMIPRAMINE

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.011.00208	C												C														
329.011.00209	C						C												C								
329.011.00284	C																		C								
329.011.00286	C																					P					
329.012.00026	C																										
329.012.00219	C																										
329.012.00221	C																										
329.012.00223	B										P		C						P								
329.012.00227	C																										
329.012.00230	B																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder



Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Patient ID	Treatment = PLACEBO																										
	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.001.00062	C										C																
329.001.00064	C														C												
329.001.00069	C										C							C									
329.001.00071	C											C												P			
329.001.00123	C					C																					
329.001.00207	C														C			C									
329.002.00049	C																										
329.002.00059	C											C															
329.002.00060	C																										
329.002.00097	C																										
329.002.00101	C														P	C		C		P	P						
329.002.00107	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Patient ID	Treatment = PLACEBO																										
	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.002.00241	C																										
329.002.00246	C										C		C														
329.002.00320	C																										
329.002.00323	C												C														
329.003.00074	C																										
329.003.00078	C																										
329.003.00085	C																										
329.003.00086	B					P		P																			
329.003.00094	C										C		C														
329.003.00251	C						P				C		C									P					
329.003.00252	C																										
329.003.00291	C					C	C	C	C		C		C				P										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia), 10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

---

Treatment = PLACEBO

---

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.003.00315	C																										
329.003.00316	C					C												C									
329.004.00016	C																										
329.004.00018	B											C				P											
329.004.00020	C						P									C											
329.004.00213	C					C																					
329.005.00001	B					P		C			C		C														
329.005.00005	C														P			P									
329.005.00010	C																										
329.005.00012	C																										
329.005.00111	B																										
329.005.00114	C																										

---

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

55

Paroxetine - Protocol 329  
 Appendix B.3  
 Listing of K-SADS-L Diagnostic Criteria at Screening  
 Intent-to-Treat Population

Treatment = PLACEBO

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.005.00115	C																										
329.005.00120	C					C					C		C			P											
329.005.00253	C																										
329.005.00254	C										C		C														
329.005.00293	C										C																
329.005.00298	C																										
329.005.00331	B												C														
329.005.00334	C																										
329.006.00037	C																										
329.006.00042	C																										
329.006.00259	C																										
329.007.00141	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

56

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = PLACEBO

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.007.00144	C																										
329.007.00266	C																										
329.007.00267	C					P																					
329.007.00311	C																										
329.008.00158	C																										
329.008.00162	C																										
329.008.00191	C																										
329.009.00128	C																										
329.009.00129	C														P												
329.009.00135	B																										
329.009.00136	B						P																				
329.009.00169	B																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = PLACEBO

Patient ID	----- Disorders: Past or Continuing Episodes -----																											
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	
329.009.00174	C														C													
329.009.00197	C																											
329.009.00198	C																											
329.009.00200	B																											
329.009.00202	B																											
329.009.00237	B																		B									
329.009.00238	B																											
329.009.00276	C																											
329.009.00302	C																											
329.009.00306	B																											
329.009.00312	B																											
329.009.00327	B																											

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

Treatment = PLACEBO

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.009.00330	B											C															
329.010.00183	C														P	C		C									
329.010.00263	P																										
329.010.00277	P																										
329.010.00282	P																										
329.011.00164	C											C															
329.011.00210	C																		C								
329.011.00285	C					C		C					C														
329.011.00287	C																		C								
329.012.00027	B																										
329.012.00217	C																		C								
329.012.00218	C																										

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia, 7=Separation anxiety disorder, 8=Panic disorder (without agoraphobia), 9=Panic disorder (with agoraphobia), 10=Agoraphobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder, 14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder, 18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse, 23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder

Paroxetine - Protocol 329  
Appendix B.3  
Listing of K-SADS-L Diagnostic Criteria at Screening  
Intent-to-Treat Population

---

Treatment = PLACEBO

---

Patient ID	----- Disorders: Past or Continuing Episodes -----																										
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
329.012.00224	C						C																				
329.012.00225	C																										

---

P=Past, C=Continuing, B=Both

1=Major Depressive Episode, 2=Hypomanic Episode, 3=Manic Episode, 4=Anorexia Nervosa, 5=Bulimia Nervosa, 6=Specific Phobia,  
7=Separation anxiety disorder, 8=Panic disorder (without agorophobia), 9=Panic disorder (with agorophobia),  
10=Agorophobia (no panic), 11=Social Phobia, 12=Obsessive Compulsive Disorder, 13=Generalized anxiety disorder,  
14=Post-traumatic stress disorder, 15=Attention-deficit/hyperactivity, 16=Conduct Disorder, 17=Antisocial personality disorder,  
18=Oppositional Defiant disorder, 19=Alcohol Dependence, 20=Alcohol abuse, 21=Substance dependence, 22=Substance abuse,  
23=Tic Disorders, 24=Schizophrenia, 25=Schizoaffective disorder, 26=Brief psychotic disorder, 27=Delusional disorder



Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PAROXETINE					
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks
329.001.00063	SC	02NOV94	-6 , .	31-40	31-40
329.001.00065	SC	07NOV94	-10 , .	31-40	31-40
329.001.00068	SC	01FEB95	-7 , .	31-40	31-40
329.001.00072	SC	07MAR95	-13 , .	31-40	31-40
329.001.00121	SC	22MAR95	-13 , -69	31-40	31-40
329.001.00205	SC	29JAN96	-9 , .	31-40	31-40
329.001.00206	SC	12FEB96	-9 , .	31-40	31-40
329.002.00055	SC	09JUN94	-15 , -70	41-50	41-50
	20	10NOV94	140 , 85	.	41-50
329.002.00058	SC	08SEP94	-12 , -70	41-50	41-50
329.002.00099	SC	23FEB95	-7 , -62	61-70	61-70
	32	26OCT95	239 , 184	31-40	41-50
329.002.00102	SC	03APR95	-10 , -64	51-60	51-60
	32	05DEC96	603 , 549	81-90	.
329.002.00105	SC	20JUL95	-7 , .	51-60	51-60
329.002.00106	SC	20JUL95	-7 , .	51-60	51-60
329.002.00242	SC	26JAN96	-12 , -70	51-60	51-60
	20	10JUL96	155 , 97	71-80	.

\* days relative to start of acute phase, days relative to start of continuation phase

61

CONFIDENTIAL

BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PAROXETINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.002.00245	SC	21MAR96	-7 , .	41-50	41-50	
329.002.00319	SC	23APR96	-7 , -63	51-60	51-60	
	32	17DEC96	232 , 176	51-60	81-90	
329.003.00075	SC	18JAN95	-7 , -63	41-50	41-50	
	32	13SEP95	232 , 176	41-50	71-80	
329.003.00077	SC	01MAR95	-5 , -64	41-50	41-50	
329.003.00081	SC	04DEC95	-7 , .	41-50	41-50	
329.003.00087	SC	23JAN95	-8 , .	41-50	41-50	
329.003.00089	SC	24FEB95	-11 , .	41-50	41-50	
329.003.00091	SC	14MAR95	-10 , -64	51-60	51-60	
	32	07NOV95	229 , 175	61-70	61-70	
329.003.00248	SC	14FEB96	-16 , .	41-50	41-50	
329.003.00250	SC	05MAR96	-9 , -66	41-50	41-50	
329.003.00292	SC	02AUG96	-5 , -63	51-60	51-60	
329.003.00313	SC	08MAY96	-9 , .	41-50	41-50	
329.004.00015	SC	30NOV94	-8 , -65	51-60	51-60	
	28	14JUN95	189 , 132	41-50	71-80	
329.004.00017	SC	15MAR95	-7 , -63	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PAROXETINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.004.00017	32	01NOV95	225 ,169	41-50	71-80	
329.004.00019	SC	24MAY95	-7 , .	51-60	51-60	
329.004.00212	SC	24MAY96	-10 , .	21-30	31-40	
329.004.00214	SC	27SEP96	-7 , -67	51-60	51-60	
329.005.00002	SC	20MAY94	-5 , -61	41-50	51-60	
329.005.00004	SC	22SEP94	-18 , -77	51-60	51-60	
329.005.00008	SC	10NOV94	-6 , -61	51-60	51-60	
	24	10MAY95	176 ,121	51-60	71-80	
329.005.00011	SC	06DEC94	-7 , -63	51-60	51-60	
329.005.00109	SC	22DEC94	-8 , -61	61-70	41-50	
329.005.00112	SC	17JAN95	-9 , -64	81-90	51-60	
329.005.00116	SC	30JAN95	-8 , -66	71-80	51-60	
	24	26JUL95	170 ,112	51-60	51-60	
329.005.00119	SC	27JUN95	-14 , -73	51-60	51-60	
	24	02JAN96	176 ,117	51-60	51-60	
329.005.00151	SC	29AUG95	-8 , -65	51-60	51-60	
	32	01MAY96	239 ,182	51-60	71-80	
329.005.00152	SC	12OCT95	-14 , .	41-50	51-60	

\* days relative to start of acute phase, days relative to start of continuation phase

63

CONFIDENTIAL

BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
 Appendix B.4  
 Listing of C-GAS Scores by Treatment Group  
 Intent-to-Treat Population

Treatment = PAROXETINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.005.00257	SC 32	05MAR96 21OCT96	-6 , -62 225 , 169	41-50 91-100	41-50	.
329.005.00258	SC	06FEB96	-35 , .	51-60	51-60	
329.005.00299	SC 20	28MAY96 05NOV96	-11 , -71 151 , 91	51-60 51-60	51-60 51-60	
329.005.00300	SC	12SEP96	-7 , .	51-60	51-60	
329.005.00333	SC	15JAN97	-8 , .	51-60	51-60	
329.005.00336	SC	26FEB97	-6 , .	71-80	51-60	
329.006.00038	SC	01FEB95	-14 , .	61-70	61-70	
329.006.00039	SC	03FEB95	-5 , -66	41-50	41-50	
329.006.00260	SC	12JUL96	-6 , -64	51-60	51-60	
329.006.00261	SC	07NOV96	-19 , -77	31-40	41-50	
329.007.00140	SC	07SEP95	-8 , -63	41-50	41-50	
329.007.00142	SC	12OCT95	-6 , .	41-50	41-50	
329.007.00145	SC 32	04JAN96 23AUG96	-7 , -63 226 , 170	41-50 .	41-50 81-90	
329.007.00265	SC	25JAN96	-7 , .	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

64

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
 Appendix B.4  
 Listing of C-GAS Scores by Treatment Group  
 Intent-to-Treat Population

Treatment = PAROXETINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.007.00268	SC 32	21MAR96 05DEC96	-11 , -70 249 , 190	41-50 71-80	41-50 71-80	
329.007.00294	SC	20FEB97	-8 , .	41-50	41-50	
329.007.00309	SC 32	02JUL96 13MAR97	-13 , -65 242 , 190	41-50 .	41-50 71-80	
329.007.00310	SC 32	19SEP96 12JUN97	-7 , -67 260 , 200	41-50 .	41-50 91-100	
329.007.00318	SC	22NOV96	-10 , .	41-50	41-50	
329.008.00157	SC	16AUG95	-14 , -69	41-50	41-50	
329.008.00160	SC 32	25OCT95 23JUL96	-7 , -73 266 , 200	51-60 81-90	51-60 81-90	
329.008.00188	SC	14DEC95	-21 , .	41-50	41-50	
329.008.00271	SC 32	25JAN96 05NOV96	-46 , *** 240 , 176	41-50 .	51-60 71-80	
329.008.00275	SC 32	30APR96 16DEC96	-8 , -63 223 , 168	41-50 .	41-50 81-90	
329.009.00130	SC	12APR95	-6 , -62	41-50	41-50	
329.009.00131	SC	26APR95	-6 , -62	31-40	41-50	
329.009.00133	SC	07JUN95	-6 , .	31-40	31-40	

\* days relative to start of acute phase, days relative to start of continuation phase

65

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PAROXETINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.009.00138	SC	02OCT95	-8 , .	41-50	41-50	
329.009.00170	SC	26OCT95	-12 , -69	41-50	41-50	
	32	24JUN96	231 , 174	41-50	71-80	
329.009.00173	SC	08NOV95	-12 , -75	31-40	31-40	
329.009.00193	SC	21NOV95	-7 , .	31-40	31-40	
329.009.00196	SC	11DEC95	-7 , .	51-60	51-60	
329.009.00201	SC	31JAN96	-6 , .	31-40	31-40	
329.009.00204	SC	13MAR96	-6 , -62	41-50	41-50	
329.009.00235	SC	10DEC96	-8 , -62	41-50	41-50	
	16	14APR97	118 , 64	51-60	51-60	
329.009.00240	SC	03JAN97	-11 , .	41-50	41-50	
329.009.00303	SC	25MAR96	-8 , -64	41-50	41-50	
	32	10DEC96	253 , 197	81-90	81-90	
329.009.00304	SC	03APR96	-6 , -62	31-40	31-40	
329.009.00324	SC	21OCT96	-7 , .	41-50	41-50	
329.009.00328	SC	30SEP96	-7 , .	41-50	41-50	
329.009.00329	SC	01OCT96	-8 , .	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

66

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PAROXETINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.010.00182	SC	05DEC95	-14 , .	31-40	31-40	
329.010.00278	SC	02FEB96	-7 , -63	41-50	41-50	
	32	19SEP96	224 , 168	41-50	81-90	
329.010.00280	SC	10MAY96	-7 , -62	41-50	41-50	
	12	21AUG96	97 , 42	41-50	41-50	
329.011.00283	SC	30JAN96	-9 , -66	41-50	41-50	
329.011.00288	SC	01JUL96	-24 , .	41-50	41-50	
329.012.00025	SC	17OCT95	-7 , .	31-40	31-40	
329.012.00220	SC	04JUN96	-13 , -73	31-40	31-40	
329.012.00222	SC	18JUN96	-10 , -73	21-30	31-40	
329.012.00226	SC	26NOV96	-7 , .	41-50	41-50	
329.012.00228	SC	04MAR97	-15 , .	41-50	41-50	
329.012.00231	SC	26FEB97	-9 , -70	51-60	41-50	
	24	19AUG97	166 , 105	.	61-70	

\* days relative to start of acute phase, days relative to start of continuation phase

67

CONFIDENTIAL

BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = IMIPRAMINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.001.00061	SC	19JUL94	-10 , .	31-40	31-40	
329.001.00066	SC	14NOV94	-8 , .	41-50	41-50	
329.001.00067	SC	15NOV94	-7 , .	31-40	31-40	
329.001.00070	SC	14FEB95	-8 , .	31-40	31-40	
329.001.00122	SC	13JUN95	-7 , -64	31-40	31-40	
329.002.00050	SC	10MAR95	-13 , .	31-40	31-40	
329.002.00056	SC	24JUN94	-25 , .	51-60	51-60	
329.002.00057	SC	11AUG94	-28 , -85	31-40	31-40	
329.002.00098	SC	03JAN95	1 , .	51-60	51-60	
329.002.00100	SC 16	16FEB95 06JUL95	-19 , -77 122 , 64	51-60	51-60 41-50	
329.002.00103	SC 16	11APR95 10AUG95	-9 , -65 113 , 57	51-60 71-80	51-60 61-70	
329.002.00104	SC 32	28APR95 02JAN96	-6 , -62 244 , 188	51-60 61-70	51-60 81-90	
329.002.00243	SC	27FEB96	-16 , .	51-60	51-60	
329.002.00244	SC	14MAR96	-7 , -64	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

68

CONFIDENTIAL

BRL-029060-329-  
individual-data



Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = IMIPRAMINE					
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks
329.002.00321	SC	15MAY96	-8 , .	51-60	51-60
329.002.00322	SC	06JAN97	-3 , .	51-60	51-60
329.003.00073	SC	11JAN95	-8 , .	31-40	31-40
329.003.00076	SC	24JAN95	-7 , -62	41-50	41-50
	32	11OCT95	254 , 199	71-80	71-80
329.003.00079	SC	14APR95	-19 , .	41-50	41-50
329.003.00088	SC	06FEB95	-22 , .	41-50	41-50
329.003.00090	SC	08MAR95	-6 , .	41-50	41-50
329.003.00092	SC	13APR95	-20 , -78	51-60	51-60
	32	02JAN96	245 , 187	71-80	71-80
329.003.00093	SC	08JUN95	-13 , -76	41-50	41-50
	16	03OCT95	105 , 42	71-80	71-80
329.003.00247	SC	05JAN96	-27 , -81	41-50	41-50
329.003.00249	SC	01MAR96	-6 , .	31-40	31-40
329.003.00289	SC	12FEB96	-16 , -72	31-40	31-40
	32	11OCT96	227 , 171	71-80	71-80
329.003.00290	SC	06MAR96	-5 , .	41-50	41-50
329.003.00317	SC	12DEC96	-7 , .	41-50	41-50

\* days relative to start of acute phase, days relative to start of continuation phase

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = IMIPRAMINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.004.00013	SC 32	05JUL94 10MAR95	-14 , -73 235 , 176	51-60	51-60 91-100	
329.004.00014	SC	22NOV94	-7 , .	41-50	41-50	
329.004.00211	SC	24JAN96	-9 , .	31-40	31-40	
329.004.00215	SC	12MAR97	-8 , .	31-40	41-50	
329.005.00003	SC	12SEP94	-8 , .	41-50	31-40	
329.005.00006	SC	27OCT94	-8 , -68	71-80	51-60	
329.005.00007	SC	02NOV94	-7 , -70	51-60	41-50	
329.005.00009	SC	07DEC94	-5 , .	51-60	51-60	
329.005.00110	SC	04JAN95	-7 , .	51-60	41-50	
329.005.00113	SC	20JAN95	-10 , .	51-60	31-40	
329.005.00117	SC	06MAR95	-12 , .	51-60	51-60	
329.005.00118	SC	09MAY95	-8 , .	51-60	41-50	
329.005.00153	SC 32	11JAN96 04SEP96	-14 , -70 224 , 168	41-50 41-50	41-50 81-90	
329.005.00255	SC	26FEB96	-7 , .	51-60	51-60	
329.005.00256	SC	20FEB96	-14 , -70	51-60	51-60	

\* days relative to start of acute phase, days relative to start of continuation phase

70

CONFIDENTIAL

BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
 Appendix B.4  
 Listing of C-GAS Scores by Treatment Group  
 Intent-to-Treat Population

Treatment = IMIPRAMINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.005.00256	16	02JUL96	120 , 64	51-60	61-70	
329.005.00295	SC	21MAR96	-7 , .	51-60	41-50	
329.005.00297	SC	28MAR96	-22 , .	51-60	41-50	
329.005.00332	SC	05DEC96	-7 , .	41-50	41-50	
329.005.00335	SC	20FEB97	-8 , .	61-70	51-60	
329.006.00040	SC	10FEB95	-6 , .	51-60	51-60	
329.006.00041	SC	22MAR95	-14 , -78	61-70	61-70	
	32	21NOV95	231 , 167	71-80	71-80	
329.007.00139	SC	04MAY95	-4 , .	41-50	41-50	
329.007.00143	SC	26OCT95	-14 , .	31-40	31-40	
329.007.00146	SC	18JAN96	-7 , -60	41-50	41-50	
	32	09SEP96	229 , 176	71-80	71-80	
329.007.00269	SC	04APR96	-7 , .	31-40	31-40	
329.007.00270	SC	02MAY96	-7 , .	41-50	41-50	
329.007.00307	SC	09MAY96	-7 , .	41-50	41-50	
329.007.00308	SC	27JUN96	-5 , .	41-50	41-50	
329.008.00159	SC	06SEP95	-7 , -69	41-50	51-60	

\* days relative to start of acute phase, days relative to start of continuation phase

71

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

---

Treatment = IMIPRAMINE

Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks
329.008.00161	SC	31OCT95	-16 , -71	51-60	51-60
329.008.00187	SC	15NOV95	-14 , .	41-50	41-50
329.008.00192	SC	14FEB96	-20 , .	51-60	41-50
329.008.00272	SC	19MAR96	-15 , -71	41-50	41-50
329.008.00273	SC	19APR96	-28 , -91	61-70	61-70
329.009.00127	SC	03APR95	-7 , .	31-40	51-60
329.009.00132	SC	17MAY95	-6 , -63	41-50	41-50
329.009.00134	SC	28JUN95	-8 , .	41-50	41-50
329.009.00137	SC	03OCT95	-7 , .	31-40	31-40
329.009.00171	SC	31OCT95	-7 , .	41-50	41-50
329.009.00172	SC 32	06NOV95 08JUL96	-7 , -64 239 , 182	41-50 41-50	41-50 71-80
329.009.00194	SC	28NOV95	-7 , -63	41-50	41-50
329.009.00195	SC	06DEC95	-9 , .	41-50	41-50
329.009.00199	SC	10JAN96	-6 , .	31-40	41-50
329.009.00203	SC	28FEB96	-5 , .	41-50	41-50

---

\* days relative to start of acute phase, days relative to start of continuation phase

72

**CONFIDENTIAL**  
BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
 Appendix B.4  
 Listing of C-GAS Scores by Treatment Group  
 Intent-to-Treat Population

Treatment = IMIPRAMINE						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.009.00236	SC	17DEC96	-13 , .	41-50	41-50	
329.009.00239	SC	11NOV96	-8 , -65	41-50	41-50	
329.009.00262	SC	07FEB97	-10 , .	41-50	41-50	
329.009.00264	SC	25OCT96	-7 , .	41-50	41-50	
329.009.00301	SC	06MAR96	-13 , -69	31-40	41-50	
329.009.00305	SC 32	01MAY96 10JAN97	-6 , -63 249 , 192	41-50 81-90	41-50 81-90	
329.009.00325	SC 16	21AUG96 16DEC96	-6 , -61 112 , 57	41-50 41-50	41-50 41-50	
329.009.00326	SC 16	26AUG96 16DEC96	-10 , -63 103 , 50	41-50 41-50	41-50 41-50	
329.010.00279	SC 32	08MAR96 06NOV96	-14 , -70 230 , 174	31-40 31-40	41-50 61-70	
329.010.00281	SC 24	19JUL96 03JAN97	-7 , -68 162 , 101	41-50 41-50	41-50 41-50	
329.011.00163	SC	18NOV95	-7 , .	41-50	41-50	
329.011.00208	SC	22AUG96	-15 , -74	51-60	51-60	
329.011.00209	SC	23AUG96	-19 , -81	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

73

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

---

Treatment = IMIPRAMINE

Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks
329.011.00284	SC	13MAR96	-9 , -65	41-50	41-50
329.011.00286	SC	15MAY96	-22 , -90	51-60	51-60
329.012.00026	SC	09NOV95	-19 , .	41-50	41-50
329.012.00219	SC	24MAY96	-7 , -67	31-40	41-50
	32	24JAN97	239 , 179	.	71-80
329.012.00221	SC	18JUN96	-7 , -70	21-30	31-40
329.012.00223	SC	23AUG96	-7 , .	41-50	51-60
329.012.00227	SC	12DEC96	-6 , -75	61-70	61-70
	32	19AUG97	245 , 176	.	71-80
329.012.00230	SC	20FEB97	-8 , -77	41-50	51-60

---

\* days relative to start of acute phase, days relative to start of continuation phase

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PLACEBO						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.001.00062	SC	06OCT94	-14 , .	31-40	31-40	
329.001.00064	SC	04NOV94	-6 , -60	41-50	41-50	
329.001.00069	SC	07FEB95	-9 , .	31-40	31-40	
329.001.00071	SC	02FEB95	-21 , .	31-40	31-40	
329.001.00123	SC	14DEC95	-21 , .	31-40	31-40	
329.001.00207	SC	19FEB96	-9 , .	41-50	41-50	
329.002.00049	SC	03MAR95	-6 , .	41-50	41-50	
329.002.00059	SC	03NOV94	-7 , .	51-60	51-60	
329.002.00060	SC	24JAN95	-7 , -63	51-60	51-60	
329.002.00097	SC 32	20DEC94 05SEP95	-14 , -72 246 , 188	51-60 61-70	51-60 61-70	
329.002.00101	SC	20MAR95	-8 , -66	51-60	51-60	
329.002.00107	SC 32	18JAN96 26SEP96	-7 , -63 246 , 190	41-50 61-70	41-50 81-90	
329.002.00241	SC	25JAN96	-12 , -68	51-60	61-70	
329.002.00246	SC	01APR96	-17 , .	51-60	51-60	
329.002.00320	SC	09MAY96	-7 , -68	51-60	51-60	

\* days relative to start of acute phase, days relative to start of continuation phase

75

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PLACEBO						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.002.00323	SC 32	04NOV96 12JUN97	-8 , -66 213 , 155	61-70 61-70	61-70 71-80	
329.003.00074	SC 32	18JAN95 11OCT95	-7 , -63 260 , 204	41-50 41-50	41-50 61-70	
329.003.00078	SC	11APR95	-15 , .	51-60	51-60	
329.003.00080	SC	27NOV95	1 , .	41-50	41-50	
329.003.00085	SC	26OCT94	-13 , .	41-50	41-50	
329.003.00086	SC 32	09NOV94 17AUG95	-19 , -76 263 , 206	41-50 .	41-50 71-80	
329.003.00094	SC	20OCT95	-4 , .	41-50	41-50	
329.003.00251	SC	19MAR96	-9 , .	31-40	31-40	
329.003.00252	SC	19MAR96	-22 , .	41-50	41-50	
329.003.00291	SC	01JUL96	-2 , -67	41-50	41-50	
329.003.00315	SC	29OCT96	-14 , .	41-50	41-50	
329.003.00316	SC	05DEC96	-12 , .	41-50	41-50	
329.004.00016	SC	01MAR95	-12 , .	51-60	51-60	
329.004.00018	SC	19APR95	-14 , .	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

76

CONFIDENTIAL  
BRL-029060-329-  
individual-data



Paroxetine - Protocol 329  
 Appendix B.4  
 Listing of C-GAS Scores by Treatment Group  
 Intent-to-Treat Population

Treatment = PLACEBO						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.004.00020	SC	02NOV95	-7 , .	31-40	31-40	
329.004.00213	SC	18JUL96	-15 , -69	51-60	41-50	
	32	19MAR97	230 , 176	41-50	71-80	
329.005.00001	SC	11APR94	-9 , .	41-50	41-50	
329.005.00005	SC	24OCT94	-8 , .	51-60	51-60	
329.005.00010	SC	07DEC94	-6 , -63	51-60	41-50	
	32	09AUG95	240 , 183	61-70	91-100	
329.005.00012	SC	12DEC94	-7 , -66	61-70	51-60	
329.005.00111	SC	05JAN95	-6 , -62	51-60	41-50	
329.005.00114	SC	23JAN95	-8 , -65	51-60	41-50	
329.005.00115	SC	27JAN95	-10 , -81	51-60	51-60	
329.005.00120	SC	22AUG95	-8 , .	51-60	51-60	
329.005.00253	SC	31JAN96	-8 , .	51-60	51-60	
329.005.00254	SC	08FEB96	-7 , -62	51-60	41-50	
	32	16OCT96	245 , 190	51-60	81-90	
329.005.00293	SC	06MAR97	-6 , .	51-60	41-50	
329.005.00298	SC	15MAY96	-7 , -63	51-60	41-50	
	32	13JAN97	237 , 181	51-60	81-90	

\* days relative to start of acute phase, days relative to start of continuation phase

77

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PLACEBO						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.005.00331	SC	14NOV96	-7 , .	51-60	41-50	
329.005.00334	SC	24JAN97	-7 , .	51-60	51-60	
329.006.00037	SC	20JAN95	-8 , .	61-70	61-70	
329.006.00042	SC	01DEC95	-6 , -63	61-70	51-60	
	32	16JUL96	223 , 166	61-70	71-80	
329.006.00259	SC	22APR96	-32 , .	51-60	51-60	
329.007.00141	SC	14SEP95	-7 , .	41-50	41-50	
329.007.00144	SC	30NOV95	-7 , -63	41-50	41-50	
329.007.00266	SC	29FEB96	-7 , .	41-50	41-50	
329.007.00267	SC	29FEB96	-7 , .	41-50	41-50	
329.007.00311	SC	26SEP96	-7 , -67	41-50	41-50	
329.008.00158	SC	06SEP95	-7 , -69	41-50	41-50	
329.008.00162	SC	26OCT95	-6 , -71	41-50	41-50	
	32	02JUL96	245 , 180	71-80	71-80	
329.008.00191	SC	12JAN96	-20 , -81	41-50	41-50	
329.009.00128	SC	05APR95	-6 , .	41-50	51-60	
329.009.00129	SC	22MAR95	-20 , .	41-50	51-60	

\* days relative to start of acute phase, days relative to start of continuation phase

78

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PLACEBO						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.009.00135	SC	25SEP95	-7 , .	21-30	21-30	
329.009.00136	SC	26SEP95	-7 , .	41-50	41-50	
329.009.00169	SC	25OCT95	-6 , -71	41-50	41-50	
329.009.00174	SC	14NOV95	-7 , -64	31-40	31-40	
329.009.00197	SC	20DEC95	-9 , -63	41-50	41-50	
	32	20AUG96	236 , 182	41-50	81-90	
329.009.00198	SC	19DEC95	-14 , .	41-50	41-50	
329.009.00200	SC	17JAN96	-6 , .	31-40	31-40	
329.009.00202	SC	14FEB96	-6 , .	31-40	41-50	
329.009.00237	SC	04NOV96	-7 , .	41-50	41-50	
329.009.00238	SC	28OCT96	-15 , .	51-60	51-60	
329.009.00276	SC	17JAN97	-4 , .	41-50	41-50	
329.009.00302	SC	20MAR96	-7 , .	41-50	41-50	
329.009.00306	SC	03JUN96	-8 , .	31-40	31-40	
329.009.00312	SC	30OCT96	-5 , .	41-50	41-50	
329.009.00327	SC	09SEP96	-7 , .	41-50	41-50	

\* days relative to start of acute phase, days relative to start of continuation phase

Paroxetine - Protocol 329  
Appendix B.4  
Listing of C-GAS Scores by Treatment Group  
Intent-to-Treat Population

Treatment = PLACEBO						
Patient ID	Week	Date	Relative Days*	----- Q1 ----- Current Episode	----- Q2 ----- Last 2 Weeks	
329.009.00330	SC	15OCT96	-6 , .	41-50	41-50	
329.010.00183	SC	21NOV95	-12 , .	41-50	41-50	
329.010.00263	SC	24JUL96	-16 , .	51-60	51-60	
329.010.00277	SC 24	23FEB96 07AUG96	-7 , -63 160 , 104	41-50 81-90	41-50 81-90	
329.010.00282	SC	19JUL96	-7 , .	51-60	51-60	
329.011.00164	SC	15DEC95	-7 , .	31-40	31-40	
329.011.00210	SC	13SEP96	-15 , -81	51-60	51-60	
329.011.00285	SC	08MAY96	-10 , .	41-50	41-50	
329.011.00287	SC	25JUN96	-8 , .	51-60	51-60	
329.012.00027	SC	23NOV95	-13 , .	41-50	31-40	
329.012.00217	SC	14MAY96	-7 , .	21-30	31-40	
329.012.00218	SC	04JUN96	-12 , -70	31-40	31-40	
329.012.00224	SC	30AUG96	-17 , -83	21-30	31-40	
329.012.00225	SC 32	19NOV96 30JUL97	-7 , -71 247 , 183	41-50 .	41-50 91-100	

\* days relative to start of acute phase, days relative to start of continuation phase

80

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.001.00063	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.001.00065	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.001.00068	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.001.00072	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.001.00121	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Junior College (A.A.)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.001.00205	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.001.00206	Graduated JHS	Dropped out of JHS	Skilled manual employees	Unskilled employees
329.002.00055	Dropped out of HS	Received G.E.D.	Unskilled employees	Unskilled employees
329.002.00058	Dropped out of HS	Graduated JHS	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.002.00099	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.002.00102	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Not relevant (e.g., was never employed)

81

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.002.00105	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Skilled manual employees
329.002.00106	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.002.00242	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.002.00245	Graduated HS (do not count G.E.D.)	Received G.E.D.	Skilled manual employees	Skilled manual employees
329.002.00319	Dropped out of College	Graduated HS (do not count G.E.D.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.003.00077	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Not relevant (e.g., was never employed)
329.003.00081		Dropped out of JHS		Not relevant (e.g., was never employed)
329.003.00087	Dropped out of HS	Dropped out of College	Machine operators, semi-skilled employees	Business managers in large concerns, proprietors of medium-sized businesses
329.003.00089	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Business managers in large concerns, proprietors of medium-sized businesses	Higher executive, proprietors of large concerns, major professionals
329.003.00091	Dropped out of College	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.003.00248	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Unskilled employees

82

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.003.00250	Graduated Junior College (A.A.)	Dropped out of College	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.003.00292	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.003.00313	Graduated JHS	Graduated JHS	Unskilled employees	Unskilled employees
329.004.00015	Graduated HS (do not count G.E.D.)	Dropped out of College	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.004.00017	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Doctoral, Medical, Law or Comparable Degree	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.004.00019			Unskilled employees	Administrative personnel, owners of small independent businesses
329.004.00212		Dropped out of HS		Unskilled employees
329.004.00214	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.005.00002	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.005.00004	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.005.00008	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Machine operators, semi-skilled employees

83

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.005.00011	Completed Doctoral, Medical, Law or Comparable Degree	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.005.00109	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Unskilled employees
329.005.00112	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Not relevant (e.g., was never employed)	Not relevant (e.g., was never employed)
329.005.00116	Dropped out of College	Graduated Senior College (B.A., B.S., B.F.A., etc)	Unskilled employees	Administrative personnel, owners of small independent businesses
329.005.00119	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals
329.005.00151	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Skilled manual employees	Machine operators, semi-skilled employees
329.005.00152	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Clerical and sales workers, technicians, owners of little businesses
329.005.00257	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.005.00258	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.005.00299	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.005.00300	Graduated HS (do not count G.E.D.)	Graduated JHS	Not relevant (e.g., was never employed)	Not relevant (e.g., was never employed)

84

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.005.00333	Completed Doctoral, Medical, Law or Comparable Degree	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.005.00336	Graduated HS (do not count G.E.D.)	Graduated JHS	Skilled manual employees	Not relevant (e.g., was never employed)
329.006.00038	Dropped out of JHS	Graduated HS (do not count G.E.D.)	Skilled manual employees	Skilled manual employees
329.006.00039	Completed Doctoral, Medical, Law or Comparable Degree	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals
329.006.00260	Graduated HS (do not count G.E.D.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Administrative personnel, owners of small independent businesses	Higher executive, proprietors of large concerns, major professionals
329.006.00261	Dropped out of JHS	Dropped out of JHS	Skilled manual employees	Unskilled employees
329.007.00140	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.007.00142	Dropped out of College	Dropped out of College	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.007.00145	Dropped out of HS	Dropped out of HS	Machine operators, semi-skilled employees	Machine operators, semi-skilled employees
329.007.00265	Dropped out of HS	Dropped out of HS	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.007.00268	Dropped out of College	Dropped out of College	Skilled manual employees	Administrative personnel, owners of small independent businesses

85

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.007.00294	Graduated HS (do not count G.E.D.)	Dropped out of College	Not relevant (e.g., was never employed)	Administrative personnel, owners of small independent businesses
329.007.00309	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.007.00310	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.007.00318	Dropped out of College	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.008.00157	Graduated Junior College (A.A.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.008.00160	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Clerical and sales workers, technicians, owners of little businesses
329.008.00188	Graduated JHS	Graduated JHS	Skilled manual employees	Skilled manual employees
329.008.00271	Graduated Junior College (A.A.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.008.00275	Completed Doctoral, Medical, Law or Comparable Degree	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals
329.009.00130	Dropped out of College	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.009.00131	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Junior College (A.A.)	Higher executive, proprietors of large concerns, major professionals	Administrative personnel, owners of small independent businesses

86

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.009.00133		Dropped out of College		Clerical and sales workers, technicians, owners of little businesses
329.009.00138	Received G.E.D.	Graduated HS (do not count G.E.D.)	Not relevant (e.g., was never employed)	Skilled manual employees
329.009.00170	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Not relevant (e.g., was never employed)	Business managers in large concerns, proprietors of medium-sized businesses
329.009.00173	Graduated Junior College (A.A.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Not relevant (e.g., was never employed)	Clerical and sales workers, technicians, owners of little businesses
329.009.00193	Graduated HS (do not count G.E.D.)	Dropped out of HS	Unskilled employees	Not relevant (e.g., was never employed)
329.009.00196	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00201	Graduated HS (do not count G.E.D.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Clerical and sales workers, technicians, owners of little businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.009.00204	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Machine operators, semi-skilled employees
329.009.00235	Graduated JHS	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Machine operators, semi-skilled employees
329.009.00240	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00303	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Higher executive, proprietors of large concerns, major professionals	Business managers in large concerns, proprietors of medium-sized businesses

87

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.009.00304	Graduated HS (do not count G.E.D.)	Dropped out of HS	Clerical and sales workers, technicians, owners of little businesses	Not relevant (e.g., was never employed)
329.009.00324	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.009.00328	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Machine operators, semi-skilled employees
329.009.00329	Received G.E.D.	Dropped out of College	Machine operators, semi-skilled employees	Not relevant (e.g., was never employed)
329.010.00182	Completed Doctoral, Medical, Law or Comparable Degree	Completed Doctoral, Medical, Law or Comparable Degree	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals
329.010.00278	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.010.00280	Graduated JHS	Received G.E.D.	Not relevant (e.g., was never employed)	Not relevant (e.g., was never employed)
329.011.00283	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Business managers in large concerns, proprietors of medium-sized businesses
329.011.00288	Graduated HS (do not count G.E.D.)	Dropped out of College	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.012.00025	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.012.00220	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses

88

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.012.00222	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.012.00226	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.012.00228	Dropped out of JHS	Dropped out of HS	Machine operators, semi-skilled employees	Unskilled employees
329.012.00231	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
 Intent-to-Treat Population

-----  
 ----- Treatment Group=IMIPRAMINE -----  
 -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.001.00061	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.001.00066	Completed Doctoral, Medical, Law or Comparable Degree	Graduated Senior College (B.A., B.S., B.F.A., etc)	Unskilled employees	Administrative personnel, owners of small independent businesses
329.001.00067	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Unskilled employees
329.001.00070	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.001.00122	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.002.00050	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.002.00056	Dropped out of College	Graduated HS (do not count G.E.D.)	Unskilled employees	Unskilled employees
329.002.00057	Graduated Senior College (B.A., B.S., B.F.A., etc)	Dropped out of College	Skilled manual employees	Skilled manual employees
329.002.00098	Dropped out of College	Dropped out of College	Administrative personnel, owners of small independent businesses	Not relevant (e.g., was never employed)
329.002.00100	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Unskilled employees
329.002.00103	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses

90

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.002.00104	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.002.00243	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.002.00244	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Business managers in large concerns, proprietors of medium-sized businesses
329.002.00321	Dropped out of HS	Dropped out of College	Machine operators, semi-skilled employees	Unskilled employees
329.002.00322	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Not relevant (e.g., was never employed)
329.003.00073	Graduated HS (do not count G.E.D.)	Dropped out of College	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.003.00076	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.003.00079		Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.003.00088	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.003.00090	Completed Doctoral, Medical, Law or Comparable Degree	Graduated Senior College (B.A., B.S., B.F.A., etc)	Higher executive, proprietors of large concerns, major professionals	Business managers in large concerns, proprietors of medium-sized businesses
329.003.00092	Graduated JHS	Graduated Junior College (A.A.)	Skilled manual employees	Higher executive, proprietors of large concerns, major professionals

91

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.003.00093	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.003.00247	Dropped out of College	Dropped out of College	Higher executive, proprietors of large concerns, major professionals	Administrative personnel, owners of small independent businesses
329.003.00249	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.003.00289	Received G.E.D.	Dropped out of HS	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.003.00290	Graduated JHS	Graduated JHS	Skilled manual employees	Not relevant (e.g., was never employed)
329.003.00314	Graduated HS (do not count G.E.D.)	Dropped out of College	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.003.00317	Graduated Junior College (A.A.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Skilled manual employees
329.004.00013	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.004.00014		Graduated Senior College (B.A., B.S., B.F.A., etc)		Administrative personnel, owners of small independent businesses
329.004.00211	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses

92

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
 Intent-to-Treat Population

-----  
 ----- Treatment Group=IMIPRAMINE -----  
 -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.004.00215	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Unskilled employees
329.005.00003	Graduated JHS	Graduated JHS	Not relevant (e.g., was never employed)	Not relevant (e.g., was never employed)
329.005.00006	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Not relevant (e.g., was never employed)
329.005.00007	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)		Clerical and sales workers, technicians, owners of little businesses
329.005.00009	Graduated Junior College (A.A.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals
329.005.00110	Graduated JHS	Graduated JHS	Unskilled employees	Not relevant (e.g., was never employed)
329.005.00113	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Not relevant (e.g., was never employed)	Unskilled employees
329.005.00117	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Unskilled employees
329.005.00118	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.005.00153	Graduated JHS	Graduated Senior College (B.A., B.S., B.F.A., etc)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.005.00255	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Doctoral, Medical, Law or Comparable Degree	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.005.00256	Graduated JHS	Graduated JHS	Unskilled employees	Unskilled employees

93

CONFIDENTIAL

BRL-029060-329-  
 individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.005.00295	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.005.00297	Completed Doctoral, Medical, Law or Comparable Degree	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.005.00332	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Not relevant (e.g., was never employed)
329.005.00335	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Not relevant (e.g., was never employed)
329.006.00040	Graduated JHS	Dropped out of College	Not relevant (e.g., was never employed)	Skilled manual employees
329.006.00041	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.007.00139	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)		Clerical and sales workers, technicians, owners of little businesses
329.007.00143		Graduated HS (do not count G.E.D.)		Clerical and sales workers, technicians, owners of little businesses
329.007.00146	Dropped out of College	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.007.00269	Dropped out of HS	Dropped out of College	Machine operators, semi-skilled employees	Machine operators, semi-skilled employees
329.007.00270	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses

94

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.007.00307	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.007.00308	Dropped out of College	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.008.00159	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.008.00161	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.008.00187		Graduated Junior College (A.A.)		Administrative personnel, owners of small independent businesses
329.008.00192	Graduated Junior College (A.A.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.008.00272	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Not relevant (e.g., was never employed)
329.008.00273	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.009.00127	Dropped out of JHS	Dropped out of HS	Unskilled employees	Unskilled employees
329.009.00132	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.009.00134	Dropped out of College	Graduated Senior College (B.A., B.S., B.F.A., etc)	Not relevant (e.g., was never employed)	Administrative personnel, owners of small independent businesses

95

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.009.00137	Received G.E.D.	Graduated HS (do not count G.E.D.)	Unskilled employees	Clerical and sales workers, technicians, owners of little businesses
329.009.00171	Received G.E.D.	Graduated HS (do not count G.E.D.)	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.009.00172	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated HS (do not count G.E.D.)	Higher executive, proprietors of large concerns, major professionals	Clerical and sales workers, technicians, owners of little businesses
329.009.00194	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.009.00195	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.009.00199	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Administrative personnel, owners of small independent businesses
329.009.00203	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.009.00236	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.009.00239	Dropped out of College	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00262	Graduated HS (do not count G.E.D.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Clerical and sales workers, technicians, owners of little businesses	Business managers in large concerns, proprietors of medium-sized businesses

96

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.009.00264	Dropped out of JHS	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.009.00301	Dropped out of College	Dropped out of College	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.009.00305	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Higher executive, proprietors of large concerns, major professionals	Administrative personnel, owners of small independent businesses
329.009.00325	Dropped out of HS	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.009.00326	Graduated HS (do not count G.E.D.)	Dropped out of College	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.010.00279	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Not relevant (e.g., was never employed)
329.010.00281	Graduated HS (do not count G.E.D.)	Dropped out of College	Business managers in large concerns, proprietors of medium-sized businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.011.00163	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.011.00208	Graduated HS (do not count G.E.D.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Administrative personnel, owners of small independent businesses	Business managers in large concerns, proprietors of medium-sized businesses
329.011.00209	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Machine operators, semi-skilled employees

97

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.011.00284	Completed Doctoral, Medical, Law or Comparable Degree	Graduated Junior College (A.A.)	Higher executive, proprietors of large concerns, major professionals	Business managers in large concerns, proprietors of medium-sized businesses
329.011.00286	Graduated Junior College (A.A.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.012.00026	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.012.00219	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.012.00221	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.012.00223	Graduated JHS	Graduated JHS	Unskilled employees	Unskilled employees
329.012.00227	Received G.E.D.	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.012.00230	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses

98

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.001.00062	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.001.00064	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.001.00069	Dropped out of College	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Clerical and sales workers, technicians, owners of little businesses	Administrative personnel, owners of small independent businesses
329.001.00071	Completed Doctoral, Medical, Law or Comparable Degree	Completed Doctoral, Medical, Law or Comparable Degree	Higher executive, proprietors of large concerns, major professionals	Business managers in large concerns, proprietors of medium-sized businesses
329.001.00123	Graduated HS (do not count G.E.D.)	Graduated JHS	Administrative personnel, owners of small independent businesses	Skilled manual employees
329.001.00207	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.002.00049	Completed Doctoral, Medical, Law or Comparable Degree	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	
329.002.00059	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.002.00060	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.002.00097	Dropped out of College	Dropped out of College	Administrative personnel, owners of small independent businesses	Not relevant (e.g., was never employed)

69

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.002.00101	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Not relevant (e.g., was never employed)
329.002.00107	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.002.00241	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.002.00246	Graduated HS (do not count G.E.D.)	Received G.E.D.	Machine operators, semi-skilled employees	Not relevant (e.g., was never employed)
329.002.00320	Graduated HS (do not count G.E.D.)	Dropped out of College	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.002.00323	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Machine operators, semi-skilled employees
329.003.00074	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Machine operators, semi-skilled employees
329.003.00078	Graduated JHS	Graduated Senior College (B.A., B.S., B.F.A., etc)	Skilled manual employees	Business managers in large concerns, proprietors of medium-sized businesses
329.003.00080			Business managers in large concerns, proprietors of medium-sized businesses	Not relevant (e.g., was never employed)
329.003.00085	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.003.00086	Received G.E.D.	Graduated Junior College (A.A.)	Skilled manual employees	Administrative personnel, owners of small independent businesses

100

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.003.00094	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.003.00252	Graduated HS (do not count G.E.D.)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Skilled manual employees	Business managers in large concerns, proprietors of medium-sized businesses
329.003.00291	Dropped out of JHS	Dropped out of JHS	Unskilled employees	Not relevant (e.g., was never employed)
329.003.00315	Dropped out of College	Graduated HS (do not count G.E.D.)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.003.00316	Received G.E.D.	Received G.E.D.	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.004.00016	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.004.00018	Dropped out of College	Dropped out of JHS	Clerical and sales workers, technicians, owners of little businesses	Machine operators, semi-skilled employees
329.004.00020	Dropped out of HS	Dropped out of College	Unskilled employees	Clerical and sales workers, technicians, owners of little businesses
329.004.00213	Dropped out of JHS	Dropped out of College	Machine operators, semi-skilled employees	Administrative personnel, owners of small independent businesses
329.005.00001	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Machine operators, semi-skilled employees
329.005.00005	Graduated JHS	Graduated Junior College (A.A.)	Not relevant (e.g., was never employed)	Unskilled employees

101

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
 Intent-to-Treat Population

-----  
 ----- Treatment Group=PLACEBO -----  
 -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.005.00010	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Unskilled employees
329.005.00012	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Administrative personnel, owners of small independent businesses
329.005.00111	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Skilled manual employees
329.005.00114	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.005.00115	Graduated HS (do not count G.E.D.)	Dropped out of HS	Skilled manual employees	Not relevant (e.g., was never employed)
329.005.00120	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.005.00253	Completed Doctoral, Medical, Law or Comparable Degree	Graduated Senior College (B.A., B.S., B.F.A., etc)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.005.00254	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Unskilled employees	Administrative personnel, owners of small independent businesses
329.005.00293	Graduated HS (do not count G.E.D.)	Graduated JHS	Skilled manual employees	Not relevant (e.g., was never employed)
329.005.00298	Graduated Junior College (A.A.)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.005.00331	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Not relevant (e.g., was never employed)	Clerical and sales workers, technicians, owners of little businesses

102

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.005.00334	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.006.00037	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Skilled manual employees
329.006.00042	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.006.00259	Completed Doctoral, Medical, Law or Comparable Degree	Graduated Senior College (B.A., B.S., B.F.A., etc)	Higher executive, proprietors of large concerns, major professionals	Administrative personnel, owners of small independent businesses
329.007.00141	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Administrative personnel, owners of small independent businesses
329.007.00144	Graduated JHS	Graduated JHS	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.007.00266	Dropped out of College	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Machine operators, semi-skilled employees
329.007.00267	Graduated HS (do not count G.E.D.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.007.00311	Dropped out of College	Graduated Junior College (A.A.)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.008.00158	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses

103

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.008.00162	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.008.00191	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Higher executive, proprietors of large concerns, major professionals	Higher executive, proprietors of large concerns, major professionals
329.009.00128	Graduated HS (do not count G.E.D.)	Dropped out of College	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00129	Graduated Junior College (A.A.)	Graduated Junior College (A.A.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.009.00135	Graduated Senior College (B.A., B.S., B.F.A., etc)	Dropped out of College	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00136	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Not relevant (e.g., was never employed)	Skilled manual employees
329.009.00169	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Not relevant (e.g., was never employed)	Not relevant (e.g., was never employed)
329.009.00174	Dropped out of College	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Not relevant (e.g., was never employed)
329.009.00197	Received G.E.D.	Dropped out of HS	Skilled manual employees	Machine operators, semi-skilled employees
329.009.00198	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00200	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses

104

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.009.00202	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Junior College (A.A.)	Business managers in large concerns, proprietors of medium-sized businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00237	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Not relevant (e.g., was never employed)
329.009.00238	Received G.E.D.	Dropped out of College	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.009.00276	Graduated HS (do not count G.E.D.)	Graduated JHS	Clerical and sales workers, technicians, owners of little businesses	Clerical and sales workers, technicians, owners of little businesses
329.009.00302	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Higher executive, proprietors of large concerns, major professionals	Administrative personnel, owners of small independent businesses
329.009.00306		Dropped out of HS	Not relevant (e.g., was never employed)	Not relevant (e.g., was never employed)
329.009.00312	Graduated Senior College (B.A., B.S., B.F.A., etc)	Dropped out of College	Clerical and sales workers, technicians, owners of little businesses	Not relevant (e.g., was never employed)
329.009.00327	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Junior College (A.A.)	Higher executive, proprietors of large concerns, major professionals	Administrative personnel, owners of small independent businesses
329.009.00330	Graduated JHS	Graduated JHS	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.010.00183	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses

105

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.010.00263	Graduated JHS	Graduated HS (do not count G.E.D.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.010.00277	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Skilled manual employees	Clerical and sales workers, technicians, owners of little businesses
329.010.00282	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Higher executive, proprietors of large concerns, major professionals	Clerical and sales workers, technicians, owners of little businesses
329.011.00164	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Skilled manual employees
329.011.00210	Dropped out of College	Received G.E.D.	Skilled manual employees	Not relevant (e.g., was never employed)
329.011.00285	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Machine operators, semi-skilled employees	Clerical and sales workers, technicians, owners of little businesses
329.011.00287	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Clerical and sales workers, technicians, owners of little businesses	Machine operators, semi-skilled employees
329.012.00027	Graduated HS (do not count G.E.D.)	Graduated Junior College (A.A.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.012.00217	Graduated HS (do not count G.E.D.)	Graduated HS (do not count G.E.D.)	Administrative personnel, owners of small independent businesses	Clerical and sales workers, technicians, owners of little businesses
329.012.00218	Graduated Senior College (B.A., B.S., B.F.A., etc)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Business managers in large concerns, proprietors of medium-sized businesses

106

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Highest Level of Education for Father	Highest Level of Education for Mother	Occupation for Father	Occupation for Mother
329.012.00224	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Graduated Senior College (B.A., B.S., B.F.A., etc)	Administrative personnel, owners of small independent businesses	Administrative personnel, owners of small independent businesses
329.012.00225	Graduated Senior College (B.A., B.S., B.F.A., etc)	Completed Masters Degree (M.A., M.S., M.S.W., etc.)	Administrative personnel, owners of small independent businesses	Business managers in large concerns, proprietors of medium-sized businesses

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.001.00063	2 parent home	6	Natural offspring	Regular education	
329.001.00065	1 parent & 1 step-parent	6	Natural offspring	Regular education	
329.001.00068	2 parent home	3	Natural offspring	Regular education	
329.001.00072	2 parent home	5	Natural offspring	Regular education	
329.001.00121	2 parent home	5	Natural offspring	Regular education	
329.001.00205	2 parent home	5	Natural offspring	Special education	LD CLASSES REMIDIAL SUPPORT
329.001.00206	2 parent home	4	Natural offspring	Regular education	
329.002.00055	Single parent alone	2	Natural offspring	Special education	FOR MILD TO MODERATE LEARNING DISABILITY
329.002.00058	Single parent alone	3	Natural offspring	Special education	ATTENTIONAL DIFFICULTIES
329.002.00099	Single parent alone	3	Natural offspring	Regular education	
329.002.00102	2 parent home	5	Natural offspring	Regular education	
329.002.00105	Single parent alone	3	Natural offspring	Regular education	
329.002.00106	2 parent home	4	Natural offspring	Regular education	
329.002.00242	2 parent home	4	Natural offspring	Regular education	
329.002.00245	Single parent alone	5	Natural offspring	Special education	BEHAVIORIAL&ACADEMIC DIFFICULTIES
329.002.00319	Single parent alone	4	Natural offspring	Regular education	
329.003.00077	Single parent alone	4	Natural offspring	Regular education	
329.003.00081	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.003.00087	2 parent home	3	Natural offspring	Regular education	

108

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.003.00089	2 parent home	3	Natural offspring	Regular education	
329.003.00091	Single parent alone	4	Natural offspring	Regular education	
329.003.00248	2 parent home	5	Natural offspring	Regular education	
329.003.00250	Single parent alone	3	Natural offspring	Regular education	
329.003.00292	2 parent home	4	Natural offspring	Regular education	
329.003.00313	2 parent home	4	Natural offspring	Regular education	
329.004.00015	Single parent alone	2	Natural offspring	Regular education	
329.004.00017	2 parent home	4	Natural offspring	Regular education	
329.004.00019	Other relative(s) is (are) caregiver(s)	2	Natural offspring	Regular education	
329.004.00212		1	Natural offspring	Regular education	
329.004.00214	2 parent home	4	Natural offspring	Regular education	
329.005.00002	2 parent home	3	Natural offspring	Regular education	
329.005.00004	Single parent alone	2	Natural offspring	Regular education	
329.005.00008	Single parent alone	3	Natural offspring	Regular education	
329.005.00011	2 parent home	4	Adopted	Regular education	
329.005.00109	Other relative(s) is (are) caregiver(s)	5	Natural offspring	Regular education	
329.005.00112	2 parent home	7	Natural offspring	Regular education	
329.005.00116	Other relative(s) is (are) caregiver(s)	6	Natural offspring	Regular education	
329.005.00119	1 parent & 1 step-parent	5	Natural offspring	Regular education	

109

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.005.00151	Single parent alone	3	Natural offspring	Regular education	
329.005.00152	Single parent alone	2	Natural offspring	Regular education	HONORS CLASSES
329.005.00257	2 parent home	4	Natural offspring	Regular education	
329.005.00258	Single parent alone	3	Natural offspring	Regular education	
329.005.00299	Single parent alone	3	Natural offspring	Regular education	
329.005.00300	Single parent alone	4	Natural offspring	Regular education	
329.005.00333	Single parent alone	2	Natural offspring	Special education	ADVANCED PLACEMENT
329.005.00336	Single parent alone	7	Natural offspring	Regular education	
329.006.00038	1 parent & 1 step-parent	6	Natural offspring	Regular education	
329.006.00039	2 parent home	3	Natural offspring	Regular education	ART SPECIALTY
329.006.00260	Single parent alone	3	Natural offspring	Regular education	
329.006.00261	2 parent home	7	Natural offspring	Regular education	
329.007.00140	Single parent alone	4	Natural offspring	Regular education	
329.007.00142	2 parent home	3	Natural offspring	Regular education	
329.007.00145	2 parent home	4	Natural offspring	Regular education	
329.007.00265	1 parent & 1 step-parent	6	Natural offspring	Regular education	
329.007.00268	Single parent alone	2	Natural offspring	Regular education	
329.007.00294	Single parent alone	3	Natural offspring	Regular education	
329.007.00309	Other relative(s) is (are) caregiver(s)	3	Natural offspring	Regular education	
329.007.00310	2 parent home	4	Natural offspring	Regular education	

110

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.007.00318	2 parent home	4	Natural offspring	Regular education	
329.008.00157	Single parent alone	2	Natural offspring	Regular education	
329.008.00160	Parent & other relative(s) are caregiver(s)	2	Natural offspring	Regular education	
329.008.00188	Single parent alone	4	Natural offspring	Regular education	
329.008.00271	2 parent home	4	Natural offspring	Regular education	3MOS AGO HOME SCHOOL-NOW COMBO.PUBLIC SC
329.008.00275	2 parent home	4	Natural offspring	Regular education	HE IS DISLEXIC
329.009.00130	2 parent home	6	Adopted	Regular education	
329.009.00131	2 parent home	4	Natural offspring	Regular education	
329.009.00133	Single parent alone	3	Natural offspring	Regular education	
329.009.00138	Single parent alone	2	Natural offspring	Regular education	
329.009.00170	Single parent alone	2	Natural offspring	Regular education	
329.009.00173	Single parent alone	5	Natural offspring	Regular education	
329.009.00193	Single parent alone	3	Natural offspring	Regular education	
329.009.00196	2 parent home	4	Natural offspring	Regular education	
329.009.00201	Single parent alone	3	Natural offspring	Regular education	
329.009.00204	2 parent home	7	Natural offspring	Special education	HERMAN READING PROGRAM
329.009.00235	2 parent home	4	Natural offspring	Regular education	
329.009.00240	2 parent home	5	Natural offspring	Regular education	
329.009.00303	2 parent home	4	Natural offspring	Regular education	

111

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.009.00304	2 parent home	7	Natural offspring	Regular education	
329.009.00324	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.009.00328	2 parent home	5	Natural offspring	Regular education	
329.009.00329	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.010.00182	2 parent home	5	Natural offspring	Regular education	
329.010.00278	2 parent home	3	Natural offspring	Regular education	
329.010.00280	Other relative(s) is (are) caregiver(s)	2	Natural offspring	Regular education	
329.011.00283	1 parent & 1 common-law parent	5	Natural offspring	Regular education	
329.011.00288	Single parent alone	4	Natural offspring	Special education	12:1:1
329.012.00025	2 parent home	4	Natural offspring	Regular education	
329.012.00220	2 parent home	5	Natural offspring	Regular education	
329.012.00222	Single parent alone	2	Natural offspring	Regular education	
329.012.00226	2 parent home	4	Adopted	Regular education	
329.012.00228	Single parent alone	3	Natural offspring	Regular education	
329.012.00231	1 parent & 1 common-law parent	4	Adopted	Regular education	

112

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.001.00061	Parent & other relative(s) are caregiver(s)	3	Natural offspring	Regular education	
329.001.00066	2 parent home	4	Natural offspring	Regular education	
329.001.00067	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.001.00070	2 parent home	3	Natural offspring	Regular education	
329.001.00122	2 parent home	7	Natural offspring	Regular education	
329.002.00050	Single parent alone	2	Natural offspring	Regular education	
329.002.00056	2 parent home	4	Natural offspring	Regular education	
329.002.00057	2 parent home	5	Natural offspring	Special education	MAINSTREAMED
329.002.00098	2 parent home	5	Natural offspring	Regular education	
329.002.00100	1 parent & 1 step-parent	4	Natural offspring	Special education	HAS INDIVIDUALIZED EDUCATION PLAN/MAINST
329.002.00103	2 parent home	4	Natural offspring	Regular education	
329.002.00104	2 parent home	5	Natural offspring	Regular education	
329.002.00243	Single parent alone	4	Natural offspring	Regular education	
329.002.00244	2 parent home	4	Natural offspring	Regular education	
329.002.00321	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.002.00322	1 parent & 1 step-parent	6	Natural offspring	Regular education	
329.003.00073	2 parent home	5	Natural offspring	Regular education	
329.003.00076	Single parent alone	2	Natural offspring	Regular education	
329.003.00079	Single parent alone	2	Natural offspring	Regular education	

113

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.003.00088	Single parent alone	2	Natural offspring	Regular education	
329.003.00090	2 parent home	5	Natural offspring	Regular education	
329.003.00092	Single parent alone	4	Natural offspring	Regular education	
329.003.00093	Single parent alone	3	Natural offspring	Regular education	
329.003.00247	1 parent & 1 step-parent	5	Natural offspring	Special education	EAC PORT WASHINGTON
329.003.00249	1 parent & 1 common-law parent	3	Natural offspring	Regular education	
329.003.00289	Single parent alone	3	Natural offspring	Regular education	
329.003.00290	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.003.00314	Parent & other relative(s) are caregiver(s)	5	Natural offspring	Regular education	
329.003.00317	2 parent home	4	Natural offspring	Regular education	
329.004.00013	2 parent home	5	Natural offspring	Regular education	
329.004.00014	Single parent alone	2	Natural offspring	Regular education	
329.004.00211	2 parent home	3	Natural offspring	Regular education	
329.004.00215	2 parent home	4	Natural offspring	Regular education	
329.005.00003	Other relative(s) is (are) caregiver(s)	3	Adopted	Regular education	
329.005.00006	2 parent home	3	Natural offspring	Regular education	NOTE:ALL ADVANCED PLACEMENT CLASSES
329.005.00007	Single parent alone	3	Natural offspring	Regular education	
329.005.00009	2 parent home	6	Natural offspring	Regular education	+1HONORS CLASS

114

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.005.00110	Other relative(s) is (are) caregiver(s)	3	Natural offspring	Regular education	
329.005.00113	Single parent alone	3	Natural offspring	Regular education	
329.005.00117	2 parent home	4	Natural offspring	Regular education	
329.005.00118	2 parent home	5	Natural offspring	Regular education	
329.005.00153	Single parent alone	2	Adopted	Special education	MOST CLASSES
329.005.00255	2 parent home	4	Natural offspring	Regular education	
329.005.00256	Single parent alone	4	Natural offspring	Regular education	
329.005.00295	2 parent home	3	Natural offspring	Regular education	
329.005.00297	2 parent home	4	Natural offspring	Special education	ENGLISH AND HISTORY - LEARNING DISABLED
329.005.00332	2 parent home	5	Natural offspring	Regular education	
329.005.00335	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.006.00040	2 parent home	3	Natural offspring	Special education	WILLOWPARK H.S.
329.006.00041	2 parent home	4	Natural offspring	Regular education	
329.007.00139	Single parent alone	3	Natural offspring	Regular education	
329.007.00143	Other relative(s) is (are) caregiver(s)	2	Natural offspring	Special education	EMOTIONALLY DISABLED
329.007.00146	2 parent home	3	Adopted	Regular education	
329.007.00269	Single parent alone	3	Natural offspring	Regular education	
329.007.00270	Single parent alone	4	Natural offspring	Regular education	
329.007.00307	2 parent home	5	Natural offspring	Regular education	

115

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.007.00308	2 parent home	5	Natural offspring	Regular education	
329.008.00159	Single parent alone	6	Natural offspring	Regular education	
329.008.00161	Single parent alone	3	Natural offspring	Regular education	
329.008.00187	Single parent alone	3	Natural offspring	Regular education	
329.008.00192	2 parent home	4	Natural offspring	Regular education	
329.008.00272	1 parent & 1 step-parent	6	Natural offspring	Regular education	
329.008.00273	1 parent & 1 common-law parent	3	Natural offspring	Regular education	
329.009.00127	Single parent alone	4	Natural offspring	Regular education	
329.009.00132	2 parent home	5	Adopted	Regular education	
329.009.00134	Single parent alone	2	Natural offspring	Regular education	
329.009.00137	Single parent alone	3	Natural offspring	Regular education	
329.009.00171	1 parent & 1 step-parent	6	Natural offspring		
329.009.00172	Single parent alone	2	Natural offspring	Regular education	
329.009.00194	Single parent alone	3	Natural offspring	Regular education	
329.009.00195	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.009.00199	Single parent alone	5	Natural offspring	Special education	CONTENT MASTERY
329.009.00203	1 parent & 1 step-parent	6	Natural offspring	Regular education	
329.009.00236	Single parent alone	2	Natural offspring	Regular education	
329.009.00239	2 parent home	3	Adopted	Regular education	
329.009.00262	1 parent & 1 step-parent	5	Natural offspring	Regular education	

116

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.009.00264	1 parent & 1 step-parent	3	Natural offspring	Special education	RESOURCE FOR EVERY CLASS EXCEPT BAND
329.009.00301	Single parent alone	3	Natural offspring	Regular education	
329.009.00305	2 parent home	5	Natural offspring	Regular education	
329.009.00325	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.009.00326	Single parent alone	3	Natural offspring	Regular education	
329.010.00279	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.010.00281	Single parent alone	5	Natural offspring	Special education	LD (READING & LANG. ARTS)
329.011.00163	2 parent home	7	Natural offspring	Special education	REGULAR CLASS WITH RESOURCE ROOM
329.011.00208	Single parent alone	2	Natural offspring	Regular education	
329.011.00209	2 parent home	4	Natural offspring	Regular education	
329.011.00284	2 parent home	5	Natural offspring	Regular education	
329.011.00286	2 parent home	5	Natural offspring	Regular education	
329.012.00026	Single parent alone	3	Natural offspring	Regular education	
329.012.00219	2 parent home	4	Natural offspring	Regular education	
329.012.00221	Single parent alone	5	Natural offspring	Regular education	
329.012.00223	Parent & other relative(s) are caregiver(s)	4	Natural offspring	Regular education	
329.012.00227	2 parent home	3	Natural offspring	Regular education	
329.012.00230	Single parent alone	4	Natural offspring	Regular education	

117

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.001.00062	1 parent & 1 common-law parent	3	Natural offspring	Regular education	
329.001.00064	2 parent home	4	Natural offspring	Regular education	
329.001.00069	1 parent & 1 step-parent	3	Natural offspring	Regular education	
329.001.00071	2 parent home	4	Natural offspring	Regular education	
329.001.00123	2 parent home	5	Natural offspring	Regular education	
329.001.00207	Single parent alone	4	Natural offspring	Regular education	
329.002.00049	2 parent home	3	Natural offspring	Regular education	
329.002.00059	Single parent alone	3	Natural offspring	Regular education	
329.002.00060	2 parent home	5	Natural offspring	Regular education	
329.002.00097	2 parent home	5	Natural offspring	Regular education	
329.002.00101	2 parent home	3	Natural offspring	Regular education	
329.002.00107	Single parent alone	3	Natural offspring	Regular education	
329.002.00241	2 parent home	4	Natural offspring	Regular education	
329.002.00246	Parent & other relative(s) are caregiver(s)	3	Natural offspring	Regular education	
329.002.00320	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.002.00323	2 parent home	4	Natural offspring	Regular education	
329.003.00074	Single parent alone	4	Natural offspring	Regular education	
329.003.00078	2 parent home	5	Natural offspring	Regular education	
329.003.00080	1 parent & 1 step-parent	3	Natural offspring	Regular education	

118

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.003.00085	2 parent home	5	Natural offspring	Regular education	
329.003.00086	2 parent home	5	Natural offspring	Regular education	
329.003.00094	2 parent home	3	Natural offspring	Regular education	
329.003.00252	Single parent alone	2	Natural offspring	Regular education	
329.003.00291	2 parent home	6	Natural offspring	Regular education	
329.003.00315	Single parent alone	4	Natural offspring	Regular education	
329.003.00316	2 parent home	6	Natural offspring	Regular education	
329.004.00016	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.004.00018	Single parent alone	3	Natural offspring	Regular education	
329.004.00020	2 parent home	4	Natural offspring	Regular education	
329.004.00213	2 parent home	4	Natural offspring	Regular education	
329.005.00001	Single parent alone	2	Natural offspring	Regular education	
329.005.00005	Single parent alone	4	Natural offspring	Regular education	
329.005.00010	2 parent home	8	Natural offspring	Regular education	
329.005.00012	2 parent home	4	Natural offspring	Regular education	
329.005.00111	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.005.00114	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.005.00115	2 parent home	4	Natural offspring	Regular education	
329.005.00120	Single parent alone	3	Natural offspring	Regular education	
329.005.00253	Single parent alone	4	Natural offspring	Regular education	

119

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.005.00254	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.005.00293	Single parent alone	7	Natural offspring	Regular education	
329.005.00298	Single parent alone	5	Natural offspring	Special education	"QUEST" - ACCELERATED CLASSES
329.005.00331	1 parent & 1 step-parent	4	Natural offspring	Special education	ADVANCED CLASSES
329.005.00334	2 parent home	4	Natural offspring	Regular education	
329.006.00037	2 parent home	4	Natural offspring	Regular education	
329.006.00042	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.006.00259	2 parent home	5	Natural offspring	Regular education	
329.007.00141	2 parent home	4	Natural offspring	Regular education	
329.007.00144	1 parent & 1 step-parent	3	Natural offspring	Regular education	
329.007.00266	2 parent home	4	Natural offspring	Regular education	
329.007.00267	2 parent home	3	Natural offspring	Regular education	
329.007.00311	2 parent home	4	Natural offspring	Regular education	
329.008.00158	Single parent alone	6	Natural offspring	Regular education	
329.008.00162	Single parent alone	2	Natural offspring	Regular education	
329.008.00191	Other relative(s) is (are) caregiver(s)	5	Natural offspring	Regular education	
329.009.00128	2 parent home	4	Natural offspring	Special education	EMOTIONALLY DISTURBED MAINSTREAM FROM CL
329.009.00129	2 parent home	4	Natural offspring	Regular education	
329.009.00135	Single parent alone	2	Natural offspring	Regular education	

120

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.009.00136	Single parent alone	2	Natural offspring	Regular education	
329.009.00169	Other relative(s) is (are) caregiver(s)	3	Natural offspring	Regular education	
329.009.00174	2 parent home	4	Natural offspring	Regular education	
329.009.00197	2 parent home	5	Natural offspring	Special education	CONTENT MASTERY-SPELLING READING
329.009.00198	Single parent alone	3	Natural offspring	Regular education	
329.009.00200	2 parent home	2	Natural offspring		
329.009.00202	Single parent alone	2	Natural offspring	Regular education	
329.009.00237	2 parent home	8	Natural offspring	Regular education	
329.009.00238	2 parent home	4	Natural offspring	Regular education	
329.009.00276	Other relative(s) is (are) caregiver(s)	2	Natural offspring	Regular education	
329.009.00302	2 parent home	5	Natural offspring	Regular education	
329.009.00306	Other relative(s) is (are) caregiver(s)	3	Adopted	Special education	LEARNING DISABILITIES
329.009.00312	Single parent alone	7	Natural offspring	Regular education	
329.009.00327	1 parent & 1 step-parent	4	Natural offspring	Regular education	
329.009.00330	1 parent & 1 common-law parent	3	Natural offspring	Regular education	
329.010.00183	1 parent & 1 step-parent	5	Natural offspring	Regular education	
329.010.00263	1 parent & 1 step-parent	8	Natural offspring	Special education	HISTORY, SCIENCE, ENGLISH, & MATH

121

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.5

Listing of Personal History by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Composition	Number of People in Household	Adopted/Natural Offspring	School Placement	Specify
329.010.00277	Single parent alone	2	Natural offspring	Regular education	
329.010.00282	Single parent alone	4	Natural offspring	Regular education	
329.011.00164	Single parent alone	3	Natural offspring	Regular education	
329.011.00210	2 parent home	5	Natural offspring	Regular education	
329.011.00285	2 parent home	4	Natural offspring	Regular education	
329.011.00287	2 parent home	6	Natural offspring	Regular education	
329.012.00027	Single parent alone	2	Natural offspring	Regular education	
329.012.00217	2 parent home	4	Natural offspring	Regular education	
329.012.00218	2 parent home	5	Natural offspring	Regular education	
329.012.00224	2 parent home	4	Natural offspring	Regular education	
329.012.00225	2 parent home	4	Natural offspring	Regular education	

122

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.001.00063	Biologic Mother	40	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Biologic Father	43	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	14	Female	No	1	1	0	0	.	.	.	1	1	1	1	.	.	0	0
	Sibling #2	13	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #3	10	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #4	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.001.00068	Biologic Mother	41	Female	No	.	.	0	0	0	.	.	1	1	.	.	.	.	0	0
	Biologic Father	43	Male	No	.	.	0	0	0	.	.	.	.	.	.	.	.	0	0
	Sibling #1	19	Female	No	.	.	0	0	0	.	.	.	.	.	.	.	.	0	0
	Sibling #2	13	Female	No	1	1	0	0	0	1	1	1	1	1	1	1	1	0	0
329.001.00072	Biologic Mother	45	Female	No	1	1	0	0	.	1	1	1	1	1	1	1	.	0	0
	Biologic Father	45	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	15	Male	No	1	1	0	0	.	.	.	1	1	1	1	1	1	0	0
	Sibling #2	12	Female	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #3	10	Male	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	0
329.001.00121	Biologic Mother	43	Female	No	1	1	0	0	1	0	0	1	1	1	1	.	.	.	0
	Biologic Father	46	Male	No	.	.	0	0	.	0	0	.	.	.	.	.	.	.	0
	Sibling #1	15	Male	No	1	1	0	0	.	0	0	1	1	1	1	.	.	.	0
	Sibling #2	12	Male	No	1	1	0	0	.	0	0	.	.	1	1	1	1	.	0
	Sibling #3	10	Female	No	.	.	0	0	.	0	0	.	.	.	.	.	.	1	0
329.001.00205	Biologic Mother	37	Female	No	.	.	0	0	0	.	.	1	1	.	.	.	.	.	0
	Biologic Father	38	Male	No	.	.	0	0	0	.	.	.	.	.	.	1	1	.	0
	Sibling #1	12	Male	No	1	1	0	0	0	1	1	1	1	1	1	.	1	.	0
	Sibling #2	10	Female	No	.	.	0	0	0	.	.	.	.	.	.	.	1	1	0
	Sibling #3	5	Female	No	.	.	0	0	0	.	.	.	.	.	.	.	1	.	0
329.001.00206	Biologic Mother	52	Female	No	1	1	0	0	0	.	.	1	.	.	.	.	.	0	0
	Biologic Father	54	Male	No	1	.	0	0	0	.	.	1	.	.	.	1	.	0	0
	Sibling #1	17	Male	No	1	1	0	0	0	1	1	1	1	1	1	1	1	0	0
	Sibling #2	14	Female	No	.	.	0	0	0	.	.	1	.	.	.	.	.	0	0
329.002.00055	Biologic Mother	48	Female	No	.	1	.	9	.	.	.	1	.	1	1	1	1	9	9
	Biologic Father	43	Male	No	1	.	.	9	.	.	.	.	.	.	.	.	.	9	9
	Sibling #1	29	Female	No	1	1	.	9	.	.	1	1	.	.	.	.	.	9	9
	Sibling #2	23	Male	Yes	1	1	1	9	1	1	1	1	1	1	1	1	1	9	9
	Sibling #3	26	Male	No	.	.	.	9	.	.	.	.	.	.	.	.	.	9	9

0 = NO; 1 = YES; 9 = DON'T KNOW

123

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.002.00055	Sibling #4	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00058	Biologic Mother	42	Female	No	1	1	0	0	1	1	.	1	1	1	1	1	1	0	0
	Biologic Father	36	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	24	Male	No	.	.	0	0	.	1	.	1	.	.	.	.	.	0	0
	Sibling #2	22	Male	No	1	1	0	0	.	1	.	.	.	.	.	.	.	0	0
	Sibling #3	16	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00099	Biologic Mother	37	Female	Yes	0	.	0	0	0	0	.	1	0	.	0	.	.	1	0
	Biologic Father	47	Male	No	0	1	0	0	0	0	.	1	0	.	0	1	1	1	0
	Sibling #1	15	Male	No	0	.	0	0	0	0	.	1	0	1	0	.	.	1	0
	Sibling #2	9	Female	No	0	.	0	0	0	0	.	1	0	.	0	.	.	1	0
329.002.00102	Biologic Mother	35	Female	No	0	1	0	0	1	1	1	1	1	1	1	1	1	1	.
	Biologic Father	39	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	0	.	0	0	.	.	.	1	.	.	.	1	1	1	1
	Sibling #2	13	Female	No	0	.	0	0	.	1	1	.	.	.	.	1	1	.	.
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00105	Biologic Mother	43	Female	No	0	0	0	0	.	0	0	.	.	.	.	.	.	0	0
	Biologic Father	52	Male	Yes	0	0	0	0	.	0	0	.	.	.	.	.	.	0	0
	Sibling #1	17	Male	No	0	0	0	0	1	0	0	1	.	.	.	.	.	0	0
	Sibling #2	16	Male	Yes	0	0	0	0	.	0	0	1	1	1	1	1	1	0	0
329.002.00106	Biologic Mother	32	Female	No	.	.	0	0	0	.	.	.	.	.	0	.	.	0	.
	Biologic Father	36	Male	No	1	.	0	0	0	1	.	.	.	.	0	.	.	0	.
	Sibling #1	15	Female	No	.	1	0	0	0	1	1	1	1	1	0	1	1	0	.
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00242	Biologic Mother	36	Female	No	.	1	.	0	.	.	.	1	1	1	1	.	.	0	0
	Biologic Father	39	Male	No	.	1	.	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	15	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	.	0	0
	Sibling #2	12	Male	No	1	1	1	0	.	1	1	1	.	.	.	1	1	0	0
329.002.00245	Biologic Mother	36	Female	No	0	.	.	0	.	.	.	1	0	1	0	.	.	0	0
	Biologic Father	44	Male	No	0	.	.	0	.	.	.	.	0	.	0	.	.	0	0
	Sibling #1	14	Female	No	0	1	1	0	1	1	1	1	0	1	0	1	.	0	0
	Sibling #2	18	Male	No	0	1	.	0	.	.	.	.	0	.	0	.	.	0	0
	Sibling #3	16	Female	No	0	.	.	0	.	.	.	1	0	.	0	.	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

124

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.002.00245	Sibling #4	11	Female	No	0	.	.	0	.	.	.	.	0	.	0	.	.	0	0
	Sibling #5	9	Male	No	0	1	.	0	.	.	.	.	0	.	0	.	.	0	0
329.002.00319	Biologic Mother	42	Female	No	.	.	0	0	0	0	.	.	.	0	.	.	.	0	.
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Male	No	.	.	0	0	0	0	.	.	.	0	.	1	1	0	.
	Sibling #2	17	Male	No	.	.	0	0	0	0	.	.	.	0	.	.	.	.	0
	Sibling #3	16	Female	No	1	1	0	0	0	0	.	1	1	0	.	1	1	0	.
329.003.00077	.	.	.	.	.	.	.	0	.	.	.	.	0	.	.	.	.	0	0
	Biologic Mother	45	Female	No	1	1	1	0	1	1	.	1	0	1	1	1	1	0	0
	Biologic Father	55	Male	No	.	.	.	0	.	.	1	.	0	.	.	.	.	0	0
	Sibling #1	29	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00087	Biologic Mother	49	Female	No	.	.	0	0	.	.	.	.	.	1	.	.	.	0	0
	Biologic Father	50	Male	No	1	1	0	0	1	.	.	1	1	1	1	1	1	0	0
	Sibling #1	14	Female	Yes	1	1	0	0	.	1	1	1	1	1	1	.	.	0	0
329.003.00089	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	60	Male	No	1	1	1	0	1	0	0	1	0	.	0	0	0	0	0
	Sibling #1	14	Female	No	1	1	.	0	1	0	0	1	0	1	0	0	0	0	0
329.003.00091	Biologic Mother	.	Female	No	.	1	.	0	.	.	.	1	.	1	.	.	.	0	0
	Biologic Father	.	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	.	Male	No	.	1	.	0	.	1	1	1	1	1	.	1	.	0	0
	Sibling #3	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00248	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	22	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	8	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.003.00250	Biologic Mother	43	Female	No	0	0	0	0	0	0	9	9	9	.	9	.	9	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

125

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.003.00250	Biologic Father	42	Male	No	0	0	0	0	0	0	9	9	9	.	9	1	9	.	0
	Sibling #1	18	Female	No	0	0	0	0	0	0	9	9	9	1	9	1	9	1	0
	Sibling #2	15	Female	No	0	0	0	0	0	0	9	9	9	1	9	1	9	1	0
	Sibling #3	8	Female	No	0	0	0	0	0	0	9	9	9	.	9	.	9	.	0
	Sibling #4	2	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00292	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	.	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0	.	0	0	0	0	0
	Sibling #1	16	Male	No	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0	.	0	0	0	0	0
329.003.00313	Biologic Mother	36	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	37	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	.	0	0	0	0	0	0
	Sibling #2	18	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
329.004.00015	Biologic Mother	42	Female	No	1	1	0	0	1	9	9	1	1	1	1	1	1	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	.	.	0	0	.	9	9	1	.	1	1	1	1	0	0
329.004.00017	Biologic Mother	50	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	52	Male	No	0	0	0	0	0	0	.	0	.	0	.	1	1	0	.
	Sibling #1	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00019	Biologic Mother	.	Female	No	1	1	1	0	0	1	1	1	1	1	1	1	1	0	0
	Biologic Father	.	Male	No	1	.	.	0	0	1	1	.	.	.	.	.	.	0	0
	Sibling #1	.	Female	No	1	1	.	0	0	1	1	1	1	1	1	1	1	0	0
329.004.00212	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00214	Biologic Mother	41	Female	No	1	1	0	0	1	0	1	1	1	1	1	1	1	0	0
	Biologic Father	43	Male	No	1	1	0	0	1	0	1	1	1	1	1	1	1	0	0
	Sibling #1	21	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	1	.	0	0	1	0	.	1	1	1	1	1	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

126

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.005.00002	Biologic Mother	35	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	0	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00004	Biologic Mother	41	Female	No	0	1	0	0	0	0	0	.	.	.	.	.	.	0	0
	Biologic Father	44	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Male	Yes	0	.	0	0	0	0	0	1	1	1	0	1	1	0	0
329.005.00008	Biologic Mother	34	Female	No	0	1	0	0	0	.	0	1	1	1	1	1	0	0	
	Biologic Father	33	Male	No	0	1	0	0	0	1	0	.	.	.	.	.	0	0	
	Sibling #1	12	Male	No	0	1	0	0	0	.	0	1	1	1	.	1	1	0	0
	Sibling #2	9	Male	No	0	1	0	0	0	.	0	1	.	.	.	.	.	0	0
329.005.00109	Biologic Mother	31	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	28	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	15	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00112	Biologic Mother	61	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	0	0	
	Biologic Father	54	Female	No	.	1	.	0	.	.	.	.	.	.	.	.	0	0	
	Sibling #1	21	Female	No	.	1	.	0	.	.	.	1	.	.	1	.	0	0	
	Sibling #2	18	Male	No	1	1	1	0	1	1	1	1	.	.	1	1	0	0	
	Sibling #3	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Female	No	1	1	.	0	.	1	1	1	1	1	.	1	.	0	0
	Sibling #5	13	Male	No	1	1	.	0	.	1	1	1	1	.	.	1	.	0	0
329.005.00116	Biologic Mother	39	Female	No	.	.	.	0	.	1	1	1	1	1	9	.	.	0	0
	Biologic Father	51	Male	No	1	1	1	0	.	1	1	.	.	1	9	.	.	0	0
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	25	Female	No	1	1	.	0	1	.	.	1	1	.	9	.	.	0	0
	Sibling #3	24	Female	No	.	1	.	0	.	.	.	1	.	.	9	.	.	0	0
	Sibling #4	22	Male	No	.	.	.	0	.	.	.	.	.	.	9	.	.	0	0
	Sibling #5	16	Female	No	1	1	1	0	1	.	.	1	1	1	9	1	1	0	0
	Child #1	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	329.005.00119	Biologic Mother	44	Female	No	.	1	0	0	.	.	0	.	.	.	.	.	.	0
Biologic Father		46	Male	No	1	1	0	0	1	.	0	1	1	1	1	1	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

127

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.005.00119	Sibling #1	19	Female	No	1	1	0	0	1	1	0	1	1	1	1	1	1	0	0
	Sibling #2	14	Female	No	1	1	0	0	1	.	0	1	1	1	1	1	1	0	0
	Sibling #3	7	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00151	Biologic Mother	40	Female	No	1	1	.	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	40	Male	No	1	1	.	0	.	1	1	1	1	1	1	1	1	0	0
	Sibling #1	17	Male	No	1	1	.	0	1	.	.	1	1	1	1	1	1	0	0
	Sibling #2	15	Male	No	1	1	1	0	1	1	1	1	1	.	.	1	1	0	0
	Sibling #3	14	Female	No	1	1	.	0	.	1	1	1	1	1	1	1	1	0	0
	Sibling #4	13	Female	No	1	1	.	0	.	.	.	1	1	.	.	.	.	0	0
329.005.00152	Biologic Mother	37	Female	No	1	1	1	0	1	0	0	1	1	1	0	.	0	0	0
	Biologic Father	39	Male	No	.	.	.	0	.	0	0	.	.	.	0	.	0	0	0
	Sibling #1	15	Female	No	.	1	.	0	.	0	0	1	1	1	0	1	0	0	0
329.005.00257	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	1	.	.	.	0	0	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	.	.	.	.	0	0	0	0
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0
329.005.00258	Biologic Mother	45	Male	No	1	1	1	.	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	44	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	.	.
	Sibling #1	14	Female	No	1	.	.	.	.	.	.	1	1	1	1	1	1	.	.
	Sibling #2	9	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00299	Biologic Mother	34	Female	No	1	1	0	0	.	0	0	1	.	1	.	0	0	0	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	1	1	0	0	.	0	0	1	1	1	1	0	0	0	0
	Sibling #2	9	Male	No	.	.	0	0	1	0	0	.	.	.	.	0	0	0	0
329.005.00300	Biologic Mother	45	Female	No	0	1	0	0	1	0	0	1	1	1	1	1	1	0	0
	Biologic Father	50	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	0	1	0	0	1	0	0	.	.	.	.	.	.	0	0
	Sibling #2	12	Male	No	0	1	0	0	1	0	0	1	.	.	.	1	1	0	0
	Sibling #3	9	Male	No	0	1	0	0	.	0	0	.	.	.	.	.	.	0	0
329.005.00333	Biologic Mother	46	Female	No	1	1	0	0	1	1	1	1	1	.	.	1	1	0	0
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	19	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #2	16	Female	No	.	.	0	0	.	1	1	1	1	1	1	1	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

128

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number																
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B		
329.005.00336	Biologic Mother	42	Female	No	1	1	1	.	1	1	1	1	1	1	1	1	1	1	1	1	
	Biologic Father	41	Male	No	.	.	.	1	1	1	1	.	.	1	1	1	1	.	.	.	
	Sibling #1	16	Female	No	.	1	.	.	.	1	1	1	1	1	1	1	1	.	.	.	
	Sibling #2	14	Female	No	.	1	.	.	.	1	1	1	1	1	1	1	1	1	.	.	.
	Sibling #3	7	Male	No	.	1	.	.	1	1	1	.	.	.	.	.	.	.	.	.	.
329.006.00038	Biologic Mother	35	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	.	.	.	
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	1	1	1	.	1	1	.	1	.	1	.	1	1	.	.	.	1
	Sibling #3	12	Female	No	1	1	.	.	.	1	.	.	.	.	.	.	.	.	.	.	1
329.006.00039	Biologic Mother	47	Female	No	.	.	0	0	.	.	0	.	.	.	.	.	.	.	0	.	.
	Biologic Father	48	Male	No	.	.	0	0	.	.	0	.	.	.	.	.	.	.	0	.	.
	Sibling #1	24	Male	No	.	.	0	0	.	.	0	.	.	.	.	.	.	.	0	.	.
	Sibling #2	21	Male	No	.	.	0	0	.	.	0	.	.	.	.	.	.	.	0	.	.
	Sibling #3	15	Female	No	1	1	0	0	.	1	0	1	1	1	1	1	1	1	0	.	.
329.006.00260	Biologic Mother	56	Female	No	.	1	0	0	1	0	.	1	1	1	.	1	1	0	.	.	
	Biologic Father	56	Male	Yes	1	.	0	0	.	0	.	1	.	.	.	.	.	0	.	.	
	Sibling #1	17	Female	No	.	1	0	0	.	0	.	1	1	1	1	.	.	0	.	.	
	Sibling #2	10	Male	No	.	1	0	0	.	0	.	.	.	.	.	.	.	0	.	.	
329.006.00261	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	38	Male	No	0	.	0	0	0	.	.	.	.	0	0	.	.	.	.	.	.
	Sibling #1	19	Female	No	0	.	0	0	0	.	.	.	.	0	0	.	.	.	1	1	.
	Sibling #2	17	Male	No	0	1	0	0	0	1	1	1	1	0	0	1	1	.	.	.	.
	Sibling #3	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00140	Biologic Mother	32	Female	No	0	.	0	0	0	.	0	.	.	.	0	1	.	1	0	0	
	Biologic Father	37	Male	No	0	.	0	0	0	1	0	.	.	.	0	.	.	.	.	.	0
	Sibling #1	11	Male	No	0	1	0	0	0	.	0	1	1	1	0	1	1	1	1	0	
	Sibling #2	9	Male	No	0	.	0	0	0	.	0	.	.	.	0	.	.	.	.	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

129

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.007.00142	Biologic Mother	44	Female	No	1	1	0	0	1	1	0	1	1	1	1	1	1	0	.
	Biologic Father	46	Male	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	.
	Sibling #1	15	Male	No	.	1	0	0	.	.	0	1	1	1	1	1	1	0	.
329.007.00145	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	41	Male	No	0	0	0	0	0	0	.	.	0	.	0	0	.	9	.
	Sibling #1	23	Female	No	0	0	0	0	0	0	.	.	0	.	0	0	.	9	.
	Sibling #2	16	Male	No	0	0	0	0	0	0	.	1	0	1	0	0	.	9	.
Sibling #3	14	Female	No	0	0	0	0	0	0	.	.	0	.	0	0	.	9	.	
329.007.00265	Biologic Mother	34	Female	No	1	1	0	0	9	.	.	1	.	1	.	0	.	0	.
	Biologic Father	29	Male	Yes	1	.	0	0	9	1	1	1	1	1	1	0	.	0	.
	Sibling #1	16	Female	No	.	1	0	0	9	1	1	1	1	1	1	0	.	0	.
	Sibling #2	13	Male	No	.	1	0	0	9	.	.	.	.	.	.	0	.	0	.
	Sibling #3	12	Male	No	.	1	0	0	9	.	.	.	.	.	.	0	.	0	.
Sibling #4	6	Female	No	.	1	0	0	9	.	.	.	.	.	.	0	.	0	.	
329.007.00268	Biologic Mother	37	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	.
	Biologic Father	33	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #1	13	Female	No	.	.	0	0	.	.	.	1	1	1	1	1	.	0	.
329.007.00294	Biologic Mother	37	Female	No	.	.	.	0	.	1	0	1	1	1	.	1	.	0	0
	Biologic Father	40	Male	No	.	.	.	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #1	15	Female	No	1	1	.	0	.	1	0	1	1	1	1	1	1	0	0
	Sibling #2	14	Male	No	1	1	1	0	1	1	0	1	1	1	.	1	1	0	0
329.007.00309	Biologic Mother	39	Female	No	0	.	0	0	.	.	.	1	1	1	.	0	.	0	.
	Biologic Father	44	Male	No	0	.	0	0	.	.	.	.	.	.	.	0	.	0	.
	Sibling #1	18	Female	No	0	1	0	0	1	1	1	1	1	1	1	0	.	0	.
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.007.00310	.	.	.	.	.	.	0	0	.	0	.	.	.	.	0	.	0	0	.
	Biologic Mother	41	Female	No	.	1	0	0	.	0	.	1	1	.	0	.	0	0	.
	Biologic Father	41	Male	No	1	1	0	0	1	0	.	1	.	1	0	1	0	0	.
	Sibling #1	16	Female	No	.	1	0	0	.	0	.	1	.	1	0	1	0	0	.
Sibling #2	15	Male	No	.	1	0	0	.	0	.	.	.	.	0	.	0	0	.	
329.007.00318	Biologic Mother	44	Female	No	0	1	.	.	1	.	0	1	0	.	0	1	1	.	0
	Biologic Father	62	Male	No	0	.	.	1	.	.	0	1	0	.	0	1	1	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

130

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.007.00318	Sibling #1	15	Male	No	0	1	.	1	1	.	0	1	0	.	0	1	1	.	0
	Sibling #2	13	Male	No	0	1	.	.	.	.	0	.	0	.	0	1	1	.	0
	Sibling #3	18	Female	No	0	1	1	.	1	1	0	1	0	1	0	1	1	1	1
329.008.00157	Biologic Mother	47	Female	No	.	1	0	0	0	1	1	1	0	1	1	1	1	0	0
	Biologic Father	39	Male	No	1	1	0	0	0	.	.	1	0	1	1	.	.	0	0
329.008.00160	Biologic Mother	38	Female	No	1	1	0	.	1	1	.	1	1	1	1	1	1	0	0
	Biologic Father	43	Male	No	1	1	0	1	.	1	1	1	1	1	1	1	1	0	0
329.008.00188	Biologic Mother	37	Female	No	.	.	0	0	1	0	0	1	1	1	1	1	1	0	0
	Biologic Father	42	Male	No	1	1	0	0	1	0	0	1	1	1	1	.	.	0	0
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	.	.	0	0	.	0	0	.	.	.	.	.	.	0	0
329.008.00271	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Mother	41	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	41	Male	No	.	.	.	0	1	.	.	1	1	1	1	.	.	0	0
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.008.00275	Sibling #2	10	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	0	0
	Biologic Mother	44	Female	No	1	1	0	0	1	0	0	1	1	1	1	1	.	0	0
	Biologic Father	46	Male	No	.	.	0	0	.	0	0	.	1	.	.	1	1	0	0
	Sibling #1	19	Male	No	.	.	0	0	.	0	0	.	.	.	.	.	.	0	0
329.009.00130	Sibling #2	17	Female	No	.	.	0	0	.	0	0	.	.	.	.	.	0	0	
	Biologic Mother	49	Female	No	.	1	0	0	.	.	.	.	.	1	.	.	.	.	0
	Biologic Father	52	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	.	0
	Sibling #1	16	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0
	Sibling #2	15	Male	No	1	1	0	0	.	.	.	1	1	1	1	1	1	.	0
	Sibling #3	10	Female	No	1	1	0	0	1	.	.	1	1	1	1	1	1	.	0
	Sibling #4	7	Female	No	.	1	0	0	.	.	.	.	.	.	.	1	.	.	0
329.009.00131	Biologic Mother	.	Female	No	1	1	.	0	.	1	1	1	1	1	1	1	1	1	1
	Biologic Father	41	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	1	1	.	0	1	1	1	1	1	1	1	1	1	.	.
	Sibling #2	13	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1
329.009.00133	Biologic Mother	37	Female	No	.	0	0	0	1	.	.	.	.	.	.	.	.	0	.
	Biologic Father	37	Male	No	.	0	0	0	.	1	.	.	.	.	.	.	.	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

131

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.009.00133	Sibling #1	16	Female	No	1	0	0	0	.	1	1	1	1	1	1	1	1	0	.
	Sibling #2	14	Male	No	.	0	0	0	.	.	.	1	1	.	.	.	.	0	.
329.009.00138	Biologic Mother	34	Female	No	1	.	.	.	.	.	.	1	.	.	.	.	.	0	0
	Biologic Father	33	Male	No	.	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	13	Female	No	1	1	.	.	1	1	1	1	1	1	1	1	1	0	0
	Sibling #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0
329.009.00170	Biologic Mother	41	Female	No	.	1	0	0	1	1	0	1	1	1	1	1	1	.	9
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	1	.	0	0	.	.	0	1	1	1	1	1	1	.	9
	Sibling #2	22	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #4	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00173	Biologic Mother	43	Female	No	.	1	.	0	1	1	1	1	1	1	1	1	1	.	.
	Biologic Father	45	Male	Yes	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1
	Sibling #1	12	Female	No	.	1	.	0	.	1	1	1	1	1	1	1	1	.	.
329.009.00193	Biologic Mother	36	Female	No	0	1	0	9	1	1	0	1	1	1	1	1	1	.	0
	Biologic Father	38	Male	No	0	.	0	9	.	1	0	1	.	.	.	.	.	.	0
	Sibling #1	12	Female	No	0	.	0	9	.	1	0	1	1	1	1	1	1	1	0
	Sibling #2	3	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00196	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	0	.	0	0	0	.	.	.	.	.	1	.	.	0	.
	Sibling #1	17	Female	No	0	1	0	0	0	1	1	1	1	1	1	1	.	0	.
	Sibling #2	9	Female	No	0	.	0	0	0	.	.	.	.	.	.	.	.	0	.
329.009.00201	Biologic Mother	43	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Biologic Father	47	Male	No	.	.	0	0	.	1	1	1	.	.	.	.	.	0	0
	Sibling #1	17	Male	No	1	1	0	0	1	.	.	.	.	.	.	.	.	0	0
	Sibling #2	14	Male	No	1	1	0	0	.	1	1	1	1	1	1	1	1	0	0
329.009.00204	Biologic Mother	39	Female	No	.	1	0	0	.	.	0	1	1	1	.	.	.	0	.
	Sibling #6	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	47	Male	No	1	1	0	0	1	1	0	1	1	1	1	1	1	0	.
	Sibling #1	13	Male	No	.	.	0	0	.	1	0	1	.	1	.	1	1	0	.
	Sibling #2	12	Male	No	1	1	0	0	1	1	0	1	1	.	.	1	1	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

132

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.009.00204	Sibling #3	10	Female	No	.	.	0	0	.	.	0	1	.	.	.	.	.	0	.
	Sibling #4	9	Male	No	1	1	0	0	.	.	0	1	.	.	.	.	.	0	.
	Sibling #5	21	Female	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	.
	Child #1	.	.	.	.	.	0	0	.	.	0	.	.	.	.	.	.	0	.
329.009.00235	Biologic Mother	32	Female	No	0	.	0	0	0	0	0	.	0	.	0	0	0	0	0
	Biologic Father	30	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0
	Sibling #2	8	Male	No	0	.	0	0	0	0	0	.	0	.	0	0	0	0	0
329.009.00240	Biologic Mother	48	Female	No	.	.	0	0	.	0	0	1	.	.	.	.	.	0	0
	Biologic Father	52	Male	No	.	.	0	0	.	0	0	1	.	.	1	1	0	0	
	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	14	Male	No	1	1	0	0	1	0	0	1	1	1	1	1	1	0	0
Sibling #4	13	Female	No	.	.	0	0	.	0	0	.	.	.	.	.	.	0	0	
329.009.00303	Biologic Mother	43	Female	No	0	1	0	0	1	0	.	.	.	1	.	.	.	0	.
	Biologic Father	49	Male	No	0	1	0	0	.	0	.	.	.	1	.	.	.	0	.
	Sibling #1	17	Male	No	0	1	0	0	.	0	.	1	1	1	1	1	1	0	.
	Sibling #2	14	Female	No	0	1	0	0	.	0	.	.	.	.	.	.	.	0	.
329.009.00304	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	23	Male	No	.	.	0	0	0	.	.	1	.	.	.	.	.	0	.
	Sibling #2	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #3	16	Male	No	1	1	0	0	0	1	.	1	1	1	1	1	1	1	0	.
329.009.00324	Biologic Mother	33	Female	No	0	0	0	0	1	0	0	0	0	0	0	.	.	.	0
	Biologic Father	35	Female	No	0	0	0	0	.	0	0	0	0	0	0	1	1	.	0
	Sibling #1	13	Female	No	0	0	0	0	.	0	0	0	0	0	0	.	.	1	0
	Sibling #2	8	Female	No	0	0	0	0	.	0	0	0	0	0	0	.	.	.	0
Sibling #3	5	Female	No	0	0	0	0	.	0	0	0	0	0	0	.	.	.	0	
329.009.00328	Biologic Mother	45	Female	No	0	1	0	0	1	1	0	1	1	1	0	1	1	0	0
	Biologic Father	46	Male	No	0	.	0	0	.	0	1	1	1	1	0	.	.	0	0
	Sibling #1	23	Male	No	0	.	0	0	1	.	0	1	.	.	0	.	.	0	0
	Sibling #2	21	Male	No	0	.	0	0	1	.	0	1	1	1	0	1	1	0	0
	Sibling #3	14	Male	No	0	.	0	0	.	.	0	1	.	.	0	.	.	0	0
Sibling #4	12	Male	No	0	1	0	0	.	.	0	1	.	.	0	.	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

133

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.009.00329	Biologic Mother	32	Female	No	0	.	.	0	.	0	0	.	.	.	.	1	1	0	0	
	Biologic Father	34	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	14	Male	No	0	1	1	0	1	0	0	1	1	1	1	.	.	0	0	
	Sibling #2	10	Male	No	0	.	.	0	.	0	0	.	.	.	.	.	.	.	0	0
	Sibling #3	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.010.00182	Biologic Mother	42	Female	No	0	0	0	0	0	.	.	1	1	1	1	0	.	0	.	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	18	Male	No	0	0	0	0	0	1	1	1	1	1	1	0	.	0	.	
	Sibling #2	17	Female	No	0	0	0	0	0	.	.	1	1	1	1	0	.	0	.	
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.010.00278	Biologic Mother	49	Female	No	.	.	0	0	0	0	.	.	.	.	.	.	.	0	.	
	Biologic Father	49	Male	No	1	1	0	0	0	0	.	.	.	.	.	.	.	0	.	
	Sibling #1	20	Female	No	.	.	0	0	0	0	.	.	.	.	.	.	.	0	.	
	Sibling #2	17	Female	No	.	.	0	0	0	0	.	1	1	1	1	1	1	0	.	
329.010.00280	Biologic Mother	33	Female	No	.	.	0	0	0	1	1	.	.	0	.	0	.	0	.	
	Biologic Father	32	Male	No	.	.	0	0	0	1	1	.	.	0	.	0	.	0	.	
	Sibling #1	13	Female	No	1	1	0	0	0	.	.	1	1	0	.	0	.	0	.	
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.011.00283	Biologic Mother	36	Female	No	0	1	0	0	.	.	.	1	1	1	.	.	.	0	0	
	Biologic Father	42	Male	No	0	1	0	0	1	1	.	1	1	1	.	1	1	0	0	
	Sibling #1	16	Male	No	0	1	0	0	.	1	1	1	1	1	1	1	1	0	0	
329.011.00288	Biologic Mother	41	Female	No	0	.	.	.	0	.	0	1	.	1	1	1	1	0	0	
	Biologic Father	45	Male	No	0	.	1	1	0	1	0	.	.	.	.	.	.	0	0	
	Sibling #1	15	Male	No	0	1	.	.	0	.	0	1	1	1	1	1	1	0	0	
329.012.00025	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	21	Female	No	0	.	.	0	0	.	0	.	.	.	.	.	.	0	0	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	14	Female	No	0	1	1	0	0	1	0	1	1	1	1	1	1	0	0	
329.012.00220	Biologic Mother	40	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	.	
	Biologic Father	41	Male	No	.	.	0	0	.	.	.	.	.	1	1	.	.	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

134

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.012.00220	Sibling #1	17	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	.	
	Sibling #2	15	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0	.
	Sibling #3	13	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	.	
329.012.00222	Biologic Mother	37	Female	No	.	1	.	0	1	.	.	.	.	.	.	1	1	.	0	
	Biologic Father	38	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	0	
	Sibling #1	15	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	0
329.012.00226	Biologic Mother	50	Female	No	.	.	0	0	.	0	0	1	.	.	.	.	.	0	0	
	Biologic Father	50	Male	No	.	.	0	0	.	0	0	1	.	.	.	.	.	0	0	
	Sibling #1	23	Female	No	.	.	0	0	1	0	0	1	.	.	.	.	.	0	0	
	Sibling #2	18	Male	No	.	.	0	0	.	0	0	1	.	1	1	.	.	0	0	
	Sibling #3	16	Male	No	1	1	0	0	1	0	0	1	1	1	1	1	1	1	0	0
329.012.00228	Biologic Mother	40	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	15	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0	0
	Sibling #2	12	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.001.00061	Biologic Mother	39	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	16	Female	No	1	1	.	.	.	.	1	1	1	1	1	1	1	0	0
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0
329.001.00066	Biologic Mother	48	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	52	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	17	Female	No	1	1	.	0	.	.	.	1	1	1	1	1	.	0	0
	Sibling #2	13	Male	No	.	.	.	0	.	.	.	1	1	1	1	.	.	0	0
329.001.00067	Biologic Mother	42	Female	No	.	.	.	0	.	.	.	.	.	.	.	.	.	0	.
	Biologic Father	44	Male	No	1	1	.	0	.	.	.	1	.	1	.	1	1	0	.
	Sibling #1	21	Female	No	.	.	.	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #2	16	Female	No	1	1	1	0	1	1	1	1	1	.	.	.	.	0	.
	Sibling #3	14	Male	No	1	1	.	0	.	1	1	1	1	1	1	1	1	0	.
329.001.00070	Biologic Mother	47	Female	No	1	1	0	0	1	0	0	1	.	1	.	1	.	0	0
	Biologic Father	46	Male	No	.	.	0	0	.	0	0	.	.	.	1	1	0	0	
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	12	Male	No	1	.	0	0	.	0	0	1	1	1	1	1	.	0	0
329.001.00122	Biologic Mother	53	Female	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #6	16	Male	No	.	1	0	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #7	15	Male	No	.	1	0	0	.	1	0	1	1	1	.	.	.	0	0
	Biologic Father	58	Male	No	.	.	0	0	.	.	0	1	1	1	.	1	1	0	0
	Sibling #1	26	Female	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #2	23	Female	No	1	1	0	0	1	1	0	1	1	1	.	1	1	0	0
	Sibling #3	22	Female	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #4	20	Male	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #5	20	Female	No	.	.	0	0	.	.	0	.	.	.	.	.	.	0	0
329.002.00050	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	49	Male	No	.	.	0	0	0	0	0	.	.	.	.	.	.	.	.
	Sibling #1	19	Male	No	.	.	0	0	0	0	0	.	.	.	.	.	.	0	0
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	16	Male	No	1	1	0	0	0	0	0	1	1	1	1	1	1	0	0
329.002.00056	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	41	Male	No	0	.	0	0	0	0	0	.	.	.	.	.	.	0	.
	Sibling #1	18	Female	No	0	1	0	0	0	0	0	1	1	1	1	1	1	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

136

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.002.00056	Sibling #2	10	Male	No	0	1	0	0	0	0	0	.	.	.	.	1	.	0	.	
329.002.00057	Biologic Mother	33	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	36	Male	No	.	1	.	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	1	1	1	0	.	1	1	1	1	1	1	1	1	1	1	1
	Sibling #2	14	Female	No	.	1	.	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	12	Male	No	.	1	.	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	.	.	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00098	Biologic Mother	43	Female	No	0	1	0	0	1	1	1	1	1	.	0	1	0	0	0	0
	Biologic Father	45	Male	No	0	1	0	0	.	1	1	1	1	.	0	.	0	0	0	0
	Sibling #1	16	Female	No	0	1	0	0	.	1	1	1	1	1	0	1	0	0	0	0
	Sibling #2	13	Female	No	0	1	0	0	.	1	1	1	1	1	0	1	0	0	0	0
	Sibling #3	9	Male	No	0	1	0	0	.	.	.	.	.	.	0	.	0	0	0	0
329.002.00100		.	.	No	.	.	0	0	.	0	0	.	.	.	.	.	.	.	1	.
	Biologic Mother	36	Female	No	1	1	0	0	1	0	0	1	1	1	1	1	1	1	.	.
	Biologic Father	35	Male	No	.	.	0	0	.	0	0	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Male	No	1	1	0	0	.	0	0	1	1	.	.	.	.	.	.	1
	Sibling #2	9	Female	No	.	.	0	0	1	0	0	.	.	.	.	.	.	.	.	.
329.002.00103	Biologic Mother	39	Female	No	0	1	0	0	0	0	.	0	.	0	.	.	.	0	.	
	Biologic Father	38	Male	No	0	.	0	0	0	0	.	0	.	0	.	.	.	0	.	
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Female	No	0	.	0	0	0	0	.	0	.	0	.	1	1	0	.	.
329.002.00104	Biologic Mother	41	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0	0
	Biologic Father	46	Male	No	1	1	.	0	1	1	1	1	1	1	1	1	1	0	0	0
	Sibling #1	18	Female	No	.	.	.	0	.	.	1	.	.	.	.	.	.	0	0	0
	Sibling #2	15	Female	No	1	1	.	0	1	1	1	1	1	1	1	1	1	0	0	0
	Sibling #3	13	Male	No	1	1	.	0	1	1	1	1	1	1	1	1	1	0	0	0
329.002.00243	Biologic Mother	39	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	44	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	20	Female	No	1	1	.	0	.	1	1	1	1	1	1	1	1	.	0	0
	Sibling #2	17	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	0	0
	Sibling #3	15	Female	No	1	1	.	0	1	1	1	1	1	1	1	1	1	1	.	0
329.002.00244	Biologic Mother	40	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

137

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.002.00244	Sibling #1	17	Female	No	.	.	0	0	.	.	.	1	1	1	1	1	.	0	0
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00321	Biologic Mother	39	Female	No	.	1	.	9	.	.	.	.	.	.	.	.	.	0	.
	Biologic Father	37	Male	No	.	.	.	9	.	.	.	.	.	.	.	.	.	0	.
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0	.
	Sibling #2	17	Male	No	.	1	.	9	.	.	.	.	.	.	.	.	.	0	.
	Sibling #3	14	Male	No	1	1	1	9	1	1	1	1	1	1	1	1	1	1	0
329.002.00322	Biologic Mother	34	Female	No	.	1	.	9	1	0	0	1	1	1	1	1	1	0	0
	Biologic Father	56	Male	No	.	.	.	9	.	0	0	.	.	.	.	.	.	0	0
	Sibling #1	14	Don't	No	.	.	.	9	.	0	0	.	.	.	.	.	.	0	0
	Sibling #2	14	Don't	No	1	1	1	9	1	0	0	1	1	.	.	1	1	0	0
	Sibling #3	10	Don't	No	.	.	.	9	.	0	0	1	.	.	.	.	.	0	0
	Sibling #4	8	Don't	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #5	6	Don't	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00073	Biologic Mother	39	Female	No	.	1	0	0	0	1	1	1	.	1	1	1	.	.	0
	Biologic Father	41	Male	No	.	1	0	0	0	1	1	1	.	.	.	1	1	1	0
	Sibling #1	19	Female	No	1	1	0	0	0	1	1	1	1	.	.	1	1	.	0
	Sibling #2	17	Female	No	.	1	0	0	0	1	1	1	1	.	.	1	1	1	0
	Sibling #3	16	Female	No	.	1	0	0	0	1	1	1	1	.	.	1	1	.	0
Sibling #4	11	Male	No	.	1	0	0	0	1	1	1	.	.	.	.	.	.	0	
329.003.00076	Biologic Mother	35	Female	No	0	.	0	0	0	0	0	1	.	.	.	1	0	.	0
	Biologic Father	45	Male	No	0	.	0	0	0	0	0	.	.	.	.	.	0	.	0
	Sibling #1	16	Female	No	0	1	0	0	0	0	0	1	1	1	1	1	0	1	0
329.003.00079	.	.	.	.	.	.	1	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Mother	.	Female	No	1	1	.	.	1	1	.	1	.	.	.	.	.	.	.
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	.	Female	No	1	1	.	.	1	1	.	1	.	.	.	.	.	.	.
Sibling #2	.	Female	No	1	1	.	.	1	1	.	1	.	.	.	.	.	.	.	
329.003.00088	Biologic Mother	46	Female	No	0	1	0	0	0	0	0	1	0	1	0	0	0	0	0
	Biologic Father	50	Male	No	0	.	0	0	0	0	0	.	0	.	0	0	0	0	0
	Sibling #1	24	Female	No	0	.	0	0	0	0	0	.	0	.	0	0	0	0	0
	Sibling #2	21	Female	No	0	.	0	0	0	0	0	.	0	.	0	0	0	0	0
	Sibling #3	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

138

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.003.00090	Biologic Mother	44	Female	No	0	.	0	0	0	0	0	.	.	0	0	1	1	0	0	
	Biologic Father	51	Male	No	0	.	0	0	0	0	0	.	.	0	0	.	.	0	0	
	Sibling #1	18	Male	No	0	1	0	0	0	0	0	.	.	0	0	.	.	0	0	
	Sibling #2	16	Male	No	0	1	0	0	0	0	0	.	.	0	0	.	.	0	0	
	Sibling #3	14	Female	No	0	.	0	0	0	0	0	1	1	0	0	.	.	0	0	
329.003.00092	Biologic Mother	42	Female	No	1	1	0	.	1	1	0	1	1	1	1	1	1	1	.	
	Biologic Father	43	Male	No	.	.	0	1	.	.	0	.	.	.	.	1	.	1	.	
	Sibling #1	16	Female	No	1	1	0	.	.	.	0	.	.	.	1	.	1	1		
	Sibling #2	12	Female	No	1	1	0	.	.	.	0	1	1	1	.	1	1	1		
329.003.00093	Biologic Mother	50	Female	No	0	1	0	0	0	1	0	1	.	1	0	1	0	.	0	
	Biologic Father	53	Male	Yes	0	1	0	0	0	.	0	.	.	.	0	.	0	.	0	
	Sibling #1	21	Male	No	0	1	0	0	0	.	0	.	.	.	0	.	0	.	0	
	Sibling #2	17	Female	No	0	1	0	0	0	.	0	1	1	1	0	1	0	1	0	
329.003.00247	Biologic Mother	41	Female	No	0	.	0	0	.	0	0	.	0	.	0	9	9	9	9	
	Biologic Father	44	Male	No	0	1	0	0	1	0	0	1	0	.	0	9	9	9	9	
	Sibling #1	16	Male	No	0	.	0	0	.	0	0	1	0	1	0	9	9	9	9	
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00249	Biologic Mother	46	Female	No	9	9	9	0	9	0	0	9	0	0	0	9	9	9	9	
	Biologic Father	52	Male	No	9	9	9	0	9	0	0	9	0	0	0	9	9	9	9	
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00289	.	.	.	.	0	0	0	0	0	.	9	.	0	.	0	.	0	0	0	
	Biologic Mother	41	Female	No	0	0	0	0	0	1	9	.	0	.	0	1	0	0	0	
	Biologic Father	45	Male	No	0	0	0	0	0	.	9	.	0	.	0	.	0	0	0	
	Sibling #1	16	Female	No	0	0	0	0	0	1	9	.	0	1	0	1	0	0	0	
	Sibling #2	13	Male	No	0	0	0	0	0	.	9	1	0	.	0	.	0	0	0	
329.003.00290	Biologic Mother	37	Female	No	.	0	0	0	0	0	0	.	.	.	.	1	.	1	1	
	Biologic Father	48	Male	No	.	0	0	0	0	0	0	.	.	.	.	.	.	1	1	
	Sibling #1	3	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	13	Male	No	1	0	0	0	0	0	0	1	1	1	1	1	1	.	.	
	Sibling #3	10	Male	No	.	0	0	0	0	0	0	.	.	.	.	.	.	1	1	
	Sibling #4	17	Male	No	.	0	0	0	0	0	0	.	.	.	.	.	.	1	1	

0 = NO; 1 = YES; 9 = DON'T KNOW

139

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.003.00314	Biologic Mother	39	Female	No	0	1	0	0	0	.	.	1	.	.	.	0	0	0	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	1	0	0	0	1	1	1	1	1	1	0	0	0	0
	Sibling #2	12	Female	No	0	1	0	0	0	.	.	.	.	.	.	0	0	0	0
329.003.00317	Biologic Mother	50	Female	No	0	1	1	0	0	0	0	.	0	.	.	.	.	0	0
	Biologic Father	50	Male	No	0	.	.	0	0	0	0	1	0	1	1	1	1	0	0
	Sibling #1	17	Don't	No	0	.	.	0	0	0	0	.	0	1	.	.	.	0	0
	Sibling #2	16	Female	No	0	.	.	0	0	0	0	1	0	.	1	1	1	0	0
329.004.00013	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00014	Biologic Mother	52	Female	No	1	1	0	0	1	0	0	1	1	1	1	9	9	0	0
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00211	Biologic Mother	49	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	1	1	0	0	1	0	.	1	1	1	1	1	1	0	.
	Sibling #2	18	Female	No	1	1	0	0	.	0	.	1	1	1	1	.	.	0	.
329.004.00215	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	.	0	0	0	.	.	.	1	.	1	1	1	1	0	0
	Sibling #1	14	Female	No	1	0	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00003	Biologic Mother	30	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	1	1	0	0	0	1	.	1	1	1	1	1	1	0	0
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	7	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	5	Male	No	1	1	0	0	0	.	.	.	.	.	.	.	.	0	0
329.005.00006	Biologic Mother	47	Female	No	1	1	0	0	1	0	0	1	1	1	0	1	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

140

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.005.00006	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00007	Biologic Mother	41	Female	No	.	.	0	0	.	.	.	1	.	.	.	1	1	.	.
	Biologic Father	44	Male	No	1	.	0	0	.	1	1	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	1	1	0	0	1	1	1	1	.	1	1	1	1	1	1
	Sibling #2	15	Female	No	1	.	0	0	.	.	.	1	1	1	1	1	1	1	.
329.005.00009	Biologic Mother	47	Female	No	0	1	0	0	0	0	0	1	.	.	.	.	.	0	0
	Biologic Father	46	Male	No	0	1	0	0	0	0	0	.	.	.	.	.	.	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	.	0	0	0	0	0	1	1	1	1	1	1	1	0
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00117	Biologic Mother	47	Female	No	0	0	0	0	0	.	0	.	.	.	.	.	.	1	0
	Biologic Father	49	Male	No	0	0	0	0	0	.	0	1	1	1	.	1	1	.	0
	Sibling #1	22	Female	No	0	0	0	0	0	.	0	.	.	.	.	.	.	.	0
	Sibling #2	16	Female	No	0	0	0	0	0	1	0	1	1	1	.	1	1	.	0
	Sibling #3	12	Male	No	0	0	0	0	0	.	0	.	.	.	.	.	.	1	0
329.005.00118	Biologic Mother	46	Female	No	.	1	0	0	0	.	.	1	1	1	1	.	.	0	0
	Biologic Father	47	Male	No	.	1	0	0	0	.	.	.	.	.	.	.	.	0	0
	Sibling #1	17	Female	No	.	.	0	0	0	.	.	1	1	1	1	.	.	0	0
	Sibling #2	15	Male	No	1	1	0	0	0	1	1	1	1	1	1	1	1	1	0
	Sibling #3	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00153	Biologic Mother	44	Female	No	.	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Biologic Father	51	Male	No	.	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #1	18	Female	No	1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
329.005.00255	Biologic Mother	47	Female	No	0	1	0	0	0	.	.	1	1	1	1	1	.	0	0
	Biologic Father	48	Male	No	0	1	0	0	0	1	1	1	1	1	1	1	.	0	0
	Sibling #1	17	Male	No	0	1	0	0	0	.	.	.	.	1	.	1	.	0	0
	Sibling #2	15	Female	No	0	1	0	0	0	.	.	1	1	1	1	1	1	1	0
329.005.00256	Biologic Mother	55	Female	No	1	1	0	0	1	0	0	1	1	.	0	0	0	0	0
	Biologic Father	52	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Female	No	.	.	0	0	.	0	0	.	.	1	0	0	0	0	
	Sibling #2	23	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

141

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.005.00256	Sibling #4	16	Female	No	1	.	0	0	.	0	0	1	1	1	0	0	0	0	0
329.005.00295	Biologic Mother	31	Female	No	0	0	0	0	0	0	0	.	.	.	.	0	0	0	0
	Biologic Father	36	Male	No	0	0	0	0	0	0	0	.	.	.	.	0	0	0	0
	Sibling #1	13	Female	No	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0
329.005.00297	Biologic Mother	46	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Male	No	.	.	0	0	.	.	.	1	1	1	1	1	1	0	0
329.005.00332	Biologic Mother	50	Female	No	.	1	0	0	.	0	0	1	.	1	.	.	.	1	0
	Biologic Father	54	Male	No	1	1	0	0	1	0	0	1	1	1	1	1	1	.	0
	Sibling #1	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	.	.	0	0	.	0	0	1	1	1	1	1	.	.	0
329.005.00335	Biologic Mother	37	Female	No	1	1	.	.	1	0	0	1	1	1	0	1	1	0	0
	Biologic Father	39	Male	No	.	.	1	1	.	0	0	.	.	.	0	.	.	0	0
	Sibling #1	15	Female	No	.	.	.	.	.	0	0	1	1	1	0	1	1	0	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	6	Female	No	1	1	.	.	1	0	0	.	.	.	0	.	.	0	0
329.006.00040	Biologic Mother	46	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	.
	Biologic Father	66	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #1	28	Male	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #2	18	Female	No	1	.	0	0	1	1	.	1	1	1	.	1	1	0	.
329.006.00041	Biologic Mother	44	Female	No	0	.	0	0	0	0	.	.	.	.	0	.	.	0	.
	Biologic Father	50	Male	No	0	1	0	0	0	0	.	1	1	1	0	1	1	0	.
	Sibling #1	21	Male	No	0	.	0	0	0	0	.	.	.	.	0	.	.	0	.
	Sibling #2	18	Male	No	0	1	0	0	0	0	.	1	.	1	0	.	.	0	.
329.007.00139	Biologic Mother	38	Female	No	1	1	.	0	1	0	.	1	1	1	1	1	1	0	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	1	1	1	0	1	0	.	1	1	1	1	1	1	0	0
329.007.00143	Biologic Mother	28	Female	No	1	1	1	9	1	0	.	1	1	1	1	1	0	1	1
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	.	1	1	9	1	0	.	.	.	.	.	1	0	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

142

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.007.00143	Sibling #2	.			.	.	.	9	.	0	.	.	.	.	.	.	0	.	.
329.007.00146	Biologic Mother	39	Female	No	0	.	0	0	0	0	.	.	.	.	.	.	.	0	.
	Biologic Father	39	Male	No	0	.	0	0	0	0	.	.	.	.	.	.	.	0	.
	Sibling #1	15	Female	No	0	1	0	0	0	0	.	1	1	1	1	1	1	1	0
329.007.00269	Biologic Mother	45	Female	No	1	1	0	0	1	.	.	1	1	1	1	1	1	1	0
	Biologic Father	60	Male	Yes	.	.	0	0	.	.	.	.	.	.	.	1	.	0	
	Sibling #1	15	Male	No	1	1	0	0	.	1	1	1	1	1	1	1	1	0	
	Sibling #2	12	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	
329.007.00270	Biologic Mother	34	Female	No	0	1	0	0	1	.	.	1	1	1	1	1	1	1	0
	Biologic Father	35	Male	No	0	.	0	0	.	1	1	.	.	.	.	.	.	0	
	Sibling #1	15	Male	No	0	1	0	0	.	1	.	1	.	1	1	1	1	0	
	Sibling #2	10	Male	No	0	1	0	0	.	.	.	1	.	.	.	.	.	0	
	Sibling #3	8	Male	No	0	1	0	0	.	1	.	1	.	.	.	.	.	0	
Sibling #4	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.007.00307	Biologic Mother	42	Female	No	9	1	0	0	1	1	1	1	1	1	1	1	1	1	0
	Biologic Father	43	Male	No	9	.	0	0	.	.	.	.	.	.	.	.	.	0	
	Sibling #1	15	Female	No	9	.	0	0	.	.	1	.	1	1	1	1	1	0	
	Sibling #2	14	Female	No	9	.	0	0	.	.	.	.	.	.	.	.	.	0	
329.007.00308	Biologic Mother	45	Female	No	0	.	.	.	1	.	.	.	.	.	.	.	.	0	
	Biologic Father	43	Male	No	0	.	.	.	.	.	.	.	.	.	.	.	.	0	
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
Sibling #3	14	Male	No	0	1	1	1	1	1	1	1	1	1	1	1	1	1	0	
329.008.00159	Biologic Mother	47	Female	No	.	1	.	0	1	.	.	1	1	1	.	1	.	0	
	Biologic Father	49	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	18	Female	No	.	1	.	0	1	.	.	1	1	.	.	.	.	0	
	Sibling #3	16	Female	No	.	1	.	0	1	.	.	1	1	1	.	1	1	1	
329.008.00161	Biologic Mother	44	Female	No	0	1	0	0	1	1	1	1	1	1	1	1	1	0	
	Biologic Father	45	Male	No	0	.	0	0	.	.	.	.	.	.	.	.	.	0	
	Sibling #1	4	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	4	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

143

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.008.00187	Biologic Mother	47	Female	No	0	1	0	0	1	0	.	0	.	0	.	1	.	0	.
	Sibling #1	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.008.00192	Biologic Mother	35	Female	No	1	1	0	.	1	0	0	1	1	1	1	1	1	0	0
	Biologic Father	40	Male	No	.	.	0	1	.	0	0	.	.	.	.	.	.	0	0
	Sibling #1	5	Female	No	.	.	0	.	1	0	0	.	.	.	.	.	.	0	0
329.008.00272	Biologic Mother	42	Female	No	0	1	0	0	1	0	0	1	1	1	1	0	0	0	0
	Biologic Father	62	Male	No	0	.	0	0	.	0	0	.	.	.	.	0	0	0	0
	Sibling #1	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.008.00273	Biologic Mother	42	Female	No	1	1	0	0	0	0	0	1	1	1	1	1	1	0	0
	Biologic Father	43	Male	No	.	1	0	0	0	0	0	.	.	.	.	.	.	0	0
	Sibling #1	15	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00127	Biologic Mother	31	Female	No	1	.	0	0	.	.	.	.	.	.	.	1	1	0	.
	Biologic Father	41	Male	No	1	.	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #1	12	Female	No	1	1	0	0	1	1	1	.	.	.	.	1	1	0	.
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00132	Biologic Mother	30	Female	No	1	.	0	.	.	1	1	1	1	1	.	.	.	0	.
	Biologic Father	31	Male	No	1	1	0	1	.	1	1	1	1	1	.	1	1	0	.
	Sibling #1	13	Male	No	.	1	0	.	1	1	1	1	1	1	1	1	1	0	.
	Sibling #2	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00134	Biologic Mother	38	Female	No	.	1	0	0	0	1	0	1	1	1	1	1	1	0	.
	Biologic Father	31	Male	Yes	.	1	0	0	0	.	0	1	1	.	.	.	.	0	.
	Sibling #1	15	Female	No	1	1	0	0	0	.	0	1	1	1	1	1	1	0	.
	Sibling #2	.	.	.	.	.	0	0	0	.	0	.	.	.	.	1	.	0	.
329.009.00137	Biologic Mother	34	Female	No	.	1	.	0	.	0	.	1	.	1	0	1	1	0	.
	Biologic Father	41	Male	No	.	1	1	0	1	0	.	.	.	.	0	.	.	0	.
	Sibling #1	20	Female	No	.	1	.	0	.	0	.	.	.	.	0	.	.	0	.
	Sibling #2	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	1	1	.	0	.	0	.	1	1	.	0	1	1	0	.
	Sibling #4	12	Female	No	.	.	.	0	.	0	.	.	.	.	0	.	.	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

144

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.009.00171	Biologic Mother	38	Female	No	.	.	9	.	9	.	9	.	.	.	.	.	9	9	9	
	Biologic Father	41	Male	No	.	.	9	1	9	1	9	.	.	.	.	.	9	9	9	
	Sibling #1	23	Male	No	.	.	9	.	9	.	9	.	.	.	.	.	9	9	9	
	Sibling #2	16	Female	No	1	1	9	.	9	.	9	1	1	1	1	1	9	9	9	
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	12	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #5	4	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00172	Biologic Mother	43	Female	No	.	1	0	0	1	0	.	1	1	1	.	1	1	0	.	
	Biologic Father	45	Male	No	.	.	0	0	.	0	.	.	.	.	.	.	.	0	.	
	Sibling #1	23	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	19	Female	No	.	.	0	0	.	0	.	1	1	1	.	.	.	0	.	
Sibling #3	13	Female	No	1	1	0	0	.	0	.	1	1	1	.	1	.	0	.		
329.009.00194	Biologic Mother	36	Female	No	0	1	0	9	1	9	.	1	1	1	1	1	1	9	9	
	Biologic Father	33	Male	No	0	.	0	9	.	9	.	.	.	.	.	.	.	9	9	
	Sibling #1	12	Male	No	0	1	0	9	.	9	.	1	1	1	1	1	1	9	9	
	Sibling #2	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	3	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00195	Biologic Mother	39	Female	No	.	1	.	0	.	.	.	1	.	.	.	1	.	.		
	Biologic Father	40	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	
	Sibling #1	16	Female	No	.	1	.	0	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	14	Female	No	.	1	.	0	.	.	.	1	1	1	.	1	.	.		
	Sibling #3	12	Male	No	.	1	.	0	.	.	.	.	.	.	.	.	.	.		
329.009.00199	Biologic Mother	49	Female	No	.	1	.	0	.	.	.	1	.	.	.	.	.	.		
	Biologic Father	56	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	18	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1		
	Sibling #2	14	Female	No	1	1	.	0	.	.	.	1	1	1	1	1	1	.		
	Sibling #3	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.009.00203	Biologic Mother	36	Female	No	1	1	0	0	1	.	.	1	1	1	.	1	1	0	0	
	Biologic Father	38	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0	
	Sibling #1	12	Female	Yes	.	.	0	0	.	1	1	1	1	1	1	1	1	0	0	
	Sibling #2	5	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00236	Biologic Mother	45	Female	No	1	1	.	.	1	1	.	1	1	1	1	1	1	.	.	
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		

0 = NO; 1 = YES; 9 = DON'T KNOW

145

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.009.00236	Sibling #2	16	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Sibling #3	13	Female	No	.	.	.	.	.	.	.	1	1	1	1	.	.	.	.
329.009.00262	Biologic Mother	38	Female	No	.	1	.	.	1	.	.	1	.	.	.	.	.	0	0
	Biologic Father	43	Male	No	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	13	Male	No	.	1	.	.	.	.	.	1	1	1	1	.	.	0	0
	Sibling #2	11	Male	No	.	1	.	.	.	.	.	.	.	.	.	.	.	0	0
329.009.00264	Biologic Mother	37	Female	No	.	.	0	0	0	.	.	1	.	1	.	.	.	1	0
	Biologic Father	40	Male	No	1	1	0	0	0	1	.	1	1	1	1	1	1	1	0
	Sibling #1	14	Female	No	.	1	0	0	0	1	1	1	1	1	1	1	.	1	0
329.009.00301	Biologic Mother	39	Female	No	0	1	0	0	0	0	.	1	.	1	.	.	.	0	.
	Biologic Father	39	Male	No	0	1	0	0	0	0	.	1	.	1	.	.	.	0	.
	Sibling #1	17	Male	No	0	1	0	0	0	0	.	1	1	1	1	1	1	0	.
	Sibling #2	10	Male	No	0	.	0	0	0	0	.	1	.	1	.	.	.	0	.
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00305	Biologic Mother	44	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	.
	Biologic Father	45	Male	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #1	17	Female	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #2	14	Male	No	.	1	0	0	.	.	.	1	1	1	1	1	1	0	.
329.009.00325	Biologic Mother	33	Female	No	9	.	.	9	9	9	0	.	.	.	.	.	.	.	.
	Biologic Father	38	Male	No	9	1	1	9	9	9	0	1	.	.	1	1	.	.	
	Sibling #1	15	Female	No	9	1	.	9	9	9	0	1	1	1	1	1	1	1	
329.009.00326	Biologic Mother	31	Female	No	0	0	0	0	0	.	0	.	.	.	1	.	1	0	
	Biologic Father	34	Male	No	0	0	0	0	0	1	0	1	1	1	.	.	.	0	
	Sibling #1	13	Male	No	0	0	0	0	0	1	0	1	1	1	1	1	1	0	
	Sibling #2	9	Male	No	0	0	0	0	0	.	0	.	.	.	.	.	1	0	
329.010.00279	Biologic Mother	37	Female	No	.	0	0	0	0	0	.	1	.	.	.	.	.	0	
	Biologic Father	48	Male	No	1	0	0	0	0	0	.	1	1	1	1	.	.	0	
	Sibling #1	13	Female	No	1	0	0	0	0	0	.	1	1	1	1	1	1	0	
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
Sibling #3	1	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		

0 = NO; 1 = YES; 9 = DON'T KNOW

146

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.010.00281	Biologic Mother	43	Female	No	.	.	.	0	.	0	.	.	.	.	.	.	.	0	.
	Biologic Father	48	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	.	.	.	0	.	0	.	.	1	1	1	1	0	.	
	Sibling #2	16	Male	No	.	.	.	0	.	0	.	.	.	.	.	.	.	0	.
	Sibling #3	14	Female	No	.	.	.	0	.	0	.	.	.	.	.	.	.	0	.
	Sibling #4	13	Male	No	1	1	1	0	1	0	.	1	1	1	1	1	1	0	.
329.011.00163	Biologic Mother	42	Female	No	0	.	0	0	.	0	0	.	.	.	.	0	0	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	1	0	0	1	0	0	1	1	1	1	0	0	0	0
	Sibling #2	9	Male	No	0	1	0	0	1	0	0	.	.	.	.	0	0	0	0
329.011.00208	Biologic Mother	51	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	44	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	.	1	.	0	.	.	.	1	1	1	.	1	.	.	
329.011.00209	Biologic Mother	41	Female	No	1	1	0	0	1	0	0	1	1	1	1	.	.	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Male	No	.	.	0	0	.	0	0	1	1	1	1	1	1	0	0
	Sibling #2	10	Female	No	.	.	0	0	.	0	0	.	.	.	.	.	.	0	0
329.011.00284	Biologic Mother	46	Female	No	0	1	0	0	.	.	.	1	.	.	.	.	0	0	
	Biologic Father	47	Male	No	0	1	0	0	.	.	.	.	.	.	.	.	0	0	
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Male	No	0	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #3	10	Male	No	0	.	0	0	.	.	.	.	.	.	.	.	.	0	0
329.011.00286	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	1	.	.	.	1	1	.	0
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	.	.	.	.	.	.	0	0
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	.	.	.	.	.	.	0	0
	Sibling #2	15	Female	No	0	0	0	0	0	0	0	1	1	1	9	1	1	1	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00026	Biologic Mother	37	Female	No	.	.	0	0	.	0	.	0	.	.	0	.	.	0	.
	Biologic Father	36	Male	No	.	.	0	0	.	0	.	0	.	.	0	.	.	0	.
	Sibling #1	15	Female	No	1	1	0	0	1	0	.	0	.	.	0	.	.	0	.
	Sibling #2	14	Male	No	.	1	0	0	.	0	.	0	.	1	0	1	1	0	.
329.012.00219	Biologic Mother	42	Female	No	.	.	.	0	.	.	.	.	.	.	.	.	.	0	0
	Biologic Father	42	Male	No	1	1	1	0	1	1	1	1	1	1	.	.	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

147

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.012.00219	Sibling #1	16	Female	No	.	.	.	0	.	.	.	.	.	.	.	.	.	0	0	
	Sibling #2	14	Male	No	1	1	.	0	1	1	1	1	1	1	1	1	1	1	0	0
329.012.00221	Biologic Mother	44	Female	No	.	.	0	0	.	0	0	.	.	0	0	0	0	0	0	0
	Biologic Father	44	Male	No	.	.	0	0	.	0	0	.	.	0	0	0	0	0	0	0
	Sibling #1	17	Male	No	1	1	0	0	1	0	0	1	1	0	0	0	0	0	0	0
	Sibling #2	15	Male	No	.	1	0	0	.	0	0	.	.	0	0	0	0	0	0	0
	Sibling #3	14	Female	No	.	1	0	0	.	0	0	1	.	0	0	0	0	0	0	0
329.012.00223	Biologic Mother	32	Female	No	.	1	0	0	1	0	.	1	1	.	.	.	.	.	0	
	Biologic Father	34	Male	No	.	.	0	0	.	0	.	.	.	.	.	.	.	.	0	
	Sibling #1	13	Female	No	1	1	0	0	.	0	.	1	1	1	1	1	1	1	0	
	Sibling #2	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.012.00227	Biologic Mother	49	Female	No	.	.	.	0	0	0	0	.	.	1	1	.	0	.	0	
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	27	Male	No	.	.	.	0	0	0	0	.	.	.	.	.	0	.	0	
	Sibling #2	22	Male	No	.	.	.	0	0	0	0	.	.	.	.	1	0	.	0	
	Sibling #3	16	Male	No	1	1	1	0	0	0	0	1	1	1	1	.	0	1	0	
329.012.00230	Biologic Mother	36	Female	No	1	1	.	.	1	1	1	1	1	1	1	1	1	0	0	
	Biologic Father	53	Male	Yes	1	.	1	1	.	1	1	1	1	1	1	1	.	0	0	
	Sibling #1	15	Male	No	1	1	.	.	1	1	1	1	1	1	1	1	1	0	0	
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

148

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B	
329.001.00062	Biologic Mother	38	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0	
	Biologic Father	37	Male	No	1	.	.	0	.	1	.	.	.	.	.	.	.	0	0	
	Sibling #1	18	Female	No	.	.	.	0	.	.	.	1	.	1	.	1	.	0	0	
	Sibling #2	16	Female	No	1	.	.	0	.	1	.	1	1	1	1	1	1	1	0	0
	Sibling #3	15	Female	No	1	1	.	0	.	.	.	1	1	1	1	1	1	1	0	0
329.001.00064	Biologic Mother	32	Female	No	0	.	0	0	.	0	0	1	.	1	.	.	.	0	0	
	Biologic Father	42	Male	No	0	.	0	0	.	0	0	.	.	.	.	.	.	0	0	
	Sibling #1	13	Male	No	0	1	0	0	1	0	0	1	1	1	1	1	1	0	0	
	Sibling #2	8	Male	No	0	.	0	0	.	0	0	.	.	.	.	1	1	0	0	
329.001.00069	Biologic Mother	49	Female	No	.	.	.	0	.	.	.	.	.	.	.	1	1	.	.	
	Biologic Father	55	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	
	Sibling #1	26	Female	No	1	.	.	0	.	.	.	1	1	1	1	.	.	.	.	
	Sibling #2	24	Male	No	1	1	.	0	1	.	.	1	1	1	1	.	.	.	.	
	Sibling #3	22	Female	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	16	Male	No	1	1	.	0	1	.	.	1	.	1	1	.	.	.	.	
329.001.00071	Biologic Mother	48	Female	No	1	1	0	0	.	0	0	1	1	1	1	1	1	0	0	
	Biologic Father	46	Male	No	1	1	0	0	1	0	0	1	1	1	.	1	.	0	0	
	Sibling #1	18	Male	No	1	1	0	0	1	0	0	1	1	.	.	.	.	0	0	
	Sibling #2	13	Female	No	1	1	0	0	.	0	0	1	1	1	1	1	1	1	0	0
329.001.00123	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	47	Male	No	1	1	0	0	0	.	.	1	1	1	1	.	.	0	0	
	Sibling #1	22	Male	No	.	.	0	0	0	1	1	.	.	.	.	.	.	0	0	
	Sibling #2	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	16	Female	No	1	1	0	0	0	1	1	1	1	1	1	1	1	1	0	0
329.001.00207	Biologic Mother	48	Female	No	.	.	0	0	0	.	.	1	.	.	.	.	.	0	.	
	Biologic Father	49	Male	No	.	.	0	0	0	.	.	1	.	.	.	.	.	0	.	
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	14	Male	No	1	1	0	0	0	1	1	1	1	1	1	1	1	1	0	.
329.002.00049	Biologic Mother	52	Female	No	0	.	0	0	.	.	9	1	1	.	9	1	1	0	0	
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	23	Male	No	0	1	0	0	.	.	9	.	.	.	9	1	1	0	0	
	Sibling #3	20	Male	No	0	.	0	0	.	1	9	.	.	.	9	.	.	0	0	
	Sibling #4	16	Male	No	0	1	0	0	1	.	9	1	.	1	9	1	1	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

149

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.002.00059	Biologic Mother	46	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	50	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	.	.	0	0	1	1	1	1	1	1	1	1	1	0	0
329.002.00060	Biologic Mother	47	Female	No	.	1	.	0	.	0	.	1	1	1	1	0	.	0	.
	Biologic Father	45	Male	No	1	1	1	0	1	0	.	1	1	1	1	0	.	0	.
	Sibling #1	16	Female	No	.	.	.	0	.	0	.	1	.	.	0	.	0	.	
	Sibling #2	14	Female	No	.	1	.	0	.	0	.	1	1	1	1	0	.	0	.
	Sibling #3	11	Male	No	.	.	.	0	.	0	.	.	.	.	.	0	.	0	.
329.002.00097	Biologic Mother	43	Female	No	0	1	0	0	1	1	1	1	1	.	0	1	0	0	0
	Biologic Father	45	Male	No	0	1	0	0	.	1	1	1	1	.	0	.	0	0	0
	Sibling #1	16	Female	No	0	1	0	0	.	1	1	1	1	1	0	1	0	0	0
	Sibling #2	13	Female	No	0	1	0	0	.	1	1	1	1	1	0	1	0	0	0
	Sibling #3	9	Male	No	0	1	0	0	.	.	.	.	.	.	0	.	0	0	0
329.002.00101	Biologic Mother	48	Female	No	.	1	.	.	.	.	.	1	1	.	.	.	.	1	0
	Biologic Father	52	Male	No	1	1	1	.	1	1	1	1	1	1	1	1	1	1	0
	Sibling #1	26	Male	No	.	1	.	.	.	.	.	1	.	1	.	.	.	1	0
	Sibling #2	28	Female	No	.	1	.	.	.	.	.	1	.	.	.	.	.	1	0
	Sibling #3	22	Female	No	.	1	.	.	.	.	.	1	.	.	.	.	.	1	0
329.002.00107	Biologic Mother	47	Female	No	1	1	0	0	1	.	1	1	1	1	1	1	1	.	0
	Biologic Father	53	Male	Yes	.	.	0	0	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	27	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	.	0
	Sibling #2	20	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	.	0
	Sibling #3	18	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0
329.002.00241	Biologic Mother	38	Female	No	0	.	0	0	0	.	.	.	.	1	.	.	.	0	0
	Biologic Father	42	Male	No	0	.	0	0	0	.	.	.	.	1	.	.	.	0	0
	Sibling #1	15	Male	No	0	1	0	0	0	1	1	1	1	1	1	1	1	0	0
	Sibling #2	17	Male	No	0	.	0	0	0	.	.	.	.	1	.	.	.	0	0
	329.002.00246	Biologic Mother	34	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Biologic Father		35	Male	No	.	.	.	.	.	.	.	1	1	.	.	1	1	.	.
Sibling #1		17	Female	No	1	1	.	.	.	.	.	1	1	1	1	1	1	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

150

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.002.00246	Sibling #2	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	2	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00320	Biologic Mother	40	Female	No	0	.	0	.	.	.	.	1	.	1	.	1	.	0	0
	Biologic Father	44	Male	No	0	.	0	1	.	1	1	.	.	.	.	.	.	0	0
	Sibling #1	16	Male	No	0	.	0	.	.	.	.	.	.	.	.	.	.	0	0
	Sibling #2	13	Female	No	0	1	0	.	.	.	.	1	1	1	1	1	1	0	0
	Sibling #3	9	Female	No	0	1	0	.	1	.	.	.	.	.	.	.	.	0	0
329.002.00323	Biologic Mother	44	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	1	1	0	0	1	0	0	.	.	9	0	1	1	0	0
	Sibling #2	17	Female	No	1	1	0	0	.	0	0	1	1	9	0	1	1	0	0
329.003.00074	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	Sibling #2	5	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00078	Biologic Mother	40	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	9	9
	Biologic Father	47	Male	No	.	1	0	0	.	.	.	1	.	.	.	.	.	9	9
	Sibling #1	17	Female	No	.	1	0	0	.	.	.	.	.	.	1	.	9	9	
	Sibling #2	15	Female	No	1	1	0	0	.	1	1	1	1	1	1	1	1	9	9
	Sibling #3	12	Female	No	.	1	0	0	.	.	.	.	.	.	.	.	.	9	9
329.003.00080	Biologic Mother	43	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	48	Male	No	1	.	0	0	0	.	0	1	0	.	.	.	.	0	0
	Sibling #1	16	Female	No	1	1	0	0	0	1	0	1	0	1	1	1	1	0	0
	Sibling #2	14	Male	No	.	.	0	0	0	1	0	.	0	.	.	.	.	0	0
329.003.00085	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	0	1	0	0	0	1	1	1	1	1	1	1	1	1	1
	Sibling #2	14	Female	No	0	.	0	0	0	.	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00086	Biologic Mother	38	Female	No	0	.	0	0	0	.	.	.	.	.	.	0	0	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	0	1	0	0	0	1	1	1	1	1	1	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

151

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11
329.003.00086	Sibling #2	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00094	Biologic Mother	55	Female	No	0	0	0	0	1	0	0	.	.	9	0	0	0	0
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	13	Female	No	0	0	0	0	.	0	0	1	1	9	0	0	0	0
329.003.00252	Biologic Mother	42	Female	No	0	1	0	0	1	0	0	1	1	1	9	1	1	1
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	0	.	0	0	.	0	0	1	.	1	9	1	.	0
329.003.00291	Biologic Mother	38	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	35	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	13	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #2	.	.	.	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.003.00315	Biologic Mother	52	Female	No	.	.	.	.	.	1	1	.	.	.	.	.	.	0
	Biologic Father	52	Male	No	1	1	1	1	1	1	1	1	1	1	1	1	1	0
	Sibling #1	16	Female	No	.	.	.	.	.	.	.	1	1	1	1	1	.	0
	Sibling #2	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00316	Biologic Mother	40	Female	No	1	.	.	.	.	1	1	1	1	.	1	1	1	.
	Biologic Father	38	Male	No	.	.	.	.	.	1	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	1	1	1	1	1	1	.	.	.	1	.	1	1	1
	Sibling #2	16	Female	No	1	.	.	.	.	1	.	1	1	1	1	1	1	.
	Sibling #3	10	Female	No	1	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	6	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00016	Biologic Mother	46	Female	No	1	1	0	0	1	1	.	1	1	1	1	1	0	0
	Biologic Father	46	Male	No	.	1	0	0	.	1	1	.	.	.	.	.	0	0
	Sibling #1	22	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	.	1	0	0	.	.	.	1	1	1	1	1	1	0
329.004.00018	Biologic Mother	42	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	0	.
	Biologic Father	49	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

152

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.004.00018	Sibling #1	17	Female	No	1	1	.	.	.	1	1	1	1	1	1	1	1	0	.
	Sibling #2	14	Male	No	1	1	1	.	1	1	1	1	1	1	1	1	1	0	.
329.004.00020	Biologic Mother	38	Female	No	1	1	0	0	1	1	1	1	1	.	.	.	.	0	.
	Biologic Father	45	Male	No	.	1	0	0	1	.	.	1	.	.	.	.	.	0	.
	Sibling #1	18	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	.
	Sibling #2	14	Female	No	1	1	0	0	.	1	1	1	1	1	1	1	1	0	.
329.004.00213	Biologic Mother	45	Female	No	.	.	0	0	.	0	.	.	.	.	.	.	.	0	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	1	1	0	0	.	0	.	1	1	1	1	1	1	0	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00001	Biologic Mother	41	Female	No	1	.	.	0	.	.	.	1	1	.	.	1	1	.	.
	Biologic Father	45	Male	No	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	1	.	.	0	.	.	.	1	1	.	.	.	.	.	.
	Sibling #3	16	Female	No	1	1	.	0	.	1	1	1	1	1	.	1	.	.	.
329.005.00005	Biologic Mother	40	Female	No	.	.	0	1	.	0	0	1	.	.	.	0	0	0	0
	Biologic Father	46	Male	No	.	.	0	.	.	0	0	.	.	.	.	0	0	0	0
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Male	No	1	1	0	.	1	0	0	1	1	1	1	0	0	0	0
329.005.00010	Biologic Mother	45	Female	No	0	.	.	0	0	0	0	.	.	.	0	.	.	0	0
	Biologic Father	47	Male	No	0	.	.	0	0	0	0	1	1	1	0	1	1	0	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Female	No	0	.	.	0	0	0	0	1	1	1	0	1	1	0	0
	Sibling #5	15	Female	No	0	.	.	0	0	0	0	.	.	.	0	.	.	0	0
	Child #1	12	Male	No	0	1	1	0	0	0	0	.	.	.	0	.	.	0	0
329.005.00012	Biologic Mother	41	Female	No	0	1	0	0	1	0	0	1	1	1	1	1	1	0	0
	Biologic Father	44	Male	No	0	.	0	0	.	0	0	.	.	.	.	.	.	0	0
	Sibling #1	18	Male	No	0	.	0	0	.	0	0	.	.	.	.	.	.	0	0
	Sibling #2	14	Female	No	0	.	0	0	.	0	0	1	1	1	.	.	.	0	0
329.005.00111	Biologic Mother	36	Female	No	0	.	0	0	.	.	.	.	.	.	.	.	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

153

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.005.00111	Biologic Father	40	Male	No	0	1	0	0	1	1	1	1	1	1	1	.	.	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	.	0	0	.	.	.	1	1	1	.	1	1	0	0
	Sibling #3	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00114	Biologic Mother	47	Female		1	1	1	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	55	Male		.	.	.	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	22	Male	No	.	1	.	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #2	16	Male	No	.	.	.	0	.	.	.	1	1	1	1	1	1	0	0
Sibling #3	25	Female	No	1	1	.	0	1	.	.	1	1	1	1	1	1	1	0	0
329.005.00115	Biologic Mother	41	Female	Yes	0	0	0	.	0	1	0	.	.	.	.	.	.	.	0
	Biologic Father	0	Male	Yes	0	0	0	1	0	.	0	.	.	.	.	.	.	.	0
	Sibling #1	25	Male	No	0	0	0	.	0	1	0	.	.	.	.	.	.	0	
	Sibling #2	18	Female	No	0	0	0	.	0	.	0	1	1	1	1	1	1	1	0
Sibling #3	17	Male	No	0	0	0	.	0	1	0	.	.	.	.	.	.	.	0	
329.005.00120	Biologic Mother	36	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	1	1	0	0	.	.	.	1	1	1	1	1	1	0	0
	Sibling #2	9	Male	No	1	1	0	0	1	1	1	.	.	.	.	.	.	0	0
329.005.00253	Biologic Mother	44	Female	No	1	1	1	.	1	1	1	1	1	1	0	1	.	0	0
	Biologic Father	44	Male	No	.	1	1	1	.	.	.	.	.	.	0	1	1	0	0
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	.	1	.	.	.	.	.	1	1	1	0	1	1	0	0
Sibling #3	10	Male	No	.	1	.	.	.	.	.	.	.	.	0	.	.	0	0	
329.005.00254	Biologic Mother	41	Female	No	.	1	1	1	1	1	1	.	.	1	1	1	1	1	1
	Biologic Father	45	Male	No	.	1	1	1	1	1	1	1	1	1	.	.	.	.	.
	Sibling #1	16	Female	No	.	.	.	.	.	1	.	1	1	1	1	1	1	.	.
	Sibling #2	12	Female	No	1	1	.	.	.	1	.	1	.	.	.	.	.	.	.
Sibling #3	9	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00293	Biologic Mother	42	Female	No	1	1	1	.	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	41	Male	No	.	.	.	1	1	1	1	.	.	1	1	1	1	1	.
	Sibling #1	16	Female	No	.	1	.	.	.	1	1	1	1	1	1	1	1	.	.
	Sibling #2	14	Female	No	.	1	.	.	.	1	1	1	1	1	1	1	1	.	.
Sibling #3	7	Male	No	.	1	.	.	1	1	1	.	.	.	.	.	.	.	.	
Sibling #4	12	Male	No	.	1	.	.	1	1	1	.	.	.	.	1	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

154

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.005.00293	Child #1	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Child #2	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00298	Biologic Mother	42	Female	No	0	1	0	0	1	1	0	1	1	1	1	1	1	0	0
	Biologic Father	44	Male	No	0	.	0	0	.	.	0	.	.	.	.	.	.	0	0
	Sibling #1	14	Female	No	0	1	0	0	.	.	0	1	.	.	.	.	.	0	0
	Sibling #2	13	Female	No	0	1	0	0	.	.	0	1	1	1	1	1	1	0	0
	Sibling #3	8	Male	No	0	1	0	0	.	.	0	1	.	.	.	.	.	0	0
329.005.00331	Sibling #4	6	Male	No	0	1	0	0	.	.	0	1	.	.	.	.	0	0	
	Biologic Mother	38	Female	No	1	1	0	1	.	.	0	1	.	1	1	1	1	0	0
	Biologic Father	48	Male	Unknown	1	1	0	.	1	1	0	1	1	.	.	.	0	0	
	Sibling #1	15	Female	No	.	1	0	.	.	.	0	1	1	1	1	1	1	0	0
329.005.00334	Sibling #2	11	Female	No	.	.	0	.	.	.	0	1	.	.	.	1	1	0	0
	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
329.006.00037	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	0	.	0	0	0	0	0
	Biologic Mother	59	Female	No	1	1	0	0	1	.	.	1	.	1	1	1	1	1	0
	Biologic Father	55	Male	No	1	1	0	0	1	.	.	.	.	.	.	1	1	1	0
	Sibling #1	39	Male	No	.	.	0	0	.	.	.	.	.	.	1	1	1	0	
	Sibling #2	36	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	1	0
329.006.00042	Sibling #3	17	Female	No	.	1	0	0	1	.	.	1	1	1	1	1	1	1	0
	Biologic Mother	40	Female	No	0	9	0	0	0	.	.	.	.	.	0	.	.	0	.
	Biologic Father	43	Male	No	0	9	0	0	0	1	1	1	.	.	0	.	.	0	.
	Sibling #1	18	Male	No	0	9	0	0	0	.	.	1	1	1	0	1	1	0	.
	Sibling #2	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.006.00259	Sibling #3	9	Male	No	0	9	0	0	0	.	.	.	.	0	.	.	0	.	
	Sibling #4	7	Female	No	0	9	0	0	0	.	.	.	.	0	.	.	0	.	
	Biologic Mother	49	Female	No	0	1	0	0	.	0	.	.	.	.	.	.	9	0	.
	Biologic Father	53	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00141	Sibling #1	17	Male	No	0	1	0	0	1	0	.	1	1	1	1	1	9	0	.
	Sibling #2	15	Male	No	0	.	0	0	.	0	.	.	.	.	.	9	0	.	
	Sibling #3	10	Female	No	0	.	0	0	.	0	.	.	.	.	.	9	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

155

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.007.00141	Biologic Father	32	Male	No	.	.	.	.	.	.	.	.	.	1	.	.	.	.	0
	Sibling #1	13	Male	No	.	1	.	.	.	.	.	1	.	1	.	1	.	.	0
	Sibling #2	9	Female	Yes	.	1	.	.	.	.	.	1	.	.	.	1	.	.	0
329.007.00144	Biologic Mother	28	Female	No	0	0	0	0	0	0	.	.	.	1	1	1	1	0	.
	Biologic Father	39	Male	No	0	0	0	0	0	0	.	.	.	.	.	.	.	0	.
	Sibling #1	12	Female	No	0	0	0	0	0	0	.	1	1	1	1	1	1	0	.
329.007.00266	Biologic Mother	33	Female	No	1	1	1	1	1	1	1	1	1	1	1	.	1	1	
	Biologic Father	34	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	12	Female	No	.	.	.	.	.	1	.	1	1	1	.	1	1	1	
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.007.00267	Biologic Mother	46	Female	No	0	1	0	9	0	0	.	.	0	.	0	.	0	0	
	Biologic Father	46	Male	No	0	.	0	9	0	0	.	.	0	.	0	.	0	0	
	Sibling #1	16	Male	No	0	1	0	9	0	0	.	1	0	1	0	1	0	0	
329.007.00311	Biologic Mother	44	Female	No	0	1	.	.	1	.	0	1	0	1	0	.	.	1	
	Biologic Father	62	Male	No	0	1	.	.	1	.	0	.	0	1	0	.	.	0	
	Sibling #1	18	Female	No	0	1	1	1	1	1	0	1	0	1	0	1	1	1	
	Sibling #2	15	Male	No	0	1	.	.	1	1	0	1	0	1	0	.	.	1	
	Sibling #3	13	Male	No	0	1	.	.	1	.	0	1	0	1	0	1	.	1	
329.008.00158	Biologic Mother	47	Female	No	.	.	.	0	.	.	.	.	1	.	.	.	.	0	
	Biologic Father	49	Male	No	1	1	1	0	1	1	1	1	1	.	1	1	1	0	
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	18	Female	No	.	1	.	0	1	.	.	1	.	.	.	.	.	0	
	Sibling #3	16	Female	No	.	1	.	0	1	.	.	1	.	1	.	1	1	0	
	Child #2	.	.	.	.	.	.	0	.	.	.	.	.	.	1	.	.	0	
329.008.00162	Biologic Mother	46	Female	No	0	0	0	.	1	1	0	1	1	1	1	1	1	0	
	Biologic Father	41	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	27	Male	No	0	0	0	1	.	.	0	.	.	.	.	.	.	0	
329.008.00191	Biologic Mother	43	Female	No	.	1	0	0	1	0	0	1	1	1	1	1	1	0	
	Biologic Father	45	Male	No	.	.	0	0	.	0	0	1	.	.	.	.	.	0	
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

156

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.008.00191	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	.			.	.	0	0	.	0	0	.	.	.	.	.	0	0	
329.009.00128	Biologic Mother	50	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	49	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	23	Male	No	1	1	0	0	.	1	1	1	1	.	.	.	.	0	0
	Sibling #2	13	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #3	10	Female	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	0
329.009.00129	Biologic Mother	42	Female	No	1	1	0	0	1	1	.	1	1	1	1	1	1	1	.
	Biologic Father	47	Male	No	.	.	0	0	.	1	.	1	1	1	1	1	1	.	.
	Sibling #1	16	Male	No	1	1	0	0	1	1	.	1	1	1	1	1	1	.	.
	Sibling #2	12	Female	No	.	.	0	0	.	.	.	1	1	1	1	1	.	.	.
329.009.00135	Biologic Mother	48	Female	No	1	1	0	0	0	.	.	1	.	1	1	.	.	0	.
	Biologic Father	48	Male	No	.	1	0	0	0	.	.	1	.	.	.	.	.	0	.
	Sibling #1	17	Female	No	1	.	0	0	0	1	1	1	1	1	1	1	1	0	.
329.009.00136	Biologic Mother	39	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #6	15	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #7	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #8	14	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #9	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	48	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	23	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #5	16	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
329.009.00169	Biologic Mother	27	Female	No	9	9	0	.	0	1	1	.	.	0	.	.	.	0	.
	Biologic Father	32	Male	No	9	9	0	1	0	1	1	.	.	0	.	.	.	0	.
	Sibling #1	13	Male	No	9	9	0	.	0	1	1	1	1	0	.	1	1	0	.
	Sibling #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00174	Biologic Mother	44	Female	No	0	1	0	0	1	0	.	1	1	1	1	1	1	0	.
	Biologic Father	48	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

157

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.009.00174	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	26	Male	No	0	.	0	0	.	0	.	.	.	.	1	1	0	.	
	Sibling #3	15	Female	No	0	.	0	0	.	0	.	1	1	1	1	1	1	0	.
329.009.00197	Biologic Mother	29	Female	No	0	0	0	0	1	0	.	1	1	0	.	1	0	0	.
	Biologic Father	31	Male	No	0	0	0	0	.	0	.	.	.	0	.	.	0	0	.
	Sibling #1	12	Male	No	0	0	0	0	.	0	.	.	.	0	.	.	0	0	.
	Sibling #2	4	Female	No	0	0	0	0	.	0	.	.	.	0	.	.	0	0	.
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00198	Biologic Mother	34	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	.	0
	Biologic Father	35	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	17	Female	No	1	1	0	0	.	1	1	1	1	1	1	1	1	.	0
	Sibling #2	15	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	.	0
	Sibling #3	13	Female	No	.	.	0	0	.	.	.	.	.	.	.	.	.	1	0
329.009.00200	Biologic Mother	49	Female	No	.	.	.	0	.	.	.	1	.	.	.	1	1	0	.
	Biologic Father	53	Male	No	1	.	.	0	.	1	1	1	1	1	1	.	.	0	.
	Sibling #1	17	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	.
	Sibling #2	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00202	Biologic Mother	40	Female	No	1	1	.	.	1	1	1	1	1	1	.	1	1	.	0
	Biologic Father	41	Male	No	1	.	.	1	.	1	1	1	.	.	.	.	.	.	0
	Sibling #1	19	Male	No	1	1	1	.	.	.	1	1	.	.	.	.	.	.	0
	Sibling #2	15	Female	No	1	1	.	.	.	1	1	1	1	1	1	1	1	1	0
	Sibling #3	14	Male	No	1	1	.	.	1	1	1	1	1	.	.	.	.	.	0
329.009.00237	Biologic Mother	43	Female	No	0	.	0	0	0	0	0	1	.	1	1	.	0	1	0
	Sibling #6	9	Female	No	0	.	0	0	0	0	0	.	.	.	.	.	0	1	0
	Biologic Father	44	Male	No	0	.	0	0	0	0	0	.	.	.	.	1	0	1	0
	Sibling #1	21	Male	No	0	.	0	0	0	0	0	.	.	.	.	.	0	1	0
	Sibling #2	19	Female	No	0	.	0	0	0	0	0	.	.	.	.	.	0	1	0
	Sibling #3	17	Male	No	0	1	0	0	0	0	0	1	1	1	1	1	0	1	0
	Sibling #4	12	Male	No	0	.	0	0	0	0	0	.	.	.	.	.	0	1	0
	Sibling #5	10	Male	No	0	.	0	0	0	0	0	.	.	.	.	.	0	1	0
329.009.00238	Biologic Mother	42	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	42	Male	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Sibling #1	21	Male	Yes	.	.	0	0	.	.	.	.	.	.	.	.	0	0	0
	Sibling #2	16	Female	Yes	.	1	0	0	.	.	.	1	1	1	1	1	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

158

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.009.00238	Sibling #3	9	Female	Yes	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
329.009.00276	Biologic Mother	30	Female	No	1	1	0	1	0	1	1	.	.	.	.	.	.	1	0
	Biologic Father	32	Male	No	1	.	0	.	0	1	.	.	.	.	.	.	.	.	0
	Sibling #1	13	Male	No	1	.	0	.	0	1	1	1	1	1	1	1	1	1	0
329.009.00302	Biologic Mother	40	Female	No	0	.	0	0	.	.	.	.	.	.	.	.	.	0	.
	Biologic Father	41	Male	No	0	1	0	0	.	.	.	.	1	.	.	.	.	0	.
	Sibling #1	17	Male	No	0	1	0	0	1	1	1	1	1	1	1	1	1	0	.
	Sibling #2	10	Female	No	0	.	0	0	.	.	.	.	.	.	.	.	.	0	.
329.009.00306	Biologic Mother	28	Female	Yes	9	0	0	0	0	1	1	1	0	9	.	0	.	0	.
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	9	0	0	0	0	.	.	1	0	9	.	0	.	0	.
329.009.00312	Biologic Mother	48	Female	No	1	1	1	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	55	Male	No	.	1	.	0	.	1	1	.	.	.	.	.	.	0	0
	Sibling #1	17	Female	No	1	1	.	0	1	1	1	1	1	1	1	1	1	0	0
329.009.00327	Biologic Mother	40	Female	No	0	1	0	0	0	.	0	1	1	1	0	1	1	0	0
	Biologic Father	42	Male	No	0	.	0	0	0	1	0	.	.	.	0	.	.	0	0
	Sibling #1	18	Male	No	0	1	0	0	0	1	0	.	.	.	0	.	.	0	0
	Sibling #2	16	Female	No	0	1	0	0	0	1	0	1	.	1	0	.	.	0	0
329.009.00330	Biologic Mother	33	Female	No	1	1	1	1	1	0	0	1	1	1	1	1	1	.	0
	Biologic Father	36	Male	No	.	1	.	1	.	0	0	1	.	.	.	.	.	0	.
	Sibling #1	14	Female	No	.	1	.	.	.	0	0	.	.	.	.	.	.	.	0
	Sibling #2	12	Male	No	.	1	.	.	1	0	0	1	.	.	.	1	1	.	0
	Sibling #3	9	Male	No	.	1	.	.	.	0	0	.	.	.	.	.	.	1	0
329.010.00183	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	0	0	0	0	0	0	.	.	.	.	.	.	.	0	.
	Sibling #1	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	0	0	0	0	0	0	.	1	1	1	1	1	1	0	.
	Sibling #3	13	Female	No	0	0	0	0	0	0	.	.	.	.	.	.	.	0	.
329.010.00263	Biologic Mother	40	Female	No	1	1	0	0	1	.	.	1	1	1	1	1	1	0	0
	Biologic Father	60	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	21	Male	No	1	1	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #2	18	Male	No	1	1	0	0	.	1	.	1	1	1	1	1	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

159

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.010.00263	Sibling #3	15	Female	No	1	1	0	0	.	1	1	1	1	1	1	.	.	0	0
329.010.00277	Biologic Mother	35	Female	No	0	.	0	0	0	0	.	1	.	1	.	1	.	0	.
	Biologic Father	38	Male	No	0	.	0	0	0	0	.	.	.	.	.	.	.	0	.
	Sibling #1	14	Female	No	0	1	0	0	0	0	.	1	1	1	1	1	1	0	.
329.010.00282	Biologic Mother	45	Female	No	0	1	0	0	0	0	.	.	.	.	0	.	.	0	.
	Biologic Father	46	Male	No	0	1	0	0	0	0	.	.	.	.	0	.	.	0	.
	Sibling #1	18	Female	No	0	1	0	0	0	0	.	.	.	.	0	.	.	0	.
	Sibling #2	15	Female	No	0	1	0	0	0	0	.	1	1	1	0	1	1	0	.
	Sibling #3	12	Male	No	0	1	0	0	0	0	.	.	.	.	0	.	.	0	.
329.011.00164	Biologic Mother	43	Female	No	0	.	0	0	0	.	.	1	.	1	.	1	1	0	.
	Biologic Father	43	Male	No	0	.	0	0	0	.	.	.	.	.	.	.	.	0	.
	Sibling #1	24	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	20	Male	No	0	1	0	0	0	.	.	.	.	1	.	.	.	0	.
	Sibling #3	18	Male	No	0	.	0	0	0	.	.	1	.	1	.	.	.	0	.
329.011.00210	Sibling #4	15	Male	No	0	.	0	0	0	1	1	1	1	1	1	1	1	0	.
329.011.00210	Biologic Mother	32	Female	No	0	.	0	0	.	.	0	.	.	.	.	.	.	.	0
	Biologic Father	41	Male	No	0	1	0	0	1	.	0	1	1	1	1	1	1	1	0
	Sibling #1	14	Female	No	0	.	0	0	.	1	0	1	1	1	1	1	1	.	0
	Sibling #2	10	Male	No	0	1	0	0	1	.	0	.	.	.	.	.	.	.	0
329.011.00285	Biologic Mother	42	Female	No	0	.	0	0	0	.	0	.	.	.	.	.	.	0	0
	Biologic Father	44	Male	No	0	.	0	0	0	.	0	.	.	.	.	.	.	0	0
	Sibling #1	16	Male	No	0	1	0	0	0	1	0	1	1	1	1	1	1	0	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.011.00287	Biologic Mother	41	Female	No	0	.	0	0	0	.	.	.	.	.	.	.	.	0	0
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	.	0	0	0	.	.	1	.	.	.	.	.	0	0
	Sibling #2	14	Female	No	0	1	0	0	0	1	1	1	1	1	1	1	1	0	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00027	Sibling #4	4	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.012.00027	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	.	.	.	0	.	.	.	0
	Biologic Father	38	Male	No	.	.	.	1	1	.	.	1	.	1	0	1	1	1	0
	Sibling #1	15	Male	No	1	1	1	.	.	1	1	1	1	1	0	1	1	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

160

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part I  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					2	3	4	5	6	7	7B	8	8B	9	9B	10	10B	11	11B
329.012.00217	Biologic Mother	45	Female	No	.	1	0	0	1	.	.	.	.	1	.	.	.	0	0
	Biologic Father	45	Male	No	.	1	0	0	.	.	.	.	.	.	.	1	1	0	0
	Sibling #1	22	Male	No	.	.	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Female	No	1	1	0	0	.	1	1	1	1	1	1	1	.	.	0
329.012.00218	Biologic Mother	46	Female	No	.	.	0	0	.	0	.	.	.	.	.	0	.	0	0
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	1	1	0	0	1	0	.	1	1	1	1	0	.	0	0
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00224	Biologic Mother	41	Female	No	1	1	0	0	1	1	1	1	1	1	1	1	1	0	0
	Biologic Father	41	Male	No	.	1	0	0	.	.	.	.	.	.	.	.	.	0	0
	Sibling #1	14	Female	No	1	1	0	0	1	.	.	1	1	1	1	1	1	0	0
	Sibling #2	7	Female	No	.	1	0	0	.	.	.	.	.	.	.	1	1	0	0
329.012.00225	Biologic Mother	48	Female	No	.	1	0	0	1	0	0	.	.	1	.	1	1	0	.
	Biologic Father	48	Male	No	.	.	0	0	.	0	0	1	1	1	.	.	.	0	.
	Sibling #1	14	Male	No	1	1	0	0	1	0	0	1	1	1	1	1	1	0	.
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

161

0 = NO; 1 = YES; 9 = DON'T KNOW

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.001.00063	Biologic Mother	40	Female	No	0	0	0	0	0	0	1	1	0	0	0	0	.	0
	Biologic Father	43	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	.	0
	Sibling #1	14	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	.	0
	Sibling #2	13	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	1	0
	Sibling #3	10	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	.	0
329.001.00068	Biologic Mother	41	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	1	.
329.001.00072	Biologic Mother	45	Female	No	1	0	1	0	0	0	1	.	1	0	1	1	0	0
329.001.00121	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.001.00205	Biologic Mother	37	Female	No	.	0	0	.	0	.	1	0	0	.	.	0	.	0
329.001.00206	Biologic Mother	52	Female	No	0	0	0	0	.	0	0	0	0	0	0	.	0	0
329.002.00055	Biologic Mother	48	Female	No	9	.	9	.	1	.	1	.	1	1	1	1	1	1

0 = NO; 1 = YES; 9 = DON'T KNOW

162

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.002.00055	Sibling #4	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00058	Biologic Mother	42	Female	No	0	0	1	1	.	.	1	1	.	.	.	.	1	0
	Biologic Father	36	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	24	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #2	22	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #3	16	Female	No	0	0	1	1	1	1	.	.	1	1	1	1	1	0
329.002.00099	Biologic Mother	37	Female	Yes	0	.	0	.	.	9	.	0	0	.	0	.	0	.
	Biologic Father	47	Male	No	0	.	0	.	.	9	1	0	0	.	0	.	0	.
329.002.00102	Sibling #1	15	Male	No	0	.	0	.	.	9	1	0	0	.	0	.	0	.
	Sibling #2	9	Female	No	0	.	0	.	1	9	.	0	0	.	0	.	0	.
329.002.00105	Biologic Mother	35	Female	No	.	.	1	1	1	1	.	0	1	1	0	0	1	0
	Biologic Father	39	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	1	1	1	1	1	1	1	0	.	.	0	0	1	0
	Sibling #2	13	Female	No	.	.	1	1	1	1	.	0	1	1	0	0	1	0
329.002.00106	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Mother	43	Female	No	1	0	0	0	0	0	.	0	0	0	.	.	0	0
	Biologic Father	52	Male	Yes	.	0	0	0	0	0	.	0	0	0	1	1	0	0
	Sibling #1	17	Male	No	.	0	0	0	0	0	1	0	0	0	1	1	0	0
329.002.00106	Sibling #2	16	Male	Yes	1	0	0	0	0	0	1	0	0	0	1	1	0	0
	Biologic Mother	32	Female	No	0	.	.	.	0	.	0	.	1	.	.	.	.	0
	Biologic Father	36	Male	No	0	.	.	.	0	.	0	.	.	.	.	.	.	0
329.002.00242	Sibling #1	15	Female	No	0	.	1	1	0	.	0	.	1	1	1	1	1	0
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Mother	36	Female	No	0	0	1	1	1	0	.	.	1	1	1	1	1	1
329.002.00245	Biologic Father	39	Male	No	0	0	.	.	.	0	.	.	1	1	1	1	.	.
	Sibling #1	15	Female	No	0	0	.	.	.	0	1	1	.	.	.	.	1	.
	Sibling #2	12	Male	No	0	0	.	.	.	0	1	.	1	1	.	.	.	.
329.002.00245	Biologic Mother	36	Female	No	0	0	0	0	1	0	0	0	0	0	0	.	0	0
	Biologic Father	44	Male	No	0	0	0	0	.	0	0	0	0	0	0	.	0	0
	Sibling #1	14	Female	No	0	0	0	0	.	0	0	0	0	0	0	1	0	0
	Sibling #2	18	Male	No	0	0	0	0	.	0	0	0	0	0	0	.	0	0
	Sibling #3	16	Female	No	0	0	0	0	.	0	0	0	0	0	0	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

163

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.002.00245	Sibling #4	11	Female	No	0	0	0	0	.	0	0	0	0	0	0	.	0	0
	Sibling #5	9	Male	No	0	0	0	0	.	0	0	0	0	0	0	.	0	0
329.002.00319	Biologic Mother	42	Female	No	0	.	0	.	0	.	0	.	1	0	1	0	1	0
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Male	No	0	.	0	.	0	.	0	.	.	0	1	0	.	0
	Sibling #2	17	Male	No	0	.	0	.	0	.	0	.	.	0	1	0	.	0
	Sibling #3	16	Female	No	0	.	0	.	0	.	0	.	.	0	.	0	1	0
329.003.00077	.	.	.	.	1	0	.	.	.	.	.	0	0	1	0	0	.	0
	Biologic Mother	45	Female	No	.	0	1	1	1	1	1	0	0	.	0	0	1	0
	Biologic Father	55	Male	No	.	0	.	.	.	.	.	0	0	.	0	0	.	0
	Sibling #1	29	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #5	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00087	Biologic Mother	49	Female	No	.	0	.	.	1	1	.	.	.	.	.	0	1	0
	Biologic Father	50	Male	No	1	0	.	1	.	.	1	1	1	1	1	0	.	0
	Sibling #1	14	Female	Yes	.	0	1	1	1	1	1	1	1	1	1	.	0	.
329.003.00089	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	60	Male	No	0	0	0	0	0	0	0	0	0	0	0	.	0	0
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	1	0	0
329.003.00091	Biologic Mother	.	Female	No	0	0	1	.	1	0	.	0	1	1	0	0	0	0
	Biologic Father	.	Male	No	0	0	1	1	.	0	1	0	.	.	0	0	0	0
	Sibling #1	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	.	Male	No	0	0	.	.	.	0	.	0	.	.	0	0	0	0
	Sibling #3	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00248	Biologic Mother	43	Female	No	0	0	0	0	0	0	1	0	0	.	0	.	0	0
	Biologic Father	46	Male	No	0	0	0	0	0	0	.	0	0	.	0	.	0	0
	Sibling #1	22	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	12	Female	No	0	0	0	0	0	0	.	0	0	1	0	1	0	0
	Sibling #3	8	Male	No	0	0	0	0	0	0	.	0	0	.	0	.	0	0
329.003.00250	.	.	.	.	.	0	9	0	0	0	9	9	.	1	1	1	.	9
	Biologic Mother	43	Female	No	.	0	9	0	0	0	9	9	.	.	.	.	.	9

0 = NO; 1 = YES; 9 = DON'T KNOW

164

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.003.00250	Biologic Father	42	Male	No	.	0	9	0	0	0	9	9	.	.	.	.	.	9	
	Sibling #1	18	Female	No	1	0	9	0	0	0	9	9	1	.	.	.	1	9	
	Sibling #2	15	Female	No	1	0	9	0	0	0	9	9	.	.	.	.	1	9	
	Sibling #3	8	Female	No	1	0	9	0	0	0	9	9	.	.	.	.	1	9	
	Sibling #4	2	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #5	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00292	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	16	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.003.00313	Biologic Mother	36	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	37	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
	Sibling #2	18	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	
329.004.00015	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.004.00017	Biologic Mother	50	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	52	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	
	Sibling #1	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	15	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.004.00019	Biologic Mother	.	Female	No	0	0	1	0	.	0	0	1	0	0	0	0	0	0	
	Biologic Father	.	Male	No	0	0	.	0	.	0	0	.	0	0	0	0	0	0	
	Sibling #1	.	Female	No	0	0	1	0	1	0	0	.	0	0	0	0	0	0	
329.004.00212	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.004.00214	Biologic Mother	41	Female	No	0	0	1	1	0	0	0	.	0	0	.	0	.	.	
	Biologic Father	43	Male	No	0	0	.	.	0	0	0	.	0	0	.	0	.	.	
	Sibling #1	21	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	15	Female	No	0	0	.	.	0	0	0	.	0	0	1	0	1	1	

0 = NO; 1 = YES; 9 = DON'T KNOW

165

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.005.00002	Biologic Mother	35	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	0	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00004	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	44	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Male	Yes	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.005.00008	Biologic Mother	34	Female	No	0	0	0	0	0	0	1	0	0	0	1	1	1	0
	Biologic Father	33	Male	No	0	0	0	0	0	0	.	0	0	0	.	.	.	0
	Sibling #1	12	Male	No	0	0	0	0	0	0	1	0	0	0	1	.	1	0
	Sibling #2	9	Male	No	0	0	0	0	0	0	.	0	0	0	1	.	.	0
329.005.00109	Biologic Mother	31	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	28	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	15	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00112	Biologic Mother	61	Male	No	0	0	.	.	.	.	0	0	.	9	0	0	0	0
	Biologic Father	54	Female	No	0	0	.	.	.	.	0	0	.	9	0	0	0	0
	Sibling #1	21	Female	No	0	0	.	.	.	.	0	0	.	9	0	0	0	0
	Sibling #2	18	Male	No	0	0	1	1	1	9	0	0	1	9	0	0	0	0
	Sibling #3	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Female	No	0	0	.	.	.	.	0	0	.	9	0	0	0	0
	Sibling #5	13	Male	No	0	0	.	.	.	.	0	0	.	9	0	0	0	0
329.005.00116	Biologic Mother	39	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	51	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	25	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	24	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #4	22	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #5	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Child #1	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00119	Biologic Mother	44	Female	No	0	0	.	0	.	.	.	0	0	.	0	0	0	0
	Biologic Father	46	Male	No	0	0	.	0	.	.	1	0	0	.	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

166

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.005.00119	Sibling #1	19	Female	No	0	0	.	0	.	.	1	0	0	.	0	0	0	0
	Sibling #2	14	Female	No	0	0	1	0	1	1	.	0	0	.	0	0	0	0
	Sibling #3	7	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00151	Biologic Mother	40	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Biologic Father	40	Male	No	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	Sibling #1	17	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #2	15	Male	No	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	Sibling #3	14	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
329.005.00152	Biologic Mother	37	Female	No	.	0	0	0	0	0	1	.	0	0	0	0	0	0
	Biologic Father	39	Male	No	.	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #1	15	Female	No	1	0	0	0	0	0	1	1	0	0	0	0	0	0
329.005.00257	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	.	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	1	0
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	0	0	1	1	.	0
329.005.00258	Biologic Mother	45	Male	No	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	44	Female	No	.	.	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	14	Female	No	.	.	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	9	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00299	Biologic Mother	34	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	9	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.005.00300	Biologic Mother	45	Female	No	0	0	1	1	0	0	1	1	0	0	.	.	0	0
	Biologic Father	50	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	18	Male	No	0	0	.	.	0	0	.	.	0	0	.	.	0	0
	Sibling #2	12	Male	No	0	0	.	.	0	0	.	.	0	0	1	1	0	0
	Sibling #3	9	Male	No	0	0	.	.	0	0	.	.	0	0	.	.	0	0
329.005.00333	Biologic Mother	46	Female	No	0	0	0	0	0	0	1	.	0	0	0	0	1	0
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	19	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	.	0
	Sibling #2	16	Female	No	0	0	0	0	0	0	1	1	0	0	0	0	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

167

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.005.00336	Biologic Mother	42	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
	Biologic Father	41	Male	No	.	.	.	.	.	.	1	.	.	.	.	.	.	.	
	Sibling #1	16	Female	No	.	.	.	.	.	.	1	.	1	1	1	1	1	1	
	Sibling #2	14	Female	No	1	.	.	.	.	.	.	.	1	1	1	1	1	1	.
	Sibling #3	7	Male	No	1	.	1	.	.	.	.	.	.	.	1	1	.	.	.
329.006.00038	Biologic Mother	35	Female	No	.	.	.	.	1	1	1	0	0	0	0	0	0	1	0
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	0	0	0	0	0	0	1	0
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	.	.	1	1	.	.	1	0	0	0	0	0	0	1	0
	Sibling #3	12	Female	No	1	.	1	.	.	.	.	0	0	0	0	0	0	1	0
329.006.00039	Biologic Mother	47	Female	No	0	.	.	.	.	.	.	0	0	.	.	.	.	.	.
	Biologic Father	48	Male	No	0	.	1	1	1	1	1	0	0	.	.	.	1	1	1
	Sibling #1	24	Male	No	0	.	.	.	.	.	.	0	0	.	.	.	1	1	1
	Sibling #2	21	Male	No	0	.	1	.	.	.	.	0	0	.	.	.	1	1	1
	Sibling #3	15	Female	No	0	.	1	.	.	.	.	0	0	.	.	.	1	1	1
329.006.00260	Biologic Mother	56	Female	No	1	0	0	.	0	.	.	0	0	.	0	.	0	.	
	Biologic Father	56	Male	Yes	1	0	0	.	0	.	1	0	0	.	0	.	0	.	
	Sibling #1	17	Female	No	.	0	0	.	0	.	.	0	0	.	0	.	0	.	
	Sibling #2	10	Male	No	.	0	0	.	0	.	.	0	0	.	0	.	0	.	
329.006.00261	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	38	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	19	Female	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	17	Male	No	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00140	Biologic Mother	32	Female	No	1	0	1	0	0	.	0	.	.	.	.	.	0	.	
	Biologic Father	37	Male	No	1	0	.	0	0	.	0	.	.	.	.	.	0	.	
	Sibling #1	11	Male	No	1	0	1	0	0	.	0	.	1	1	1	1	0	.	
	Sibling #2	9	Male	No	1	0	.	0	0	.	0	.	.	.	.	.	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

168

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.007.00142	Biologic Mother	44	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Biologic Father	46	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #1	15	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.007.00145	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	41	Male	No	0	.	0	.	0	.	0	.	1	0	1	1	1	0
	Sibling #1	23	Female	No	0	.	0	.	0	.	0	.	.	0	.	.	1	0
	Sibling #2	16	Male	No	0	.	0	.	0	.	0	.	.	0	.	.	1	0
Sibling #3	14	Female	No	0	.	0	.	0	.	0	.	.	0	.	.	1	0	
329.007.00265	Biologic Mother	34	Female	No	0	.	.	.	.	0	1	0	0	.	0	.	0	.
	Biologic Father	29	Male	Yes	0	.	1	1	1	0	1	0	0	.	0	.	0	.
	Sibling #1	16	Female	No	0	.	.	.	.	0	.	0	0	.	0	.	0	.
	Sibling #2	13	Male	No	0	.	.	.	.	0	.	0	0	.	0	.	0	.
	Sibling #3	12	Male	No	0	.	.	.	.	0	.	0	0	.	0	.	0	.
Sibling #4	6	Female	No	0	.	.	.	.	0	.	0	0	.	0	.	0	.	
329.007.00268	Biologic Mother	37	Female	No	.	0	1	1	1	1	0	.	1	1	1	1	0	.
	Biologic Father	33	Male	No	.	0	.	.	.	.	0	.	.	.	.	.	0	.
	Sibling #1	13	Female	No	1	0	.	.	.	.	0	.	.	.	.	.	0	.
329.007.00294	Biologic Mother	37	Female	No	.	0	1	0	1	0	1	0	.	.	.	.	1	1
	Biologic Father	40	Male	No	.	0	.	0	.	0	.	0	.	.	.	.	.	.
	Sibling #1	15	Female	No	1	0	.	0	.	0	.	0	.	.	.	.	.	.
	Sibling #2	14	Male	No	1	0	.	0	.	0	.	0	1	1	1	1	.	.
329.007.00309	Biologic Mother	39	Female	No	0	.	.	.	.	.	.	0	0	.	.	0	0	.
	Biologic Father	44	Male	No	0	.	.	.	.	.	.	0	0	.	1	0	0	.
	Sibling #1	18	Female	No	0	.	1	1	1	1	1	0	0	.	.	0	0	.
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00310	.	.	.	.	.	0	.	1	0	.	0	.	.	.	.	.	.	0
	Biologic Mother	41	Female	No	.	0	.	.	0	.	0	.	1	.	1	.	1	0
	Biologic Father	41	Male	No	.	0	1	.	0	.	0	.	.	.	1	1	.	0
	Sibling #1	16	Female	No	1	0	1	.	0	.	0	.	1	1	1	.	1	0
Sibling #2	15	Male	No	.	0	.	.	0	.	0	.	.	.	1	.	.	0	
329.007.00318	Biologic Mother	44	Female	No	.	0	0	0	0	0	1	0	0	0	.	.	.	0
	Biologic Father	62	Male	No	.	0	0	0	0	0	1	0	0	0	.	.	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

169

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.007.00318	Sibling #1	15	Male	No	.	0	0	0	0	0	0	.	0	0	0	1	1	1	0
	Sibling #2	13	Male	No	.	0	0	0	0	0	0	.	0	0	0	1	1	1	0
	Sibling #3	18	Female	No	1	0	0	0	0	0	0	.	0	0	0	.	.	.	0
329.008.00157	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	39	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.008.00160	Biologic Mother	38	Female	No	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0	0
329.008.00188	Biologic Mother	37	Female	No	0	0	1	1	1	1	0	0	0	0	0	0	0	1	1
	Biologic Father	42	Male	No	0	0	.	.	.	.	0	0	0	0	0	0	.	.	
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	15	Female	No	0	0	.	.	.	.	0	0	0	0	0	0	.	.	
Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.008.00271	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	41	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	10	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.008.00275	Biologic Mother	44	Female	No	0	0	1	0	0	0	1	1	0	0	0	0	0	0	
	Biologic Father	46	Male	No	0	0	.	0	0	0	.	.	0	0	0	0	0	0	
	Sibling #1	19	Male	No	0	0	.	0	0	0	.	.	0	0	0	0	0	0	
	Sibling #2	17	Female	No	0	0	.	0	0	0	.	.	0	0	0	0	0	0	
329.009.00130	Biologic Mother	49	Female	No	.	0	.	.	0	0	.	.	.	.	0	0	0	0	
	Biologic Father	52	Male	No	1	0	.	.	0	0	1	1	.	.	0	0	0	0	
	Sibling #1	16	Male	No	1	0	.	.	0	0	1	.	.	.	0	0	0	0	
	Sibling #2	15	Male	No	.	0	.	.	0	0	1	1	1	1	0	0	0	0	
	Sibling #3	10	Female	No	.	0	1	1	0	0	1	.	1	1	0	0	0	0	
	Sibling #4	7	Female	No	.	0	.	.	0	0	.	.	.	.	0	0	0	0	
329.009.00131	Biologic Mother	.	Female	No	1	1	1	1	9	9	1	1	0	.	0	.	1	1	
	Biologic Father	41	Male	No	.	.	.	.	9	9	.	.	0	.	0	.	.	.	
	Sibling #1	16	Female	No	.	.	1	1	9	9	1	1	0	.	0	.	1	1	
	Sibling #2	13	Female	No	1	1	.	.	9	9	1	1	0	.	0	.	.	.	
329.009.00133	Biologic Mother	37	Female	No	0	.	0	.	0	.	1	1	1	1	1	1	0	0	
	Biologic Father	37	Male	No	0	.	0	.	0	.	.	.	.	.	.	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

170

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.009.00133	Sibling #1	16	Female	No	0	.	0	.	0	.	.	.	.	.	.	.	0	0
	Sibling #2	14	Male	No	0	.	0	.	0	.	.	.	.	.	.	.	0	0
329.009.00138		.			.	0	.	.	.	.	.	.	0	.	0	.	0	.
	Biologic Mother	34	Female	No	.	0	1	1	1	1	1	.	0	.	0	.	0	.
	Biologic Father	33	Male	No	.	0	.	.	.	.	.	.	0	.	0	.	0	.
	Sibling #1	13	Female	No	1	0	1	1	1	1	1	1	0	.	0	.	0	.
	Sibling #2	10	Male	No	.	0	.	1	.	.	1	1	0	.	0	.	0	.
329.009.00170	Biologic Mother	41	Female	No	9	9	1	9	.	.	1	1	1	1	.	.	1	1
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	9	9	1	9	1	1	1	1	1	1	1	1	1	.
	Sibling #2	22	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00173	Biologic Mother	43	Female	No	.	.	0	.	1	0	1	1	0	.	0	.	0	.
	Biologic Father	45	Male	Yes	1	1	0	.	.	0	1	1	0	.	0	.	0	.
	Sibling #1	12	Female	No	.	.	0	.	.	0	1	1	0	.	0	.	0	.
329.009.00193	Biologic Mother	36	Female	No	0	.	1	1	1	1	1	0	0	.	1	0	0	0
	Biologic Father	38	Male	No	0	.	.	.	.	.	.	0	0	.	.	0	0	0
	Sibling #1	12	Female	No	0	.	1	.	1	.	1	0	0	.	1	0	0	0
	Sibling #2	3	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00196	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.
	Sibling #1	17	Female	No	0	.	0	.	0	.	0	.	0	.	1	1	0	.
	Sibling #2	9	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.
329.009.00201	Biologic Mother	43	Female	No	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	Biologic Father	47	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #1	17	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #2	14	Male	No	0	0	0	0	0	0	1	1	0	0	0	0	0	0
329.009.00204	Biologic Mother	39	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.
	Sibling #6	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	47	Male	No	.	0	0	.	0	.	1	.	0	.	0	.	0	.
	Sibling #1	13	Male	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.
	Sibling #2	12	Male	No	1	0	0	.	0	.	.	.	0	.	0	.	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

171

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.009.00204	Sibling #3	10	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.	
	Sibling #4	9	Male	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.	
	Sibling #5	21	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.	
	Child #1	.	.	.	.	0	0	.	0	.	.	.	0	.	0	.	0	.	
329.009.00235	Biologic Mother	32	Female	No	0	0	0	0	0	0	0	0	0	0	0	.	.	.	0
	Biologic Father	30	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	1	1	.	0
	Sibling #2	8	Male	No	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0
329.009.00240	Biologic Mother	48	Female	No	.	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Biologic Father	52	Male	No	1	0	0	0	0	0	0	0	0	0	0	.	0	0	0
	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	0	0	0	0	0	0	0	0	0	0	.	0	0	0
Sibling #4	13	Female	No	.	0	0	0	0	0	0	0	0	0	0	.	0	0	0	
329.009.00303	Biologic Mother	43	Female	No	0	.	.	.	.	.	.	.	0	.	0	.	0	.	
	Biologic Father	49	Male	No	0	.	.	.	.	.	.	.	0	.	0	.	0	.	
	Sibling #1	17	Male	No	0	.	1	1	1	1	1	1	0	.	0	.	0	.	
	Sibling #2	14	Female	No	0	.	.	.	.	.	.	.	0	.	0	.	0	.	
329.009.00304	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	23	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	
	Sibling #2	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	16	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	
329.009.00324	Biologic Mother	33	Female	No	.	0	1	0	.	0	1	0	.	0	1	0	1	0	
	Biologic Father	35	Female	No	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #1	13	Female	No	1	0	.	0	1	0	1	0	1	0	.	0	.	0	
	Sibling #2	8	Female	No	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #3	5	Female	No	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
329.009.00328	Biologic Mother	45	Female	No	0	0	0	0	0	0	1	0	0	0	0	0	1	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	1	0	0	0	0	0	1	0	
	Sibling #1	23	Male	No	0	0	0	0	0	0	1	0	0	0	0	0	.	0	
	Sibling #2	21	Male	No	0	0	0	0	0	0	.	0	0	0	0	0	1	0	
	Sibling #3	14	Male	No	0	0	0	0	0	0	.	0	0	0	0	0	1	0	
	Sibling #4	12	Male	No	0	0	0	0	0	0	.	0	0	0	0	0	.	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

172

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.009.00329	Biologic Mother	32	Female	No	.	0	1	0	1	0	0	0	1	1	0	0	0	0
	Biologic Father	34	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Male	No	1	0	.	0	.	0	0	0	.	.	0	0	0	0
	Sibling #2	10	Male	No	.	0	.	0	.	0	0	0	.	.	0	0	0	0
	Sibling #3	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.010.00182	Biologic Mother	42	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #2	17	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.010.00278	Biologic Mother	49	Female	No	0	.	0	.	0	.	0	.	0	.	1	1	0	.
	Biologic Father	49	Male	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.
	Sibling #1	20	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.
	Sibling #2	17	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.
329.010.00280	Biologic Mother	33	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Biologic Father	32	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #1	13	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.011.00283	Biologic Mother	36	Female	No	.	0	1	0	.	.	.	.	0	0	.	0	.	0
	Biologic Father	42	Male	No	.	0	.	0	1	1	1	1	0	0	.	0	.	0
	Sibling #1	16	Male	No	1	0	.	0	1	1	1	1	0	0	1	0	1	0
329.011.00288	Biologic Mother	41	Female	No	.	0	0	0	.	.	1	1	1	0	1	1	1	1
	Biologic Father	45	Male	No	.	0	0	0	.	.	.	.	.	0	.	.	.	.
	Sibling #1	15	Male	No	1	0	0	0	1	1	1	1	.	0	.	.	1	1
329.012.00025	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	0	0	0	0	0	.	0	.	0	.	0	.	0	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Female	No	0	0	0	0	0	.	0	.	0	.	0	.	0	.
329.012.00220	Biologic Mother	40	Female	No	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	41	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

173

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.012.00220	Sibling #1	17	Male	No	0	0	.	.	.	.	.	.	.	.	1	.	.	.
	Sibling #2	15	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	13	Female	No	0	0	.	.	.	.	.	.	.	.	1	.	.	.
329.012.00222	Biologic Mother	37	Female	No	0	.	.	0	.	.	0	.	0	.	1	0	0	.
	Biologic Father	38	Male	No	0	.	.	0	.	.	0	.	0	.	.	0	0	.
	Sibling #1	15	Female	No	0	.	1	0	1	1	0	.	0	.	.	0	0	.
329.012.00226	Biologic Mother	50	Female	No	0	0	0	0	0	0	.	0	0	0	1	0	.	.
	Biologic Father	50	Male	No	0	0	0	0	0	0	.	0	0	0	1	0	.	.
	Sibling #1	23	Female	No	0	0	0	0	0	0	.	0	0	0	.	0	.	.
	Sibling #2	18	Male	No	0	0	0	0	0	0	.	0	0	0	.	0	1	1
	Sibling #3	16	Male	No	0	0	0	0	0	0	1	0	0	0	.	0	1	1
329.012.00228	Biologic Mother	40	Female	No	.	0	.	0	1	0	0	0	.	.	.	0	.	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	.	0	1	0	.	0	0	0	1	1	1	0	1	0
	Sibling #2	12	Female	No	1	0	.	0	.	0	0	0	.	.	.	0	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

174

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.001.00061	Biologic Mother	39	Female	No	0	0	1	0	1	1	0	0	1	1	.	.	1	.
	Biologic Father	46	Male	No	0	0	.	0	.	.	0	0	.	.	.	.	1	1
	Sibling #1	16	Female	No	0	0	1	0	1	1	0	0	.	.	1	1	.	.
	Sibling #2	14	Male	No	0	0	.	0	.	.	0	0	.	.	1	1	.	.
329.001.00066	Biologic Mother	48	Female	No	0	0	0	0	0	0	1	1	0	0	0	0	0	0
	Biologic Father	52	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #1	17	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
	Sibling #2	13	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	0	0
329.001.00067	Biologic Mother	42	Female	No	.	.	.	.	.	.	1	0	0	.	0	.	0	.
	Biologic Father	44	Male	No	.	.	1	1	1	1	1	0	0	.	0	.	0	.
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	0	0	.	0	.	0	.
	Sibling #2	16	Female	No	1	1	.	.	.	.	.	0	0	.	0	.	0	.
329.001.00070	Biologic Mother	47	Female	No	.	0	1	0	0	0	1	.	0	0	1	0	0	0
	Biologic Father	46	Male	No	.	0	.	0	0	0	.	.	0	0	.	0	0	0
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	12	Male	No	1	0	.	0	0	0	1	1	0	0	.	0	0	0
329.001.00122	Biologic Mother	53	Female	No	0	0	0	0	.	.	1	.	0	0	0	0	0	0
	Sibling #6	16	Male	No	0	0	0	0	.	.	.	.	0	0	0	0	0	0
	Sibling #7	15	Male	No	0	0	0	0	1	1	1	1	0	0	0	0	0	0
	Biologic Father	58	Male	No	0	0	0	0	.	.	1	.	0	0	0	0	0	0
	Sibling #1	26	Female	No	0	0	0	0	.	.	.	.	0	0	0	0	0	0
	Sibling #2	23	Female	No	0	0	0	0	.	.	1	1	0	0	0	0	0	0
	Sibling #3	22	Female	No	0	0	0	0	.	.	.	.	0	0	0	0	0	0
	Sibling #4	20	Male	No	0	0	0	0	.	.	.	.	0	0	0	0	0	0
Sibling #5	20	Female	No	0	0	0	0	.	.	.	.	0	0	0	0	0	0	
329.002.00050	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	.	0	0	0	0	0
	Sibling #1	19	Male	No	0	0	0	0	0	0	0	0	1	0	0	0	0	0
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00056	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	41	Male	No	0	.	.	.	.	0	0	.	0	.	0	.	.	.
	Sibling #1	18	Female	No	0	.	1	1	1	0	0	.	0	.	0	.	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

175

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.002.00056	Sibling #2	10	Male	No	0	.	1	1	.	0	0	.	0	.	0	.	1	0
329.002.00057	Biologic Mother	33	Female	No	1	1	0	0	1	1	1	1	1	0	1	0	0	0
	Biologic Father	36	Male	No	.	.	0	0	.	.	.	.	.	0	.	0	0	0
	Sibling #1	15	Female	No	.	.	0	0	.	.	1	.	1	0	1	0	0	0
	Sibling #2	14	Female	No	.	.	0	0	.	.	.	.	.	0	.	0	0	0
	Sibling #3	12	Male	No	.	.	0	0	.	.	.	.	.	0	.	0	0	0
	Sibling #4	.	.	.	.	.	0	0	.	.	.	.	.	0	.	0	0	0
329.002.00098	Biologic Mother	43	Female	No	0	0	1	1	1	1	0	0	1	1	0	0	1	0
	Biologic Father	45	Male	No	0	0	.	.	.	.	0	0	.	.	0	0	.	0
	Sibling #1	16	Female	No	0	0	.	.	.	.	0	0	.	.	0	0	.	0
	Sibling #2	13	Female	No	0	0	.	.	.	.	0	0	1	.	0	0	.	0
	Sibling #3	9	Male	No	0	0	.	.	.	.	0	0	.	.	0	0	.	0
329.002.00100	.	.	.	.	.	.	0	0	0	.	0	0	0	0	0	0	0	0
	Biologic Mother	36	Female	No	.	.	0	0	0	.	0	0	0	0	0	0	0	0
	Biologic Father	35	Male	No	.	.	0	0	0	.	0	0	0	0	0	0	0	0
	Sibling #1	15	Male	No	1	1	0	0	0	.	0	0	0	0	0	0	0	0
	Sibling #2	9	Female	No	.	.	0	0	0	.	0	0	0	0	0	0	0	0
329.002.00103	Biologic Mother	39	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	0	.
	Biologic Father	38	Male	No	.	0	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Female	No	1	0	0	.	0	.	0	.	0	.	0	.	0	.
329.002.00104	Biologic Mother	41	Female	No	.	.	1	1	1	1	1	1	1	0	0	.	1	1
	Biologic Father	46	Male	No	.	.	.	.	.	.	1	.	.	0	0	.	.	.
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	0	0	.	.	.
	Sibling #2	15	Female	No	1	1	.	.	.	.	1	1	.	0	0	.	.	.
	Sibling #3	13	Male	No	.	.	.	.	.	.	.	1	.	0	0	.	.	.
329.002.00243	Biologic Mother	39	Female	No	0	.	0	.	0	.	1	1	1	.	1	1	1	1
	Biologic Father	44	Male	No	0	.	0	.	0	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	0	.	0	.	0	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	0	.	0	.	0	.	.	.	.	1	.	.	.	.
	Sibling #3	15	Female	No	0	.	0	.	0	.	.	.	.	.	.	.	.	.
329.002.00244	Biologic Mother	40	Female	No	0	0	1	0	0	0	1	1	1	1	0	0	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

176

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.002.00244	Sibling #1	17	Female	No	0	0	.	0	0	0	.	.	.	.	0	0	0	0
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00321	Biologic Mother	39	Female	No	0	.	1	.	.	0	1	0	0	.	0	.	0	.
	Biologic Father	37	Male	No	0	.	.	.	.	0	.	0	0	.	0	.	0	.
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	0	.	.	.	.	0	.	0	0	.	0	.	0	.
	Sibling #3	14	Male	No	0	.	1	1	1	0	.	0	0	.	0	.	0	.
329.002.00322	Biologic Mother	34	Female	No	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	56	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Don't	No	0	0	.	.	.	.	1	.	.	.	.	.	.	.
	Sibling #2	14	Don't	No	0	0	.	.	.	.	1	.	.	.	.	.	.	.
	Sibling #3	10	Don't	No	0	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	8	Don't	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00073	Biologic Mother	39	Female	No	.	0	.	.	1	1	1	0	.	.	1	1	.	0
	Biologic Father	41	Male	No	1	0	.	.	.	.	1	0	.	.	.	.	1	0
	Sibling #1	19	Female	No	.	0	1	1	.	.	.	0	.	.	.	.	.	0
	Sibling #2	17	Female	No	1	0	.	.	.	.	.	0	.	.	.	.	.	0
	Sibling #3	16	Female	No	.	0	1	1	1	1	1	0	1	1	.	.	.	0
329.003.00076	Biologic Mother	35	Female	No	.	0	0	0	0	0	1	0	.	0	0	0	0	0
	Biologic Father	45	Male	No	.	0	0	0	0	0	.	0	.	0	0	0	0	0
	Sibling #1	16	Female	No	1	0	0	0	0	0	1	0	1	0	0	0	0	0
329.003.00079	Biologic Mother	.	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	.	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	.	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00088	Biologic Mother	46	Female	No	0	0	0	0	1	1	1	0	0	0	1	.	.	0
	Biologic Father	50	Male	No	0	0	0	0	.	.	.	0	0	0	.	.	.	0
	Sibling #1	24	Female	No	0	0	0	0	1	1	.	0	0	0	.	1	.	0
	Sibling #2	21	Female	No	0	0	0	0	1	1	1	0	0	0	1	.	1	0
	Sibling #3	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

177

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.003.00090	Biologic Mother	44	Female	No	0	0	0	0	0	0	.	0	0	0	0	0	9	0	
	Biologic Father	51	Male	No	0	0	0	0	0	0	1	0	0	0	0	0	9	0	
	Sibling #1	18	Male	No	0	0	0	0	0	0	.	0	0	0	0	0	9	0	
	Sibling #2	16	Male	No	0	0	0	0	0	0	.	0	0	0	0	0	9	0	
	Sibling #3	14	Female	No	0	0	0	0	0	0	.	0	0	0	0	0	9	0	
329.003.00092	Biologic Mother	42	Female	No	.	.	1	1	1	0	0	.	0	.	1	1	0	.	
	Biologic Father	43	Male	No	.	.	.	.	.	0	0	.	0	.	.	.	0	.	
	Sibling #1	16	Female	No	1	1	1	1	.	0	0	.	0	.	1	1	0	.	
	Sibling #2	12	Female	No	.	.	.	.	.	0	0	.	0	.	1	1	0	.	
329.003.00093	Biologic Mother	50	Female	No	.	.	1	0	.	.	0	.	0	.	0	.	0	0	
	Biologic Father	53	Male	Yes	.	.	.	0	.	.	0	.	0	.	0	.	0	0	
	Sibling #1	21	Male	No	.	.	.	0	.	.	0	.	0	.	0	.	0	0	
	Sibling #2	17	Female	No	1	1	1	0	1	1	0	1	0	.	0	.	0	0	
329.003.00247	Biologic Mother	41	Female	No	9	9	9	9	9	9	9	9	9	9	9	.	0	9	9
	Biologic Father	44	Male	No	9	9	9	9	9	9	9	9	9	9	9	.	0	9	9
	Sibling #1	16	Male	No	9	9	9	9	9	9	9	9	9	9	9	1	0	9	9
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00249	Biologic Mother	46	Female	No	9	9	9	9	9	9	.	9	0	0	0	0	0	0	
	Biologic Father	52	Male	No	9	9	9	9	9	9	1	9	0	0	0	0	0	0	
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00289	.	.	.	.	0	0	.	.	.	.	.	1	.	.	.	.	.	.	
	Biologic Mother	41	Female	No	0	0	1	1	1	1	1	.	1	1	1	1	1	1	
	Biologic Father	45	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	16	Female	No	0	0	1	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	13	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00290	Biologic Mother	37	Female	No	1	0	0	0	.	0	0	0	0	0	0	0	.	0	
	Biologic Father	48	Male	No	1	0	0	0	.	0	0	0	0	0	0	0	.	0	
	Sibling #1	3	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	13	Male	No	.	0	0	0	.	0	0	0	0	0	0	0	1	0	
	Sibling #3	10	Male	No	1	0	0	0	.	0	0	0	0	0	0	0	.	0	
	Sibling #4	17	Male	No	1	0	0	0	1	0	0	0	0	0	0	0	.	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

178

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.003.00314	Biologic Mother	39	Female	No	0	0	0	0	0	0	.	0	0	0	0	0	0	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	Sibling #2	12	Female	No	0	0	0	0	0	0	.	0	0	0	0	0	0	0
329.003.00317		.			0	0	0	0	0	0	.	.	0	0	.	0	.	0
	Biologic Mother	50	Female	No	0	0	0	0	0	0	1	.	0	0	1	0	1	0
	Biologic Father	50	Male	No	0	0	0	0	0	0	.	.	0	0	.	0	.	0
	Sibling #1	17	Don't	No	0	0	0	0	0	0	.	.	0	0	.	0	.	0
Sibling #2	16	Female	No	0	0	0	0	0	0	.	1	0	0	.	0	1	0	
329.004.00013	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00014	Biologic Mother	52	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00211	Biologic Mother	49	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #2	18	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.004.00215	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00003	Biologic Mother	30	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	0	0	0	0	0	9	9	1	0	0	0	0	0	0
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	7	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	5	Male	No	0	0	0	0	0	9	9	.	0	0	0	0	0	0
Sibling #5	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00006	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

179

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

Treatment Group=IMIPRAMINE

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.005.00006	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00007	Biologic Mother	41	Female	No	.	.	0	0	0	0	.	0	0	0	1	1	.	.
	Biologic Father	44	Male	No	.	.	0	0	0	0	.	0	0	0	.	.	.	.
	Sibling #1	20	Female	No	1	1	0	0	0	0	.	0	0	0	.	.	.	.
	Sibling #2	15	Female	No	.	.	0	0	0	0	1	0	0	0	.	.	1	1
329.005.00009	Biologic Mother	47	Female	No	0	0	.	0	1	0	1	0	0	0	0	0	0	0
	Biologic Father	46	Male	No	0	0	.	0	1	0	.	0	0	0	0	0	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	0	1	0	1	0	1	0	0	0	0	0	0	0
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00117	Biologic Mother	47	Female	No	.	0	.	.	.	.	.	.	.	.	1	1	1	0
	Biologic Father	49	Male	No	.	0	1	1	1	1	1	1	1	1	1	1	1	0
	Sibling #1	22	Female	No	.	0	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #2	16	Female	No	1	0	.	.	1	.	.	.	.	.	.	.	1	0
	Sibling #3	12	Male	No	.	0	.	.	.	.	.	.	.	.	.	.	1	0
329.005.00118	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	47	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	17	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00153	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	Biologic Father	51	Male	No	0	0	0	0	0	0	0	0	0	0	.	0	0	0
	Sibling #1	18	Female	No	0	0	0	0	0	0	0	0	0	0	.	0	0	0
329.005.00255	Biologic Mother	47	Female	No	.	0	0	0	0	0	0	0	1	1	1	1	0	0
	Biologic Father	48	Male	No	.	0	0	0	0	0	0	0	.	.	.	.	0	0
	Sibling #1	17	Male	No	.	0	0	0	0	0	0	0	.	.	.	.	0	0
	Sibling #2	15	Female	No	1	0	0	0	0	0	0	0	.	.	.	.	0	0
329.005.00256	Biologic Mother	55	Female	No	0	0	1	1	1	1	1	1	1	1	0	0	0	0
	Biologic Father	52	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Female	No	0	0	.	.	.	.	.	.	.	.	0	0	0	0
	Sibling #2	23	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

180

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.005.00256	Sibling #4	16	Female	No	0	0	.	.	.	.	.	.	.	.	0	0	0	0
329.005.00295	Biologic Mother	31	Female	No	0	0	0	0	0	0	0	0	.	0	.	0	0	0
	Biologic Father	36	Male	No	0	0	0	0	0	0	0	0	1	0	1	0	0	0
	Sibling #1	13	Female	No	0	0	0	0	0	0	0	0	.	0	.	0	0	0
329.005.00297	Biologic Mother	46	Female	No	0	0	1	1	1	1	1	0	1	1	0	0	1	1
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Male	No	0	0	.	.	.	.	1	0	.	.	0	0	1	.
329.005.00332	Biologic Mother	50	Female	No	1	0	1	1	1	0	0	0	1	1	1	1	.	0
	Biologic Father	54	Male	No	.	0	.	.	.	0	0	0	.	.	.	.	.	0
	Sibling #1	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	.	0	.	.	.	0	0	0	.	.	.	.	1	0
329.005.00335	Biologic Mother	37	Female	No	.	0	1	1	0	0	1	0	0	0	0	0	1	0
	Biologic Father	39	Male	No	.	0	.	.	0	0	.	0	0	0	0	0	.	0
	Sibling #1	15	Female	No	1	0	.	.	0	0	.	0	0	0	0	0	.	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	6	Female	No	.	0	.	.	0	0	1	0	0	0	0	0	.	0
329.006.00040	Biologic Mother	46	Female	No	0	.	.	.	0	.	0	.	.	.	.	0	.	.
	Biologic Father	66	Male	No	0	.	.	.	0	.	0	.	.	.	.	0	.	.
	Sibling #1	28	Male	No	0	.	.	.	0	.	0	.	.	.	.	0	.	.
	Sibling #2	18	Female	No	0	.	1	1	0	.	0	.	1	1	1	0	1	1
329.006.00041	Biologic Mother	44	Female	No	.	0	.	.	.	.	.	.	9	.	.	.	.	0
	Biologic Father	50	Male	No	1	0	1	1	1	1	1	1	9	.	1	1	1	0
	Sibling #1	21	Male	No	1	0	.	.	.	.	.	.	9	.	.	.	.	0
	Sibling #2	18	Male	No	.	0	.	.	.	.	1	1	9	.	.	.	1	0
329.007.00139	Biologic Mother	38	Female	No	0	0	1	1	1	1	1	.	1	1	0	0	0	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	0	.	.	.	.	.	1	.	.	0	0	0	0
329.007.00143	Biologic Mother	28	Female	No	.	0	.	0	0	.	0	.	.	.	0	.	.	.
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	1	0	1	0	0	.	0	.	.	1	0	.	1	1

0 = NO; 1 = YES; 9 = DON'T KNOW

181

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.007.00143	Sibling #2	.			.	0	.	0	.	0	.	0	.	1	.	0	.	.
329.007.00146	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	0	.	.	0	0	.
	Biologic Father	39	Male	No	0	.	0	.	0	.	0	.	0	.	.	0	0	.
	Sibling #1	15	Female	No	0	.	0	.	0	.	0	.	0	.	1	0	0	.
329.007.00269	Biologic Mother	45	Female	No	0	.	1	0	1	0	1	0	0	.	1	1	.	0
	Biologic Father	60	Male	Yes	0	.	.	0	.	0	.	0	0	.	.	.	1	0
	Sibling #1	15	Male	No	0	.	.	0	.	0	.	0	0	.	1	1	.	0
	Sibling #2	12	Female	No	0	.	.	0	.	0	.	0	0	.	1	.	.	0
329.007.00270	Biologic Mother	34	Female	No	.	0	0	.	0	.	1	1	.	0	0	.	1	0
	Biologic Father	35	Male	No	.	0	0	.	0	.	.	.	.	0	0	.	.	0
	Sibling #1	15	Male	No	1	0	0	.	0	.	1	.	.	0	0	.	.	0
	Sibling #2	10	Male	No	.	0	0	.	0	.	.	.	1	0	0	.	.	0
	Sibling #3	8	Male	No	.	0	0	.	0	.	.	.	.	0	0	.	.	0
	Sibling #4	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00307	Biologic Mother	42	Female	No	.	0	0	.	1	0	1	0	0	.	0	.	0	.
	Biologic Father	43	Male	No	.	0	0	.	.	0	.	0	0	.	0	.	0	.
	Sibling #1	15	Female	No	1	0	0	.	.	0	.	0	0	.	0	.	0	.
	Sibling #2	14	Female	No	.	0	0	.	.	0	.	0	0	.	0	.	0	.
329.007.00308	Biologic Mother	45	Female	No	0	.	0	.	0	.	1	1	0	.	0	.	0	.
	Biologic Father	43	Male	No	0	.	0	.	0	.	.	.	0	.	0	.	0	.
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	0	.	0	.	0	.	.	.	0	.	0	.	0	.
329.008.00159	Biologic Mother	47	Female	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0
	Biologic Father	49	Male	No	0	0	1	1	1	1	1	1	0	0	0	0	0	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0
	Sibling #3	16	Female	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0
329.008.00161	Biologic Mother	44	Female	No	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	Biologic Father	45	Male	No	0	0	0	0	0	0	.	0	0	0	0	0	0	0
	Sibling #1	4	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	4	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

182

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.008.00187	Biologic Mother	47	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	
	Sibling #1	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.008.00192	Biologic Mother	35	Female	No	0	0	1	1	1	1	0	0	0	0	0	0	0	0	
	Biologic Father	40	Male	No	0	0	.	.	.	.	0	0	0	0	0	0	0	0	
	Sibling #1	5	Female	No	0	0	.	.	.	.	0	0	0	0	0	0	0	0	
329.008.00272	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	62	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.008.00273	Biologic Mother	42	Female	No	0	0	1	0	1	1	1	1	0	0	0	0	0	0	
	Biologic Father	43	Male	No	0	0	.	0	.	.	.	.	0	0	0	0	0	0	
	Sibling #1	15	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00127	Biologic Mother	31	Female	No	0	0	.	.	.	.	.	.	0	.	0	.	1	.	
	Biologic Father	41	Male	No	0	0	.	.	.	.	.	.	0	.	0	.	.	.	
	Sibling #1	12	Female	No	0	0	1	1	1	1	1	1	0	.	0	.	1	1	
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00132	Biologic Mother	30	Female	No	0	.	.	.	0	.	1	.	0	.	0	.	.	0	
	Biologic Father	31	Male	No	0	.	1	1	0	.	1	1	0	.	0	.	1	0	
	Sibling #1	13	Male	No	0	.	1	.	0	.	1	1	0	.	0	.	.	0	
	Sibling #2	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00134	Biologic Mother	38	Female	No	0	.	1	1	1	1	1	.	0	.	0	.	0	.	
	Biologic Father	31	Male	Yes	0	.	.	.	.	.	.	.	0	.	0	.	0	.	
	Sibling #1	15	Female	No	0	.	.	.	.	.	1	1	0	.	0	.	0	.	
	Sibling #2	.	.	.	0	.	.	.	.	.	.	.	0	.	0	.	0	.	
329.009.00137	Biologic Mother	34	Female	No	0	.	0	.	1	0	0	.	0	.	0	.	0	.	
	Biologic Father	41	Male	No	0	.	0	.	.	0	0	.	0	.	0	.	0	.	
	Sibling #1	20	Female	No	0	.	0	.	.	0	0	.	0	.	0	.	0	.	
	Sibling #2	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	0	.	0	.	.	0	0	.	0	.	0	.	0	.	
	Sibling #4	12	Female	No	0	.	0	.	.	0	0	.	0	.	0	.	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

183

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.009.00171	Biologic Mother	38	Female	No	9	9	9	9	9	9	1	9	.	9	9	9	.	0
	Biologic Father	41	Male	No	9	9	9	9	9	9	.	9	.	9	9	9	.	0
	Sibling #1	23	Male	No	9	9	9	9	9	9	.	9	.	9	9	9	.	0
	Sibling #2	16	Female	No	9	9	9	9	9	9	1	9	1	9	9	9	1	0
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	12	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00172	Biologic Mother	43	Female	No	0	.	0	.	.	0	1	0	0	.	0	.	1	0
	Biologic Father	45	Male	No	0	.	0	.	1	0	1	0	0	.	0	.	.	0
	Sibling #1	23	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	19	Female	No	0	.	0	.	.	0	.	0	0	.	0	.	.	0
	Sibling #3	13	Female	No	0	.	0	.	1	0	.	0	0	.	0	.	.	0
329.009.00194	Biologic Mother	36	Female	No	1	9	9	9	9	9	1	0	9	.	9	9	9	9
	Biologic Father	33	Male	No	.	9	9	9	9	9	.	0	9	.	9	9	9	9
	Sibling #1	12	Male	No	.	9	9	9	9	9	.	0	9	.	9	9	9	9
	Sibling #2	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	3	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00195	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	.	0	.	0	.	.	.
	Biologic Father	40	Male	No	1	1	.	.	.	.	1	1	0	.	0	.	1	1
	Sibling #1	16	Female	No	.	.	.	.	.	.	.	.	0	.	0	.	.	.
	Sibling #2	14	Female	No	1	.	1	1	1	1	1	1	0	.	0	.	.	.
	Sibling #3	12	Male	No	.	.	.	.	.	.	.	.	0	.	0	.	.	.
329.009.00199	Biologic Mother	49	Female	No	.	.	0	0	0	0	.	0	0	0	0	0	0	0
	Biologic Father	56	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Female	No	1	1	0	0	0	0	1	0	0	0	0	0	0	0
	Sibling #2	14	Female	No	.	.	0	0	0	0	.	0	0	0	0	0	0	0
	Sibling #3	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00203	Biologic Mother	36	Female	No	0	.	0	.	1	1	1	1	1	1	0	.	1	0
	Biologic Father	38	Male	No	0	.	0	.	.	.	.	.	.	.	0	.	.	0
	Sibling #1	12	Female	Yes	0	.	0	.	.	.	1	.	.	.	0	.	1	0
	Sibling #2	5	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00236	Biologic Mother	45	Female	No	.	9	.	.	1	1	1	1	0	0	1	1	0	0
	Biologic Father	44	Male	No	.	9	.	.	.	.	.	.	0	0	.	.	0	0
	Sibling #1	20	Male	No	.	9	.	.	.	.	.	.	0	0	.	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

184

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.009.00236	Sibling #2	16	Female	No	1	9	1	1	1	1	.	.	0	0	.	.	0	0
	Sibling #3	13	Female	No	.	9	.	.	.	.	.	.	0	0	.	.	0	0
329.009.00262	Biologic Mother	38	Female	No	0	0	9	0	1	0	.	.	.	.	0	0	0	0
	Biologic Father	43	Male	No	0	0	9	0	.	0	1	1	1	1	0	0	0	0
	Sibling #1	13	Male	No	0	0	9	0	1	0	1	.	.	.	0	0	0	0
	Sibling #2	11	Male	No	0	0	9	0	1	0	.	.	.	.	0	0	0	0
329.009.00264	Biologic Mother	37	Female	No	0	0	0	0	.	.	.	0	0	0	.	0	.	.
	Biologic Father	40	Male	No	0	0	0	0	1	1	1	0	0	0	.	0	1	1
	Sibling #1	14	Female	No	0	0	0	0	1	1	1	0	0	0	1	0	1	1
329.009.00301	Biologic Mother	39	Female	No	0	.	.	.	0	.	1	0	0	.	0	.	0	.
	Biologic Father	39	Male	No	0	.	.	.	0	.	.	0	0	.	0	.	0	.
	Sibling #1	17	Male	No	0	.	.	.	0	.	1	0	0	.	0	.	0	.
	Sibling #2	10	Male	No	0	.	1	1	0	.	.	0	0	.	0	.	0	.
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00305	Biologic Mother	44	Female	No	.	0	0	.	0	.	1	1	0	.	0	.	0	.
	Biologic Father	45	Male	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.
	Sibling #1	17	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.
	Sibling #2	14	Male	No	1	0	0	.	0	.	.	.	0	.	0	.	0	.
	Sibling #3	12	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	0	.
329.009.00325	Biologic Mother	33	Female	No	.	.	.	.	.	.	.	.	.	0	.	0	0	0
	Biologic Father	38	Male	No	.	.	.	.	.	.	.	.	.	0	.	0	0	0
	Sibling #1	15	Female	No	1	1	1	1	1	1	1	1	1	1	0	1	0	0
329.009.00326	Biologic Mother	31	Female	No	.	0	1	1	0	0	.	0	0	0	0	0	.	0
	Biologic Father	34	Male	No	.	0	.	.	0	0	.	0	0	0	0	0	.	0
	Sibling #1	13	Male	No	1	0	.	.	0	0	1	0	0	0	0	0	1	0
	Sibling #2	9	Male	No	1	0	.	.	0	0	.	0	0	0	0	0	.	0
329.010.00279	Biologic Mother	37	Female	No	0	.	0	.	0	0	0	.	0	.	0	.	0	.
	Biologic Father	48	Male	No	0	.	0	.	0	0	0	.	0	.	0	.	0	.
	Sibling #1	13	Female	No	0	.	0	.	0	0	0	.	0	.	0	.	0	.
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	1	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

185

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.010.00281	Biologic Mother	43	Female	No	0	.	.	0	0	.	0	.	0	.	.	.	0	.
	Biologic Father	48	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	0	.	.	0	0	.	0	.	0	.	.	.	0	.
	Sibling #2	16	Male	No	0	.	1	0	0	.	0	.	0	.	1	1	0	.
	Sibling #3	14	Female	No	0	.	.	0	0	.	0	.	0	.	.	.	0	.
329.011.00163	Biologic Mother	42	Female	No	.	0	.	.	0	1	.	0	0	.	.	1	0	
Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
Sibling #1	15	Female	No	1	0	1	.	1	0	1	1	0	0	1	1	.	0	
Sibling #2	9	Male	No	1	0	1	1	.	0	.	.	0	0	.	.	.	0	
329.011.00208	Biologic Mother	51	Female	No	1	0	1	1	1	1	1	0	1	1	1	1	.	.
	Biologic Father	44	Male	No	.	0	.	.	.	.	.	0	.	.	.	.	1	1
	Sibling #1	13	Male	No	.	0	.	.	.	.	1	0	.	.	.	.	.	
329.011.00209	Biologic Mother	41	Female	No	0	0	0	0	0	0	.	0	1	0	0	0	1	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Male	No	0	0	0	0	0	0	1	0	.	0	0	0	1	0
	Sibling #2	10	Female	No	0	0	0	0	0	0	.	0	1	0	0	0	.	0
329.011.00284	Biologic Mother	46	Female	No	0	0	.	0	.	0	.	0	0	0	.	.	.	0
	Biologic Father	47	Male	No	0	0	.	0	1	0	1	0	0	0	.	.	.	0
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	0	0	1	0	.	0	.	0	0	0	1	1	1	0
	Sibling #3	10	Male	No	0	0	.	0	.	0	.	0	0	0	.	.	.	0
329.011.00286	Biologic Mother	41	Female	No	0	0	0	0	0	0	1	0	.	0	1	0	.	0
	Biologic Father	44	Male	No	0	0	0	0	0	0	.	0	.	0	1	0	.	0
	Sibling #1	16	Female	No	0	0	0	0	0	0	.	0	.	0	1	0	.	0
	Sibling #2	15	Female	No	0	0	0	0	0	0	.	0	1	0	.	0	1	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00026	Biologic Mother	37	Female	No	.	0	0	.	0	.	0	.	1	0	1	1	0	.
	Biologic Father	36	Male	No	.	0	0	.	0	.	0	.	.	0	1	.	0	.
	Sibling #1	15	Female	No	.	0	0	.	0	.	0	.	.	0	.	.	0	.
	Sibling #2	14	Male	No	1	0	0	.	0	.	0	.	.	0	.	.	0	.
329.012.00219	Biologic Mother	42	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	.	0
	Biologic Father	42	Male	No	0	0	1	0	0	0	0	0	0	0	0	0	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

186

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.012.00219	Sibling #1	16	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	1	0
	Sibling #2	14	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	.	0
329.012.00221	Biologic Mother	44	Female	No	1	0	.	.	0	0	.	0	0	0	1	0	.	0
	Biologic Father	44	Male	No	.	0	.	.	0	0	1	0	0	0	.	0	.	0
	Sibling #1	17	Male	No	1	0	1	1	0	0	.	0	0	0	.	0	1	0
	Sibling #2	15	Male	No	.	0	.	.	0	0	.	0	0	0	.	0	1	0
	Sibling #3	14	Female	No	.	0	.	.	0	0	.	0	0	0	.	0	.	0
329.012.00223	Biologic Mother	32	Female	No	0	.	0	.	.	0	0	.	0	.	0	.	0	.
	Biologic Father	34	Male	No	0	.	0	.	.	0	0	.	0	.	0	.	0	.
	Sibling #1	13	Female	No	0	.	0	.	1	0	0	.	0	.	0	.	0	.
	Sibling #2	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00227	Biologic Mother	49	Female	No	.	0	0	0	0	0	0	0	0	0	0	0	.	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	27	Male	No	1	0	0	0	0	0	0	0	0	0	0	0	1	0
	Sibling #2	22	Male	No	.	0	0	0	0	0	0	0	0	0	0	0	.	0
	Sibling #3	16	Male	No	1	0	0	0	0	0	0	0	0	0	0	0	.	0
329.012.00230	Biologic Mother	36	Female	No	0	0	1	1	1	1	1	0	1	1	.	.	.	.
	Biologic Father	53	Male	Yes	0	0	.	.	.	.	1	0	.	.	1	1	.	.
	Sibling #1	15	Male	No	0	0	.	.	.	.	1	0	.	.	1	1	1	1
	Sibling #2	13	Male	No	0	0	.	.	.	.	.	0	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.001.00062	Biologic Mother	38	Female	No	1	0	1	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	37	Male	No	.	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Female	No	.	0	.	.	.	.	.	.	.	1	1	1	1	.
	Sibling #2	16	Female	No	1	0	1	.	1	1	.	.	1	.	.	.	1	.
	Sibling #3	15	Female	No	.	0	.	.	.	.	1	1	1	.	.	.	1	1
329.001.00064	Biologic Mother	32	Female	No	.	0	0	0	0	0	1	0	1	0	.	.	.	.
	Biologic Father	42	Male	No	.	0	0	0	0	0	.	0	.	0	.	.	1	.
	Sibling #1	13	Male	No	.	0	0	0	0	0	.	0	.	0	.	1	1	1
	Sibling #2	8	Male	No	1	0	0	0	0	0	.	0	.	0	1	1	.	.
329.001.00069	Biologic Mother	49	Female	No	.	.	.	.	.	.	.	.	0	0	.	.	.	0
	Biologic Father	55	Male	No	1	1	1	1	1	1	1	1	0	0	.	.	1	0
	Sibling #1	26	Female	No	.	.	.	.	.	.	1	1	0	0	.	.	.	0
	Sibling #2	24	Male	No	.	.	1	.	.	.	.	.	0	0	.	.	.	0
	Sibling #3	22	Female	No	.	.	.	.	.	.	.	.	0	0	1	1	.	0
329.001.00071	Biologic Mother	48	Female	No	.	0	1	0	0	0	.	.	0	0	1	1	1	1
	Biologic Father	46	Male	No	.	0	.	0	0	0	1	.	0	0	.	.	.	.
	Sibling #1	18	Male	No	1	0	.	0	0	0	1	.	0	0	.	.	.	.
	Sibling #2	13	Female	No	.	0	.	0	0	0	.	.	0	0	1	1	.	.
	329.001.00123	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.
Biologic Father		47	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
Sibling #1		22	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
Sibling #2		20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #3		16	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.001.00207	Biologic Mother	48	Female	No	0	.	0	.	0	.	0	.	0	.	0	0	.	.
	Biologic Father	49	Male	No	0	.	0	.	0	.	0	.	0	.	0	0	.	.
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	0	.	0	.	0	.	0	.	0	.	1	0	0	.
329.002.00049	Biologic Mother	52	Female	No	1	1	0	0	0	0	0	0	0	0	0	0	1	1
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	23	Male	No	.	.	0	0	0	0	0	0	0	0	0	0	1	1
	Sibling #3	20	Male	No	.	.	0	0	0	0	0	0	0	0	0	0	.	.
Sibling #4	16	Male	No	.	1	0	0	0	0	0	0	0	0	0	0	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

188

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.002.00059	Biologic Mother	46	Female	No	0	0	1	1	1	1	1	1	1	1	1	1	1	0
	Biologic Father	50	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	0
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	1	0
329.002.00060	Biologic Mother	47	Female	No	0	.	0	.	0	.	.	0	1	0	1	0	1	0
	Biologic Father	45	Male	No	0	.	0	.	0	.	1	0	.	0	.	0	.	0
	Sibling #1	16	Female	No	0	.	0	.	0	.	.	0	.	0	.	0	.	0
	Sibling #2	14	Female	No	0	.	0	.	0	.	.	0	.	0	.	0	.	0
	Sibling #3	11	Male	No	0	.	0	.	0	.	.	0	1	0	.	0	.	0
329.002.00097	Biologic Mother	43	Female	No	0	0	1	1	1	1	0	0	1	1	0	0	1	0
	Biologic Father	45	Male	No	0	0	.	.	.	.	0	0	.	.	0	0	.	0
	Sibling #1	16	Female	No	0	0	.	.	.	.	0	0	.	.	0	0	.	0
	Sibling #2	13	Female	No	0	0	.	.	.	.	0	0	1	.	0	0	.	0
	Sibling #3	9	Male	No	0	0	.	.	.	.	0	0	.	.	0	0	.	0
329.002.00101	Biologic Mother	48	Female	No	.	0	0	.	0	.	.	1	0	.	0	.	9	.
	Biologic Father	52	Male	No	.	0	0	.	0	.	1	1	0	.	0	.	9	.
	Sibling #1	26	Male	No	1	0	0	.	0	.	.	.	0	.	0	.	9	.
	Sibling #2	28	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	9	.
	Sibling #3	22	Female	No	.	0	0	.	0	.	.	.	0	.	0	.	9	.
329.002.00107	Biologic Mother	47	Female	No	.	0	.	.	.	.	1	0	1	1	.	.	1	0
	Biologic Father	53	Male	Yes	.	0	.	.	.	.	.	0	.	.	1	1	.	0
	Sibling #1	27	Male	No	.	0	.	.	.	.	.	0	.	.	.	.	.	0
	Sibling #2	20	Male	No	.	0	.	.	.	.	.	0	.	.	.	.	.	0
	Sibling #3	18	Male	No	1	0	1	1	1	1	.	0	1	1	1	.	.	0
329.002.00241	Biologic Mother	38	Female	No	0	0	0	0	0	.	0	.	0	0	1	1	0	0
	Biologic Father	42	Male	No	0	0	0	0	0	.	0	.	0	0	.	.	0	0
	Sibling #1	15	Male	No	0	0	0	0	0	.	0	.	0	0	1	.	0	0
	Sibling #2	17	Male	No	0	0	0	0	0	.	0	.	0	0	.	.	0	0
	329.002.00246	Biologic Mother	34	Female	No	1	1	1	9	9	.	1	1	9	.	9	.	.
Biologic Father		35	Male	No	.	.	.	9	9	.	.	.	9	.	9	.	.	0
Sibling #1		17	Female	No	.	.	1	9	9	.	1	1	9	.	9	.	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

189

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.002.00246	Sibling #2	8	Male	No	.	.	.	9	9	.	.	.	9	.	9	.	1	0	
	Sibling #3	2	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00320	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	.	0	.	.	.	0	.
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	.	0	.	.	.	0	.
	Sibling #1	16	Male	No	0	0	0	0	0	0	0	0	.	0	.	.	.	0	.
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	.	0	.	1	1	0	.
	Sibling #3	9	Female	No	0	0	0	0	0	0	0	0	.	0	.	.	.	0	.
329.002.00323	Biologic Mother	44	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	0	0	0	0	0	0	0	0	1	0	0	0	0	9	0
	Sibling #2	17	Female	No	0	0	0	0	0	0	0	0	0	.	0	0	0	9	0
329.003.00074	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	0	0	0	0	0	0	1	0	0	0	0	0	0	9	9
	Sibling #2	5	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00078	Biologic Mother	40	Female	No	.	0	1	0	1	0	1	9	1	0	.	9	9	9	
	Biologic Father	47	Male	No	.	0	.	0	1	0	.	9	.	0	.	9	9	9	
	Sibling #1	17	Female	No	1	0	.	0	.	0	.	9	1	0	1	9	9	9	
	Sibling #2	15	Female	No	.	0	.	0	.	0	.	9	.	0	.	9	9	9	
	Sibling #3	12	Female	No	.	0	.	0	1	0	.	9	.	0	.	9	9	9	
	Biologic Mother	43	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00080	Biologic Father	48	Male	No	0	0	0	0	1	1	.	0	0	0	0	0	.	0	
	Sibling #1	16	Female	No	0	0	0	0	.	.	1	0	0	0	0	0	1	0	
	Sibling #2	14	Male	No	0	0	0	0	.	.	.	0	0	0	0	0	1	0	
	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00085	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	17	Female	No	1	0	1	1	0	0	1	1	1	1	1	1	1	1	
	Sibling #2	14	Female	No	.	0	.	.	0	0	.	.	.	.	.	.	.	.	
	Sibling #3	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00086	Biologic Mother	38	Female	No	0	0	0	0	1	1	0	0	0	0	0	0	0	0	
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	14	Female	No	0	0	0	0	.	.	0	0	0	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

190

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.003.00086	Sibling #2	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00094	Biologic Mother	55	Female	No	0	0	0	0	0	0	0	0	0	0	.	0	.	0
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	1	0
329.003.00252	Biologic Mother	42	Female	No	1	0	1	0	1	1	1	0	0	0	.	0	1	0
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	1	0	.	0	1	.	.	0	0	0	1	0	.	0
329.003.00291	Biologic Mother	38	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	35	Male	No	0	0	0	0	0	0	.	9	.	.	.	1	.	.
	Sibling #1	13	Female	No	0	0	0	0	0	0	1	9	1	1	1	.	1	1
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #2	.	.	.	0	0	0	0	0	0	.	9	.	.	.	.	.	.
329.003.00315	Biologic Mother	52	Female	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	52	Male	No	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	16	Female	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00316	Biologic Mother	40	Female	No	1	0	1	.	1	0	1	0	0	0	0	.	0	.
	Biologic Father	38	Male	No	.	0	1	1	.	0	1	0	0	0	0	0	.	0
	Sibling #1	18	Male	No	1	0	.	.	.	0	.	0	0	0	0	0	.	0
	Sibling #2	16	Female	No	.	0	.	.	.	0	.	0	0	0	0	0	1	0
	Sibling #3	10	Female	No	.	0	.	.	.	0	.	0	0	0	0	0	.	0
	Sibling #4	6	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.004.00016	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	22	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.004.00018	Biologic Mother	42	Female	No	0	0	1	.	1	1	1	.	1	1	.	.	.	0
	Biologic Father	49	Male	No	0	0	.	.	.	.	.	.	.	.	.	.	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

191

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.004.00018	Sibling #1	17	Female	No	0	0	1	.	1	.	1	.	.	.	1	1	.	0
	Sibling #2	14	Male	No	0	0	1	1	1	1	1	1	1	1	1	1	.	1
329.004.00020	Biologic Mother	38	Female	No	0	.	1	0	1	1	1	0	0	.	0	.	0	.
	Biologic Father	45	Male	No	0	.	.	0	.	.	.	0	0	.	0	.	0	.
	Sibling #1	18	Male	No	0	.	.	0	.	.	.	0	0	.	0	.	0	.
	Sibling #2	14	Female	No	0	.	.	0	.	.	.	0	0	.	0	.	0	.
329.004.00213	Biologic Mother	45	Female	No	0	0	.	0	.	0	0	0	0	0	.	.	0	.
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	0	1	0	1	0	0	0	0	0	1	.	0	.
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00001	Biologic Mother	41	Female	No	.	.	.	.	.	.	1	0	0	0	1	0	0	9
	Biologic Father	45	Male	No	1	1	.	.	.	.	.	0	0	0	.	0	0	9
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	.	.	.	.	.	.	.	0	0	0	.	0	0	9
	Sibling #3	16	Female	No	.	.	1	1	1	1	1	1	0	0	0	.	0	0
329.005.00005	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.005.00010	Biologic Mother	45	Female	No	0	0	.	0	0	0	.	.	.	0	0	0	0	0
	Biologic Father	47	Male	No	0	0	1	0	0	0	1	1	1	0	0	0	0	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Female	No	0	0	.	0	0	0	.	.	.	0	0	0	0	0
	Sibling #5	15	Female	No	0	0	.	0	0	0	.	.	.	0	0	0	0	0
	Child #1	12	Male	No	0	0	.	0	0	0	.	.	.	0	0	0	0	0
329.005.00012	Biologic Mother	41	Female	No	0	0	0	0	1	0	1	0	0	0	0	0	0	0
	Biologic Father	44	Male	No	0	0	0	0	1	0	.	0	0	0	0	0	0	0
	Sibling #1	18	Male	No	0	0	0	0	.	0	.	0	0	0	0	0	0	0
	Sibling #2	14	Female	No	0	0	0	0	.	0	.	0	0	0	0	0	0	0
329.005.00111	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

192

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.005.00111	Biologic Father	40	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00114	Biologic Mother	47	Female		0	0	1	1	1	1	1	1	0	0	0	0	0	0
	Biologic Father	55	Male		0	0	.	.	.	.	.	.	0	0	0	0	0	0
	Sibling #1	22	Male	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0
	Sibling #2	16	Male	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0
	Sibling #3	25	Female	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0
329.005.00115	Biologic Mother	41	Female	Yes	0	0	0	0	.	0	.	0	.	0	0	0	.	0
	Biologic Father	0	Male	Yes	0	0	0	0	.	0	.	0	.	0	0	0	.	0
	Sibling #1	25	Male	No	0	0	0	0	.	0	.	0	.	0	0	0	.	0
	Sibling #2	18	Female	No	0	0	0	0	1	0	1	0	1	0	0	0	1	0
	Sibling #3	17	Male	No	0	0	0	0	.	0	.	0	.	0	0	0	.	0
329.005.00120	Biologic Mother	36	Female	No	0	0	1	0	1	0	1	1	1	1	.	1	0	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	0	0	.	0	.	0	1	.	.	.	.	0	0	
	Sibling #2	9	Male	No	0	0	.	0	.	0	.	.	.	.	1	.	0	0
329.005.00253	Biologic Mother	44	Female	No	1	1	1	0	0	0	1	0	0	0	1	1	1	0
	Biologic Father	44	Male	No	.	.	.	0	0	0	1	0	0	0	1	1	.	0
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	1	.	.	0	0	0	.	0	0	0	.	.	.	0
	Sibling #3	10	Male	No	.	.	.	0	0	0	.	0	0	0	.	.	.	0
329.005.00254	Biologic Mother	41	Female	No	.	0	1	1	1	1	1	1	.	.	.	.	.	.
	Biologic Father	45	Male	No	.	0	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	.	0	.	.	.	.	.	.	.	.	.	.	1	1
	Sibling #2	12	Female	No	.	0	1	1	.	.	.	.	1	1	1	1	.	.
	Sibling #3	9	Male	No	1	0	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00293	Biologic Mother	42	Female	No	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	Biologic Father	41	Male	No	.	.	.	.	.	.	1	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	.	.	.	.	.	.	1	.	1	1	1	1	1	1
	Sibling #2	14	Female	No	1	.	.	.	.	.	.	.	1	1	1	1	1	.
	Sibling #3	7	Male	No	1	.	1	.	.	.	.	.	.	.	1	1	.	.
	Sibling #4	12	Male	No	.	.	.	.	1	.	.	.	.	.	1	1	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

193

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.005.00293	Child #1	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #2	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00298	Biologic Mother	42	Female	No	1	0	1	1	1	.	1	1	1	1	0	0	1	1
	Biologic Father	44	Male	No	.	0	.	.	.	.	.	.	.	.	0	0	.	.
	Sibling #1	14	Female	No	1	0	.	.	.	.	.	.	.	.	0	0	.	.
	Sibling #2	13	Female	No	1	0	1	.	1	.	.	.	.	.	0	0	.	.
	Sibling #3	8	Male	No	.	0	.	.	.	.	.	.	.	.	0	0	.	.
329.005.00331	Biologic Mother	38	Female	No	.	0	1	9	1	0	.	9	9	9	.	.	1	0
	Biologic Father	48	Male	Unknown	.	0	.	9	.	0	.	9	9	9	.	.	.	0
	Sibling #1	15	Female	No	1	0	1	9	.	0	1	9	9	9	1	1	1	0
	Sibling #2	11	Female	No	.	0	.	9	.	0	1	9	9	9	.	.	.	0
329.005.00334	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	44	Male	No	.	0	0	0	0	0	0	0	1	0	1	0	0	0
	Sibling #1	15	Female	No	.	0	0	0	0	0	0	0	.	0	.	0	0	0
	Sibling #2	13	Female	No	1	0	0	0	0	0	0	0	.	0	.	0	0	0
329.006.00037	Biologic Mother	59	Female	No	1	9	.	.	.	.	1	0	1	.	1	.	.	0
	Biologic Father	55	Male	No	1	9	1	.	.	.	.	0	1	1	1	1	.	0
	Sibling #1	39	Male	No	1	9	1	.	1	1	.	0	.	.	.	.	0	0
	Sibling #2	36	Female	No	1	9	1	1	1	1	1	0	.	.	1	.	.	0
	Sibling #3	17	Female	No	1	9	1	1	.	1	.	0	.	.	.	.	1	0
329.006.00042	Biologic Mother	40	Female	No	.	.	0	.	0	.	0	.	0	.	0	.	1	.
	Biologic Father	43	Male	No	.	.	0	.	0	.	0	.	0	.	0	.	1	.
	Sibling #1	18	Male	No	.	.	0	.	0	.	0	.	0	.	0	.	1	1
	Sibling #2	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Male	No	1	1	0	.	0	.	0	.	0	.	0	.	.	.
329.006.00259	Biologic Mother	49	Female	No	0	.	0	.	.	.	0	.	0	.	.	.	0	.
	Biologic Father	53	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	0	.	0	.	.	.	0	.	0	.	.	.	0	.
	Sibling #2	15	Male	No	0	.	0	.	.	.	0	.	0	.	.	.	0	.
	Sibling #3	10	Female	No	0	.	0	.	1	1	0	.	0	.	1	1	0	.
329.007.00141	Biologic Mother	32	Female	No	0	.	1	1	1	1	1	0	0	.	0	.	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

194

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B	
329.007.00141	Biologic Father	32	Male	No	0	.	.	.	.	.	.	0	0	.	0	.	1	0	
	Sibling #1	13	Male	No	0	.	1	.	1	.	.	0	0	.	0	.	1	0	
	Sibling #2	9	Female	Yes	0	.	.	.	.	.	.	0	0	.	0	.	1	0	
329.007.00144	Biologic Mother	28	Female	No	0	.	0	.	0	.	1	1	0	.	0	.	0	.	
	Biologic Father	39	Male	No	0	.	0	.	0	.	.	.	0	.	0	.	0	.	
	Sibling #1	12	Female	No	0	.	0	.	0	.	.	.	0	.	0	.	0	.	
329.007.00266	Biologic Mother	33	Female	No	1	1	1	1	0	.	1	1	0	.	0	.	.	0	
	Biologic Father	34	Male	No	.	.	.	.	0	.	.	.	0	.	0	.	.	0	
	Sibling #1	12	Female	No	1	1	.	.	0	.	1	.	0	.	0	.	1	0	
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00267	Biologic Mother	46	Female	No	0	.	.	9	0	.	0	.	.	.	0	.	1	0	
	Biologic Father	46	Male	No	0	.	.	9	0	.	0	.	.	.	0	.	.	0	
	Sibling #1	16	Male	No	0	.	1	9	0	.	0	.	1	1	0	.	1	0	
329.007.00311	Biologic Mother	44	Female	No	.	.	0	.	0	.	.	.	0	.	0	.	0	.	
	Biologic Father	62	Male	No	.	.	0	.	0	.	.	.	0	.	0	.	0	.	
	Sibling #1	18	Female	No	1	1	0	.	0	.	.	.	0	.	0	.	0	.	
	Sibling #2	15	Male	No	.	.	0	.	0	.	1	1	0	.	0	.	0	.	
329.008.00158	Sibling #3	13	Male	No	.	.	0	.	0	.	.	.	0	.	0	.	0	.	
	Child #2	.	.	.	0	0	.	.	.	.	.	.	0	0	0	0	0	0	
	Biologic Mother	47	Female	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0	
	Biologic Father	49	Male	No	0	0	1	1	1	1	1	1	0	0	0	0	0	0	
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	18	Female	No	0	0	.	.	.	.	.	.	0	0	0	0	0	0	
329.008.00162	Sibling #3	16	Female	No	0	0	.	.	.	.	.	0	0	0	0	0	0	0	
	Biologic Mother	46	Female	No	0	0	1	1	1	1	1	1	0	0	0	0	0	0	
	Biologic Father	41	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.008.00191	Sibling #1	27	Male	No	0	0	.	.	.	.	.	0	0	0	0	0	0	0	
	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.008.00191	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

195

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.008.00191	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	.			0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.009.00128	Biologic Mother	50	Female	No	0	0	1	0	.	0	1	1	0	0	0	0	0	0
	Biologic Father	49	Male	No	0	0	.	0	.	0	.	.	0	0	0	0	0	0
	Sibling #1	23	Male	No	0	0	.	0	.	0	.	.	0	0	0	0	0	0
	Sibling #2	13	Male	No	0	0	.	0	1	0	1	.	0	0	0	0	0	0
	Sibling #3	10	Female	No	0	0	.	0	.	0	.	.	0	0	0	0	0	0
329.009.00129	Biologic Mother	42	Female	No	1	0	1	1	1	0	1	1	0	.	0	.	1	0
	Biologic Father	47	Male	No	.	0	.	.	.	0	.	.	0	.	0	.	.	0
	Sibling #1	16	Male	No	.	0	.	.	.	0	1	1	0	.	0	.	1	0
	Sibling #2	12	Female	No	.	0	.	.	.	0	1	.	0	.	0	.	.	0
329.009.00135	Biologic Mother	48	Female	No	0	.	.	.	.	0	.	.	0	.	0	.	1	0
	Biologic Father	48	Male	No	0	.	.	.	1	0	.	.	0	.	0	.	.	0
	Sibling #1	17	Female	No	0	.	1	1	.	0	1	1	0	.	0	.	.	0
329.009.00136	Biologic Mother	39	Female	No	0	.	.	.	.	.	.	.	.	.	1	1	.	.
	Sibling #6	15	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #7	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #8	14	Female	No	0	.	.	.	.	.	1	1	.	.	.	.	1	1
	Sibling #9	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	48	Male	No	0	.	1	1	1	1	1	1	1	1	1	.	.	1
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	23	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #5	16	Female	No	0	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00169	Biologic Mother	27	Female	No	0	0	0	.	0	.	0	0	0	.	0	.	0	.
	Biologic Father	32	Male	No	0	0	0	.	0	.	0	0	0	.	0	.	0	.
	Sibling #1	13	Male	No	0	0	0	.	0	.	0	0	0	.	0	.	0	.
	Sibling #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00174	Biologic Mother	44	Female	No	0	.	0	.	1	1	1	0	0	.	0	.	0	.
	Biologic Father	48	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

196

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.009.00174	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	26	Male	No	0	.	0	.	.	.	.	0	0	.	0	.	0	
	Sibling #3	15	Female	No	0	.	0	.	.	.	.	0	0	.	0	.	0	
329.009.00197	Biologic Mother	29	Female	No	0	.	0	.	0	.	1	0	0	.	0	.	0	
	Biologic Father	31	Male	No	0	.	0	.	0	.	.	0	0	.	0	.	0	
	Sibling #1	12	Male	No	0	.	0	.	0	.	1	0	0	.	0	.	0	
	Sibling #2	4	Female	No	0	.	0	.	0	.	.	0	0	.	0	.	0	
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00198	Biologic Mother	34	Female	No	0	.	.	.	.	.	1	1	0	.	0	.	0	
	Biologic Father	35	Male	No	0	.	.	.	.	.	.	.	0	.	0	.	0	
	Sibling #1	17	Female	No	0	.	1	1	1	1	1	.	0	.	0	.	0	
	Sibling #2	15	Female	No	0	.	.	.	.	.	.	.	1	0	.	0	.	0
	Sibling #3	13	Female	No	0	.	.	.	.	.	.	.	0	.	0	.	0	
329.009.00200	Biologic Mother	49	Female	No	0	.	0	.	.	.	1	.	0	.	.	.	0	
	Biologic Father	53	Male	No	0	.	0	.	1	1	1	1	0	.	.	.	0	
	Sibling #1	17	Female	No	0	.	0	.	.	.	1	1	0	.	1	1	0	
	Sibling #2	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00202	Biologic Mother	40	Female	No	1	.	1	1	1	1	1	0	1	0	.	1	0	
	Biologic Father	41	Male	No	1	.	.	.	.	.	.	0	.	0	.	.	0	
	Sibling #1	19	Male	No	1	.	.	.	.	.	.	0	.	0	.	.	0	
	Sibling #2	15	Female	No	1	.	.	.	.	.	1	0	.	0	1	1	0	
	Sibling #3	14	Male	No	1	1	.	.	.	.	.	0	.	0	.	.	0	
329.009.00237	Biologic Mother	43	Female	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Sibling #6	9	Female	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Biologic Father	44	Male	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Sibling #1	21	Male	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Sibling #2	19	Female	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Sibling #3	17	Male	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Sibling #4	12	Male	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
	Sibling #5	10	Male	No	0	0	9	.	0	0	0	0	0	0	0	0	0	
329.009.00238	Biologic Mother	42	Female	No	0	0	.	.	0	0	1	1	0	0	.	0	0	
	Biologic Father	42	Male	No	0	0	1	1	0	0	1	1	0	0	1	0	0	
	Sibling #1	21	Male	Yes	0	0	.	.	0	0	.	.	0	0	.	0	0	
	Sibling #2	16	Female	Yes	0	0	.	.	0	0	.	.	0	0	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

197

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.009.00238	Sibling #3	9	Female	Yes	0	0	.	.	0	0	.	.	0	0	.	0	0	0
329.009.00276	Biologic Mother	30	Female	No	.	0	0	.	0	.	1	0	0	.	0	.	0	.
	Biologic Father	32	Male	No	.	0	0	.	0	.	.	0	0	.	0	.	0	.
	Sibling #1	13	Male	No	1	0	0	.	0	.	.	0	0	.	0	.	0	.
329.009.00302	Biologic Mother	40	Female	No	0	.	0	0	1	0	0	.	0	.	.	.	0	0
	Biologic Father	41	Male	No	0	.	0	0	.	0	0	.	0	.	.	.	0	0
	Sibling #1	17	Male	No	0	.	0	0	.	0	0	.	0	.	1	1	0	0
	Sibling #2	10	Female	No	0	.	0	0	.	0	0	.	0	.	1	1	0	0
329.009.00306	Biologic Mother	28	Female	Yes	0	.	9	.	0	.	0	.	0	0	.	.	1	0
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	.	9	.	0	.	0	.	0	0	1	1	1	0
329.009.00312	Biologic Mother	48	Female	No	0	0	1	1	1	1	1	1	1	1	0	0	0	0
	Biologic Father	55	Male	No	0	0	1	.	1	.	1	1	.	.	0	0	0	0
	Sibling #1	17	Female	No	0	0	.	.	.	.	1	1	.	.	0	0	0	0
329.009.00327	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	1	0
	Biologic Father	42	Male	No	0	0	0	0	0	0	0	0	0	0	.	0	.	0
	Sibling #1	18	Male	No	0	0	0	0	0	0	0	0	0	0	1	0	.	0
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	.	0
329.009.00330	Biologic Mother	33	Female	No	.	.	0	0	0	0	1	0	0	0	0	0	1	1
	Biologic Father	36	Male	No	.	.	0	0	0	0	.	0	0	0	0	0	.	.
	Sibling #1	14	Female	No	.	.	0	0	0	0	.	0	0	0	0	0	.	.
	Sibling #2	12	Male	No	1	1	0	0	0	0	.	0	0	0	0	0	.	.
	Sibling #3	9	Male	No	.	.	0	0	0	0	.	0	0	0	0	0	.	.
329.010.00183	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #1	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #3	13	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.010.00263	Biologic Mother	40	Female	No	0	0	1	1	1	1	0	0	0	0	.	.	.	.
	Biologic Father	60	Male	No	0	0	.	.	.	.	0	0	0	0	.	.	.	.
	Sibling #1	21	Male	No	0	0	.	.	.	.	0	0	0	0	.	.	.	.
	Sibling #2	18	Male	No	0	0	.	.	.	.	0	0	0	0	1	1	1	1

0 = NO; 1 = YES; 9 = DON'T KNOW

198

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.010.00263	Sibling #3	15	Female	No	0	0	.	.	.	.	0	0	0	0	.	.	.	.
329.010.00277	Biologic Mother	35	Female	No	0	.	1	0	0	.	0	.	0	.	1	1	.	0
	Biologic Father	38	Male	No	0	.	.	0	0	.	0	.	0	.	.	.	.	0
	Sibling #1	14	Female	No	0	.	.	0	0	.	0	.	0	.	.	.	1	0
329.010.00282	Biologic Mother	45	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Biologic Father	46	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #1	18	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #2	15	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #3	12	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.011.00164	Biologic Mother	43	Female	No	0	.	.	0	0	.	1	0	0	.	0	.	0	.
	Biologic Father	43	Male	No	0	.	.	0	0	.	.	0	0	.	0	.	0	.
	Sibling #1	24	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	20	Male	No	0	.	.	0	0	.	.	0	0	.	0	.	0	.
	Sibling #3	18	Male	No	0	.	.	0	0	.	.	0	0	.	0	.	0	.
329.011.00210	Biologic Mother	32	Female	No	.	0	.	.	.	.	0	0	0	0	1	1	0	0
	Biologic Father	41	Male	No	1	0	.	.	.	.	0	0	0	0	.	.	0	0
	Sibling #1	14	Female	No	.	0	1	1	1	1	0	0	0	0	1	1	0	0
	Sibling #2	10	Male	No	.	0	.	.	1	1	0	0	0	0	1	1	0	0
	Biologic Mother	42	Female	No	0	0	0	0	.	.	.	.	.	9	.	.	.	0
329.011.00285	Biologic Father	44	Male	No	0	0	0	0	.	.	.	.	.	9	.	.	.	0
	Sibling #1	16	Male	No	0	0	0	0	1	1	1	1	1	9	1	1	1	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.011.00287	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	4	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00027	Biologic Mother	39	Female	No	0	.	.	.	.	0	.	.	9	.	1	9	0	.
	Biologic Father	38	Male	No	0	.	1	1	.	0	1	1	9	.	.	9	0	.
	Sibling #1	15	Male	No	0	.	1	1	1	0	1	1	9	.	.	9	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

199

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part II  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					12	12B	13	13B	14	14B	15	15B	16	16B	17	17B	18	18B
329.012.00217	Biologic Mother	45	Female	No	0	0	1	0	.	.	1	0	0	0	0	0	0	0
	Biologic Father	45	Male	No	0	0	1	0	1	1	1	0	0	0	0	0	0	0
	Sibling #1	22	Male	No	0	0	.	0	.	.	1	0	0	0	0	0	0	0
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Female	No	0	0	.	0	.	.	.	0	0	0	0	0	0	0
329.012.00218	Biologic Mother	46	Female	No	0	.	0	.	0	.	.	0	0	.	0	.	0	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.012.00224	Biologic Mother	41	Female	No	0	0	1	0	0	0	1	0	0	0	0	0	0	0
	Biologic Father	41	Male	No	0	0	.	0	0	0	.	0	0	0	0	0	0	0
	Sibling #1	14	Female	No	0	0	.	0	0	0	1	0	0	0	0	0	0	0
	Sibling #2	7	Female	No	0	0	.	0	0	0	.	0	0	0	0	0	0	0
329.012.00225	Biologic Mother	48	Female	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.
	Biologic Father	48	Male	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.
	Sibling #1	14	Male	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

200

0 = NO; 1 = YES; 9 = DON'T KNOW

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.001.00063	Biologic Mother	40	Female	No	0	.	0	0	0	0	0	0	.	.	0	.	1	.	0
	Biologic Father	43	Male	No	0	.	0	0	0	0	0	0	1	1	0	.	1	1	0
	Sibling #1	14	Female	No	0	.	0	0	0	0	0	0	.	.	0	.	.	.	0
	Sibling #2	13	Female	No	0	.	0	0	0	0	0	0	.	.	0	.	.	.	0
	Sibling #3	10	Male	No	0	.	0	0	0	0	0	0	.	.	0	.	.	.	0
329.001.00068	Biologic Mother	41	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0
329.001.00072	Biologic Mother	45	Female	No	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.001.00121	Biologic Mother	43	Female	No	1	0	0	0	0	0	.	0	0	0	0	0	.	0	0
329.001.00205	Biologic Mother	37	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0
329.001.00206	Biologic Mother	52	Female	No	0	0	0	0	0	0	0	0	1	.	0	0	.	0	.
329.002.00055	Biologic Mother	48	Female	No	.	.	0	.	9	.	9	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

201

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.002.00055	Sibling #4	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.002.00058	Biologic Mother	42	Female	No	1	0	1	1	.	0	0	0	.	.	.	.	0	0	.	
	Biologic Father	36	Male	No	.	0	.	.	.	0	0	0	1	1	1	1	0	0	1	
	Sibling #1	24	Male	No	.	0	.	.	.	0	0	0	1	1	1	1	0	0	1	
	Sibling #2	22	Male	No	.	0	.	.	.	0	0	0	1	1	1	1	0	0	1	
	Sibling #3	16	Female	No	.	0	.	.	1	0	0	0	.	.	.	.	0	0	.	
	Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00099	Biologic Mother	37	Female	Yes	.	0	0	.	0	.	0	.	0	.	0	.	0	0		
	Biologic Father	47	Male	No	1	0	0	.	0	.	0	.	0	.	0	.	1	0	0	
	Sibling #1	15	Male	No	.	0	0	.	0	.	0	.	0	.	0	.	0	0	0	
	Sibling #2	9	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	0	0	0	
329.002.00102	Biologic Mother	35	Female	No	1	0	0	0	0	0	0	.	0	.	0	.	0	.	0	
	Biologic Father	39	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	17	Female	No	.	0	0	0	0	0	0	.	0	.	0	.	0	.	0	
	Sibling #2	13	Female	No	.	0	0	0	0	0	0	.	0	.	0	.	0	.	0	
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00105	Biologic Mother	43	Female	No	0	0	1	0	0	0	0	0	0	0	.	.	0	0	0	
	Biologic Father	52	Male	Yes	0	0	.	0	0	0	0	0	0	0	.	.	0	0	0	
	Sibling #1	17	Male	No	0	0	.	0	0	0	0	0	0	0	1	1	0	0	0	
	Sibling #2	16	Male	Yes	0	0	.	0	0	0	0	0	0	0	.	.	0	0	0	
329.002.00106	Biologic Mother	32	Female	No	0	.	0	.	.	0	0	.	0	.	0	.	.	.	.	
	Biologic Father	36	Male	No	0	.	0	.	.	0	0	.	0	.	0	.	1	1	1	
	Sibling #1	15	Female	No	0	.	0	.	1	0	0	.	0	.	0	.	.	.	.	
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00242	Biologic Mother	36	Female	No	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	
	Biologic Father	39	Male	No	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	
	Sibling #1	15	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	.	0	0	
	Sibling #2	12	Male	No	0	0	1	0	0	0	0	0	0	0	0	0	.	0	0	
329.002.00245	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	.	.	1	0	1	0	1	
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	1	1	1	0	1	0	1	
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	.	.	1	0	.	0	.	
	Sibling #2	18	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	.	0	.	
	Sibling #3	16	Female	No	0	0	0	0	0	0	0	0	.	.	1	0	.	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

202

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.002.00245	Sibling #4	11	Female	No	0	0	0	0	0	0	0	0	.	.	.	0	.	0	.	
	Sibling #5	9	Male	No	0	0	0	0	0	0	0	0	.	.	.	0	.	0	.	
329.002.00319	Biologic Mother	42	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	24	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #2	17	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #3	16	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
329.003.00077	.	.	.	.	0	0	0	0	.	0	0	0	.	0	0	0	0	0	0	
	Biologic Mother	45	Female	No	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	
	Biologic Father	55	Male	No	0	0	0	0	.	0	0	0	.	0	0	0	0	0	0	
	Sibling #1	29	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	26	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00087	Biologic Mother	49	Female	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	50	Male	No	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
	Sibling #1	14	Female	Yes	.	0	0	0	0	0	0	0	0	0	0	0	0	.	0	
329.003.00089	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	60	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.003.00091	Biologic Mother	.	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
	Biologic Father	.	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	
	Sibling #1	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	.	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
	Sibling #3	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00248	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	.	0	
	Sibling #1	22	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #3	8	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.003.00250	Biologic Mother	43	Female	No	.	9	.	9	9	0	0	0	0	0	0	0	9	9	9	

0 = NO; 1 = YES; 9 = DON'T KNOW

203

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.003.00250	Biologic Father	42	Male	No	.	9	.	9	9	0	0	0	0	0	0	0	9	9	9	
	Sibling #1	18	Female	No	1	9	1	9	9	0	0	0	0	0	0	0	9	9	9	
	Sibling #2	15	Female	No	.	9	1	9	9	0	0	0	0	0	0	0	9	9	9	
	Sibling #3	8	Female	No	.	9	.	9	9	0	0	0	0	0	0	0	9	9	9	
	Sibling #4	2	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00292	Biologic Mother	43	Female	No	0	.	1	0	0	0	1	9	0	0	0	0	0	9	0	
	Biologic Father	43	Male	No	0	1	1	0	0	0	1	9	0	0	0	0	0	9	0	
	Sibling #1	16	Male	No	0	.	1	0	0	0	1	9	0	0	0	0	0	9	0	
	Sibling #2	15	Male	No	0	.	1	0	0	0	1	9	0	0	0	0	0	9	0	
329.003.00313	Biologic Mother	36	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	37	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	14	Female	No	0	0	0	0	.	0	.	0	0	0	0	0	0	0	.	
	Sibling #2	18	Male	No	0	0	0	0	1	0	1	0	0	0	0	0	0	0	1	
329.004.00015	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0	
329.004.00017	Biologic Mother	50	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	52	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	0	.	1	
	Sibling #1	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	15	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.004.00019	Biologic Mother	.	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
	Biologic Father	.	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	
	Sibling #1	.	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
329.004.00212	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.004.00214	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	21	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

204

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.005.00002	Biologic Mother	35	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	0	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00004	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Biologic Father	44	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Male	Yes	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0
329.005.00008	Biologic Mother	34	Female	No	.	0	0	0	0	0	0	0	0	0	0	0	1	.	0
	Biologic Father	33	Male	No	1	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	Sibling #1	12	Male	No	.	0	0	0	0	0	0	0	0	0	0	0	.	.	0
	Sibling #2	9	Male	No	.	0	0	0	0	0	0	0	0	0	0	0	.	.	0
329.005.00109	Biologic Mother	31	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	28	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	15	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00112	Biologic Mother	61	Male	No	0	0	0	0	.	9	0	0	.	.	9	9	0	0	.
	Biologic Father	54	Female	No	0	0	0	0	.	9	0	0	.	.	9	9	0	0	.
	Sibling #1	21	Female	No	0	0	0	0	.	9	0	0	.	.	9	9	0	0	.
	Sibling #2	18	Male	No	0	0	0	0	1	9	0	0	1	1	9	9	0	0	1
	Sibling #3	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Female	No	0	0	0	0	.	9	0	0	.	.	9	9	0	0	1
	Sibling #5	13	Male	No	0	0	0	0	.	9	0	0	.	.	9	9	0	0	.
329.005.00116	Biologic Mother	39	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	1
	Biologic Father	51	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	.
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	25	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
	Sibling #3	24	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
	Sibling #4	22	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
	Sibling #5	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	.
	Child #1	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Child #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00119	Biologic Mother	44	Female	No	0	0	1	.	0	0	0	0	.	.	.	0	.	.	0
	Biologic Father	46	Male	No	0	0	.	.	0	0	0	0	1	1	1	0	1	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

205

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.005.00119	Sibling #1	19	Female	No	0	0	.	.	0	0	0	0	.	.	.	0	.	.	0	
	Sibling #2	14	Female	No	0	0	.	.	0	0	0	0	.	.	1	0	.	.	0	
	Sibling #3	7	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00151	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	
	Biologic Father	40	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	
	Sibling #1	17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
	Sibling #3	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
	Sibling #4	13	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
329.005.00152	Biologic Mother	37	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	
	Biologic Father	39	Male	No	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	.	0	.	0	0	
329.005.00257	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.005.00258	Biologic Mother	45	Male	No	0	0	0	0	0	0	0	0	.	.	.	.	.	.	0	
	Biologic Father	44	Female	No	0	0	0	0	0	0	0	0	1	1	1	1	1	1	0	
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	.	.	0	
	Sibling #2	9	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00299	Biologic Mother	34	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	9	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.005.00300	Biologic Mother	45	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	50	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	18	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	12	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #3	9	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.005.00333	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	19	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

206

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.005.00336	Biologic Mother	42	Female	No	0	0	.	0	1	0	0	0	.	.	.	.	.	0		
	Biologic Father	41	Male	No	0	0	.	0	.	0	0	0	1	1	1	1	1	0		
	Sibling #1	16	Female	No	0	0	.	0	.	0	0	0	.	.	.	.	.	0		
	Sibling #2	14	Female	No	0	0	.	0	.	0	0	0	.	.	.	.	.	0		
	Sibling #3	7	Male	No	0	0	1	0	.	0	0	0	.	.	.	.	.	0		
329.006.00038	Biologic Mother	35	Female	No	0	0	1	.	0	0	0	.	0	.	1	.	0	0		
	Biologic Father	40	Male	No	0	0	.	.	0	0	0	.	0	.	.	.	0	0		
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	15	Female	No	0	0	1	1	0	0	0	.	0	.	.	.	0	0		
	Sibling #3	12	Female	No	0	0	.	.	0	0	0	.	0	.	.	.	0	0		
329.006.00039	Biologic Mother	47	Female	No	.	0	.	0	0	.	0	.	0	.	0	.	0	.		
	Biologic Father	48	Male	No	.	0	1	0	0	.	0	.	0	.	0	.	0	1		
	Sibling #1	24	Male	No	.	0	.	0	0	.	0	.	0	.	0	.	0	1		
	Sibling #2	21	Male	No	1	0	1	0	0	.	0	.	0	.	0	.	0	.		
	Sibling #3	15	Female	No	.	0	.	0	0	.	0	.	0	.	0	.	0	.		
329.006.00260	Biologic Mother	56	Female	No	.	.	0	.	0	.	.	0	.	0	.	0	.	0		
	Biologic Father	56	Male	Yes	1	1	0	.	0	.	1	1	0	.	0	.	0	0		
	Sibling #1	17	Female	No	.	.	0	.	0	.	.	0	.	0	.	0	.	0		
	Sibling #2	10	Male	No	.	.	0	.	0	.	.	0	.	0	.	0	.	0		
329.006.00261	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	38	Male	No	0	0	0	0	.	.	0	0	1	0	0	0	0	0		
	Sibling #1	19	Female	No	0	0	0	0	.	.	0	0	.	0	0	0	0	0		
	Sibling #2	17	Male	No	0	0	0	0	1	1	0	0	.	0	0	0	0	0		
	Sibling #3	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #4	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.007.00140	Biologic Mother	32	Female	No	1	0	0	.	.	0	0	.	.	9	9	.	.	9		
	Biologic Father	37	Male	No	.	0	0	.	.	0	0	.	1	9	9	.	1	9		
	Sibling #1	11	Male	No	.	0	0	.	1	0	0	.	.	9	9	.	.	9		
	Sibling #2	9	Male	No	.	0	0	.	.	0	0	.	.	9	9	.	.	9		

0 = NO; 1 = YES; 9 = DON'T KNOW

207

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.007.00142	Biologic Mother	44	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	1	0	0
	Biologic Father	46	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	1	0	0
	Sibling #1	15	Male	No	0	.	0	.	0	.	0	.	.	.	0	.	.	0	0
329.007.00145	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	41	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0
	Sibling #1	23	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0
	Sibling #2	16	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0
329.007.00265	Biologic Mother	34	Female	No	0	.	.	.	.	9	.	0	1	1	1	0	1	.	.
	Biologic Father	29	Male	Yes	0	.	1	1	1	9	1	0	1	1	1	0	1	1	1
	Sibling #1	16	Female	No	0	.	.	.	.	9	.	0	.	.	.	0	.	.	.
	Sibling #2	13	Male	No	0	.	.	.	.	9	.	0	.	.	.	0	.	.	.
329.007.00268	Biologic Mother	37	Female	No	0	.	0	.	0	.	0	.	1	.	0	.	0	.	0
	Biologic Father	33	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	0	.	0
	Sibling #1	13	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	0	.	0
	Biologic Mother	37	Female	No	0	0	1	1	0	0	0	0	.	.	0	0	1	0	.
329.007.00294	Biologic Father	40	Male	No	0	0	.	.	0	0	0	0	1	1	0	0	.	0	1
	Sibling #1	15	Female	No	0	0	.	.	0	0	0	0	.	.	0	0	.	0	.
	Sibling #2	14	Male	No	0	0	.	.	0	0	0	0	.	.	0	0	.	0	.
	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	.	0
329.007.00309	Biologic Father	44	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	.	0
	Sibling #1	18	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	1	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00310	Biologic Mother	41	Female	No	.	0	.	0	0	.	0	.	0	.	0	.	.	0	0
	Biologic Father	41	Male	No	1	0	1	0	0	.	0	.	0	.	0	.	1	0	0
	Sibling #1	16	Female	No	.	0	.	0	0	.	0	.	0	.	0	.	.	0	0
	Sibling #2	15	Male	No	.	0	.	0	0	.	0	.	0	.	0	.	.	0	0
329.007.00318	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	.	0	.
	Biologic Father	62	Male	No	0	0	0	0	0	0	0	0	1	1	.	.	1	0	1

0 = NO; 1 = YES; 9 = DON'T KNOW

208

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.007.00318	Sibling #1	15	Male	No	0	0	0	0	0	0	0	0	.	.	.	.	.	0	.	
	Sibling #2	13	Male	No	0	0	0	0	0	0	0	0	.	.	.	.	.	0	.	
	Sibling #3	18	Female	No	0	0	0	0	0	0	0	0	.	.	1	1	.	0	1	
329.008.00157	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	.	.	.	
	Biologic Father	39	Male	No	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	
329.008.00160	Biologic Mother	38	Female	No	0	0	0	0	0	0	0	0	0	0	1	.	1	1	.	
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	
329.008.00188	Biologic Mother	37	Female	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	.	
	Biologic Father	42	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	15	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	.	
329.008.00271	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.	
	Biologic Father	41	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.008.00275	Sibling #2	10	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.	
	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	19	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.009.00130	Sibling #2	17	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Mother	49	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Biologic Father	52	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	
	Sibling #1	16	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Sibling #3	10	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Sibling #4	7	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Biologic Mother	.	Female	No	.	9	.	.	1	1	1	1	0	.	0	.	.	0	0	
329.009.00131	Biologic Father	41	Male	No	.	9	.	.	.	.	.	.	0	.	0	.	1	0	0	
	Sibling #1	16	Female	No	1	9	1	1	.	.	.	.	0	.	0	.	.	0	0	
	Sibling #2	13	Female	No	.	9	.	.	.	.	.	.	0	.	0	.	.	0	0	
	Biologic Mother	37	Female	No	0	.	0	0	0	.	0	.	0	.	0	.	1	.	0	
329.009.00133	Biologic Father	37	Male	No	0	.	0	0	0	.	0	.	0	.	0	.	1	1	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

209

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B
329.009.00133	Sibling #1	16	Female	No	0	.	0	0	0	.	0	.	0	.	0	.	.	0
	Sibling #2	14	Male	No	0	.	0	0	0	.	0	.	0	.	0	.	.	0
329.009.00138	.	.	.	.	.	.	.	.	.	1	0	.	.	.	.	.	.	.
	Biologic Mother	34	Female	No	1	1	1	1	1	.	0	.	1	1	.	.	.	.
	Biologic Father	33	Male	No	.	.	.	.	.	.	0	.	1	1	1	1	1	1
	Sibling #1	13	Female	No	.	.	.	.	.	.	0	.	.	.	1	1	.	.
	Sibling #2	10	Male	No	.	.	1	1	.	.	0	.	.	.	.	.	.	.
329.009.00170	Biologic Mother	41	Female	No	.	0	9	.	9	.	9	.	9	.	9	.	9	.
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	1	0	9	.	9	.	9	.	9	.	9	.	9	.
	Sibling #2	22	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00173	Biologic Mother	43	Female	No	1	1	0	.	.	.	.	.	0	.	.	0	0	.
	Biologic Father	45	Male	Yes	.	.	0	.	1	1	1	1	0	.	1	0	0	.
	Sibling #1	12	Female	No	.	.	0	.	.	.	.	.	0	.	.	0	0	.
329.009.00193	Biologic Mother	36	Female	No	0	.	0	.	0	.	0	.	.	.	1	1	1	1
	Biologic Father	38	Male	No	0	.	0	.	0	.	0	.	1	1	1	1	1	1
	Sibling #1	12	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.
	Sibling #2	3	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00196	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0
	Sibling #1	17	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0
	Sibling #2	9	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0
329.009.00201	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.
	Biologic Father	47	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	Sibling #1	17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.
	Sibling #2	14	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.
329.009.00204	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0
	Sibling #6	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	47	Male	No	0	.	0	.	0	.	0	.	0	.	1	0	1	0
	Sibling #1	13	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0
	Sibling #2	12	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

210

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.009.00204	Sibling #3	10	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0	0
	Sibling #4	9	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0
	Sibling #5	21	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0
	Child #1	.	.	.	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0
329.009.00235	Biologic Mother	32	Female	No	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	30	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	8	Male	No	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0
329.009.00240	Biologic Mother	48	Female	No	1	0	0	0	0	0	0	0	0	0	0	0	0	0	.
	Biologic Father	52	Male	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0	.
	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Sibling #4	13	Female	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	.
329.009.00303	Biologic Mother	43	Female	No	0	.	.	.	0	.	0	.	0	.	0	.	1	1	.
	Biologic Father	49	Male	No	0	.	.	.	0	.	0	.	0	.	0	.	1	1	.
	Sibling #1	17	Male	No	0	.	1	1	0	.	0	.	0	.	0	.	.	.	.
	Sibling #2	14	Female	No	0	.	.	.	0	.	0	.	0	.	0	.	.	.	1
329.009.00304	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	23	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	1
	Sibling #2	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #3	16	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	.	
329.009.00324	Biologic Mother	33	Female	No	1	0	0	0	0	0	0	0	.	0	.	0	0	0	0
	Biologic Father	35	Female	No	.	0	0	0	0	0	0	0	1	0	1	0	0	0	0
	Sibling #1	13	Female	No	.	0	0	0	0	0	0	0	.	0	.	0	0	0	0
	Sibling #2	8	Female	No	.	0	0	0	0	0	0	0	.	0	.	0	0	0	0
Sibling #3	5	Female	No	.	0	0	0	0	0	0	0	.	0	.	0	0	0	0	
329.009.00328	Biologic Mother	45	Female	No	0	0	1	0	0	0	0	0	0	0	.	0	.	0	.
	Biologic Father	46	Male	No	0	0	.	0	0	0	0	0	0	0	.	0	1	0	0
	Sibling #1	23	Male	No	0	0	.	0	0	0	0	0	0	0	1	0	.	0	1
	Sibling #2	21	Male	No	0	0	.	0	0	0	0	0	0	0	1	0	1	0	1
	Sibling #3	14	Male	No	0	0	.	0	0	0	0	0	0	0	.	0	.	0	.
Sibling #4	12	Male	No	0	0	.	0	0	0	0	0	0	0	.	0	.	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

211

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.009.00329	Biologic Mother	32	Female	No	0	0	1	0	0	0	0	0	1	0	0	0	0	1		
	Biologic Father	34	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	14	Male	No	0	0	.	0	0	0	0	0	.	0	0	0	0	.		
	Sibling #2	10	Male	No	0	0	.	0	0	0	0	0	.	0	0	0	0	0	.	
	Sibling #3	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.010.00182	Biologic Mother	42	Female	No	0	.	0	.	.	.	.	.	0	.	.	.	.	.	0	
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	18	Male	No	0	.	0	.	1	1	1	1	0	.	1	1	1	1	0	
	Sibling #2	17	Female	No	0	.	0	.	.	.	.	.	0	.	.	.	.	.	.	0
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.010.00278	Biologic Mother	49	Female	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.	0	
	Biologic Father	49	Male	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.	0	
	Sibling #1	20	Female	No	0	.	0	.	0	.	0	.	1	0	0	.	0	.	0	
	Sibling #2	17	Female	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.	0	
329.010.00280	Biologic Mother	33	Female	No	0	.	0	.	0	.	0	.	0	.	1	1	0	.	1	
	Biologic Father	32	Male	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.	1	
	Sibling #1	13	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.	.	
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.011.00283	Biologic Mother	36	Female	No	.	.	.	.	0	0	.	.	.	.	0	0	.	.	0	
	Biologic Father	42	Male	No	1	1	1	1	0	0	1	1	1	1	0	0	1	1	0	
	Sibling #1	16	Male	No	1	.	1	1	0	0	.	.	.	.	0	0	.	.	0	
329.011.00288	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	1	0	.	.	0	0	0	
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	
	Sibling #1	15	Male	No	0	0	0	0	0	0	0	0	.	0	.	.	0	0	0	
329.012.00025	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	21	Female	No	0	.	0	.	0	.	0	.	0	.	9	9	0	.	0	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	14	Female	No	0	.	0	.	0	.	0	.	0	.	9	9	0	.	0	
329.012.00220	Biologic Mother	40	Female	No	.	.	0	.	1	0	0	.	1	.	0	0	1	.	0	
	Biologic Father	41	Male	No	1	1	0	.	.	0	0	.	1	1	0	0	1	1	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

212

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.012.00220	Sibling #1	17	Male	No	.	.	0	.	.	0	0	.	.	.	0	0	.	.	0
	Sibling #2	15	Male	No	1	.	0	.	.	0	0	.	.	.	0	0	.	.	0
	Sibling #3	13	Female	No	.	.	0	.	.	0	0	.	.	.	0	0	.	.	0
329.012.00222	Biologic Mother	37	Female	No	0	.	0	.	0	.	0	.	.	.	9	0	1	0	0
	Biologic Father	38	Male	No	0	.	0	.	0	.	0	.	1	1	9	0	1	0	0
	Sibling #1	15	Female	No	0	.	0	.	0	.	0	.	.	.	9	0	.	0	0
329.012.00226	Biologic Mother	50	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	50	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	23	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	18	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	16	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.012.00228	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	0	.	0	0	0	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	0	0	.	0	0	0	.

213

0 = NO; 1 = YES; 9 = DON'T KNOW

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.001.00061	Biologic Mother	39	Female	No	0	0	0	0	0	0	0	0	1	0	1	0	1	0	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	.	0	.	0	1	0	0	
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	.	0	.	0	.	0	0	
	Sibling #2	14	Male	No	0	0	0	0	0	0	0	0	.	0	.	0	.	0	0	
329.001.00066	Biologic Mother	48	Female	No	0	0	1	1	.	.	.	.	0	0	.	.	0	0	0	
	Biologic Father	52	Male	No	0	0	.	.	1	1	1	1	0	0	1	1	0	0	0	
	Sibling #1	17	Female	No	0	0	.	.	.	.	.	.	0	0	.	.	0	0	0	
	Sibling #2	13	Male	No	0	0	.	.	.	.	.	.	0	0	.	.	0	0	0	
329.001.00067	Biologic Mother	42	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	1	.	.	
	Biologic Father	44	Male	No	1	0	0	.	0	.	0	.	0	.	0	.	1	1	1	
	Sibling #1	21	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	1	.	.	
	Sibling #2	16	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	.	.	1	
329.001.00070	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	.	0	0	0	.	0	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	12	Male	No	0	0	0	0	0	0	0	0	.	0	0	0	.	0	0	
329.001.00122	Biologic Mother	53	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #6	16	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #7	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	58	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	26	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	23	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #3	22	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #4	20	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #5	20	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.002.00050	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	
	Sibling #1	19	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.002.00056	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	41	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	0	.	0	
	Sibling #1	18	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	0	.	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

214

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B
329.002.00056	Sibling #2	10	Male	No	0	.	0	.	0	.	0	.	.	0	.	0	.	0
329.002.00057	Biologic Mother	33	Female	No	0	0	1	1	0	0	0	0	0	0	1	1	1	0
	Biologic Father	36	Male	No	0	0	.	.	0	0	0	0	0	0	.	.	1	0
	Sibling #1	15	Female	No	0	0	.	.	0	0	0	0	0	0	.	.	.	0
	Sibling #2	14	Female	No	0	0	.	.	0	0	0	0	0	0	.	.	.	0
	Sibling #3	12	Male	No	0	0	.	.	0	0	0	0	0	0	.	.	.	0
	Sibling #4	.	.	No	0	0	.	.	0	0	0	0	0	0	.	.	.	0
329.002.00098	Biologic Mother	43	Female	No	0	0	0	.	0	.	0	.	1	1	0	.	.	0
	Biologic Father	45	Male	No	0	0	0	.	0	.	0	.	1	1	0	.	1	0
	Sibling #1	16	Female	No	0	0	0	.	0	.	0	.	1	.	0	.	.	0
	Sibling #2	13	Female	No	0	0	0	.	0	.	0	.	.	.	0	.	.	0
	Sibling #3	9	Male	No	0	0	0	.	0	.	0	.	.	.	0	.	.	0
329.002.00100	.	.	.	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0
	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0
	Biologic Father	35	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0
	Sibling #1	15	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0
	Sibling #2	9	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0
329.002.00103	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	1	1
	Biologic Father	38	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	.	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	.	0
329.002.00104	Biologic Mother	41	Female	No	1	0	0	.	.	.	0	.	0	.	0	.	0	.
	Biologic Father	46	Male	No	1	0	0	.	.	.	0	.	0	.	0	.	0	.
	Sibling #1	18	Female	No	.	0	0	.	.	.	0	.	0	.	0	.	0	.
	Sibling #2	15	Female	No	.	0	0	.	1	1	0	.	0	.	0	.	0	.
	Sibling #3	13	Male	No	.	0	0	.	.	.	0	.	0	.	0	.	0	.
329.002.00243	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	1	0	0	.	0	.
	Biologic Father	44	Male	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.
	Sibling #1	20	Female	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.
	Sibling #2	17	Male	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.
	Sibling #3	15	Female	No	0	.	0	.	0	.	0	.	.	0	0	.	0	.
329.002.00244	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

215

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B
329.002.00244	Sibling #1	17	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.002.00321	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.
	Biologic Father	37	Male	No	0	.	0	.	0	.	0	.	1	1	1	1	1	1
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.
329.002.00322	Biologic Mother	34	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	.	9
	Biologic Father	56	Male	No	0	0	0	0	0	0	0	0	1	1	1	1	1	9
	Sibling #1	14	Don't	No	0	0	0	0	0	0	0	0	.	.	.	.	.	9
	Sibling #2	14	Don't	No	0	0	0	0	0	0	0	0	.	.	.	.	.	9
	Sibling #3	10	Don't	No	0	0	0	0	0	0	0	0	.	.	.	.	.	9
	Sibling #4	8	Don't	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00073	Biologic Mother	39	Female	No	1	0	0	0	0	0	.	.	0	0	.	.	1	0
	Biologic Father	41	Male	No	.	0	0	0	0	0	.	.	0	0	.	.	.	0
	Sibling #1	19	Female	No	.	0	0	0	0	0	1	1	0	0	1	1	1	0
	Sibling #2	17	Female	No	.	0	0	0	0	0	.	.	0	0	1	.	.	0
	Sibling #3	16	Female	No	.	0	0	0	0	0	.	.	0	0	.	.	.	0
	Sibling #4	11	Male	No	.	0	0	0	0	0	.	.	0	0	.	.	.	0
329.003.00076	Biologic Mother	35	Female	No	.	0	1	1	.	9	0	0	0	.	0	0	1	0
	Biologic Father	45	Male	No	.	0	.	.	.	9	0	0	0	1	0	0	.	0
	Sibling #1	16	Female	No	1	0	.	.	1	9	0	0	0	.	0	0	.	0
329.003.00079	Biologic Mother	.	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	.	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	.	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00088	Biologic Mother	46	Female	No	0	0	1	1	0	0	0	0	0	0	0	0	1	0
	Biologic Father	50	Male	No	0	0	.	.	0	0	0	0	0	0	0	0	.	0
	Sibling #1	24	Female	No	0	0	1	.	0	0	0	0	0	0	0	0	.	0
	Sibling #2	21	Female	No	0	0	1	.	0	0	0	0	0	0	0	0	.	0
Sibling #3	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

216

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.003.00090	Biologic Mother	44	Female	No	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	51	Male	No	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	18	Male	No	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	16	Male	No	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #3	14	Female	No	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0	
329.003.00092	Biologic Mother	42	Female	No	.	.	1	1	0	.	0	.	1	1	1	1	0	.	0	
	Biologic Father	43	Male	No	.	.	.	.	0	.	0	.	1	1	1	1	0	.	0	
	Sibling #1	16	Female	No	.	.	1	1	0	.	0	.	.	.	.	.	0	.	0	
	Sibling #2	12	Female	No	1	1	1	1	0	.	0	.	.	.	.	.	0	.	0	
329.003.00093	Biologic Mother	50	Female	No	0	0	1	0	1	1	0	.	0	.	0	.	1	1	0	
	Biologic Father	53	Male	Yes	0	0	.	0	1	1	0	.	0	.	0	.	.	.	0	
	Sibling #1	21	Male	No	0	0	.	0	.	.	0	.	0	.	0	.	.	.	0	
	Sibling #2	17	Female	No	0	0	.	0	1	1	0	.	0	.	0	.	.	.	0	
329.003.00247	Biologic Mother	41	Female	No	9	9	9	9	0	0	0	0	.	.	1	.	9	9	9	
	Biologic Father	44	Male	No	9	9	9	9	0	0	0	0	1	1	1	1	9	9	9	
	Sibling #1	16	Male	No	9	9	9	9	0	0	0	0	.	.	.	.	9	9	9	
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00249	Biologic Mother	46	Female	No	9	9	9	9	9	9	9	9	0	0	9	9	1	1	9	
	Biologic Father	52	Male	No	9	9	9	9	9	9	9	9	0	0	9	9	.	.	9	
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00289	.	.	.	.	.	.	.	0	0	0	0	0	.	.	.	.	.	0	.	
	Biologic Mother	41	Female	No	.	.	.	0	0	0	0	0	1	.	1	1	1	0	.	
	Biologic Father	45	Male	No	.	.	.	0	0	0	0	0	1	1	1	1	1	0	1	
	Sibling #1	16	Female	No	1	1	1	0	0	0	0	0	.	.	.	.	.	0	.	
329.003.00290	Sibling #2	13	Male	No	.	.	.	0	0	0	0	0	.	.	.	.	.	0	.	
	Biologic Mother	37	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	48	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	3	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	13	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #3	10	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
Sibling #4	17	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0		

0 = NO; 1 = YES; 9 = DON'T KNOW

217

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.003.00314	Biologic Mother	39	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.003.00317	Biologic Mother	50	Female	No	.	.	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	50	Male	No	.	.	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #1	17	Don't	No	.	.	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	16	Female	No	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.004.00013	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.004.00014	Biologic Mother	52	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.004.00211	Biologic Mother	49	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	21	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
	Sibling #2	18	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
329.004.00215	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.005.00003	Biologic Mother	30	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	13	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	9	9	0	
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	7	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	5	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	9	9	0	
329.005.00006	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

218

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.005.00006	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00007	Biologic Mother	41	Female	No	0	0	1	0	.	0	0	0	.	.	.	.	.	.	
	Biologic Father	44	Male	No	0	0	.	0	.	0	0	0	1	1	1	1	1	1	
	Sibling #1	20	Female	No	0	0	.	0	.	0	0	0	1	1	1	1	1	1	
	Sibling #2	15	Female	No	0	0	.	0	1	0	0	0	.	.	.	.	.	.	
329.005.00009	Biologic Mother	47	Female	No	0	0	0	0	.	0	0	0	0	0	0	0	.	0	0
	Biologic Father	46	Male	No	0	0	0	0	.	0	0	0	0	0	0	0	1	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	0	0	0	1	0	0	0	0	0	0	0	.	0	0
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00117	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	Sibling #1	22	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
	Sibling #3	12	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	.
329.005.00118	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0
	Biologic Father	47	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Sibling #1	17	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0
	Sibling #3	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.005.00153	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	.
	Biologic Father	51	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
	Sibling #1	18	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	.
329.005.00255	Biologic Mother	47	Female	No	0	0	1	0	.	0	0	0	1	1	1	0	.	0	0
	Biologic Father	48	Male	No	0	0	.	0	.	0	0	0	.	.	1	0	1	0	0
	Sibling #1	17	Male	No	0	0	.	0	.	0	0	0	.	.	0	0	0	0	0
	Sibling #2	15	Female	No	0	0	.	0	1	0	0	0	.	.	.	0	.	0	0
329.005.00256	Biologic Mother	55	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0
	Biologic Father	52	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	Sibling #2	23	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

219

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.005.00256	Sibling #4	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.005.00295	Biologic Mother	31	Female	No	0	0	0	0	0	0	0	0	0	0	0	1	0	.	0	0
	Biologic Father	36	Male	No	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
	Sibling #1	13	Female	No	0	0	0	0	0	0	0	0	0	0	0	.	0	.	0	0
329.005.00297	Biologic Mother	46	Female	No	1	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Male	No	.	0	.	.	0	0	0	0	0	0	0	0	0	0	0	0
329.005.00332	Biologic Mother	50	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	54	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.005.00335	Biologic Mother	37	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	0	0	.	
	Biologic Father	39	Male	No	0	0	0	0	0	0	0	0	1	1	1	1	0	0	1	
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	0	0	.	
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	6	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	0	0	.	
329.006.00040	Biologic Mother	46	Female	No	0	.	.	0	0	.	0	.	0	.	0	.	1	0	0	
	Biologic Father	66	Male	No	0	.	1	0	0	.	0	.	0	.	0	.	1	0	0	
	Sibling #1	28	Male	No	0	.	.	0	0	.	0	.	0	.	0	.	.	0	0	
	Sibling #2	18	Female	No	0	.	1	0	0	.	0	.	0	.	0	.	.	0	0	
329.006.00041	Biologic Mother	44	Female	No	.	9	.	.	0	.	0	.	.	.	0	.	1	0	0	
	Biologic Father	50	Male	No	1	9	1	1	0	.	0	.	1	1	0	.	.	0	0	
	Sibling #1	21	Male	No	.	9	.	.	0	.	0	.	.	.	0	.	.	0	0	
	Sibling #2	18	Male	No	1	9	.	.	0	.	0	.	.	.	0	.	.	0	0	
329.007.00139	Biologic Mother	38	Female	No	.	.	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	1	1	0	0	0	0	0	0	0	0	0	0	0	.	0	0
329.007.00143	Biologic Mother	28	Female	No	0	.	0	.	1	0	1	1	1	1	1	1	1	1	0	0
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	0	.	0	.	.	0	.	.	.	.	.	.	.	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

220

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number													
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B
329.007.00143	Sibling #2	.			0	.	0	.	.	0	.	.	.	.	.	.	0	0
329.007.00146	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	1
	Biologic Father	39	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #1	15	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.007.00269	Biologic Mother	45	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0
	Biologic Father	60	Male	Yes	0	.	0	.	0	.	0	.	0	.	0	.	1	0
	Sibling #1	15	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	1
	Sibling #2	12	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.007.00270	Biologic Mother	34	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	9	0
	Biologic Father	35	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	9	0
	Sibling #1	15	Male	No	0	.	0	.	0	.	0	.	.	.	0	.	9	0
	Sibling #2	10	Male	No	0	.	0	.	0	.	0	.	.	.	0	.	9	0
	Sibling #3	8	Male	No	0	.	0	.	0	.	0	.	.	.	0	.	9	0
	Sibling #4	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.007.00307	Biologic Mother	42	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0
	Biologic Father	43	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	1
	Sibling #1	15	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
	Sibling #2	14	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.
329.007.00308	Biologic Mother	45	Female	No	0	.	1	1	0	.	0	.	.	0	9	0	1	0
	Biologic Father	43	Male	No	0	.	.	.	0	.	0	.	1	0	9	0	.	0
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	0	.	.	.	0	.	0	.	.	0	9	0	.	0
329.008.00159	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	0
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	1	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	0
	Sibling #3	16	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	0
329.008.00161	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	Sibling #1	4	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	4	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

221

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.008.00187	Biologic Mother	47	Female	No	0	.	0	.	1	.	0	.	0	.	1	0	1	.	0
	Sibling #1	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.008.00192	Biologic Mother	35	Female	No	0	0	0	0	0	0	0	0	1	.	.	.	.	.	.
	Biologic Father	40	Male	No	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	Sibling #1	5	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.
329.008.00272	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	.	0	0	0	0	0	0
	Biologic Father	62	Male	No	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
	Sibling #1	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.008.00273	Biologic Mother	42	Female	No	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	0	0	.	0	0	0	0	0	0	0	0	0	0
	Sibling #1	15	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00127	Biologic Mother	31	Female	No	0	.	0	.	0	.	0	0	.	.	0	0	.	.	0
	Biologic Father	41	Male	No	0	.	0	.	0	.	0	0	1	1	0	0	1	1	0
	Sibling #1	12	Female	No	0	.	0	.	0	.	0	0	.	.	0	0	.	.	0
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00132	Biologic Mother	30	Female	No	0	.	0	.	0	.	0	.	1	1	.	.	1	1	.
	Biologic Father	31	Male	No	0	.	0	.	0	.	0	.	1	1	1	1	1	1	1
	Sibling #1	13	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.	.
	Sibling #2	8	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00134	Biologic Mother	38	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	1	0	0
	Biologic Father	31	Male	Yes	.	0	0	.	0	.	0	.	0	.	0	.	1	0	0
	Sibling #1	15	Female	No	1	0	0	.	0	.	0	.	0	.	0	.	.	0	0
	Sibling #2	.	.	.	.	0	0	.	0	.	0	.	0	.	0	.	.	0	0
329.009.00137	Biologic Mother	34	Female	No	.	.	.	.	.	.	.	.	1	1	.	.	0	.	.
	Biologic Father	41	Male	No	1	1	1	1	1	1	1	1	1	1	1	1	0	.	1
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	0	.	.
	Sibling #2	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	0	.	.
	Sibling #4	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	0	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

222

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.009.00171	Biologic Mother	38	Female	No	9	9	9	9	9	9	9	9	1	.	.	.	9	9	.	
	Biologic Father	41	Male	No	9	9	9	9	9	9	9	9	1	1	.	.	9	9	1	
	Sibling #1	23	Male	No	9	9	9	9	9	9	9	9	1	1	1	1	9	9	1	
	Sibling #2	16	Female	No	9	9	9	9	9	9	9	9	.	.	.	.	9	9	.	
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	12	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #5	4	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00172	Biologic Mother	43	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Biologic Father	45	Male	No	.	0	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #1	23	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	19	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	0	.	0	
Sibling #3	13	Female	No	.	0	0	.	0	.	0	.	0	.	0	.	0	.	0		
329.009.00194	Biologic Mother	36	Female	No	9	9	9	9	9	9	9	9	9	9	1	1	.	.	9	
	Biologic Father	33	Male	No	9	9	9	9	9	9	9	9	9	9	1	.	1	1	9	
	Sibling #1	12	Male	No	9	9	9	9	9	9	9	9	9	9	.	.	.	.	9	
	Sibling #2	6	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	3	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00195	Biologic Mother	39	Female	No	0	.	0	.	0	.	.	.	0	.	0	.	.	.	0	
	Biologic Father	40	Male	No	0	.	0	.	0	.	.	.	0	.	0	.	1	1	0	
	Sibling #1	16	Female	No	0	.	0	.	0	.	.	.	0	.	0	.	.	.	0	
	Sibling #2	14	Female	No	0	.	0	.	0	.	1	1	0	.	0	.	.	.	0	
	Sibling #3	12	Male	No	0	.	0	.	0	.	.	.	0	.	0	.	.	.	0	
329.009.00199	Biologic Mother	49	Female	No	0	0	0	0	.	.	0	0	0	0	0	0	1	1	0	
	Biologic Father	56	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	18	Female	No	0	0	0	0	.	.	0	0	0	0	0	0	1	1	0	
	Sibling #2	14	Female	No	0	0	0	0	1	1	0	0	0	0	0	0	.	.	0	
	Sibling #3	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00203	Biologic Mother	36	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	.	0	
	Biologic Father	38	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	1	0	
	Sibling #1	12	Female	Yes	0	.	0	.	0	.	0	.	0	.	0	.	.	.	0	
	Sibling #2	5	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00236	Biologic Mother	45	Female	No	1	0	1	1	.	0	0	0	.	.	.	.	0	0	.	
	Biologic Father	44	Male	No	1	0	.	.	1	0	0	0	1	1	1	1	0	0	1	
	Sibling #1	20	Male	No	.	0	.	.	.	0	0	0	1	.	.	.	0	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

223

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.009.00236	Sibling #2	16	Female	No	1	0	.	.	1	0	0	0	.	.	1	1	0	0	.	
	Sibling #3	13	Female	No	.	0	.	.	.	0	0	0	.	.	.	.	0	0	.	
329.009.00262	Biologic Mother	38	Female	No	0	0	0	0	0	0	0	0	.	.	1	0	.	0	0	
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	
	Sibling #1	13	Male	No	0	0	0	0	0	0	0	0	.	.	.	0	.	0	0	
	Sibling #2	11	Male	No	0	0	0	0	0	0	0	0	.	.	.	0	.	0	0	
329.009.00264	Biologic Mother	37	Female	No	0	0	0	0	.	0	0	0	.	.	.	.	0	0	0	
	Biologic Father	40	Male	No	0	0	0	0	1	0	0	0	1	1	1	1	0	0	0	
	Sibling #1	14	Female	No	0	0	0	0	.	0	0	0	.	.	.	.	0	0	0	
329.009.00301	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	.	0	
	Biologic Father	39	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	.	0	
	Sibling #1	17	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	1	0	
	Sibling #2	10	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	.	0	
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.009.00305	Biologic Mother	44	Female	No	0	.	0	.	0	.	0	.	1	1	.	.	1	0	0	
	Biologic Father	45	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0	0	
	Sibling #1	17	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0	0	
	Sibling #2	14	Male	No	0	.	0	.	0	.	0	.	.	.	1	0	.	0	0	
329.009.00325	Biologic Mother	33	Female	No	0	0	.	0	.	.	0	0	.	.	.	.	.	0	.	
	Biologic Father	38	Male	No	0	0	.	0	.	.	0	0	1	1	1	0	1	0	1	
	Sibling #1	15	Female	No	0	0	1	0	1	1	1	0	0	.	.	1	.	0	1	
329.009.00326	Biologic Mother	31	Female	No	0	0	0	0	0	0	0	0	0	.	.	0	0	1	0	0
	Biologic Father	34	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	.	0	0	
	Sibling #1	13	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	.	0	0	
	Sibling #2	9	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	.	0	0	
329.010.00279	Biologic Mother	37	Female	No	0	.	0	.	0	.	.	.	.	.	0	.	0	.	0	
	Biologic Father	48	Male	No	0	.	0	.	0	.	.	1	1	1	0	.	0	.	0	
	Sibling #1	13	Female	No	0	.	0	.	0	.	.	.	.	.	0	.	0	.	0	
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.010.00279	Sibling #3	1	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

224

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number														
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26
329.010.00281	Biologic Mother	43	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0
	Biologic Father	48	Male	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0	0
	Sibling #2	16	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0	0
	Sibling #3	14	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0	0
329.011.00163	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
329.011.00163	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.011.00163	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.011.00163	Sibling #2	9	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
329.011.00208	Biologic Mother	51	Female	No	.	.	1	1	0	0	0	0	1	0	0	0	.	.	0
	Biologic Father	44	Male	No	1	1	.	.	0	0	0	0	.	0	0	0	1	1	0
	Sibling #1	13	Male	No	.	.	.	.	0	0	0	0	.	0	0	0	.	.	0
329.011.00209	Biologic Mother	41	Female	No	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Male	No	0	0	.	.	0	0	0	0	0	0	0	0	0	0	0
	Sibling #2	10	Female	No	0	0	.	.	0	0	0	0	0	0	0	0	0	0	0
329.011.00284	Biologic Mother	46	Female	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0
	Biologic Father	47	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	Sibling #3	10	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0
329.011.00286	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	.	.	0	0
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	.	.	0	0
	Sibling #2	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	.	.	0	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	329.012.00026	Biologic Mother	37	Female	No	0	.	0	.	.	0	.	.	.	0	.	1	0	0
329.012.00026	Biologic Father	36	Male	No	0	.	0	.	.	0	.	1	1	0	.	.	0	0	
329.012.00026	Sibling #1	15	Female	No	0	.	0	.	.	0	.	.	.	0	.	.	0	0	
329.012.00026	Sibling #2	14	Male	No	0	.	0	.	1	1	0	.	.	0	.	.	0	0	
329.012.00219	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
	Biologic Father	42	Male	No	0	0	0	0	0	0	0	0	1	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

225

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.012.00219	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	.	0	0	0	0	0		
	Sibling #2	14	Male	No	0	0	0	0	0	0	0	0	.	0	0	0	0	0		
329.012.00221	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #1	17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #3	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.012.00223	Biologic Mother	32	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0		
	Biologic Father	34	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0		
	Sibling #1	13	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
	Sibling #2	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.012.00227	Biologic Mother	49	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	27	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	22	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #3	16	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0		
329.012.00230	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	0	0		
	Biologic Father	53	Male	Yes	0	0	0	0	0	0	0	0	1	1	1	1	0	0		
	Sibling #1	15	Male	No	0	0	0	0	0	0	0	0	.	.	.	.	0	0		
	Sibling #2	13	Male	No	0	0	0	0	0	0	0	0	.	.	.	.	0	0		

0 = NO; 1 = YES; 9 = DON'T KNOW

226

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.001.00062	Biologic Mother	38	Female	No	1	1	1	0	0	0	0	0	.	.	0	0	.	.		
	Biologic Father	37	Male	No	.	.	.	0	0	0	0	0	1	1	0	0	1	1		
	Sibling #1	18	Female	No	.	.	.	0	0	0	0	0	.	.	0	0	.	.		
	Sibling #2	16	Female	No	.	.	.	0	0	0	0	0	.	.	0	0	1	1		
	Sibling #3	15	Female	No	.	.	.	0	0	0	0	0	.	.	0	0	.	.		
329.001.00064	Biologic Mother	32	Female	No	0	0	1	0	0	0	0	.	0	.	0	.	1	1		
	Biologic Father	42	Male	No	0	0	.	0	0	0	0	.	0	.	0	.	1	.		
	Sibling #1	13	Male	No	0	0	.	0	0	0	0	.	0	.	0	.	.	0		
	Sibling #2	8	Male	No	0	0	.	0	0	0	0	.	0	.	0	.	.	0		
329.001.00069	Biologic Mother	49	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	.	.		
	Biologic Father	55	Male	No	0	0	0	0	0	0	1	1	0	0	0	0	1	1		
	Sibling #1	26	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	.	.		
	Sibling #2	24	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	.	.		
	Sibling #3	22	Female	No	0	0	0	0	0	0	.	.	0	0	0	0	.	.		
	Sibling #4	16	Male	No	0	0	0	0	0	0	.	.	0	0	0	0	.	.		
329.001.00071	Biologic Mother	48	Female	No	0	0	0	0	0	0	0	0	1	1	.	0	0	0		
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	1	1	.	0	0	0		
	Sibling #1	18	Male	No	0	0	0	0	0	0	0	0	.	.	1	0	0	0		
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	.	.	.	0	0	0		
329.001.00123	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	47	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	.		
	Sibling #1	22	Male	No	0	.	0	.	0	.	0	.	0	.	1	1	1	1		
	Sibling #2	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #3	16	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	.	.		
329.001.00207	Biologic Mother	48	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0		
	Biologic Father	49	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0		
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	14	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0		
329.002.00049	Biologic Mother	52	Female	No	0	0	1	1	0	0	0	0	0	0	0	0	1	0		
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	23	Male	No	0	0	.	.	0	0	0	0	0	0	0	0	.	0		
	Sibling #3	20	Male	No	0	0	.	.	0	0	0	0	0	0	0	0	.	0		
	Sibling #4	16	Male	No	0	0	.	.	0	0	0	0	0	0	0	0	.	0		

0 = NO; 1 = YES; 9 = DON'T KNOW

227

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.002.00059	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
	Biologic Father	50	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	25	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	17	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
329.002.00060	Biologic Mother	47	Female	No	.	0	.	.	0	.	0	.	.	0	0	.	0	.	0	
	Biologic Father	45	Male	No	1	0	1	1	0	.	0	.	1	0	0	.	0	.	0	
	Sibling #1	16	Female	No	.	0	.	.	0	.	0	.	.	0	0	.	0	.	0	
	Sibling #2	14	Female	No	.	0	.	.	0	.	0	.	.	0	0	.	0	.	0	
	Sibling #3	11	Male	No	.	0	.	.	0	.	0	.	.	0	0	.	0	.	0	
329.002.00097	Biologic Mother	43	Female	No	0	0	0	.	0	.	0	.	1	1	0	.	.	0	0	
	Biologic Father	45	Male	No	0	0	0	.	0	.	0	.	1	1	0	.	1	0	0	
	Sibling #1	16	Female	No	0	0	0	.	0	.	0	.	.	.	0	.	.	0	0	
	Sibling #2	13	Female	No	0	0	0	.	0	.	0	.	.	.	0	.	.	0	0	
	Sibling #3	9	Male	No	0	0	0	.	0	.	0	.	.	.	0	.	.	0	0	
329.002.00101	Biologic Mother	48	Female	No	9	.	9	.	.	0	0	0	.	.	.	.	0	.	.	
	Biologic Father	52	Male	No	9	.	9	.	1	0	0	0	.	.	.	.	0	.	.	
	Sibling #1	26	Male	No	9	.	9	.	.	0	0	0	.	.	.	.	0	.	.	
	Sibling #2	28	Female	No	9	.	9	.	.	0	0	0	.	.	.	.	0	.	.	
	Sibling #3	22	Female	No	9	.	9	.	.	0	0	0	.	.	.	.	0	.	.	
Sibling #4	16	Male	No	9	.	9	.	.	0	0	0	1	1	1	1	1	0	.	1	
329.002.00107	Biologic Mother	47	Female	No	0	.	0	.	.	0	0	.	.	.	9	.	.	.	0	
	Biologic Father	53	Male	Yes	0	.	0	.	1	0	0	0	.	.	9	.	.	.	0	
	Sibling #1	27	Male	No	0	.	0	.	.	0	0	0	1	1	9	.	1	1	0	
	Sibling #2	20	Male	No	0	.	0	.	.	0	0	0	.	.	9	.	.	.	0	
	Sibling #3	18	Male	No	0	.	0	.	.	0	0	0	.	.	9	.	.	.	0	
Sibling #4	15	Female	No	0	.	0	.	.	0	0	0	.	.	9	.	.	.	0		
329.002.00241	Biologic Mother	38	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	42	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	15	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
329.002.00246	Biologic Mother	34	Female	No	.	.	.	0	1	1	1	1	1	1	1	1	1	1	1	
	Biologic Father	35	Male	No	1	1	1	0	.	.	.	.	1	1	.	.	.	.	.	
	Sibling #1	17	Female	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

228

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.002.00246	Sibling #2	8	Male	No	.	.	.	0	.	.	.	.	.	.	.	.	.	.		
	Sibling #3	2	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.002.00320	Biologic Mother	40	Female	No	0	.	0	.	0	.	0	.	.	.	.	1	.	0		
	Biologic Father	44	Male	No	0	.	0	.	0	.	0	.	1	1	1	1	1	1	0	
	Sibling #1	16	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0		
	Sibling #2	13	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0		
	Sibling #3	9	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0		
329.002.00323	Biologic Mother	44	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	20	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	17	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.003.00074	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	13	Male	No	9	9	0	0	0	0	0	0	9	0	9	9	9	0	0	
	Sibling #2	5	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.003.00078	Biologic Mother	40	Female	No	1	0	9	9	9	9	0	0	0	0	0	0	0	0		
	Biologic Father	47	Male	No	.	0	9	9	9	9	0	0	0	0	0	0	0	0		
	Sibling #1	17	Female	No	1	0	9	9	9	9	0	0	0	0	0	0	0	0		
	Sibling #2	15	Female	No	.	0	9	9	9	9	0	0	0	0	0	0	0	0		
	Sibling #3	12	Female	No	.	0	9	9	9	9	0	0	0	0	0	0	0	0		
329.003.00080	Biologic Mother	43	Female	Yes	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	48	Male	No	.	0	0	0	0	0	0	0	1	1	0	0	0	0		
	Sibling #1	16	Female	No	1	0	0	0	0	0	0	0	.	.	0	0	0	0		
	Sibling #2	14	Male	No	.	0	0	0	0	0	0	0	.	.	0	0	0	0		
329.003.00085	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	17	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.003.00086	Biologic Mother	38	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		

0 = NO; 1 = YES; 9 = DON'T KNOW

229

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.003.00086	Sibling #2	12	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.003.00094	Biologic Mother	55	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.003.00252	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.003.00291	Biologic Mother	38	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	35	Male	No	.	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #1	13	Female	No	1	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #4	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Child #2	.	.	.	.	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.003.00315	Biologic Mother	52	Female	No	0	0	0	0	0	0	1	1	1	1	0	0	0	0	1	
	Biologic Father	52	Male	No	0	0	0	0	0	0	.	.	1	1	0	0	0	0	.	
	Sibling #1	16	Female	No	0	0	0	0	0	0	.	.	.	.	0	0	0	0	.	
	Sibling #2	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.003.00316	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	.	.	.	.	.		
	Biologic Father	38	Male	No	0	0	0	0	0	0	0	0	0	1	1	1	1	.	.	
	Sibling #1	18	Male	No	0	0	0	0	0	0	0	0	0	.	.	1	1	1	1	
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	0	.	.	.	.	.	.	
	Sibling #3	10	Female	No	0	0	0	0	0	0	0	0	0	.	.	.	.	.	.	
	Sibling #4	6	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.004.00016	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	0	0	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	
	Sibling #1	22	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	17	Male	No	0	0	0	0	0	0	0	0	0	0	.	.	0	0	0	
329.004.00018	Biologic Mother	42	Female	No	.	.	.	.	1	1	.	.	1	1	0	.	1	0	0	
	Biologic Father	49	Male	No	.	.	.	.	.	.	.	.	.	.	0	.	1	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

230

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.004.00018	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	0	.	.	0	0	
	Sibling #2	14	Male	No	1	1	1	1	1	1	1	1	.	.	0	.	.	0	0	
329.004.00020	Biologic Mother	38	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Biologic Father	45	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #1	18	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #2	14	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
329.004.00213	Biologic Mother	45	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0	
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	15	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0	
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00001	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Sibling #3	16	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
329.005.00005	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	1	1	1	0	0	0	.	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	.	.	.	0	0	0	1	
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00010	Sibling #3	9	Male	No	0	0	0	0	0	0	0	0	.	.	.	0	0	0	.	
	Biologic Mother	45	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
	Biologic Father	47	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0	
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	21	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #4	16	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0	
	Sibling #5	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0	
329.005.00012	Child #1	12	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	0	0	
	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	0	
	Sibling #1	18	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	
329.005.00111	Sibling #2	14	Female	No	0	0	0	0	0	0	0	0	0	0	0	.	.	0	0	
	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	1	.	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

231

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.005.00111	Biologic Father	40	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	.	.	0	
	Sibling #3	13	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.005.00114	Biologic Mother	47	Female		0	0	0	0	0	0	0	0	.	.	0	0	9	9	0	
	Biologic Father	55	Male		0	0	0	0	0	0	0	0	1	1	0	0	9	9	0	
	Sibling #1	22	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	9	9	0	
	Sibling #2	16	Male	No	0	0	0	0	0	0	0	0	.	.	0	0	9	9	0	
	Sibling #3	25	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	9	9	0	
329.005.00115	Biologic Mother	41	Female	Yes	.	0	0	0	.	0	0	0	1	1	1	1	.	.	.	
	Biologic Father	0	Male	Yes	.	0	0	0	.	0	0	0	1	1	1	1	.	.	.	
	Sibling #1	25	Male	No	.	0	0	0	.	0	0	0	1	1	1	1	1	1	.	
	Sibling #2	18	Female	No	1	0	0	0	1	0	0	0	.	.	.	.	.	.	1	
	Sibling #3	17	Male	No	.	0	0	0	.	0	0	0	.	.	.	.	.	.	.	
329.005.00120	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	13	Male	No	0	0	0	0	0	0	0	0	0	0	.	0	.	0	0	
	Sibling #2	9	Male	No	0	0	0	0	0	0	0	0	0	0	.	0	.	0	0	
329.005.00253	Biologic Mother	44	Female	No	0	0	0	0	0	0	1	0	.	.	0	0	1	1	0	
	Biologic Father	44	Male	No	0	0	0	0	0	0	.	0	1	1	0	0	1	1	0	
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	16	Female	No	0	0	0	0	0	0	.	0	.	.	0	0	1	1	0	
	Sibling #3	10	Male	No	0	0	0	0	0	0	.	0	.	.	0	0	.	.	0	
329.005.00254	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	.	.	1	.	1	.	.	
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	
	Sibling #2	12	Female	No	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	
	Sibling #3	9	Male	No	0	0	0	0	0	0	0	0	.	.	.	.	.	.	.	
329.005.00293	Biologic Mother	42	Female	No	0	0	.	0	1	0	0	0	.	.	.	.	.	.	0	
	Biologic Father	41	Male	No	0	0	.	0	.	0	0	0	1	1	1	1	1	1	0	
	Sibling #1	16	Female	No	0	0	.	0	.	0	0	0	.	.	.	.	.	.	0	
	Sibling #2	14	Female	No	0	0	.	0	.	0	0	0	.	.	.	.	.	.	0	
	Sibling #3	7	Male	No	0	0	1	0	.	0	0	0	.	.	.	.	.	.	0	
	Sibling #4	12	Male	No	0	0	.	0	.	0	0	0	.	.	.	.	.	.	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

232

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.005.00293	Child #1	1	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Child #2	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.005.00298	Biologic Mother	42	Female	No	1	0	1	1	0	0	0	0	.	.	0	0	0	0		
	Biologic Father	44	Male	No	.	0	.	.	0	0	0	0	1	1	0	0	0	0		
	Sibling #1	14	Female	No	.	0	.	.	0	0	0	0	.	.	0	0	0	0		
	Sibling #2	13	Female	No	.	0	.	.	0	0	0	0	.	.	0	0	0	0		
	Sibling #3	8	Male	No	.	0	.	.	0	0	0	0	.	.	0	0	0	0		
	Sibling #4	6	Male	No	.	0	.	.	0	0	0	0	.	.	0	0	0	0		
329.005.00331	Biologic Mother	38	Female	No	0	0	0	0	.	.	.	.	.	.	1	0	.	.		
	Biologic Father	48	Male	Unknown	0	0	0	0	1	1	1	1	1	1	1	0	1	1		
	Sibling #1	15	Female	No	0	0	0	0	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	11	Female	No	0	0	0	0	.	.	.	.	.	.	.	.	.	.		
329.005.00334	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
329.006.00037	Biologic Mother	59	Female	No	.	0	1	1	.	.	.	.	.	.	.	1	1	0		
	Biologic Father	55	Male	No	1	0	1	.	1	1	1	.	1	1	1	1	1	0		
	Sibling #1	39	Male	No	.	0	1	.	.	.	.	.	1	1	1	1	1	0		
	Sibling #2	36	Female	No	.	0	1	.	.	.	.	.	.	.	.	.	.	0		
	Sibling #3	17	Female	No	.	0	1	.	.	.	.	.	.	.	.	.	.	0		
329.006.00042	Biologic Mother	40	Female	No	0	.	0	.	0	.	0	.	.	.	1	0	.	0		
	Biologic Father	43	Male	No	0	.	0	.	0	.	0	.	1	1	1	0	1	0		
	Sibling #1	18	Male	No	0	.	0	.	0	.	0	.	.	.	.	0	.	0		
	Sibling #2	16	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #3	9	Male	No	0	.	0	.	0	.	0	.	.	.	.	0	.	0		
	Sibling #4	7	Female	No	0	.	0	.	0	.	0	.	.	.	.	0	.	0		
329.006.00259	Biologic Mother	49	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
	Biologic Father	53	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #1	17	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
	Sibling #2	15	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
	Sibling #3	10	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
329.007.00141	Biologic Mother	32	Female	No	0	.	1	0	0	.	0	.	1	1	1	1	1	1		

0 = NO; 1 = YES; 9 = DON'T KNOW

233

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----  
-----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.007.00141	Biologic Father	32	Male	No	0	.	.	0	0	.	0	.	.	.	.	1	.	.		
	Sibling #1	13	Male	No	0	.	.	0	0	.	0	.	.	.	.	.	.	.		
	Sibling #2	9	Female	Yes	0	.	.	0	0	.	0	.	.	.	.	.	.	.		
329.007.00144	Biologic Mother	28	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0	
	Biologic Father	39	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0	
	Sibling #1	12	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0	
329.007.00266	Biologic Mother	33	Female	No	1	1	1	1	0	.	1	1	1	1	1	1	1	0	0	
	Biologic Father	34	Male	No	.	.	.	.	0	.	.	.	.	.	1	.	.	0	0	
	Sibling #1	12	Female	No	.	.	.	.	0	.	.	.	.	.	.	.	.	0	0	
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.007.00267	Biologic Mother	46	Female	No	1	1	1	0	0	.	0	.	1	1	1	1	0	.	0	
	Biologic Father	46	Male	No	.	.	.	0	0	.	0	.	1	1	1	1	0	.	0	
	Sibling #1	16	Male	No	.	.	.	0	0	.	0	.	.	.	1	1	0	.	0	
329.007.00311	Biologic Mother	44	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0	.	
	Biologic Father	62	Male	No	0	.	0	.	0	.	0	.	1	1	.	.	1	0	1	
	Sibling #1	18	Female	No	0	.	0	.	0	.	0	.	.	.	1	1	.	0	1	
	Sibling #2	15	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0	.	
329.008.00158	Sibling #3	13	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	0	.	
	Child #2	.	.	.	0	0	0	0	0	0	0	0	0	0	.	.	0	0	0	
	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	0	0	.	0
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	0	0	.	0
329.008.00162	Sibling #3	16	Female	No	0	0	0	0	0	0	0	0	0	.	.	0	0	.	0	
	Child #2	.	.	.	0	0	0	0	0	0	0	0	0	.	.	0	0	.	0	
	Biologic Mother	46	Female	No	1	1	1	1	0	0	0	0	1	.	.	.	0	0	.	
329.008.00191	Biologic Father	41	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	27	Male	No	.	.	.	.	0	0	0	0	1	1	1	1	0	0	1	
329.008.00191	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

234

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number																
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26		
329.008.00191	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.			
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.			
	Sibling #4	.			0	0	0	0	0	0	0	0	0	.	.	0	0	0	0	0	
329.009.00128	Biologic Mother	50	Female	No	.	0	0	0	0	0	0	0	0	.	0	0	0	0	9	0	0
	Biologic Father	49	Male	No	.	0	0	0	0	0	0	0	0	1	0	0	0	0	9	0	0
	Sibling #1	23	Male	No	.	0	0	0	0	0	0	0	0	.	0	0	0	0	9	0	0
	Sibling #2	13	Male	No	1	0	0	0	0	0	0	0	0	.	0	0	0	0	9	0	0
	Sibling #3	10	Female	No	.	0	0	0	0	0	0	0	0	.	0	0	0	0	9	0	0
329.009.00129	Biologic Mother	42	Female	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.	0	.	0
	Biologic Father	47	Male	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.	0	.	0
	Sibling #1	16	Male	No	0	.	0	.	0	.	.	0	0	.	0	.	0	.	0	.	0
	Sibling #2	12	Female	No	0	.	0	.	0	.	1	0	0	.	0	.	0	.	0	.	0
329.009.00135	Biologic Mother	48	Female	No	1	1	1	9	0	.	0	.	0	.	0	.	1	1	0	.	0
	Biologic Father	48	Male	No	.	.	.	9	0	.	0	.	0	.	0	.	1	1	0	.	0
	Sibling #1	17	Female	No	.	.	.	9	0	.	0	.	0	.	0	.	.	.	0	.	0
329.009.00136	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.	.	.	.
	Sibling #6	15	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #7	14	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #8	14	Female	No	0	.	0	.	0	.	0	.	0	.	.	.	0	.	.	.	.
	Sibling #9	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Biologic Father	48	Male	No	0	.	0	.	0	.	0	.	0	.	1	1	0	.	.	.	1
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	23	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #5	16	Female	No	0	.	0	.	0	.	0	.	0	.	1	1	0	.	.	.	1
329.009.00169	Biologic Mother	27	Female	No	0	.	0	.	0	.	0	.	1	1	.	.	.	.	.	.	.
	Biologic Father	32	Male	No	0	.	0	.	0	.	0	.	1	1	1	1	1	1	1	.	1
	Sibling #1	13	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.	.	.	.
	Sibling #2	10	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
329.009.00174	Biologic Mother	44	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0	.	0
	Biologic Father	48	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

235

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.009.00174	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
	Sibling #2	26	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
	Sibling #3	15	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	0		
329.009.00197	Biologic Mother	29	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0		
	Biologic Father	31	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	1		
	Sibling #1	12	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0		
	Sibling #2	4	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0		
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.009.00198	Biologic Mother	34	Female	No	0	.	0	.	.	.	.	0	.	.	0	.	0	0		
	Biologic Father	35	Male	No	0	.	0	.	.	.	0	1	1	0	0	0	0	0		
	Sibling #1	17	Female	No	0	.	0	.	1	1	1	0	.	0	.	0	.	0		
	Sibling #2	15	Female	No	0	.	0	.	.	.	.	0	.	.	0	.	0	0		
	Sibling #3	13	Female	No	0	.	0	.	.	.	.	0	.	.	0	.	0	0		
329.009.00200	Biologic Mother	49	Female	No	0	.	0	.	.	.	0	.	1	1	1	0	.	0		
	Biologic Father	53	Male	No	0	.	0	.	.	.	0	.	1	1	.	0	.	0		
	Sibling #1	17	Female	No	0	.	0	.	1	1	0	.	.	.	1	0	1	0		
	Sibling #2	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.009.00202	Biologic Mother	40	Female	No	0	0	0	.	1	1	0	0	.	.	1	0	0	0		
	Biologic Father	41	Male	No	0	0	0	.	.	.	0	0	1	1	1	0	0	0		
	Sibling #1	19	Male	No	0	0	0	.	.	.	0	0	1	1	1	0	0	0		
	Sibling #2	15	Female	No	0	0	0	.	1	.	0	0	1	.	1	0	0	0		
	Sibling #3	14	Male	No	0	0	0	.	.	.	0	0	.	.	.	0	0	0		
	329.009.00237	Biologic Mother	43	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.	
Sibling #6		9	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.		
Biologic Father		44	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.		
Sibling #1		21	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.		
Sibling #2		19	Female	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.		
Sibling #3		17	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	1	.		
Sibling #4		12	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.		
Sibling #5		10	Male	No	0	0	0	0	0	0	0	0	0	0	0	0	.	.		
329.009.00238		Biologic Mother	42	Female	No	0	0	0	0	.	0	0	0	.	.	1	.	.	0	
	Biologic Father	42	Male	No	0	0	0	0	1	0	0	0	1	1	1	1	1	0		
	Sibling #1	21	Male	Yes	0	0	0	0	.	0	0	0	.	.	.	.	.	0		
	Sibling #2	16	Female	Yes	0	0	0	0	.	0	0	0	.	.	.	.	.	0		

0 = NO; 1 = YES; 9 = DON'T KNOW

236

CONFIDENTIAL  
BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.009.00238	Sibling #3	9	Female	Yes	0	0	0	0	.	0	0	0	.	.	.	.	.	0		
329.009.00276	Biologic Mother	30	Female	No	0	.	0	.	0	.	0	.	1	1	1	1	0	.	1	
	Biologic Father	32	Male	No	0	.	0	.	0	.	0	.	.	.	1	1	0	.	.	
	Sibling #1	13	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	0	.	.	
329.009.00302	Biologic Mother	40	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0	
	Biologic Father	41	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	1	0	0	
	Sibling #1	17	Male	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0	
	Sibling #2	10	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	.	0	0	
329.009.00306	Biologic Mother	28	Female	Yes	0	.	0	.	9	.	0	.	0	.	9	.	9	.	0	
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	16	Female	No	0	.	0	.	9	.	0	.	0	.	9	.	9	.	0	
329.009.00312	Biologic Mother	48	Female	No	.	.	.	9	.	.	0	0	0	0	0	0	1	1	0	
	Biologic Father	55	Male	No	1	1	1	9	.	.	0	0	0	0	0	0	1	1	0	
	Sibling #1	17	Female	No	.	.	.	9	1	1	0	0	0	0	0	0	1	.	0	
329.009.00327	Biologic Mother	40	Female	No	1	0	0	0	0	0	0	0	.	.	.	.	1	.	.	
	Biologic Father	42	Male	No	.	0	0	0	0	0	0	0	1	1	1	1	1	1	1	
	Sibling #1	18	Male	No	.	0	0	0	0	0	0	0	.	.	1	1	1	.	1	
	Sibling #2	16	Female	No	.	0	0	0	0	0	0	0	.	.	.	.	1	.	.	
329.009.00330	Biologic Mother	33	Female	No	1	1	1	0	0	0	0	0	1	1	1	1	1	0	1	
	Biologic Father	36	Male	No	.	.	.	0	0	0	0	0	1	1	1	1	.	0	1	
	Sibling #1	14	Female	No	.	.	.	0	0	0	0	0	.	.	.	.	.	0	.	
	Sibling #2	12	Male	No	.	.	.	0	0	0	0	0	.	.	.	.	.	0	1	
	Sibling #3	9	Male	No	.	.	.	0	0	0	0	0	.	.	.	.	.	0	.	
329.010.00183	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Biologic Father	45	Male	No	0	.	0	.	0	.	0	.	1	1	1	1	1	1	0	
	Sibling #1	16	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	14	Male	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.	0	
	Sibling #3	13	Female	No	0	.	0	.	0	.	0	.	.	.	.	.	.	.	0	
329.010.00263	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	1	0	0	
	Biologic Father	60	Male	No	0	0	0	0	0	0	0	0	0	0	.	.	1	0	0	
	Sibling #1	21	Male	No	0	0	0	0	0	0	0	0	0	0	1	1	.	0	0	
	Sibling #2	18	Male	No	0	0	0	0	0	0	0	0	0	0	.	.	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

237

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.010.00263	Sibling #3	15	Female	No	0	0	0	0	0	0	0	0	0	0	.	.	.	0	0	
329.010.00277	Biologic Mother	35	Female	No	0	.	0	.	0	.	0	.	0	.	.	0	0	.	.	
	Biologic Father	38	Male	No	0	.	0	.	0	.	0	.	0	.	1	0	0	.	1	
	Sibling #1	14	Female	No	0	.	0	.	0	.	0	.	0	.	.	0	0	.	.	
329.010.00282	Biologic Mother	45	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	0	.	0	
	Biologic Father	46	Male	No	0	.	0	.	0	.	0	.	1	1	0	.	0	.	0	
	Sibling #1	18	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	0	.	0	
	Sibling #2	15	Female	No	0	.	0	.	0	.	0	.	.	.	0	.	0	.	0	
	Sibling #3	12	Male	No	0	.	0	.	0	.	0	.	.	.	0	.	0	.	0	
329.011.00164	Biologic Mother	43	Female	No	0	.	0	.	0	.	0	.	.	.	.	0	.	.	.	
	Biologic Father	43	Male	No	0	.	0	.	0	.	0	.	1	1	1	0	.	.	.	
	Sibling #1	24	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #2	20	Male	No	0	.	0	.	0	.	0	.	.	.	.	0	1	1	1	
	Sibling #3	18	Male	No	0	.	0	.	0	.	0	.	.	.	.	0	.	.	.	
329.011.00210	Sibling #4	15	Male	No	0	.	0	.	0	.	0	.	.	.	0	.	.	.		
329.011.00210	Biologic Mother	32	Female	No	.	0	0	0	0	0	0	0	0	.	0	.	0	0	0	
	Biologic Father	41	Male	No	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	
	Sibling #1	14	Female	No	.	0	0	0	0	0	0	0	0	.	0	.	0	0	0	
	Sibling #2	10	Male	No	.	0	0	0	0	0	0	0	0	.	0	.	0	0	0	
329.011.00285	Biologic Mother	42	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	.	0	0	
	Biologic Father	44	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	1	0	0	
	Sibling #1	16	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	.	0	0	
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.011.00287	Biologic Mother	41	Female	No	0	0	0	0	.	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	16	Female	No	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	14	Female	No	0	0	0	0	.	0	0	0	0	0	0	0	0	0	0	
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.011.00287	Sibling #4	4	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.		
329.012.00027	Biologic Mother	39	Female	No	.	0	0	.	9	.	0	.	.	.	.	0	.	0	0	
	Biologic Father	38	Male	No	.	0	0	.	9	.	0	.	1	1	1	0	1	0	0	
	Sibling #1	15	Male	No	1	0	0	.	9	.	0	.	.	.	.	0	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

238

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part III  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number															
					19	19B	20	20B	21	21B	22	22B	23	23B	24	24B	25	25B	26	
329.012.00217	Biologic Mother	45	Female	No	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	45	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	22	Male	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	14	Female	No	0	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
329.012.00218	Biologic Mother	46	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #1	17	Female	No	0	.	0	.	0	.	0	.	0	.	0	.	0	.	0	
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
329.012.00224	Biologic Mother	41	Female	No	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
	Biologic Father	41	Male	No	.	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #1	14	Female	No	.	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
	Sibling #2	7	Female	No	.	0	.	0	0	0	0	0	0	0	0	0	0	0	0	
329.012.00225	Biologic Mother	48	Female	No	1	0	0	.	1	0	0	.	1	0	0	.	.	0	0	
	Biologic Father	48	Male	No	1	0	0	.	1	0	0	.	.	0	0	.	1	0	0	
	Sibling #1	14	Male	No	.	0	0	.	.	0	0	.	.	0	0	.	.	0	0	
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	

239

0 = NO; 1 = YES; 9 = DON'T KNOW

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.001.00063	Biologic Mother	40	Female	No	.	.	.	.	0	0	0	0	0
	Biologic Father	43	Male	No	.	.	1	1	0	0	0	0	0
	Sibling #1	14	Female	No	.	.	.	.	0	0	0	0	0
	Sibling #2	13	Female	No	.	.	.	.	0	0	0	0	0
	Sibling #3	10	Male	No	1	1	.	.	0	0	0	0	0
329.001.00068	Biologic Mother	41	Female	No	.	.	1	.	0	.	.	0	.
	Biologic Father	43	Male	No	.	.	1	.	0	.	.	0	.
	Sibling #1	19	Female	No	.	.	.	.	0	.	.	0	.
	Sibling #2	13	Female	No	1	1	1	1	0	.	1	0	.
329.001.00072	Biologic Mother	45	Female	No	.	0	.	0	.	.	0	1	0
	Biologic Father	45	Male	No	.	0	.	0	.	.	0	.	0
	Sibling #1	15	Male	No	1	0	1	0	1	1	0	.	0
	Sibling #2	12	Female	No	1	0	.	0	.	.	0	.	0
	Sibling #3	10	Male	No	1	0	.	0	1	1	0	.	0
329.001.00121	Biologic Mother	43	Female	No	0	0	.	0	.	0	0	0	0
	Biologic Father	46	Male	No	0	0	.	0	.	0	0	0	0
	Sibling #1	15	Male	No	0	0	.	0	.	0	0	0	0
	Sibling #2	12	Male	No	0	0	1	0	1	0	0	0	0
	Sibling #3	10	Female	No	0	0	.	0	.	0	0	0	0
329.001.00205	Biologic Mother	37	Female	No	0	.	.	0	1	1	0	0	0
	Biologic Father	38	Male	No	0	.	1	0	1	1	0	0	0
	Sibling #1	12	Male	No	0	.	.	0	.	.	0	0	0
	Sibling #2	10	Female	No	0	.	.	0	1	1	0	0	0
	Sibling #3	5	Female	No	0	.	.	0	.	1	0	0	0
329.001.00206	Biologic Mother	52	Female	No	0	0	.	.	.	0	.	0	0
	Biologic Father	54	Male	No	0	0	1	1	.	0	1	0	0
	Sibling #1	17	Male	No	0	0	1	.	1	0	1	0	0
	Sibling #2	14	Female	No	0	0	.	.	.	0	.	0	0
329.002.00055	Biologic Mother	48	Female	No	.	.	.	0	.	9	.	.	.
	Biologic Father	43	Male	No	.	.	.	0	.	9	.	.	.
	Sibling #1	29	Female	No	.	.	1	0	1	9	1	.	.
	Sibling #2	23	Male	Yes	1	1	1	0	.	9	.	.	1
	Sibling #3	26	Male	No	.	.	1	0	.	9	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

240

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.002.00055	Sibling #4	13	Male	No	.	.	.	.	.	.	.	.	.
329.002.00058	Biologic Mother	42	Female	No	1	1	.	.	.	.	.	0	0
	Biologic Father	36	Male	No	.	.	1	.	.	.	.	0	0
	Sibling #1	24	Male	No	.	.	1	.	.	.	1	0	0
	Sibling #2	22	Male	No	.	.	1	1	.	.	1	0	0
	Sibling #3	16	Female	No	1	1	1	.	1	1	1	0	0
	Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.
329.002.00099	Biologic Mother	37	Female	Yes	.	0	0	.	.	.	0	0	.
	Biologic Father	47	Male	No	.	0	0	.	.	.	0	0	.
	Sibling #1	15	Male	No	.	0	0	.	1	1	0	0	.
	Sibling #2	9	Female	No	1	0	0	.	.	.	0	0	.
329.002.00102	Biologic Mother	35	Female	No	1	.	.	0	.	.	0	0	.
	Biologic Father	39	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	.	.	.	0	1	1	0	0	.
	Sibling #2	13	Female	No	1	1	1	0	.	.	0	0	.
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.
329.002.00105	Biologic Mother	43	Female	No	0	0	.	0	.	.	.	0	0
	Biologic Father	52	Male	Yes	0	0	.	0	.	.	.	0	0
	Sibling #1	17	Male	No	0	0	1	0	1	1	1	0	0
	Sibling #2	16	Male	Yes	0	0	.	0	.	.	.	0	0
329.002.00106	Biologic Mother	32	Female	No	0	.	.	.	.	.	.	.	0
	Biologic Father	36	Male	No	0	.	1	1	.	.	1	1	0
	Sibling #1	15	Female	No	0	.	1	.	1	1	.	.	0
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.
329.002.00242	Biologic Mother	36	Female	No	.	.	1	.	.	.	.	0	0
	Biologic Father	39	Male	No	.	.	.	.	.	.	.	0	0
	Sibling #1	15	Female	No	.	.	1	1	1	1	.	0	0
	Sibling #2	12	Male	No	1	1	1	1	1	1	1	0	0
329.002.00245	Biologic Mother	36	Female	No	9	0	1	.	.	9	.	0	0
	Biologic Father	44	Male	No	9	0	1	.	.	9	.	0	0
	Sibling #1	14	Female	No	9	0	1	.	1	9	1	0	0
	Sibling #2	18	Male	No	9	0	.	.	1	9	.	0	0
	Sibling #3	16	Female	No	9	0	1	.	.	9	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

241

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.002.00245	Sibling #4	11	Female	No	9	0	1	.	.	9	.	0	0
	Sibling #5	9	Male	No	9	0	.	.	1	9	.	0	0
329.002.00319	Biologic Mother	42	Female	No	0	.	0	.	0	.	0	0	.
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Male	No	0	.	0	.	0	.	0	0	.
	Sibling #2	17	Male	No	0	.	0	.	0	.	0	0	.
	Sibling #3	16	Female	No	0	.	0	.	0	.	0	0	.
329.003.00077	.	.	.	.	.	0	0	0	0	0	0	.	0
	Biologic Mother	45	Female	No	1	0	0	0	0	0	0	1	0
	Biologic Father	55	Male	No	.	0	0	0	0	0	0	.	0
	Sibling #1	29	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Male	No	.	.	.	.	.	.	.	.	.
329.003.00087	Biologic Mother	49	Female	No	.	.	0	0	.	.	0	0	0
	Biologic Father	50	Male	No	.	.	0	0	1	1	0	0	0
	Sibling #1	14	Female	Yes	1	1	0	0	.	.	0	0	0
329.003.00089	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	60	Male	No	0	0	0	0	.	.	0	0	0
	Sibling #1	14	Female	No	0	0	0	0	1	1	0	0	0
329.003.00091	Biologic Mother	.	Female	No	0	0	.	0	0	0	0	0	0
	Biologic Father	.	Male	No	0	0	.	0	0	0	0	0	0
	Sibling #1	.	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	.	Male	No	0	0	1	0	0	0	0	0	0
	Sibling #3	16	Female	No	.	.	.	.	.	.	.	.	.
329.003.00248	Biologic Mother	43	Female	No	.	.	1	1	.	.	1	0	0
	Biologic Father	46	Male	No	1	1	1	.	1	1	1	0	0
	Sibling #1	22	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	12	Female	No	.	.	.	.	.	.	.	0	0
	Sibling #3	8	Male	No	1	.	.	.	.	.	.	0	0
329.003.00250	.	.	.	.	9	9	9	9	9	9	0	.	0
	Biologic Mother	43	Female	No	9	9	9	9	9	9	0	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

242

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.003.00250	Biologic Father	42	Male	No	9	9	9	9	9	9	0	.	0
	Sibling #1	18	Female	No	9	9	9	9	9	9	0	1	0
	Sibling #2	15	Female	No	9	9	9	9	9	9	0	1	0
	Sibling #3	8	Female	No	9	9	9	9	9	9	0	.	0
	Sibling #4	2	Male	No	.	.	.	.	.	.	.	.	.
329.003.00292	Biologic Mother	43	Female	No	9	9	0	0	0	9	0	0	0
	Biologic Father	43	Male	No	9	9	0	0	0	9	0	0	0
	Sibling #1	16	Male	No	9	9	0	0	0	9	0	0	0
	Sibling #2	15	Male	No	9	9	0	0	0	9	0	0	0
329.003.00313	Biologic Mother	36	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	37	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	.	0	.	.	.	.	.	0	0
	Sibling #2	18	Male	No	1	0	1	1	1	1	1	0	0
329.004.00015	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0
329.004.00017	Biologic Mother	50	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	52	Male	No	0	.	0	.	0	.	0	0	.
	Sibling #1	16	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	.	.	.	.	.	.	.	.	.
329.004.00019	Biologic Mother	.	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	.	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	.	Female	No	0	0	0	0	0	0	0	0	0
329.004.00212	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.
329.004.00214	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	21	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	0	0	0	0	0	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

243

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number									
					27	27B	28	28B	29	29B	30	31	31B	
329.005.00002	Biologic Mother	35	Female	No	.	.	.	.	.	.	.	.	.	
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.	
	Sibling #1	0	Female	Yes	.	.	.	.	.	.	.	.	.	
329.005.00004	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0	
	Biologic Father	44	Male	Yes	.	.	.	.	.	.	.	.	.	
	Sibling #1	16	Male	Yes	0	0	0	0	0	0	0	0	0	
329.005.00008	Biologic Mother	34	Female	No	0	0	0	0	1	1	.	0	0	
	Biologic Father	33	Male	No	0	0	0	0	.	.	1	0	0	
	Sibling #1	12	Male	No	0	0	0	0	.	.	.	0	0	
	Sibling #2	9	Male	No	0	0	0	0	.	.	.	0	0	
329.005.00109	Biologic Mother	31	Female	Yes	.	.	.	.	.	.	.	.	.	
	Biologic Father	28	Male	Yes	.	.	.	.	.	.	.	.	.	
	Sibling #1	18	Male	No	.	.	.	.	.	.	.	.	.	
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.	
	Sibling #3	15	Female	No	.	.	.	.	.	.	.	.	.	
	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.	
329.005.00112	Biologic Mother	61	Male	No	0	0	.	.	0	0	0	1	0	
	Biologic Father	54	Female	No	0	0	.	.	0	0	0	.	0	
	Sibling #1	21	Female	No	0	0	.	.	0	0	0	.	0	
	Sibling #2	18	Male	No	0	0	1	1	0	0	0	.	0	
	Sibling #3	17	Male	No	.	.	.	.	.	.	.	.	.	
	Sibling #4	16	Female	No	0	0	1	1	0	0	0	.	0	
329.005.00116	Biologic Mother	39	Female	No	0	0	.	0	.	.	.	.	0	
	Biologic Father	51	Male	No	0	0	.	0	.	.	.	1	0	
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.	
	Sibling #2	25	Female	No	0	0	1	0	.	.	1	.	0	
	Sibling #3	24	Female	No	0	0	.	0	.	.	.	.	0	
	Sibling #4	22	Male	No	0	0	1	0	.	.	1	.	0	
	Sibling #5	16	Female	No	0	0	1	0	1	1	1	.	0	
	Child #1	12	Female	No	.	.	.	.	.	.	.	.	.	
	Child #2	10	Male	No	.	.	.	.	.	.	.	.	.	
329.005.00119	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0	
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

244

CONFIDENTIAL  
BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.005.00119	Sibling #1	19	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	14	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #3	7	Male	No	.	.	.	.	.	.	.	.	.
329.005.00151	Biologic Mother	40	Female	No	0	0	.	.	.	.	.	0	0
	Biologic Father	40	Male	No	0	0	.	.	1	1	.	0	0
	Sibling #1	17	Male	No	0	0	1	1	1	1	1	0	0
	Sibling #2	15	Male	No	0	0	1	.	1	1	.	0	0
	Sibling #3	14	Female	No	0	0	.	.	1	1	1	0	0
	Sibling #4	13	Female	No	0	0	1	1	1	1	1	0	0
329.005.00152	Biologic Mother	37	Female	No	0	0	0	0	0	0	0	1	0
	Biologic Father	39	Male	No	0	0	0	0	0	0	0	.	0
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	.	0
329.005.00257	Biologic Mother	43	Female	No	0	0	0	0	.	0	0	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	0	0	0	1	0	0	0	0
	Sibling #2	12	Female	No	0	0	0	0	.	0	0	0	0
329.005.00258	Biologic Mother	45	Male	No	0	0	0	0	0	0	0	1	0
	Biologic Father	44	Female	No	0	0	0	0	0	0	0	.	0
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	.	0
	Sibling #2	9	Male	No	.	.	.	.	.	.	.	.	.
329.005.00299	Biologic Mother	34	Female	No	0	0	0	0	.	0	0	0	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	0	0	0	0	.	0	0	0	0
	Sibling #2	9	Male	No	0	0	0	0	1	0	0	0	0
329.005.00300	Biologic Mother	45	Female	No	.	.	0	0	.	.	0	0	0
	Biologic Father	50	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	.	.	0	0	.	.	0	0	0
	Sibling #2	12	Male	No	1	1	0	0	.	.	0	0	0
	Sibling #3	9	Male	No	.	.	0	0	1	1	0	0	0
329.005.00333	Biologic Mother	46	Female	No	1	0	0	0	.	0	0	0	0
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	19	Male	No	1	0	0	0	1	0	0	0	0
	Sibling #2	16	Female	No	.	0	0	0	.	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

245

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.005.00336	Biologic Mother	42	Female	No	.	.	1	0	.	.	.	0	0
	Biologic Father	41	Male	No	.	.	.	0	.	.	.	0	0
	Sibling #1	16	Female	No	.	.	.	0	.	.	1	0	0
	Sibling #2	14	Female	No	.	.	1	0	1	.	.	0	0
	Sibling #3	7	Male	No	1	1	.	0	1	1	.	0	0
	Sibling #4	12	Male	No	.	.	.	0	1	1	.	0	0
329.006.00038	Biologic Mother	35	Female	No	1	.	.	.	.	.	.	.	0
	Biologic Father	40	Male	No	.	.	1	.	.	.	.	.	0
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	.	.	1	.	.	.	1	1	0
	Sibling #3	12	Female	No	.	.	1	1	1	1	1	.	0
	Sibling #4	11	Female	No	.	1	.	.	.	.	.	.	0
329.006.00039	Biologic Mother	47	Female	No	.	.	.	0	1	.	0	0	.
	Biologic Father	48	Male	No	1	1	.	0	.	.	0	0	.
	Sibling #1	24	Male	No	1	1	1	0	.	.	0	0	.
	Sibling #2	21	Male	No	1	1	1	0	.	.	0	0	.
	Sibling #3	15	Female	No	1	1	1	0	.	.	0	0	.
	329.006.00260	Biologic Mother	56	Female	No	.	.	0	.	.	.	.	.
Biologic Father		56	Male	Yes	.	.	0	.	.	.	.	.	0
Sibling #1		17	Female	No	.	.	0	.	1	.	.	1	0
Sibling #2		10	Male	No	1	1	0	.	1	1	1	1	0
329.006.00261	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	38	Male	No	0	0	.	0	0	0	0	0	0
	Sibling #1	19	Female	No	0	0	1	0	0	0	0	0	0
	Sibling #2	17	Male	No	0	0	1	0	0	0	0	0	0
	Sibling #3	16	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #4	14	Male	No	.	.	.	.	.	.	.	.	.
329.007.00140	Biologic Mother	32	Female	No	.	0	0	.	.	.	0	.	0
	Biologic Father	37	Male	No	.	0	0	.	.	.	0	.	0
	Sibling #1	11	Male	No	.	0	0	.	.	.	0	1	0
	Sibling #2	9	Male	No	1	0	0	.	1	1	0	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

246

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number									
					27	27B	28	28B	29	29B	30	31	31B	
329.007.00142	Biologic Mother	44	Female	No	1	0	1	0	0	.	0	0	.	
	Biologic Father	46	Male	No	.	0	.	0	0	.	0	0	.	
	Sibling #1	15	Male	No	.	0	.	0	0	.	0	0	.	
329.007.00145	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.	
	Biologic Father	41	Male	No	.	0	.	0	.	.	.	0	.	
	Sibling #1	23	Female	No	1	0	1	0	.	.	.	0	.	
	Sibling #2	16	Male	No	1	0	1	0	1	1	1	0	.	
	Sibling #3	14	Female	No	1	0	.	0	.	.	.	0	.	
329.007.00265	Biologic Mother	34	Female	No	0	.	1	.	.	0	1	0	.	
	Biologic Father	29	Male	Yes	0	.	.	.	.	0	1	0	.	
	Sibling #1	16	Female	No	0	.	1	1	1	0	1	0	.	
	Sibling #2	13	Male	No	0	.	1	.	.	0	.	0	.	
	Sibling #3	12	Male	No	0	.	1	.	1	0	.	0	.	
	Sibling #4	6	Female	No	0	.	.	.	.	0	.	0	.	
329.007.00268	Biologic Mother	37	Female	No	.	.	1	1	.	.	.	1	0	
	Biologic Father	33	Male	No	.	.	1	1	.	.	1	.	0	
	Sibling #1	13	Female	No	1	1	.	.	1	1	.	.	0	
329.007.00294	Biologic Mother	37	Female	No	.	.	0	0	.	.	.	.	0	
	Biologic Father	40	Male	No	.	.	0	0	.	.	.	.	0	
	Sibling #1	15	Female	No	.	.	0	0	.	.	.	.	0	
	Sibling #2	14	Male	No	1	1	0	0	1	1	1	1	0	
329.007.00309	Biologic Mother	39	Female	No	1	0	.	0	0	.	.	0	.	
	Biologic Father	44	Male	No	.	0	1	0	0	.	.	0	.	
	Sibling #1	18	Female	No	.	0	.	0	0	.	1	0	.	
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.	
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.	
329.007.00310	.	.	.	.	.	.	.	0	.	.	0	0	.	
	Biologic Mother	41	Female	No	1	1	.	0	.	.	0	0	.	
	Biologic Father	41	Male	No	1	.	1	0	1	.	0	0	.	
	Sibling #1	16	Female	No	.	.	.	0	.	.	0	0	.	
	Sibling #2	15	Male	No	.	.	.	0	1	1	0	0	.	
329.007.00318	Biologic Mother	44	Female	No	.	0	.	.	.	.	.	0	0	
	Biologic Father	62	Male	No	.	0	.	.	.	.	.	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

247

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.007.00318	Sibling #1	15	Male	No	1	0	1	.	1	1	1	0	0
	Sibling #2	13	Male	No	.	0	.	.	1	1	.	0	0
	Sibling #3	18	Female	No	.	0	1	1	.	.	.	0	0
329.008.00157	Biologic Mother	47	Female	No	0	0	.	.	.	.	.	0	0
	Biologic Father	39	Male	No	0	0	1	.	1	1	1	0	0
329.008.00160	Biologic Mother	38	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0
329.008.00188	Biologic Mother	37	Female	No	0	0	1	0	0	0	.	1	0
	Biologic Father	42	Male	No	0	0	.	0	0	0	1	1	0
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	15	Female	No	0	0	1	0	0	0	1	.	0
	Child #1	0	Female	No	.	.	.	.	.	.	.	.	.
329.008.00271	Biologic Mother	41	Female	No	0	0	0	0	.	.	0	0	0
	Biologic Father	41	Male	No	0	0	0	0	.	.	0	0	0
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	10	Male	No	0	0	0	0	1	1	0	0	0
329.008.00275	Biologic Mother	44	Female	No	0	0	.	0	0	0	.	0	0
	Biologic Father	46	Male	No	0	0	1	0	0	0	.	0	0
	Sibling #1	19	Male	No	0	0	1	0	0	0	.	0	0
	Sibling #2	17	Female	No	0	0	.	0	0	0	1	0	0
329.009.00130	Biologic Mother	49	Female	No	1	1	.	.	.	.	.	0	0
	Biologic Father	52	Male	No	.	.	.	.	1	1	.	0	0
	Sibling #1	16	Male	No	.	.	1	.	.	.	.	0	0
	Sibling #2	15	Male	No	1	1	1	.	1	.	.	0	0
	Sibling #3	10	Female	No	1	1	.	1	1	1	1	0	0
	Sibling #4	7	Female	No	.	.	.	.	.	.	.	0	0
329.009.00131	Biologic Mother	.	Female	No	0	.	.	.	.	.	0	.	0
	Biologic Father	41	Male	No	0	.	.	.	.	.	0	.	0
	Sibling #1	16	Female	No	0	.	.	.	1	1	0	1	0
	Sibling #2	13	Female	No	0	.	1	1	1	1	0	.	0
329.009.00133	Biologic Mother	37	Female	No	9	9	0	.	0	.	0	0	0
	Biologic Father	37	Male	No	9	9	0	.	0	.	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

248

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00133	Sibling #1	16	Female	No	9	9	0	.	0	.	0	0	0
	Sibling #2	14	Male	No	9	9	0	.	0	.	0	0	0
329.009.00138	.	.	.	.	.	.	.	.	.	.	.	0	.
	Biologic Mother	34	Female	No	.	.	.	.	.	.	.	0	.
	Biologic Father	33	Male	No	.	.	1	1	1	1	1	0	.
	Sibling #1	13	Female	No	1	1	1	1	1	1	1	0	.
	Sibling #2	10	Male	No	1	1	.	.	.	.	.	0	.
329.009.00170	Biologic Mother	41	Female	No	.	.	9	.	9	.	9	9	.
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	1	1	9	.	9	.	9	9	.
	Sibling #2	22	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Female	No	.	.	.	.	.	.	.	.	.
329.009.00173	Biologic Mother	43	Female	No	.	.	.	.	0	.	9	.	.
	Biologic Father	45	Male	Yes	.	.	1	1	0	.	9	1	1
	Sibling #1	12	Female	No	1	1	.	.	0	.	9	.	.
329.009.00193	Biologic Mother	36	Female	No	0	.	1	1	1	1	1	.	0
	Biologic Father	38	Male	No	0	.	1	1	1	1	.	.	0
	Sibling #1	12	Female	No	0	.	.	.	1	1	1	1	0
	Sibling #2	3	Female	No	.	.	.	.	.	.	.	.	.
329.009.00196	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	.	.	0	.	.	0	0	0	.
	Sibling #1	17	Female	No	1	1	0	.	.	0	0	0	.
	Sibling #2	9	Female	No	1	1	0	.	1	0	0	0	.
329.009.00201	Biologic Mother	43	Female	No	0	0	.	.	.	.	.	0	0
	Biologic Father	47	Male	No	0	0	.	.	1	1	.	0	0
	Sibling #1	17	Male	No	0	0	.	.	1	1	.	0	0
	Sibling #2	14	Male	No	0	0	1	1	.	.	1	0	0
329.009.00204	Biologic Mother	39	Female	No	.	0	1	0	.	.	0	0	.
	Sibling #6	8	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	47	Male	No	.	0	1	0	.	.	0	0	.
	Sibling #1	13	Male	No	.	0	1	0	1	1	0	0	.
	Sibling #2	12	Male	No	.	0	1	0	1	1	0	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

249

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00204	Sibling #3	10	Female	No	1	0	1	0	.	.	0	0	.
	Sibling #4	9	Male	No	.	0	1	0	1	.	0	0	.
	Sibling #5	21	Female	No	.	0	1	0	.	.	0	0	.
	Child #1	.	.	.	1	0	1	0	.	.	0	0	.
329.009.00235	Biologic Mother	32	Female	No	.	.	0	0	0	0	0	0	0
	Biologic Father	30	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Female	No	.	.	0	0	0	0	0	0	0
	Sibling #2	8	Male	No	1	1	0	0	0	0	0	0	0
329.009.00240	Biologic Mother	48	Female	No	0	0	.	0	.	.	.	0	0
	Biologic Father	52	Male	No	0	0	.	0	.	.	.	0	0
	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	0	0	1	0	1	1	1	0	0
	Sibling #4	13	Female	No	0	0	.	0	1	1	.	0	0
329.009.00303	Biologic Mother	43	Female	No	0	.	0	0	.	0	0	0	.
	Biologic Father	49	Male	No	0	.	0	0	1	0	0	0	.
	Sibling #1	17	Male	No	0	.	0	0	.	0	0	0	.
	Sibling #2	14	Female	No	0	.	0	0	.	0	0	0	.
329.009.00304	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	23	Male	No	0	.	.	0	0	.	0	0	.
	Sibling #2	20	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	16	Male	No	0	.	1	0	0	.	0	0	.
329.009.00324	Biologic Mother	33	Female	No	.	0	.	0	.	.	0	.	0
	Biologic Father	35	Female	No	.	0	.	0	.	.	0	.	0
	Sibling #1	13	Female	No	.	0	1	0	1	1	0	1	0
	Sibling #2	8	Female	No	1	0	1	0	.	.	0	.	0
	Sibling #3	5	Female	No	1	0	.	0	.	.	0	.	0
329.009.00328	Biologic Mother	45	Female	No	0	0	1	0	1	0	1	0	0
	Biologic Father	46	Male	No	0	0	1	0	1	0	1	0	0
	Sibling #1	23	Male	No	0	0	1	0	.	0	.	0	0
	Sibling #2	21	Male	No	0	0	1	0	1	0	.	0	0
	Sibling #3	14	Male	No	0	0	.	0	1	0	1	0	0
	Sibling #4	12	Male	No	0	0	.	0	.	0	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

250

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00329	Biologic Mother	32	Female	No	0	0	1	0	.	0	.	0	0
	Biologic Father	34	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Male	No	0	0	.	0	.	0	1	0	0
	Sibling #2	10	Male	No	0	0	.	0	1	0	.	0	0
	Sibling #3	6	Male	No	.	.	.	.	.	.	.	.	.
329.010.00182	Biologic Mother	42	Female	No	0	.	0	.	0	.	0	0	.
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	0	.	0	.	0	.	0	0	.
	Sibling #2	17	Female	No	0	.	0	.	0	.	0	0	.
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.
329.010.00278	Biologic Mother	49	Female	No	0	.	0	.	0	.	0	.	0
	Biologic Father	49	Male	No	0	.	0	.	0	.	0	1	0
	Sibling #1	20	Female	No	0	.	0	.	0	.	0	.	0
	Sibling #2	17	Female	No	0	.	0	.	0	.	0	.	0
329.010.00280	Biologic Mother	33	Female	No	0	.	.	.	0	.	0	0	.
	Biologic Father	32	Male	No	0	.	.	.	0	.	0	0	.
	Sibling #1	13	Female	No	0	.	1	1	0	.	0	0	.
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #4	6	Male	No	.	.	.	.	.	.	.	.	.
329.011.00283	Biologic Mother	36	Female	No	1	1	.	.	.	.	.	0	0
	Biologic Father	42	Male	No	.	.	1	1	1	.	1	0	0
	Sibling #1	16	Male	No	1	1	1	1	1	1	1	0	0
329.011.00288	Biologic Mother	41	Female	No	1	1	1	1	1	1	.	.	0
	Biologic Father	45	Male	No	.	.	1	1	.	.	.	1	0
	Sibling #1	15	Male	No	.	.	1	1	1	1	1	.	0
329.012.00025	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	0	.	1	1	0	.	0	0	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Female	No	0	.	.	.	0	.	0	0	.
329.012.00220	Biologic Mother	40	Female	No	0	0	.	0	.	.	.	0	0
	Biologic Father	41	Male	No	0	0	.	0	.	.	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

251

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.012.00220	Sibling #1	17	Male	No	0	0	1	0	.	.	1	0	0
	Sibling #2	15	Male	No	0	0	.	0	1	1	.	0	0
	Sibling #3	13	Female	No	0	0	.	0	.	.	.	0	0
329.012.00222	Biologic Mother	37	Female	No	.	.	0	.	0	.	0	.	0
	Biologic Father	38	Male	No	.	.	0	.	0	.	0	.	0
	Sibling #1	15	Female	No	1	1	0	.	0	.	0	1	0
329.012.00226	Biologic Mother	50	Female	No	1	0	1	0	0	0	.	.	0
	Biologic Father	50	Male	No	.	0	1	0	0	0	1	.	0
	Sibling #1	23	Female	No	.	0	1	0	0	0	.	.	0
	Sibling #2	18	Male	No	.	0	1	0	0	0	.	.	0
	Sibling #3	16	Male	No	.	0	1	0	0	0	.	1	0
329.012.00228	Biologic Mother	40	Female	No	.	.	.	0	0	0	.	.	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	1	1	1	0	0	0	1	1	0
	Sibling #2	12	Female	No	.	.	.	0	0	0	.	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number									
					27	27B	28	28B	29	29B	30	31	31B	
329.001.00061	Biologic Mother	39	Female	No	1	1	1	0	0	0	0	1	0	
	Biologic Father	46	Male	No	.	.	.	0	0	0	0	.	0	
	Sibling #1	16	Female	No	.	.	.	0	0	0	0	.	0	
	Sibling #2	14	Male	No	.	.	.	0	0	0	0	.	0	
329.001.00066	Biologic Mother	48	Female	No	0	0	0	0	0	0	0	.	0	
	Biologic Father	52	Male	No	0	0	0	0	0	0	0	1	0	
	Sibling #1	17	Female	No	0	0	0	0	0	0	0	.	0	
	Sibling #2	13	Male	No	0	0	0	0	0	0	0	.	0	
329.001.00067	Biologic Mother	42	Female	No	0	.	.	.	.	.	.	.	0	
	Biologic Father	44	Male	No	0	.	1	1	.	.	1	.	0	
	Sibling #1	21	Female	No	0	.	1	.	.	.	.	.	0	
	Sibling #2	16	Female	No	0	.	1	1	1	1	1	1	0	
	Sibling #3	14	Male	No	0	.	1	1	1	1	1	.	0	
329.001.00070	Biologic Mother	47	Female	No	0	0	.	0	.	.	.	.	0	
	Biologic Father	46	Male	No	0	0	1	0	1	1	.	.	0	
	Sibling #1	21	Female	No	.	.	.	.	.	.	.	.	.	
	Sibling #2	12	Male	No	0	0	.	0	1	1	1	1	0	
329.001.00122	Biologic Mother	53	Female	No	.	.	.	0	.	.	0	0	0	
	Sibling #6	16	Male	No	1	1	1	0	.	.	0	0	0	
	Sibling #7	15	Male	No	.	.	1	0	1	1	0	0	0	
	Biologic Father	58	Male	No	.	.	.	0	.	.	0	0	0	
	Sibling #1	26	Female	No	1	1	1	0	.	.	0	0	0	
	Sibling #2	23	Female	No	1	1	1	0	.	.	0	0	0	
	Sibling #3	22	Female	No	1	1	1	0	.	.	0	0	0	
	Sibling #4	20	Male	No	.	.	1	0	.	.	0	0	0	
	Sibling #5	20	Female	No	.	.	1	0	.	.	0	0	0	
329.002.00050	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.	
	Biologic Father	49	Male	No	0	0	0	0	.	.	.	0	0	
	Sibling #1	19	Male	No	0	0	0	0	.	.	.	0	0	
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.	
	Sibling #3	16	Male	No	0	0	0	0	1	1	1	0	0	
329.002.00056	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.	
	Biologic Father	41	Male	No	.	.	0	.	0	.	0	0	.	
	Sibling #1	18	Female	No	.	.	0	.	0	.	0	0	.	

0 = NO; 1 = YES; 9 = DON'T KNOW

253

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.002.00056	Sibling #2	10	Male	No	1	1	0	.	0	.	0	0	.
329.002.00057	Biologic Mother	33	Female	No	1	1	1	1	1	1	1	1	0
	Biologic Father	36	Male	No	.	.	1	1	.	.	1	.	0
	Sibling #1	15	Female	No	.	.	1	1	1	1	1	1	0
	Sibling #2	14	Female	No	.	.	.	.	.	.	1	.	0
	Sibling #3	12	Male	No	.	.	.	.	.	.	1	.	0
	Sibling #4	.	.	.	.	.	.	.	.	1	.	0	
329.002.00098	Biologic Mother	43	Female	No	1	1	.	0	.	.	.	0	.
	Biologic Father	45	Male	No	.	.	.	0	.	.	.	0	.
	Sibling #1	16	Female	No	1	1	.	0	.	.	1	0	.
	Sibling #2	13	Female	No	.	.	.	0	1	1	.	0	.
	Sibling #3	9	Male	No	.	.	1	0	.	.	.	0	.
329.002.00100		.	.	.	0	0	.	.	.	.	0	0	0
	Biologic Mother	36	Female	No	0	0	.	.	.	.	0	0	0
	Biologic Father	35	Male	No	0	0	.	.	.	.	0	0	0
	Sibling #1	15	Male	No	0	0	1	.	.	.	0	0	0
	Sibling #2	9	Female	No	0	0	.	.	1	1	0	0	0
329.002.00103	Biologic Mother	39	Female	No	0	.	0	.	0	.	0	0	.
	Biologic Father	38	Male	No	0	.	0	.	0	.	0	0	.
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Female	No	0	.	0	.	0	.	0	0	.
329.002.00104	Biologic Mother	41	Female	No	.	.	.	.	.	0	0	1	0
	Biologic Father	46	Male	No	.	.	.	.	.	0	0	.	0
	Sibling #1	18	Female	No	.	.	.	.	.	0	0	.	0
	Sibling #2	15	Female	No	.	.	1	1	1	0	0	.	0
	Sibling #3	13	Male	No	1	1	.	.	1	0	0	.	0
329.002.00243	Biologic Mother	39	Female	No	0	.	.	.	.	.	.	.	0
	Biologic Father	44	Male	No	0	.	.	.	.	.	.	.	0
	Sibling #1	20	Female	No	0	.	1	.	.	.	1	1	0
	Sibling #2	17	Male	No	0	.	1	.	1	1	1	.	0
	Sibling #3	15	Female	No	0	.	.	.	.	.	.	.	0
329.002.00244	Biologic Mother	40	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

254

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.002.00244	Sibling #1	17	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	13	Male	No	.	.	.	.	.	.	.	.	.
329.002.00321	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	0	.
	Biologic Father	37	Male	No	.	.	1	1	.	.	.	0	.
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	.	.	.	.	1	1	1	0	.
	Sibling #3	14	Male	No	1	1	1	.	1	1	1	0	.
329.002.00322	Biologic Mother	34	Female	No	1	1	.	0	.	.	.	0	0
	Biologic Father	56	Male	No	.	.	.	0	.	.	.	0	0
	Sibling #1	14	Don't	No	.	.	1	0	.	.	1	0	0
	Sibling #2	14	Don't	No	.	.	.	0	.	.	1	0	0
	Sibling #3	10	Don't	No	.	.	.	0	1	1	.	0	0
	Sibling #4	8	Don't	No	.	.	.	.	.	.	.	.	.
329.003.00073	Biologic Mother	39	Female	No	.	.	.	.	.	0	.	0	0
	Biologic Father	41	Male	No	.	.	1	1	1	0	1	0	0
	Sibling #1	19	Female	No	.	.	1	1	.	0	.	0	0
	Sibling #2	17	Female	No	.	.	1	1	.	0	1	0	0
	Sibling #3	16	Female	No	1	1	1	1	.	0	.	0	0
329.003.00076	Biologic Mother	35	Female	No	1	9	.	0	.	0	0	9	0
	Biologic Father	45	Male	No	.	9	.	0	.	0	0	9	0
	Sibling #1	16	Female	No	1	9	1	0	1	0	0	9	0
329.003.00079	Biologic Mother	.	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	.	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	.	Female	No	.	.	.	.	.	.	.	.	.
329.003.00088	Biologic Mother	46	Female	No	0	9	0	0	0	0	0	0	0
	Biologic Father	50	Male	No	0	9	0	0	0	0	0	0	0
	Sibling #1	24	Female	No	0	9	0	0	0	0	0	0	0
	Sibling #2	21	Female	No	0	9	0	0	0	0	0	0	0
	Sibling #3	14	Female	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

255

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.003.00090	Biologic Mother	44	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	51	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	18	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #2	16	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #3	14	Female	No	0	0	0	0	0	0	0	0	0
329.003.00092	Biologic Mother	42	Female	No	1	0	1	0	1	.	1	0	.
	Biologic Father	43	Male	No	.	0	1	0	1	1	1	0	.
	Sibling #1	16	Female	No	1	0	1	0	1	1	1	0	.
	Sibling #2	12	Female	No	1	0	.	0	1	1	.	0	.
329.003.00093	Biologic Mother	50	Female	No	.	0	0	0	0	0	0	0	0
	Biologic Father	53	Male	Yes	.	0	0	0	0	0	0	0	0
	Sibling #1	21	Male	No	1	0	0	0	0	0	0	0	0
	Sibling #2	17	Female	No	1	0	0	0	0	0	0	0	0
329.003.00247	Biologic Mother	41	Female	No	9	9	.	.	.	0	.	0	0
	Biologic Father	44	Male	No	9	9	.	.	.	0	.	0	0
	Sibling #1	16	Male	No	9	9	1	1	1	0	1	0	0
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	0	Male	No	.	.	.	.	.	.	.	.	.
329.003.00249	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	9	9
	Biologic Father	52	Male	No	0	0	0	0	0	0	0	9	9
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.
329.003.00289	.	.	.	.	0	0	0	0	0	0	0	0	0
	Biologic Mother	41	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	13	Male	No	0	0	0	0	0	0	0	0	0
329.003.00290	Biologic Mother	37	Female	No	9	9	9	9	9	9	9	0	0
	Biologic Father	48	Male	No	9	9	9	9	9	9	9	0	0
	Sibling #1	3	Male	Yes	.	.	.	.	.	.	.	.	.
	Sibling #2	13	Male	No	9	9	9	9	9	9	9	0	0
	Sibling #3	10	Male	No	9	9	9	9	9	9	9	0	0
	Sibling #4	17	Male	No	9	9	9	9	9	9	9	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

256

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.003.00314	Biologic Mother	39	Female	No	0	0	.	.	0	0	0	0	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	0	0	1	1	0	0	0	0	0
	Sibling #2	12	Female	No	0	0	.	.	0	0	0	0	0
329.003.00317		.			0	0	.	0	.	.	0	.	0
	Biologic Mother	50	Female	No	0	0	.	0	.	.	0	.	0
	Biologic Father	50	Male	No	0	0	.	0	.	.	0	.	0
	Sibling #1	17	Don't	No	0	0	.	0	.	.	0	.	0
	Sibling #2	16	Female	No	0	0	1	0	1	1	0	1	0
329.004.00013	Biologic Mother	37	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.
329.004.00014	Biologic Mother	52	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	.	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Male	No	.	.	.	.	.	.	.	.	.
329.004.00211	Biologic Mother	49	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	21	Female	No	0	.	0	.	0	.	0	0	.
	Sibling #2	18	Female	No	0	.	0	.	0	.	0	0	.
329.004.00215	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	14	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.
329.005.00003	Biologic Mother	30	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	1	1	9	9	.	.	9	9	0
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	7	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	5	Male	No	.	.	9	9	1	1	9	9	0
	Sibling #5	2	Female	No	.	.	.	.	.	.	.	.	
329.005.00006	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

257

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.005.00006	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	.	.	.	.	.	.	.	.	.
329.005.00007	Biologic Mother	41	Female	No	.	.	.	.	0	0	.	.	0
	Biologic Father	44	Male	No	.	.	.	.	0	0	.	.	0
	Sibling #1	20	Female	No	.	.	1	1	0	0	1	.	0
	Sibling #2	15	Female	No	1	1	.	.	0	0	.	1	0
329.005.00009	Biologic Mother	47	Female	No	1	1	0	0	0	0	0	0	0
	Biologic Father	46	Male	No	.	.	0	0	0	0	0	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	.	.	0	0	0	0	0	0	0
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.
329.005.00117	Biologic Mother	47	Female	No	1	.	1	.	.	.	.	0	0
	Biologic Father	49	Male	No	.	.	1	1	.	.	.	0	0
	Sibling #1	22	Female	No	.	.	1	1	.	.	1	0	0
	Sibling #2	16	Female	No	1	.	1	1	1	1	1	0	0
	Sibling #3	12	Male	No	.	.	.	.	.	.	.	0	0
329.005.00118	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	47	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	17	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	15	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #3	11	Male	No	.	.	.	.	.	.	.	.	.
329.005.00153	Biologic Mother	44	Female	No	0	0	.	0	.	.	.	0	0
	Biologic Father	51	Male	No	0	0	1	0	1	1	1	0	0
	Sibling #1	18	Female	No	0	0	1	0	.	.	.	0	0
329.005.00255	Biologic Mother	47	Female	No	.	.	0	0	1	1	0	1	0
	Biologic Father	48	Male	No	1	1	0	0	1	1	0	.	0
	Sibling #1	17	Male	No	.	.	0	0	1	1	0	.	0
	Sibling #2	15	Female	No	1	1	0	0	1	1	0	.	0
329.005.00256	Biologic Mother	55	Female	No	.	.	0	0	0	0	0	0	0
	Biologic Father	52	Male	Yes	.	.	.	.	.	.	.	.	.
	Sibling #1	24	Female	No	1	1	0	0	0	0	0	0	0
	Sibling #2	23	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	19	Male	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

258

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.005.00256	Sibling #4	16	Female	No	1	1	0	0	0	0	0	0	0
329.005.00295	Biologic Mother	31	Female	No	0	0	0	0	0	0	0	.	0
	Biologic Father	36	Male	No	0	0	0	0	0	0	0	.	0
	Sibling #1	13	Female	No	0	0	0	0	0	0	0	1	0
329.005.00297	Biologic Mother	46	Female	No	0	0	.	.	.	.	.	0	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Male	No	0	0	1	1	1	1	1	0	0
329.005.00332	Biologic Mother	50	Female	No	1	0	0	0	.	0	0	0	0
	Biologic Father	54	Male	No	1	0	0	0	.	0	0	0	0
	Sibling #1	25	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	.	0	0	0	1	0	0	0	0
329.005.00335	Biologic Mother	37	Female	No	.	.	1	0	0	0	0	1	0
	Biologic Father	39	Male	No	.	.	1	0	0	0	0	.	0
	Sibling #1	15	Female	No	.	.	.	0	0	0	0	.	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	6	Female	No	1	1	.	0	0	0	0	.	0
329.006.00040	Biologic Mother	46	Female	No	0	.	.	.	0	.	.	0	.
	Biologic Father	66	Male	No	0	.	1	1	0	.	1	0	.
	Sibling #1	28	Male	No	0	.	.	.	0	.	.	0	.
	Sibling #2	18	Female	No	0	.	.	.	0	.	.	0	.
329.006.00041	Biologic Mother	44	Female	No	.	.	0	.	.	.	0	0	.
	Biologic Father	50	Male	No	1	1	0	.	1	1	0	0	.
	Sibling #1	21	Male	No	.	.	0	.	.	.	0	0	.
	Sibling #2	18	Male	No	1	1	0	.	.	.	0	0	.
329.007.00139	Biologic Mother	38	Female	No	0	0	.	.	0	0	0	1	0
	Biologic Father	36	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	0	1	1	0	0	0	.	0
329.007.00143	Biologic Mother	28	Female	No	0	.	1	1	0	.	0	0	.
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Female	No	0	.	.	.	0	.	0	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

259

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.007.00143	Sibling #2	.			0	.	.	.	0	.	0	0	.
329.007.00146	Biologic Mother	39	Female	No	0	.	1	0	.	.	0	0	.
	Biologic Father	39	Male	No	0	.	1	0	.	.	0	0	.
	Sibling #1	15	Female	No	0	.	1	0	1	1	0	0	.
329.007.00269	Biologic Mother	45	Female	No	.	.	.	.	.	.	0	0	.
	Biologic Father	60	Male	Yes	.	.	.	.	.	.	0	0	.
	Sibling #1	15	Male	No	1	1	1	1	1	1	0	0	.
	Sibling #2	12	Female	No	.	.	1	.	.	.	0	0	.
329.007.00270	Biologic Mother	34	Female	No	.	.	.	9	.	9	0	0	.
	Biologic Father	35	Male	No	.	.	.	9	.	9	0	0	.
	Sibling #1	15	Male	No	.	.	.	9	1	9	0	0	.
	Sibling #2	10	Male	No	1	1	1	9	1	9	0	0	.
	Sibling #3	8	Male	No	.	.	.	9	1	9	0	0	.
	Sibling #4	1	Male	No	.	.	.	.	.	.	.	.	.
329.007.00307	Biologic Mother	42	Female	No	.	.	.	.	.	0	.	0	.
	Biologic Father	43	Male	No	.	.	1	1	.	0	1	0	.
	Sibling #1	15	Female	No	1	1	.	.	.	0	.	0	.
	Sibling #2	14	Female	No	.	.	.	.	1	0	.	0	.
329.007.00308	Biologic Mother	45	Female	No	0	.	.	.	.	0	.	0	.
	Biologic Father	43	Male	No	0	.	.	.	.	0	.	0	.
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	0	.	1	1	1	0	1	0	.
329.008.00159	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #3	16	Female	No	0	0	0	0	0	0	0	0	0
329.008.00161	Biologic Mother	44	Female	No	0	0	0	0	.	.	0	0	0
	Biologic Father	45	Male	No	0	0	0	0	1	1	0	0	0
	Sibling #1	4	Male	Yes	.	.	.	.	.	.	.	.	.
	Sibling #2	4	Male	Yes	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

260

CONFIDENTIAL  
BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.008.00187	Biologic Mother	47	Female	No	0	.	0	.	0	.	0	0	.
	Sibling #1	11	Male	No	.	.	.	.	.	.	.	.	.
329.008.00192	Biologic Mother	35	Female	No	0	0	0	0	.	.	.	0	0
	Biologic Father	40	Male	No	0	0	0	0	1	1	1	0	0
	Sibling #1	5	Female	No	0	0	0	0	.	.	.	0	0
329.008.00272	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	1	0
	Biologic Father	62	Male	No	0	0	0	0	0	0	0	.	0
	Sibling #1	1	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	1	Male	No	.	.	.	.	.	.	.	.	.
329.008.00273	Biologic Mother	42	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	15	Male	No	.	.	.	.	.	.	.	.	.
329.009.00127	Biologic Mother	31	Female	No	.	.	.	.	.	.	.	.	0
	Biologic Father	41	Male	No	1	1	1	1	1	1	.	1	0
	Sibling #1	12	Female	No	1	1	.	.	1	1	1	.	0
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.
329.009.00132	Biologic Mother	30	Female	No	0	.	.	0	.	.	0	9	0
	Biologic Father	31	Male	No	0	.	1	0	1	1	0	9	0
	Sibling #1	13	Male	No	0	.	.	0	1	1	0	9	0
	Sibling #2	8	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	2	Female	No	.	.	.	.	.	.	.	.	.
329.009.00134	Biologic Mother	38	Female	No	0	.	0	.	0	.	0	0	.
	Biologic Father	31	Male	Yes	0	.	0	.	0	.	0	0	.
	Sibling #1	15	Female	No	0	.	0	.	0	.	0	0	.
	Sibling #2	.	.	.	0	.	0	.	0	.	0	0	.
329.009.00137	Biologic Mother	34	Female	No	.	.	.	.	.	.	.	.	0
	Biologic Father	41	Male	No	.	.	.	.	1	.	.	.	0
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	1	0
	Sibling #2	19	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	.	1	1	1	.	1	.	0
	Sibling #4	12	Female	No	1	1	.	.	.	.	.	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

261

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00171	Biologic Mother	38	Female	No	9	9	.	.	9	9	.	1	0
	Biologic Father	41	Male	No	9	9	1	.	9	9	1	.	0
	Sibling #1	23	Male	No	9	9	1	1	9	9	1	.	0
	Sibling #2	16	Female	No	9	9	1	.	9	9	1	1	0
	Sibling #3	12	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	12	Male	No	.	.	.	.	.	.	.	.	.
329.009.00172	Biologic Mother	43	Female	No	.	.	0	.	0	.	0	0	.
	Biologic Father	45	Male	No	.	.	0	.	0	.	0	0	.
	Sibling #1	23	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	19	Female	No	.	.	0	.	0	.	0	0	.
	Sibling #3	13	Female	No	1	1	0	.	0	.	0	0	.
329.009.00194	Biologic Mother	36	Female	No	9	9	1	1	1	1	.	1	0
	Biologic Father	33	Male	No	9	9	.	.	.	.	.	.	0
	Sibling #1	12	Male	No	9	9	.	.	1	.	1	.	0
	Sibling #2	6	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	3	Male	No	.	.	.	.	.	.	.	.	.
329.009.00195	Biologic Mother	39	Female	No	.	.	.	0	.	.	0	0	.
	Biologic Father	40	Male	No	1	1	.	0	.	.	0	0	.
	Sibling #1	16	Female	No	.	.	.	0	.	.	0	0	.
	Sibling #2	14	Female	No	.	.	1	0	1	1	0	0	.
	Sibling #3	12	Male	No	.	.	.	0	1	1	0	0	.
329.009.00199	Biologic Mother	49	Female	No	1	1	.	.	9	9	0	.	0
	Biologic Father	56	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Female	No	1	1	1	1	9	9	0	1	0
	Sibling #2	14	Female	No	.	.	.	.	9	9	0	.	0
	Sibling #3	25	Female	No	.	.	.	.	.	.	.	.	.
329.009.00203	Biologic Mother	36	Female	No	0	.	0	.	.	.	0	0	.
	Biologic Father	38	Male	No	0	.	0	.	.	.	0	0	.
	Sibling #1	12	Female	Yes	0	.	0	.	1	1	0	0	.
	Sibling #2	5	Male	Yes	.	.	.	.	.	.	.	.	.
329.009.00236	Biologic Mother	45	Female	No	0	0	1	.	.	9	.	.	.
	Biologic Father	44	Male	No	0	0	1	.	.	9	.	.	.
	Sibling #1	20	Male	No	0	0	1	.	.	9	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

262

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00236	Sibling #2	16	Female	No	0	0	1	1	1	9	1	1	1
	Sibling #3	13	Female	No	0	0	1	.	.	9	.	.	.
329.009.00262	Biologic Mother	38	Female	No	0	0	1	0	0	0	0	0	0
	Biologic Father	43	Male	No	0	0	1	0	0	0	0	0	0
	Sibling #1	13	Male	No	0	0	1	0	0	0	0	0	0
	Sibling #2	11	Male	No	0	0	1	0	0	0	0	0	0
329.009.00264	Biologic Mother	37	Female	No	.	.	0	0	0	0	.	0	0
	Biologic Father	40	Male	No	.	.	0	0	0	0	1	0	0
	Sibling #1	14	Female	No	1	0	0	0	0	0	.	0	0
329.009.00301	Biologic Mother	39	Female	No	0	.	0	.	.	.	0	0	.
	Biologic Father	39	Male	No	0	.	0	.	.	.	0	0	.
	Sibling #1	17	Male	No	0	.	0	.	.	.	0	0	.
	Sibling #2	10	Male	No	0	.	0	.	1	1	0	0	.
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.
329.009.00305	Biologic Mother	44	Female	No	1	1	0	.	.	.	0	0	.
	Biologic Father	45	Male	No	.	.	0	.	.	.	0	0	.
	Sibling #1	17	Female	No	.	.	0	.	.	.	0	0	.
	Sibling #2	14	Male	No	.	.	0	.	1	1	0	0	.
	Sibling #3	12	Female	No	.	.	0	.	.	.	0	0	.
329.009.00325	Biologic Mother	33	Female	No	.	.	1	.	.	.	.	.	0
	Biologic Father	38	Male	No	.	.	1	1	1	1	1	.	0
	Sibling #1	15	Female	No	1	1	1	.	1	1	.	1	0
329.009.00326	Biologic Mother	31	Female	No	1	1	1	1	.	.	1	0	0
	Biologic Father	34	Male	No	.	.	.	.	.	.	.	0	0
	Sibling #1	13	Male	No	.	.	.	.	1	1	.	0	0
	Sibling #2	9	Male	No	1	.	.	.	1	1	.	0	0
329.010.00279	Biologic Mother	37	Female	No	0	.	1	1	0	0	0	0	0
	Biologic Father	48	Male	No	0	.	.	.	0	0	0	0	0
	Sibling #1	13	Female	No	0	.	.	.	0	0	0	0	0
	Sibling #2	2	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	1	Female	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

263

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.010.00281	Biologic Mother	43	Female	No	.	.	.	0	.	.	.	0	.
	Biologic Father	48	Male	Yes	.	.	.	.	.	.	.	.	.
	Sibling #1	18	Male	No	.	.	.	0	1	1	.	0	.
	Sibling #2	16	Male	No	.	.	.	0	.	.	.	0	.
	Sibling #3	14	Female	No	.	.	1	0	.	.	.	0	.
329.011.00163	Biologic Mother	42	Female	No	1	0	0	0	.	.	0	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	.	0	0	0	1	1	0	0	0
	Sibling #2	9	Male	No	.	0	0	0	1	1	0	0	0
	329.011.00208	Biologic Mother	51	Female	No	.	0	0	0	0	0	0	1
Biologic Father		44	Male	No	.	0	0	0	0	0	0	.	0
Sibling #1		13	Male	No	1	0	0	0	0	0	0	.	0
329.011.00209	Biologic Mother	41	Female	No	.	.	0	0	0	0	0	0	0
	Biologic Father	42	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	12	Male	No	.	.	0	0	0	0	0	0	0
	Sibling #2	10	Female	No	1	1	0	0	0	0	0	0	0
329.011.00284	Biologic Mother	46	Female	No	.	0	0	0	0	0	0	0	0
	Biologic Father	47	Male	No	.	0	0	0	0	0	0	0	0
	Sibling #1	19	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	1	0	0	0	0	0	0	0	0
	Sibling #3	10	Male	No	1	0	0	0	0	0	0	0	0
329.011.00286	Biologic Mother	41	Female	No	0	0	1	0	.	0	0	0	0
	Biologic Father	44	Male	No	0	0	1	0	.	0	0	0	0
	Sibling #1	16	Female	No	0	0	.	0	.	0	0	0	0
	Sibling #2	15	Female	No	0	0	1	0	1	0	0	0	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.
329.012.00026	Biologic Mother	37	Female	No	.	0	.	0	.	.	.	0	.
	Biologic Father	36	Male	No	.	0	.	0	.	.	.	0	.
	Sibling #1	15	Female	No	1	0	1	0	1	1	.	0	.
	Sibling #2	14	Male	No	1	0	.	0	.	.	1	0	.
329.012.00219	Biologic Mother	42	Female	No	0	0	1	0	0	0	.	.	0
	Biologic Father	42	Male	No	0	0	1	0	0	0	.	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

264

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.012.00219	Sibling #1	16	Female	No	0	0	.	0	0	0	.	.	0
	Sibling #2	14	Male	No	0	0	.	0	0	0	1	1	0
329.012.00221	Biologic Mother	44	Female	No	0	0	0	0	.	0	.	0	0
	Biologic Father	44	Male	No	0	0	0	0	.	0	.	0	0
	Sibling #1	17	Male	No	0	0	0	0	.	0	.	0	0
	Sibling #2	15	Male	No	0	0	0	0	1	0	1	0	0
	Sibling #3	14	Female	No	0	0	0	0	.	0	1	0	0
329.012.00223	Biologic Mother	32	Female	No	0	.	.	.	0	.	.	0	.
	Biologic Father	34	Male	No	0	.	1	1	0	.	1	0	.
	Sibling #1	13	Female	No	0	.	.	.	0	.	.	0	.
	Sibling #2	9	Female	No	.	.	.	.	.	.	.	.	.
329.012.00227	Biologic Mother	49	Female	No	0	0	.	0	.	.	.	.	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	27	Male	No	0	0	.	0	1	1	.	.	0
	Sibling #2	22	Male	No	0	0	1	0	.	.	1	.	0
	Sibling #3	16	Male	No	0	0	.	0	1	1	.	1	0
329.012.00230	Biologic Mother	36	Female	No	.	.	0	0	.	.	.	0	0
	Biologic Father	53	Male	Yes	.	.	0	0	.	.	.	0	0
	Sibling #1	15	Male	No	1	1	0	0	1	1	1	0	0
	Sibling #2	13	Male	No	.	.	0	0	.	.	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

265

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.001.00062	Biologic Mother	38	Female	No	1	.	.	.	1	.	.	.	0
	Biologic Father	37	Male	No	.	.	1	1	1	.	1	1	0
	Sibling #1	18	Female	No	1	.	.	.	1	1	.	.	0
	Sibling #2	16	Female	No	1	1	1	1	1	1	1	1	0
	Sibling #3	15	Female	No	1	1	.	.	1	.	.	.	0
329.001.00064	Biologic Mother	32	Female	No	.	0	1	0	.	.	0	0	.
	Biologic Father	42	Male	No	.	0	.	0	.	.	0	0	.
	Sibling #1	13	Male	No	1	0	.	0	1	1	0	0	.
	Sibling #2	8	Male	No	1	0	.	0	1	.	0	0	.
329.001.00069	Biologic Mother	49	Female	No	.	.	.	0	.	0	.	0	0
	Biologic Father	55	Male	No	.	.	.	0	1	0	.	0	0
	Sibling #1	26	Female	No	.	.	1	0	.	0	1	0	0
	Sibling #2	24	Male	No	.	.	.	0	.	0	.	0	0
	Sibling #3	22	Female	No	.	.	.	0	.	0	.	0	0
	Sibling #4	16	Male	No	1	1	.	0	.	0	.	0	0
329.001.00071	Biologic Mother	48	Female	No	0	0	.	0	.	.	.	0	0
	Biologic Father	46	Male	No	0	0	1	0	.	.	.	0	0
	Sibling #1	18	Male	No	0	0	.	0	1	1	1	0	0
	Sibling #2	13	Female	No	0	0	.	0	.	.	.	0	0
329.001.00123	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	47	Male	No	0	0	.	0	0	.	.	0	0
	Sibling #1	22	Male	No	0	0	1	0	0	.	1	0	0
	Sibling #2	20	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	16	Female	No	0	0	.	0	0	.	.	0	0
329.001.00207	Biologic Mother	48	Female	No	1	0	0	.	.	.	0	0	0
	Biologic Father	49	Male	No	.	0	0	.	.	.	0	0	0
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	1	0	0	.	1	1	0	0	0
329.002.00049	Biologic Mother	52	Female	No	1	0	0	0	.	.	0	0	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	27	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	23	Male	No	.	0	0	0	.	.	0	0	0
	Sibling #3	20	Male	No	.	0	0	0	.	.	0	0	0
	Sibling #4	16	Male	No	.	0	0	0	1	1	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

266

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number									
					27	27B	28	28B	29	29B	30	31	31B	
329.002.00059	Biologic Mother	46	Female	No	1	9	0	0	0	0	0	0	1	0
	Biologic Father	50	Male	No	.	9	0	0	0	0	0	.	0	
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.	.
	Sibling #2	25	Female	No	.	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	1	9	0	0	0	0	0	0	.	0
329.002.00060	Biologic Mother	47	Female	No	1	0	.	0	0	.	0	0	.	
	Biologic Father	45	Male	No	.	0	1	0	0	.	0	0	.	
	Sibling #1	16	Female	No	.	0	.	0	0	.	0	0	.	
	Sibling #2	14	Female	No	1	0	.	0	0	.	0	0	.	
	Sibling #3	11	Male	No	.	0	.	0	0	.	0	0	.	
329.002.00097	Biologic Mother	43	Female	No	1	1	.	0	.	.	.	0	.	
	Biologic Father	45	Male	No	.	.	.	0	.	.	.	0	.	
	Sibling #1	16	Female	No	1	1	.	0	.	.	1	0	.	
	Sibling #2	13	Female	No	.	.	.	0	1	1	.	0	.	
	Sibling #3	9	Male	No	.	.	1	0	.	.	.	0	.	
329.002.00101	Biologic Mother	48	Female	No	0	.	0	.	.	.	.	0	.	
	Biologic Father	52	Male	No	0	.	0	.	.	.	.	0	.	
	Sibling #1	26	Male	No	0	.	0	.	.	.	.	0	.	
	Sibling #2	28	Female	No	0	.	0	.	.	.	.	0	.	
	Sibling #3	22	Female	No	0	.	0	.	.	.	.	0	.	
	Sibling #4	16	Male	No	0	.	0	.	1	1	1	0	.	
329.002.00107	Biologic Mother	47	Female	No	0	.	.	.	.	.	0	.	0	
	Biologic Father	53	Male	Yes	0	.	.	.	.	.	0	.	0	
	Sibling #1	27	Male	No	0	.	1	1	1	1	0	.	0	
	Sibling #2	20	Male	No	0	.	1	.	.	.	0	.	0	
	Sibling #3	18	Male	No	0	.	1	.	.	.	0	1	0	
	Sibling #4	15	Female	No	0	.	.	.	.	.	0	.	0	
329.002.00241	Biologic Mother	38	Female	No	.	0	.	0	0	0	.	0	0	
	Biologic Father	42	Male	No	.	0	.	0	0	0	.	0	0	
	Sibling #1	15	Male	No	.	0	.	0	0	0	.	0	0	
	Sibling #2	17	Male	No	1	0	1	0	0	0	1	0	0	
329.002.00246	Biologic Mother	34	Female	No	.	.	1	1	.	.	0	1	0	
	Biologic Father	35	Male	No	.	.	.	.	.	.	0	.	0	
	Sibling #1	17	Female	No	.	.	.	.	.	.	0	.	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

267

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
 Intent-to-Treat Population

-----  
 ----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	Family History Item Number								
					27	27B	28	28B	29	29B	30	31	31B
329.002.00246	Sibling #2	8	Male	No	1	1	.	.	1	1	0	.	0
	Sibling #3	2	Male	No	.	.	.	.	.	.	.	.	.
329.002.00320	Biologic Mother	40	Female	No	.	0	.	0	.	.	0	0	.
	Biologic Father	44	Male	No	.	0	.	0	.	.	0	0	.
	Sibling #1	16	Male	No	1	0	1	0	.	.	0	0	.
	Sibling #2	13	Female	No	.	0	.	0	.	.	0	0	.
	Sibling #3	9	Female	No	.	0	.	0	1	1	0	0	.
329.002.00323	Biologic Mother	44	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	20	Female	No	0	0	0	0	0	0	.	0	0
	Sibling #2	17	Female	No	0	0	0	0	0	0	1	0	0
329.003.00074	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	9	0	9	0	0	0	9	0	0
	Sibling #2	5	Male	No	.	.	.	.	.	.	.	.	.
329.003.00078	.	.	.	.	9	9	.	1	.	9	0	0	0
	Biologic Mother	40	Female	No	9	9	1	.	1	9	0	0	0
	Biologic Father	47	Male	No	9	9	.	.	.	9	0	0	0
	Sibling #1	17	Female	No	9	9	.	.	.	9	0	0	0
	Sibling #2	15	Female	No	9	9	.	.	1	9	0	0	0
329.003.00080	Biologic Mother	43	Female	No	9	9	.	.	1	9	0	0	0
	Biologic Father	48	Male	No	0	0	0	0	.	0	0	0	0
	Sibling #1	16	Female	No	0	0	0	0	.	0	0	0	0
	Sibling #2	14	Male	No	0	0	0	0	1	0	0	0	0
	.	.	.	.	.	.	.	.	.	.	.	.	.
329.003.00085	Biologic Mother	42	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	43	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	.	0	1	1	1	1	0	0	0
	Sibling #2	14	Female	No	1	0	.	.	.	.	0	0	0
	Sibling #3	8	Female	No	.	.	.	.	.	.	.	.	.
329.003.00086	Biologic Mother	38	Female	No	0	0	.	.	0	0	.	0	0
	Biologic Father	44	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	0	0	1	1	0	0	1	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

268

CONFIDENTIAL

BRL-029060-329-  
 individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.003.00086	Sibling #2	12	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.
329.003.00094	Biologic Mother	55	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	55	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	0
329.003.00252	Biologic Mother	42	Female	No	1	0	.	0	.	9	0	0	0
	Biologic Father	45	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	14	Female	No	.	0	1	0	1	9	0	0	0
329.003.00291	Biologic Mother	38	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	35	Male	No	0	0	1	.	.	.	.	0	0
	Sibling #1	13	Female	No	0	0	.	1	.	1	1	0	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	8	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #4	17	Female	No	.	.	.	.	.	.	.	.	.
	Child #2	.	.	.	0	0	.	.	1	.	.	0	0
329.003.00315	Biologic Mother	52	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	52	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	16	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	14	Female	No	.	.	.	.	.	.	.	.	.
329.003.00316	Biologic Mother	40	Female	No	0	0	.	.	1	1	1	0	0
	Biologic Father	38	Male	No	0	0	.	.	.	.	.	0	0
	Sibling #1	18	Male	No	0	0	1	1	1	1	1	0	0
	Sibling #2	16	Female	No	0	0	1	.	.	.	.	0	0
	Sibling #3	10	Female	No	0	0	.	.	1	1	.	0	0
	Sibling #4	6	Female	No	.	.	.	.	.	.	.	.	.
329.004.00016	Biologic Mother	46	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	46	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	22	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	17	Male	No	0	0	0	0	0	0	0	0	0
329.004.00018	Biologic Mother	42	Female	No	.	.	.	0	.	.	0	1	0
	Biologic Father	49	Male	No	.	.	.	0	.	.	0	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

269

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.004.00018	Sibling #1	17	Female	No	1	1	1	0	.	.	0	.	0
	Sibling #2	14	Male	No	.	.	.	0	1	1	0	.	0
329.004.00020	Biologic Mother	38	Female	No	0	.	.	0	0	.	.	.	0
	Biologic Father	45	Male	No	0	.	.	0	0	.	.	.	0
	Sibling #1	18	Male	No	0	.	.	0	0	.	1	.	0
	Sibling #2	14	Female	No	0	.	1	0	0	.	1	1	0
329.004.00213	Biologic Mother	45	Female	No	9	.	9	.	9	.	.	9	0
	Biologic Father	52	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	15	Female	No	9	.	9	.	9	.	1	9	0
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.
329.005.00001	Biologic Mother	41	Female	No	0	0	0	0	0	0	.	.	0
	Biologic Father	45	Male	No	0	0	0	0	0	0	.	1	0
	Sibling #1	19	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	17	Male	No	0	0	0	0	0	0	.	.	0
	Sibling #3	16	Female	No	0	0	0	0	0	0	1	.	0
329.005.00005	Biologic Mother	40	Female	No	0	0	.	0	.	.	0	0	0
	Biologic Father	46	Male	No	0	0	.	0	.	.	0	0	0
	Sibling #1	13	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	11	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Male	No	0	0	1	0	1	1	0	0	0
329.005.00010	Biologic Mother	45	Female	No	0	0	0	0	0	0	.	0	0
	Biologic Father	47	Male	No	0	0	0	0	0	0	.	0	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	21	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	20	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #4	16	Female	No	0	0	0	0	0	0	.	0	0
	Sibling #5	15	Female	No	0	0	0	0	0	0	1	0	0
	Child #1	12	Male	No	0	0	0	0	0	0	.	0	0
329.005.00012	Biologic Mother	41	Female	No	.	.	0	0	0	0	.	0	0
	Biologic Father	44	Male	No	.	.	0	0	0	0	.	0	0
	Sibling #1	18	Male	No	1	1	0	0	0	0	1	0	0
	Sibling #2	14	Female	No	.	.	0	0	0	0	.	0	0
329.005.00111	Biologic Mother	36	Female	No	0	0	0	0	0	0	0	0	

0 = NO; 1 = YES; 9 = DON'T KNOW

270

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.005.00111	Biologic Father	40	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	18	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #3	13	Male	No	.	.	.	.	.	.	.	.	.
329.005.00114	Biologic Mother	47	Female		.	.	.	0	0	0	0	1	0
	Biologic Father	55	Male		1	1	.	0	0	0	0	.	0
	Sibling #1	22	Male	No	.	.	1	0	0	0	0	.	0
	Sibling #2	16	Male	No	.	.	1	0	0	0	0	.	0
329.005.00115	Biologic Mother	41	Female	Yes	0	0	.	.	.	.	.	0	0
	Biologic Father	0	Male	Yes	0	0	.	.	.	.	.	0	0
	Sibling #1	25	Male	No	0	0	1	1	.	.	1	0	0
	Sibling #2	18	Female	No	0	0	1	1	1	1	1	0	0
329.005.00120	Biologic Mother	36	Female	No	0	0	1	1	1	1	1	1	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	13	Male	No	0	0	.	.	.	.	.	.	0
	Sibling #2	9	Male	No	0	0	.	.	.	1	.	.	0
329.005.00253	Biologic Mother	44	Female	No	0	0	0	0	.	.	.	0	0
	Biologic Father	44	Male	No	0	0	0	0	.	.	.	0	0
	Sibling #1	20	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	16	Female	No	0	0	0	0	.	.	1	0	0
329.005.00254	Biologic Mother	41	Female	No	.	.	.	.	.	.	.	0	0
	Biologic Father	45	Male	No	.	.	1	1	.	.	1	0	0
	Sibling #1	16	Female	No	.	.	1	.	1	.	.	0	0
	Sibling #2	12	Female	No	1	1	.	.	1	1	.	0	0
329.005.00293	Biologic Mother	42	Female	No	.	.	1	0	.	.	.	0	0
	Biologic Father	41	Male	No	.	.	.	0	.	.	.	0	0
	Sibling #1	16	Female	No	.	.	.	0	.	.	1	0	0
	Sibling #2	14	Female	No	.	.	1	0	1	.	.	0	0
	Sibling #3	7	Male	No	1	1	.	0	1	1	.	0	0
	Sibling #4	12	Male	No	.	.	.	0	1	1	.	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

271

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.005.00293	Child #1	1	Male	No	.	.	.	.	.	.	.	.	.
	Child #2	0	Female	No	.	.	.	.	.	.	.	.	.
329.005.00298	Biologic Mother	42	Female	No	0	0	0	0	.	.	0	0	0
	Biologic Father	44	Male	No	0	0	0	0	.	.	0	0	0
	Sibling #1	14	Female	No	0	0	0	0	.	.	0	0	0
	Sibling #2	13	Female	No	0	0	0	0	1	1	0	0	0
	Sibling #3	8	Male	No	0	0	0	0	.	.	0	0	0
	Sibling #4	6	Male	No	0	0	0	0	.	.	0	0	0
329.005.00331	Biologic Mother	38	Female	No	.	.	1	1	9	9	0	.	0
	Biologic Father	48	Male	Unknown	.	.	1	1	9	9	0	1	0
	Sibling #1	15	Female	No	.	.	.	.	9	9	0	.	0
	Sibling #2	11	Female	No	1	1	.	.	9	9	0	.	0
329.005.00334	Biologic Mother	43	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	44	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	15	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #2	13	Female	No	0	0	0	0	0	0	0	0	0
329.006.00037	Biologic Mother	59	Female	No	1	1	.	9	.	9	9	0	0
	Biologic Father	55	Male	No	1	.	1	9	1	9	9	0	0
	Sibling #1	39	Male	No	1	1	1	9	.	9	9	0	0
	Sibling #2	36	Female	No	.	.	.	9	.	9	9	0	0
	Sibling #3	17	Female	No	1	1	.	9	1	9	9	0	0
329.006.00042	Biologic Mother	40	Female	No	0	.	.	0	.	.	0	0	.
	Biologic Father	43	Male	No	0	.	1	0	1	1	0	0	.
	Sibling #1	18	Male	No	0	.	.	0	.	.	0	0	.
	Sibling #2	16	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Male	No	0	.	.	0	1	1	0	0	.
	Sibling #4	7	Female	No	0	.	.	0	.	.	0	0	.
329.006.00259	Biologic Mother	49	Female	No	.	.	0	.	0	.	0	0	.
	Biologic Father	53	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Male	No	1	1	0	.	0	.	0	0	.
	Sibling #2	15	Male	No	1	1	0	.	0	.	0	0	.
	Sibling #3	10	Female	No	.	.	0	.	0	.	0	0	.
329.007.00141	Biologic Mother	32	Female	No	0	.	1	0	0	.	1	1	0

0 = NO; 1 = YES; 9 = DON'T KNOW

272

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.007.00141	Biologic Father	32	Male	No	0	.	.	0	0	.	.	.	0
	Sibling #1	13	Male	No	0	.	.	0	0	.	.	.	0
	Sibling #2	9	Female	Yes	0	.	.	0	0	.	.	.	0
329.007.00144	Biologic Mother	28	Female	No	0	.	1	1	.	.	1	0	.
	Biologic Father	39	Male	No	0	.	1	1	1	1	1	0	.
	Sibling #1	12	Female	No	0	.	.	.	.	.	.	0	.
329.007.00266	Biologic Mother	33	Female	No	0	.	1	9	.	.	0	1	0
	Biologic Father	34	Male	No	0	.	.	9	.	.	0	.	0
	Sibling #1	12	Female	No	0	.	.	9	1	1	0	.	0
	Sibling #2	10	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	9	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	1	Male	No	.	.	.	.	.	.	.	.	.
329.007.00267	Biologic Mother	46	Female	No	0	.	1	.	.	.	.	0	.
	Biologic Father	46	Male	No	0	.	1	.	.	.	.	0	.
	Sibling #1	16	Male	No	0	.	1	1	1	1	1	0	.
329.007.00311	Biologic Mother	44	Female	No	.	0	.	.	.	.	0	0	.
	Biologic Father	62	Male	No	.	0	.	.	.	.	0	0	.
	Sibling #1	18	Female	No	.	0	1	.	.	.	0	0	.
	Sibling #2	15	Male	No	1	0	1	.	1	.	0	0	.
	Sibling #3	13	Male	No	.	0	.	.	1	1	0	0	.
329.008.00158	.	.	.	.	0	0	0	0	0	0	0	0	0
	Biologic Mother	47	Female	No	0	0	0	0	0	0	0	0	0
	Biologic Father	49	Male	No	0	0	0	0	0	0	0	0	0
	Sibling #1	24	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	18	Female	No	0	0	0	0	0	0	0	0	0
	Sibling #3	16	Female	No	0	0	0	0	0	0	0	0	0
	Child #2	.	.	.	0	0	0	0	0	0	0	0	0
329.008.00162	Biologic Mother	46	Female	No	1	0	.	.	.	.	.	1	0
	Biologic Father	41	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	27	Male	No	1	0	1	1	1	1	1	.	0
329.008.00191	Biologic Mother	43	Female	No	1	.	0	0	.	.	0	0	0
	Biologic Father	45	Male	No	.	.	0	0	.	.	0	0	0
	Sibling #1	17	Female	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

273

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.008.00191	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	10	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #4	.	.	.	.	.	0	0	1	1	0	0	0
329.009.00128	Biologic Mother	50	Female	No	0	0	9	0	.	.	0	0	0
	Biologic Father	49	Male	No	0	0	9	0	.	.	0	0	0
	Sibling #1	23	Male	No	0	0	9	0	.	.	0	0	0
	Sibling #2	13	Male	No	0	0	9	0	1	1	0	0	0
	Sibling #3	10	Female	No	0	0	9	0	.	.	0	0	0
329.009.00129	Biologic Mother	42	Female	No	0	.	0	.	1	1	0	1	0
	Biologic Father	47	Male	No	0	.	0	.	1	1	0	.	0
	Sibling #1	16	Male	No	0	.	0	.	1	1	0	.	0
	Sibling #2	12	Female	No	0	.	0	.	1	1	0	.	0
329.009.00135	Biologic Mother	48	Female	No	0	0	.	0	0	.	.	0	.
	Biologic Father	48	Male	No	0	0	1	0	0	.	1	0	.
	Sibling #1	17	Female	No	0	0	.	0	0	.	.	0	.
329.009.00136	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	0	.
	Sibling #6	15	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #7	14	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #8	14	Female	No	1	1	.	.	.	.	.	0	.
	Sibling #9	13	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	48	Male	No	.	.	1	1	1	1	1	0	.
	Sibling #1	26	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #3	23	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	18	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #5	16	Female	No	.	.	1	1	1	1	1	0	.
329.009.00169	Biologic Mother	27	Female	No	0	.	.	.	.	.	.	.	0
	Biologic Father	32	Male	No	0	.	1	.	1	1	1	.	0
	Sibling #1	13	Male	No	0	.	.	.	1	1	.	1	0
	Sibling #2	10	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	5	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	0	Male	No	.	.	.	.	.	.	.	.	.
329.009.00174	Biologic Mother	44	Female	No	.	.	.	0	.	.	0	0	.
	Biologic Father	48	Male	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

274

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00174	Sibling #1	20	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	26	Male	No	.	.	1	0	.	.	0	0	.
	Sibling #3	15	Female	No	1	1	.	0	1	1	0	0	.
329.009.00197	Biologic Mother	29	Female	No	.	.	1	.	0	.	.	0	.
	Biologic Father	31	Male	No	.	.	1	.	0	.	1	0	.
	Sibling #1	12	Male	No	.	.	.	.	0	.	.	0	.
	Sibling #2	4	Female	No	1	1	.	.	0	.	.	0	.
	Sibling #3	0	Female	No	.	.	.	.	.	.	.	.	.
329.009.00198	Biologic Mother	34	Female	No	.	.	.	.	.	.	.	1	0
	Biologic Father	35	Male	No	.	.	.	.	.	.	.	.	0
	Sibling #1	17	Female	No	1	1	1	1	1	1	1	1	0
	Sibling #2	15	Female	No	.	.	.	.	.	.	.	.	0
	Sibling #3	13	Female	No	.	.	.	.	.	.	1	.	0
329.009.00200	Biologic Mother	49	Female	No	0	.	.	0	.	.	.	0	.
	Biologic Father	53	Male	No	0	.	.	0	1	1	1	0	.
	Sibling #1	17	Female	No	0	.	1	0	1	1	.	0	.
	Sibling #2	16	Male	No	.	.	.	.	.	.	.	.	.
329.009.00202	Biologic Mother	40	Female	No	0	.	.	.	.	.	.	.	0
	Biologic Father	41	Male	No	0	.	.	.	.	.	.	.	0
	Sibling #1	19	Male	No	0	.	1	1	.	.	1	1	0
	Sibling #2	15	Female	No	0	.	1	.	.	.	.	.	0
	Sibling #3	14	Male	No	0	.	.	.	1	1	.	.	0
329.009.00237	Biologic Mother	43	Female	No	0	0	.	.	.	.	.	0	0
	Sibling #6	9	Female	No	0	0	.	.	.	.	.	0	0
	Biologic Father	44	Male	No	0	0	.	.	.	.	.	0	0
	Sibling #1	21	Male	No	0	0	.	.	.	.	.	0	0
	Sibling #2	19	Female	No	0	0	.	.	.	.	.	0	0
	Sibling #3	17	Male	No	0	0	1	1	1	.	1	0	0
	Sibling #4	12	Male	No	0	0	.	.	.	.	.	0	0
	Sibling #5	10	Male	No	0	0	.	.	1	1	.	0	0
329.009.00238	Biologic Mother	42	Female	No	1	1	0	0	.	0	0	0	0
	Biologic Father	42	Male	No	.	.	0	0	.	0	0	0	0
	Sibling #1	21	Male	Yes	.	.	0	0	1	0	0	0	0
	Sibling #2	16	Female	Yes	.	.	0	0	1	0	0	0	0

0 = NO; 1 = YES; 9 = DON'T KNOW

275

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.009.00238	Sibling #3	9	Female	Yes	.	.	0	0	1	0	0	0	0
329.009.00276	Biologic Mother	30	Female	No	0	.	1	1	.	0	0	0	.
	Biologic Father	32	Male	No	0	.	.	.	.	0	0	0	.
	Sibling #1	13	Male	No	0	.	.	.	1	0	0	0	.
329.009.00302	Biologic Mother	40	Female	No	1	.	0	.	.	0	0	0	.
	Biologic Father	41	Male	No	.	.	0	.	.	0	0	0	.
	Sibling #1	17	Male	No	.	.	0	.	1	0	0	0	.
	Sibling #2	10	Female	No	1	.	0	.	.	0	0	0	.
329.009.00306	Biologic Mother	28	Female	Yes	0	.	1	0	1	0	0	0	.
	Biologic Father	.	Male	Unknown	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	.	.	0	.	0	0	0	.
329.009.00312	Biologic Mother	48	Female	No	0	0	0	0	0	0	0	1	0
	Biologic Father	55	Male	No	0	0	0	0	0	0	0	.	0
	Sibling #1	17	Female	No	0	0	0	0	0	0	0	.	0
329.009.00327	Biologic Mother	40	Female	No	0	0	.	.	0	0	.	0	0
	Biologic Father	42	Male	No	0	0	1	1	0	0	.	0	0
	Sibling #1	18	Male	No	0	0	1	1	0	0	1	0	0
	Sibling #2	16	Female	No	0	0	1	1	0	0	.	0	0
329.009.00330	Biologic Mother	33	Female	No	0	0	.	.	.	.	.	.	0
	Biologic Father	36	Male	No	0	0	.	.	.	.	.	.	0
	Sibling #1	14	Female	No	0	0	.	.	.	.	1	.	0
	Sibling #2	12	Male	No	0	0	1	1	1	1	1	1	0
	Sibling #3	9	Male	No	0	0	.	.	.	.	.	.	0
329.010.00183	Biologic Mother	39	Female	No	.	.	.	.	.	.	.	.	.
	Biologic Father	45	Male	No	.	.	0	.	.	.	.	.	0
	Sibling #1	16	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	14	Male	No	1	1	0	.	1	1	.	1	0
	Sibling #3	13	Female	No	.	.	0	.	.	.	1	.	0
329.010.00263	Biologic Mother	40	Female	No	.	.	.	.	.	.	.	.	0
	Biologic Father	60	Male	No	.	.	.	.	.	.	.	.	0
	Sibling #1	21	Male	No	.	.	1	1	.	.	1	1	0
	Sibling #2	18	Male	No	1	1	.	.	1	1	.	.	0

0 = NO; 1 = YES; 9 = DON'T KNOW

276

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.010.00263	Sibling #3	15	Female	No	.	.	1	.	.	.	1	.	0
329.010.00277	Biologic Mother	35	Female	No	0	.	0	.	.	.	.	0	.
	Biologic Father	38	Male	No	0	.	0	.	.	.	.	0	.
	Sibling #1	14	Female	No	0	.	0	.	1	1	1	0	.
329.010.00282	Biologic Mother	45	Female	No	0	.	0	.	.	.	0	0	.
	Biologic Father	46	Male	No	0	.	0	.	.	.	0	0	.
	Sibling #1	18	Female	No	0	.	0	.	.	.	0	0	.
	Sibling #2	15	Female	No	0	.	0	.	1	1	0	0	.
	Sibling #3	12	Male	No	0	.	0	.	1	1	0	0	.
329.011.00164	Biologic Mother	43	Female	No	0	.	.	.	0	.	0	0	.
	Biologic Father	43	Male	No	0	.	.	.	0	.	0	0	.
	Sibling #1	24	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #2	20	Male	No	0	.	.	.	0	.	0	0	.
	Sibling #3	18	Male	No	0	.	1	.	0	.	0	0	.
	Sibling #4	15	Male	No	0	.	1	1	0	.	0	0	.
329.011.00210	Biologic Mother	32	Female	No	1	1	1	1	.	.	0	0	0
	Biologic Father	41	Male	No	.	.	.	.	.	.	0	0	0
	Sibling #1	14	Female	No	.	.	.	.	1	.	0	0	0
	Sibling #2	10	Male	No	.	.	.	.	1	1	0	0	0
329.011.00285	Biologic Mother	42	Female	No	0	0	1	.	.	0	.	0	0
	Biologic Father	44	Male	No	0	0	1	1	.	0	1	0	0
	Sibling #1	16	Male	No	0	0	1	.	1	0	.	0	0
	Sibling #2	13	Female	No	.	.	.	.	.	.	.	.	.
329.011.00287	Biologic Mother	41	Female	No	0	0	.	0	1	1	.	.	0
	Biologic Father	40	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	16	Female	No	0	0	1	0	.	.	1	1	0
	Sibling #2	14	Female	No	0	0	.	0	.	.	.	1	0
	Sibling #3	10	Female	No	.	.	.	.	.	.	.	.	.
	Sibling #4	4	Male	No	.	.	.	.	.	.	.	.	.
329.012.00027	Biologic Mother	39	Female	No	0	.	1	0	.	.	0	0	.
	Biologic Father	38	Male	No	0	.	.	0	.	.	0	0	.
	Sibling #1	15	Male	No	0	.	.	0	1	1	0	0	.

0 = NO; 1 = YES; 9 = DON'T KNOW

277

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.6

Listing of Family History - Epidemiologic by Treatment Group and Patient: Part IV  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	Family Member	Age	Sex	Deceased	----- Family History Item Number -----								
					27	27B	28	28B	29	29B	30	31	31B
329.012.00217	Biologic Mother	45	Female	No	0	0	.	0	0	0	0	0	0
	Biologic Father	45	Male	No	0	0	.	0	0	0	0	0	0
	Sibling #1	22	Male	No	0	0	.	0	0	0	0	0	0
	Sibling #2	19	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Female	No	0	0	1	0	0	0	0	0	0
329.012.00218	Biologic Mother	46	Female	No	0	.	1	0	0	.	0	0	.
	Biologic Father	46	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #1	17	Female	No	0	.	1	0	0	.	0	0	.
	Sibling #2	14	Male	No	.	.	.	.	.	.	.	.	.
	Sibling #3	14	Male	No	.	.	.	.	.	.	.	.	.
329.012.00224	Biologic Mother	41	Female	No	1	1	.	0	0	0	0	0	0
	Biologic Father	41	Male	No	.	.	.	0	0	0	0	0	0
	Sibling #1	14	Female	No	1	1	.	0	0	0	0	0	0
	Sibling #2	7	Female	No	1	1	1	0	0	0	0	0	0
329.012.00225	Biologic Mother	48	Female	No	.	0	1	0	.	.	0	0	.
	Biologic Father	48	Male	No	.	0	.	0	.	1	0	0	.
	Sibling #1	14	Male	No	1	0	.	0	1	.	0	0	.
	Sibling #2	11	Female	No	.	.	.	.	.	.	.	.	.

0 = NO; 1 = YES; 9 = DON'T KNOW

278

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.001.00063	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1994
	ALLERGY POLLEN	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1983
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
	PAIN LEFT WRIST (POSSIBLE SPRAIN)	SPRAINS/STRAINS	INJURY/POISONING	CUR	1994
	SLIGHTLY OBESE	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1994
329.001.00065	DIZZINESS UPON CHANGING POSITIONS	DIZZINESS, POSTURAL	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	HAND TREMORS	TREMOR	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1989
	STOMACH UPSET (NAUSEA)	NAUSEA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	OSGOOD SCHLATTER DISEASE	OSTEOCHONDROPATHIES	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1991
329.001.00068	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1993
	FEVER BLISTERS	VIRAL DIS/EXANTHEM	INFECTIOUS/PARASITIC DIS	CUR	1990
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
	NAUSEA STOMACH UPSET	NAUSEA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
	INFECTED {BIOPSY MARK RIGHT SUPRACLAVICULAR ARM}	COMPLIC OF MED CARE	INJURY/POISONING	PRV	1991
	LYMPH NODE BIOPSY (ENLARGED NODES)	OPERATION, LYMPH	OPERATIONS	PRV	1991
329.001.00072	STRESS FRACTURE BACK	BONE/CARTIL DISORD, OTHER	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1993
329.001.00121	DECREASED WHITE BLOOD CELL	LEUKOPENIA	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1995

CUR = Current, PRV = Past

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.001.00121	BIRTHMARK REMOVED	OPERATION, SKIN/SUBCUT	OPERATIONS	PRV	1989
	CHICKEN POX	VIRAL DIS/EXANTHEM	INFECTIOUS/PARASITIC DIS	PRV	1987
	CYST REMOVED FROM CHEST	OPERATION, SKIN/SUBCUT	OPERATIONS	PRV	1981
329.001.00205	SINUS CONGESTION	UPPER RESP DISORD, OTHER	RESPIRATORY SYST DIS	CUR	1984
	FACIAL LACERATIONS{DOG BITE}	OPEN WOUND	INJURY/POISONING	PRV	1986
	PLASTIC SURGERY FOR FACIAL SCARS	OPERATION, SKIN/SUBCUT	OPERATIONS	PRV	1994
329.001.00206	ENVIRONMENTAL ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	
329.002.00055	ALLERGIES-BEE STING	TOXIC EFFECTS, VENOM	INJURY/POISONING	CUR	1987
	ALLERGY-CAT FUR(MILD)	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1987
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
329.002.00058	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	ATTENTION DEFICIT DISORDER	MENTAL STATUS, IMPAIRED	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1983
329.002.00099	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	
329.002.00105	ALLERGIES{CATS, POLLEN}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1990
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	HEARTBURN	HEARTBURN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.002.00242	HEADACHES {RECURRENT}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995

CUR = Current, PRV = Past

280

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.002.00245	MIGRAINE HEADACHES {ACCORDING TO PATIENT}	MIGRAINE	NERVOUS SYST/SENSE ORGAN DIS	CUR	1995
329.002.00319	HEADACHES {FRONTAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.003.00075	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
329.003.00081	HEADACHES {DAILY}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.003.00087	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1994
329.003.00313	OVERWEIGHT	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	
	TUBERCULOSIS	TUBERCULOSIS	INFECTIOUS/PARASITIC DIS	PRV	
329.004.00015	ENURESIS	INCONTINENCE, URINARY	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1990
	URETERS BILATERALLY REEMBEDDED	OPERATION, OTHER URINARY	OPERATIONS	PRV	1990
329.004.00212	ALLERGIES {ENVIRONMENTAL}	ALLERGY, NEC	INJURY/POISONING	CUR	1995
	AMENORRHEA	AMENORRHEA	GENITOURINARY SYST DIS	CUR	1996
329.004.00214	COLD {COMMON}	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1996
	JOINT PAIN - FLEXIBLE JOINTS	PAIN, JOINT	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1996
	HEAD LACERATION	OPEN WOUND	INJURY/POISONING	PRV	1987
329.005.00002	CANNABIS USE	DRUG ABUSE	MENTAL DISORD	CUR	1994

CUR = Current, PRV = Past

281

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.005.00109	POSTPARTUM - NOT BREAST FEEDING	POSTPARTUM CARE	FAMILY/PERSONAL HISTORY	CUR	1994
	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1979
	BLEEDING ULCER {NOS}	CONDITIONS, OTHER, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1993
329.005.00112	BURNING STOMACH	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.005.00119	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
329.005.00151	BACK PAIN	BACK PAIN	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1989
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1991
329.005.00152	BROKEN ARM	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1985
329.005.00257	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1995
329.005.00258	OCCULT BLOOD IN URINE - PATIENT MENSTRUATING	HEMATURIA	GENITOURINARY SYST DIS	CUR	1996
	PROTEIN IN URINE - PATIENT MENSTRUATING	PROTEINURIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.005.00299	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
	KNEE PAIN {RIGHT-MILD AFTER RUNNING}	PAIN, LIMB	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1996
329.005.00333	ENVIRONMENTAL ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	
	TONSILLECTOMY AND ADENOIDECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1990

CUR = Current, PRV = Past

282

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.005.00336	BACKACHE	BACK PAIN	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1997
329.006.00038	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1990
329.006.00039	HEADACHES-FREQUENT	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
329.006.00260	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1996
	HEADACHES {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.006.00261	ASTHMA {VERY MILD}	ASTHMA	RESPIRATORY SYST DIS	CUR	1984
	DYSHYDROSIS {MILD ON HAND AND PENIS}	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1996
	TINEA PEDIS {BOTH FEET}	MYCOSES	INFECTIOUS/PARASITIC DIS	CUR	1996
329.007.00140	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	VESICULAR DYSHIDROSIS	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1995
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1989
329.007.00142	MILD LYMPHADENOPATHY, LEFT ANTERIOR CERVICAL, PERSISTENT	LYMPHADENOPATHY	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	OCCASIONAL HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1985
	CAT SCRATCH FEVER	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1993
	INGUINAL HERNIA	HERNIA, ABDOMINAL	DIGESTIVE SYST	PRV	1983
	SORE THROAT	PHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1995
329.007.00145	ELEVATED MONOCYTES	MONOCYTOSIS	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996

CUR = Current, PRV = Past

283

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.007.00145	LOW WHITE BLOOD CELL COUNT	LEUKOPENIA	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	BROKEN LEFT ARM	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1991
329.007.00265	ANEMIA	ANEMIA, OTHER	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.007.00268	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1995
	LYMPH NODE INFECTION{BILATERAL GROIN NODES}	LYMPHADENITIS, ACUTE	SKIN/SUBCUTANEOUS TISSUE DIS	PRV	1991
329.007.00294	BACKACHES	BACK PAIN	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1994
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	RASH, PLANTAR SURFACE RIGHT FOOT	RASH/OTHER SKIN ERUPTION	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
	WEIGHT GAIN	WEIGHT GAIN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
	10 BONE FUSIONS IN BACK	OPERATION, BONE/JOINT	OPERATIONS	PRV	1995
	ROD PLACEMENT {BACK}	OPERATION, BONE/JOINT	OPERATIONS	PRV	1995
	SCOLIOSIS	DEFORMITY, ACQUIRED	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1995
329.007.00309	"ULCER-LIKE" SYMPTOMS (BURNING, INDIGESTION), NO ULCER	DYSPEPSIA	DIGESTIVE SYST	CUR	1996
	HEADACHES {FREQUENT}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	NAUSEA {CHRONIC}	NAUSEA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995

CUR = Current, PRV = Past



Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.007.00310	HEADACHES {FREQUENT}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1996
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1994
329.007.00318	ATTENTION DEFICIT HYPERACTIVITY DISORDER	CONDUCT DISORD	MENTAL DISORD	PRV	1984
	EUSTACHIAN TUBE {BILATERAL}	OPERATION, EAR	OPERATIONS	PRV	1985
329.008.00157	SURGERY TO REPAIR A HERNIA	OPERATION, HERNIA REPAIR	OPERATIONS	PRV	1980
329.008.00160	EPIGLOTTITIS	EPIGLOTTITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1990
329.008.00271	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1984
329.008.00275	ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	1994
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	INSOMNIA	INSOMNIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
329.009.00130	NERVOUS STOMACH	STOMACH/DUODENUM DISORD	DIGESTIVE SYST	CUR	1989
329.009.00131	OCCASIONAL HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	HEART MURMUR, GRADE 1, ASYMPTOMATIC	CARDIAC MURMURS	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1984
329.009.00133	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993

CUR = Current, PRV = Past

285

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00133	PREMENSTRUAL TENSION (OCCASIONAL)	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1993
	SINUS INFECTIONS	SINUSITIS, NOS	RESPIRATORY SYST DIS	CUR	1985
	FEVER OF UNKNOWN ORIGIN	PYREXIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1993
	STREP THROAT	INFECTION, BACTERIAL	INFECTIOUS/PARASITIC DIS	PRV	1985
329.009.00138	OCCASIONAL HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	OCCASIONAL STOMACH ACHE	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
329.009.00170	BILATERAL LEG PAIN: MUSCULAR ORIGIN	MYALGIA	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995
	OCCASIONAL HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	SCOLIOSIS	DEFORMITY, ACQUIRED	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1989
329.009.00173	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	STOMACH ACHE	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	UPPER RESPIRATORY TRACT INFECTION	UPPER RESP INFECT, ACUTE	RESPIRATORY SYST DIS	CUR	1995
329.009.00193	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.009.00196	ALLERGIES TO ASPIRIN	ADVERSE EFF/ANALGESIC	EXT CAUSES OF INJURY/POISONING	CUR	1995
	ALLERGIES TO SULFA DRUGS	ADVERSE EFF/ANTI-INFECT	EXT CAUSES OF INJURY/POISONING	CUR	1995
	ANEMIA	ANEMIA, OTHER	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1995
	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1993
	HEADACHES {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994

CUR = Current, PRV = Past

286

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00196	MENSTRUAL CRAMPS{OCCASIONAL}	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1994
	OBESITY{MILD}	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1995
329.009.00201	FEVER	PYREXIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	STREP THROAT	INFECTION, BACTERIAL	INFECTIOUS/PARASITIC DIS	CUR	1996
329.009.00204	ATTENTION DEFICIT HYPERACTIVITY DISORDER	CONDUCT DISORD	MENTAL DISORD	CUR	1986
	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	WEIGHT GAIN	WEIGHT GAIN	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1996
329.009.00235	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1996
	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	FLU SYMPTOMS	INFLUENZA	RESPIRATORY SYST DIS	PRV	1996
329.009.00240	HEADACHES (OCCASIONAL)	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SLEEP DISTURBANCE	DISTURBANCE, SLEEP, UNSPEC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	MENINGITIS	MENINGITIS	NERVOUS SYST/SENSE ORGAN DIS	PRV	1984
329.009.00303	HEADACHE{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	SINUS INFECTION	SINUSITIS, NOS	RESPIRATORY SYST DIS	CUR	1996
329.009.00304	HEADACHE{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995

CUR = Current, PRV = Past

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00324	HEADACHES (OCCASIONAL)	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	
	SINUS CONGESTION	UPPER RESP DISORD, OTHER	RESPIRATORY SYST DIS	CUR	1996
	UNCONSCIOUS AT AGE 1 - HIT HEAD IN FALL	COMA AND STUPOR	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1984
329.009.00328	BIVENTRICULAR HYPERTROPHY	CARDIOMEGALY	CIRCULATORY SYST	CUR	1996
	HEADACHES {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	STOMACH ACHES {OCCASIONAL}	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
329.009.00329	HEADACHES {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	REPOLARIZATION ON ECG {EARLY}	CARDIOVAS FUNCTIONS/ECG, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SINUS BRADYCARDIA {MARKED}	BRADYCARDIA	CIRCULATORY SYST	CUR	1996
329.010.00182	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.010.00278	ABDOMINAL PAIN	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	POLYCYSTIC OVARY	OVARIAN DYSFUNC	ENDOCR/METAB/IMMUNITY DISORD	CUR	1995
	ACUTE PANCREATITIS	PANCREATITIS	DIGESTIVE SYST	PRV	1994
329.010.00280	ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	ASTHMA ATTACK	ASTHMA	RESPIRATORY SYST DIS	PRV	
329.011.00288	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1987

CUR = Current, PRV = Past

288

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.011.00288	PROTEINURIA	PROTEINURIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.012.00025	ALLERGIES (SKIN)	INFLAM SKIN/SUBCUT	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1995
329.012.00220	ALLERGIC TO SUDAFED	ADVERSE EFF ON AUTONOMIC NS	EXT CAUSES OF INJURY/POISONING	CUR	1984
	ATTENTION DEFICIT HYPERACTIVE DISORDER	CONDUCT DISORD	MENTAL DISORD	CUR	1987
	BED-WETTING	INCONTINENCE, URINARY	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1986
	BLADDER INFECTIONS	CYSTITIS	GENITOURINARY SYST DIS	PRV	1986
	OBSESSIVE COMPULSIVE SYMPTOMS	NEUROSES	MENTAL DISORD	PRV	1994
	TOURETTES (TIC DISORDER).	TICS	MENTAL DISORD	PRV	1987
329.012.00222	HAYFEVER-LATE SPRING, SUMMER MONTHS ONLY	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1994
329.012.00226	MILD RECURRENT HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	FRACTURE RIGHT LEG	FRACTURE, LOWER LIMB	INJURY/POISONING	PRV	1988
	SURGERY FOR STRABISMUS	OPERATION, EYE	OPERATIONS	PRV	1983
329.012.00231	ECZEMA	INFLAM SKIN/SUBCUT	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1996

CUR = Current, PRV = Past

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.001.00061	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	INSOMNIA	INSOMNIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
	REPEATED SINUS INFECTIONS ABOUT ONE TIME PER MONTH	SINUSITIS, OTHER	RESPIRATORY SYST DIS	CUR	1989
	FOOT CASTED	THERAPY, REHAB	PROCEDURES	PRV	1977
	FOOT TURNED AT BIRTH	CONG ANOM, MUSCULOSKEL	ANOMALIES	PRV	1977
	REPEATED STREP THROAT	INFECTION, BACTERIAL	INFECTIOUS/PARASITIC DIS	PRV	1978
	RESPIRATORY DIFFICULTIES AT BIRTH	CONDITIONS, PERINATAL	PERINATAL COND	PRV	1977
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1989
329.001.00066	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
	MILD ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1994
	MOLE LEFT KNEE-RAISED	NEOPLASMS BENIGN	NEOPLASMS	CUR	1994
	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
	MOLE EXCISED BELOW UMBILICUS/BENIGN	OPERATION, SKIN/SUBCUT	OPERATIONS	PRV	1984
	SUTURES IN CHIN	OPERATION, SKIN/SUBCUT	OPERATIONS	PRV	1980
329.001.00070	ALLERGIC TO CAFFEINE	ADVERSE EFF/PSYCHOTROPICS	EXT CAUSES OF INJURY/POISONING	CUR	1992
	ALLERGIC TO CHOCOLATE	ALLERGIC REACTION, FOOD	INJURY/POISONING	CUR	1992
	ALLERGIC TO MOLD	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1992
	ENLARGED LYMPH NODES	LYMPHADENOPATHY	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1991

CUR = Current, PRV = Past

290

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.001.00070	BRUISED FOOT	CONTUSION	INJURY/POISONING	PRV	1990
	BRUISED HAND	CONTUSION	INJURY/POISONING	PRV	1993
	EAR INFECTIONS	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	PRV	1983
	SINUS INFECTIONS	SINUSITIS,NOS	RESPIRATORY SYST DIS	PRV	1991
	SPRAINED ANKLE	SPRAINS/STRAINS	INJURY/POISONING	PRV	1992
	SPRAINED FOOT	SPRAINS/STRAINS	INJURY/POISONING	PRV	1990
329.001.00122	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1994
	HEAVY PERSPIRATION	HYPERHIDROSIS	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	HERNIA REPAIR	OPERATION, HERNIA REPAIR	OPERATIONS	PRV	1988
	RIGHT FOOT INFECTION {TOENAILS}	CELLULITIS/ABSCESS	SKIN/SUBCUTANEOUS TISSUE DIS	PRV	1985
329.002.00050	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1991
	INTERMITTENT GLUCOSE (DECREASED)	HYPOGLYCEMIA	ENDOCR/METAB/IMMUNITY DISORD	CUR	1995
	HYPOSPADIAS {MALE}	CONG ANOM, GU	ANOMALIES	PRV	1978
	LEFT URETERAL DUPLICATION	CONG ANOM, GU	ANOMALIES	PRV	1978
	RIGHT VESICoureTERAL REFLUX	KIDNEY DISORD	GENITOURINARY SYST DIS	PRV	1978
329.002.00056	MISCARRIAGE	PREGNANCY, COMPLICATIONS	COMPLIC OF PREGNANCY/BIRTH	PRV	1994
	PREGNANCY	PREGNANCY	FAMILY/PERSONAL HISTORY	PRV	1994
329.002.00057	HEARTBURN	HEARTBURN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994

CUR = Current, PRV = Past

291

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.002.00057	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	SCHUEERMANN'S KYPHOSIS	OSTEOCHONDROPATHIES	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1994
	STOMACH PROBLEMS	STOMACH/DUODENUM DISORD	DIGESTIVE SYST	CUR	1994
	CHILDHOOD MIGRAINES	MIGRAINE	NERVOUS SYST/SENSE ORGAN DIS	PRV	1984
	CONCUSSION	INJURY, INTRACRANIAL	INJURY/POISONING	PRV	1985
	HERNIA OPERATION	OPERATION, HERNIA REPAIR	OPERATIONS	PRV	1985
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1983
	TUBES IN EARS	OPERATION, EAR	OPERATIONS	PRV	1983
329.002.00100	DEPRESSION	DEPRESSION	MENTAL DISORD	CUR	1995
	HAND TREMOR	TREMOR	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	SWEATING AT BROW	HYPERHIDROSIS	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
329.002.00103	HEADACHES (DAILY)	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.002.00104	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1994
329.002.00243	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	SHAKINESS	NERVOUSNESS	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	SORE THROAT-TONSILLITIS	TONSILLITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1996
329.002.00244	HEAVY CRAMPS DUE TO MENSES	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	P&C	1990
	NAUSEA DUE TO MENSES	NAUSEA	SIGNS, SYMPTOMS, ILL-DEFINED CON	P&C	1990

CUR = Current, PRV = Past

292

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.002.00321	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.003.00073	SPRAINED ANKLE	SPRAINS/STRAINS	INJURY/POISONING	CUR	1995
329.003.00076	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	
	GLASSES FOR DISTANCE SINCE GRADE 4	VISUAL DISTURB	NERVOUS SYST/SENSE ORGAN DIS	PRV	1988
	HISTORY FUNCTIONAL HEART MURMUR	CARDIAC MURMURS	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	
	SPRAINED ANKLE	SPRAINS/STRAINS	INJURY/POISONING	PRV	1994
329.003.00090	IRRITABLE BOWEL SYNDROME	DIGESTIVE DISORD, OTHER	DIGESTIVE SYST	CUR	1987
329.003.00093	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1989
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
329.003.00249	CIGARETTE SMOKER	TOBACCO USE	MENTAL DISORD	CUR	
	DYSMENORRHEA	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1991
	NEAR-SIGHTED	VISUAL DISTURB	NERVOUS SYST/SENSE ORGAN DIS	CUR	
	SCARS LEFT AND RIGHT FOREARM	SCARRING	SKIN/SUBCUTANEOUS TISSUE DIS	PRV	
329.003.00289	ALLERGIES {TO POLLEN, TREES, DUST}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	
	DYSMENORRHEA	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1993

CUR = Current, PRV = Past

293

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.003.00289	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
	ASTHMA {AS YOUNG CHILD}	ASTHMA	RESPIRATORY SYST DIS	PRV	1981
329.003.00290	NEARSIGHTED	VISUAL DISTURB	NERVOUS SYST/SENSE ORGAN DIS	CUR	
	SORE THROATS {FREQUENT}	PHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1994
	TONSILLECTOMY AND ADENOIDECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1994
329.003.00314	PHARYNGITIS	PHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1996
329.003.00317	ALLERGIC RHINITIS	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	
	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	
329.004.00013	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1994
329.004.00215	LOW ENERGY	MALAISE AND FATIGUE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.005.00003	EAR INFECTION	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	CUR	1994
	ENVIRONMENTAL ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	1988
	HISTORY OF HEART MURMUR	CARDIAC MURMURS	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	
329.005.00006	HISTORY OF ENVIRONMENTAL ALLERGIES-DUST	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	PRV	
	HISTORY OF ENVIRONMENTAL ALLERGIES-POLLEN	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	PRV	
	HISTORY OF RECURRENT TONSILLITIS	TONSILS/ADENOIDS DIS	RESPIRATORY SYST DIS	PRV	

CUR = Current, PRV = Past

294

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.005.00006	STATUS POST MONONUCLEOSIS	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1994
329.005.00007	QUESTIONABLE OVARIAN CYST	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1994
329.005.00009	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	HAY FEVER	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	PRV	1984
329.005.00110	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1984
329.005.00113	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1985
	ABORTION	PREGNANCY, COMPLICATIONS	COMPLIC OF PREGNANCY/BIRTH	PRV	1994
329.005.00117	HISTORY OF CHRONIC OTITIS MEDIA	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	PRV	1979
	MILD HEARING LOSS	HEARING LOSS	NERVOUS SYST/SENSE ORGAN DIS	PRV	1979
	STATUS POST HIP SURGERY	OPERATION, BONE/JOINT	OPERATIONS	PRV	1989
329.005.00118	GYNECOMASTIA	GYNECOMASTIA	GENITOURINARY SYST DIS	CUR	
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.005.00153	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1995
	COLD {COMMON}	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1996
	INCREASED LYMPHOCYTES	LYMPHOCYTOSIS	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	INCREASED NEUTROPHIL SEGS	LEUCOCYTOSIS	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	TRACE PROTEIN IN URINE	PROTEINURIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996

CUR = Current, PRV = Past

295

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.005.00255	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1986
	ENVIRONMENTAL ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	
	URINARY TRACT INFECTION	URINARY TRACT INFECTION	GENITOURINARY SYST DIS	CUR	1996
	STRABISMUS	EYE DISORD, OTHER	NERVOUS SYST/SENSE ORGAN DIS	PRV	
329.005.00256	DECREASED LYMPHOCYTES	LYMPHOPENIA	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
329.005.00295	BODY ACHES	PAIN, GENERAL	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	COLD {COMMON}	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1996
	DIARRHEA	DIARRHEA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	FLU	INFLUENZA	RESPIRATORY SYST DIS	CUR	1996
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.005.00335	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1997
329.006.00040	ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	1985
	OVARIAN CYST	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1994
329.006.00041	RIGHTWARD AXIS ON ELECTROCARDIOGRAM	CARDIOVAS FUNCTIONS/ECG, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.007.00139	FRACTURED RIGHT ARM	FRACTURE, UPPER LIMB	INJURY/POISONING	CUR	1995
329.007.00143	COLD SYMPTOMS	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1995
	MILD OBESITY	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1994

CUR = Current, PRV = Past

296

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.007.00143	STATUS POST HOSPITALIZATION FOR DEPRESSION	DEPRESSION	MENTAL DISORD	PRV	1994
	URINARY TRACT INFECTION	URINARY TRACT INFECTION	GENITOURINARY SYST DIS	PRV	1994
329.007.00146	COLD SYMPTOMS	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1996
	HEADACHE{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	JOINT PAIN{RIGHT WRIST}	PAIN, JOINT	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1996
	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1983
	SWELLING{LEFT CALF}	SWELLING, LIMB	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995
329.007.00269	HEADACHE{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	RECURRENT SINUSITIS{SEASONAL ALLERGIES}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1996
	UPSET STOMACH	DYSPEPSIA	DIGESTIVE SYST	CUR	1996
	ACHILLES TENDON CASTED TIMES 6 WEEKS	THERAPY, REHAB	PROCEDURES	PRV	1994
	BILATERAL HERNIA REPAIR	OPERATION, HERNIA REPAIR	OPERATIONS	PRV	1980
	SEVER'S DISEASE	OSTEOCHONDROPATHIES	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1994
329.007.00270	FOOD ALLERGIES{MILK PRODUCTS}	ALLERGIC REACTION, FOOD	INJURY/POISONING	CUR	1985
	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	RINGWORM	MYCOSES	INFECTIOUS/PARASITIC DIS	CUR	1996

CUR = Current, PRV = Past

297

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.007.00270	STREP THROAT	INFECTION, BACTERIAL	INFECTIOUS/PARASITIC DIS	CUR	1996
	BROKEN LEFT FEMUR{FELL OUT OF TREE}	FRACTURE, LOWER LIMB	INJURY/POISONING	PRV	1994
329.007.00307	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
	INSOMNIA	INSOMNIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1993
	SINUSITIS	SINUSITIS, NOS	RESPIRATORY SYST DIS	PRV	1995
329.007.00308	URINE {1+ PROTEIN}	PROTEINURIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SPINAL MENINGITIS	MENINGITIS	NERVOUS SYST/SENSE ORGAN DIS	PRV	1982
329.008.00161	NECROTIZING ENTEROCOLITIS AT BIRTH-NO COMPLICATIONS	CONDITIONS, PERINATAL	PERINATAL COND	PRV	1978
329.008.00187	COLITIS	ENTERITIS/COLITIS	DIGESTIVE SYST	CUR	1981
	OCCASIONAL MILD HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	VAGINAL WARTS	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	CUR	1995
329.008.00192	ATTENTION DEFICIT HYPERACTIVITY DISORDER	CONDUCT DISORD	MENTAL DISORD	PRV	1996
329.008.00272	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1996
329.008.00273	TEMPOROMANDIBULAR JOINT PAIN	DENTOFACIAL ANOM	DIGESTIVE SYST	CUR	1996
329.009.00127	INITIAL INSOMNIA	INSOMNIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995

CUR = Current, PRV = Past

298

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00127	SEPARATION ANXIETY	STRESS REACTION	MENTAL DISORD	CUR	1995
329.009.00132	HEADACHES (OCCASIONAL)	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
329.009.00134	DERMATOLOGICAL FUNGUS	MYCOSES	INFECTIOUS/PARASITIC DIS	CUR	1995
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1993
	OCCASIONAL STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	SPRAINED ARM MUSCLES	SPRAINS/STRAINS	INJURY/POISONING	PRV	1995
329.009.00171	ALLERGY TO IODINE	ADVERSE EFF/OTHER DRUG	EXT CAUSES OF INJURY/POISONING	CUR	1994
	PREGNANCY	PREGNANCY	FAMILY/PERSONAL HISTORY	PRV	1994
	SEXUAL ASSAULT {STATUS POST, NO POST-TRAUMATIC STRESS DISORDER SYNDROME}	RAPE	EXT CAUSES OF INJURY/POISONING	PRV	1992
	SUICIDE ATTEMPT {NOT IN CURRENT EPISODE}	SUICIDE	EXT CAUSES OF INJURY/POISONING	PRV	1994
	WEIGHT LOSS {52LBS. - PLANNED}	WEIGHT LOSS	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1995
	{CHILDBIRTH}	PREGNANCY, COMPLICATIONS	COMPLIC OF PREGNANCY/BIRTH	PRV	1994
329.009.00172	OCCASIONAL HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	STOMACH ACHE	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.009.00194	ALLERGIES TO MILK	ALLERGIC REACTION, FOOD	INJURY/POISONING	CUR	1993
	ANKLE PAIN {SECONDARY TO SURGICAL CORRECTION RIGHT FOOT (CLUB)}	OPERATION, MUSCLE/TENDON	OPERATIONS	CUR	1984

CUR = Current, PRV = Past

299

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00194	HEADACHE{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	MYALGIA{UNSPECIFIED}	MYALGIA	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995
329.009.00195	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1991
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1994
	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1995
329.009.00199	ALLERGY TO CECLOR	ADVERSE EFF/ANTIBIOTIC	EXT CAUSES OF INJURY/POISONING	CUR	1995
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	MUSCULAR NECK PAIN	MYALGIA	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995
329.009.00203	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1990
	LEFT AXIS DEVIATION	CARDIOVAS FUNCTIONS/ECG, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1994
329.009.00236	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1996
	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.009.00239	MIGRAINES	MIGRAINE	NERVOUS SYST/SENSE ORGAN DIS	CUR	1991
	SINUS ARRHYTHMIA	ARRHYTHMIA	CIRCULATORY SYST	CUR	1996
	SINUS BRADYCARDIA	BRADYCARDIA	CIRCULATORY SYST	CUR	1996
	DRUG ALLERGY - PENICILLIN	ADVERSE EFF/ANTIBIOTIC	EXT CAUSES OF INJURY/POISONING	P&C	1995

CUR = Current, PRV = Past

300

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00239	MONONUCLEOSIS	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1995
329.009.00262	ENCOPRETIC	PSYCHOGENIC PHYSIOL DYSFUNC	MENTAL DISORD	CUR	1993
	EYE INFECTION (LEFT AND RIGHT EYE)	EYE DISORD, OTHER	NERVOUS SYST/SENSE ORGAN DIS	CUR	1997
	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
	CHRONIC EAR INFECTIONS	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	PRV	1986
	TUBES IN EARS	OPERATION, EAR	OPERATIONS	PRV	1986
329.009.00264	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	ASTHMA - NO PROBLEMS FOR 2 YRS	ASTHMA	RESPIRATORY SYST DIS	PRV	1991
329.009.00301	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1983
	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	ASTHMA ATTACKS{HOSPITALIZED}	ASTHMA	RESPIRATORY SYST DIS	PRV	1990
	BROKEN LEFT ARM{X2}	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1988
	BROKEN RIGHT ARM	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1989
329.009.00325	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1990
	HEADACHE {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1995

CUR = Current, PRV = Past

301

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00325	NAUSEA {STOMACH UPSET}	DYSPEPSIA	DIGESTIVE SYST	CUR	1995
329.009.00326	COLD SYMPTOMS	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1996
329.010.00279	THYROID-STIMULATING HORMONE DECREASE	THYROID FUNCTION, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	WBC DECREASE	LEUKOPENIA	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
329.010.00281	BILATERAL TUBE PLACEMENT IN EARS	OPERATION, EAR	OPERATIONS	PRV	1984
	CHICKEN POX	VIRAL DIS/EXANTHEM	INFECTIOUS/PARASITIC DIS	PRV	1987
	JAUNDICE DUE TO ABO INCOMPATIBILITY {NOS}	COMPLIC OF MED CARE	INJURY/POISONING	PRV	1983
	REMOVAL OF BAKER'S CYST FROM RIGHT LEG	OPERATION, SOFT TISSUE	OPERATIONS	PRV	1989
329.011.00163	MIGRAINE HEADACHES	MIGRAINE	NERVOUS SYST/SENSE ORGAN DIS	CUR	1989
	STRESS INDUCED ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1994
	TEMPOROMANDIBULAR JOINT SYNDROME	DENTOFACIAL ANOM	DIGESTIVE SYST	CUR	1994
	CORRECTIVE SURGERY (BOTH EYES) FOR STRABISMUS	OPERATION, EYE	OPERATIONS	PRV	1985
329.011.00208	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	ADENOIDECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1989
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1989
329.011.00209	ALLERGIES {ENVIRONMENTAL}	ALLERGY, NEC	INJURY/POISONING	CUR	1996

CUR = Current, PRV = Past

302

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.011.00209	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.011.00284	LOW NEUTROPHILS	LEUKOPENIA	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	LOW WHITE BLOOD CELLS	LEUKOPENIA	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	CROUP	LARYNGITIS/TRACH, ACUTE	RESPIRATORY SYST DIS	PRV	1979
	PECTUS EXCAVATUM	CONG ANOM, MUSCULOSKEL	ANOMALIES	PRV	1978
	PSEUDOMONAS INFECTION	BACT DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1988
329.011.00286	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1990
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
	SINUSITIS	SINUSITIS, NOS	RESPIRATORY SYST DIS	CUR	
329.012.00219	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	EAR INFECTIONS	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	PRV	1985
329.012.00221	HEADACHES {MODERATE}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1989
329.012.00223	ALLERGIES	ALLERGY, NEC	INJURY/POISONING	CUR	1996
	BENIGN LUMP LEFT FOOT	SWELLING, MASS, LOCALIZED	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	BRONCHOSPASM	RESP DIS, OTHER	RESPIRATORY SYST DIS	CUR	1996
	HEADACHES {FREQUENT}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	FATTY INFILTRATION OF THE LIVER {CLINICALLY NORMAL}	LIVER DISORD	DIGESTIVE SYST	PRV	1996
	HISTORY OF HIGH AVERAGE/BORDERLINE HIGH BLOOD PRESSURE	BLOOD PRESSURE, ELEVATED	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1995

CUR = Current, PRV = Past

303

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.012.00223	PYELONEPHRITIS	KIDNEY INFECT	GENITOURINARY SYST DIS	PRV	1995
	RADIAL FRACTURE	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1994
	URINARY TRACT INFECTION'S {FREQUENT}	URINARY TRACT INFECTION	GENITOURINARY SYST DIS	PRV	1984
329.012.00230	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1993

CUR = Current, PRV = Past

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.001.00062	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1979
	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1988
329.001.00064	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
	SINUS INFECTION	SINUSITIS, NOS	RESPIRATORY SYST DIS	CUR	1994
	BROKEN ARM	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1994
	BROKEN RIGHT WRIST	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1994
	COLD (HEAD)	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1994
	EAR INFECTION	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	PRV	1983
	MYRINGOTOMY	OPERATION, EAR	OPERATIONS	PRV	1983
	PNEUMONIA	PNEUMONIA, OTHER	RESPIRATORY SYST DIS	PRV	1981
329.001.00069	PHARYNGITIS	PHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	CUR	1995
	RIGHT OTITIS MEDIA	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	CUR	1995
	SINUS INFECTIONS	SINUSITIS, NOS	RESPIRATORY SYST DIS	CUR	1985
	FEVER	PYREXIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1994
	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1994
	PNEUMONIA	PNEUMONIA, OTHER	RESPIRATORY SYST DIS	PRV	1994
329.001.00071	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	FLU	INFLUENZA	RESPIRATORY SYST DIS	PRV	1995
	PRESSURE EQUALIZATION TUBES IN EARS	OPERATION, EAR	OPERATIONS	PRV	1983
	SINUSITIS	SINUSITIS, NOS	RESPIRATORY SYST DIS	PRV	1995

CUR = Current, PRV = Past

305

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.001.00123	BACTERIAL VAGINAL RASH	VAGINITIS	GENITOURINARY SYST DIS	CUR	1995
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1992
	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1993
	BROKEN ANKLE	FRACTURE, LOWER LIMB	INJURY/POISONING	PRV	1990
	BROKEN WRIST	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1988
	FEMORAL EPIPHYSIS RIGHT HIP{JOINT DISORDER}	JOINT DISORD, OTHER	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1989
	HIP LEFT FEMORAL EPIPHYSIS{JOINT DISORDER}	JOINT DISORD, OTHER	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1990
	SURGERY PINNING LEFT HIP	OPERATION, BONE/JOINT	OPERATIONS	PRV	1990
	SURGERY REMOVAL OF PINS IN RIGHT,LEFT HIPS	OPERATION, BONE/JOINT	OPERATIONS	PRV	1991
	SURGERY-PLACEMENT OF CANNULATED LOG SCREW RIGHT HIP	OPERATION, BONE/JOINT	OPERATIONS	PRV	1989
329.001.00207	OBESITY	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1995
	MUSCLE STRAIN	SPRAINS/STRAINS	INJURY/POISONING	PRV	1996
	SORE THROAT WITH COLD SYMPTOMS	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1996
329.002.00049	BILATERAL HERNIORRHAPHY	OPERATION, HERNIA REPAIR	OPERATIONS	PRV	1980
329.002.00059	HISTORY OF MITRAL VALVE PROLAPSE-NO FUNCTIONAL IMPAIRMENT	MITRAL VALVE DISORD	CIRCULATORY SYST	CUR	1987

CUR = Current, PRV = Past

306

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.002.00097	HEADACHES, DAILY 2-3 TIMES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	UPPER RESPIRATORY INFECTION	UPPER RESP INFECT, ACUTE	RESPIRATORY SYST DIS	CUR	1994
329.002.00101	HISTORY OF APNEA AND RESUSCITATION IN FIRST YEAR OF LIFE (SIDS)	SUDDEN INFANT DEATH SYNDROME	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1979
329.002.00107	EPIGASTRIC DISTRESS	DYSPEPSIA	DIGESTIVE SYST	CUR	1995
	FAINING {OCCASIONAL}	SYNCOPE AND COLLAPSE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	MISSED MENSES	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1996
329.002.00241	ALLERGIES {TO PENICILLIN}	ADVERSE EFF/ANTIBIOTIC	EXT CAUSES OF INJURY/POISONING	CUR	1991
	ALLERGIES {TO POLLEN, POULTRY DUST}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1991
	NASAL CONGESTION	UPPER RESP DISORD, OTHER	RESPIRATORY SYST DIS	CUR	1996
	SINUS RHYTHM ALTERNATING WITH ECTOPIC ATRIAL RHYTHM	EXTRASYSTOLES, ATRIAL	CIRCULATORY SYST	CUR	1996
329.002.00246	GASTROINTESTINAL DISTRESS	GASTROINTEST PROB, NEC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	WEIGHT GAIN	WEIGHT GAIN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	{PAST} ALCOHOL USE	ALCOHOL INGESTION, OTHER	FAMILY/PERSONAL HISTORY	PRV	1994
	{PAST} MARIJUANA USE	DRUG ABUSE	MENTAL DISORD	PRV	1994
329.002.00320	BILATERAL KNEE PAIN	PAIN, LIMB	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995

CUR = Current, PRV = Past

307

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.002.00320	CHRONIC BACK PAIN	BACK PAIN	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1994
	DIZZINESS	DIZZINESS AND GIDDINESS	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	FRACTURED LEFT FEMUR	FRACTURE, LOWER LIMB	INJURY/POISONING	PRV	1990
	FRACTURED RIGHT TIBIA	FRACTURE, LOWER LIMB	INJURY/POISONING	PRV	1990
	FRACTURED SKULL	FRACTURE, SKULL	INJURY/POISONING	PRV	1990
	LYME DISEASE	ARTHROPOD-BORNE DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1995
	SPRAINED WRIST	SPRAINS/STRAINS	INJURY/POISONING	PRV	1990
	SUBDURAL HEMATOMA	INJURY, INTRACRANIAL	INJURY/POISONING	PRV	1990
329.002.00323	BACK PAIN	BACK PAIN	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1996
	ELEVATED CHOLESTEROL	CHOLEST/TRIGLYCERIDE, ELEVATED	ENDOCR/METAB/IMMUNITY DISORD	PRV	
	HEART MURMUR	CARDIAC MURMURS	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1993
329.003.00074	STATUS POST ACUTE APPENDICITIS	APPENDICITIS	DIGESTIVE SYST	PRV	1994
329.003.00080	FATIGUE	MALaise AND FATIGUE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
329.003.00085	EKG SHOWS RAPID HEART RATE DUE TO PREVIOUS BLOOD DRAWING-NORMAL	TACHYCARDIA, UNSPEC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	OBESITY	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1988

CUR = Current, PRV = Past

308

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.003.00086	ABDOMINAL PAIN	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	RHINORRHEA	UPPER RESP DISORD, OTHER	RESPIRATORY SYST DIS	CUR	1993
329.003.00094	ALLERGY TO PENICILLIN {PATIENT GETS A RASH}	INFLAM SKIN/SUBCUT	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	
	SKIN CUTS MULTIPLE {SUPERFICIAL ON LEFT FOREARM}	OPEN WOUND	INJURY/POISONING	CUR	1995
	SKIN CUTS MULTIPLE {SUPERFICIAL ON RIGHT THIGH}	OPEN WOUND	INJURY/POISONING	CUR	1995
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1989
329.003.00251	MYRINGOTOMY {TUBE PLACEMENT}	OPERATION, EAR	OPERATIONS		
	DIZZINESS	DIZZINESS AND GIDDINESS	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	SHORTNESS OF BREATH	DYSPNEA, OTHER	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.003.00252	ALLERGIC TO SULFA DRUGS	ADVERSE EFF/ANTI-INFECT	EXT CAUSES OF INJURY/POISONING	CUR	
	ANEMIA	ANEMIA, OTHER	BLOOD/BLOOD FORMING ORGAN DIS	CUR	
	FACIAL CYSTIC ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	
	MURMUR {I/VI SYSTOLIC EJECTION MURMUR}	CARDIAC MURMURS	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
329.004.00016	ALLERGIES-ANIMAL HAIR & POLLENS	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1988
329.004.00018	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1991

CUR = Current, PRV = Past

309

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.004.00018	UPPER RESPIRATORY TRACT INFECTION	UPPER RESP INFECT, ACUTE	RESPIRATORY SYST DIS	CUR	1995
329.004.00020	ANXIETY	ANXIETY	MENTAL DISORD	CUR	1995
329.004.00213	BACKACHES	BACK PAIN	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1996
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.005.00001	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1992
329.005.00010	DISLOCATED RIGHT HIP AT BIRTH	CONG ANOM, MUSCULOSKEL	ANOMALIES	PRV	1978
	HERNIA REPAIR AT AGE 7	OPERATION, HERNIA REPAIR	OPERATIONS	PRV	1987
	RUPTURED RIGHT EAR DRUM AT BIRTH	CONGEN ANOM, HEAD/NECK	ANOMALIES	PRV	1978
329.005.00012	TOXOPLASMOSIS{RIGHT EYE}	INFECT/PARASIT DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1994
329.005.00114	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1993
329.005.00115	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1984
329.005.00120	RASH ON ARMS AND CHEST{FOLLICULITIS}	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1995
329.005.00253	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1996
	BRONCHITIS	BRONCHITIS, OTHER	RESPIRATORY SYST DIS	CUR	1996

CUR = Current, PRV = Past

310

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.005.00253	POSITIVE URINE DRUG SCREEN FOR CODEINE AND MORPHINE.	DRUG DEPEND	MENTAL DISORD	CUR	1996
329.005.00254	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.005.00293	RBC IN URINE POST PARTUM	HEMATURIA	GENITOURINARY SYST DIS	CUR	1997
	SQUAMOUS CELLS IN URINE POST PARTUM	URINARY CASTS/WBC'S	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
	2 VAGINAL DELIVERY BIRTHS	PREGNANCY, COMPLICATIONS	COMPLIC OF PREGNANCY/BIRTH	PRV	1996
329.005.00298	ALLERGIES {SEASONAL}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1988
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1996
329.005.00331	25% HEARING LOSS RIGHT EAR	HEARING LOSS	NERVOUS SYST/SENSE ORGAN DIS	CUR	1982
	ALLERGIES {CAT AND DOG HAIR, DUST, TREES}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1983
	RECURRENT EAR INFECTIONS	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	CUR	1982
	SINUS INFECTION	SINUSITIS, NOS	RESPIRATORY SYST DIS	CUR	1996
	TUBES PLACED IN RIGHT EAR X6	OPERATION, EAR	OPERATIONS	CUR	1982
329.005.00334	ABNORMAL LAB VALUES URINALYSIS +3 OCCULT BLOOD/RED	HEMATURIA	GENITOURINARY SYST DIS	CUR	1997
	ABNORMAL LAB VALUES URINALYSIS MODERATE BACTERIA/CLOUDY	URINARY TRACT INFECTION	GENITOURINARY SYST DIS	CUR	1997

CUR = Current, PRV = Past

311

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.005.00334	REPAIR OF LEFT FOOT - BONE REALIGNMENT	OPERATION, BONE/JOINT	OPERATIONS	CUR	1997
	BROKEN ARM	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1995
329.006.00042	ECG-SINUS ARRHYTHMIA (MILD)	ARRHYTHMIA	CIRCULATORY SYST	CUR	1995
	OBESITY	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1990
329.006.00259	FACIAL ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1994
	FATIGUE	MALaise AND FATIGUE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	NORMAL SINUS RHYTHM WITH SHORT PR ON EKG	CARDIOVAS FUNCTIONS/ECG, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	LOW THYROID FUNCTION	HYPOTHYROIDISM	ENDOCR/METAB/IMMUNITY DISORD	PRV	1996
329.007.00141	ANGINA	ANGINA PECTORIS	CIRCULATORY SYST	CUR	1995
	INSOMNIA	INSOMNIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	EUSTACHIAN TUBE PLACEMENT	OPERATION, EAR	OPERATIONS	PRV	1982
	HYPERTENSION	HYPERTENSION	CIRCULATORY SYST	PRV	1994
329.007.00267	HEADACHE{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	OBESE{MILDLY}	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1995
	POSITIVE DRUG SCREEN{CANNABINOIDS}	DRUG ABUSE	MENTAL DISORD	CUR	1996
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1981
329.007.00311	PROTEIN IN URINE	PROTEINURIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	BRONCHITIS	BRONCHITIS, OTHER	RESPIRATORY SYST DIS	PRV	1996

CUR = Current, PRV = Past

312

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.007.00311	CONCUSSION	INJURY, INTRACRANIAL	INJURY/POISONING	PRV	1994
	EUSTACHIAN TUBES LEFT EAR {FOR SEVERE, CHRONIC EAR INFECTION}	OPERATION, EAR	OPERATIONS	PRV	1984
	EUSTACHIAN TUBES RIGHT EAR {FOR SEVERE, CHRONIC EAR INFECTION}	OPERATION, EAR	OPERATIONS	PRV	1987
329.008.00158	GASTRIC REFLUX	ESOPHAGITIS	DIGESTIVE SYST	CUR	
	APPENDICITIS	APPENDICITIS	DIGESTIVE SYST	PRV	1989
329.008.00191	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	CUR	1995
329.009.00128	GENERALIZED ANXIETY DISORDER	NEUROSES	MENTAL DISORD	CUR	1994
	SEASONAL ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1993
	ATTENTION DEFICIT DISORDER	MENTAL STATUS, IMPAIRED	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1994
329.009.00129	BROKEN COLLAR BONE	FRACTURE, UPPER LIMB	INJURY/POISONING	PRV	1992
329.009.00135	DYSMENORRHEA{OCCASIONAL}	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1995
	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	HYPOTHYROID	HYPOTHYROIDISM	ENDOCR/METAB/IMMUNITY DISORD	CUR	1992
	MENSTRUAL CRAMPS{OCCASIONAL}	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1995
	PARTIAL THYROIDECTOMY	OPERATION, ENDOCR	OPERATIONS	PRV	1991

CUR = Current, PRV = Past

313

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00136	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1992
	SINUS CONGESTION	UPPER RESP DISORD, OTHER	RESPIRATORY SYST DIS	CUR	1995
	SPRAINED LEFT ANKLE	SPRAINS/STRAINS	INJURY/POISONING	PRV	1995
329.009.00174	ALLERGIES (SEASONAL)	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1994
	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1990
	MILD OBESITY	OBESITY	ENDOCR/METAB/IMMUNITY DISORD	CUR	1995
	TEMPOROMANDIBULAR JOINT SYNDROME	DENTOFACIAL ANOM	DIGESTIVE SYST	CUR	1995
329.009.00197	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	STOMACH PAIN	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.009.00198	ALLERGY TO CODEINE	ADVERSE EFF/ANALGESIC	EXT CAUSES OF INJURY/POISONING	CUR	1995
	HEADACHES{OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	OTITIS MEDIA BILATERAL{PROBABLE}	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	CUR	1995
	UPPER RESPIRATORY TRACT INFECTION (FLU)	INFLUENZA	RESPIRATORY SYST DIS	CUR	1994
	GRAVIDA 1, PARA 0, ABORTION {PREGNANCY}	PREGNANCY	FAMILY/PERSONAL HISTORY	PRV	1993
329.009.00200	ANEMIC	ANEMIA, OTHER	BLOOD/BLOOD FORMING ORGAN DIS	CUR	1996
	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994

CUR = Current, PRV = Past

314

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00200	{COMMON} COLD	NASOPHARYNGITIS, ACUTE	RESPIRATORY SYST DIS	PRV	1996
329.009.00202	HEADACHES {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1995
	SEASONAL ALLERGY	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1995
329.009.00237	ACNE	SKIN/SUBCUT DISORD, OTHER	SKIN/SUBCUTANEOUS TISSUE DIS	P&C	
	OCCASIONAL HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	P&C	
	SINUS BRADYCARDIA	BRADYCARDIA	CIRCULATORY SYST	P&C	1996
329.009.00238	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.009.00276	EARLY REPOLARIZATION {EKG}	CARDIOVAS FUNCTIONS/ECG, ABN	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
	HEADACHES (OCCASIONAL)	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
	STOMACH ACHES	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1997
329.009.00302	ABDOMINAL CYST-SURGERY	OPERATION, OTHER ABDOM	OPERATIONS	PRV	1990
	TENDONITIS	RHEUMATIC DISORD	MUSCULOSKEL/CONNECT TISSUE DIS	PRV	1996
329.009.00306	NON MALIGNANT LUMP REMOVED FROM (LEFT) BREAST	OPERATION, BREAST	OPERATIONS	PRV	1996
329.009.00312	ALLERGIES TO ERYTHROCIN	ADVERSE EFF/ANTIBIOTIC	EXT CAUSES OF INJURY/POISONING	CUR	
	OCCASIONAL HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	SINUS ALLERGIES	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1996

CUR = Current, PRV = Past

315

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.009.00312	STOMACH ULCER	ULCER, GASTRIC	DIGESTIVE SYST	CUR	1996
329.009.00327	HEADACHE {OCCASIONAL}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1994
	INSECT BITES	INJURY, SUPERFICIAL	INJURY/POISONING	CUR	1996
	MENSTRUAL CRAMPS	GENITAL FEMALE DISORD, OTHER	GENITOURINARY SYST DIS	CUR	1994
	SINUS ALLERGIES {CONGESTION}	RHINITIS, ALLERGIC	RESPIRATORY SYST DIS	CUR	1996
	STOMACHACHE {OCCASIONAL}	PAIN, ABDOMINO-PELVIC	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
329.009.00330	ATTENTION-DEFICIT HYPERACTIVITY DISORDER	CONDUCT DISORD	MENTAL DISORD	CUR	1996
	BROKEN EAR DRUM	EAR/MASTOID DISORD	NERVOUS SYST/SENSE ORGAN DIS	CUR	1996
	POSSIBLE VENTRICULAR HYPERTROPHY	CARDIOMEGALY	CIRCULATORY SYST	CUR	1996
	SINUS ARRHYTHMIA	ARRHYTHMIA	CIRCULATORY SYST	CUR	1996
	SINUS BRADYCARDIA	BRADYCARDIA	CIRCULATORY SYST	CUR	1996
329.010.00183	INCREASED CREATININE	CREATININE, INCREASED	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	INCREASED URINE NITROGEN	URINE, ABN, OTHER	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	ASTHMATIC REACTION{BRIEF}	ASTHMA	RESPIRATORY SYST DIS	PRV	1994
	SEIZURE{UNKNOWN ETIOLOGY 1X}	CONVULSIONS	SIGNS, SYMPTOMS, ILL-DEFINED CON	PRV	1989
329.010.00263	MONONUCLEOSIS	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1996
329.010.00277	HEADACHES{FREQUENT}	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	

CUR = Current, PRV = Past

316

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Patient  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.010.00277	PROTEINURIA	PROTEINURIA	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1996
329.010.00282	BRONCHITIS	BRONCHITIS, OTHER	RESPIRATORY SYST DIS	CUR	1996
	MENINGITIS	MENINGITIS	NERVOUS SYST/SENSE ORGAN DIS	PRV	1980
	TONSILLECTOMY	OPERATION, NOSE/MOUTH	OPERATIONS	PRV	1996
329.011.00164	LYME DISEASE	ARTHROPOD-BORNE DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1993
	MENINGITIS	MENINGITIS	NERVOUS SYST/SENSE ORGAN DIS	PRV	1993
329.011.00210	HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
329.011.00285	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	
	KNEE PROBLEMS{RIGHT}	JOINT DISORD, OTHER	MUSCULOSKEL/CONNECT TISSUE DIS	CUR	1995
	EPSTEIN BARR VIRUS	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1993
329.012.00027	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	CUR	1985
	OTITIS MEDIA	OTITIS MEDIA	NERVOUS SYST/SENSE ORGAN DIS	CUR	1995
	TENSION HEADACHES	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1993
329.012.00217	HEADACHE	HEADACHE	SIGNS, SYMPTOMS, ILL-DEFINED CON	CUR	1995
	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1995
	INJURY TO LEFT KNEE{PARAGLIDING}	TRAUMA/INJURIES, UNSPEC	INJURY/POISONING	PRV	1993
	LIGAMENT TEARS{LEFT FOOT, ANKLE}	SPRAINS/STRAINS	INJURY/POISONING	PRV	1995

CUR = Current, PRV = Past

317

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.7

Listing of Medical/Surgical History and Physical Examination  
by Treatment Group and Patient  
Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	VERBATIM TERM	PREFERRED TERM	DISEASE CLASSIFICATION (LEVEL 1)	STATUS	DIAGYR
329.012.00217	MONONUCLEOSIS{(2 EPISODES IN ONE YEAR)}	VIRUS/CHLAMYD DIS, OTHER	INFECTIOUS/PARASITIC DIS	PRV	1995
329.012.00218	ANXIETY	ANXIETY	MENTAL DISORD	CUR	1996
	ASTHMA	ASTHMA	RESPIRATORY SYST DIS	PRV	1986

CUR = Current, PRV = Past

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
BLOOD/BLOOD FORMING ORGAN DIS	ANEMIA, OTHER	ANEMIA	329.007.00265	CUR	1996
	ANEMIA, OTHER	ANEMIA	329.009.00196	CUR	1995
	LEUKOPENIA	DECREASED WHITE BLOOD CELL	329.001.00121	CUR	1995
	LEUKOPENIA	LOW WHITE BLOOD CELL COUNT	329.007.00145	CUR	1996
	MONOCYTOSIS	ELEVATED MONOCYTES	329.007.00145	CUR	1996
CIRCULATORY SYST	BRADYCARDIA	SINUS BRADYCARDIA {MARKED}	329.009.00329	CUR	1996
	CARDIOMEGALY	BIVENTRICULAR HYPERTROPHY	329.009.00328	CUR	1996
DIGESTIVE SYST	DYSPEPSIA	"ULCER-LIKE" SYMPTOMS (BURNING, INDIGESTION), NO ULCER	329.007.00309	CUR	1996
	HERNIA, ABDOMINAL	INGUINAL HERNIA	329.007.00142	PRV	1983
	PANCREATITIS	ACUTE PANCREATITIS	329.010.00278	PRV	1994
	STOMACH/DUODENUM DISORD	NERVOUS STOMACH	329.009.00130	CUR	1989
ENDOCR/METAB/IMMUNITY DISORD	OBESITY	OBESITY{MILD}	329.009.00196	CUR	1995
	OBESITY	OVERWEIGHT	329.003.00313	CUR	
	OBESITY	SLIGHTLY OBESE	329.001.00063	CUR	1994
	OVARIAN DYSFUNC	POLYCYSTIC OVARY	329.010.00278	CUR	1995
EXT CAUSES OF INJURY/POISONING	ADVERSE EFF ON AUTONOMIC NS	ALLERGIC TO SUDAFED	329.012.00220	CUR	1984
	ADVERSE EFF/ANALGESIC	ALLERGIES TO ASPIRIN	329.009.00196	CUR	1995
	ADVERSE EFF/ANTI-INFECT	ALLERGIES TO SULFA DRUGS	329.009.00196	CUR	1995

CUR = Current, PRV = Past

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
FAMILY/PERSONAL HISTORY	POSTPARTUM CARE	POSTPARTUM - NOT BREAST FEEDING	329.005.00109	CUR	1994
GENITOURINARY SYST DIS	AMENORRHEA	AMENORRHEA	329.004.00212	CUR	1996
	CYSTITIS	BLADDER INFECTIONS	329.012.00220	PRV	1986
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.007.00268	CUR	1995
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.007.00310	CUR	1996
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS{OCCASIONAL}	329.009.00196	CUR	1994
	GENITAL FEMALE DISORD, OTHER	PREMENSTRUAL TENSION(OCCASIONAL)	329.009.00133	CUR	1993
	HEMATURIA	OCCULT BLOOD IN URINE - PATIENT MENSTRUATING	329.005.00258	CUR	1996
INFECTIOUS/PARASITIC DIS	INFECTION, BACTERIAL	STREP THROAT	329.009.00133	PRV	1985
	INFECTION, BACTERIAL	STREP THROAT	329.009.00201	CUR	1996
	MYCOSES	TINEA PEDIS {BOTH FEET}	329.006.00261	CUR	1996
	TUBERCULOSIS	TUBERCULOSIS	329.003.00313	PRV	
	VIRAL DIS/EXANTHEM	CHICKEN POX	329.001.00121	PRV	1987
	VIRAL DIS/EXANTHEM	FEVER BLISTERS	329.001.00068	CUR	1990
	VIRUS/CHLAMYD DIS, OTHER	CAT SCRATCH FEVER	329.007.00142	PRV	1993
INJURY/POISONING	ALLERGY, NEC	ALLERGIES	329.008.00275	CUR	1994
	ALLERGY, NEC	ALLERGIES	329.010.00280	CUR	

CUR = Current, PRV = Past

320

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
INJURY/POISONING	ALLERGY, NEC	ALLERGIES{ENVIRONMENTAL}	329.004.00212	CUR	1995
	ALLERGY, NEC	ENVIRONMENTAL ALLERGIES	329.001.00206	CUR	
	ALLERGY, NEC	ENVIRONMENTAL ALLERGIES	329.005.00333	CUR	
	COMPLIC OF MED CARE	INFECTED {BIOPSY MARK RIGHT SUPRACLAVICULAR ARM}	329.001.00068	PRV	1991
	FRACTURE, LOWER LIMB	FRACTURE RIGHT LEG	329.012.00226	PRV	1988
	FRACTURE, UPPER LIMB	BROKEN ARM	329.005.00152	PRV	1985
	FRACTURE, UPPER LIMB	BROKEN LEFT ARM	329.007.00145	PRV	1991
	OPEN WOUND	FACIAL LACERATIONS{DOG BITE}	329.001.00205	PRV	1986
	OPEN WOUND	HEAD LACERATION	329.004.00214	PRV	1987
	SPRAINS/STRAINS	PAIN LEFT WRIST(POSSIBLE SPRAIN)	329.001.00063	CUR	1994
TOXIC EFFECTS, VENOM	ALLERGIES-BEE STING	329.002.00055	CUR	1987	
MENTAL DISORD	CONDUCT DISORD	ATTENTION DEFICIT HYPERACTIVE DISORDER	329.012.00220	CUR	1987
	CONDUCT DISORD	ATTENTION DEFICIT HYPERACTIVITY DISORDER	329.007.00318	PRV	1984
	CONDUCT DISORD	ATTENTION DEFICIT HYPERACTIVITY DISORDER	329.009.00204	CUR	1986
	DRUG ABUSE	CANNABIS USE	329.005.00002	CUR	1994
	NEUROSES	OBSESSIVE COMPULSIVE SYMPTOMS	329.012.00220	PRV	1994
	TICS	TOURETTES (TIC DISORDER).	329.012.00220	PRV	1987

CUR = Current, PRV = Past

321

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
MUSCULOSKEL/CONNECT TISSUE DIS	BACK PAIN	BACK PAIN	329.005.00151	CUR	1989
	BACK PAIN	BACKACHE	329.005.00336	PRV	1997
	BACK PAIN	BACKACHES	329.007.00294	CUR	1994
	BONE/CARTIL DISORD, OTHER	STRESS FRACTURE BACK	329.001.00072	PRV	1993
	DEFORMITY, ACQUIRED	SCOLIOSIS	329.007.00294	PRV	1995
	DEFORMITY, ACQUIRED	SCOLIOSIS	329.009.00170	CUR	1989
	MYALGIA	BILATERAL LEG PAIN:MUSCULAR ORIGIN	329.009.00170	CUR	1995
	OSTEOCHONDROPATHIES	OSGOOD SCHLATTER DISEASE	329.001.00065	PRV	1991
	PAIN, JOINT	JOINT PAIN - FLEXIBLE JOINTS	329.004.00214	CUR	1996
	PAIN, LIMB	KNEE PAIN {RIGHT-MILD AFTER RUNNING}	329.005.00299	CUR	1996
NERVOUS SYST/SENSE ORGAN DIS	MENINGITIS	MENINGITIS	329.009.00240	PRV	1984
	MIGRAINE	MIGRAINE HEADACHES {ACCORDING TO PATIENT}	329.002.00245	CUR	1995
OPERATIONS	OPERATION, BONE/JOINT	10 BONE FUSIONS IN BACK	329.007.00294	PRV	1995
	OPERATION, BONE/JOINT	ROD PLACEMENT {BACK}	329.007.00294	PRV	1995
	OPERATION, EAR	EUSTACHIAN TUBE {BILATERAL}	329.007.00318	PRV	1985
	OPERATION, EYE	SURGERY FOR STRABISMUS	329.012.00226	PRV	1983
	OPERATION, HERNIA REPAIR	SURGERY TO REPAIR A HERNIA	329.008.00157	PRV	1980
	OPERATION, LYMPH	LYMPH NODE BIOPSY (ENLARGED NODES)	329.001.00068	PRV	1991

CUR = Current, PRV = Past

322

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
OPERATIONS	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.007.00140	PRV	1989
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.007.00310	PRV	1994
	OPERATION, NOSE/MOUTH	TONSILLECTOMY AND ADENOIDECTOMY	329.005.00333	PRV	1990
	OPERATION, OTHER URINARY	URETERS BILATERALLY REEMBEDDED	329.004.00015	PRV	1990
	OPERATION, SKIN/SUBCUT	BIRTHMARK REMOVED	329.001.00121	PRV	1989
	OPERATION, SKIN/SUBCUT	CYST REMOVED FROM CHEST	329.001.00121	PRV	1981
	OPERATION, SKIN/SUBCUT	PLASTIC SURGERY FOR FACIAL SCARS	329.001.00205	PRV	1994
RESPIRATORY SYST DIS	ASTHMA	ASTHMA	329.003.00075	CUR	
	ASTHMA	ASTHMA	329.003.00087	PRV	1994
	ASTHMA	ASTHMA	329.005.00109	PRV	1979
	ASTHMA	ASTHMA	329.006.00038	CUR	1990
	ASTHMA	ASTHMA	329.008.00271	CUR	1984
	ASTHMA	ASTHMA	329.009.00196	CUR	1993
	ASTHMA	ASTHMA	329.011.00288	CUR	1987
	ASTHMA	ASTHMA ATTACK	329.010.00280	PRV	
	ASTHMA	ASTHMA {VERY MILD}	329.006.00261	CUR	1984
	EPIGLOTTITIS, ACUTE	EPIGLOTTITIS	329.008.00160	PRV	1990
	INFLUENZA	FLU SYMPTOMS	329.009.00235	PRV	1996
	NASOPHARYNGITIS, ACUTE	COLD {COMMON}	329.004.00214	CUR	1996
	PHARYNGITIS, ACUTE	SORE THROAT	329.007.00142	PRV	1995

CUR = Current, PRV = Past

323

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
RESPIRATORY SYST DIS	RHINITIS, ALLERGIC	ALLERGIES{CATS,POLLEN}	329.002.00105	CUR	1990
	RHINITIS, ALLERGIC	ALLERGY POLLEN	329.001.00063	CUR	1983
	RHINITIS, ALLERGIC	ALLERGY-CAT FUR(MILD)	329.002.00055	CUR	1987
	RHINITIS, ALLERGIC	HAYFEVER-LATE SPRING,SUMMER MONTHS ONLY	329.012.00222	CUR	1994
	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.002.00099	CUR	
	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.009.00324	CUR	
	SINUSITIS,NOS	SINUS INFECTION	329.009.00303	CUR	1996
	SINUSITIS,NOS	SINUS INFECTIONS	329.009.00133	CUR	1985
	UPPER RESP DISORD, OTHER	SINUS CONGESTION	329.001.00205	CUR	1984
	UPPER RESP DISORD, OTHER	SINUS CONGESTION	329.009.00324	CUR	1996
	UPPER RESP INFECT, ACUTE	UPPER RESPIRATORY TRACT INFECTION	329.009.00173	CUR	1995
SIGNS,SYMPTOMS,ILL-DEFINED CON	CARDIAC MURMURS	HEART MURMUR, GRADE 1, ASYMPTOMATIC	329.009.00131	PRV	1984
	CARDIOVAS FUNCTIONS/ECG, ABN	REPOLARIZATION ON ECG {EARLY}	329.009.00329	CUR	1996
	COMA AND STUPOR	UNCONSCIOUS AT AGE 1 - HIT HEAD IN FALL	329.009.00324	PRV	1984
	CONDITIONS, OTHER, ABN	BLEEDING ULCER {NOS}	329.005.00109	PRV	1993
	DISTURBANCE, SLEEP, UNSPEC	SLEEP DISTURBANCE	329.009.00240	CUR	1996
	DIZZINESS, POSTURAL	DIZZINESS UPON CHANGING POSITIONS	329.001.00065	CUR	1994
	HEADACHE	HEADACHE	329.007.00265	CUR	1996

CUR = Current, PRV = Past

324

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	HEADACHE	HEADACHE	329.009.00133	CUR	1993
	HEADACHE	HEADACHE	329.009.00173	CUR	1995
	HEADACHE	HEADACHE	329.009.00193	CUR	1995
	HEADACHE	HEADACHE	329.009.00201	CUR	1996
	HEADACHE	HEADACHES	329.001.00063	CUR	1990
	HEADACHE	HEADACHES	329.001.00065	CUR	1989
	HEADACHE	HEADACHES	329.001.00068	CUR	1992
	HEADACHE	HEADACHES	329.002.00055	CUR	1993
	HEADACHE	HEADACHES	329.002.00058	CUR	1994
	HEADACHE	HEADACHES	329.002.00105	CUR	1995
	HEADACHE	HEADACHES	329.003.00075	CUR	
	HEADACHE	HEADACHES	329.005.00151	CUR	1991
	HEADACHE	HEADACHES	329.005.00299	CUR	
	HEADACHE	HEADACHES	329.007.00294	CUR	1994
	HEADACHE	HEADACHES	329.008.00275	CUR	1995
	HEADACHE	HEADACHES	329.010.00182	CUR	1995
	HEADACHE	HEADACHES	329.010.00280	CUR	1996
	HEADACHE	HEADACHES (OCCASIONAL)	329.009.00240	CUR	1996
	HEADACHE	HEADACHES (OCCASIONAL)	329.009.00324	CUR	1996
	HEADACHE	HEADACHES {FREQUENT}	329.007.00309	CUR	1996
	HEADACHE	HEADACHES {FREQUENT}	329.007.00310	CUR	1995
	HEADACHE	HEADACHES {FRONTAL}	329.002.00319	CUR	1995

CUR = Current, PRV = Past

325

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	HEADACHE	HEADACHES {OCCASIONAL}	329.006.00260	CUR	1996
	HEADACHE	HEADACHES {OCCASIONAL}	329.009.00328	CUR	1994
	HEADACHE	HEADACHES {OCCASIONAL}	329.009.00329	CUR	1995
	HEADACHE	HEADACHES {RECURRENT}	329.002.00242	CUR	1995
	HEADACHE	HEADACHES-FREQUENT	329.006.00039	CUR	1992
	HEADACHE	HEADACHES{DAILY}	329.003.00081	CUR	1995
	HEADACHE	HEADACHES{OCCASIONAL}	329.007.00268	CUR	1994
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00196	CUR	1994
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00204	CUR	1994
	HEADACHE	HEADACHE{OCCASIONAL}	329.009.00303	CUR	1994
	HEADACHE	HEADACHE{OCCASIONAL}	329.009.00304	CUR	1995
	HEADACHE	MILD RECURRENT HEADACHES	329.012.00226	CUR	1993
	HEADACHE	OCCASIONAL HEADACHE	329.007.00142	CUR	1985
	HEADACHE	OCCASIONAL HEADACHE	329.009.00131	CUR	1995
	HEADACHE	OCCASIONAL HEADACHE	329.009.00138	CUR	1995
	HEADACHE	OCCASIONAL HEADACHE	329.009.00170	CUR	1994
	HEADACHE	OCCASIONAL HEADACHES	329.007.00140	CUR	1994
	HEADACHE	OCCASIONAL HEADACHES	329.009.00235	CUR	1996
	HEARTBURN	HEARTBURN	329.002.00105	CUR	1995
	INCONTINENCE, URINARY	BED-WETTING	329.012.00220	PRV	1986
	INCONTINENCE, URINARY	ENURESIS	329.004.00015	PRV	1990
	INSOMNIA	INSOMNIA	329.008.00275	CUR	1994

CUR = Current, PRV = Past

326

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	LYMPHADENOPATHY	MILD LYMPHADENOPATHY, LEFT ANTERIOR CERVICAL, PERSISTENT	329.007.00142	CUR	1995
	MENTAL STATUS, IMPAIRED	ATTENTION DEFICIT DISORDER	329.002.00058	PRV	1983
	NAUSEA	NAUSEA STOMACH UPSET	329.001.00068	CUR	1992
	NAUSEA	NAUSEA {CHRONIC}	329.007.00309	CUR	1995
	NAUSEA	STOMACH UPSET (NAUSEA)	329.001.00065	CUR	1994
	PAIN, ABDOMINO-PELVIC	ABDOMINAL PAIN	329.010.00278	CUR	1994
	PAIN, ABDOMINO-PELVIC	BURNING STOMACH	329.005.00112	CUR	1995
	PAIN, ABDOMINO-PELVIC	OCCASIONAL STOMACH ACHE	329.009.00138	CUR	1990
	PAIN, ABDOMINO-PELVIC	STOMACH ACHE	329.009.00173	CUR	1995
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.005.00119	CUR	1993
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES {OCCASIONAL}	329.009.00328	CUR	1994
	PROTEINURIA	PROTEIN IN URINE - PATIENT MENSTRUATING	329.005.00258	CUR	1996
	PROTEINURIA	PROTEINURIA	329.011.00288	CUR	1996
	PYREXIA	FEVER	329.009.00201	CUR	1996
	PYREXIA	FEVER OF UNKNOWN ORIGIN	329.009.00133	PRV	1993
	RASH/OTHER SKIN ERUPTION	RASH, PLANTAR SURFACE RIGHT FOOT	329.007.00294	CUR	1997
	TREMOR	HAND TREMORS	329.001.00065	CUR	1994
	WEIGHT GAIN	WEIGHT GAIN	329.007.00294	CUR	1997
	WEIGHT GAIN	WEIGHT GAIN	329.009.00204	PRV	1996

CUR = Current, PRV = Past

327

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SKIN/SUBCUTANEOUS TISSUE DIS	INFLAM SKIN/SUBCUT	ALLERGIES (SKIN)	329.012.00025	CUR	1995
	INFLAM SKIN/SUBCUT	ECZEMA	329.012.00231	CUR	1996
	LYMPHADENITIS, ACUTE	LYMPH NODE INFECTION{BILATERAL GROIN NODES}	329.007.00268	PRV	1991
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.001.00063	CUR	1994
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.001.00068	CUR	1993
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.005.00257	CUR	1995
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.006.00260	CUR	1996
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.009.00235	CUR	1996
	SKIN/SUBCUT DISORD, OTHER	DYSHYDROSIS {MILD ON HAND AND PENIS}	329.006.00261	CUR	1996
	SKIN/SUBCUT DISORD, OTHER	VESICULAR DYSHIDROSIS	329.007.00140	CUR	1995

CUR = Current, PRV = Past

328

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
ANOMALIES	CONG ANOM, GU	HYOSPADIAS {MALE}	329.002.00050	PRV	1978
	CONG ANOM, GU	LEFT URETERAL DUPLICATION	329.002.00050	PRV	1978
	CONG ANOM, MUSCULOSKEL	FOOT TURNED AT BIRTH	329.001.00061	PRV	1977
	CONG ANOM, MUSCULOSKEL	PECTUS EXCAVATUM	329.011.00284	PRV	1978
BLOOD/BLOOD FORMING ORGAN DIS	LEUCOCYTOSIS	INCREASED NEUTROPHIL SEGS	329.005.00153	CUR	1996
	LEUKOPENIA	LOW NEUTROPHILS	329.011.00284	CUR	1996
	LEUKOPENIA	LOW WHITE BLOOD CELLS	329.011.00284	CUR	1996
	LEUKOPENIA	WBC DECREASE	329.010.00279	CUR	1996
	LYMPHOCYTOSIS	INCREASED LYMPHOCYTES	329.005.00153	CUR	1996
	LYMPHOPENIA	DECREASED LYMPHOCYTES	329.005.00256	CUR	1996
CIRCULATORY SYST	ARRHYTHMIA	SINUS ARRHYTHMIA	329.009.00239	CUR	1996
	BRADYCARDIA	SINUS BRADYCARDIA	329.009.00239	CUR	1996
COMPLIC OF PREGNANCY/BIRTH	PREGNANCY, COMPLICATIONS	ABORTION	329.005.00113	PRV	1994
	PREGNANCY, COMPLICATIONS	MISCARRIAGE	329.002.00056	PRV	1994
	PREGNANCY, COMPLICATIONS	{CHILDBIRTH}	329.009.00171	PRV	1994
DIGESTIVE SYST	DENTOFACIAL ANOM	TEMPOROMANDIBULAR JOINT PAIN	329.008.00273	CUR	1996
	DENTOFACIAL ANOM	TEMPOROMANDIBULAR JOINT SYNDROME	329.011.00163	CUR	1994
	DIGESTIVE DISORD, OTHER	IRRITABLE BOWEL SYNDROME	329.003.00090	CUR	1987
	DYSPEPSIA	NAUSEA {STOMACH UPSET}	329.009.00325	CUR	1995

CUR = Current, PRV = Past

329

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
DIGESTIVE SYST	DYSPEPSIA	UPSET STOMACH	329.007.00269	CUR	1996
	ENTERITIS/COLITIS	COLITIS	329.008.00187	CUR	1981
	LIVER DISORD	FATTY INFILTRATION OF THE LIVER {CLINICALLY NORMAL}	329.012.00223	PRV	1996
	STOMACH/DUODENUM DISORD	STOMACH PROBLEMS	329.002.00057	CUR	1994
ENDOCR/METAB/IMMUNITY DISORD	HYPOGLYCEMIA	INTERMITTENT GLUCOSE (DECREASED)	329.002.00050	CUR	1995
	OBESITY	MILD OBESITY	329.007.00143	CUR	1994
EXT CAUSES OF INJURY/POISONING	ADVERSE EFF/ANTIBIOTIC	ALLERGY TO CECLOR	329.009.00199	CUR	1995
	ADVERSE EFF/ANTIBIOTIC	DRUG ALLERGY - PENICILLIN	329.009.00239	P&C	1995
	ADVERSE EFF/OTHER DRUG	ALLERGY TO IODINE	329.009.00171	CUR	1994
	ADVERSE EFF/PSYCHOTROPICS	ALLERGIC TO CAFFEINE	329.001.00070	CUR	1992
	RAPE	SEXUAL ASSAULT{STATUS POST,NO POST-TRAUMATIC STRESS DISORDER SYNDROME}	329.009.00171	PRV	1992
	SUICIDE	SUICIDE ATTEMPT{NOT IN CURRENT EPISODE}	329.009.00171	PRV	1994
FAMILY/PERSONAL HISTORY	PREGNANCY	PREGNANCY	329.002.00056	PRV	1994
	PREGNANCY	PREGNANCY	329.009.00171	PRV	1994
GENITOURINARY SYST DIS	GENITAL FEMALE DISORD, OTHER	DYSMENORRHEA	329.003.00249	CUR	1991
	GENITAL FEMALE DISORD, OTHER	DYSMENORRHEA	329.003.00289	CUR	1993

CUR = Current, PRV = Past

330

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
GENITOURINARY SYST DIS	GENITAL FEMALE DISORD, OTHER	HEAVY CRAMPS DUE TO MENSES	329.002.00244	P&C	1990
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.003.00076	CUR	
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.005.00335	CUR	1997
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.007.00146	CUR	1996
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00134	CUR	1993
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00195	CUR	1994
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00236	CUR	1996
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00325	CUR	1995
	GENITAL FEMALE DISORD, OTHER	OVARIAN CYST	329.006.00040	CUR	1994
	GENITAL FEMALE DISORD, OTHER	QUESTIONABLE OVARIAN CYST	329.005.00007	CUR	1994
	GYNECOMASTIA	GYNECOMASTIA	329.005.00118	CUR	
	KIDNEY DISORD	RIGHT VESICoureTERAL REFLUX	329.002.00050	PRV	1978
	KIDNEY INFECT	PYELONEPHRITIS	329.012.00223	PRV	1995
	URINARY TRACT INFECTION	URINARY TRACT INFECTION	329.005.00255	CUR	1996
	URINARY TRACT INFECTION	URINARY TRACT INFECTION	329.007.00143	PRV	1994
	URINARY TRACT INFECTION	URINARY TRACT INFECTION'S {FREQUENT}	329.012.00223	PRV	1984

CUR = Current, PRV = Past

331

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
INFECTIOUS/PARASITIC DIS	BACT DIS, OTHER	PSEUDOMONAS INFECTION	329.011.00284	PRV	1988
	INFECTION, BACTERIAL	REPEATED STREP THROAT	329.001.00061	PRV	1978
	INFECTION, BACTERIAL	STREP THROAT	329.007.00270	CUR	1996
	MYCOSES	DERMATOLOGICAL FUNGUS	329.009.00134	CUR	1995
	MYCOSES	RINGWORM	329.007.00270	CUR	1996
	VIRAL DIS/EXANTHEM	CHICKEN POX	329.010.00281	PRV	1987
	VIRUS/CHLAMYD DIS, OTHER	MONONUCLEOSIS	329.009.00239	PRV	1995
	VIRUS/CHLAMYD DIS, OTHER	STATUS POST MONONUCLEOSIS	329.005.00006	PRV	1994
VIRUS/CHLAMYD DIS, OTHER	VAGINAL WARTS	329.008.00187	CUR	1995	
INJURY/POISONING	ALLERGIC REACTION, FOOD	ALLERGIC TO CHOCOLATE	329.001.00070	CUR	1992
	ALLERGIC REACTION, FOOD	ALLERGIES TO MILK	329.009.00194	CUR	1993
	ALLERGIC REACTION, FOOD	FOOD ALLERGIES {MILK PRODUCTS}	329.007.00270	CUR	1985
	ALLERGY, NEC	ALLERGIES	329.006.00040	CUR	1985
	ALLERGY, NEC	ALLERGIES	329.012.00223	CUR	1996
	ALLERGY, NEC	ALLERGIES {ENVIRONMENTAL}	329.011.00209	CUR	1996
	ALLERGY, NEC	ENVIRONMENTAL ALLERGIES	329.005.00003	CUR	1988
	ALLERGY, NEC	ENVIRONMENTAL ALLERGIES	329.005.00255	CUR	
	COMPLIC OF MED CARE	JAUNDICE DUE TO ABO INCOMPATIBILTY {NOS}	329.010.00281	PRV	1983
	CONTUSION	BRUISED FOOT	329.001.00070	PRV	1990
CONTUSION	BRUISED HAND	329.001.00070	PRV	1993	

CUR = Current, PRV = Past

332

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
INJURY/POISONING	FRACTURE, LOWER LIMB	BROKEN LEFT FEMUR{FELL OUT OF TREE}	329.007.00270	PRV	1994
	FRACTURE, UPPER LIMB	BROKEN LEFT ARM{X2}	329.009.00301	PRV	1988
	FRACTURE, UPPER LIMB	BROKEN RIGHT ARM	329.009.00301	PRV	1989
	FRACTURE, UPPER LIMB	FRACTURED RIGHT ARM	329.007.00139	CUR	1995
	FRACTURE, UPPER LIMB	RADIAL FRACTURE	329.012.00223	PRV	1994
	INJURY, INTRACRANIAL	CONCUSSION	329.002.00057	PRV	1985
	SPRAINS/STRAINS	SPRAINED ANKLE	329.001.00070	PRV	1992
	SPRAINS/STRAINS	SPRAINED ANKLE	329.003.00073	CUR	1995
	SPRAINS/STRAINS	SPRAINED ANKLE	329.003.00076	PRV	1994
	SPRAINS/STRAINS	SPRAINED ARM MUSCLES	329.009.00134	PRV	1995
SPRAINS/STRAINS	SPRAINED FOOT	329.001.00070	PRV	1990	
MENTAL DISORD	CONDUCT DISORD	ATTENTION DEFICIT HYPERACTIVITY DISORDER	329.008.00192	PRV	1996
	DEPRESSION	DEPRESSION	329.002.00100	CUR	1995
	DEPRESSION	STATUS POST HOSPITALIZATION FOR DEPRESSION	329.007.00143	PRV	1994
	PSYCHOGENIC PHYSIOL DYSFUNC	ENCOPRETIC	329.009.00262	CUR	1993
	STRESS REACTION	SEPARATION ANXIETY	329.009.00127	CUR	1995
	TOBACCO USE	CIGARETTE SMOKER	329.003.00249	CUR	
MUSCULOSKEL/CONNECT TISSUE DIS	MYALGIA	MUSCULAR NECK PAIN	329.009.00199	CUR	1995

CUR = Current, PRV = Past

333

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
MUSCULOSKEL/CONNECT TISSUE DIS	MYALGIA	MYALGIA{UNSPECIFIED}	329.009.00194	CUR	1995
	OSTEOCHONDROPATHIES	SCHUEERMANN'S KYPHOSIS	329.002.00057	CUR	1994
	OSTEOCHONDROPATHIES	SEVER'S DISEASE	329.007.00269	PRV	1994
	PAIN, JOINT	JOINT PAIN{RIGHT WRIST}	329.007.00146	CUR	1995
	SWELLING, LIMB	SWELLING{LEFT CALF}	329.007.00146	CUR	1995
NEOPLASMS	NEOPLASMS BENIGN	MOLE LEFT KNEE-RAISED	329.001.00066	CUR	1994
NERVOUS SYST/SENSE ORGAN DIS	EYE DISORD, OTHER	EYE INFECTION (LEFT AND RIGHT EYE)	329.009.00262	CUR	1997
	EYE DISORD, OTHER	STRABISMUS	329.005.00255	PRV	
	HEARING LOSS	MILD HEARING LOSS	329.005.00117	PRV	1979
	MENINGITIS	SPINAL MENINGITIS	329.007.00308	PRV	1982
	MIGRAINE	CHILDHOOD MIGRAINES	329.002.00057	PRV	1984
	MIGRAINE	MIGRAINE HEADACHES	329.011.00163	CUR	1989
	MIGRAINE	MIGRAINES	329.009.00239	CUR	1991
	OTITIS MEDIA	CHRONIC EAR INFECTIONS	329.009.00262	PRV	1986
	OTITIS MEDIA	EAR INFECTION	329.005.00003	CUR	1994
	OTITIS MEDIA	EAR INFECTIONS	329.001.00070	PRV	1983
	OTITIS MEDIA	EAR INFECTIONS	329.012.00219	PRV	1985
	OTITIS MEDIA	HISTORY OF CHRONIC OTITIS MEDIA	329.005.00117	PRV	1979
	VISUAL DISTURB	GLASSES FOR DISTANCE SINCE GRADE 4	329.003.00076	PRV	1988

CUR = Current, PRV = Past

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
NERVOUS SYST/SENSE ORGAN DIS	VISUAL DISTURB	NEAR-SIGHTED	329.003.00249	CUR	
	VISUAL DISTURB	NEARSIGHTED	329.003.00290	CUR	
OPERATIONS	OPERATION, BONE/JOINT	STATUS POST HIP SURGERY	329.005.00117	PRV	1989
	OPERATION, EAR	BILATERAL TUBE PLACEMENT IN EARS	329.010.00281	PRV	1984
	OPERATION, EAR	TUBES IN EARS	329.002.00057	PRV	1983
	OPERATION, EAR	TUBES IN EARS	329.009.00262	PRV	1986
	OPERATION, EYE	CORRECTIVE SURGERY (BOTH EYES) FOR STRABISMUS	329.011.00163	PRV	1985
	OPERATION, HERNIA REPAIR	BILATERAL HERNIA REPAIR	329.007.00269	PRV	1980
	OPERATION, HERNIA REPAIR	HERNIA OPERATION	329.002.00057	PRV	1985
	OPERATION, HERNIA REPAIR	HERNIA REPAIR	329.001.00122	PRV	1988
	OPERATION, MUSCLE/TENDON	ANKLE PAIN{SECONDARY TO SURGICAL CORRECTION RIGHT FOOT (CLUB) }	329.009.00194	CUR	1984
	OPERATION, NOSE/MOUTH	ADENOIDECTOMY	329.011.00208	PRV	1989
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.001.00061	PRV	1989
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.002.00057	PRV	1983
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.011.00208	PRV	1989
	OPERATION, NOSE/MOUTH	TONSILLECTOMY AND ADENOIDECTOMY	329.003.00290	PRV	1994
	OPERATION, SKIN/SUBCUT	MOLE EXCISED BELOW UMBILICUS/BENIGN	329.001.00066	PRV	1984
OPERATION, SKIN/SUBCUT	SUTURES IN CHIN	329.001.00066	PRV	1980	

CUR = Current, PRV = Past

335

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
OPERATIONS	OPERATION, SOFT TISSUE	REMOVAL OF BAKER'S CYST FROM RIGHT LEG	329.010.00281	PRV	1989
PERINATAL COND	CONDITIONS, PERINATAL	NECROTIZING ENTEROCOLITIS AT BIRTH-NO COMPLICATIONS	329.008.00161	PRV	1978
	CONDITIONS, PERINATAL	RESPIRATORY DIFFICULTIES AT BIRTH	329.001.00061	PRV	1977
PROCEDURES	THERAPY, REHAB	ACHILLES TENDON CASTED TIMES 6 WEEKS	329.007.00269	PRV	1994
	THERAPY, REHAB	FOOT CASTED	329.001.00061	PRV	1977
RESPIRATORY SYST DIS	ASTHMA	ASTHMA	329.003.00093	CUR	1989
	ASTHMA	ASTHMA	329.003.00317	CUR	
	ASTHMA	ASTHMA	329.005.00110	PRV	1984
	ASTHMA	ASTHMA	329.005.00113	CUR	1985
	ASTHMA	ASTHMA	329.005.00255	CUR	1986
	ASTHMA	ASTHMA	329.009.00203	CUR	1990
	ASTHMA	ASTHMA	329.009.00301	CUR	1983
	ASTHMA	ASTHMA	329.009.00325	CUR	1990
	ASTHMA	ASTHMA	329.011.00286	CUR	1990
	ASTHMA	ASTHMA	329.012.00230	PRV	1993
	ASTHMA	ASTHMA - NO PROBLEMS FOR 2 YRS	329.009.00264	PRV	1991
	ASTHMA	ASTHMA ATTACKS{HOSPITALIZED}	329.009.00301	PRV	1990

CUR = Current, PRV = Past

336

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
RESPIRATORY SYST DIS	ASTHMA	ASTHMA {AS YOUNG CHILD}	329.003.00289	PRV	1981
	ASTHMA	STRESS INDUCED ASTHMA	329.011.00163	CUR	1994
	INFLUENZA	FLU	329.005.00295	CUR	1996
	LARYNGITIS/TRACH, ACUTE	CROUP	329.011.00284	PRV	1979
	NASOPHARYNGITIS, ACUTE	COLD SYMPTOMS	329.007.00143	CUR	1995
	NASOPHARYNGITIS, ACUTE	COLD SYMPTOMS	329.007.00146	CUR	1996
	NASOPHARYNGITIS, ACUTE	COLD SYMPTOMS	329.009.00326	PRV	1996
	NASOPHARYNGITIS, ACUTE	COLD {COMMON}	329.005.00153	CUR	1996
	NASOPHARYNGITIS, ACUTE	COLD {COMMON}	329.005.00295	CUR	1996
	PHARYNGITIS, ACUTE	PHARYNGITIS	329.003.00314	PRV	1996
	PHARYNGITIS, ACUTE	SORE THROATS {FREQUENT}	329.003.00290	PRV	1994
	RESP DIS, OTHER	BRONCHOSPASM	329.012.00223	CUR	1996
	RHINITIS, ALLERGIC	ALLERGIC RHINITIS	329.003.00317	CUR	
	RHINITIS, ALLERGIC	ALLERGIC TO MOLD	329.001.00070	CUR	1992
	RHINITIS, ALLERGIC	ALLERGIES {TO POLLEN, TREES, DUST}	329.003.00289	CUR	
	RHINITIS, ALLERGIC	HAY FEVER	329.005.00009	PRV	1984
	RHINITIS, ALLERGIC	HISTORY OF ENVIRONMENTAL ALLERGIES-DUST	329.005.00006	PRV	
	RHINITIS, ALLERGIC	HISTORY OF ENVIRONMENTAL ALLERGIES-POLLEN	329.005.00006	PRV	
	RHINITIS, ALLERGIC	RECURRENT SINUSITIS {SEASONAL ALLERGIES}	329.007.00269	CUR	1996

CUR = Current, PRV = Past

337

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
RESPIRATORY SYST DIS	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.007.00146	CUR	1983
	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.007.00307	CUR	1993
	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.009.00195	CUR	1995
	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.009.00203	CUR	1994
	SINUSITIS, OTHER	REPEATED SINUS INFECTIONS ABOUT ONE TIME PER MONTH	329.001.00061	CUR	1989
	SINUSITIS,NOS	SINUS INFECTIONS	329.001.00070	PRV	1991
	SINUSITIS,NOS	SINUSITIS	329.007.00307	PRV	1995
	SINUSITIS,NOS	SINUSITIS	329.011.00286	CUR	
	TONSILLITIS, ACUTE	SORE THROAT-TONSILLITIS	329.002.00243	CUR	1996
	TONSILS/ADENOIDS DIS	HISTORY OF RECURRENT TONSILLITIS	329.005.00006	PRV	
SIGNS, SYMPTOMS, ILL-DEFINED CON	BLOOD PRESSURE, ELEVATED	HISTORY OF HIGH AVERAGE/BORDERLINE HIGH BLOOD PRESSURE	329.012.00223	PRV	1995
	CARDIAC MURMURS	HISTORY FUNCTIONAL HEART MURMUR	329.003.00076	PRV	
	CARDIAC MURMURS	HISTORY OF HEART MURMUR	329.005.00003	PRV	
	CARDIOVAS FUNCTIONS/ECG, ABN	LEFT AXIS DEVIATION	329.009.00203	CUR	1996
	CARDIOVAS FUNCTIONS/ECG, ABN	RIGHTWARD AXIS ON ELECTROCARDIOGRAM	329.006.00041	CUR	1995
	DIARRHEA	DIARRHEA	329.005.00295	CUR	1996
	HEADACHE	HEADACHE	329.005.00009	CUR	1994
HEADACHE	HEADACHE {OCCASIONAL}	329.009.00325	CUR	1990	

CUR = Current, PRV = Past

338

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	HEADACHE	HEADACHES	329.001.00061	CUR	1993
	HEADACHE	HEADACHES	329.001.00066	CUR	1992
	HEADACHE	HEADACHES	329.001.00070	CUR	1991
	HEADACHE	HEADACHES	329.002.00243	CUR	1994
	HEADACHE	HEADACHES	329.002.00321	CUR	1995
	HEADACHE	HEADACHES	329.003.00093	CUR	1990
	HEADACHE	HEADACHES	329.003.00289	CUR	
	HEADACHE	HEADACHES	329.005.00118	CUR	1995
	HEADACHE	HEADACHES	329.005.00295	CUR	1996
	HEADACHE	HEADACHES	329.008.00272	PRV	1996
	HEADACHE	HEADACHES	329.009.00195	CUR	1991
	HEADACHE	HEADACHES	329.009.00199	CUR	1995
	HEADACHE	HEADACHES	329.009.00236	CUR	1996
	HEADACHE	HEADACHES	329.009.00264	CUR	1994
	HEADACHE	HEADACHES	329.011.00208	CUR	1993
	HEADACHE	HEADACHES	329.011.00209	CUR	1996
	HEADACHE	HEADACHES	329.011.00286	CUR	
	HEADACHE	HEADACHES	329.012.00219	CUR	1996
	HEADACHE	HEADACHES {FREQUENT}	329.012.00223	CUR	1994
	HEADACHE	HEADACHES {MODERATE}	329.012.00221	CUR	1989
	HEADACHE	HEADACHES (DAILY)	329.002.00103	CUR	1995
	HEADACHE	HEADACHES (OCCASIONAL)	329.009.00132	CUR	1990

CUR = Current, PRV = Past

339

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	HEADACHE	HEADACHES{OCCASIONAL}	329.007.00270	CUR	1993
	HEADACHE	HEADACHES{OCCASIONAL}	329.007.00307	CUR	1992
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00301	CUR	1995
	HEADACHE	HEADACHE{OCCASIONAL}	329.007.00146	CUR	1994
	HEADACHE	HEADACHE{OCCASIONAL}	329.007.00269	CUR	1995
	HEADACHE	HEADACHE{OCCASIONAL}	329.009.00194	CUR	1995
	HEADACHE	OCCASIONAL HEADACHE	329.009.00172	CUR	1994
	HEADACHE	OCCASIONAL HEADACHES	329.002.00057	CUR	1994
	HEADACHE	OCCASIONAL HEADACHES	329.002.00100	CUR	1995
	HEADACHE	OCCASIONAL HEADACHES	329.009.00262	CUR	1997
	HEADACHE	OCCASIONAL MILD HEADACHES	329.008.00187	CUR	1995
	HEARTBURN	HEARTBURN	329.002.00057	CUR	1994
	HYPERHIDROSIS	HEAVY PERSPIRATION	329.001.00122	CUR	1994
	HYPERHIDROSIS	SWEATING AT BROW	329.002.00100	CUR	1994
	INSOMNIA	INITIAL INSOMNIA	329.009.00127	CUR	1995
	INSOMNIA	INSOMNIA	329.001.00061	CUR	
	INSOMNIA	INSOMNIA	329.007.00307	CUR	1996
	LYMPHADENOPATHY	ENLARGED LYMPH NODES	329.001.00070	CUR	1995
	MALaise AND FATIGUE	LOW ENERGY	329.004.00215	CUR	1996
	NAUSEA	NAUSEA DUE TO MENSES	329.002.00244	P&C	1990
	NERVOUSNESS	SHAKINESS	329.002.00243	CUR	1994
	PAIN, ABDOMINO-PELVIC	OCCASIONAL STOMACH ACHES	329.009.00134	CUR	1993

CUR = Current, PRV = Past

340

CONFIDENTIAL

BRL-029060-329-  
individual-data



Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	PAIN, ABDOMINO-PELVIC	STOMACH ACHE	329.009.00172	CUR	1995
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.001.00066	CUR	1992
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.009.00236	CUR	1996
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.009.00262	CUR	1997
	PAIN, GENERAL	BODY ACHES	329.005.00295	CUR	1996
	PROTEINURIA	TRACE PROTEIN IN URINE	329.005.00153	CUR	1996
	PROTEINURIA	URINE {1+ PROTEIN}	329.007.00308	CUR	1996
	SWELLING, MASS, LOCALIZED	BENIGN LUMP LEFT FOOT	329.012.00223	CUR	1995
	THYROID FUNCTION, ABN	THYROID-STIMULATING HORMONE DECREASE	329.010.00279	CUR	1996
	TREMOR	HAND TREMOR	329.002.00100	CUR	1994
WEIGHT LOSS	WEIGHT LOSS {52LBS. - PLANNED}	329.009.00171	PRV	1995	
SKIN/SUBCUTANEOUS TISSUE DIS	CELLULITIS/ABSCESS	RIGHT FOOT INFECTION {TOENAILS}	329.001.00122	PRV	1985
	SCARRING	SCARS LEFT AND RIGHT FOREARM	329.003.00249	PRV	
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.001.00122	CUR	1994
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.002.00050	CUR	1991
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.002.00104	CUR	1994
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.004.00013	CUR	1994
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.005.00153	CUR	1995
SKIN/SUBCUT DISORD, OTHER	MILD ACNE	329.001.00066	CUR	1994	

CUR = Current, PRV = Past

341

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
ANOMALIES	CONG ANOM, MUSCULOSKEL	DISLOCATED RIGHT HIP AT BIRTH	329.005.00010	PRV	1978
	CONGEN ANOM, HEAD/NECK	RUPTURED RIGHT EAR DRUM AT BIRTH	329.005.00010	PRV	1978
BLOOD/BLOOD FORMING ORGAN DIS	ANEMIA, OTHER	ANEMIA	329.003.00252	CUR	
	ANEMIA, OTHER	ANEMIC	329.009.00200	CUR	1996
CIRCULATORY SYST	ANGINA PECTORIS	ANGINA	329.007.00141	CUR	1995
	ARRHYTHMIA	ECG-SINUS ARRHYTHMIA (MILD)	329.006.00042	CUR	1995
	ARRHYTHMIA	SINUS ARRHYTHMIA	329.009.00330	CUR	1996
	BRADYCARDIA	SINUS BRADYCARDIA	329.009.00237	P&C	1996
	BRADYCARDIA	SINUS BRADYCARDIA	329.009.00330	CUR	1996
	CARDIOMEGALY	POSSIBLE VENTRICULAR HYPERTROPHY	329.009.00330	CUR	1996
	EXTRASYSTOLES, ATRIAL	SINUS RHYTHM ALTERNATING WITH ECTOPIC ATRIAL RHYTHM	329.002.00241	CUR	1996
	HYPERTENSION	HYPERTENSION	329.007.00141	PRV	1994
	MITRAL VALVE DISORD	HISTORY OF MITRAL VALVE PROLAPSE-NO FUNCTIONAL IMPAIRMENT	329.002.00059	CUR	1987
COMPLIC OF PREGNANCY/BIRTH	PREGNANCY, COMPLICATIONS	2 VAGINAL DELIVERY BIRTHS	329.005.00293	PRV	1996
DIGESTIVE SYST	APPENDICITIS	APPENDICITIS	329.008.00158	PRV	1989
	APPENDICITIS	STATUS POST ACUTE APPENDICITIS	329.003.00074	PRV	1994

CUR = Current, PRV = Past

342

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
DIGESTIVE SYST	DENTOFACIAL ANOM	TEMPOROMANDIBULAR JOINT SYNDROME	329.009.00174	CUR	1995
	DYSPEPSIA	EPIGASTRIC DISTRESS	329.002.00107	CUR	1995
	ESOPHAGITIS	GASTRIC REFLUX	329.008.00158	CUR	
	ULCER, GASTRIC	STOMACH ULCER	329.009.00312	CUR	1996
ENDOCR/METAB/IMMUNITY DISORD	CHOLEST/TRIGLYCERIDE, ELEVATED	ELEVATED CHOLESTEROL	329.002.00323	PRV	
	HYPOTHYROIDISM	HYPOTHYROID	329.009.00135	CUR	1992
	HYPOTHYROIDISM	LOW THYROID FUNCTION	329.006.00259	PRV	1996
	OBESITY	MILD OBESITY	329.009.00174	CUR	1995
	OBESITY	OBESE{MILDLY}	329.007.00267	CUR	1995
	OBESITY	OBESITY	329.001.00207	CUR	1995
	OBESITY	OBESITY	329.003.00085	CUR	1988
	OBESITY	OBESITY	329.006.00042	CUR	1990
EXT CAUSES OF INJURY/POISONING	ADVERSE EFF/ANALGESIC	ALLERGY TO CODEINE	329.009.00198	CUR	1995
	ADVERSE EFF/ANTI-INFECT	ALLERGIC TO SULFA DRUGS	329.003.00252	CUR	
	ADVERSE EFF/ANTIBIOTIC	ALLERGIES TO ERYTHROCIN	329.009.00312	CUR	
	ADVERSE EFF/ANTIBIOTIC	ALLERGIES {TO PENICILLIN}	329.002.00241	CUR	1991
FAMILY/PERSONAL HISTORY	ALCOHOL INGESTION, OTHER	{PAST} ALCOHOL USE	329.002.00246	PRV	1994
	PREGNANCY	GRAVIDA 1, PARA 0, ABORTION {PREGNANCY}	329.009.00198	PRV	1993

CUR = Current, PRV = Past

343

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
GENITOURINARY SYST DIS	GENITAL FEMALE DISORD, OTHER	DYSMENORRHEA{OCCASIONAL}	329.009.00135	CUR	1995
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.001.00123	CUR	1992
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.005.00298	CUR	1996
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00136	CUR	1992
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00202	CUR	1995
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS	329.009.00327	CUR	1994
	GENITAL FEMALE DISORD, OTHER	MENSTRUAL CRAMPS{OCCASIONAL}	329.009.00135	CUR	1995
	GENITAL FEMALE DISORD, OTHER	MISSED MENSES	329.002.00107	CUR	1996
	HEMATURIA	ABNORMAL LAB VALUES URINALYSIS +3 OCCULT BLOOD/RED	329.005.00334	CUR	1997
	HEMATURIA	RBC IN URINE POST PARTUM	329.005.00293	CUR	1997
	URINARY TRACT INFECTION	ABNORMAL LAB VALUES URINALYSIS MODERATE BACTERIA/CLOUDY	329.005.00334	CUR	1997
	VAGINITIS	BACTERIAL VAGINAL RASH	329.001.00123	CUR	1995
	INFECTIOUS/PARASITIC DIS	ARTHROPOD-BORNE DIS, OTHER	LYME DISEASE	329.002.00320	PRV
ARTHROPOD-BORNE DIS, OTHER		LYME DISEASE	329.011.00164	PRV	1993
INFECT/PARASIT DIS, OTHER		TOXOPLASMOSIS{RIGHT EYE}	329.005.00012	PRV	1994

CUR = Current, PRV = Past

344

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
INFECTIOUS/PARASITIC DIS	VIRUS/CHLAMYD DIS, OTHER	EPSTEIN BARR VIRUS	329.011.00285	PRV	1993
	VIRUS/CHLAMYD DIS, OTHER	MONONUCLEOSIS	329.010.00263	PRV	1996
	VIRUS/CHLAMYD DIS, OTHER	MONONUCLEOSIS{(2 EPISODES IN ONE YEAR)}	329.012.00217	PRV	1995
INJURY/POISONING	FRACTURE, LOWER LIMB	BROKEN ANKLE	329.001.00123	PRV	1990
	FRACTURE, LOWER LIMB	FRACTURED LEFT FEMUR	329.002.00320	PRV	1990
	FRACTURE, LOWER LIMB	FRACTURED RIGHT TIBIA	329.002.00320	PRV	1990
	FRACTURE, SKULL	FRACTURED SKULL	329.002.00320	PRV	1990
	FRACTURE, UPPER LIMB	BROKEN ARM	329.001.00064	PRV	1994
	FRACTURE, UPPER LIMB	BROKEN ARM	329.005.00334	PRV	1995
	FRACTURE, UPPER LIMB	BROKEN COLLAR BONE	329.009.00129	PRV	1992
	FRACTURE, UPPER LIMB	BROKEN RIGHT WRIST	329.001.00064	PRV	1994
	FRACTURE, UPPER LIMB	BROKEN WRIST	329.001.00123	PRV	1988
	INJURY, INTRACRANIAL	CONCUSSION	329.007.00311	PRV	1994
	INJURY, INTRACRANIAL	SUBDURAL HEMATOMA	329.002.00320	PRV	1990
	INJURY, SUPERFICIAL	INSECT BITES	329.009.00327	CUR	1996
	OPEN WOUND	SKIN CUTS MULTIPLE {SUPERFICIAL ON LEFT FOREARM}	329.003.00094	CUR	1995
	OPEN WOUND	SKIN CUTS MULTIPLE {SUPERFICIAL ON RIGHT THIGH}	329.003.00094	CUR	1995
	SPRAINS/STRAINS	LIGAMENT TEARS{LEFT FOOT, ANKLE}	329.012.00217	PRV	1995

CUR = Current, PRV = Past

345

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
INJURY/POISONING	SPRAINS/STRAINS	MUSCLE STRAIN	329.001.00207	PRV	1996
	SPRAINS/STRAINS	SPRAINED LEFT ANKLE	329.009.00136	PRV	1995
	SPRAINS/STRAINS	SPRAINED WRIST	329.002.00320	PRV	1990
	TRAUMA/INJURIES, UNSPEC	INJURY TO LEFT KNEE{PARAGLIDING}	329.012.00217	PRV	1993
MENTAL DISORD	ANXIETY	ANXIETY	329.004.00020	CUR	1995
	ANXIETY	ANXIETY	329.012.00218	CUR	1996
	CONDUCT DISORD	ATTENTION-DEFICIT HYPERACTIVITY DISORDER	329.009.00330	CUR	1996
	DRUG ABUSE	POSITIVE DRUG SCREEN{CANNABINOIDS}	329.007.00267	CUR	1996
	DRUG ABUSE	{PAST} MARIJUANA USE	329.002.00246	PRV	1994
	DRUG DEPEND	POSITIVE URINE DRUG SCREEN FOR CODEINE AND MORPHINE.	329.005.00253	CUR	1996
	NEUROSES	GENERALIZED ANXIETY DISORDER	329.009.00128	CUR	1994
MUSCULOSKEL/CONNECT TISSUE DIS	BACK PAIN	BACK PAIN	329.002.00323	CUR	1996
	BACK PAIN	BACKACHES	329.004.00213	CUR	1996
	BACK PAIN	CHRONIC BACK PAIN	329.002.00320	CUR	1994
	JOINT DISORD, OTHER	FEMORAL EPIPHYSIS RIGHT HIP{JOINT DISORDER}	329.001.00123	PRV	1989
	JOINT DISORD, OTHER	HIP LEFT FEMORAL EPIPHYSIS{JOINT DISORDER}	329.001.00123	PRV	1990
	JOINT DISORD, OTHER	KNEE PROBLEMS{RIGHT}	329.011.00285	CUR	1995

CUR = Current, PRV = Past

346

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
MUSCULOSKEL/CONNECT TISSUE DIS	PAIN, LIMB	BILATERAL KNEE PAIN	329.002.00320	CUR	1995
	RHEUMATIC DISORD	TENDONITIS	329.009.00302	PRV	1996
NERVOUS SYST/SENSE ORGAN DIS	EAR/MASTOID DISORD	BROKEN EAR DRUM	329.009.00330	CUR	1996
	HEARING LOSS	25% HEARING LOSS RIGHT EAR	329.005.00331	CUR	1982
	MENINGITIS	MENINGITIS	329.010.00282	PRV	1980
	MENINGITIS	MENINGITIS	329.011.00164	PRV	1993
	OTITIS MEDIA	EAR INFECTION	329.001.00064	PRV	1983
	OTITIS MEDIA	OTITIS MEDIA	329.012.00027	CUR	1995
	OTITIS MEDIA	OTITIS MEDIA BILATERAL{PROBABLE}	329.009.00198	CUR	1995
	OTITIS MEDIA	RECURRENT EAR INFECTIONS	329.005.00331	CUR	1982
OPERATIONS	OTITIS MEDIA	RIGHT OTITIS MEDIA	329.001.00069	CUR	1995
	OPERATION, BONE/JOINT	REPAIR OF LEFT FOOT - BONE REALIGNMENT	329.005.00334	CUR	1997
	OPERATION, BONE/JOINT	SURGERY PINNING LEFT HIP	329.001.00123	PRV	1990
	OPERATION, BONE/JOINT	SURGERY REMOVAL OF PINS IN RIGHT,LEFT HIPS	329.001.00123	PRV	1991
	OPERATION, BONE/JOINT	SURGERY-PLACEMENT OF CANNULATED LOG SCREW RIGHT HIP	329.001.00123	PRV	1989
	OPERATION, BREAST	NON MALIGNANT LUMP REMOVED FROM (LEFT) BREAST	329.009.00306	PRV	1996
OPERATION, EAR	EUSTACHIAN TUBE PLACEMENT	329.007.00141	PRV	1982	

CUR = Current, PRV = Past

347

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
OPERATIONS	OPERATION, EAR	EUSTACHIAN TUBES LEFT EAR {FOR SEVERE, CHRONIC EAR INFECTION}	329.007.00311	PRV	1984
	OPERATION, EAR	EUSTACHIAN TUBES RIGHT EAR {FOR SEVERE, CHRONIC EAR INFECTION}	329.007.00311	PRV	1987
	OPERATION, EAR	MYRINGOTOMY	329.001.00064	PRV	1983
	OPERATION, EAR	MYRINGOTOMY {TUBE PLACEMENT}	329.003.00251		
	OPERATION, EAR	PRESSURE EQUALIZATION TUBES IN EARS	329.001.00071	PRV	1983
	OPERATION, EAR	TUBES PLACED IN RIGHT EAR X6	329.005.00331	CUR	1982
	OPERATION, ENDOCR	PARTIAL THYROIDECTOMY	329.009.00135	PRV	1991
	OPERATION, HERNIA REPAIR	BILATERAL HERNIORRHAPHY	329.002.00049	PRV	1980
	OPERATION, HERNIA REPAIR	HERNIA REPAIR AT AGE 7	329.005.00010	PRV	1987
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.003.00094	PRV	1989
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.007.00267	PRV	1981
	OPERATION, NOSE/MOUTH	TONSILLECTOMY	329.010.00282	PRV	1996
	OPERATION, OTHER ABDOM	ABDOMINAL CYST-SURGERY	329.009.00302	PRV	1990
RESPIRATORY SYST DIS	ASTHMA	ASTHMA	329.001.00123	PRV	1993
	ASTHMA	ASTHMA	329.005.00114	CUR	1993
	ASTHMA	ASTHMA	329.005.00115	CUR	1984
	ASTHMA	ASTHMA	329.012.00027	CUR	1985
	ASTHMA	ASTHMA	329.012.00217	PRV	1995

CUR = Current, PRV = Past

348

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
RESPIRATORY SYST DIS	ASTHMA	ASTHMA	329.012.00218	PRV	1986
	ASTHMA	ASTHMATIC REACTION{BRIEF}	329.010.00183	PRV	1994
	BRONCHITIS, OTHER	BRONCHITIS	329.005.00253	CUR	1996
	BRONCHITIS, OTHER	BRONCHITIS	329.007.00311	PRV	1996
	BRONCHITIS, OTHER	BRONCHITIS	329.010.00282	CUR	1996
	INFLUENZA	FLU	329.001.00071	PRV	1995
	INFLUENZA	UPPER RESPIRATORY TRACT INFECTION (FLU)	329.009.00198	CUR	1994
	NASOPHARYNGITIS, ACUTE	COLD (HEAD)	329.001.00064	PRV	1994
	NASOPHARYNGITIS, ACUTE	SORE THROAT WITH COLD SYMPTOMS	329.001.00207	PRV	1996
	NASOPHARYNGITIS, ACUTE	{COMMON} COLD	329.009.00200	PRV	1996
	PHARYNGITIS, ACUTE	PHARYNGITIS	329.001.00069	CUR	1995
	PNEUMONIA, OTHER	PNEUMONIA	329.001.00064	PRV	1981
	PNEUMONIA, OTHER	PNEUMONIA	329.001.00069	PRV	1994
	RHINITIS, ALLERGIC	ALLERGIES {CAT AND DOG HAIR, DUST, TREES}	329.005.00331	CUR	1983
	RHINITIS, ALLERGIC	ALLERGIES {SEASONAL}	329.005.00298	CUR	1988
	RHINITIS, ALLERGIC	ALLERGIES {TO POLLEN, POULTRY DUST}	329.002.00241	CUR	1991
	RHINITIS, ALLERGIC	ALLERGIES (SEASONAL)	329.009.00174	CUR	1994
	RHINITIS, ALLERGIC	ALLERGIES-ANIMAL HAIR & POLLENS	329.004.00016	CUR	1988
	RHINITIS, ALLERGIC	SEASONAL ALLERGIES	329.009.00128	CUR	1993

CUR = Current, PRV = Past

349

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
RESPIRATORY SYST DIS	RHINITIS, ALLERGIC	SEASONAL ALLERGY	329.009.00202	CUR	1995
	RHINITIS, ALLERGIC	SINUS ALLERGIES	329.009.00312	CUR	1996
	RHINITIS, ALLERGIC	SINUS ALLERGIES {CONGESTION}	329.009.00327	CUR	1996
	SINUSITIS,NOS	SINUS INFECTION	329.001.00064	CUR	1994
	SINUSITIS,NOS	SINUS INFECTION	329.005.00331	CUR	1996
	SINUSITIS,NOS	SINUS INFECTIONS	329.001.00069	CUR	1985
	SINUSITIS,NOS	SINUSITIS	329.001.00071	PRV	1995
	UPPER RESP DISORD, OTHER	NASAL CONGESTION	329.002.00241	CUR	1996
	UPPER RESP DISORD, OTHER	RHINORRHEA	329.003.00086	CUR	1993
	UPPER RESP DISORD, OTHER	SINUS CONGESTION	329.009.00136	CUR	1995
UPPER RESP INFECT, ACUTE	UPPER RESPIRATORY INFECTION	329.002.00097	CUR	1994	
	UPPER RESPIRATORY TRACT INFECTION	329.004.00018	CUR	1995	
SIGNS, SYMPTOMS, ILL-DEFINED CON	CARDIAC MURMURS	HEART MURMUR	329.002.00323	PRV	1993
	CARDIAC MURMURS	MURMUR {I/VI SYSTOLIC EJECTION MURMUR}	329.003.00252	CUR	
	CARDIOVAS FUNCTIONS/ECG, ABN	EARLY REPOLARIZATION {EKG}	329.009.00276	CUR	1997
	CARDIOVAS FUNCTIONS/ECG, ABN	NORMAL SINUS RHYTHM WITH SHORT PR ON EKG	329.006.00259	CUR	1996
	CONVULSIONS	SEIZURE{UNKNOWN ETIOLOGY 1X}	329.010.00183	PRV	1989
	CREATININE, INCREASED	INCREASED CREATININE	329.010.00183	CUR	1995

CUR = Current, PRV = Past

350

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	DIZZINESS AND GIDDINESS	DIZZINESS	329.002.00320	CUR	
	DIZZINESS AND GIDDINESS	DIZZINESS	329.003.00251	CUR	1996
	DYSPNEA, OTHER	SHORTNESS OF BREATH	329.003.00251	CUR	1996
	GASTROINTEST PROB, NEC	GASTROINTESTINAL DISTRESS	329.002.00246	CUR	1994
	HEADACHE	HEADACHE	329.001.00069	PRV	1994
	HEADACHE	HEADACHE	329.009.00200	CUR	1994
	HEADACHE	HEADACHE	329.011.00285	CUR	
	HEADACHE	HEADACHE	329.012.00217	CUR	1995
	HEADACHE	HEADACHE {OCCASIONAL}	329.009.00327	CUR	1994
	HEADACHE	HEADACHES	329.001.00062	CUR	1979
	HEADACHE	HEADACHES	329.001.00064	CUR	1990
	HEADACHE	HEADACHES	329.001.00071	CUR	1993
	HEADACHE	HEADACHES	329.002.00246	CUR	1994
	HEADACHE	HEADACHES	329.002.00320	CUR	1990
	HEADACHE	HEADACHES	329.004.00018	CUR	1991
	HEADACHE	HEADACHES	329.004.00213	CUR	1996
	HEADACHE	HEADACHES	329.005.00001	CUR	1992
	HEADACHE	HEADACHES	329.005.00254	CUR	1996
	HEADACHE	HEADACHES	329.009.00174	CUR	1990
	HEADACHE	HEADACHES	329.009.00238	CUR	1995
	HEADACHE	HEADACHES	329.011.00210	CUR	
	HEADACHE	HEADACHES (OCCASIONAL)	329.009.00276	CUR	1996

CUR = Current, PRV = Past

351

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	HEADACHE	HEADACHES, DAILY 2-3 TIMES	329.002.00097	CUR	1994
	HEADACHE	HEADACHES{FREQUENT}	329.010.00277	CUR	
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00135	CUR	1995
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00136	CUR	1993
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00198	CUR	1995
	HEADACHE	HEADACHES{OCCASIONAL}	329.009.00202	CUR	1995
	HEADACHE	HEADACHE{OCCASIONAL}	329.007.00267	CUR	1995
	HEADACHE	OCCASIONAL HEADACHE	329.009.00312	CUR	1995
	HEADACHE	OCCASIONAL HEADACHES	329.009.00197	CUR	1995
	HEADACHE	OCCASIONAL HEADACHES	329.009.00237	P&C	
	HEADACHE	TENSION HEADACHES	329.012.00027	CUR	1993
	INSOMNIA	INSOMNIA	329.007.00141	CUR	1994
	MALaise AND FATIGUE	FATIGUE	329.003.00080	CUR	
	MALaise AND FATIGUE	FATIGUE	329.006.00259	CUR	1995
	MENTAL STATUS, IMPAIRED	ATTENTION DEFICIT DISORDER	329.009.00128	PRV	1994
	PAIN, ABDOMINO-PELVIC	ABDOMINAL PAIN	329.003.00086	CUR	1994
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.001.00062	PRV	1988
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.002.00320	CUR	1994
	PAIN, ABDOMINO-PELVIC	STOMACH ACHES	329.009.00276	CUR	1997
	PAIN, ABDOMINO-PELVIC	STOMACH PAIN	329.009.00197	CUR	1995
	PAIN, ABDOMINO-PELVIC	STOMACHACHE {OCCASIONAL}	329.009.00327	CUR	1995
	PROTEINURIA	PROTEIN IN URINE	329.007.00311	CUR	1996

CUR = Current, PRV = Past

352

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.8

Listing of Medical/Surgical History and Physical Examination  
 by Treatment Group and Disease Classification  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

DISEASE CLASSIFICATION (LEVEL 1)	PREFERRED TERM	VERBATIM TERM	PATIENT NUMBER	STATUS	DIAGYR
SIGNS, SYMPTOMS, ILL-DEFINED CON	PROTEINURIA	PROTEINURIA	329.010.00277	CUR	1996
	PYREXIA	FEVER	329.001.00069	PRV	1994
	SUDDEN INFANT DEATH SYNDROME	HISTORY OF APNEA AND RESUSCITATION IN FIRST YEAR OF LIFE(SIDS)	329.002.00101	PRV	1979
	SYNCOPE AND COLLAPSE	FAINTING{OCCASIONAL}	329.002.00107	CUR	1995
	TACHYCARDIA, UNSPEC	EKG SHOWS RAPID HEART RATE DUE TO PREVIOUS BLOOD DRAWING-NORMAL	329.003.00085	CUR	1994
	URINARY CASTS/WBC'S	SQUAMOUS CELLS IN URINE POST PARTUM	329.005.00293	CUR	1997
	URINE, ABN, OTHER	INCREASED URINE NITROGEN	329.010.00183	CUR	1995
	WEIGHT GAIN	WEIGHT GAIN	329.002.00246	CUR	1994
SKIN/SUBCUTANEOUS TISSUE DIS	INFLAM SKIN/SUBCUT	ALLERGY TO PENICILLIN {PATIENT GETS A RASH}	329.003.00094	CUR	
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.005.00253	CUR	1996
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.008.00191	CUR	1995
	SKIN/SUBCUT DISORD, OTHER	ACNE	329.009.00237	P&C	
	SKIN/SUBCUT DISORD, OTHER	FACIAL ACNE	329.006.00259	CUR	1994
	SKIN/SUBCUT DISORD, OTHER	FACIAL CYSTIC ACNE	329.003.00252	CUR	
	SKIN/SUBCUT DISORD, OTHER	RASH ON ARMS AND CHEST{FOLLICULITIS}	329.005.00120	CUR	1995

CUR = Current, PRV = Past

353

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

PAROXETINE - PROTOCOL 329

Appendix B.9

Listing of Concomitant Medications  
by WHO ATC Classification and Generic Term  
Screening Failures Only

```
=====
```

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ANTIINFECTIVES,S YSTEMIC	ANTIBIOTICS	Clarithromycin	Biaxin	329.009.90170	-8	25APR95	06MAY95

354

\* days relative to screening date

PAROXETINE - PROTOCOL 329

## Appendix B.9

Listing of Concomitant Medications  
by WHO ATC Classification and Generic Term  
Screening Failures Only

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Chlorphenamine Maleate	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Dextromethorphan Hydrobromide	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Paracetamol	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Pseudoephedrine Hydrochloride	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96

355

\* days relative to screening date

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.9

Listing of Concomitant Medications  
by WHO ATC Classification and Generic Term  
Screening Failures Only

```
=====
```

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Ibuprofen	Advil	329.005.00296	-16	19MAR96	19MAR96
				329.009.90168	.	.	.

356

CONFIDENTIAL

BRL-029060-329-  
individual-data

\* days relative to screening date



## Appendix B.9

Listing of Concomitant Medications  
by WHO ATC Classification and Generic Term  
Screening Failures Only

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	ANTI-ASTHMATICS	Beclometasone Dipropionate	Vancenase	329.009.90170	-3	30APR95	.
	COUGH AND COLD PREP	Chlorphenamine Maleate	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Dextromethorphan Hydrobromide	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Guaifenesin	Guaifed-Pd	329.009.90170	-18	15APR95	.
		Paracetamol	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Pseudoephedrine Hydrochloride	Guaifed-Pd	329.009.90170	-18	15APR95	.
			Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
	NASAL PREP	Beclometasone Dipropionate	Vancenase	329.009.90170	-3	30APR95	.
		Mepyramine Maleate	Poly-Histine D	329.009.90170	-8	25APR95	.
		Pheniramine Maleate	Poly-Histine D	329.009.90170	-8	25APR95	.
		Phenylpropanolamine Hydrochloride	Poly-Histine D	329.009.90170	-8	25APR95	.
		Phenyltoloxamine Citrate	Poly-Histine D	329.009.90170	-8	25APR95	.
	SYSTEMIC ANTIHISTAMINES	Chlorphenamine Maleate	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Dextromethorphan Hydrobromide	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Guaifenesin	Guaifed-Pd	329.009.90170	-18	15APR95	.
		Mepyramine Maleate	Poly-Histine D	329.009.90170	-8	25APR95	.

\* days relative to screening date

PAROXETINE - PROTOCOL 329

## Appendix B.9

Listing of Concomitant Medications  
by WHO ATC Classification and Generic Term  
Screening Failures Only

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	SYSTEMIC ANTIHISTAMINES	Paracetamol	Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96
		Pheniramine Maleate	Poly-Histine D	329.009.90170	-8	25APR95	.
		Phenylpropanolamine Hydrochloride	Poly-Histine D	329.009.90170	-8	25APR95	.
		Phenyltoloxamine Citrate	Poly-Histine D	329.009.90170	-8	25APR95	.
		Pseudoephedrine Hydrochloride	Guaifed-Pd	329.009.90170	-18	15APR95	.
			Tylenol - Cough And Cold	329.005.00296	-17	18MAR96	22MAR96

358

\* days relative to screening date

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

## Appendix B.11

Listing of Adverse Experiences by ADECS Body System and Preferred Term  
Screening Failures Only

=====

----- Body System=Cardiovascular System -----

Preferred Term	Verbatim Term	Patient ID	AE Onset Date	Relative Days *	Duration	No. Epi	Inv Int	Act- ion	Inv Rel	Corr Ther	SAE
Bundle Branch Block	{BROAD QRS}	329.007.90181	30NOV95	.	Not Stated	CON	MIL	NO	UNR	No	No

\* days relative to screening date

Number of Episodes [No. Epi]: CON = Continuous

Investigator Intensity [Inv Int] : MIL = Mild, MOD = Moderate, SEV = Severe

Action Taken on Study Medication [Action] : DCR = Dose Decreased, INC = Dose Increased, NO = None, STP = Drug Stopped

Investigator Relationship [Inv Rel]: PBU = Probably Unrelated, PSR = Possibly Related, REL = Related, UNR = Not Related

Corrective Therapy [Corr Ther]

Serious AE as Judged according to SB Criteria by Investigator [SAE]

PAROXETINE - PROTOCOL 329

## Appendix B.11

Listing of Adverse Experiences by ADECS Body System and Preferred Term  
Screening Failures Only

```

=====
----- Body System=Digestive System -----

```

Preferred Term	Verbatim Term	Patient ID	AE Onset Date	Relative Days *	Duration	No. Epi	Inv Int	Act- ion	Inv Rel	Corr Ther	SAE
Dry Mouth	DRY MOUTH	329.003.90112	21JUL95	.	1 Days	1	MIL	NO	UNR	No	No

\* days relative to screening date  
Number of Episodes [No. Epi]: CON = Continuous  
Investigator Intensity [Inv Int] : MIL = Mild, MOD = Moderate, SEV = Severe  
Action Taken on Study Medication [Action] : DCR = Dose Decreased, INC = Dose Increased, NO = None, STP = Drug Stopped  
Investigator Relationship [Inv Rel]: PBU = Probably Unrelated, PSR = Possibly Related, REL = Related, UNR = Not Related  
Corrective Therapy [Corr Ther]  
Serious AE as Judged according to SB Criteria by Investigator [SAE]

PAROXETINE - PROTOCOL 329

## Appendix B.11

Listing of Adverse Experiences by ADECS Body System and Preferred Term  
Screening Failures Only

=====

----- Body System=Nervous System -----

Preferred Term	Verbatim Term	Patient ID	AE Onset Date	Relative Days *	Duration	No. Epi	Inv Int	Act- ion	Inv Rel	Corr Ther	SAE
Drug Dependence	POSITIVE URINE DRUG SCREEN FOR CANNABINOIDS	329.005.90379	27JUN96	.	1 Days	CON	SEV	NO	UNR	No	No
Emotional Lability	SUICIDAL IDEATION	329.010.90272	03DEC95	.	Not Stated	CON	SEV	NO	UNR	No	Yes

\* days relative to screening date  
 Number of Episodes [No. Epi]: CON = Continuous  
 Investigator Intensity [Inv Int] : MIL = Mild, MOD = Moderate, SEV = Severe  
 Action Taken on Study Medication [Action] : DCR = Dose Decreased, INC = Dose Increased, NO = None, STP = Drug Stopped  
 Investigator Relationship [Inv Rel]: PBU = Probably Unrelated, PSR = Possibly Related, REL = Related, UNR = Not Related  
 Corrective Therapy [Corr Ther]  
 Serious AE as Judged according to SB Criteria by Investigator [SAE]

PAROXETINE - PROTOCOL 329

## Appendix B.12

Listing of Adverse Experiences by Patient  
Screening Failures Only

```

=====

```

Patient ID	Preferred Term	Verbatim Term	AE Onset Date	Relative Days *	Duration	No. Epi	Inv Int	Act- ion	Inv Rel	Corr Ther	SAE
329.003.90112	Dry Mouth	DRY MOUTH	21JUL95	.	1 Days	1	MIL	NO	UNR	No	No
329.005.90379	Drug Dependence	POSITIVE URINE DRUG SCREEN FOR CANNABINOIDS	27JUN96	.	1 Days	CON	SEV	NO	UNR	No	No
329.007.90181	Bundle Branch Block	{BROAD QRS}	30NOV95	.	Not Stated	CON	MIL	NO	UNR	No	No
329.010.90272	Emotional Lability	SUICIDAL IDEATION	03DEC95	.	Not Stated	CON	SEV	NO	UNR	No	Yes

\* days relative to screening date

Number of Episodes [No. Epi]: CON = Continuous

Investigator Intensity [Inv Int] : MIL = Mild, MOD = Moderate, SEV = Severe

Action Taken on Study Medication [Action] : DCR = Dose Decreased, INC = Dose Increased, NO = None, STP = Drug Stopped

Investigator Relationship [Inv Rel]: PBU = Probably Unrelated, PSR = Possibly Related, REL = Related, UNR = Not Related

Corrective Therapy [Corr Ther]

Serious AE as Judged according to SB Criteria by Investigator [SAE]

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
ALIMENTARY TRACT/METAB	ANTACID/ANITFLAT/ANT IPEPTIC	Aluminium Hydroxide	Maalox	329.004.00017	232, 176	08NOV95	08NOV95	
			Maalox Liquid	329.009.00170	238, 181	01JUL96	.	
		Calcium Carbonate	Tums	329.005.00299	.	.	.	.
				329.009.00130	149, 93	13SEP95	.	
		Dihydroxyaluminum Sodium Carbonate	Rolaids	329.001.00068	-982, .	01JUN92	08FEB95	
				329.009.00196	10, .	27DEC95	.	
		Famotidine	Pepcid Ac	329.009.00196	10, .	27DEC95	.	
		Magnesium Hydroxide	Maalox Maalox Liquid	329.004.00017	232, 176	08NOV95	08NOV95	
				329.009.00170	238, 181	01JUL96	.	
		Ranitidine Hydrochloride	Zantac	329.005.00109	123, 70	01MAY95	08MAY95	
	329.007.00309			-44, -96	01JUN96	20JUN96#		
	ANTIDIARRHEA/GI ANTIBIOTICS	Bismuth Subsalicylate	Pepto Bismol	329.007.00310	52, -9	16NOV96	17NOV96	
				329.009.00133	28, .	10JUL95	.	
			Charcoal, Activated	Charcoal	329.005.00011	156, 100	17MAY95	17MAY95
			Loperamide Hydrochloride	Imodium-Ad	329.005.00333	30, .	21FEB97	21FEB97
Neomycin			Neomycin	329.007.00268	88, 29	27JUN96	29JUN96	
	Polymyxin B	Polymyxin	329.007.00268	88, 29	27JUN96	29JUN96		
ANTIOBESITY PREP	Appetite Suppressant	Appetite Suppressant {Nos}	329.007.00294	-58, .	01JAN97	10FEB97#		
GI ANTISPAS/ANTICHOLIN	Atropine Sulfate	Donnatal	329.009.00130	-1568, -1624	01JAN91	18APR95		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication



Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ALIMENTARY TRACT/METAB	GI ANTISPAS/ANTICHOLIN	Hyoscine Hydrobromide	Donnatal	329.009.00130	-1568,-1624	01JAN91	18APR95
		Hyoscyamine Sulfate	Donnatal	329.009.00130	-1568,-1624	01JAN91	18APR95
		Phenobarbital	Donnatal	329.009.00130	-1568,-1624	01JAN91	18APR95
	LAXATIVES	Bisacodyl	Dulcolax	329.007.00268	233, 174 233, 174	19NOV96 19NOV96	19NOV96 19NOV96
		Docusate Sodium	Correctol	329.009.00131	21, -36	22MAY95	22MAY95
		Yellow Phenolphthalein	Correctol	329.009.00131	21, -36	22MAY95	22MAY95
	MINERAL SUPPLEMENTS	Calcium Carbonate	Tums	329.005.00299 329.009.00130	., 149, 93	. 13SEP95	. .
		Sodium Chloride	Normal Saline Solution	329.005.00011	156, 100	17MAY95	19MAY95
		Neomycin	Neomycin	329.007.00268	88, 29	27JUN96	29JUN96
	MOUTH PREP	Triamcinolone	Triamcinolone	329.007.00140	34, -22	18OCT95	22OCT95
		VITAMINS	Ascorbic Acid	Vitamin C	329.004.00015 329.005.00257	5, -53 3, -54	12DEC94 13MAR96
	Calcium Pantothenate		Vitamin B Complex	329.004.00017	48, -9	08MAY95	.
	Minerals Nos		Centrum	329.004.00015	5, -53	12DEC94	13DEC94
	Nicotinamide		Vitamin B Complex	329.004.00017	48, -9	08MAY95	.
	Pyridoxine Hydrochloride		Vitamin B Complex	329.004.00017	48, -9	08MAY95	.
	Riboflavin	Vitamin B Complex	329.004.00017	48, -9	08MAY95	.	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

365

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ALIMENTARY TRACT/METAB	VITAMINS	Thiamine Hydrochloride	Vitamin B Complex	329.004.00017	48, -9	08MAY95	.
		Vitamins Nos	Centrum	329.004.00015	5, -53	12DEC94	13DEC94
			Multiple Vitamin	329.001.00068	-69, .	01DEC94	08FEB95
			Prenatal Vitamin	329.005.00109	-395, -448	30NOV93	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date		
ANTIINFECTIVES, SYSTEMIC	ANTIBIOTICS	Amoxicillin	Amoxicillin	329.001.00063	29, .	06DEC94	16DEC94		
				329.002.00058	60, 2	18NOV94	28NOV94		
				329.003.00091	211, 157	20OCT95	30OCT95		
				329.005.00116	26, -33	04MAR95	14MAR95		
				329.005.00151	41, -17	16OCT95	02NOV95		
				329.005.00257	145, 89	02AUG96	09AUG96		
				329.009.00130	140, 84	04SEP95	13SEP95		
				Amoxicillin Trihydrate	Amoxil	329.007.00142	-14, .	04OCT95	13OCT95#
						329.009.00130	8, -49	25APR95	04MAY95
						329.009.00133	32, .	14JUL95	20JUL95
		Augmentin	Augmentin	329.012.00222	21, -43	18JUL96	22JUL96		
				329.005.00116	25, -34	03MAR95	13MAR95		
				329.007.00310	85, 25	19DEC96	29DEC96		
				329.009.00201	-9, .	28JAN96	06FEB96		
		Antibiotic Nos	Antibiotic {Nos} Antibiotics Ear Drops {Nos}	329.008.00275	49, -7	25JUN96	09JUL96		
				329.005.00257	145, 89	02AUG96	09AUG96		
		Cefaclor	Ceclor	329.005.00257	15, -42	25MAR96	05APR96		
				329.007.00310	43, -14	22APR96	06MAY96		
				329.007.00310	19, -42	14OCT96	27OCT96		
		Cefalexin	Cephalexin	329.007.00268	173, 113	17MAR97	28MAR97		
				329.007.00268	82, 23	21JUN96	23JUN96		
		Cefalexin Monohydrate	Keflex	329.007.00268	87, 28	26JUN96	29JUN96		
				329.010.00278	92, 33	01JUL96	10JUL96		
329.010.00278	221, 165			16SEP96	19SEP96				
Cefixime	Cefixime	329.009.00196	56, .	11FEB96	.				
Cefuroxime Axetil	Ceftin	329.005.00116	141, 83	27JUN95	07JUL95				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ANTIINFECTIVES, SYSTEMIC	ANTIBIOTICS	Clarithromycin	Biaxin	329.008.00271	45, -20	24APR96	30APR96
				329.009.00303	-32, -88	01MAR96	.
		Clavulanic Acid	Augmentin	329.005.00116	25, -34	03MAR95	13MAR95
				329.007.00310	85, 25	19DEC96	29DEC96
				329.009.00201	-9, .	28JAN96	06FEB96
					56, .	01APR96	.
		Doxycycline	Doxycycline	329.008.00160	20, -47	20NOV95	.
		Erythromycin	Erythromycin	329.005.00151	48, -10	23OCT95	07NOV95
				329.007.00309	61, 9	13SEP96	19SEP96
				329.012.00220	71, 19	23SEP96	01OCT96
				113, 53	07OCT96	14OCT96	
		Minocycline	Minocycline	329.009.00235	-33, -87	15NOV96	.
		Neomycin	Neomycin	329.007.00268	88, 29	27JUN96	29JUN96
		Penicillin Nos	Penicillin	329.003.00091	182, 128	21SEP95	01OCT95
		Polymyxin B	Polymyxin	329.007.00268	88, 29	27JUN96	29JUN96
		Tetracycline	Tetracycline	329.006.00260	-6, -64	12JUL96	.
		Tetracycline Hydrochloride	Apo-Tetra	329.004.00214	-16, -76	18SEP96	18SEP96#
					10, -51	13OCT96	13OCT96
	14, -47			17OCT96	20OCT96		
	ANTIMYCOTICS	Miconazole Nitrate	Micatin Monistat 7	329.012.00231 329.005.00257	84, 23 242, 186	29MAY97 07NOV96	. 14NOV96
CHEMOTHERAPEUTICS	Sulfamethoxazole	Septra Double Strength	329.004.00015	82, 25	27FEB95	05MAR95	
			329.004.00015	82, 25	27FEB95	05MAR95	
		Trimethoprim	Septra Double Strength	329.004.00015	82, 25	27FEB95	05MAR95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ANTIINFECTIVES,S YSTEMIC	VACCINES	Hepatitis B Vaccine	Hepatitis B Shot {Vaccine}	329.004.00214	60, -1	02DEC96	02DEC96
			Hepatitis B {Vaccine}	329.004.00214	-1, -61	03OCT96	03OCT96#

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ANTINEOPLASTIC & IMMUNOSUP	ANTINEOPLASTIC,HORMO NES	Diethylstilbestrol Dipropionate	Cyclen	329.012.00222	-119, -182	01MAR96	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
BLOOD/BLOOD FORM ORGANS	ANTIANAEMIC PREP	Ferrous Sulfate	Ferrous Sulfate	329.005.00109	-133, -186	19AUG94	.
	PLASMA SUBSTIT/PERF SOLUT	I.V. Fluids	Iv Fluids	329.005.00109	129, 76	07MAY95	10MAY95
		Sodium Chloride	Normal Saline Solution	329.005.00011	156, 100	17MAY95	19MAY95
					156, 100	17MAY95	19MAY95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CARDIOVASCULAR	DIURETICS	Theophylline	Slo-Bid	329.005.00257	54, -3	03MAY96	10MAY96
	VASOPROTECTIVES	Benzocaine	Benzocaine	329.006.00038	-410, .	01JAN94	.
		Betamethasone	Betamethasone	329.012.00231	32, -30	07APR97	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication



Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
CENTRAL NERVOUS SYSTEM	ANAESTHETICS	Epinephrine	Xylocaine-Epinephrine	329.007.00309	74, 22	26SEP96	26SEP96	
		Fentanyl	Fentanyl	329.007.00309	74, 22	26SEP96	26SEP96	
		Lidocaine Hydrochloride	Xylocaine-Epinephrine	329.007.00309	74, 22	26SEP96	26SEP96	
		Methohexital Sodium	Brevital	329.007.00309	74, 22	26SEP96	26SEP96	
		Midazolam Hydrochloride	Versed	329.007.00309	74, 22	26SEP96	26SEP96	
		ANALGESICS	Nitrous Oxide	Nitrous Oxide	329.007.00309	74, 22	26SEP96	26SEP96
	Acetylsalicylic Acid		Aspirin	329.001.00068	-617, .	01JUN93	08FEB95	
				329.002.00105	16, .	11AUG95	24AUG95	
				329.002.00242	-6, -64	01FEB96	01FEB96#	
				329.006.00260	56, -3	11SEP96	11SEP96	
				329.007.00268	29, -31	29APR96	29APR96	
				329.007.00310	218, 158	01MAY97	08MAY97	
				329.010.00182	10, .	28DEC95	28DEC95	
				329.010.00278	-39, -95	01JAN96	.	
			Bayer Aspirin Extra Strength	329.005.00011	156, 100	17MAY95	17MAY95	
			Excedrin	329.004.00019	7, .	06JUN95	06JUN95	
				329.006.00260	-2390, -2448	01JAN90	.	
					6, -53	23JUL96	16SEP96	
					8, -51	25JUL96	25JUL96	
					20, -39	06AUG96	06AUG96	
					83, 25	08OCT96	08OCT96	
				329.008.00271	89, 25	07JUN96	07JUN96	
				329.009.00193	-331, .	01JAN95	.	
			Excedrin	329.005.00336	32, .	04APR97	09APR97	
			Extra-Strength		38, .	10APR97	12APR97	
					48, .	20APR97	23APR97	
			Extra Strength	329.007.00145	111, 55	30APR96	13MAY96	
			Excedrin					

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

373

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date		
CENTRAL NERVOUS SYSTEM	ANALGESICS	Acetylsalicylic Acid	Fiorinal	329.006.00038	57, .	12APR95	12APR95		
			Midol	329.007.00309	34, -19	17AUG96	19AUG96		
				329.007.00310	-8, -68	18SEP96	18SEP96#		
		Analgesics	Unknown Headache Medicine {Analgesic Nos}	329.007.00294	-4, .	24FEB97	24FEB97#		
		Butalbital	Fiorinal	329.006.00038	57, .	12APR95	12APR95		
			Phrenilin	329.007.00310	175, 115	19MAR97	23MAR97		
					236, 176	19MAY97	23MAY97		
		Caffeine	Excedrin		329.004.00019	7, .	06JUN95	06JUN95	
					329.006.00260	-2390, -2448	01JAN90	.	
						6, -53	23JUL96	16SEP96	
						8, -51	25JUL96	25JUL96	
						20, -39	06AUG96	06AUG96	
						83, 25	08OCT96	08OCT96	
						329.008.00271	89, 25	07JUN96	07JUN96
						329.009.00193	-331, .	01JAN95	.
					Excedrin Extra-Strength	329.005.00336	32, .	04APR97	09APR97
							38, .	10APR97	12APR97
					48, .	20APR97	23APR97		
			Extra Strength Excedrin	329.007.00145	111, 55	30APR96	13MAY96		
			Fiorinal	329.006.00038	57, .	12APR95	12APR95		
	Midol	329.007.00309	34, -19	17AUG96	19AUG96				
		329.007.00310	-8, -68	18SEP96	18SEP96#				
Chlorphenamine Maleate	Tylenol Cold And Flu		329.001.00205	-27, .	11JAN96	11JAN96#			
			329.009.00303	-32, -88	01MAR96	.			
		Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.			
Cinnamedrine Hydrochloride	Midol	329.007.00309	34, -19	17AUG96	19AUG96				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

374

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Cinnamedrine Hydrochloride	Midol	329.007.00310	-8, -68	18SEP96	18SEP96#
		Codeine Phosphate	Tylenol #1	329.001.00065	-2115, .	01FEB89	.
			Tylenol Iii	329.007.00309	71, 19	23SEP96	27SEP96
		Dextromethorphan Hydrobromide	Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
			Tylenol Cold {Medicine}	329.009.00303	-32, -88	01MAR96	.
				329.009.00173	-19, -82	01NOV95	.
		Oxycodone Hydrochloride	Percocet	329.010.00278	37, -20	16MAR96	17MAR96
		Oxycodone Terephthalate	Percocet	329.010.00278	37, -20	16MAR96	17MAR96
		Pain Reliever	Premenstrual Syndrome Pain Relief {Nos}	329.009.00133	-893, .	01JAN93	.
		Paracetamol	Acetaminophen	329.010.00280	-10, -65	07MAY96	07MAY96#
			Excedrin	329.004.00019	7, .	06JUN95	06JUN95
				329.006.00260	-2390, -2448	01JAN90	.
					6, -53	23JUL96	16SEP96
					8, -51	25JUL96	25JUL96
					20, -39	06AUG96	06AUG96
			83, 25	08OCT96	08OCT96		
			89, 25	07JUN96	07JUN96		
			329.008.00271	89, 25	07JUN96	07JUN96	
			329.009.00193	-331, .	01JAN95	.	
	Excedrin Extra-Strength	329.005.00336	32, .	04APR97	09APR97		
			38, .	10APR97	12APR97		
			48, .	20APR97	23APR97		
	Extra Strength Excedrin	329.007.00145	111, 55	30APR96	13MAY96		
	Extra Strength Tylenol	329.005.00151	1, -57	06SEP95	06SEP95		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

375

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Extra Strength Tylenol	329.007.00145	125, 69	14MAY96	15MAY96
				329.007.00294	-2, .	26FEB97	26FEB97#
			Percocet	329.010.00278	37, -20	16MAR96	17MAR96
			Phrenilin	329.007.00310	175, 115	19MAR97	23MAR97
					236, 176	19MAY97	23MAY97
			Sinutabs	329.004.00212	-215, .	01NOV95	.
			Tylenol	329.001.00063	-1529, .	01SEP90	.
				329.001.00068	20, .	27FEB95	28MAR95
				329.002.00055	123, 68	24OCT94	.
				329.002.00058	122, 64	19JAN95	19JAN95
				329.002.00099	33, -23	03APR95	03APR95
				329.002.00105	1, .	27JUL95	03AUG95
				329.002.00242	42, -17	19MAR96	19MAR96
				329.002.00245	-452, .	01JAN95	.
				329.003.00075	-7, -63	18JAN95	.
					16, -41	09FEB95	14FEB95
				329.003.00081	-193, .	01JUN95	.
				329.003.00089	8, .	14MAR95	.
					42, .	17APR95	18APR95
				329.003.00091	9, -46	01APR95	01APR95
					36, -19	28APR95	02MAY95
				329.003.00248	60, .	29APR96	.
				329.004.00015	13, -45	20DEC94	20DEC94
		69, 12	14FEB95	14FEB95			
		79, 22	24FEB95	24FEB95			
	329.004.00017	161, 105	29AUG95	30AUG95			
	329.004.00214	36, -25	08NOV96	09NOV96			
		44, -17	16NOV96	16NOV96			
		83, 23	25DEC96	25DEC96			
		84, 24	26DEC96	26DEC96			
		85, 25	27DEC96	27DEC96			
		87, 27	29DEC96	29DEC96			
	329.005.00002	-5, -61	20MAY94	20MAY94#			
		54, -3	17JUL94	20JUL94			
	329.005.00004	81, 22	29DEC94	30DEC94			
	329.005.00011	8, -49	20DEC94	03JAN95			
	329.005.00109	81, 28	20MAR95	22MAR95			
	329.005.00112	-2, -57	24JAN95	26JAN95			

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

376

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Tylenol	329.005.00116	25, -34	03MAR95	04APR95	
				329.005.00119	7, -53	17JUL95	17JUL95	
				329.005.00151	-25, -82	12AUG95	12AUG95#	
					40, -18	15OCT95	17OCT95	
					44, -14	19OCT95	19OCT95	
					21, .	01APR96	01APR96	
					28, .	08APR96	08APR96	
					138, 78	23OCT96	23OCT96	
					2, .	24JAN97	24JAN97	
					-12, .	20FEB97	21FEB97#	
					329.006.00038	57, .	12APR95	12APR95
					329.007.00140	-622, -677	01JAN94	.
					329.007.00142	-3942, .	01JAN85	.
					329.007.00265	-3, .	29JAN96	31JAN96#
					329.007.00294	14, .	13MAR97	13MAR97
						18, .	17MAR97	17MAR97
						22, .	21MAR97	23MAR97
						40, .	08APR97	08APR97
					329.007.00309	-15, -67	30JUN96	30JUN96#
						43, -10	26AUG96	26AUG96
						46, -7	29AUG96	29AUG96
						107, 55	29OCT96	29OCT96
						237, 185	08MAR97	08MAR97
					329.007.00310	15, -46	10OCT96	15OCT96
					329.009.00133	-893, .	01JAN93	.
					329.009.00173	-19, -82	01NOV95	.
					329.009.00196	-716, .	01JAN94	.
					329.009.00201	-9, .	28JAN96	.
					329.009.00204	-808, -864	01JAN94	.
					329.009.00303	-32, -88	01MAR96	.
					329.009.00329	-647, .	01JAN95	.
					329.010.00182	-7, .	12DEC95	12DEC95#
					329.010.00280	40, -16	25JUN96	25JUN96
		42, -14	27JUN96	27JUN96				
	329.011.00283	33, -25	11MAR96	11MAR96				
	329.012.00231	49, -13	24APR97	.				
		109, 48	23JUN97	.				
		329.001.00065	Tylenol #1	329.001.00065	-2115, .	01FEB89	.	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

377

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date		
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Tylenol (Liquid)	329.009.00235	-11, -65	07DEC96	07DEC96#		
			Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#		
				329.009.00303	-32, -88	01MAR96	.		
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.		
			Tylenol Es Gel Caps	329.007.00294	5, .	04MAR97	07MAR97		
			Tylenol Extra Strength	329.004.00015	4, -54	11DEC94	11DEC94		
					34, -24	10JAN95	10JAN95		
					41, -17	17JAN95	17JAN95		
					53, -5	29JAN95	29JAN95		
					131, 74	17APR95	17APR95		
					329.004.00214	-8, -68	26SEP96	26SEP96#	
					329.005.00151	, .	. .	03SEP95#	
					329.008.00271	-5, -69	06MAR96	17MAR96	
						28, -37	07APR96	07APR96	
						63, -2	12MAY96	12MAY96	
						91, 27	09JUN96	09JUN96	
						329.009.00324	-88, .	01AUG96	.
					Tylenol Iii	329.007.00309	71, 19	23SEP96	27SEP96
					Tylenol Sinus	329.009.00196	55, .	10FEB96	.
						329.009.00324	-88, .	01AUG96	.
		Phenacetin	Fiorinal	329.006.00038	57, .	12APR95	12APR95		
			Sinutabs	329.004.00212	-215, .	01NOV95	.		
		Phenylpropanolamine Hydrochloride	Sinutabs	329.004.00212	-215, .	01NOV95	.		
		Phenyltoloxamine Citrate	Sinutabs	329.004.00212	-215, .	01NOV95	.		
		Pseudoephedrine Hydrochloride	Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#		
				329.009.00303	-32, -88	01MAR96	.		
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.		
			Tylenol Sinus	329.009.00196	55, .	10FEB96	.		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

378

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Pseudoephedrine Hydrochloride	Tylenol Sinus	329.009.00324	-88, .	01AUG96	.
		Tramadol Hydrochloride	Ultram	329.010.00278	38, -19	17MAR96	19MAR96
	PSYCHOANALEPTICS	Caffeine	Vivarin	329.005.00333	14, .	05FEB97	05FEB97
		Cannabis	Marijuana	329.010.00182	-1448, .	01JAN92	.
		Fluoxetine	Prozac	329.009.00303	-23, -79	10MAR96	17MAR96#
		Methylphenidate Hydrochloride	Ritalin	329.007.00318	-854, .	01AUG94	11AUG96#
			Ritalin Sr	329.009.00204 329.012.00220	-808, -864 -148, -208	01JAN94 21JAN96	01MAR96# 15MAY96#
		Nefazodone	Nefazodone	329.009.00130	170, 114	04OCT95	.
		Sertraline Hydrochloride	Zoloft	329.002.00245	-27, .	01MAR96	14MAR96#
		PSYCHOLEPTICS	Methohexital Sodium	Brevital	329.007.00309	74, 22	26SEP96
	Prochlorperazine		Compazine	329.007.00268	218, 159	04NOV96	04NOV96
	Tranquilizer		Tranquilizer {Nos}	329.006.00038	17, .	03MAR95	03MAR95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

379

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date			
DERMATOLOGICALS	ANTI-ACNE PREP	Isotretinoin	Accutane	329.005.00257	-121, -177	11NOV95	.			
						-121, -177	11NOV95	.		
		Sulfur	Clearasil	329.009.00131	29, -28	30MAY95	.			
		Triclosan	Clearasil	329.009.00131	29, -28	30MAY95	.			
	ANTIBIOTIC&CHEMOTHERAPEUT	Erythromycin	Erythromycin	Erythromycin	329.005.00151	48, -10	23OCT95	07NOV95		
					329.007.00309	61, 9	13SEP96	19SEP96		
					329.012.00220	71, 19	23SEP96	01OCT96		
						113, 53	07OCT96	14OCT96		
					Neomycin	Neomycin	329.007.00268	88, 29	27JUN96	29JUN96
					Tetracycline	Tetracycline	329.006.00260	-6, -64	12JUL96	.
					Tetracycline Hydrochloride	Apo-Tetra	329.004.00214	-16, -76	18SEP96	18SEP96#
					10, -51	13OCT96	13OCT96			
					14, -47	17OCT96	20OCT96			
	ANTIFUNGALS	Clotrimazole	Clotrimazole	Clotrimazole	329.007.00140	39, -17	23OCT95	24OCT95		
				329.007.00140	41, -15	25OCT95	03NOV95			
				329.012.00231	84, 23	29MAY97	.			
ANTIPRURITICS	Benzocaine	Benzocaine	Benzocaine	329.005.00257	242, 186	07NOV96	14NOV96			
				329.006.00038	-410, .	01JAN94	.			
				329.001.00063	-4086, .	01SEP83	.			
				329.002.00099	34, -22	04APR95	11APR95			
				329.002.00105	-329, .	01SEP94	.			
	329.003.00250	47, -11	29APR96	29APR96						
	329.007.00145	22, -35	01FEB96	01FEB96						
	329.008.00275	-738, -793	01MAY94	.						
				-1, -56	07MAY96	07MAY96#				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

380

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date			
DERMATOLOGICALS	ANTIPRURITICS	Diphenhydramine Hydrochloride	Benadryl	329.008.00275	8, -48	15MAY96	.			
					56, 1	02JUL96	.			
					77, 22	23JUL96	24JUL96			
					132, 77	16SEP96	17SEP96			
					202, 147	25NOV96	26NOV96			
				329.009.00303	23, -34	24APR96	24APR96			
				329.010.00280	34, -22	19JUN96	21JUN96			
					39, -17	24JUN96	26JUN96			
				Benylin	329.004.00017	177, 121	14SEP95	16SEP95		
		CORTICOSTEROIDS	Betamethasone	Betamethasone	329.012.00231	32, -30	07APR97	.		
					Budesonide	Rhinocort	329.012.00222	-36, -99	23MAY96	.
					Fluticasone Propionate	Flonase	329.005.00257	43, -14	22APR96	28APR96
					Triamcinolone	Triamcinolone	329.007.00140	34, -22	18OCT95	22OCT95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

381

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
GU SYSTEM/SEX HORMONES	ANTIINFECTIVES/ANTIS EPTICS	Clotrimazole	Clotrimazole	329.007.00140	39, -17	23OCT95	24OCT95
		Miconazole Nitrate	Micatin Monistat 7	329.012.00231 329.005.00257	84, 23 242, 186	29MAY97 07NOV96	. 14NOV96
	SEX HORMONES/STIMULANTS	Desogestrel	Desogen 28	329.005.00109	14, -40	12JAN95	.
		Diethylstilbestrol Dipropionate	Cyclen	329.012.00222	-119, -182	01MAR96	.
		Ethinylestradiol	Desogen 28	329.005.00109	14, -40	12JAN95	.
			Ortho 777	329.004.00212	-215, .	01NOV95	.
			Ortho Novum 1/35-28	329.009.00235	40, -15	26JAN97	.
			Ortho Tri-Cyclen	329.012.00231	32, -30	07APR97	.
		Norethisterone	Ortho 777	329.004.00212	-215, .	01NOV95	.
			Ortho Novum 1/35-28	329.009.00235	40, -15	26JAN97	.
		Norgestimate	Ortho Tri-Cyclen	329.012.00231	32, -30	07APR97	.
		Oral Contraceptive	Birth Control Pill	329.004.00214	-32, -92	02SEP96	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Etodolac	Lodine	329.009.00133	32, .	14JUL95	17JUL95
		Ibuprofen	Advil	329.002.00055	123, 68	24OCT94	.
				329.005.00116	65, 7	12APR95	12APR95
					111, 53	28MAY95	30MAY95
				329.005.00119	47, -13	26AUG95	26AUG95
				329.005.00257	157, 101	14AUG96	21AUG96
				329.005.00299	., .	.	.
				329.005.00333	23, .	14FEB97	16FEB97
					33, .	24FEB97	24FEB97
				329.006.00038	57, .	12APR95	12APR95
				329.006.00039	-1134, -1195	01JAN92	.
				329.006.00260	53, -6	08SEP96	08SEP96
				329.006.00261	58, -1	22JAN97	22JAN97
				329.007.00309	29, -24	12AUG96	13AUG96
					33, -20	16AUG96	16AUG96
					72, 20	24SEP96	03OCT96
					176, 124	06JAN97	13JAN97
					184, 132	14JAN97	12FEB97
				329.007.00310	14, -47	09OCT96	09OCT96
					50, -11	14NOV96	17NOV96
				329.008.00275	-493, -548	01JAN95	.
					-1, -56	07MAY96	.
					56, 1	02JUL96	.
				329.009.00240	-13, .	01JAN97	.
				329.009.00303	-822, -878	01JAN94	.
				329.009.00304	-464, -520	01JAN95	.
				329.009.00324	-88, .	01AUG96	.
		Ibuprofen		329.006.00038	57, .	12APR95	12APR95
					57, .	12APR95	12APR95
				329.007.00268	10, -50	10APR96	10APR96
					57, -3	27MAY96	30MAY96
				329.007.00294	-1154, .	01JAN94	.
				329.007.00309	-44, -96	01JUN96	.
				329.008.00271	21, -44	31MAR96	31MAR96
				329.009.00193	15, .	12DEC95	27DEC95
				329.009.00196	-716, .	01JAN94	.
				329.009.00235	-11, -65	07DEC96	07DEC96#

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

383

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date		
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Ibuprofen	Motrin	329.003.00075	-7, -63	18JAN95	.		
				329.007.00268	16, -41	09FEB95	14FEB95		
					-821, -880	01JAN94	.		
					57, -3	27MAY96	07JUN96		
					98, 39	07JUL96	10JUL96		
					102, 43	11JUL96	07NOV96		
					184, 125	01OCT96	07NOV96		
		329.009.00170	246, 189	09JUL96	.				
		Ketoprofen	Orudis Kt	329.007.00310	53, -8	17NOV96	30NOV96		
				Naproxen Sodium	Aleve	329.002.00319	203, 147	18NOV96	18NOV96
						329.007.00294	34, .	02APR97	02APR97
		Anaprox	Skelaxin	329.006.00039	39, .	07APR97	07APR97		
					-44, -96	01JUN96	.		
					-56, -116	01AUG96	.		
14, -47	09OCT96				09OCT96				
MUSCLE RELAXANTS	Metaxalone	329.007.00310	76, 15	24APR95	28APR95				
			TOPICAL ANTIRHEU PROD	Eucalyptus Oil	Hall'S Cough Drops	329.009.00193	15, .	12DEC95	27DEC95
						Menthol	Hall'S Cough Drops	329.009.00193	15, .
		Vicks Cough Drop	329.008.00271	42, -23	21APR96			21APR96	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

384

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
RESPIRATORY	ANTI-ASTHMATICS	Acrivastine	Semprex-D	329.005.00257	14, -43	24MAR96	24MAR96	
		Budesonide	Rhinocort	329.012.00222	-36, -99	23MAY96	.	
		Ephedrine Sulfate	Marax	329.005.00257	202, 146	28SEP96	.	
		Hydroxyzine Hydrochloride	Marax	329.005.00257	202, 146	28SEP96	.	
		Loratadine	Claritin-D	329.007.00310	85, 25	19DEC96	30DEC96	
		Pseudoephedrine	Semprex-D	329.005.00257	14, -43	24MAR96	24MAR96	
		Pseudoephedrine Sulfate	Claritin-D	329.007.00310	85, 25	19DEC96	30DEC96	
		Salbutamol	Albuterol	329.005.00257	43, -14	22APR96	06MAY96	
					43, -14	22APR96	06MAY96	
					329.006.00038	-1871, .	01JAN90	.
						-1871, .	01JAN90	.
					329.008.00271	-3722, -3786	01JAN86	.
						-3722, -3786	01JAN86	.
					329.009.00196	-1081, .	01JAN93	.
						-1081, .	01JAN93	.
				Albuterol Inhaler	329.009.00196	-1081, .	01JAN93	.
						-1081, .	01JAN93	.
				Proventil	329.003.00075	, , .	. . .	.
						, , .	. . .	.
					329.006.00261	-4713, -4771	01JAN84	01JAN96#
				-4713, -4771	01JAN84	01JAN96#		
		Proventil Inhaler	329.008.00271	-3722, -3786	01JAN86	.		
				-3722, -3786	01JAN86	.		
		Ventolin Inhaler	329.005.00116	26, -33	04MAR95	14MAR95		
				26, -33	04MAR95	14MAR95		
			329.008.00160	20, -47	20NOV95	.		
				20, -47	20NOV95	.		
		Theophylline	Marax	329.005.00257	202, 146	28SEP96	.	
			Slo-Bid	329.005.00257	54, -3	03MAY96	10MAY96	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

385

CONFIDENTIAL  
BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	CHEST RUBS/INHALANTS	Menthol	Vicks Cough Drop	329.008.00271	42, -23	21APR96	21APR96
	COUGH AND COLD PREP	Carbinoxamine Maleate	Naldecon	329.011.00288	2, .	26JUL96	01AUG96
			Rondec Dm	329.009.00196	56, .	11FEB96	.
		Chlorphenamine Maleate	Contac Cold	329.006.00260	83, 25	08OCT96	08OCT96
			Dristan	329.007.00142	44, .	30NOV95	30NOV95
			Histussin Hc	329.007.00309	47, -6	30AUG96	02SEP96
			Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
			Tylenol Cold {Medicine}	329.009.00303	-32, -88	01MAR96	.
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.
	Cough Cold Preparations Nos	Ggg-Cold {Cold Preparation Nos}	Ggg-Cold {Cold Preparation Nos}	329.007.00145	224, 168	21AUG96	23AUG96
	Cough Syrup/Med	Smith Brothers Cough Drop	Smith Brothers Cough Drop	329.005.00116	75, 17	22APR95	07MAY95
		Unknown Cough Drop	Unknown Cough Drop	329.007.00294	34, .	02APR97	02APR97
	Dextromethorphan Hydrobromide	Contac Cold	Contac Cold	329.006.00260	83, 25	08OCT96	08OCT96
		Nyquil	Nyquil	329.002.00099	18, -38	19MAR95	21MAR95
				329.005.00119	79, 20	27SEP95	27SEP95
				329.009.00193	15, .	12DEC95	27DEC95
		Robitussin-Dm	Robitussin-Dm	329.011.00288	8, .	01AUG96	.
		Rondec Dm	Rondec Dm	329.009.00196	56, .	11FEB96	.
		Tylenol Cold And Flu	Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
				329.009.00303	-32, -88	01MAR96	.
		Tylenol Cold {Medicine}	Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.
	Doxylamine Succinate	Nyquil	Nyquil	329.002.00099	18, -38	19MAR95	21MAR95
				329.005.00119	79, 20	27SEP95	27SEP95
				329.009.00193	15, .	12DEC95	27DEC95
	Ethanol	Robitussin-Dm	Robitussin-Dm	329.011.00288	8, .	01AUG96	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	COUGH AND COLD PREP	Eucalyptus Oil	Hall'S Cough Drops	329.009.00193	15, .	12DEC95	27DEC95
		Guaifenesin	Entex	329.009.00196	54, .	09FEB96	09FEB96
			Panmist La	329.007.00310	19, -42	14OCT96	29OCT96
			Robitussin	329.005.00116	75, 17	22APR95	07MAY95
				329.005.00119	80, 21	28SEP95	28SEP95
				329.005.00258	2, .	13MAR96	13MAR96
				329.005.00299	109, 49	24SEP96	02OCT96
					140, 80	25OCT96	25OCT96
			Robitussin-Dm	329.011.00288	8, .	01AUG96	.
		Hydrocodone	Hydrocodone	329.007.00309	74, 22	26SEP96	26SEP96
		Hydrocodone Bitartrate	Codimal Dh	329.009.00201	56, .	01APR96	.
			Histussin Hc	329.007.00309	47, -6	30AUG96	02SEP96
		Menthol	Hall'S Cough Drops	329.009.00193	15, .	12DEC95	27DEC95
		Mepyramine Maleate	Codimal Dh	329.009.00201	56, .	01APR96	.
		Paracetamol	Contac Cold	329.006.00260	83, 25	08OCT96	08OCT96
			Dristan	329.007.00142	44, .	30NOV95	30NOV95
			Nyquil	329.002.00099	18, -38	19MAR95	21MAR95
				329.005.00119	79, 20	27SEP95	27SEP95
				329.009.00193	15, .	12DEC95	27DEC95
			Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
				329.009.00303	-32, -88	01MAR96	.
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.
		Phenylephrine Hydrochloride	Codimal Dh	329.009.00201	56, .	01APR96	.
			Dristan	329.007.00142	44, .	30NOV95	30NOV95
			Entex	329.009.00196	54, .	09FEB96	09FEB96
			Histussin Hc	329.007.00309	47, -6	30AUG96	02SEP96
			Naldecon	329.011.00288	2, .	26JUL96	01AUG96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

387

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	COUGH AND COLD PREP	Phenylpropanolamine Hydrochloride	Contac Cold	329.006.00260	83, 25	08OCT96	08OCT96
			Entex	329.009.00196	54, .	09FEB96	09FEB96
		Phenyltoloxamine Citrate	Naldecon	329.011.00288	2, .	26JUL96	01AUG96
			Naldecon	329.011.00288	2, .	26JUL96	01AUG96
		Pseudoephedrine	Panmist La	329.007.00310	19, -42	14OCT96	29OCT96
		Pseudoephedrine Hydrochloride	Nyquil	329.002.00099	18, -38	19MAR95	21MAR95
				329.005.00119	79, 20	27SEP95	27SEP95
				329.009.00193	15, .	12DEC95	27DEC95
			Rondec Dm	329.009.00196	56, .	11FEB96	.
			Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
			329.009.00303	-32, -88	01MAR96	.	
			329.009.00173	-19, -82	01NOV95	.	
			Tylenol Cold {Medicine}				
	NASAL PREP	Acrivastine	Semprex-D	329.005.00257	14, -43	24MAR96	24MAR96
		Aminoacetic Acid	Afrin Spray	329.002.00099	15, -41	16MAR95	21MAR95
Benzalkonium Chloride		Afrin Spray	329.002.00099	15, -41	16MAR95	21MAR95	
Brompheniramine Maleate		Dimetapp	329.005.00336	-18, .	14FEB97	16FEB97#	
Budesonide		Rhinocort	329.012.00222	-36, -99	23MAY96	.	
Chlorphenamine Maleate	Contac		329.007.00309	143, 91	04DEC96	04DEC96	
				145, 93	06DEC96	06DEC96	
				147, 95	08DEC96	08DEC96	
	Triaminic Cough Syrup	329.008.00271	-5, -69	06MAR96	06MAR96#		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

388

CONFIDENTIAL  
BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	NASAL PREP	Chlorphenamine Tannate	Rynatan	329.005.00257	15, -42	25MAR96	27MAR96
		Clemastine Fumarate	Tavist-D	329.010.00280	-2, -57	15MAY96	15MAY96#
		Dexbrompheniramine Maleate	Drixoral	329.007.00309	52, -1	04SEP96	04SEP96
			Drixoral Pills	329.004.00015	110, 5, -53	01NOV96 12DEC94	01NOV96 13DEC94
		Fluticasone Propionate	Flonase	329.005.00257	43, -14	22APR96	28APR96
		Mepyramine Tannate	Rynatan	329.005.00257	15, -42	25MAR96	27MAR96
		Oxymetazoline Hydrochloride	Afrin Spray	329.002.00099	15, -41	16MAR95	21MAR95
		Paracetamol	Tylenol Sinus	329.009.00196 329.009.00324	55, . -88, .	10FEB96 01AUG96	. .
		Phenylephrine Hydrochloride	Dimetapp	329.005.00336	-18, .	14FEB97	16FEB97#
		Phenylephrine Tannate	Rynatan	329.005.00257	15, -42	25MAR96	27MAR96
		Phenylmercuric Acetate	Afrin Spray	329.002.00099	15, -41	16MAR95	21MAR95
		Phenylpropanolamine Hydrochloride	Contac	329.007.00309	143, 91	04DEC96	04DEC96
					145, 93	06DEC96	06DEC96
					147, 95	08DEC96	08DEC96
			Dimetapp	329.005.00336	-18, .	14FEB97	16FEB97#
			Tavist-D	329.010.00280	-2, -57	15MAY96	15MAY96#
			Triaminic Cough Syrup	329.008.00271	-5, -69	06MAR96	06MAR96#

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

389

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
RESPIRATORY	NASAL PREP	Prednisone	Prednisone	329.005.00116	135, 77	21JUN95	28JUN95	
					143, 85	29JUN95	02JUL95	
					147, 89	03JUL95	07JUL95	
					152, 94	08JUL95	12JUL95	
				329.009.00196	56, .	11FEB96	.	
				329.010.00278	221, 165	16SEP96	17SEP96	
					223, 167	18SEP96	19SEP96	
					225, 169	20SEP96	21SEP96	
					227, 171	22SEP96	23SEP96	
					229, 173	24SEP96	25SEP96	
			Pseudoephedrine	Semprex-D	329.005.00257	14, -43	24MAR96	24MAR96
			Pseudoephedrine Hydrochloride	Actifed	329.001.00063	-4086, .	01SEP83	.
		Sudafed		329.002.00099	28, -28	29MAR95	29MAR95	
					329.004.00212	-215, .	01NOV95	.
					329.009.00324	-88, .	01AUG96	.
			329.009.00196	55, .	10FEB96	.		
			329.009.00324	-88, .	01AUG96	.		
		Pseudoephedrine Sulfate	Drixoral	329.007.00309	52, -1	04SEP96	04SEP96	
			Drixoral Pills	329.004.00015	110, 58	01NOV96	01NOV96	
				5, -53	12DEC94	13DEC94		
		Sodium Chloride	Normal Saline Solution	329.005.00011	156, 100	17MAY95	19MAY95	
		Sorbitol	Afrin Spray	329.002.00099	15, -41	16MAR95	21MAR95	
		Tripolidine Hydrochloride	Actifed	329.001.00063	-4086, .	01SEP83	.	
	SYSTEMIC ANTIHISTAMINES	Acrivastine	Semprex-D	329.005.00257	14, -43	24MAR96	24MAR96	
		Antihistamine, Nos	Antihistamine {Nos}	329.008.00157	-3893,-3948	01JAN85	.	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

390

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	SYSTEMIC ANTIHISTAMINES	Cetirizine Hydrochloride	Reactine	329.012.00025	-115, .	01JUL95	.
			Chlorphenamine Maleate	Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96
		Dextromethorphan Hydrobromide	Tylenol Cold {Medicine}	329.009.00303	-32, -88	01MAR96	.
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.
			Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
			Tylenol Cold {Medicine}	329.009.00303	-32, -88	01MAR96	.
		Dimenhydrinate	Dramamine Gravol	329.009.00170	238, 181	01JUL96	.
				329.004.00214	37, -24	09NOV96	10NOV96
					44, -17	16NOV96	17NOV96
		Diphenhydramine Hydrochloride	Benadryl	329.001.00063	-4086, .	01SEP83	.
				329.002.00099	34, -22	04APR95	11APR95
				329.002.00105	-329, .	01SEP94	.
				329.003.00250	47, -11	29APR96	29APR96
				329.007.00145	22, -35	01FEB96	01FEB96
				329.008.00275	-738, -793	01MAY94	.
	-1, -56			07MAY96	07MAY96#		
	8, -48			15MAY96	.		
	56, 1			02JUL96	.		
	77, 22			23JUL96	24JUL96		
Fexofenadine Hydrochloride	Allegra	329.009.00303	202, 147	25NOV96	26NOV96		
		329.010.00280	23, -34	24APR96	24APR96		
			34, -22	19JUN96	21JUN96		
			39, -17	24JUN96	26JUN96		
			177, 121	14SEP95	16SEP95		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

391

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	SYSTEMIC ANTIHISTAMINES	Loratadine	Claritin	329.004.00212	-215, .	01NOV95	09JUN96
			Claritin-D	329.007.00310	85, 25	19DEC96	30DEC96
		Paracetamol	Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
			Tylenol Cold {Medicine}	329.009.00303	-32, -88	01MAR96	.
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.
			Semprex-D	329.005.00257	14, -43	24MAR96	24MAR96
		Pseudoephedrine Hydrochloride	Tylenol Cold And Flu	329.001.00205	-27, .	11JAN96	11JAN96#
			Tylenol Cold {Medicine}	329.009.00303	-32, -88	01MAR96	.
			Tylenol Cold {Medicine}	329.009.00173	-19, -82	01NOV95	.
		Pseudoephedrine Sulfate	Claritin-D	329.007.00310	85, 25	19DEC96	30DEC96
THROAT PREP	Benzocaine	Benzocaine	329.006.00038	-410, .	01JAN94	.	
		Menthol	Vicks Cough Drop	329.008.00271	42, -23	21APR96	21APR96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

392

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
SENSORY ORGANS	OPHTALMOL/OTOLOGICAL PREP	Erythromycin	Erythromycin	329.005.00151	48, -10	23OCT95	07NOV95	
				329.007.00309	61, 9	13SEP96	19SEP96	
				329.012.00220	71, 19	23SEP96	01OCT96	
					113, 53	07OCT96	14OCT96	
			Tetracycline	Tetracycline	329.006.00260	-6, -64	12JUL96	.
			Tetracycline Hydrochloride	Apo-Tetra	329.004.00214	-16, -76	18SEP96	18SEP96#
						10, -51	13OCT96	13OCT96
						14, -47	17OCT96	20OCT96
		OPHTHALMOLOGICALS	Betamethasone	Betamethasone	329.012.00231	32, -30	07APR97	.
			Gramicidin	Polysporin Eye Drops	329.004.00015	-1, -58	07DEC94	18DEC94
						27, -31	03JAN95	14JAN95
			Neomycin	Neomycin	329.007.00268	88, 29	27JUN96	29JUN96
			Polymyxin B Sulfate	Polysporin Eye Drops	329.004.00015	-1, -58	07DEC94	18DEC94
						27, -31	03JAN95	14JAN95
			Polyvidone	Refresh	329.005.00151	156, 99	08FEB96	08MAR96
			Polyvinyl Alcohol	Refresh	329.005.00151	156, 99	08FEB96	08MAR96
			Sodium Chloride	Normal Saline Solution	329.005.00011	156, 100	17MAY95	19MAY95
			Refresh	329.005.00151	156, 99	08FEB96	08MAR96	
		Tetracycline	Tetracycline	329.006.00260	-6, -64	12JUL96	.	
		Tetracycline Hydrochloride	Apo-Tetra	329.004.00214	-16, -76	18SEP96	18SEP96#	
					10, -51	13OCT96	13OCT96	
					14, -47	17OCT96	20OCT96	
		Triamcinolone	Triamcinolone	329.007.00140	34, -22	18OCT95	22OCT95	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

393

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
SENSORY ORGANS	OTOLOGICALS	Ear Medication, Nos	Ear Drops {Nos}	329.005.00116	25, -34	03MAR95	04APR95

394

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
SYSTEMIC HORMONAL	CORTICOSTEROIDS	Betamethasone	Betamethasone	329.012.00231	32, -30	07APR97	.
		Prednisone	Prednisone	329.005.00116	135, 77	21JUN95	28JUN95
					143, 85	29JUN95	02JUL95
					147, 89	03JUL95	07JUL95
		329.009.00196	329.010.00278	152, 94	08JUL95	12JUL95	
				56, .	11FEB96	.	
		Triamcinolone	Triamcinolone	329.007.00140	221, 165	16SEP96	17SEP96
					223, 167	18SEP96	19SEP96
					225, 169	20SEP96	21SEP96
					227, 171	22SEP96	23SEP96
229, 173	24SEP96	25SEP96					

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

395

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PAROXETINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
VARIOUS	GENERAL NUTRIENTS	Lysine	Lysine	329.001.00068	-366, .	07FEB94	08FEB95
		Nutritional Supplement Nos	T-Lite {Dietary Supplement}	329.007.00268	154, 95	01SEP96	02OCT96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication



PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ALIMENTARY TRACT/METAB	ANTACID/ANITFLAT/ANT IPEPTIC	Aluminium Hydroxide	Mylanta	329.003.00090	50, .	02MAY95	.
				329.003.00092	173, 115	22OCT95	23OCT95
		Calcium Carbonate	Tums	329.005.00006	23, -38	26NOV94	.
				329.010.00279	193, 137	30SEP96	30SEP96
				329.012.00230	15, -55	14MAR97	.
					76, 7	14MAY97	26MAY97
		Cimetidine	Cimetidine Tagamet	329.005.00117	41, .	27APR95	.
				329.009.00194	28, -29	01JAN96	.
		Dimeticone, Activated	Mylanta	329.003.00090	50, .	02MAY95	.
				329.003.00092	173, 115	22OCT95	23OCT95
	Famotidine	Pepcid Ac	329.003.00314	44, .	04DEC96	06DEC96	
			329.007.00269	-101, .	01JAN96	.	
			329.008.00192	-2, .	03MAR96	.	
	Magnesium Hydroxide	Milk Of Magnesia Mylanta	329.003.00092	173, 115	22OCT95	23OCT95	
			329.003.00090	50, .	02MAY95	.	
			329.003.00092	173, 115	22OCT95	23OCT95	
	Nizatidine	Axid	329.005.00256	129, 73	11JUL96	.	
	Ranitidine Hydrochloride	Zantac	329.009.00325	-604, -659	01JAN95	.	
	ANTIDIARRHEA/GI ANTIBIOTICS	Bismuth Subsalicylate	Pepto Bismol	329.003.00092	39, -20	10JUN95	10JUN95
				329.007.00146	58, 5	22MAR96	22MAR96
Pepto-Bismol			329.005.00295	162, 109	04JUL96	04JUL96	
				-9, .	19MAR96	19MAR96#	
Loperamide Hydrochloride	Imodium A-D	329.007.00308	-2, .	30JUN96	30JUN96#		
		329.009.00305	57, -1	02JUL96	02JUL96		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

397

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ALIMENTARY TRACT/METAB	ANTIEMETICS & ANTINAUSEANTS	Antiemetics & Antinauseants Nos	Antiemetic {Nos}	329.004.00211	49, .	21MAR96	22MAR96
		Caffeine	Coke Syrup	329.003.00092	173, 115	22OCT95	23OCT95
		Corn Syrup	Coke Syrup	329.003.00092	173, 115	22OCT95	23OCT95
	ANTIOBESITY PREP	Natural Flavors	Coke Syrup	329.003.00092	173, 115	22OCT95	23OCT95
		Caffeine	Dexatrim	329.003.00073	13, .	31JAN95	03FEB95
		Phenylpropanolamine Hydrochloride	Dexatrim	329.003.00073	13, .	31JAN95	03FEB95
	GI ANTISPAS/ANTICHOLIN	Cisapride	Propulsid	329.005.00117	41, .	27APR95	.
		Dicycloverine Hydrochloride	Bentyl	329.003.00073	45, .	04MAR95	06MAR95
		Hyoscyamine Sulfate	Levsinex	329.008.00187	-5445, .	01JAN81	.
	LAXATIVES	Enema, Nos	Enema Nos	329.003.00090	49, .	01MAY95	01MAY95
Laxatives, Nos		Laxative (Unknown Name)	329.012.00221	112, 49	14OCT96	01NOV96	
Senna Fruit		Senokot	329.003.00090	50, .	02MAY95	.	
MINERAL SUPPLEMENTS	Calcium Carbonate	Tums	329.005.00006	23, -38	26NOV94	.	
			329.010.00279	193, 137	30SEP96	30SEP96	
			329.012.00230	15, -55	14MAR97	.	
				76, 7	14MAY97	26MAY97	
VITAMINS	Ascorbic Acid	Vitamin C	329.004.00014	-5, .	24NOV94	.	
			329.004.00211	., .	.	.	
			329.005.00295	-24, .	04MAR96	06MAR96#	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

398

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ALIMENTARY TRACT/METAB	VITAMINS	Calcium Pantothenate	Jamieson B Complex Vitamins	329.004.00211	., .	.	.
		Minerals Nos	Centrum	329.001.00122	-80, -137	01APR95	20JUN95
		Nicotinamide	Jamieson B Complex Vitamins	329.004.00211	., .	.	.
		Pyridoxine Hydrochloride	Jamieson B Complex Vitamins	329.004.00211	., .	.	.
		Riboflavin	Jamieson B Complex Vitamins	329.004.00211	., .	.	.
		Thiamine Hydrochloride	Jamieson B Complex Vitamins	329.004.00211	., .	.	.
		Vitamins Nos	Centrum	329.001.00122	-80, -137	01APR95	20JUN95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

399

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
ANTIINFECTIVES, SYSTEMIC	ANTIBIOTICS	Amoxicillin	Amoxicillin	329.001.00070	-8, .	14FEB95	20FEB95#	
				329.002.00050	5, .	27MAR95	28MAR95	
					6, .	28MAR95	08APR95	
				329.002.00104	232, 176	21DEC95	31DEC95	
				329.007.00270	-8, .	01MAY96	13MAY96	
			329.007.00307	18, .	02JUN96	07JUN96		
			Amoxicillin Trihydrate	Amoxil	329.012.00227	42, -28	28JAN97	10FEB97
			Cefaclor	Ceclor	329.005.00006	21, -40 25, -36	24NOV94 28NOV94	28NOV94 09DEC94
			Clarithromycin	Biaxin	329.012.00230	50, -20	18APR97	24APR97
			Clindamycin Hydrochloride	Cleocin	329.002.00050	-1177, .	01JAN92	.
			Erythromycin	Erycette 2% Cream Erythromycin	329.010.00279	91, 35	20JUN96	.
		329.005.00003			-19, .	01SEP94	14SEP94#	
			Minocycline	Minocin Minocycline Monocycline	329.004.00013	-48, -107	01JUN94	01FEB95
					329.002.00050	-1177, .	01JAN92	.
					329.002.00104	-123, -179	01JAN95	.
			Phenoxymethylpenicil lin	Pen-Vee-K	329.002.00243	1, .	14MAR96	21MAR96
						1, .	14MAR96	21MAR96
	Phenoxymethylpenicil lin Potassium	Pen-Vee-K	329.003.00314	-111, .	03JUL96	13JUL96#		
		Penicillin V-K	329.012.00227	21, -49	07JAN97	15JAN97		
	Tetracycline	Tetracycline	329.005.00153	-389, -445	01JAN95	.		
	ANTIMYCOTICS	Ketoconazole	Nizoral	329.009.00134	-1, .	05JUL95	10JUL95	
	CHEMOTHERAPEUTICS	Sulfamethoxazole	Bactrim Ds	329.001.00122	-139, -196	01FEB95	.	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

400

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ANTIINFECTIVES, SYSTEMIC	CHEMOTHERAPEUTICS	Sulfamethoxazole	Sulfamethoxazole/Trimethoprim Ds	329.005.00255	36, .	08APR96	15APR96
		Trimethoprim	Bactrim Ds	329.001.00122	-139, -196	01FEB95	.
			Sulfamethoxazole/Trimethoprim Ds	329.005.00255	36, .	08APR96	15APR96
	VACCINES	Hepatitis B Vaccine	Hepatitis B Vaccine	329.011.00284	29, -28	19APR96	19APR96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

401

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
BLOOD/BLOOD FORM ORGANS	ANTIANAEMIC PREP	Cyanocobalamin	Vitamin B12	329.006.00041	-63, -127	01FEB95	05APR95
	PLASMA SUBSTIT/PERF SOLUT	I.V. Fluids	Intravenous Fluids	329.004.00211	49, .	21MAR96	22MAR96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CARDIOVASCULAR	DIURETICS	Theophylline	Theo-Dur	329.009.00301	-443, -499	01JAN95	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
CENTRAL NERVOUS SYSTEM	ANALGESICS	Acetylsalicylic Acid	Actron	329.009.00239	-263, -320	01MAR96	.	
			Alka-Seltzer	329.001.00066	-731,	21NOV92	.	
			Aspirin	329.002.00050	4,	26MAR95	26MAR95	
				329.009.00134	38,	12AUG95	.	
				329.009.00264	-732,	31OCT94	.	
				329.012.00221	78,	15 10SEP96	10SEP96	
			Bayer Aspirin	329.002.00057	83,	26 29NOV94	29NOV94	
			Bc Powder	329.007.00139	-9,	29APR95	01MAY95#	
			Excedrin	329.008.00187	-332,	01JAN95	.	
					36,	03JAN96	04JAN96	
					92,	35 18FEB97	17MAR97	
			Excedrin Extra Strength	329.008.00187	44,	11JAN96	12JAN96	
					58,	25JAN96	26JAN96	
			Midol	329.003.00076	.	.	.	
				329.005.00153	7,	-50 31JAN96	31JAN96	
			329.009.00134	-916,	01JAN93	.		
			329.009.00236	-168,	15JUL96	.		
			Analgesics	Analgesic {Nos}	329.004.00211	49,	21MAR96	22MAR96
				Pain Medication {Nos}	329.003.00073	-11,	08JAN95	.
			Caffeine	Actron	329.009.00239	-263, -320	01MAR96	.
				Bc Powder	329.007.00139	-9,	29APR95	01MAY95#
				Excedrin	329.008.00187	-332,	01JAN95	.
						36,	03JAN96	04JAN96
				92,	35 18FEB97	17MAR97		
		Excedrin Extra Strength	329.008.00187	44,	11JAN96	12JAN96		
				58,	25JAN96	26JAN96		
		Midol	329.003.00076	.	.	.		
			329.005.00153	7,	-50 31JAN96	31JAN96		
			329.009.00134	-916,	01JAN93	.		
			329.009.00236	-168,	15JUL96	.		
	Chlorphenamine Maleate	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

404

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
CENTRAL NERVOUS SYSTEM	ANALGESICS	Cinnamedrine Hydrochloride	Midol	329.003.00076	., .	.	.	
				329.005.00153	7, -50	31JAN96	31JAN96	
				329.009.00134	-916, .	01JAN93	.	
				329.009.00236	-168, .	15JUL96	.	
			Citric Acid	Actron	329.009.00239	-263, -320	01MAR96	.
				Alka-Seltzer	329.001.00066	-731, .	21NOV92	.
			Codeine Phosphate	Tylenol #2	329.008.00187	19, .	17DEC95	.
				Tylenol Number 3	329.009.00195	-14, .	01DEC95	02DEC95#
				Tylenol With Codeine	329.012.00230	50, -20	18APR97	20APR97
						53, -17	21APR97	21APR97
			Dextromethorphan Hydrobromide	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96
			Diphenhydramine Citrate	Excedrin Pm	329.001.00061	-28, .	01JUL94	28JUL94#
			Mepyramine Maleate	Pamprin	329.003.00289	., .	.	.
			Oxycodone Hydrochloride	Percocet	329.005.00117	52, .	08MAY95	15MAY95
				Percocet	329.005.00117	52, .	08MAY95	15MAY95
			Pamabrom	Pamprin	329.003.00289	., .	.	.
			Paracetamol	Acetaminophen	329.002.00057	-38, -95	01AUG94	.
					329.005.00003	-5, .	15SEP94	15SEP94#
				Actron	329.009.00239	-263, -320	01MAR96	.
	Excedrin	329.008.00187		-332, .	01JAN95	.		
					36, .	03JAN96	04JAN96	
					92, 35	18FEB97	17MAR97	
		Excedrin Extra Strength	329.008.00187	44, .	11JAN96	12JAN96		
				58, .	25JAN96	26JAN96		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

405

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Excedrin Pm	329.001.00061	-28,	01JUL94	28JUL94#	
			Pamprin	329.003.00289	.	.	.	.
			Percocet	329.005.00117	52,	08MAY95	15MAY95	.
			Tylenol	329.001.00066	-731,	21NOV92	.	.
				329.001.00070	-2,	20FEB95	20FEB95#	.
				329.002.00100	-34,	01FEB95	01MAR95#	.
					41,	16APR95	30MAY95	.
				329.002.00103	4,	23APR95	23APR95	.
					7,	26APR95	26APR95	.
				329.002.00243	22,	04APR96	04APR96	.
				329.003.00090	.	.	.	.
					50,	02MAY95	02MAY95	.
				329.003.00289	.	.	.	.
				329.003.00314	60,	20DEC96	20DEC96	.
				329.003.00317	1,	19DEC96	04FEB97	.
					34,	21JAN97	21JAN97	.
				329.004.00211	38,	10MAR96	.	.
				329.005.00007	81,	28JAN95	.	.
					180,	07MAY95	07MAY95	.
				329.005.00009	-11,	01DEC94	07DEC94#	.
					5,	16DEC94	19DEC94	.
					11,	22DEC94	27DEC94	.
					21,	01JAN95	01JAN95	.
				329.005.00113	2,	31JAN95	31JAN95	.
				329.005.00118	4,	20MAY95	23MAY95	.
				329.005.00153	.	.	17APR96	.
					28,	21FEB96	21FEB96	.
		38,	02MAR96	02MAR96	.			
		57,	21MAR96	17APR96	.			
		84,	17APR96	15MAY96	.			
		112,	15MAY96	12JUN96	.			
		140,	12JUN96	10JUL96	.			
		168,	10JUL96	05AUG96	.			
	329.005.00256	1,	05MAR96	07MAR96	.			
		13,	17MAR96	20MAR96	.			
		16,	20MAR96	21MAR96	.			
	329.005.00295	-9,	19MAR96	19MAR96#	.			
	329.005.00297	-5,	14APR96	16APR96#	.			

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

406

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Tylenol	329.005.00297	22, .	10MAY96	11MAY96
				329.005.00335	-21, .	07FEB97	08FEB97#
					-1, .	27FEB97	27FEB97#
					43, .	11APR97	11APR97
					54, .	22APR97	22APR97
					-9, .	29APR95	01MAY95#
					-1, .	08NOV95	09NOV95
					-15, -68	10JAN96	10JAN96#
					-8, -61	17JAN96	17JAN96#
					., .	.	.
					11, .	21APR96	21APR96
					-494, .	01JAN95	.
					-1, .	15MAY96	15MAY96#
					., .	.	.
					-37, -93	26FEB96	19MAR96#
					8, -49	10APR96	10APR96
					-37, -100	10APR96	.
					-681, -738	01JAN94	.
					-703, -759	01JAN94	.
					-1809, .	01JAN91	.
					-45, .	15NOV96	.
					40, .	28MAR97	28MAR97
					-443, -499	01JAN95	.
					11, -46	01APR96	01APR96
					139, 83	07AUG96	07AUG96
					40, -22	03SEP96	03SEP96
					146, 85	18DEC96	19DEC96
	-2519, .	01JAN89	.				
	-693, .	01JAN94	.				
	-2, .	23NOV95	.				
	4, .	28NOV95	.				
	-1344, -1403	01JAN93	.				
	-254, -316	01JAN96	.				
	-21, -77	01MAR96	.				
	31, -26	21APR96	21APR96				
	-2348, -2416	01JAN90	.				
	-906, -969	01JAN94	.				
	-972, .	01JAN94	.				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

407

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Tylenol	329.012.00230	32, -38	31MAR97	31MAR97	
			Tylenol #2	329.008.00187	19, .	17DEC95	.	
			Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96	
			Tylenol Extra Strength	329.005.00153	-2, -58	23JAN96	23JAN96#	
					17, -40	10FEB96	10FEB96	
					28, -29	01APR96	01APR96	
					-604, -659	01JAN95	.	
			Tylenol Gelcaps	329.005.00153	-9, -65	16JAN96	27JAN96	
					329.009.00325		.	
					329.007.00146	-754, -807	01JAN94	.
					172, 119	14JUL96	14JUL96	
					329.009.00195	-14, .	01DEC95	02DEC95#
			329.009.00194	29, -28	02JAN96	16JAN96		
			329.012.00230	50, -20	18APR97	20APR97		
				53, -17	21APR97	21APR97		
		Pseudoephedrine Hydrochloride	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96	
				329.009.00194	29, -28	02JAN96	16JAN96	
		Salicylamide	Bc Powder	329.007.00139	-9, .	29APR95	01MAY95#	
		Sodium Bicarbonate	Actron	329.009.00239	-263, -320	01MAR96	.	
				329.001.00066	-731, .	21NOV92	.	
	PSYCHOANALEPTICS	Cannabis	Cannabis	329.002.00057	., .	. .	. .	
			Marijuana	329.012.00227	53, -5	30OCT94	30OCT94	
				32, -38	18JAN97	18JAN97		
	Cyclobenzaprine	Cyclobenzaprine	329.007.00146	7, -47	31JAN96	31JAN96		
				238, 185	18SEP96	18SEP96		
	Methylphenidate Hydrochloride	Ritalin	329.008.00192	-643, .	01JUN94	01FEB96#		
	PSYCHOLEPTICS	Butalbital	329.003.00093	-171, -234	01JAN95	.		
			Chloral Hydrate	Chloral Hydrate	329.012.00221	56, -8	19AUG96	22SEP96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

408

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	PSYCHOLEPTICS	Lorazepam	Lorazepam	329.012.00221	132, 69	03NOV96	03NOV96
		Prochlorperazine	Compazine	329.005.00007	195, 132	22MAY95	22MAY95
			Compazine Suppositories	329.005.00007	196, 133	23MAY95	24MAY95
		Sleeping Pill	Sleep Aid {Nos}	329.008.00159	21, -42	03OCT95	10OCT95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
DERMATOLOGICALS	ANTI-ACNE PREP	Benzoyl Peroxide	Vanoxide-Hc Lotion	329.010.00279	91, 35	20JUN96	.	
		Edetic Acid	Vanoxide-Hc Lotion	329.010.00279	91, 35	20JUN96	.	
		Hydrocortisone Acetate	Vanoxide-Hc Lotion	329.010.00279	91, 35	20JUN96	.	
		Isotretinoin	Accutane	329.004.00013	59, -1	15SEP94	16SEP94	
		Parabens	Vanoxide-Hc Lotion	329.010.00279	91, 35	20JUN96	.	
		Paraffin, Liquid	Vanoxide-Hc Lotion	329.010.00279	91, 35	20JUN96	.	
		Propylene Glycol	Vanoxide-Hc Lotion	329.010.00279	91, 35	20JUN96	.	
	ANTIBIOTIC&CHEMOTHERAPEUT	Erythromycin	Erycette 2% Cream	329.010.00279	91, 35	20JUN96	.	
			Erythromycin	329.005.00003	-19, .	01SEP94	14SEP94#	
			Tetracycline	Tetracycline	329.005.00153	-389, -445	01JAN95	.
	ANTIFUNGALS	Butoconazole Nitrate	Femstat	329.005.00255	38, .	10APR96	15APR96	
			Clotrimazole	Lotrimin Cream	329.007.00270	-10, .	29APR96	19MAY96
			Ketoconazole	Nizoral	329.009.00134	-1, .	05JUL95	10JUL95
			Terconazole	Terazol-7	329.005.00255	47, .	19APR96	21APR96
Topical Antifungal Nos			Antifungal Cream {Nos}	329.007.00270	26, .	03JUN96	15JUN96	
ANTIPRURITICS	Bentonite	Calamine Lotion	329.007.00270	9, .	17MAY96	19MAY96		
		Calamine	Caladryl	329.002.00243	4, .	17MAR96	24MAR96	
			Caladryl Lotion	329.005.00007	2, -62	10NOV94	14NOV94	
			Calamine Lotion	329.007.00270	9, .	17MAY96	19MAY96	
Camphor	Caladryl	329.002.00243	4, .	17MAR96	24MAR96			

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

410

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
DERMATOLOGICALS	ANTIPRURITICS	Camphor	Caladryl Clear	329.010.00279	110, 54	09JUL96	12JUL96
			Caladryl Lotion	329.005.00007	157, 101	25AUG96	29AUG96
		Chlorophyllin Sodium	Caladryl Clear	329.010.00279	168, 112	05SEP96	05OCT96
			Caladryl Clear	329.010.00279	2, -62	10NOV94	14NOV94
		Diphenhydramine Citrate	Excedrin Pm	329.001.00061	110, 54	09JUL96	12JUL96
		Diphenhydramine Hydrochloride	Benadryl	329.002.00243	157, 101	25AUG96	29AUG96
			329.003.00079	15, .	17MAY95	17MAY95	
			329.003.00317	27, .	14JAN97	14JAN97	
			329.005.00007	197, 134	24MAY95	24MAY95	
			329.007.00146	-24, -77	01JAN96	.	
			329.007.00270	9, .	17MAY96	19MAY96	
			329.007.00307	-45, .	01APR96	01APR96#	
			329.009.00262	32, .	16JUN96	21JUN96	
			329.009.00325	27, .	15MAR97	15MAR97	
			329.010.00279	45, -11	10OCT96	.	
			329.011.00163	162, 106	30AUG96	05SEP96	
			Caladryl	329.011.00163	-4, .	21NOV95	21NOV95#
				329.002.00243	-4, .	21NOV95	21NOV95#
			Caladryl Clear	329.010.00279	4, .	17MAR96	24MAR96
			Caladryl Lotion	329.010.00279	110, 54	09JUL96	12JUL96
		329.010.00279		157, 101	25AUG96	29AUG96	
		Ethanol	329.010.00279	168, 112	05SEP96	05OCT96	
			329.010.00279	2, -62	10NOV94	14NOV94	
Glycerol	Caladryl	329.002.00243	110, 54	09JUL96	12JUL96		
	Caladryl Clear	329.010.00279	157, 101	25AUG96	29AUG96		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

411

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
DERMATOLOGICALS	ANTIPRURITICS	Glycerol	Caladryl Clear	329.010.00279	168, 112	05SEP96	05OCT96
			Caladryl Lotion	329.005.00007	2, -62	10NOV94	14NOV94
			Calamine Lotion	329.007.00270	9, .	17MAY96	19MAY96
		Isopropanol	Ivy Dry	329.010.00279	161, 105	29AUG96	04SEP96
			Parabens	Caladryl Clear	329.010.00279	110, 54	09JUL96
					157, 101	25AUG96	29AUG96
					168, 112	05SEP96	05OCT96
		Paracetamol	Excedrin Pm	329.001.00061	-28, .	01JUL94	28JUL94#
			Phenol, Liquefied	Calamine Lotion	329.007.00270	9, .	17MAY96
		Promethazine Hydrochloride		Phenergan	329.009.00239	41, -17	29DEC96
			Sodium Citrate	Calamine Lotion	329.007.00270	9, .	17MAY96
		Tannic Acid		Ivy Dry	329.010.00279	161, 105	29AUG96
			Zinc Oxide	Caladryl Clear	329.010.00279	110, 54	09JUL96
					157, 101	25AUG96	29AUG96
		Calamine Lotion		329.007.00270	9, .	17MAY96	19MAY96
ANTISEPTICS & DISINFECTANTS	Dofamium Chloride	Desogen	329.009.00325	27, -29	22SEP96	.	
		Phenol	Chloraseptic	329.003.00247	34, -21	05MAR96	.
CORTICOSTEROIDS	Clobetasol Propionate	Temovate Emollient Cream	329.009.00239	119, 62	17MAR97	.	
		Fluticasone Propionate	Flonase	329.012.00223	-107, .	15MAY96	.
			Methylprednisolone Sodium Succinate	Solu-Medrol	329.012.00230	50, -20	18APR97

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

412

CONFIDENTIAL  
BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
GU SYSTEM/SEX HORMONES	ANTIINFECTIVES/ANTIS EPTICS	Butoconazole Nitrate	Femstat	329.005.00255	38, .	10APR96	15APR96
		Clotrimazole	Lotrimin Cream	329.007.00270	-10, .	29APR96	19MAY96
	SEX HORMONES/STIMULANTS	Desogestrel	Desogen-28	329.003.00082	-344, .	01JAN95	.
		Ethinylestradiol	Desogen-28	329.003.00082	-344, .	01JAN95	.
			Levlen 28	329.008.00187	9, .	07DEC95	.
		Loestrin	329.006.00040	9, .	07DEC95	.	
			-63, .	15DEC94	.		
		Ovcon	329.008.00187	-332, .	01JAN95	.	
		Triphasil	329.009.00134	-1282, .	01JAN92	.	
			329.009.00171	-1282, .	01JAN92	.	
			1, .	07NOV95	.		
		1, .	07NOV95	.			
		Levonorgestrel	Levlen 28	329.008.00187	9, .	07DEC95	.
			Triphasil	329.009.00134	9, .	07DEC95	.
		329.009.00171	-1282, .	01JAN92	.		
-1282, .	01JAN92	.					
1, .	07NOV95	.					
1, .	07NOV95	.					
Norethisterone	Ovcon	329.008.00187	-332, .	01JAN95	.		
Norethisterone Acetate	Loestrin	329.006.00040	-63, .	15DEC94	.		
	-63, .	15DEC94	.				
Oral Contraceptive	Birth Control Pills	329.005.00007	-219, -282	04APR94	.		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

413

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Flurbiprofen	Ansaid	329.008.00273	-58, -121	20MAR96	10APR96#
		Ibuprofen	Advil	329.002.00100	-34, -92	01FEB95	01MAR95#
				329.003.00090	3, .	16MAR95	.
				329.003.00249	-1892, .	01JAN91	.
					3, .	09MAR96	09MAR96
					38, .	13APR96	15APR96
				329.003.00314	25, .	15NOV96	17NOV96
				329.005.00295	-7, .	21MAR96	21MAR96#
				329.006.00041	12, -53	16APR95	18APR95
				329.007.00139	-9, .	29APR95	01MAY95#
				329.007.00307	2, .	17MAY96	17MAY96
					14, .	29MAY96	29MAY96
					19, .	03JUN96	04JUN96
				329.009.00195	-1809, .	01JAN91	.
				329.009.00203	-63, .	01JAN96	.
				329.012.00230	53, -17	21APR97	23APR97
			Coadvil	329.009.00264	-732, .	31OCT94	.
			Ibuprofen	329.001.00061	-15, .	14JUL94	14JUL94#
				329.002.00321	-508, .	01JAN95	.
				329.005.00118	-20, .	27APR95	27APR95#
				329.005.00153	., .	.	.
					84, 28	17APR96	15MAY96
				329.005.00255	-3, .	01MAR96	03MAR96#
					8, .	11MAR96	11MAR96
				329.005.00335	-20, .	08FEB97	09FEB97#
				329.007.00307	-1597, .	01JAN92	.
			Motrin	329.002.00057	22, -36	29SEP94	29SEP94
				329.008.00187	4, .	02DEC95	05DEC95
			Nuprin	329.006.00041	141, 77	23AUG95	23AUG95
		Ketoprofen	Orudis Kt	329.009.00325	-2430, -2485	01JAN90	.
		Naproxen	Naproxen	329.009.00134	-34, .	02JUN95	09JUN95#
		Naproxen Sodium	Aleve	329.002.00050	5, .	27MAR95	28MAR95
				329.011.00208	-249, -308	01JAN96	.
			Anaprox	329.009.00134	-916, .	01JAN93	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

414

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Naproxen Sodium	Anaprox	329.009.00195	-713, .	01JAN94	.
		Pseudoephedrine Hydrochloride	Coadvil	329.009.00264	-732, .	31OCT94	.
	MUSCLE RELAXANTS	Baclofen	Baclofen	329.006.00040	-3698, .	01JAN85	.
		Cyclobenzaprine	Cyclobenzaprine	329.007.00146	7, -47 238, 185	31JAN96 18SEP96	31JAN96 18SEP96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	ANTI-ASTHMATICS	Antiasthmatic, Nos	Over The Counter {Asthma Nos}	329.003.00317	., .	.	.
		Beclometasone Dipropionate	Vancenase	329.006.00040	-3698, .	01JAN85	.
		Cromoglicate Sodium	Sodium (Cromoglycate)	329.012.00223	-107, .	15MAY96	.
		Orciprenaline Sulfate	Alupent	329.009.00301	-808, -864	01JAN94	.
		Pseudoephedrine	Pseudoephed	329.007.00269	-101, .	01JAN96	.
		Salbutamol	Albuterol	329.003.00093	-1997,-2060	01JAN90	.
			Proventil	329.009.00195	-348, .	01JAN95	.
				329.011.00286	-348, .	01JAN95	.
			Ventolin	329.011.00286	-2348,-2416	01JAN90	.
				329.005.00113	-2348,-2416	01JAN90	.
				329.005.00113	-3591, .	01APR85	.
				329.006.00040	-3591, .	01APR85	.
				329.006.00040	-3698, .	01JAN85	.
				329.011.00163	-3698, .	01JAN85	.
				329.011.00163	-603, .	01APR94	.
				329.011.00163	-603, .	01APR94	.
			Ventolin Inhaler	329.009.00325	-2430,-2485	01JAN90	.
				329.009.00325	-2430,-2485	01JAN90	.
		Theophylline	Theo-Dur	329.009.00301	-443, -499	01JAN95	.
	COUGH AND COLD PREP	Carbinoxamine Maleate	Naldecon	329.005.00003	., .	.	.
		Chlorphenamine Maleate	Comtrex	329.003.00249	48, .	23APR96	23APR96
			Dristan	329.012.00227	142, 73	08MAY97	09MAY97
			Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

416

CONFIDENTIAL  
BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	COUGH AND COLD PREP	Codeine Phosphate	Tussi-Organidin	329.005.00003	., .	.	.
		Cough Cold Preparations Nos	Flu Relief {Nos}	329.007.00146	12, -42	05FEB96	06FEB96
			Osco Brand Cold And Flu Medication {Nos}	329.006.00041	12, -53	16APR95	18APR95
		Cough Syrup/Med	Cough Syrup {Nos}	329.009.00194	29, -28	02JAN96	16JAN96
		Dextromethorphan Hydrobromide	Comtrex	329.003.00249	48, .	23APR96	23APR96
			Dayquil	329.006.00041	140, 76	22AUG95	22AUG95
			Nyquil	329.011.00284	9, -48	30MAR96	30MAR96
			Nyquil	329.003.00247	34, -21	05MAR96	.
			Tylenol Cold And Flu	329.009.00326	-24, -77	12AUG96	15AUG96#
			Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96
		Doxylamine Succinate	Nyquil	329.003.00247	34, -21	05MAR96	.
			Nyquil	329.009.00326	-24, -77	12AUG96	15AUG96#
		Guaifenesin	Dayquil	329.006.00041	140, 76	22AUG95	22AUG95
			Dayquil	329.011.00284	9, -48	30MAR96	30MAR96
			Robitussin	329.005.00118	3, .	19MAY95	.
			Robitussin	329.005.00297	-5, .	14APR96	16APR96#
			Robitussin	329.011.00163	6, .	30NOV95	01DEC95
		Hydrocodone Bitartrate	Codimal Dh	329.009.00203	-63, .	01JAN96	.
		Iodinated Glycerol	Tussi-Organidin	329.005.00003	., .	.	.
		Mepyramine Maleate	Codimal Dh	329.009.00203	-63, .	01JAN96	.
		Paracetamol	Comtrex	329.003.00249	48, .	23APR96	23APR96
			Dayquil	329.006.00041	140, 76	22AUG95	22AUG95
			Dayquil	329.011.00284	9, -48	30MAR96	30MAR96
			Dristan	329.012.00227	142, 73	08MAY97	09MAY97
			Nyquil	329.003.00247	34, -21	05MAR96	.
			Nyquil	329.009.00326	-24, -77	12AUG96	15AUG96#

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	COUGH AND COLD PREP	Paracetamol	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96
		Phenylephrine Hydrochloride	Codimal Dh	329.009.00203	-63, .	01JAN96	.
			Dristan Naldecon	329.012.00227 329.005.00003	142, 73 ., .	08MAY97	09MAY97 .
		Phenylpropanolamine Hydrochloride	Comtrex	329.003.00249	48, .	23APR96	23APR96
			Naldecon	329.005.00003	., .	.	.
		Phenyltoloxamine Citrate	Naldecon	329.005.00003	., .	.	.
			Pseudoephedrine Hydrochloride	Dayquil	329.006.00041	140, 76	22AUG95
		Nyquil		329.011.00284 329.003.00247	9, -48 34, -21	30MAR96 05MAR96	30MAR96 .
				Tylenol Cold And Flu	329.009.00326 329.005.00153	-24, -77 -9, -65	12AUG96 16JAN96
	NASAL PREP	Beclometasone Dipropionate	Vancenase	329.006.00040	-3698, .	01JAN85	.
		Brompheniramine Maleate	Dimetapp	329.007.00146	220, 167	31AUG96	01SEP96
		Cromoglicate Sodium	Sodium (Cromoglycate)	329.012.00223	-107, .	15MAY96	.
		Dexbrompheniramine Maleate	Drixoral	329.007.00146	-16, -69	09JAN96	09JAN96#
			329.009.00239	92, 35	18FEB97	17MAR97	
Fluticasone Propionate	Flonase	329.012.00223	-107, .	15MAY96	.		
	Ibuprofen	Coadvil	329.009.00264	-732, .	31OCT94	.	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

418

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	NASAL PREP	Mepyramine Maleate	Triaminic	329.012.00227	142, 73	08MAY97	09MAY97
		Paracetamol	Tylenol Sinus	329.009.00194	29, -28	02JAN96	16JAN96
		Pheniramine Maleate	Triaminic	329.012.00227	142, 73	08MAY97	09MAY97
		Phenylephrine Hydrochloride	Dimetapp	329.007.00146	220, 167	31AUG96	01SEP96
		Phenylpropanolamine Hydrochloride	Dimetapp	329.007.00146	220, 167	31AUG96	01SEP96
			Triaminic	329.012.00227	142, 73	08MAY97	09MAY97
		Pseudoephedrine	Pseudoephed	329.007.00269	-101, .	01JAN96	.
		Pseudoephedrine Hydrochloride	Actifed	329.007.00307	31, .	15JUN96	16JUN96
			Coadvil	329.009.00264	-732, .	31OCT94	.
			Efidac	329.007.00146	222, 169	02SEP96	06SEP96
			Efidac/24	329.007.00146	178, 125	20JUL96	22JUL96
			Sudafed	329.005.00255	32, .	04APR96	04APR96
					45, .	17APR96	18APR96
					1, -56	05MAR96	07MAR96
					20, -43	30SEP96	03OCT96
					-2348, -2416	01JAN90	.
				Tylenol Sinus	329.009.00194	29, -28	02JAN96
		Pseudoephedrine Sulfate	Drixoral	329.007.00146	-16, -69	09JAN96	09JAN96#
				329.009.00239	92, 35	18FEB97	17MAR97
		Triprolidine Hydrochloride	Actifed	329.007.00307	31, .	15JUN96	16JUN96
	SYSTEMIC ANTIHISTAMINES	Chlorphenamine Maleate	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96
		Dextromethorphan Hydrobromide	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

419

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	SYSTEMIC ANTIHISTAMINES	Dimenhydrinate	Gravol	329.012.00230	69, -1	07MAY97	07MAY97
		Diphenhydramine Citrate	Excedrin Pm	329.001.00061	-28, .	01JUL94	28JUL94#
		Diphenhydramine Hydrochloride	Benadryl	329.002.00243	4, .	17MAR96	24MAR96
				329.003.00079	15, .	17MAY95	17MAY95
				329.003.00317	27, .	14JAN97	14JAN97
				329.005.00007	197, 134	24MAY95	24MAY95
				329.007.00146	-24, -77	01JAN96	.
				329.007.00270	9, .	17MAY96	19MAY96
				329.007.00307	-45, .	01APR96	01APR96#
				329.009.00262	32, .	16JUN96	21JUN96
				329.009.00325	27, .	15MAR97	15MAR97
				329.010.00279	45, -11	10OCT96	.
				329.011.00163	162, 106	30AUG96	05SEP96
					-4, .	21NOV95	21NOV95#
					-4, .	21NOV95	21NOV95#
		Loratadine	Claritin	329.011.00209	-72, -134	01JUL96	.
		Paracetamol	Excedrin Pm Tylenol Cold And Flu	329.001.00061 329.005.00153	-28, . -9, -65	01JUL94 16JAN96	28JUL94# 27JAN96
		Promethazine Hydrochloride	Phenergan	329.009.00239	41, -17	29DEC96	29DEC96
		Pseudoephedrine Hydrochloride	Tylenol Cold And Flu	329.005.00153	-9, -65	16JAN96	27JAN96

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

420

CONFIDENTIAL  
BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
SENSORY ORGANS	OPHTALMOL/OTOLOGICAL PREP	Erythromycin	Erycette 2% Cream	329.010.00279	91, 35	20JUN96	.
			Erythromycin	329.005.00003	-19, .	01SEP94	14SEP94#
		Tetracycline	Tetracycline	329.005.00153	-389, -445	01JAN95	.
	OPHTHALMOLOGICALS	Cromoglicate Sodium	Sodium (Cromoglycate)	329.012.00223	-107, .	15MAY96	.
		Methylprednisolone Sodium Succinate	Solu-Medrol	329.012.00230	50, -20	18APR97	18APR97
		Sulfacetamide Sodium	Sulfacetamide Sodium	329.009.00262	-7, .	10FEB97	07APR97
	Tetracycline	Tetracycline	329.005.00153	-389, -445	01JAN95	.	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

421

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
SYSTEMIC HORMONAL	CORTICOSTEROIDS	Methylprednisolone Sodium Succinate	Solu-Medrol	329.012.00230	50, -20	18APR97	18APR97
	OTHER	Melatonin	Melatonin	329.009.00239	42, -16	30DEC96	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
VARIOUS	ALL OTHER THERAP PROD	Herbal Medication	Unknown Chinese Herbal Med	329.004.00215	-139, .	01NOV96	11MAR97#
		Homeopathic Preparations	Yinchia0 Tablet {Chiehtupien} {Homeopathic}	329.004.00215	7, .	26MAR97	26MAR97
	ALLERGENS	Allergenic Extract, Nos	Allergy Shots	329.009.00203	-793, .	01JAN94	.
			Homeopathic Allergy Medicine Over The Counter {Allergenic Extract Nos}	329.007.00146 329.003.00317	222, 169 . , .	02SEP96	07SEP96 .
	GENERAL NUTRIENTS	Nutritional Supplement Nos	Met-Rx {Nutritional Supplement}	329.006.00041	134, 70	16AUG95	23AUG95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

423

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
ALIMENTARY TRACT/METAB	ANTACID/ANITFLAT/ANT IPEPTIC	Aluminium Hydroxide	Mylanta	329.001.00062	-2240,	. 01SEP88	01SEP93#	
			Mylanta Double Strength	329.009.00327	-624,	. 01JAN95	.	
		Dimeticone, Activated	Mylanta	329.001.00062	-2240,	. 01SEP88	01SEP93#	
			Mylanta Double Strength	329.009.00327	-624,	. 01JAN95	.	
		Famotidine	Pepcid	329.002.00246	-838,	. 01JAN94	.	
				329.009.00197	-58,	-112 01NOV95	.	
		Magnesium Hydroxide	Mylanta Mylanta Double Strength	329.001.00062	-2240,	. 01SEP88	01SEP93#	
				329.009.00327	-624,	. 01JAN95	.	
		Omeprazole	Prilosec	329.003.00094	32,	. 24NOV95	.	
				Ranitidine Hydrochloride	Zantac	329.009.00312	-308,	. 01JAN96
		329.009.00327	-624,		. 01JAN95	.		
		ANTIDIARRHEA/GI ANTIBIOTICS	Bismuth Subsalicylate	Pepto Bismol	329.006.00042	32,	-26 07JAN96	07JAN96
				329.007.00311	113,	53 23JAN97	24JAN97	
				329.009.00174	13,	-45 03DEC95	07DEC95	
329.012.00217	29,			. 18JUN96	19JUN96			
GI ANTISPAS/ANTICHOLIN	Loperamide Hydrochloride	Imodium	329.009.00276	70,	. 31MAR97	31MAR97		
		Dicycloverine	Dicyclomine	329.009.00327	-624,	. 01JAN95	.	
LAXATIVES	Hyoscine Butylbromide	Buscopan	329.004.00016	16,	. 28MAR95	30MAR95		
		Bisacodyl	Dulcolax	329.007.00311	7,	-54 09OCT96	09OCT96	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

424

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
 by WHO ATC Classification and Generic Term and by Treatment Group  
 Intent-to-Treat Population

=====

----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ALIMENTARY TRACT/METAB	LAXATIVES	Bisacodyl	Dulcolax	329.007.00311	7, -54	09OCT96	09OCT96

425

\* days relative to start of acute phase, days relative to start of continuation phase  
 # stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date		
ANTIINFECTIVES, SYSTEMIC	ANTIBIOTICS	Amoxicillin	Amoxicillin	329.001.00069	-51, .	27DEC94	27JAN95#		
				329.001.00071	-20, .	03FEB95	13FEB95#		
				329.002.00107	236, 180	16SEP96	26SEP96		
				329.002.00323	151, 93	11APR97	18APR97		
				329.005.00111	37, -20	16FEB95	20FEB95		
				329.005.00114	7, -51	06FEB95	16FEB95		
				329.005.00115	19, -53	24FEB95	15MAR95		
				329.005.00253	-10, .	29JAN96	31JAN96#		
					-10, .	29JAN96	31JAN96#		
				329.005.00334	7, .	06FEB97	16FEB97		
				329.010.00282	-17, .	09JUL96	14JUL96#		
				Amoxicillin Trihydrate	Amoxil	329.012.00224	87, 21	11DEC96	18DEC96
						Augmentin	329.002.00320	117, 56	09SEP96
		329.005.00111	97, 41				17APR95	27APR95	
		329.005.00331	27, .				17DEC96	27DEC96	
		329.009.00197	174, 120				19JUN96	23JUN96	
		329.009.00330	-20, .				01OCT96	.	
		Antibiotic Nos	Antibiotic {Nos}	329.008.00162	29, -37	29NOV95	09DEC95		
					37, -29	07DEC95	17DEC95		
		Azithromycin	Zithromax	329.001.00123	10, .	13JAN96	18JAN96		
				329.005.00331	-22, .	30OCT96	06NOV96#		
		Cefalexin Monohydrate	Keflex	329.007.00266	52, .	27APR96	10MAY96		
		Clarithromycin	Biaxin	329.001.00207	56, .	23APR96	02MAY96		
Clavulanic Acid	Augmentin	329.002.00320	117, 56	09SEP96	19SEP96				
		329.005.00111	97, 41	17APR95	27APR95				
		329.005.00331	27, .	17DEC96	27DEC96				
		329.009.00197	174, 120	19JUN96	23JUN96				
		329.009.00330	-20, .	01OCT96	.				
Doxycycline	Doxycycline	329.005.00253	26, .	04MAR96	12MAR96				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

426

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
ANTIINFECTIVES, SYSTEMIC	ANTIBIOTICS	Doxycycline	Doxycycline	329.006.00037	10, .	06FEB95	13FEB95	
		Erythromycin	Erythromycin	329.004.00018 329.012.00027	-9, . -8, .	24APR95 28NOV95	02MAY95# 08DEC95	
		Erythromycin Ethylsuccinate	Pediazole	329.012.00225	124, 60	29MAR97	07APR97	
		Metacycline	Metacycline	329.009.00202	-415, .	01JAN95	.	
		Minocycline	Minocin	329.006.00259	-540, .	01DEC94	.	
		Sulfafurazole Acetyl	Pediazole	329.012.00225	124, 60	29MAR97	07APR97	
		Tetracycline	Tetracycline	329.008.00191	-51, -112	12DEC95	.	
		CHEMOTHERAPEUTICS	Erythromycin Ethylsuccinate	Pediazole	329.012.00225	124, 60	29MAR97	07APR97
			Sulfafurazole Acetyl	Pediazole	329.012.00225	124, 60	29MAR97	07APR97
			Sulfamethoxazole	Bactrim	329.007.00311	-27, -87 21, -40 28, -33	06SEP96 23OCT96 30OCT96	20SEP96# 24OCT96 02NOV96
	Septra Double Strength Sulfatrim		329.001.00069	1, .	16FEB95	24FEB95		
	329.007.00311		166, 106	17MAR97	31MAR97			
		Trimethoprim	Bactrim	329.007.00311	-27, -87 21, -40 28, -33	06SEP96 23OCT96 30OCT96	20SEP96# 24OCT96 02NOV96	
			Septra Double Strength Sulfatrim	329.001.00069	1, .	16FEB95	24FEB95	
			329.007.00311	166, 106	17MAR97	31MAR97		
VACCINES		Tetanus Toxoid	Tetanus {Toxoid}	329.009.00198	48, .	18FEB96	18FEB96	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

427

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
ANTINEOPLASTIC & IMMUNOSUP	ANTINEOPLASTIC,HORMONES	Diethylstilbestrol Dipropionate	Cyclen	329.004.00018	-1583, .	01JAN91	24MAY95
		Medroxyprogesterone Acetate	Depo-Provera	329.005.00293	21, .	01APR97	01APR97

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication



PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
BLOOD/BLOOD FORM ORGANS	ANTIANAEMIC PREP	Ferrous Sulfate	Feosol Liquid	329.009.00306	44, .	24JUL96	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

429

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date		
CENTRAL NERVOUS SYSTEM	ANALGESICS	Acetylsalicylic Acid	222	329.004.00213	65, 11	05OCT96	05OCT96		
			Aspirin	329.001.00123	12, .	15JAN96	.		
				329.002.00049	19, .	27MAR95	27MAR95		
				329.003.00094	49, .	11DEC95	11DEC95		
				329.005.00253	-6, .	02FEB96	14FEB96		
				329.010.00277	., .	.	.		
				329.005.00254	104, 49	28MAY96	28MAY96		
				329.004.00213	3, -52	04AUG96	04AUG96		
				329.012.00027	19, .	24DEC95	.		
				329.009.00174	-689, -746	01JAN94	.		
					13, -45	03DEC95	07DEC95		
				Midol	329.003.00252	39, .	18MAY96	18MAY96	
					329.009.00136	-1005, .	01JAN93	.	
					329.009.00202	-50, .	01JAN96	.	
				Midol (Teen)	329.005.00298	231, 175	07JAN97	09JAN97	
				Aluminium Glycinate	Bufferin	329.004.00213	3, -52	04AUG96	04AUG96
				Analgesics	Unknown {Analgesic Nos}	329.002.00323	-1, -59	11NOV96	01DEC96
					Unknown {Analgesic}	329.002.00323	49, -10	30DEC96	.
				Caffeine	Excedrin	329.009.00174	-689, -746	01JAN94	.
							13, -45	03DEC95	07DEC95
					Midol	329.003.00252	39, .	18MAY96	18MAY96
						329.009.00136	-1005, .	01JAN93	.
						329.009.00202	-50, .	01JAN96	.
		Midol (Teen)	329.005.00298	231, 175	07JAN97	09JAN97			
	Caffeine Citrate	222	329.004.00213	65, 11	05OCT96	05OCT96			
	Chlorphenamine Maleate	Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96			
		Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#			
	Cinnamedrine Hydrochloride	Midol	329.003.00252	39, .	18MAY96	18MAY96			
			329.009.00136	-1005, .	01JAN93	.			

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

430

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Cinnamedrine Hydrochloride	Midol	329.009.00202	-50, .	01JAN96	.
			Midol (Teen)	329.005.00298	231, 175	07JAN97	09JAN97
		Codeine Phosphate	222	329.004.00213	65, 11	05OCT96	05OCT96
			Tylenol#3	329.005.00111	96, 40	16APR95	17APR95
		Dextromethorphan	Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96
		Dextromethorphan Hydrobromide	Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96
			Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#
		Diphenhydramine Hydrochloride	Benadryl Cold	329.009.00200	-22, .	01JAN96	05JAN96#
		Hydrocodone Bitartrate	Vicodin	329.005.00115	19, -53	24FEB95	10MAR95
		Magnesium Carbonate	Bufferin	329.004.00213	3, -52	04AUG96	04AUG96
		Mepyramine Maleate	Pamprin	329.001.00123	-20, .	15DEC95	17DEC95#
				329.005.00298	-7, -63	15MAY96	15MAY96#
					46, -11	06JUL96	07JUL96
					167, 111	04NOV96	04NOV96
				200, 144	07DEC96	09DEC96	
Pamabrom	Pamprin	329.001.00123	-20, .	15DEC95	17DEC95#		
		329.005.00298	-7, -63	15MAY96	15MAY96#		
			46, -11	06JUL96	07JUL96		
			167, 111	04NOV96	04NOV96		
		200, 144	07DEC96	09DEC96			
Paracetamol	Acetaminophen	329.004.00213	65, 11	05OCT96	05OCT96		
			110, 56	19NOV96	19NOV96		
			122, 68	01DEC96	01DEC96		
			150, 96	29DEC96	29DEC96		
			224, 170	13MAR97	13MAR97		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

431

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Acetaminophen	329.006.00042	140, 83	24APR96	24APR96
			Benadryl Cold	329.009.00200	-22, .	01JAN96	05JAN96#
			Excedrin	329.009.00174	-689, -746	01JAN94	.
					13, -45	03DEC95	07DEC95
			Pamprin	329.001.00123	-20, .	15DEC95	17DEC95#
				329.005.00298	-7, -63	15MAY96	15MAY96#
					46, -11	06JUL96	07JUL96
					167, 111	04NOV96	04NOV96
					200, 144	07DEC96	09DEC96
			Sinutab	329.003.00315	7, .	18NOV96	20NOV96
				329.004.00213	11, -44	12AUG96	12AUG96
					134, 80	13DEC96	13DEC96
				329.012.00217	16, .	05JUN96	05JUN96
			Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96
			Sudafed Sinus	329.005.00298	202, 146	09DEC96	10DEC96
			Tylenol	329.001.00062	-5437, .	01DEC79	.
				329.001.00064	-4013, -4067	15NOV83	.
				329.001.00069	-51, .	27DEC94	27JAN95#
				329.001.00071	-17, .	06FEB95	12FEB95#
				329.001.00123	49, .	21FEB96	.
				329.001.00207	53, .	20APR96	25APR96
				329.002.00097	-15, -73	19DEC94	26DEC94#
					14, -45	16JAN95	17JAN95
					29, -30	31JAN95	07FEB95
					87, 29	30MAR95	.
				329.003.00086	-58, -115	01OCT94	08OCT94#
					36, -22	02JAN95	03JAN95
				329.003.00252	., .	.	.
				329.004.00018	-1583, .	01JAN91	03MAY95
					22, .	24MAY95	.
				329.005.00010	122, 65	13APR95	15APR95
				329.005.00012	37, -23	24JAN95	24JAN95
				329.005.00111	-4, -60	07JAN95	14FEB95
					36, -21	15FEB95	20FEB95
					65, 9	16MAR95	17MAR95
					94, 38	14APR95	15APR95
					96, 40	16APR95	17APR95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

432

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	ANALGESICS	Paracetamol	Tylenol	329.005.00114	5, -53	04FEB95	08FEB95
				329.005.00253	19, .	26FEB96	26FEB96
				329.005.00254	-13, -68	02FEB96	06FEB96#
					-4, -59	11FEB96	11FEB96#
					23, -33	08MAR96	08MAR96
					53, -3	07APR96	07APR96
					201, 146	02SEP96	02SEP96
					202, 147	03SEP96	03SEP96
				329.005.00293	-23, .	17FEB97	18FEB97#
					26, .	06APR97	06APR97
					39, .	19APR97	19APR97
				329.005.00331	1, .	21NOV96	21NOV96
					36, .	26DEC96	26DEC96
				329.005.00334	-50, .	12DEC96	19DEC96#
					32, .	03MAR97	03MAR97
					41, .	12MAR97	12MAR97
					48, .	19MAR97	20MAR97
				329.007.00144	39, -18	14JAN96	15JAN96
				329.009.00198	-366, .	01JAN95	.
				329.009.00200	-752, .	01JAN94	.
				329.009.00202	-415, .	01JAN95	.
				329.009.00238	-681, .	01JAN95	.
					50, .	31DEC96	.
				329.009.00276	-386, .	01JAN96	.
					-314, .	13MAR96	.
				329.009.00327	-989, .	01JAN94	.
				329.010.00263	6, .	14AUG96	14AUG96
					9, .	17AUG96	17AUG96
				329.010.00282	21, .	15AUG96	15AUG96
					39, .	02SEP96	02SEP96
329.011.00210	., .	.	.				
329.011.00285	-503, .	01JAN95	.				
329.012.00027	-1069, .	01JAN93	.				
	-15, .	21NOV95	07DEC95				
329.012.00217	-81, .	01MAR96	.				
329.012.00218	-8, -66	08JUN96	08JUN96#				
	26, -33	11JUL96	11JUL96				
329.012.00224	16, -51	01OCT96	01OCT96				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

433

CONFIDENTIAL  
BRL-029060-329-  
individual-data



Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
CENTRAL NERVOUS SYSTEM	PSYCHOANALEPTICS	Amitriptyline Hydrochloride	Elavil	329.009.00135	-9, .	23SEP95	24SEP95#
		Fluoxetine	Prozac	329.002.00241	108, 52	23MAY96	.
		Pemoline Magnesium	Cylert	329.009.00330	-13, .	08OCT96	08OCT96#
		Sertraline Hydrochloride	Zoloft	329.012.00217	30, .	19JUN96	.
		Venlafaxine Hydrochloride	Effexor	329.007.00311	-155, -215	01MAY96	27SEP96#
	PSYCHOLEPTICS	Diazepam	Valium	329.004.00018	26, .	28MAY95	28MAY95
				329.004.00020	-21, .	19OCT95	19OCT95#
		Lorazepam	Lorazepam	329.012.00027	16, .	21DEC95	26DEC95
		Paroxetine	Paxil	329.009.00135	36, .	06NOV95	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

435

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
DERMATOLOGICALS	ANTI-ACNE PREP	Isotretinoin	Accutane	329.009.00237	., .	.	.	
		Tretinoin	Retin-A	329.003.00252	., .	.	.	
	ANTIBIOTIC&CHEMOTHERAPEUT	Erythromycin	Erythromycin	329.004.00018	-9, .	24APR95	02MAY95#	
					329.012.00027	-8, .	28NOV95	08DEC95
		Tetracycline	Tetracycline	329.008.00191	-51, -112	12DEC95	.	
		ANTIPRURITICS	Calamine	Caladryl Lotion	329.003.00086	78, 21	13FEB95	25APR95
Camphor	Caladryl Lotion		329.003.00086	78, 21	13FEB95	25APR95		
		Diphenhydramine Hydrochloride	Benadryl	329.002.00097	-15, -73	19DEC94	26DEC94#	
					329.005.00010	81, 24	03MAR95	05MAR95
					329.007.00141	-23, .	29AUG95	30AUG95#
					329.009.00327	-259, .	01JAN96	.
					Caladryl Lotion	329.003.00086	78, 21	13FEB95
	CORTICOSTEROIDS	Glycerol	Caladryl Lotion	329.003.00086	78, 21	13FEB95	25APR95	
			Budesonide	Pulmicort	329.012.00217	29, .	18JUN96	19JUN96
			Fluticasone Propionate	Flonase	329.007.00311	21, -40	23OCT96	23NOV96
	OTHER	Methylprednisolone	Methylprednisolone	329.001.00123	10, .	13JAN96	18JAN96	
			Dermatologicals Nos	Topical Cream {Dermatological Nos}	329.005.00120	., .	.	.
			Permethrin	Elimite	329.009.00169	36, -30	05DEC95	05DEC95

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

436

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
GU SYSTEM/SEX HORMONES	SEX HORMONES/STIMULANTS	Desogestrel	Ortho-Cept 28	329.001.00123	18, .	21JAN96	.
		Diethylstilbestrol Dipropionate	Cyclen	329.004.00018	-1583, .	01JAN91	24MAY95
		Ethinylestradiol	Ortho Tri-Cyclen Ortho-Cept 28	329.004.00018	30, .	01JUN95	.
				329.001.00123	18, .	21JAN96	.
				329.006.00037	-119, .	01OCT94	.
				329.009.00312	-1038, .	01JAN94	.
		Triphasil	Triphasil	329.009.00198	-1038, .	01JAN94	.
				329.009.00198	-1096, .	01JAN93	.
		Injectable Contraceptive, Nos	Injectable Contraceptive {Nos}	329.003.00080	-51, .	07OCT95	.
				Levonorgestrel	Tri-Levlen	329.009.00312	-1038, .
		329.009.00198	-1038, .			01JAN94	.
		329.009.00198	-1096, .			01JAN93	.
		Medroxyprogesterone Acetate	Depo-Provera	329.005.00293	21, .	01APR97	01APR97
				Mestranol	Ortho Novum	329.009.00202	-50, .
		329.009.00202	-50, .			01JAN96	.
Norethisterone	Ortho Novum	329.009.00202	-50, .	01JAN96	.		
		329.006.00037	-119, .	01OCT94	.		
Norgestimate	Ortho Tri-Cyclen	329.004.00018	30, .	01JUN95	.		
Oral Contraceptive	Birth Control Pills	329.005.00115	-31, -102	06JAN95	.		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

437

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Ibuprofen	Advil	329.002.00246	48, .	04JUN96	04JUN96	
				329.005.00253	20, .	27FEB96	27FEB96	
				329.005.00298	26, -31	16JUN96	16JUN96	
					33, -24	23JUN96	23JUN96	
					56, -1	16JUL96	16JUL96	
					133, 77	01OCT96	04OCT96	
					329.005.00331	3, .	23NOV96	23NOV96
					329.005.00334	48, .	19MAR97	20MAR97
					329.007.00267	26, .	01APR96	01APR96
					329.009.00136	-275, .	01JAN95	.
					329.009.00197	-362, -416	01JAN95	.
					329.009.00302	-86, .	01JAN96	20MAR96#
					329.011.00164	19, .	09JAN96	.
					329.005.00298	-22, -78	30APR96	30APR96#
					329.002.00320	32, -30	16JUN96	22JUN96
				329.005.00254	24, -32	09MAR96	09MAR96	
				329.005.00298	149, 93	17OCT96	17OCT96	
				329.006.00042	108, 51	23MAR96	23MAR96	
					209, 152	02JUL96	02JUL96	
					210, 153	03JUL96	03JUL96	
					211, 154	04JUL96	04JUL96	
					212, 155	05JUL96	05JUL96	
					213, 156	06JUL96	06JUL96	
					216, 159	09JUL96	09JUL96	
					218, 161	11JUL96	11JUL96	
					220, 163	13JUL96	13JUL96	
					329.009.00312	-673, .	01JAN95	.
					329.010.00263	33, .	10SEP96	10SEP96
					329.012.00225	237, 173	20JUL97	23JUL97
					329.009.00327	-989, .	01JAN94	.
		329.010.00282	56, .	19SEP96	19SEP96			
		329.011.00285	18, .	04JUN96	.			
		Naproxen	Naprosyn	329.007.00311	47, -14	18NOV96	22NOV96	
		Naproxen Sodium	Aleve	329.001.00207	-7, .	21FEB96	28FEB96	
				329.005.00253	45, .	23MAR96	23MAR96	
				329.006.00042	211, 154	04JUL96	04JUL96	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

438

CONFIDENTIAL  
BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
MUSCULO-SKELETAL	ANTIINFLAM/ANTIRHEU PROD	Naproxen Sodium	Aleve	329.009.00135	-274, .	01JAN95	.
				329.009.00276	53, .	14MAR97	14MAR97
				329.010.00277	159, 103	06AUG96	06AUG96
			Anaprox	329.012.00027	-25, .	11NOV95	17NOV95#
		Oxaprozin	Daypro	329.009.00174	-13, -70	08NOV95	.
	Pseudoephedrine Hydrochloride	Advil Cold And Sinus	329.005.00298	-22, -78	30APR96	30APR96#	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	ANTI-ASTHMATICS	Beclometasone Dipropionate	Becloforte	329.012.00027	-127, .	01AUG95	20NOV95#
			Beconase Nasal Spray .042% Vancenase	329.005.00111 329.005.00111	85, 29 37, -20	05APR95 16FEB95	. .
		Budesonide	Pulmicort	329.012.00217	29, .	18JUN96	19JUN96
		Chlorphenamine Maleate	Codimal La	329.009.00327	-259, .	01JAN96	.
		Cromoglicate Sodium	Intal Nasalcrom	329.012.00027	-96, .	01SEP95	.
				329.005.00111	37, -20	16FEB95	.
		Dextromethorphan	Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96
		Paracetamol	Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96
		Pseudoephedrine	Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96
		Pseudoephedrine Hydrochloride	Codimal La	329.009.00327	-259, .	01JAN96	.
		Salbutamol	Albuterol	329.007.00311	166, 106 166, 106	17MAR97 17MAR97	24MAR97 24MAR97
				Proventil	329.005.00111	85, 29 85, 29	05APR95 05APR95
			Proventil Inhaler	329.007.00311	-27, -87 -27, -87	06SEP96 06SEP96	13SEP96# 13SEP96#
				329.005.00253	-10, . -10, .	29JAN96 29JAN96	08FEB96 08FEB96
			Ventolin	329.012.00027	-461, . -461, . 10, . 10, .	01SEP94 01SEP94 15DEC95 15DEC95	17NOV95# 17NOV95# .br/>.
		329.012.00225	130, 66	04APR97	04APR97		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

440

CONFIDENTIAL  
BRL-029060-329-  
individual-data

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
RESPIRATORY	ANTI-ASTHMATICS	Salbutamol	Ventolin	329.012.00225	130, 66	04APR97	04APR97	
			Ventolin Inhaler	329.005.00114	-565, -622	15JUL93	18OCT94#	
				329.005.00115	-565, -622	15JUL93	18OCT94#	
		Salbutamol Sulfate	Ventodisk	329.004.00016	-2628, .	01JAN88	.	
				-2628, .	01JAN88	.		
		Terbutaline Sulfate	Bricanyl Inhaler	329.012.00225	130, 66	04APR97	08APR97	
		CHEST RUBS/INHALANTS	Decongestant Nos	Unknown Decongestant {Nos}	329.005.00331	-14, .	07NOV96	17NOV96#
		COUGH AND COLD PREP	Brompheniramine Maleate	Dimetapp-C	329.004.00018	-12, .	21APR95	28APR95#
				Chlorphenamine Maleate	Dristan	329.002.00241	-36, -92	01JAN96
				Tylenol Allergy And Sinus	329.005.00298	-26, -82	26APR96	26APR96#
				Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96
				Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#
			Codeine	Promethazine With Codeine	329.005.00253	-10, .	29JAN96	31JAN96#
						-10, .	29JAN96	31JAN96#
			Codeine Phosphate	Dimetapp-C	329.004.00018	-12, .	21APR95	28APR95#
		Cough Syrup/Med	Cough Medicine Unknown Cough Syrup	329.002.00241 329.007.00311	64, 8 166, 106	09APR96 17MAR97	30APR96 24MAR97	
		Dextromethorphan	Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96	
		Dextromethorphan Hydrobromide	Nyquil	329.001.00071	-17, .	06FEB95	10FEB95#	
			Robitussin Cf	329.001.00071	-21, .	02FEB95	08FEB95#	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

441

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
RESPIRATORY	COUGH AND COLD PREP	Dextromethorphan Hydrobromide	Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96	
			Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#	
		Doxylamine Succinate	Nyquil	329.001.00071	-17, .	06FEB95	10FEB95#	
			Guaifenesin	Entex	329.009.00312	-308, .	01JAN96	.
		Entex La		329.010.00263	45, .	22SEP96	23SEP96	
		Humibid	329.007.00311	21, -40	23OCT96	24OCT96		
			329.005.00293	28, -33	30OCT96	02NOV96		
		Robitussin	329.005.00120	7, .	18MAR97	18MAR97		
			329.005.00331	19, .	17SEP95	19SEP95		
		329.009.00198	329.009.00276	55, .	23OCT95	23OCT95		
			329.012.00217	23, .	13DEC96	17DEC96		
		Robitussin Cf	329.001.00071	-366, .	01JAN95	.		
			329.001.00071	51, .	12MAR97	18MAR97		
		Hydrocodone Bitartrate	Vicodin	329.005.00115	21, .	10JUN96	12JUN96	
			329.001.00071	-21, .	02FEB95	08FEB95#		
		Paracetamol	Dristan	329.002.00241	19, -53	24FEB95	10MAR95	
			Neo Citran	329.004.00018	-36, -92	01JAN96	25JAN96#	
			Neo-Citran	329.012.00027	-12, .	21APR95	21APR95#	
			Nyquil	329.001.00071	10, .	15DEC95	17DEC95	
			Sudafed Cold And Cough	329.005.00298	-17, .	06FEB95	10FEB95#	
			Tylenol Allergy And Sinus	329.005.00298	204, 148	11DEC96	12DEC96	
			Tylenol Cold	329.005.00298	-26, -82	26APR96	26APR96#	
			Tylenol Cold Tablets	329.001.00071	39, -18	29JUN96	29JUN96	
			Vicodin	329.005.00115	-17, .	06FEB95	12FEB95#	
			Pheniramine Maleate	Neo Citran	329.004.00018	19, -53	24FEB95	10MAR95
				Neo-Citran	329.012.00027	-12, .	21APR95	21APR95#
		Phenylephrine Hydrochloride	Dimetapp-C	329.004.00018	10, .	15DEC95	17DEC95	
329.004.00018	-12, .		21APR95	28APR95#				

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	COUGH AND COLD PREP	Phenylephrine Hydrochloride	Dristan	329.002.00241	-36, -92	01JAN96	25JAN96#
			Entex	329.009.00312	-308, .	01JAN96	.
				329.010.00263	45, .	22SEP96	23SEP96
			Neo Citran	329.004.00018	-12, .	21APR95	21APR95#
			Neo-Citran	329.012.00027	10, .	15DEC95	17DEC95
		Phenylpropanolamine Hydrochloride	Dimetapp-C	329.004.00018	-12, .	21APR95	28APR95#
			Entex	329.009.00312	-308, .	01JAN96	.
				329.010.00263	45, .	22SEP96	23SEP96
			Entex La	329.007.00311	21, -40	23OCT96	24OCT96
				329.007.00311	28, -33	30OCT96	02NOV96
		Promethazine Hydrochloride	Robitussin Cf	329.001.00071	-21, .	02FEB95	08FEB95#
			Promethazine With Codeine	329.005.00253	-10, .	29JAN96	31JAN96#
		Pseudoephedrine	Promethazine With Codeine	329.005.00253	-10, .	29JAN96	31JAN96#
			Sudafed Cold And Cough	329.005.00298	204, 148	11DEC96	12DEC96
		Pseudoephedrine Hydrochloride	Nyquil	329.001.00071	-17, .	06FEB95	10FEB95#
			Tylenol Allergy And Sinus	329.005.00298	-26, -82	26APR96	26APR96#
			Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96
			Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#
		NASAL PREP	Aminoacetic Acid	Afrin	329.003.00086	-423, -480	01OCT93
Beclometasone Dipropionate	Becloforte			329.012.00027	-127, .	01AUG95	20NOV95#
	Beconase Nasal Spray .042%			329.005.00111	85, 29	05APR95	.
	Vancenase			329.005.00111	37, -20	16FEB95	.
Benzalkonium Chloride	Afrin			329.003.00086	-423, -480	01OCT93	09NOV94#

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

443

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
RESPIRATORY	NASAL PREP	Brompheniramine Maleate	Dimetapp	329.004.00018	-12, .	21APR95	21APR95#
				329.009.00128	-830, .	01JAN93	.
		Budesonide	Pulmicort	329.012.00217	29, .	18JUN96	19JUN96
		Clemastine Fumarate	Tavist D Tavist-D	329.003.00086	15, -43	12DEC94	14DEC94
				329.003.00086	169, 112	15MAY95	19MAY95
		Cromoglicate Sodium	Intal Nasalcrom	329.012.00027	-96, .	01SEP95	.
				329.005.00111	37, -20	16FEB95	.
		Decongestant Nos	Unknown Decongestant {Nos}	329.005.00331	-14, .	07NOV96	17NOV96#
				329.009.00136	-275, .	01JAN95	.
		Dexbrompheniramine Maleate	Drixoral	329.009.00174	-385, -442	01NOV94	.
				329.009.00200	-22, .	01JAN96	05JAN96#
		Diphenhydramine Hydrochloride	Benadryl Cold	329.007.00311	21, -40	23OCT96	23NOV96
		Fluticasone Propionate	Flonase	329.005.00298	-22, -78	30APR96	30APR96#
		Ibuprofen	Advil Cold And Sinus	329.003.00086	-423, -480	01OCT93	09NOV94#
		Oxymetazoline Hydrochloride	Afrin	329.009.00200	-22, .	01JAN96	05JAN96#
		Paracetamol	Benadryl Cold Sudafed Sinus Tylenol Sinus	329.005.00298	202, 146	09DEC96	10DEC96
329.005.00298	12, -45			02JUN96	05JUN96		
329.004.00018	-12, .			21APR95	21APR95#		
Phenylephrine Hydrochloride	Dimetapp	329.009.00128	-830, .	01JAN93	.		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

444

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
RESPIRATORY	NASAL PREP	Phenylmercuric Acetate	Afrin	329.003.00086	-423, -480	01OCT93	09NOV94#	
		Phenylpropanolamine Hydrochloride	Dimetapp	329.004.00018	-12, .	21APR95	21APR95#	
			Tavist D	329.009.00128	-830, .	01JAN93	.	
			Tavist-D	329.003.00086	15, -43	12DEC94	14DEC94	
		Prednisone	Prednisone	329.012.00225	169, 112	15MAY95	19MAY95	
			Pseudoephedrine Hydrochloride	Actifed	329.012.00225	130, 66	04APR97	09APR97
		Actifed		329.005.00120	15, .	13SEP95	14SEP95	
		Advil Cold And Sinus		329.005.00298	-22, -78	30APR96	30APR96#	
		Benadryl Cold		329.009.00200	-22, .	01JAN96	05JAN96#	
		Sudafed		Sudafed	329.001.00207	-21, .	07FEB96	28FEB96
				Sudafed	329.007.00311	85, 25	26DEC96	26DEC96
		Sudafed		329.009.00238	38, .	19DEC96	31DEC96	
		Sudafed		329.012.00027	10, .	15DEC95	17DEC95	
		Sudafed Sinus		329.005.00298	202, 146	09DEC96	10DEC96	
		Tylenol Sinus		329.005.00298	12, -45	02JUN96	05JUN96	
		Pseudoephedrine Sulfate	Drixoral	329.009.00136	-275, .	01JAN95	.	
			Drixoral	329.009.00174	-385, -442	01NOV94	.	
		Sorbitol	Afrin	329.003.00086	-423, -480	01OCT93	09NOV94#	
		Tripolidine Hydrochloride	Actifed	329.005.00120	15, .	13SEP95	14SEP95	
	SYSTEMIC ANTIHISTAMINES	Cetirizine Hydrochloride	Reactine	329.004.00016	13, .	25MAR95	.	
Chlorphenamine Maleate		Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96		
		Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

445

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date	
RESPIRATORY	SYSTEMIC ANTI-HISTAMINES	Codeine	Promethazine With Codeine	329.005.00253	-10, .	29JAN96	31JAN96#	
						-10, .	29JAN96	31JAN96#
		Dextromethorphan Hydrobromide	Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96	
			Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#	
		Dimenhydrinate	Gravol	329.012.00224	108, 42	01JAN97	01JAN97	
		Diphenhydramine Hydrochloride	Benadryl	329.002.00097	-15, -73	19DEC94	26DEC94#	
				329.005.00010	81, 24	03MAR95	05MAR95	
				329.007.00141	-23, .	29AUG95	30AUG95#	
				329.009.00327	-259, .	01JAN96	.	
		Benadryl Cold	329.009.00200	-22, .	01JAN96	05JAN96#		
			Loratadine	Claritin	329.004.00018	13, .	15MAY95	18MAY95
					329.005.00298	40, -17	30JUN96	01JUL96
		329.009.00312			-308, .	01JAN96	.	
		Paracetamol	Benadryl Cold	329.009.00200	-22, .	01JAN96	05JAN96#	
				Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96
				Tylenol Cold Tablets	329.001.00071	-17, .	06FEB95	12FEB95#
		Promethazine Hydrochloride	Promethazine With Codeine	329.005.00253	-10, .	29JAN96	31JAN96#	
							-10, .	29JAN96
		Pseudoephedrine Hydrochloride	Benadryl Cold	329.009.00200	-22, .	01JAN96	05JAN96#	
				Tylenol Cold	329.005.00298	39, -18	29JUN96	29JUN96
Tylenol Cold Tablets	329.001.00071			-17, .	06FEB95	12FEB95#		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

446

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
SENSORY ORGANS	OPHTALMOL/OTOLOGICAL PREP	Betamethasone Sodium Phosphate	Garasone	329.012.00027	-9, .	27NOV95	08DEC95
		Erythromycin	Erythromycin	329.004.00018 329.012.00027	-9, . -8, .	24APR95 28NOV95	02MAY95# 08DEC95
		Gentamicin Sulfate	Garasone	329.012.00027	-9, .	27NOV95	08DEC95
		Tetracycline	Tetracycline	329.008.00191	-51, -112	12DEC95	.
	OPHTHALMOLOGICALS	Cromoglicate Sodium	Intal	329.012.00027	-96, .	01SEP95	.
			Nasalcrom	329.005.00111	37, -20	16FEB95	.
		Methylprednisolone	Methylprednisolone	329.001.00123	10, .	13JAN96	18JAN96
		Steroid Eye Drops, Nos	Steroid Eye Drops {Nos}	329.005.00012	165, 106	01JUN95	.
		Tetracycline	Tetracycline	329.008.00191	-51, -112	12DEC95	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

447

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.13

Listing of Prior and Concomitant Medications  
by WHO ATC Classification and Generic Term and by Treatment Group  
Intent-to-Treat Population

=====

----- Treatment Group=PLACEBO -----

ATC Level I	ATC Level II	Generic Term	Drug Name	Patient ID	Relative Days *	Start Date	Stop Date
SYSTEMIC HORMONAL	CORTICOSTEROIDS	Corticosteroids	Steroidal Nasal Preps. {Nos}	329.005.00111	97, 41	17APR95	.
		Methylprednisolone	Methylprednisolone	329.001.00123	10, .	13JAN96	18JAN96
		Prednisone	Prednisone	329.012.00225	130, 66	04APR97	09APR97
	THYROID THERAPY	Levothyroxine Sodium	Synthroid	329.009.00135	-1370, .	01JAN92	.

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.001.00063	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM DERMATOLOGICALS RESPIRATORY	Amoxicillin	29,	06DEC94	16DEC94	750MG	EAR ACHE SORE THROAT
		Tylenol	-1529,	01SEP90	.	500MG PRN	HEADACHE
		Benadryl	-4086,	01SEP83	.	25MG PRN	ALLERGY
		Actifed	-4086,	01SEP83	.	1TAB PRN	ALLERGY
329.001.00065	CENTRAL NERVOUS SYSTEM	Tylenol #1	-2115,	01FEB89	.	1000MG	HEADACHE
		Multiple Vitamin	-69,	01DEC94	08FEB95	1TABLET	DIETARY SUPPLEMENT
329.001.00068	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM	Rolaids	-982,	01JUN92	08FEB95	2TABLET	UPSET STOMACH
		Aspirin	-617,	01JUN93	08FEB95	2TABS PRN	HEADACHE
		Tylenol	20,	27FEB95	28MAR95	1300MG	VIRAL SORE THROAT UPPER RESPIRATORY
		Lysine	-366,	07FEB94	08FEB95	1TABLET	INFE FEVER BLISTER
329.001.00205	CENTRAL NERVOUS SYSTEM RESPIRATORY	Tylenol Cold And Flu	-27,	11JAN96	11JAN96#	5TSP.	SINUS
		Tylenol Cold And Flu	-27,	11JAN96	11JAN96#	5TSP.	SINUS
329.002.00055	CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL	Tylenol	123,	68 24OCT94	.	ESTIMATE 650MG PM	HEADACHE
		Advil	123,	68 24OCT94	.	800-1200MG PRN	HEADACHE
329.002.00058	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM	Amoxicillin	60,	2 18NOV94	28NOV94	500MG	STREP THROAT
		Tylenol	122,	64 19JAN95	19JAN95	26,650MG	INTENTIONAL OVERDOSE
329.002.00099	CENTRAL NERVOUS SYSTEM DERMATOLOGICALS RESPIRATORY	Tylenol	33,	-23 03APR95	03APR95	325MG	HEADACHE
		Benadryl	34,	-22 04APR95	11APR95	100 MG	SEASONAL ALLERGIES
		Afrin Spray	15,	-41 16MAR95	21MAR95	ONE SPRAY EACH NOSTRIL	HEAD COLD
		Benadryl	34,	-22 04APR95	11APR95	100 MG	SEASONAL ALLERGIES
		Nyquil	18,	-38 19MAR95	21MAR95	2PILLS/DAY	HEAD COLD
329.002.00105	CENTRAL NERVOUS SYSTEM DERMATOLOGICALS RESPIRATORY	Sudafed	28,	-28 29MAR95	29MAR95	60MG	STUFFY NOSE
		Aspirin	16,	. 11AUG95	24AUG95	650 MG	HEADACHE
		Tylenol	1,	. 27JUL95	03AUG95	1950 MG	HEADACHE
		Benadryl	-329,	. 01SEP94	.	2 TBSP PRN	ALLERGIES
		Benadryl	-329,	. 01SEP94	.	2 TBSP PRN	ALLERGIES

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

449

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.002.00242	CENTRAL NERVOUS SYSTEM	Aspirin	-6, -64	01FEB96	01FEB96#	650 MG	HEADACHE
		Tylenol	42, -17	19MAR96	19MAR96	650 MG	HEADACHE
329.002.00245	CENTRAL NERVOUS SYSTEM	Tylenol	-452, .	01JAN95	.	PRN	HEADACHE
		Zoloft	-27, .	01MAR96	14MAR96#	25 MG	DEPRESSION
329.002.00319	MUSCULO-SKELETAL	Aleve	203, 147	18NOV96	18NOV96	1 TABLET	HEADACHE
329.003.00075	CENTRAL NERVOUS SYSTEM	Tylenol	-7, -63	18JAN95	.	PRN	HEADACHE
			16, -41	09FEB95	14FEB95	PRN	HEADACHES
	MUSCULO-SKELETAL	Motrin	-7, -63	18JAN95	.	PRN	HEADACHE
	RESPIRATORY	Proventil	16, -41	09FEB95	14FEB95	PRN 200-400	HEADACHE
			., .	.	PRN	ASTHMA	
329.003.00081	CENTRAL NERVOUS SYSTEM	Tylenol	-193, .	01JUN95	.	500MGS	HEADACHE
329.003.00089	CENTRAL NERVOUS SYSTEM	Tylenol	8, .	14MAR95	.	500MG	HEADACHE
			42, .	17APR95	18APR95	650MG	HEADACHE
329.003.00091	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	211, 157	20OCT95	30OCT95	1000 MG	COLD AND SORE THROAT
		Penicillin	182, 128	21SEP95	01OCT95	1000 MG	SORE THROAT
	CENTRAL NERVOUS SYSTEM	Tylenol	9, -46	01APR95	01APR95	650MG	HEADACHE
			36, -19	28APR95	02MAY95	650MG	COLD
329.003.00248	CENTRAL NERVOUS SYSTEM	Tylenol	60, .	29APR96	.		HEADACHE
329.003.00250	DERMATOLOGICALS	Benadryl	47, -11	29APR96	29APR96	25 MG	ALLERGY
	RESPIRATORY	Benadryl	47, -11	29APR96	29APR96	25 MG	ALLERGY
329.004.00015	ALIMENTARY TRACT/METAB	Centrum	5, -53	12DEC94	13DEC94	1	COLD-NASAL CONGESTION
		Vitamin C	5, -53	12DEC94	13DEC94	1	COLD, NASAL CONGESTION
	ANTIINFECTIVES, SYSTEMIC	Septra Double Strength	82, 25	27FEB95	05MAR95	2TABS	COLD
	CENTRAL NERVOUS SYSTEM	Tylenol	13, -45	20DEC94	20DEC94	500MG	HEADACHE
			69, 12	14FEB95	14FEB95	2TAB	HEADACHE
			79, 22	24FEB95	24FEB95	2TAB	HEADACHE
		Tylenol Extra Strength	4, -54	11DEC94	11DEC94	2000MG	HEADACHE
		34, -24	10JAN95	10JAN95	500MG	HEADACHE	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

450

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.004.00015	CENTRAL NERVOUS SYSTEM	Tylenol Extra Strength	41, -17	17JAN95	17JAN95	2000MG	HEADACHE
			53, -5	29JAN95	29JAN95	2000MG	MENSTRUAL CRAMPS
	RESPIRATORY SENSORY ORGANS	Drixoral Pills	131, 74	17APR95	17APR95	2TAB	MENSTRUAL CRAMPS
		Polysporin Eye Drops	5, -53	12DEC94	13DEC94	1	COLD NASAL CONGESTION
			-1, -58	07DEC94	18DEC94	6DROPS	BILATERAL EYE INFECTION
		27, -31	03JAN95	14JAN95	4DROPS	BILATERAL EYE INFECTION	
329.004.00017	ALIMENTARY TRACT/METAB	Maalox	232, 176	08NOV95	08NOV95	5CC	NAUSEA
		Vitamin B Complex	48, -9	08MAY95	.	ONE TAB	SHIVERING(>
	CENTRAL NERVOUS SYSTEM	Tylenol	161, 105	29AUG95	30AUG95	650MG	FEVER
	DERMATOLOGICALS	Benylin	177, 121	14SEP95	16SEP95	1TSP	COLD
329.004.00019	CENTRAL NERVOUS SYSTEM	Benylin	177, 121	14SEP95	16SEP95	1TSP	COLD
329.004.00019	CENTRAL NERVOUS SYSTEM	Excedrin	7, .	06JUN95	06JUN95	3TABS	HEADACHE
	329.004.00212	CENTRAL NERVOUS SYSTEM	Sinutabs	-215, .	01NOV95	.	1-2 TAB/DAY PRN
329.004.00212	GU SYSTEM/SEX HORMONES	Ortho 777	-215, .	01NOV95	.	1 TABLET	BIRTH CONTROL
		Claritin	-215, .	01NOV95	09JUN96	0-2 TABS	ENVIRONMENTAL ALLERGIES
	RESPIRATORY	Sudafed	-215, .	01NOV95	.	1-2 TAB/DAY PRN	ENVIRONMENTAL ALLERGIES
329.004.00214	ANTIINFECTIVES, SYSTEMIC	Apo-Tetra	-16, -76	18SEP96	18SEP96#		COLD
			10, -51	13OCT96	13OCT96	500 MG	COLD
			14, -47	17OCT96	20OCT96	500 MG	COLD
		Hepatitis B Shot {Vaccine}	60, -1	02DEC96	02DEC96		PROPHYLAXIS
	CENTRAL NERVOUS SYSTEM	Hepatitis B {Vaccine}	-1, -61	03OCT96	03OCT96#		PROPHYLAXIS
			36, -25	08NOV96	09NOV96	700 MG	HEADACHE
			44, -17	16NOV96	16NOV96	700 MG	HEADACHE
			83, 23	25DEC96	25DEC96	1000 MG	DIZZINESS
			84, 24	26DEC96	26DEC96	1000 MG	DIZZINESS
			85, 25	27DEC96	27DEC96	1000 MG	DIZZINESS
	87, 27	29DEC96	29DEC96	1000 MG	DIZZINESS		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

451

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.004.00214	CENTRAL NERVOUS SYSTEM	Tylenol Extra Strength	-8, -68	26SEP96	26SEP96#	700 MG	KNEE PAIN
	DERMATOLOGICALS	Apo-Tetra	-16, -76	18SEP96	18SEP96#		COLD
			10, -51	13OCT96	13OCT96	500 MG	COLD
			14, -47	17OCT96	20OCT96	500 MG	COLD
	GU SYSTEM/SEX HORMONES	Birth Control Pill	-32, -92	02SEP96	.	1	TO REGULATE PERIODS
	RESPIRATORY	Gravol	37, -24	09NOV96	10NOV96	100 MG	UPSET STOMACH
			44, -17	16NOV96	17NOV96	50 MG	NAUSEA
	SENSORY ORGANS	Apo-Tetra	-16, -76	18SEP96	18SEP96#		COLD
			10, -51	13OCT96	13OCT96	500 MG	COLD
			14, -47	17OCT96	20OCT96	500 MG	COLD
329.005.00002	CENTRAL NERVOUS SYSTEM	Tylenol	-5, -61	20MAY94	20MAY94#	500MG	HEADACHE
			54, -3	17JUL94	20JUL94	500MG	HEADACHE
329.005.00004	CENTRAL NERVOUS SYSTEM	Tylenol	81, 22	29DEC94	30DEC94	500MG	SORE THROAT
329.005.00011	ALIMENTARY TRACT/METAB	Charcoal	156, 100	17MAY95	17MAY95	UNKNOWN	OVERDOSE WITH BAYER EXTRA STRENGTH OVERDOSE
		Normal Saline Solution	156, 100	17MAY95	19MAY95	UNKNOWN	OVERDOSE
	BLOOD/BLOOD FORM ORGANS	Normal Saline Solution	156, 100	17MAY95	19MAY95	UNKNOWN	OVERDOSE
	CENTRAL NERVOUS SYSTEM	Bayer Aspirin Extra Strength	156, 100	17MAY95	17MAY95	UNKNOWN	OVERDOSE
		Tylenol	8, -49	20DEC94	03JAN95	500MG	HEADACHE
	RESPIRATORY	Normal Saline Solution	156, 100	17MAY95	19MAY95	UNKNOWN	OVERDOSE
	SENSORY ORGANS	Normal Saline Solution	156, 100	17MAY95	19MAY95	UNKNOWN	OVERDOSE
	329.005.00109	ALIMENTARY TRACT/METAB	Prenatal Vitamin	-395, -448	30NOV93	.	1 4X DAILY
		Zantac	123, 70	01MAY95	08MAY95		BLEEDING ULCER
BLOOD/BLOOD FORM ORGANS		Ferrous Sulfate Iv Fluids	-133, -186	19AUG94	.	320 MG	LOW IRON QUESTIONABLE
			129, 76	07MAY95	10MAY95		BLEEDING ULCER
CENTRAL NERVOUS SYSTEM		Tylenol	81, 28	20MAR95	22MAR95	1 GM	HEADACHE
GU SYSTEM/SEX HORMONES	Desogen 28	14, -40	12JAN95	.	1 4X DAILY	BIRTH CONTROL	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

452

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.005.00112	CENTRAL NERVOUS SYSTEM	Tylenol	-2, -57	24JAN95	26JAN95	1000MG	HEADACHE, FEVER
329.005.00116	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	26, -33	04MAR95	14MAR95	750MG	BRONCHITIS
		Augmentin	25, -34	03MAR95	13MAR95	UNKNOWN, THREE TIMES DAILY	EAR INFECTION
		Ceftin	141, 83	27JUN95	07JUL95	UNKNOWN MG (2PILLS)	TONSILLITIS
	CENTRAL NERVOUS SYSTEM	Tylenol	25, -34	03MAR95	04APR95	500MG	EARACHE
	MUSCULO-SKELETAL	Advil	65, 7	12APR95	12APR95	UNKNOWN	HEADACHE
			111, 53	28MAY95	30MAY95	UNKNOWN PRN	MENSTRUAL CRAMPS
	RESPIRATORY	Prednisone	135, 77	21JUN95	28JUN95	30MG	POISON IVY
			143, 85	29JUN95	02JUL95	20MG	POISON IVY
			147, 89	03JUL95	07JUL95	10MG	POISON IVY
			152, 94	08JUL95	12JUL95	10MG EVERY OTHER DAY	POISON IVY
		Robitussin	75, 17	22APR95	07MAY95	2TSP	COUGH
		Smith Brothers Cough Drop	75, 17	22APR95	07MAY95	1DAILY	COUGH
		Ventolin Inhaler	26, -33	04MAR95	14MAR95	2PUFFS 4TIME A DAY	BRONCHITIS
	SENSORY ORGANS	Ear Drops {Nos}	25, -34	03MAR95	04APR95	THREE TIMES DAILY	EARACHE
	SYSTEMIC HORMONAL	Prednisone	135, 77	21JUN95	28JUN95	30MG	POISON IVY
			143, 85	29JUN95	02JUL95	20MG	POISON IVY
			147, 89	03JUL95	07JUL95	10MG	POISON IVY
			152, 94	08JUL95	12JUL95	10MG EVERY OTHER DAY	POISON IVY
329.005.00119	CENTRAL NERVOUS SYSTEM	Tylenol	7, -53	17JUL95	17JUL95	650MG	HEADACHE
	MUSCULO-SKELETAL	Advil	47, -13	26AUG95	26AUG95	1TAB DAILY	ORTHODONTIC DISCOMFORT
	RESPIRATORY	Nyquil	79, 20	27SEP95	27SEP95		COLD SYMPTOMS
		Robitussin	80, 21	28SEP95	28SEP95	1 DOSE	COLD SYMPTOMS
329.005.00151	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	41, -17	16OCT95	02NOV95	750MG	EAR INFECTION STREP THROAT
		Erythromycin	48, -10	23OCT95	07NOV95		URI

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

453

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication		
329.005.00151	CENTRAL NERVOUS SYSTEM	Extra Strength Tylenol	1, -57	06SEP95	06SEP95	2TABS A DAY	BACK PAIN		
		Tylenol	-25, -82	12AUG95	12AUG95#	650MG	HEADACHE		
		Tylenol	40, -18	15OCT95	17OCT95	2GM	SORE THROAT/STREP		
		Tylenol	44, -14	19OCT95	19OCT95	1GM	BACK PAIN		
		Tylenol Extra Strength	., .	.	03SEP95#	650MG	BACK PAIN		
		DERMATOLOGICALS	Erythromycin	48, -10	23OCT95	07NOV95		URI	
		SENSORY ORGANS	Erythromycin	48, -10	23OCT95	07NOV95		URI	
			Refresh	156, 99	08FEB96	08MAR96		FOREIGN OBJECT IN EYE	
		329.005.00257	ALIMENTARY TRACT/METAB ANTIINFECTIVES, SYSTEMIC	Vitamin C	3, -54	13MAR96	.		"A COLD"
				Amoxicillin	145, 89	02AUG96	09AUG96		SWIMMER'S EAR
Antibiotics Ear Drops {Nos}	145, 89			02AUG96	09AUG96		SWIMMER'S EAR		
Ceclor	15, -42			25MAR96	05APR96		SINUS INFECTION		
	43, -14			22APR96	06MAY96		SINUS INFECTION		
	242, 186			07NOV96	14NOV96	TOPICAL	YEAST INFECTION		
CARDIOVASCULAR	Monistat 7			54, -3	03MAY96	10MAY96	150 MG BID	UPPER RESPIRATORY INFECTION AND SINUS IN	
	Slo-Bid								
DERMATOLOGICALS	Accutane			-121, -177	11NOV95	.		ACNE	
				-121, -177	11NOV95	.		ACNE	
	Flonase			43, -14	22APR96	28APR96	2 SQUIRTS	SINUS INFECTION	
	Monistat 7			242, 186	07NOV96	14NOV96	TOPICAL	YEAST INFECTION	
	Monistat 7			242, 186	07NOV96	14NOV96	TOPICAL	YEAST INFECTION	
GU SYSTEM/SEX HORMONES	Advil			157, 101	14AUG96	21AUG96		HEADACHE	
MUSCULO-SKELETAL	Albuterol			43, -14	22APR96	06MAY96	2 PUFF X 4	SINUS INFECTION	
RESPIRATORY	Flonase	43, -14	22APR96	28APR96	2 SQUIRTS	SINUS INFECTION			
	Marax	202, 146	28SEP96	.		EXERCISE INDUCED ASTHMA			
	Rynatan	15, -42	25MAR96	27MAR96		SINUS INFECTION			
	Semprex-D	14, -43	24MAR96	24MAR96		"A COLD"			
	Slo-Bid	54, -3	03MAY96	10MAY96	150 MG BID	UPPER RESPIRATORY INFECTION AND SINUS IN			
329.005.00258	CENTRAL NERVOUS SYSTEM	Tylenol	21, .	01APR96	01APR96	2 TABS	ORTHODONTIC DISCOMFORT		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

454

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.005.00258	CENTRAL NERVOUS SYSTEM	Tylenol	28, .	08APR96	08APR96	2 TABS	ORTHODONTIC DISCOMFORT COUGH
	RESPIRATORY	Robitussin	2, .	13MAR96	13MAR96		
329.005.00299	ALIMENTARY TRACT/METAB	Tums	., .	. .	. .	2 TABS	STOMACH HEADACHE HEADACHE "COLD" COLD SYMPTOMS
	CENTRAL NERVOUS SYSTEM	Tylenol	138, 78	23OCT96	23OCT96		
	MUSCULO-SKELETAL	Advil	., .	. .	. .		
	RESPIRATORY	Robitussin	109, 49	24SEP96	02OCT96		
329.005.00333	ALIMENTARY TRACT/METAB	Imodium-Ad	30, .	21FEB97	21FEB97	1 TBSP	DIARRHEA
	CENTRAL NERVOUS SYSTEM	Tylenol	2, .	24JAN97	24JAN97	500 MG	HEADACHE
	MUSCULO-SKELETAL	Vivarin	14, .	05FEB97	05FEB97	1 TAB	SLEEPINESS
		Advil	23, .	14FEB97	16FEB97	800 MG	HEADACHE
	RESPIRATORY	Allegra	33, .	24FEB97	24FEB97	400 MG	HEADACHE
				-236, .	01JUN96	.	
329.005.00336	CENTRAL NERVOUS SYSTEM	Excedrin Extra-Strength	32, .	04APR97	09APR97	2 GM	SORE THROAT WITH COUGH
	RESPIRATORY		38, .	10APR97	12APR97	2 GM	STUFFY NOSE, COUGH
			48, .	20APR97	23APR97	2 GM	BACKACHE
			-12, .	20FEB97	21FEB97#	500 MG	BACKACHE
			-18, .	14FEB97	16FEB97#	2	COLD SX
329.006.00038	CARDIOVASCULAR	Benzocaine	-410, .	01JAN94	.	9 TABLETS	DIETING
	CENTRAL NERVOUS SYSTEM	Fiorinal	57, .	12APR95	12APR95	10TABLETS	ATTEMPTED SUICIDE
		Tranquilizer {Nos}	17, .	03MAR95	03MAR95	UNKNOWN	DENTAL PROCEDURE
		Tylenol	57, .	12APR95	12APR95	1300MG	ATTEMPTED SUICIDE
	DERMATOLOGICALS	Benzocaine	-410, .	01JAN94	.	9 TABLETS	DIETING
	MUSCULO-SKELETAL	Advil	57, .	12APR95	12APR95	4600MG	ATTEMPTED SUICIDE
		Ibuprofen	57, .	12APR95	12APR95	4800MG	ATTEMPTED SUICIDE
			57, .	12APR95	12APR95	13800MG	ATTEMPTED SUICIDE
	RESPIRATORY	Albuterol	-1871, .	01JAN90	.	1PUFF	ASTHMA
		Benzocaine	-410, .	01JAN94	.	9 TABLETS	DIETING
329.006.00039	MUSCULO-SKELETAL	Advil	-1134, -1195	01JAN92	.	PRN-600MG	HEADACHES
		Anaprox	76, 15	24APR95	28APR95	275MG	HEADACHE
329.006.00260	ANTIINFECTIVES, SYSTEMIC	Tetracycline	-6, -64	12JUL96	.	1000MG	ACNE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

455

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.006.00260	CENTRAL NERVOUS SYSTEM	Aspirin	56, -3	11SEP96	11SEP96	2 TABS	HEADACHE	
		Excedrin	-2390,-2448	01JAN90	.	2 TABS	OCCASIONAL HEADACHES	
			6, -53	23JUL96	16SEP96	2 TABS: PRN	HEADACHE	
			8, -51	25JUL96	25JUL96	4 TABS	TOOTHACHE PAIN	
			20, -39	06AUG96	06AUG96	2 TABS	TOOTHACHE	
			83, 25	08OCT96	08OCT96	2 TAB	HEADACHE	
		DERMATOLOGICALS	Tetracycline	-6, -64	12JUL96	.	1000MG	ACNE
		MUSCULO-SKELETAL	Advil	53, -6	08SEP96	08SEP96	2 TABS	HEADACHE
		RESPIRATORY	Contac Cold	83, 25	08OCT96	08OCT96	1 PACKET	COLD
		SENSORY ORGANS	Tetracycline	-6, -64	12JUL96	.	1000MG	ACNE
329.006.00261	MUSCULO-SKELETAL RESPIRATORY	Advil	58, -1	22JAN97	22JAN97	2 TABS	HEADACHE	
		Proventil	-4713,-4771	01JAN84	01JAN96#	PRN	ASTHMA	
329.007.00140	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM DERMATOLOGICALS	Triamcinolone	34, -22	18OCT95	22OCT95	ONCE DAILY	RINGWORM	
		Tylenol	-622,-677	01JAN94	.	325MG PRN	HEADACHE	
		Clotrimazole	39, -17	23OCT95	24OCT95	ONCE DAILY	RINGWORM	
		Gris-Peg	41, -15	25OCT95	03NOV95	250MG	RINGWORM	
		Triamcinolone	34, -22	18OCT95	22OCT95	ONCE DAILY	RINGWORM	
		GU SYSTEM/SEX HORMONES	Clotrimazole	39, -17	23OCT95	24OCT95	ONCE DAILY	RINGWORM
		SENSORY ORGANS	Triamcinolone	34, -22	18OCT95	22OCT95	ONCE DAILY	RINGWORM
		SYSTEMIC HORMONAL	Triamcinolone	34, -22	18OCT95	22OCT95	ONCE DAILY	RINGWORM
329.007.00142	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM RESPIRATORY	Amoxil	-14, .	04OCT95	13OCT95#	500MG	SORE THROAT	
		Tylenol	-3942, .	01JAN85	.	500MG PRN	HEADACHE	
		Dristan	44, .	30NOV95	30NOV95	2TABS	NASAL CONGESTION	
329.007.00145	CENTRAL NERVOUS SYSTEM	Extra Strength Excedrin	111, 55	30APR96	13MAY96	1 TAB	HEADACHE	
		Extra Strength Tylenol	125, 69	14MAY96	15MAY96	1,000 MG	HEADACHE	
		DERMATOLOGICALS	Benadryl	22, -35	01FEB96	01FEB96	1TSP.	NASAL CONGESTION
		RESPIRATORY	Benadryl	22, -35	01FEB96	01FEB96	1TSP.	NASAL CONGESTION
			Ggg-Cold {Cold Preparation Nos}	224, 168	21AUG96	23AUG96	6 TSP	COLD SYMPTOMS
329.007.00265	CENTRAL NERVOUS SYSTEM	Tylenol	-3, .	29JAN96	31JAN96#	1,000MG	HEADACHE	
329.007.00268	ALIMENTARY TRACT/METAB	Dulcolax	233, 174	19NOV96	19NOV96	2 TABS	CONSTIPATION	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

456

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.007.00268	ALIMENTARY TRACT/METAB ANTIINFECTIVES, SYSTEMIC	Neomycin	88, 29	27JUN96	29JUN96	2 DROPS	LEFT EAR INFECTION
		Polymyxin	88, 29	27JUN96	29JUN96	2 DROPS	LEFT EAR INFECTION
		Cephalexin	82, 23	21JUN96	23JUN96	1000 MG	LEFT EAR INFECTION
			87, 28	26JUN96	29JUN96	1000 MG	LEFT EAR INFECTION
			92, 33	01JUL96	10JUL96	250 MG	LEFT INNER EAR INFECTION
	CENTRAL NERVOUS SYSTEM	Keflex	10, -50	10APR96	14APR96	750MG	EAR INFECTION
		Neomycin	88, 29	27JUN96	29JUN96	2 DROPS	LEFT EAR INFECTION
		Polymyxin	88, 29	27JUN96	29JUN96	2 DROPS	LEFT EAR INFECTION
		Aspirin	29, -31	29APR96	29APR96	4TABS	NAUSEA{FROM RIDE}
		Compazine	218, 159	04NOV96	04NOV96	5 MG	NAUSEA
	DERMATOLOGICALS MUSCULO-SKELETAL	Neomycin	88, 29	27JUN96	29JUN96	2 DROPS	LEFT EAR INFECTION
		Ibuprofen	10, -50	10APR96	10APR96	800MG	HEADACHE
			57, -3	27MAY96	30MAY96	1600MG	PAIN{DUE TO ACCIDENT}
		Motrin	-821, -880	01JAN94	.	800MG PRN	HEADACHES
			57, -3	27MAY96	07JUN96	1600 MG	NECK PAIN DUE TO ACCIDENT
SENSORY ORGANS VARIOUS		98, 39	07JUL96	10JUL96	1 - 2 TABS	MUSCLE ACHES DUE TO CAR ACCIDENT	
		102, 43	11JUL96	07NOV96	800 MG PRN	MUSCLE ACHES DUE TO CAR ACCIDENT	
	Neomycin	184, 125	01OCT96	07NOV96	400 MG PRN	HEADACHES	
	T-Lite {Dietary Supplement}	88, 29	27JUN96	29JUN96	2 DROPS	LEFT EAR INFECTION	
		154, 95	01SEP96	02OCT96	4 TABS	WEIGHT GAIN	
329.007.00294	ALIMENTARY TRACT/METAB	Appetite Suppressant {Nos}	-58, .	01JAN97	10FEB97#	3 TABS	WEIGHT GAIN
	CENTRAL NERVOUS SYSTEM	Extra Strength Tylenol	-2, .	26FEB97	26FEB97#	3 TABS	HEADACHE
		Tylenol	14, .	13MAR97	13MAR97	1,000 MG	HEADACHE
			18, .	17MAR97	17MAR97	1,000 MG	HEADACHE
		22, .	21MAR97	23MAR97	4 TABS	BACKACHE	
		40, .	08APR97	08APR97	2 TABS	HEADACHE	
		5, .	04MAR97	07MAR97	1,000 MG	HEADACHE	
		-4, .	24FEB97	24FEB97#	3 TABS	HEADACHE	
	Tylenol Es Gel Caps Unknown Headache Medicine {Analgesic Nos}						

\* days relative to start of acute phase, days relative to start of continuation phase

457

CONFIDENTIAL

BRL-029060-329-  
individual-data

# stop date earlier than start of study medication

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.007.00294	MUSCULO-SKELETAL	Aleve	34, .	02APR97	02APR97	2 TABS	HEADACHE
		Ibuprofen	39, .	07APR97	07APR97	2 TABS	HEADACHE & CRAMPS
	RESPIRATORY	Unknown Cough Drop	-1154, .	01JAN94	.	2 TABS PRN	HEADACHE
				34, .	02APR97	02APR97	1 TAB
329.007.00309	ALIMENTARY TRACT/METAB ANTIINFECTIVES, SYSTEMIC	Zantac	-44, -96	01JUN96	20JUN96#	300 MG	ULCER-LIKE SYMPTOMS
		Erythromycin	61, 9	13SEP96	19SEP96	750 MG	BRONCHITIS
	CENTRAL NERVOUS SYSTEM	Brevital	71, 19	23SEP96	01OCT96	2000 MG	TOOTHACHE
		Pentanyl	74, 22	26SEP96	26SEP96	70 MG	ABSCESSED TOOTH
		Midol	74, 22	26SEP96	26SEP96	1 CC	ABSCESSED TOOTH
		Nitrous Oxide	34, -19	17AUG96	19AUG96	2 TABS	MENSTRUAL CRAMP
		Tylenol	74, 22	26SEP96	26SEP96	3.0 L/M	ABSCESSED TOOTH
			-15, -67	30JUN96	30JUN96#	1 TAB	HEADACHE
			43, -10	26AUG96	26AUG96	500 MG	TOOTHACHE
			46, -7	29AUG96	29AUG96	500 MG	TOOTHACHE
			107, 55	29OCT96	29OCT96	1 TAB	HEADACHE
			237, 185	08MAR97	08MAR97	500 MG	HEADACHE
			71, 19	23SEP96	27SEP96	3 TABS	TOOTH PAIN
	DERMATOLOGICALS	Versed	74, 22	26SEP96	26SEP96	5 MG	ABSCESSED TOOTH
		Xylocaine-Epinephrine	74, 22	26SEP96	26SEP96	4 CC	ABSCESSED TOOTH
	MUSCULO-SKELETAL	Erythromycin	61, 9	13SEP96	19SEP96	750 MG	BRONCHITIS
			71, 19	23SEP96	01OCT96	2000 MG	TOOTHACHE
		Advil	29, -24	12AUG96	13AUG96	400 MG	HEADACHE
			33, -20	16AUG96	16AUG96	5 TABS	MENSTRUAL CRAMP
			72, 20	24SEP96	03OCT96	1 TAB	HEADACHES
			176, 124	06JAN97	13JAN97	2 TABS	EARACHE
			184, 132	14JAN97	12FEB97	400 MG PRN	HEADACHES
			-44, -96	01JUN96	.	1-2 TABS	HEADACHE
		-44, -96	01JUN96	.	1 TAB	HEADACHE	
		143, 91	04DEC96	04DEC96	1 TAB	FEVER & CONGESTION	
RESPIRATORY	Contac	145, 93	06DEC96	06DEC96	1 TAB	FEVER & CONGESTION	
		147, 95	08DEC96	08DEC96	1 TAB	CONGESTION	
	Drixoral	52, -1	04SEP96	04SEP96	2 CAPS	URI	
		110, 58	01NOV96	01NOV96	1 TAB	ALLERGIES	
SENSORY ORGANS	Histussin Hc	47, -6	30AUG96	02SEP96	2 TSP	URI	
	Hydrocodone	74, 22	26SEP96	26SEP96	1 TAB	ABSCESSED TOOTH	
	Erythromycin	61, 9	13SEP96	19SEP96	750 MG	BRONCHITIS	
		71, 19	23SEP96	01OCT96	2000 MG	TOOTHACHE	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

459

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.007.00310	ALIMENTARY TRACT/METAB ANTIINFECTIVES,SYSTEMIC	Pepto Bismol	52, -9	16NOV96	17NOV96	2 TABS	FOOD POISONING
		Augmentin	85, 25	19DEC96	29DEC96	1,000 MG	SORE THROAT
		Ceclor	19, -42	14OCT96	27OCT96	750 MG	SORE THROAT, EARACHE
	CENTRAL NERVOUS SYSTEM	Ceclor Cd	173, 113	17MAR97	28MAR97	1,000 MG	POSSIBLE STREP THROAT
		Aspirin	218, 158	01MAY97	08MAY97	1 TAB	SUNBURN
		Midol	-8, -68	18SEP96	18SEP96#	2 TABS	MENSTRUAL CRAMPS
		Phrenilin	175, 115	19MAR97	23MAR97	1 TAB	STIFF NECK
			236, 176	19MAY97	23MAY97	1 TAB	HEADACHE
	MUSCULO-SKELETAL	Tylenol	15, -46	10OCT96	15OCT96	4000 MG	FEVER, HEADACHE
		Advil	14, -47	09OCT96	09OCT96	500 MG	PAIN IN NECK MUSCLES
			50, -11	14NOV96	17NOV96	1,200 MG	LEFT KNEE PAIN
		Aleve	-56, -116	01AUG96	.	2 TABS	HEADACHE
			14, -47	09OCT96	09OCT96	1 TAB	PAIN IN NECK MUSCLES
	RESPIRATORY	Orudis Kt	53, -8	17NOV96	30NOV96	1-2 TABS	LEFT KNEE PAIN
		Skelaxin	14, -47	09OCT96	15OCT96	400 MG PRN	PAIN IN NECK MUSCLES
Claritin-D		85, 25	19DEC96	30DEC96	2 TABS	NASAL CONGESTION	
Panmist La		19, -42	14OCT96	29OCT96	2 TABS PRN	CONGESTION	
329.007.00318	CENTRAL NERVOUS SYSTEM	Ritalin	-854, .	01AUG94	11AUG96#	10 MG	ADHD
329.008.00157	RESPIRATORY	Antihistamine {Nos}	-3893,-3948	01JAN85	.	.	HAY FEVER
329.008.00160	ANTIINFECTIVES,SYSTEMIC	Doxycycline	20, -47	20NOV95	.	50 MG	ACNE
	RESPIRATORY	Ventolin Inhaler	20, -47	20NOV95	.	.	EXERCISE INDUCED SHORTNESS OF BREATH
329.008.00271	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM	Biaxin	45, -20	24APR96	30APR96	500 MG	RESPIRATORY INFECTION
		Excedrin	89, 25	07JUN96	07JUN96	X2 TABS	HEADACHE
		Tylenol Extra Strength	-5, -69	06MAR96	17MAR96	2 TABS	UPPER RESPIRATORY TRACT INFECTION
	MUSCULO-SKELETAL		28, -37	07APR96	07APR96	2 TABS	HEADACHE
			63, -2	12MAY96	12MAY96	2 TABS	HEADACHE
			91, 27	09JUN96	09JUN96	X2 TABS	HEADACHE
		Ibuprofen	21, -44	31MAR96	31MAR96	200 MG	NECK PAIN
		Vicks Cough Drop	42, -23	21APR96	21APR96	.	PHARYNGITIS
	RESPIRATORY	Albuterol	-3722,-3786	01JAN86	.	1TAB DAY	ASTHMA
		Proventil Inhaler	-3722,-3786	01JAN86	.	4PUFFSX1-PRN	ASTHMA
Triaminic Cough Syrup		-5, -69	06MAR96	06MAR96#	X1	RESPIRATORY INFECTION	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

460

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.008.00271	RESPIRATORY	Vicks Cough Drop	42, -23	21APR96	21APR96		PHARYNGITIS	
329.008.00275	ANTIINFECTIVES, SYSTEMIC DERMATOLOGICALS	Antibiotic {Nos}	49, -7	25JUN96	09JUL96		FOOT INFECTION	
		Benadryl	-738, -793	01MAY94	.	PRN	ALLERGIES, INSOMNIA	
	MUSCULO-SKELETAL	Advil		-1, -56	07MAY96	07MAY96#	50 MG	ALLERGY
				8, -48	15MAY96	.	50 MG	ALLERGY
				56, 1	02JUL96	.		ITCHINESS
				77, 22	23JUL96	24JUL96	50 MG	ALLERGIES
				132, 77	16SEP96	17SEP96	50 MG	ALLERGIES
				202, 147	25NOV96	26NOV96	50 MG	ALLERGIES
				-493, -548	01JAN95	.	PRN	HEADACHES
				-1, -56	07MAY96	.		HEADACHES
				56, 1	02JUL96	.		ANKLE SPRAIN
				-738, -793	01MAY94	.	PRN	ALLERGIES, INSOMNIA
	RESPIRATORY	Benadryl		-1, -56	07MAY96	07MAY96#	50 MG	ALLERGY
				8, -48	15MAY96	.	50 MG	ALLERGY
			56, 1	02JUL96	.		ITCHINESS	
			77, 22	23JUL96	24JUL96	50 MG	ALLERGIES	
						50 MG	ALLERGIES	
						50 MG	ALLERGIES	
329.009.00130	ALIMENTARY TRACT/METAB	Donnatal	-1568, -1624	01JAN91	18APR95	1-2TIMES PER WEEK	STOMACH PROBLEMS	
	ANTIINFECTIVES, SYSTEMIC	Tums	149, 93	13SEP95	.	1TAB PRN	STOMACH ACHE	
		Amoxicillin	140, 84	04SEP95	13SEP95	1500MG	SINUS INFECTION	
	CENTRAL NERVOUS SYSTEM	Amoxil	8, -49	25APR95	04MAY95	1500MG	SINUSITIS	
Nefazodone		170, 114	04OCT95	.	100MG	DEPRESSION		
329.009.00131	ALIMENTARY TRACT/METAB	Correctol	21, -36	22MAY95	22MAY95	2TABLETS	CONSTIPATION	
	DERMATOLOGICALS	Clearasil	29, -28	30MAY95	.	1GRAM	ACNE	
329.009.00133	ALIMENTARY TRACT/METAB	Pepto Bismol	28, .	10JUL95	.	2TBSP.PRN	LOOSE STOOLS	
	ANTIINFECTIVES, SYSTEMIC	Amoxil	32, .	14JUL95	20JUL95	500MG	EXTRACTED WISDOM TOOTH	
	CENTRAL NERVOUS SYSTEM	Premenstrual Syndrome Pain Relief {Nos}	-893, .	01JAN93	.	500MG PRN	PREMENSTRUAL TENSION	
		Tylenol	-893, .	01JAN93	.	500MG PRN	HEADACHE	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

461

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.009.00133	MUSCULO-SKELETAL	Lodine	32, .	14JUL95	17JUL95	200MG	EXTRACTED WIDSOM TEETH
329.009.00170	ALIMENTARY TRACT/METAB MUSCULO-SKELETAL RESPIRATORY	Maalox Liquid Motrin Dramamine	238, 181 246, 189 238, 181	01JUL96 09JUL96 01JUL96	.	8-16 TSP 400 MG 100 MG	NAUSEA DYSMENORRHEA NAUSEA
329.009.00173	CENTRAL NERVOUS SYSTEM  RESPIRATORY	Tylenol  Tylenol Cold {Medicine} Tylenol Cold {Medicine}	-19, -82  -19, -82 -19, -82	01NOV95  01NOV95 01NOV95	.	650MG PRN  2TABS PRN 2TABS PRN	UPPER RESP. TRACT INFECTION URI URI
329.009.00193	CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL  RESPIRATORY	Excedrin Hall'S Cough Drops Ibuprofen Hall'S Cough Drops Nyquil	-331, . 15, . 15, . 15, . 15, .	01JAN95 12DEC95 12DEC95 12DEC95 12DEC95	.	500PRN 1PRN 200MG PRN 1PRN 1TBS PRN	HEADACHE URI URI URI URI
329.009.00196	ALIMENTARY TRACT/METAB  ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM  MUSCULO-SKELETAL RESPIRATORY   SYSTEMIC HORMONAL	Pepcid Ac Roloids Cefixime Tylenol Tylenol Sinus Ibuprofen Albuterol Albuterol Inhaler Entex Prednisone Rondec Dm Tylenol Sinus Prednisone	10, . 10, . 56, . -716, . 55, . -716, . -1081, . -1081, . 54, . 56, . 56, . 55, . 56, .	27DEC95 27DEC95 11FEB96 01JAN94 10FEB96 01JAN94 01JAN93 01JAN93 09FEB96 11FEB96 11FEB96 11FEB96 11FEB96	.	75MG 2TABS PRN 400MG 975MG 975MG 800MG PRN 2TSP PRN 2PUFFS PRN 4TABS 5MG QD 4TABS 975MG 5MG QD	HEARTBURN HEARTBURN SINUS INFECTION HEADACHES SINUS INFECTION HEADACHES ASTHMA ASTHMA SINUS INFECTION ASTHMA SINUS INFECTION SINUS INFECTION ASTHMA
329.009.00201	ANTIINFECTIVES, SYSTEMIC  CENTRAL NERVOUS SYSTEM RESPIRATORY	Augmentin  Tylenol Codimal Dh	-9, . 56, . -9, . 56, .	28JAN96 01APR96 28JAN96 01APR96	06FEB96  .	750MG 750 MG 650 PRN 2 TSP. PRN	STREP THROAT TONSILLITIS FEVER TONSILLITIS

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

462

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.009.00204	CENTRAL NERVOUS SYSTEM	Ritalin	-808, -864	01JAN94	01MAR96#	20MG SR	ATTENTION DEFICIT HYPERACTIVITY DISORDER
		Tylenol	-808, -864	01JAN94	.	675MG PRN	OCCASIONAL HEADACHE
329.009.00235	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM GU SYSTEM/SEX HORMONES MUSCULO-SKELETAL	Minocycline	-33, -87	15NOV96	.	100MG	ACNE
		Tylenol (Liquid)	-11, -65	07DEC96	07DEC96#	2 TEASPOONS	FLU SYMPTOMS
		Ortho Novum 1/35-28	40, -15	26JAN97	.	1 PILL	BIRTH CONTROL
		Ibuprofen	-11, -65	07DEC96	07DEC96#	200 MG PRN	FLU SYMPTOMS
329.009.00240	MUSCULO-SKELETAL	Advil	-13, .	01JAN97	.	400 MG PRN	HEADACHES
329.009.00303	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM  DERMATOLOGICALS MUSCULO-SKELETAL RESPIRATORY	Biaxin	-32, -88	01MAR96	.	500MG	SINUS INFECTION
		Prozac	-23, -79	10MAR96	17MAR96#	10MG	DEPRESSION
		Tylenol	-32, -88	01MAR96	.	650 PRN	SINUS INFECTION
		Tylenol Cold And Flu	-32, -88	01MAR96	.	300MG PRN	SINUS INFECTION
		Benadryl	23, -34	24APR96	24APR96	20MG	NASAL CONGESTION
		Advil	-822, -878	01JAN94	.	200MG	OCCASIONAL HEADACHE
		Benadryl	23, -34	24APR96	24APR96	20MG	NASAL CONGESTION
Tylenol Cold And Flu	-32, -88	01MAR96	.	300MG PRN	SINUS INFECTION		
329.009.00304	MUSCULO-SKELETAL	Advil	-464, -520	01JAN95	.	400MG	OCCASIONAL HEADACHE
329.009.00324	CENTRAL NERVOUS SYSTEM  MUSCULO-SKELETAL RESPIRATORY	Tylenol Extra Strength	-88, .	01AUG96	.	500 MG PRN	OCCASIONAL HEADACHES
		Tylenol Sinus	-88, .	01AUG96	.	1 TAB PRN	SINUS CONGESTION
		Advil	-88, .	01AUG96	.	200 MG PRN	OCCASSIONAL HEADACHES
		Sudafed	-88, .	01AUG96	.	120 MG PRN	SINUS CONGESTION
		Tylenol Sinus	-88, .	01AUG96	.	1 TAB PRN	SINUS CONGESTION
329.009.00329	CENTRAL NERVOUS SYSTEM	Tylenol	-647, .	01JAN95	.	500 MG PRN	HEADACHE OCCASIONAL
329.010.00182	CENTRAL NERVOUS SYSTEM	Aspirin	10, .	28DEC95	28DEC95	325	HEADACHE
		Marijuana	-1448, .	01JAN92	.	.	ILLCIT USE
		Tylenol	-7, .	12DEC95	12DEC95#	650MG	HEADACHE
329.010.00278	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM	Keflex	221, 165	16SEP96	19SEP96	4000 MG	MONONUCLEOSIS
		Aspirin	-39, -95	01JAN96	.	325	ABDOMINAL PAIN
		Percocet	37, -20	16MAR96	17MAR96	PRN	ABDOMINAL PAIN

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

463

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication			
329.010.00278	CENTRAL NERVOUS SYSTEM RESPIRATORY	Ultram	38, -19	17MAR96	19MAR96	PRN	ABDOMINAL PAIN			
		Prednisone	221, 165	16SEP96	17SEP96	80 MG	MONONUCLEOSIS			
			223, 167	18SEP96	19SEP96	60 MG	MONONUCLEOSIS			
		SYSTEMIC HORMONAL	Prednisone	225, 169	20SEP96	21SEP96	40 MG	MONONUCLEOSIS		
	227, 171			22SEP96	23SEP96	20 MG	MONONUCLEOSIS			
	Prednisone		229, 173	24SEP96	25SEP96	10 MG	MONONUCLEOSIS			
			221, 165	16SEP96	17SEP96	80 MG	MONONUCLEOSIS			
			223, 167	18SEP96	19SEP96	60 MG	MONONUCLEOSIS			
			225, 169	20SEP96	21SEP96	40 MG	MONONUCLEOSIS			
			227, 171	22SEP96	23SEP96	20 MG	MONONUCLEOSIS			
			229, 173	24SEP96	25SEP96	10 MG	MONONUCLEOSIS			
			329.010.00280	CENTRAL NERVOUS SYSTEM	Acetaminophen	-10, -65	07MAY96	07MAY96#	650 MG	HEADACHE
					Tylenol	40, -16	25JUN96	25JUN96	1,000 MG	HEADACHE
	DERMATOLOGICALS	Benadryl		42, -14	27JUN96	27JUN96	1,000 MG	HEADACHE		
34, -22			19JUN96	21JUN96	25 MG	ALLERGIES				
RESPIRATORY	Benadryl	39, -17	24JUN96	26JUN96	25 MG + QHS	ALLERGIES				
		34, -22	19JUN96	21JUN96	25 MG	ALLERGIES				
	Tavist-D	39, -17	24JUN96	26JUN96	25 MG + QHS	ALLERGIES				
		-2, -57	15MAY96	15MAY96#	1X PILL DAY	CONGESTION				
329.011.00283	CENTRAL NERVOUS SYSTEM	Tylenol	33, -25	11MAR96	11MAR96	650MG	HEADACHE			
329.011.00288	RESPIRATORY	Naldecon	2, .	26JUL96	01AUG96	2 TSP	COUGH			
		Robitussin-Dm	8, .	01AUG96	.	.	COUGH			
329.012.00025	RESPIRATORY	Reactine	-115, .	01JUL95	.	10MG	SKIN ALLERGIES			
329.012.00220	ANTIINFECTIVES, SYSTEMIC	Erythromycin	113, 53	07OCT96	14OCT96	1000 MG	BRONCHITIS			
	CENTRAL NERVOUS SYSTEM	Ritalin Sr	-148, -208	21JAN96	15MAY96#	20 MG	ADHD			
	DERMATOLOGICALS	Erythromycin	113, 53	07OCT96	14OCT96	1000 MG	BRONCHITIS			
	SENSORY ORGANS	Erythromycin	113, 53	07OCT96	14OCT96	1000 MG	BRONCHITIS			
329.012.00222	ANTIINFECTIVES, SYSTEMIC	Amoxil	21, -43	18JUL96	22JUL96	1500 MG	BLADDER INFECTION			
	ANTINEOPLASTIC & IMMUNOSUP	Cyclen	-119, -182	01MAR96	.	1TAB	CONTRACEPTION			
	DERMATOLOGICALS	Rhinocort	-36, -99	23MAY96	.	PRN 2SPRAYS OD	HAY FEVER			
	GU SYSTEM/SEX HORMONES	Cyclen	-119, -182	01MAR96	.	1TAB	CONTRACEPTION			

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

464

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PAROXETINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.012.00222	RESPIRATORY	Rhinocort	-36, -99	23MAY96	.	PRN 2SPRAYS OD	HAY FEVER	
329.012.00231	ANTIINFECTIVES, SYSTEMIC	Micatin	84, 23	29MAY97	.	1 APPLICATION PRN	ECZEMA	
	CARDIOVASCULAR	Betamethasone	32, -30	07APR97	.		ECZEMA	
	CENTRAL NERVOUS SYSTEM	Tylenol	49, -13	24APR97	.	650 MG PRN	HEADACHE	
	DERMATOLOGICALS	Betamethasone	109, 48	23JUN97	.	500 MG PRN	MOD HEADACHES	
				32, -30	07APR97	.	1 APPLICATION PRN	ECZEMA
	GU SYSTEM/SEX HORMONES	Micatin	84, 23	29MAY97	.	1 TAB	ECZEMA	
	SENSORY ORGANS	Micatin	84, 23	29MAY97	.		CONTRACEPTIVE	
		Ortho Tri-Cyclen	32, -30	07APR97	.	1 APPLICATION PRN	ECZEMA	
		Betamethasone	32, -30	07APR97	.	1 APPLICATION PRN	ECZEMA	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

465

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.001.00061	CENTRAL NERVOUS SYSTEM	Excedrin Pm	-28, .	01JUL94	28JUL94#	1TABLET	INSOMNIA	
	DERMATOLOGICALS	Excedrin Pm	-28, .	01JUL94	28JUL94#	1TABLET	INSOMNIA	
	MUSCULO-SKELETAL	Ibuprofen	-15, .	14JUL94	14JUL94#	200MG	HEADACHE	
	RESPIRATORY	Excedrin Pm	-28, .	01JUL94	28JUL94#	1TABLET	INSOMNIA	
329.001.00066	CENTRAL NERVOUS SYSTEM	Alka-Seltzer	-731, .	21NOV92	.	2	STOMACH ACHE	
		Tylenol	-731, .	21NOV92	.	650MG	HEADACHE	
329.001.00070	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	-8, .	14FEB95	20FEB95#	.	ENLARGED LYMPH NODES	
	CENTRAL NERVOUS SYSTEM	Tylenol	-2, .	20FEB95	20FEB95#	325MG	HEADACHE	
329.001.00122	ALIMENTARY TRACT/METAB	Centrum	-80, -137	01APR95	20JUN95	ONE DAILY	HEALTH MAINTENANCE	
	ANTIINFECTIVES, SYSTEMIC	Bactrim Ds	-139, -196	01FEB95	.	2TWICE DAILY	ACNE	
329.002.00050	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	5, .	27MAR95	28MAR95	250MG	SORE THROAT	
			6, .	28MAR95	08APR95	1500MG	SORE THROAT	
		Cleocin	-1177, .	01JAN92	.	1%LOTION	ACNE	
		Minocycline	-1177, .	01JAN92	.	100MG	ACNE	
		CENTRAL NERVOUS SYSTEM	Aspirin	4, .	26MAR95	26MAR95	650MG	FEVER
		MUSCULO-SKELETAL	Aleve	5, .	27MAR95	28MAR95	1-2TABS	FEVER/SORE THROAT
329.002.00057	CENTRAL NERVOUS SYSTEM	Acetaminophen	-38, -95	01AUG94	.	650MG PRN	HEADACHE	
		Bayer Aspirin	83, 26	29NOV94	29NOV94	1500MG	HEADACHE	
		Cannabis	., .	.	.	UNKNOWN		
		MUSCULO-SKELETAL	Motrin	53, -5	30OCT94	30OCT94	UNKNOWN	
329.002.00100	CENTRAL NERVOUS SYSTEM		22, -36	29SEP94	29SEP94	800MG	HEADACHE	
		Tylenol	-34, -92	01FEB95	01MAR95#	PRN 650MG	HEADACHE	
		MUSCULO-SKELETAL	Advil	41, -18	16APR95	30MAY95	325MG	HEADACHE
329.002.00103	CENTRAL NERVOUS SYSTEM		-34, -92	01FEB95	01MAR95#	400MG	HEADACHE	
		Tylenol	4, -53	23APR95	23APR95	200MG	HEADACHE	
329.002.00104	ANTIINFECTIVES, SYSTEMIC		7, -50	26APR95	26APR95	200MG	HEADACHE	
		Amoxicillin	232, 176	21DEC95	31DEC95	1500 MG	STREP THROAT	
329.002.00243	ANTIINFECTIVES, SYSTEMIC	Monocycline	-123, -179	01JAN95	.	150 MGS	ACNE	
		Pen-Vee-K	1, .	14MAR96	21MAR96	250 4XDAY	TONSILLITIS	
			1, .	14MAR96	21MAR96	1000 MG	PROBABLE STREP THROAT	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

466

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.002.00243	CENTRAL NERVOUS SYSTEM	Tylenol	22, .	04APR96	04APR96	650 MG PRN	HEADACHES
	DERMATOLOGICALS	Benadryl	4, .	17MAR96	24MAR96	25 MG	RASH
	RESPIRATORY	Caladryl	4, .	17MAR96	24MAR96	1 APPL PRN	RASH
		Benadryl	4, .	17MAR96	24MAR96	25 MG	RASH
329.002.00321	MUSCULO-SKELETAL	Ibuprofen	-508, .	01JAN95	.	PRN	HEADACHES
329.003.00073	ALIMENTARY TRACT/METAB	Bentyl	45, .	04MAR95	06MAR95	UNKNOWN	NAUSEA
	CENTRAL NERVOUS SYSTEM	Dexatrim	13, .	31JAN95	03FEB95	UNKNOWN	DIETING
		Pain Medication {Nos}	-11, .	08JAN95	.	4 TABLETS	SPRAINED ANKLE
329.003.00076	CENTRAL NERVOUS SYSTEM	Midol	., .	.	.	.	CRAMPS
329.003.00079	DERMATOLOGICALS	Benadryl	15, .	17MAY95	17MAY95	.	SORE THROAT
	RESPIRATORY	Benadryl	15, .	17MAY95	17MAY95	.	SORE THROAT
329.003.00082	GU SYSTEM/SEX HORMONES	Desogen-28	-344, .	01JAN95	.	X 1	BIRTH CONTROL
329.003.00090	ALIMENTARY TRACT/METAB	Enema Nos	49, .	01MAY95	01MAY95	.	CONSTIPATION
		Mylanta	50, .	02MAY95	.	UNKNOWN	INDIGESTION
		Senokot	50, .	02MAY95	.	UNKNOWN	CONSTIPATION
	CENTRAL NERVOUS SYSTEM	Tylenol	., .	.	.	.	HEADACHE
	MUSCULO-SKELETAL	Advil	50, .	02MAY95	02MAY95	650MG	HEADACHE
			3, .	16MAR95	.	400MG PRN	HEADACHE
329.003.00092	ALIMENTARY TRACT/METAB	Coke Syrup	173, 115	22OCT95	23OCT95	UNKNOWN	STOMACH PROB.
		Milk Of Magnesia	173, 115	22OCT95	23OCT95	UNKNOWN	STOMACH PROB.
		Mylanta	173, 115	22OCT95	23OCT95	UNKNOWN	STOMACH PROB.
		Pepto Bismol	39, -20	10JUN95	10JUN95	2TBP	CRAMPS
329.003.00093	CENTRAL NERVOUS SYSTEM	Butalbital	-171, -234	01JAN95	.	1 DAILY PRN	HEADACHES
	RESPIRATORY	Albuterol	-1997, -2060	01JAN90	.	8 PUFFS DAILY PRN	ASTHMA
329.003.00247	DERMATOLOGICALS	Chloraseptic	34, -21	05MAR96	.	.	COLD
	RESPIRATORY	Nyquil	34, -21	05MAR96	.	.	COLD
329.003.00249	MUSCULO-SKELETAL	Advil	-1892, .	01JAN91	.	.	HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

467

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.003.00249	MUSCULO-SKELETAL	Advil	3,	09MAR96	09MAR96	200 MG	HEADACHE
	RESPIRATORY	Comtrex	38, 48,	13APR96 23APR96	15APR96 23APR96	400 MG BID 800 MG X1	MENSTRUAL CRAMPS COLD
329.003.00289	CENTRAL NERVOUS SYSTEM	Pamprin	.,	.	.	2 TABS	MENSTRUAL CRAMPS
		Tylenol	.,	.	.	1000MG	HEADACHES
329.003.00314	ALIMENTARY TRACT/METAB	Pepcid Ac	44,	04DEC96	06DEC96	ONE CAP	HEARTBURN
	ANTIINFECTIVES, SYSTEMIC	Pen-Vee-K	-111,	03JUL96	13JUL96#	TABS 2X DAY	PHARYNGITIS
	CENTRAL NERVOUS SYSTEM	Tylenol	60,	20DEC96	20DEC96	500 GRM	EARACHE
	MUSCULO-SKELETAL	Advil	25,	15NOV96	17NOV96	200 MG TID	FLU
329.003.00317	CENTRAL NERVOUS SYSTEM	Tylenol	1,	19DEC96	04FEB97	500 MG	HEADACHES
			34,	21JAN97	21JAN97	500 MG	BACKACHE
	DERMATOLOGICALS	Benadryl	27,	14JAN97	14JAN97	25 GM	ALLERGIES
		RESPIRATORY	Benadryl	27,	14JAN97	14JAN97	25 GM
		Over The Counter {Asthma Nos}	.,	.	.		ASTHMA
	VARIOUS	Over The Counter {Allergenic Extract Nos}	.,	.	.		ALLERGIC
329.004.00013	ANTIINFECTIVES, SYSTEMIC	Minocin	-48,	01JUN94	01FEB95	200MG	ACNE
	DERMATOLOGICALS	Accutane	59,	15SEP94	16SEP94	40-80MG	ACNE
329.004.00014	ALIMENTARY TRACT/METAB	Vitamin C	-5,	24NOV94	.	UNKNOWN	COMMON COLD
329.004.00211	ALIMENTARY TRACT/METAB	Antiemetic {Nos}	49,	21MAR96	22MAR96		NAUSEA&VOMITING
		Jamieson B Complex	.,	.	.	ONE CAP	HEALTH MAINTENANCE
		Vitamins	.,	.	.	500MG	HEALTH MAINTENANCE
		Vitamin C	.,	.	.		HEALTH MAINTENANCE
	BLOOD/BLOOD FORM ORGANS	Intravenous Fluids	49,	21MAR96	22MAR96		DEHYDRATION
	CENTRAL NERVOUS SYSTEM	Analgesic {Nos}	49,	21MAR96	22MAR96		MOUTH SORES
329.004.00215	VARIOUS	Tylenol	38,	10MAR96	.	2TABS	HEADACHE
		Unknown Chinese Herbal Med	-139,	01NOV96	11MAR97#		LOW ENERGY

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

468

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.004.00215	VARIOUS	Yinchia0 Tablet {Chiehtupien} {Homeopathic}	7, .	26MAR97	26MAR97	ONE TABLET	RHINITIS AND SORE THROAT
329.005.00003	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM DERMATOLOGICALS RESPIRATORY	Erythromycin	-19, .	01SEP94	14SEP94#	750MG	EAR INFECTION
		Acetaminophen	-5, .	15SEP94	15SEP94#	650MG	HEADACHE
		Erythromycin	-19, .	01SEP94	14SEP94#	750MG	EAR INFECTION
		Naldecon	., .	.	.	20ML	FOR RELIEF OF ALLERGIES
SENSORY ORGANS	Tussi-Organidin	., .	.	.	120MG	FOR RELIEF OF ALLERGIES	
	Erythromycin	-19, .	01SEP94	14SEP94#	750MG	EAR INFECTION	
329.005.00006	ALIMENTARY TRACT/METAB ANTIINFECTIVES, SYSTEMIC	Tums	23, -38	26NOV94	.	2DAILY	UPSET STOMACH
		Ceclor	21, -40	24NOV94	28NOV94	750MG	TONSILLITIS/STREP THROAT
			25, -36	28NOV94	09DEC94	1000MG	TONSILLITIS
329.005.00007	CENTRAL NERVOUS SYSTEM	Compazine	195, 132	22MAY95	22MAY95		DEHYDRATION NAUSEA, VOMITING, DIARRHEA
		Compazine Suppositories	196, 133	23MAY95	24MAY95		DEHYDRATION NAUSEA, VOMITING, DIARRHEA
		Tylenol	81, 18	28JAN95	.	500MG (PRN)	LEG CRAMPS
	DERMATOLOGICALS	Benadryl	180, 117	07MAY95	07MAY95	500MG	HEADACHE
		Benadryl	197, 134	24MAY95	24MAY95		SEIZURE
		Caladryl Lotion	2, -62	10NOV94	14NOV94	TOPICAL LOTION	HIVES-RASH ON ARMS
	GU SYSTEM/SEX HORMONES	Birth Control Pills	-219, -282	04APR94	.	1A DAY	IRREGULAR MENSTRUAL CYCLES
RESPIRATORY	Benadryl	197, 134	24MAY95	24MAY95		SEIZURE	
329.005.00009	CENTRAL NERVOUS SYSTEM	Tylenol	-11, .	01DEC94	07DEC94#	500MG	HEADACHE
			5, .	16DEC94	19DEC94	500MG	HEADACHE
			11, .	22DEC94	27DEC94	500MG	HEADACHES
			21, .	01JAN95	01JAN95	500MG	HEADACHE
329.005.00113	CENTRAL NERVOUS SYSTEM	Tylenol	2, .	31JAN95	31JAN95	500 MG	H/A

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

469

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.005.00113	RESPIRATORY	Ventolin	-3591,	01APR85	.	2 PUFFS PRN	ASTHMA
329.005.00117	ALIMENTARY TRACT/METAB	Cimetidine	41,	27APR95	.	1200MG	GASTRITIS
		Propulsid	41,	27APR95	.	40MG	GASTRITIS
	CENTRAL NERVOUS SYSTEM	Percocet	52,	08MAY95	15MAY95	1X DAILY EVERY 4HRS.AS NE	PAIN
329.005.00118	CENTRAL NERVOUS SYSTEM	Tylenol	4,	20MAY95	23MAY95	500 MG	SORE THROAT
	MUSCULO-SKELETAL	Ibuprofen	-20,	27APR95	27APR95#	400MG	HEADACHE
	RESPIRATORY	Robitussin	3,	19MAY95	.	4 TSP.	COUGH
329.005.00153	ANTIINFECTIVES,SYSTEMIC	Tetracycline	-389, -445	01JAN95	.	1000MG	ACNE
	CENTRAL NERVOUS SYSTEM	Midol	7, -50	31JAN96	31JAN96	6 TABS	MENSTRUAL CRAMPS
		Tylenol	., .	.	17APR96	2 EXTRA STRENGTH	HEADACHE X3
			28, -29	21FEB96	21FEB96	1000 MG	HEADACHE
			38, -19	02MAR96	02MAR96	1000 MG	HEADACHE
			57, 1	21MAR96	17APR96	1000 MG	HEADACHE X3
			84, 28	17APR96	15MAY96	1000 MG	HEADACHE X2
			112, 56	15MAY96	12JUN96	1000 MG	HEADACHE X6
			140, 84	12JUN96	10JUL96	1000 MG	HEADACHE X2
			168, 112	10JUL96	05AUG96	1000 MG	HEADACHE X1
		Tylenol Cold And Flu	-9, -65	16JAN96	27JAN96		COLD
		Tylenol Extra Strength	-2, -58	23JAN96	23JAN96#	500 MG	BACK PAIN
			17, -40	10FEB96	10FEB96	1000 MG	HEADACHE
		Tylenol Gelcaps	-9, -65	16JAN96	27JAN96		COLD
	DERMATOLOGICALS	Tetracycline	-389, -445	01JAN95	.	1000MG	ACNE
	MUSCULO-SKELETAL	Ibuprofen	., .	.	.	200 MG	HEADACHE
			84, 28	17APR96	15MAY96	400 MG	HEADACHE X1
	RESPIRATORY	Tylenol Cold And Flu	-9, -65	16JAN96	27JAN96		COLD
	SENSORY ORGANS	Tetracycline	-389, -445	01JAN95	.	1000MG	ACNE
329.005.00255	ANTIINFECTIVES,SYSTEMIC	Sulfamethoxazole/Tri methoprim Ds	36, .	08APR96	15APR96	1 X 2 DAY	UTI (URINARY TRACT INFECTION)
	DERMATOLOGICALS	Femstat	38, .	10APR96	15APR96		YEAST INFECTION
		Terazol-7	47, .	19APR96	21APR96		YEAST INFECTION
	GU SYSTEM/SEX HORMONES	Femstat	38, .	10APR96	15APR96		YEAST INFECTION

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

470

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.005.00255	MUSCULO-SKELETAL	Ibuprofen	-3,	01MAR96	03MAR96#	2 TABS	HA (HEADACHE)	
			8,	11MAR96	11MAR96	2 TABS	HA (HEADACHE)	
	RESPIRATORY	Sudafed	32,	04APR96	04APR96	1 X DAY	ENVIRONMENTAL ALLERGIES	
			45,	17APR96	18APR96	1 X DAY	ENVIRONMENTAL ALLERGIES	
329.005.00256	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM	Axid	129,	73	11JUL96	.	GI UPSET	
		Tylenol	1,	-56	05MAR96	07MAR96	650 MG	HA
			13,	-44	17MAR96	20MAR96	500 MG	H/A AND BACKACHE
	RESPIRATORY	Tylenol Extra Strength	16,	-41	20MAR96	21MAR96		MENSTRUAL CRAMPS
		Sudafed	28,	-29	01APR96	01APR96		SORE THROAT
			1,	-56	05MAR96	07MAR96		HA
329.005.00295	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM	Pepto-Bismol	-9,	.	19MAR96	19MAR96#	2TBSP	DIARRHEA
		Vitamin C	-24,	.	04MAR96	06MAR96#		COLD SYMPTOMS
	MUSCULO-SKELETAL	Tylenol	-9,	.	19MAR96	19MAR96#	500MG	FLU-BODY ACHES
		Advil	-7,	.	21MAR96	21MAR96#	250MG	HEADACHE
329.005.00297	CENTRAL NERVOUS SYSTEM	Tylenol	-5,	.	14APR96	16APR96#	1 GM.	HEADCOLD & NASAL CONGESTION
			22,	.	10MAY96	11MAY96	2 TABS	HA
	RESPIRATORY	Robitussin	-5,	.	14APR96	16APR96#	4 TSP	HEADCOLD & NASAL CONGESTION
329.005.00335	CENTRAL NERVOUS SYSTEM	Tylenol	-21,	.	07FEB97	08FEB97#	500 MG	MENSTRUAL CRAMPS
			-1,	.	27FEB97	27FEB97#	500 MG	HEADACHE
			43,	.	11APR97	11APR97	500 MG	HEADACHE
			54,	.	22APR97	22APR97	500 MG	HEADACHE
	MUSCULO-SKELETAL	Ibuprofen	-20,	.	08FEB97	09FEB97#	400 MG	MENSTRUAL CRAMPS
329.006.00040	GU SYSTEM/SEX HORMONES MUSCULO-SKELETAL	Loestrin	-63,	.	15DEC94	.	120	OVARIAN CYST
		Baclofen	-3698,	.	01JAN85	.	1TAB PRN	ASTHMA
	RESPIRATORY	Vancenase	-3698,	.	01JAN85	.	1TAB PRN	ALLERGIES
		Ventolin	-3698,	.	01JAN85	.	1TAB PRN	ALLERGIES
329.006.00041	BLOOD/BLOOD FORM ORGANS MUSCULO-SKELETAL	Vitamin B12	-63,	-127	01FEB95	05APR95	500MG	VITAMIN SUPPLEMENT
		Advil	12,	-53	16APR95	18APR95	600MG	SORE THROAT

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

471

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.006.00041	MUSCULO-SKELETAL RESPIRATORY	Nuprin	141, 77	23AUG95	23AUG95	TABLETSX2	HEADACHE	
		Dayquil	140, 76	22AUG95	22AUG95	2CAPSULES	COLD SYMPTOM	
	VARIOUS	Oscobrand Cold And Flu Medication {Nos}	12, -53	16APR95	18APR95	2TABS	SORE THROAT	
Met-Rx {Nutritional Supplement}		134, 70	16AUG95	23AUG95	1PACKET	HEALTH MAINTENANCE		
329.007.00139	CENTRAL NERVOUS SYSTEM	Bc Powder	-9, .	29APR95	01MAY95#	1PACK PRN	FRACTURED RIGHT ARM	
	MUSCULO-SKELETAL	Tylenol	-9, .	29APR95	01MAY95#	325MG PRN	FRACTURED RIGHT ARM	
		Advil	-9, .	29APR95	01MAY95#	200MG PRN	FRACTURED RIGHT ARM	
329.007.00143	CENTRAL NERVOUS SYSTEM	Tylenol	-1, .	08NOV95	09NOV95	1000MG	COLD	
329.007.00146	ALIMENTARY TRACT/METAB	Pepto Bismol	58, 5	22MAR96	22MAR96	2 TABS	UPSET STOMACH	
	CENTRAL NERVOUS SYSTEM	Cyclobenzaprine	162, 109	04JUL96	04JUL96	2 TABS	DIARRHEA	
				7, -47	31JAN96	31JAN96	10MG	MUSCLE SORENESS
				238, 185	18SEP96	18SEP96	1 TAB	LEFT KNEE MUSCLE SPASMS
		Tylenol	-15, -68	10JAN96	10JAN96#	1,000MG	MENSTRUAL CRAMP	
			-8, -61	17JAN96	17JAN96#	500MG	WRIST PAIN(RIGHT)	
		Tylenol Gelcaps	-754, -807	01JAN94	.	750MG PRN	OCCASIONAL HEADACHE	
			172, 119	14JUL96	14JUL96	1,000 MG	ANXIETY	
	DERMATOLOGICALS	Benadryl	-24, -77	01JAN96	.	50MG PRN	SEASONAL ALLERGIES	
	MUSCULO-SKELETAL	Cyclobenzaprine	7, -47	31JAN96	31JAN96	10MG	MUSCLE SORENESS	
			238, 185	18SEP96	18SEP96	1 TAB	LEFT KNEE MUSCLE SPASMS	
RESPIRATORY	Benadryl	-24, -77	01JAN96	.	50MG PRN	SEASONAL ALLERGIES		
	Dimetapp	220, 167	31AUG96	01SEP96	1 TAB	NASAL ALLERGIES		
	Drixoral	-16, -69	09JAN96	09JAN96#	2TABS	COLD		
	Efidac	222, 169	02SEP96	06SEP96	1 TAB	NASAL ALLERGIES		
	Efidac/24	178, 125	20JUL96	22JUL96	1 TAB	COLD		
	Flu Relief {Nos}	12, -42	05FEB96	06FEB96	15TABS	PROPHYLACTIC - FEVER		
VARIOUS	Homeopathic Allergy Medicine	222, 169	02SEP96	07SEP96	3 TABS	NASAL ALLERGIES		
329.007.00269	ALIMENTARY TRACT/METAB	Pepcid Ac	-101, .	01JAN96	.	2 TABS	UPSET STOMACH	
	CENTRAL NERVOUS SYSTEM	Tylenol	., .	.	.	500-1,000	HEADACHES	
				11, .	21APR96	21APR96	1TAB	FOOT PAIN
RESPIRATORY	Pseudoephed	-101, .	01JAN96	.	30MG	ALLERGIES		

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

472

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.007.00270	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM DERMATOLOGICALS	Amoxicillin	-8,	01MAY96	13MAY96	1500MG	STREP THROAT	
		Tylenol	-494,	01JAN95	.	750MG PRN	HEADACHE	
		Antifungal Cream {Nos}	26,	03JUN96	15JUN96	3X	RINGWORM	
	GU SYSTEM/SEX HORMONES RESPIRATORY	Benadryl	9,	17MAY96	19MAY96	3 TABS	POISON IVY	
		Calamine Lotion	9,	17MAY96	19MAY96	2X	POISON IVY	
		Lotrimin Cream	-10,	29APR96	19MAY96	2X	RINGWORM	
		Lotrimin Cream	-10,	29APR96	19MAY96	2X	RINGWORM	
		Benadryl	9,	17MAY96	19MAY96	3 TABS	POISON IVY	
329.007.00307	ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM DERMATOLOGICALS	Amoxicillin	18,	02JUN96	07JUN96	500 MG	SINUSITIS	
		Tylenol	-1,	15MAY96	15MAY96#	1TAB	HEADACHE	
		Benadryl	-45,	01APR96	01APR96#	1TAB	INSOMNIA	
	MUSCULO-SKELETAL	Advil	32,	16JUN96	21JUN96	150 MG	RASH	
			2,	17MAY96	17MAY96	1 TAB PRN	HEADACHE	
			14,	29MAY96	29MAY96	200 MG	HEADACHE	
			19,	03JUN96	04JUN96	200 MG	HEADACHE	
		RESPIRATORY	Ibuprofen	-1597,	01JAN92	.	2 TABS	HEADACHE
			Actifed	31,	15JUN96	16JUN96	2 TABS	ALLERGIES
			Benadryl	-45,	01APR96	01APR96#	1TAB	INSOMNIA
32,	16JUN96	21JUN96	150 MG	RASH				
329.007.00308	ALIMENTARY TRACT/METAB	Imodium A-D	-2,	30JUN96	30JUN96#	4 TABS	NAUSEA	
329.008.00159	CENTRAL NERVOUS SYSTEM	Sleep Aid {Nos}	21,	03OCT95	10OCT95	1TAB PRN	INSOMNIA	
		Tylenol	.,	.	.	2TABS PRN	HEADACHES	
329.008.00187	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM	Levsinex	-5445,	01JAN81	.	1-3XYR	COLITIS	
		Excedrin	-332,	01JAN95	.	1-2TABS PRN	HEADACHES	
		Excedrin Extra Strength	36,	03JAN96	04JAN96	2TABLETS	OCCAS .HEADACHE	
	GU SYSTEM/SEX HORMONES MUSCULO-SKELETAL	Excedrin Extra Strength	44,	11JAN96	12JAN96	2TABLETS	OCCAS .HEADACHE	
		Tylenol #2	58,	25JAN96	26JAN96	2TABLETS	OCCAS .HEADACHE	
		Levlen 28	19,	17DEC95	.	2TABS PRN	OCCAS .HEADACHE	
		Levlen 28	9,	07DEC95	.	1TAB DAILY	CONTRACEPTION	
		Ovcon	-332,	01JAN95	.	1XDAY	BIRTH CONTROL	
Motrin	4,	02DEC95	05DEC95	2TABS PRN	NECK SPASMS			
329.008.00192	ALIMENTARY TRACT/METAB	Pepcid Ac	-2,	03MAR96	.	1TIMES DAY	HEARTBURN	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

473

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.008.00192	CENTRAL NERVOUS SYSTEM	Ritalin	-643, .	01JUN94	01FEB96#	5MG/DAY	ATTENTION DEFICIT HYPERACTIVITY DISORDER
329.008.00272	CENTRAL NERVOUS SYSTEM	Tylenol	-37, -93 8, -49	26FEB96 10APR96	19MAR96# 10APR96	500MG/WK 500 MG	HEADACHES HEADACHE
329.008.00273	CENTRAL NERVOUS SYSTEM	Tylenol	-37, -100	10APR96	.	(ALMOST DAILY) AS NEEDED	TMJ PAIN
	MUSCULO-SKELETAL	Ansaid	-58, -121	20MAR96	10APR96#	3 PILLS/DAY	TMJ PAIN
329.009.00134	ANTIINFECTIVES, SYSTEMIC	Nizoral	-1, .	05JUL95	10JUL95	200MG	FUNGUS
	CENTRAL NERVOUS SYSTEM	Aspirin	38, .	12AUG95	.	500MG PRN	HEADACHE
	DERMATOLOGICALS	Midol	-916, .	01JAN93	.	2TABLETS	MENSTRUAL CRAMPS
	GU SYSTEM/SEX HORMONES	Nizoral	-1, .	05JUL95	10JUL95	200MG	FUNGUS
		Triphasil	-1282, .	01JAN92	.	1PILL PER DAY	BIRTH CONTROL
	MUSCULO-SKELETAL	Anaprox	-916, .	01JAN93	.	550MG PRN	MENSTRUAL CRAMPS
		Naproxen	-34, .	02JUN95	09JUN95#	500MG PRN	SPRAINED MUSCLE
329.009.00171	GU SYSTEM/SEX HORMONES	Triphasil	1, .	07NOV95	.	1TAB	BIRTH CONTROL
329.009.00172	CENTRAL NERVOUS SYSTEM	Tylenol	-681, -738	01JAN94	.	650MG	HEADACHE
329.009.00194	ALIMENTARY TRACT/METAB	Tagamet	28, -29	01JAN96	.	200MG	STOMACH ACHE
	CENTRAL NERVOUS SYSTEM	Tylenol	-703, -759	01JAN94	.	250MG PRN	ANKLE PAIN
	RESPIRATORY	Tylenol Sinus	29, -28	02JAN96	16JAN96	750MG	URI
		Cough Syrup {Nos}	29, -28	02JAN96	16JAN96	2TBL PRN	UPPER RESPIRATORY TRACT INFECTION
		Tylenol Sinus	29, -28	02JAN96	16JAN96	750MG	URI
329.009.00195	CENTRAL NERVOUS SYSTEM	Tylenol	-1809, .	01JAN91	.	650MG PRN	HEADACHE
		Tylenol Number 3	-14, .	01DEC95	02DEC95#	650MG	HEADACHE
	MUSCULO-SKELETAL	Advil	-1809, .	01JAN91	.	200MG PRN	HEADACHE
		Anaprox	-713, .	01JAN94	.	275MG PRN	MENSTRUAL CRAMPS
	RESPIRATORY	Proventil	-348, .	01JAN95	.	2PUFFS PRN	SEASONAL ALLERGIES
329.009.00203	MUSCULO-SKELETAL	Advil	-63, .	01JAN96	.	600MG	SEASONAL ALLERGIES

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

474

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.009.00203	RESPIRATORY VARIOUS	Codimal Dh	-63,	01JAN96	.	1/2TAB	SEASONAL ALLERGIES
		Allergy Shots	-793,	01JAN94	.	1X	SEASONAL ALLERGIES
329.009.00236	CENTRAL NERVOUS SYSTEM	Midol	-168,	15JUL96	.	1 TAB PRN	MENSTRUAL CRAMPS
		Tylenol	-45,	15NOV96	.	250 MG PRN	HEADACHES
329.009.00239	CENTRAL NERVOUS SYSTEM  DERMATOLOGICALS	Actron	-263,	01MAR96	.	2TABS PRN	MIGRAINE
		Excedrin	92, 35	18FEB97	17MAR97		HEADACHE
		Phenergan	41, -17	29DEC96	29DEC96	25 MG	VOMITING
		Temovate Emollient Cream	119, 62	17MAR97	.	1 APPLICATION PRN	DRY FINGERTIPS
		Drixoral	92, 35	18FEB97	17MAR97		SINUS CONGESTION
	SYSTEMIC HORMONAL	Phenergan	41, -17	29DEC96	29DEC96	25 MG	VOMITING
		Melatonin	42, -16	30DEC96	.	1TAB	INSOMNIA
329.009.00262	CENTRAL NERVOUS SYSTEM DERMATOLOGICALS RESPIRATORY SENSORY ORGANS	Tylenol	40,	28MAR97	28MAR97	500 MG	HEADACHE
		Benadryl	27,	15MAR97	15MAR97	1 TAB	COUGH
		Benadryl	27,	15MAR97	15MAR97	1 TAB	COUGH
		Sulfacetamide Sodium	-7,	10FEB97	07APR97	15 ML	EYE INFECTION (LEFT AND RIGHT EYE)
329.009.00264	CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL RESPIRATORY	Aspirin	-732,	31OCT94	.	325MG PRN	HEADACHE
		Coadvil	-732,	31OCT94	.	400MG PRN	HEADACHE
		Coadvil	-732,	31OCT94	.	400MG PRN	HEADACHE
329.009.00301	CARDIOVASCULAR CENTRAL NERVOUS SYSTEM RESPIRATORY	Theo-Dur	-443, -499	01JAN95	.	600MGI	ASTHMA
		Tylenol	-443, -499	01JAN95	.	375MG PRN	HEADACHES
		Alupent	-808, -864	01JAN94	.	2PUFFS PRN	ASTHMA
		Theo-Dur	-443, -499	01JAN95	.	600MGI	ASTHMA
329.009.00305	ALIMENTARY TRACT/METAB	Imodium A-D	57, -1	02JUL96	02JUL96	4 MG	NAUSEA
329.009.00325	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM  DERMATOLOGICALS  MUSCULO-SKELETAL	Zantac	-604, -659	01JAN95	.	2TABS PRN	STOMACH UPSET
		Tylenol Extra Strength	-604, -659	01JAN95	.	1TAB PRN	MENSTRUAL CRAMPS
		Benadryl	45, -11	10OCT96	.	150 MG	NASAL CONGESTION
		Desogen	27, -29	22SEP96	.	1 TAB DAILY	BIRTH CONTROL
		Orudis Kt	-2430, -2485	01JAN90	.	2CAPS PRN	OCCASIONAL HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

475

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.009.00325	RESPIRATORY	Benadryl	45, -11	10OCT96	.	150 MG	NASAL CONGESTION
		Ventolin Inhaler	-2430, -2485	01JAN90	.	2PUFFS PRN	ASTHMA
329.009.00326	RESPIRATORY	Nyquil	-24, -77	12AUG96	15AUG96#	6 TBS.	COLD SYMPTOMS
329.010.00279	ALIMENTARY TRACT/METAB ANTIINFECTIVES, SYSTEMIC CENTRAL NERVOUS SYSTEM	Tums	193, 137	30SEP96	30SEP96	2 TABS	STOMACH PAIN
		Erycette 2% Cream	91, 35	20JUN96	.		ACNE
		Tylenol	11, -46	01APR96	01APR96	325 MG	HEADACHE
	DERMATOLOGICALS	Benadryl	139, 83	07AUG96	07AUG96	325 MG	MOLAR ERUPTING
		Benadryl	162, 106	30AUG96	05SEP96	50 MG	POISON IVY
		Caladryl Clear	110, 54	09JUL96	12JUL96		POISON IVY
			157, 101	25AUG96	29AUG96		POISON IVY
			168, 112	05SEP96	05OCT96		POISON IVY
			91, 35	20JUN96	.		ACNE
	RESPIRATORY SENSORY ORGANS	Ivy Dry	161, 105	29AUG96	04SEP96		POISON IVY
		Vanoxide-Hc Lotion	91, 35	20JUN96	.		ACNE
		Benadryl	162, 106	30AUG96	05SEP96	50 MG	POISON IVY
329.010.00281	CENTRAL NERVOUS SYSTEM	Tylenol	40, -22	03SEP96	03SEP96	1000 MG	HEADACHE
			146, 85	18DEC96	19DEC96	1500 MG	HEADACHE
329.011.00163	CENTRAL NERVOUS SYSTEM	Tylenol	-2519, .	01JAN89	.	500MG	MIGRAINES
			-693, .	01JAN94	.	500MG	TEMPOROMANDIBULAR JOINT SYNDROME
			-2, .	23NOV95	.	500MG	HEADACHE
	DERMATOLOGICALS	Benadryl	4, .	28NOV95	.	500MG	HEADACHE
			-4, .	21NOV95	21NOV95#	25MG	DERMATITIS
			-4, .	21NOV95	21NOV95#	OINTMENT	DERMATITIS
	RESPIRATORY	Benadryl	-4, .	21NOV95	21NOV95#	25MG	DERMATITIS
			-4, .	21NOV95	21NOV95#	OINTMENT	DERMATITIS
			6, .	30NOV95	01DEC95	1 1/2TSP	SORE THROAT
			-603, .	01APR94	.	2PUFFS	ASTHMA
329.011.00208	CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL	Tylenol	-1344, -1403	01JAN93	.	1000MG	HEADACHE
		Aleve	-249, -308	01JAN96	.	1 TAB DAILY	HEADACHE
329.011.00209	CENTRAL NERVOUS SYSTEM RESPIRATORY	Tylenol	-254, -316	01JAN96	.	325MG	HEADACHE
		Claritin	-72, -134	01JUL96	.	1PILL	ALLERGIES

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

476

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.011.00209	RESPIRATORY	Sudafed	20, -43	30SEP96	03OCT96	30 MG	RUNNY NOSE
329.011.00284	ANTIINFECTIVES, SYSTEMIC	Hepatitis B Vaccine	29, -28	19APR96	19APR96		VACCINATION
	CENTRAL NERVOUS SYSTEM	Tylenol	-21, -77	01MAR96	.	650MG	HEADACHE
	RESPIRATORY	Dayquil	31, -26	21APR96	21APR96	650MG	HEADACHE
			9, -48	30MAR96	30MAR96	3TSP	SORE THROAT
329.011.00286	CENTRAL NERVOUS SYSTEM	Tylenol	-2348, -2416	01JAN90	.	1000MG	HEADACHE
	RESPIRATORY	Proventil	-2348, -2416	01JAN90	.	2PUFFS	ASTHMA
		Sudafed	-2348, -2416	01JAN90	.	2PILLS	SINUSITIS
329.012.00221	ALIMENTARY TRACT/METAB	Laxative (Unknown Name)	112, 49	14OCT96	01NOV96	1-2 TBSP EVERY 2ND DAY	CONSTIPATION
	CENTRAL NERVOUS SYSTEM	Aspirin	78, 15	10SEP96	10SEP96	1950 MG	HEADACHES
		Chloral Hydrate	56, -8	19AUG96	22SEP96	500 MG PRN	INSOMNIA
		Lorazepam	132, 69	03NOV96	03NOV96	8 MG	OVERDOSE
		Tylenol	-906, -969	01JAN94	.	500 MG PRN	HEADACHE
329.012.00223	CENTRAL NERVOUS SYSTEM	Tylenol	-972, .	01JAN94	.	500 MG PRN	HEADACHE
	DERMATOLOGICALS	Flonase	-107, .	15MAY96	.	1 PUFF PRN	BRONCHOSPASM
	RESPIRATORY	Flonase	-107, .	15MAY96	.	1 PUFF PRN	BRONCHOSPASM
		Sodium (Cromoglycate)	-107, .	15MAY96	.	2 DROPS PRN	ALLERGIC REACTION
	SENSORY ORGANS	Sodium (Cromoglycate)	-107, .	15MAY96	.	2 DROPS PRN	ALLERGIC REACTION
329.012.00227	ANTIINFECTIVES, SYSTEMIC	Amoxil	42, -28	28JAN97	10FEB97	750 MG	PHARYNGITIS
		Penicillin V-K	21, -49	07JAN97	15JAN97	2,400 MG	AC. PHARYNGITIS
	CENTRAL NERVOUS SYSTEM	Marijuana	32, -38	18JAN97	18JAN97	0.75 G	PT'S DECISIONS
	RESPIRATORY	Dristan	142, 73	08MAY97	09MAY97	2 TABS.	CONGESTION
		Triaminic	142, 73	08MAY97	09MAY97	3 TSP.	COUGH
329.012.00230	ALIMENTARY TRACT/METAB	Tums	15, -55	14MAR97	.	3-4 TABS	HEARTBURN
			76, 7	14MAY97	26MAY97	3-4 TABS	HEARTBURN
	ANTIINFECTIVES, SYSTEMIC	Biaxin	50, -20	18APR97	24APR97	500 MG	PHOPHYLAXIS TEETH EXTRACTION
	CENTRAL NERVOUS SYSTEM	Tylenol	32, -38	31MAR97	31MAR97	500 MG	HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

477

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=IMIPRAMINE -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.012.00230	CENTRAL NERVOUS SYSTEM	Tylenol With Codeine	50, -20	18APR97	20APR97	14 TSPS.	IMPACTED TEETH EXTRACTION
			53, -17	21APR97	21APR97	10 TSP.	IMPACTED TEETH EXTRACTION
	DERMATOLOGICALS	Solu-Medrol	50, -20	18APR97	18APR97	250 MG	IMPACTED TEETH EXTRACTION
	MUSCULO-SKELETAL	Advil	53, -17	21APR97	23APR97	600 MG	IMPACTED TEETH EXTRACTION
	RESPIRATORY	Gravol	69, -1	07MAY97	07MAY97	50 MG	NAUSEA
	SENSORY ORGANS	Solu-Medrol	50, -20	18APR97	18APR97	250 MG	IMPACTED TEETH EXTRACTION
	SYSTEMIC HORMONAL	Solu-Medrol	50, -20	18APR97	18APR97	250 MG	IMPACTED TEETH EXTRACTION

478

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.001.00062	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM	Mylanta Tylenol	-2240, -5437,	. 01SEP88 . 01DEC79	01SEP93# .	2TSP 1000MG	STOMACH ACHE HEADACHE
329.001.00064	CENTRAL NERVOUS SYSTEM	Tylenol	-4013,-4067	15NOV83	.	1000MG	EAR INFECTIONS, HEADACHE
329.001.00069	ANTIINFECTIVES,SYSTEMIC  CENTRAL NERVOUS SYSTEM	Amoxicillin Septra Double Strength Tylenol	-51, 1,  -51,	. 27DEC94 . 16FEB95  . 27DEC94	27JAN95# 24FEB95  27JAN95#	1TAB   650MG	PNEUMONIA PHARYNGITIS RIGHT OTITIS MEDIA FEVER PLUS HEADACHE
329.001.00071	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM  RESPIRATORY	Amoxicillin Tylenol Tylenol Cold Tablets Nyquil Robitussin Cf Tylenol Cold Tablets	-20, -17, -17, -17, -21, -17,	. 03FEB95 . 06FEB95 . 06FEB95 . 06FEB95 . 02FEB95 . 06FEB95	13FEB95# 12FEB95# 12FEB95# 10FEB95# 08FEB95# 12FEB95#	750MG 650MG 2TABS   2TABS	FLU/SINUSITIS HEADACHE FLU FLU FLU
329.001.00123	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM  DERMATOLOGICALS  GU SYSTEM/SEX HORMONES SENSORY ORGANS  SYSTEMIC HORMONAL	Zithromax Aspirin Pamprin Tylenol Methylprednisolone  Ortho-Cept 28 Methylprednisolone  Methylprednisolone	10, 12, -20, 49, 10,  18, 10,  10,	. 13JAN96 . 15JAN96 . 15DEC95 . 21FEB96 . 13JAN96  . 21JAN96 . 13JAN96  . 13JAN96	18JAN96 . 17DEC95# . 18JAN96 . . 18JAN96 . 18JAN96	1000MGX1 650MG 2TABS 650MG 4MG-24MG DAILY 1TAB 1XDAY 4MG-24MG DAILY 4MG-24MG DAILY	BRONCHITIS MENSTRUAL CRAMPS MENSTRUAL CRAMPS HEADACHE BRONCHITIS  MENSTRUAL CRAMPS BRONCHITIS  BRONCHITIS
329.001.00207	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL RESPIRATORY	Biaxin Tylenol Aleve Sudafed	56, 53, -7, -21,	. 23APR96 . 20APR96 . 21FEB96 . 07FEB96	02MAY96 25APR96 28FEB96 28FEB96	1000MG 650MG 1TAB 60MG	SINUS INFECTION HEADACHE SORE THROAT STRAINED MUSCLE COLD SYMPTOMS
329.002.00049	CENTRAL NERVOUS SYSTEM	Aspirin	19,	. 27MAR95	27MAR95	650MG	HEADACHE
329.002.00097	CENTRAL NERVOUS SYSTEM	Tylenol	-15, -73	19DEC94	26DEC94#	200MG PRN	UPPER RESPIRATORY INFECTION

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

479

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.002.00097	CENTRAL NERVOUS SYSTEM	Tylenol	14, -45 29, -30 87, 29	16JAN95 31JAN95 30MAR95	17JAN95 07FEB95 .	325MG 650MG 650PRN	FLU SYMPTOMS HEADACHE HEADACHES
	DERMATOLOGICALS	Benadryl	-15, -73	19DEC94	26DEC94#	25MG PRN	UPPER RESPIRATORY INFECTION
	RESPIRATORY	Benadryl	-15, -73	19DEC94	26DEC94#	25MG PRN	UPPER RESPIRATORY INFECTION
329.002.00107	ANTIINFECTIVES,SYSTEMIC	Amoxicillin	236, 180	16SEP96	26SEP96	1500 MG	STREP THROAT
329.002.00241	CENTRAL NERVOUS SYSTEM	Prozac	108, 52	23MAY96	.	10 MG	DEPRESSION
	RESPIRATORY	Cough Medicine	64, 8	09APR96	30APR96	18 TBSP	COUGH
		Dristan	-36, -92	01JAN96	25JAN96#	2 SPRAYS	NASAL CONGESTION
329.002.00246	ALIMENTARY TRACT/METAB	Pepcid	-838, .	01JAN94	.	PRN-10MGs	GASTROINTESTINAL DISTRESS
	MUSCULO-SKELETAL	Advil	48, .	04JUN96	04JUN96		HEADACHE
329.002.00320	ANTIINFECTIVES,SYSTEMIC	Augmentin	117, 56	09SEP96	19SEP96		EAR INFECTION
	MUSCULO-SKELETAL	Ibuprofen	32, -30	16JUN96	22JUN96	PRN	PAIN IN (EST) SHOULDER
329.002.00323	ANTIINFECTIVES,SYSTEMIC	Amoxicillin	151, 93	11APR97	18APR97	250 MG	PHARYNGITIS
	CENTRAL NERVOUS SYSTEM	Unknown {Analgesic Nos}	-1, -59	11NOV96	01DEC96		BACK PAIN
		Unknown {Analgesic}	49, -10	30DEC96	.	UNKNOWN	HEADACHES
329.003.00080	GU SYSTEM/SEX HORMONES	Injectable Contraceptive {Nos}	-51, .	07OCT95	.		BIRTH CONTROL
329.003.00086	CENTRAL NERVOUS SYSTEM	Tylenol	-58, -115 36, -22	01OCT94 02JAN95	08OCT94# 03JAN95	500MG 500MG	ABD.PAIN FEVER
	DERMATOLOGICALS	Caladryl Lotion	78, 21	13FEB95	25APR95	LOCAL TOPICAL	RASH
	RESPIRATORY	Afrin	-423, -480	01OCT93	09NOV94#	1 SPRAY PRN	RHINORRHEA
		Tavist D Tavist-D	15, -43 169, 112	12DEC94 15MAY95	14DEC94 19MAY95	2 TSP	COLD COLD
329.003.00094	ALIMENTARY TRACT/METAB	Prilosec	32, .	24NOV95	.	PRN	ACIDITY

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

480

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.003.00094	CENTRAL NERVOUS SYSTEM	Aspirin	49, .	11DEC95	11DEC95	500MG	HEADACHE
329.003.00252	CENTRAL NERVOUS SYSTEM	Midol	39, .	18MAY96	18MAY96	2 TAB	HEADACHE
	DERMATOLOGICALS	Tylenol	., .	.	.	500 MG	HEADACHE
		Retin-A	., .	.	.	.	CYSTIC ACNE
329.003.00315	CENTRAL NERVOUS SYSTEM	Sinutab	7, .	18NOV96	20NOV96	2	COLD
329.004.00016	ALIMENTARY TRACT/METAB RESPIRATORY	Buscopan	16, .	28MAR95	30MAR95	10MG	STOMACH CRAMPS
		Reactine	13, .	25MAR95	.	10MG	ALLERGIES/HAYFEVER
		Ventodisk	-2628, .	01JAN88	.	1XWK	ALLERGIES
329.004.00018	ANTIINFECTIVES, SYSTEMIC	Erythromycin	-9, .	24APR95	02MAY95#	333MG	UPPER RESPIRATORY TRACT INFECTION
	ANTINEOPLASTIC & IMMUNOSUP	Cyclen	-1583, .	01JAN91	24MAY95	1TAB	BIRTH CONTROL
	CENTRAL NERVOUS SYSTEM	Tylenol	-1583, .	01JAN91	03MAY95	650TO 1300MG	HEADACHES
			22, .	24MAY95	.	325-650	HEADACHE
		Valium	26, .	28MAY95	28MAY95	15MG	TENSION
	DERMATOLOGICALS	Erythromycin	-9, .	24APR95	02MAY95#	333MG	UPPER RESPIRATORY TRACT INFECTION
	GU SYSTEM/SEX HORMONES	Cyclen	-1583, .	01JAN91	24MAY95	1TAB	BIRTH CONTROL
		Ortho Tri-Cyclen	30, .	01JUN95	.	1TAB	BIRTH CONTROL
	RESPIRATORY	Claritin	13, .	15MAY95	18MAY95	1TAB	POLLEN ALLERGY
		Dimetapp	-12, .	21APR95	21APR95#	X1	UPPER RESPIRATORY TRACT INFECTION
		Dimetapp-C	-12, .	21APR95	28APR95#	4TEASPOONS	UPPER RESPIRATORY TRACT INFECTION
		Neo Citran	-12, .	21APR95	21APR95#	X1	UPPER RESPIRATORY TRACT INFECTION
	SENSORY ORGANS	Erythromycin	-9, .	24APR95	02MAY95#	333MG	UPPER RESPIRATORY TRACT INFECTION
329.004.00020	CENTRAL NERVOUS SYSTEM	Valium	-21, .	19OCT95	19OCT95#	5MG	ANXIETY
329.004.00213	CENTRAL NERVOUS SYSTEM	222	65, 11	05OCT96	05OCT96	375 MGS	HEADACHE
		Acetaminophen	65, 11	05OCT96	05OCT96	1000 MG	HEADACHE
			110, 56	19NOV96	19NOV96	1000 MG	HEADACHE
			122, 68	01DEC96	01DEC96	375 MG	HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

481

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.004.00213	CENTRAL NERVOUS SYSTEM	Acetaminophen	150, 96	29DEC96	29DEC96	1000 MG	HEADACHE
			224, 170	13MAR97	13MAR97	1000 MG	HEADACHE
		Bufferin	3, -52	04AUG96	04AUG96	325 MGS	HEADACHE
		Sinutab	11, -44	12AUG96	12AUG96	1 TAB	COLD
			134, 80	13DEC96	13DEC96	1 TAB	COLD
329.005.00010	CENTRAL NERVOUS SYSTEM DERMATOLOGICALS RESPIRATORY	Tylenol	122, 65	13APR95	15APR95	1GM	FOOT/ANKLE INJURY
		Benadryl	81, 24	03MAR95	05MAR95		HIVES
		Benadryl	81, 24	03MAR95	05MAR95		HIVES
329.005.00012	CENTRAL NERVOUS SYSTEM SENSORY ORGANS	Tylenol	37, -23	24JAN95	24JAN95	500MG	HEADACHE
		Steroid Eye Drops {Nos}	165, 106	01JUN95	.		OCULAR TOXOPLASMOSIS
329.005.00111	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	37, -20	16FEB95	20FEB95	750MG	SORE THROAT-STREP THROAT?
		Augmentin	97, 41	17APR95	27APR95	750MG	SINUS INFECTION
	CENTRAL NERVOUS SYSTEM	Tylenol	-4, -60	07JAN95	14FEB95	500MG	HEADACHE/BACKACHE
			36, -21	15FEB95	20FEB95	1GM	SORE THROAT/FEVER
			65, 9	16MAR95	17MAR95	1GM	SORE THROAT
			94, 38	14APR95	15APR95	2GM	H/A, PAIN-FACE, NOSE, TEETH
			96, 40	16APR95	17APR95	2GM	H/A/SORE THROAT
	RESPIRATORY	Tylenol#3	96, 40	16APR95	17APR95	60MG	H/A/SORE THROAT
		Beconase Nasal Spray .042%	85, 29	05APR95	.	4 SPRAYS	ALLERGIES/ASTHMA
		Nasalcrom	37, -20	16FEB95	.	2XADAY PUFFS PRN	SINUS STUFFINESS
		Proventil	85, 29	05APR95	07APR95	2PUFFS PRN	ALLERGIES/ASTHMA
		Vancenase	37, -20	16FEB95	.	2XADAY PUFFS PRN	SINUS STUFFINESS
	SENSORY ORGANS	Nasalcrom	37, -20	16FEB95	.	2XADAY PUFFS PRN	SINUS STUFFINESS
	SYSTEMIC HORMONAL	Steroidal Nasal Preps. {Nos}	97, 41	17APR95	.		ALLERGIES/SINUS INFECTION
329.005.00114	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	7, -51	06FEB95	16FEB95	750MG	STREP THROAT
	CENTRAL NERVOUS SYSTEM	Tylenol	5, -53	04FEB95	08FEB95	500MG	STREP THROAT-PAIN

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

482

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.005.00114	RESPIRATORY	Ventolin Inhaler	-565, -622	15JUL93	18OCT94#	2PUFFS	ASTHMA
329.005.00115	ANTIINFECTIVES,SYSTEMIC	Amoxicillin	19, -53	24FEB95	15MAR95	750 MG	TOOTH ACHE/SINUS INFECTION
	CENTRAL NERVOUS SYSTEM	Vicodin	19, -53	24FEB95	10MAR95	750 MG PRN	TOOTH ACHE/SINUS INFECTION
	GU SYSTEM/SEX HORMONES	Birth Control Pills	-31, -102	06JAN95	.	1X	PREVENT PREGNANCY
	RESPIRATORY	Ventolin Inhaler	-27, -98	10JAN95	10JAN95#	2 PUFFS PRN	ASTHMA
		Vicodin	19, -53	24FEB95	10MAR95	750 MG PRN	TOOTH ACHE/SINUS INFECTION
329.005.00120	DERMATOLOGICALS	Topical Cream {Dermatological Nos}	., .	.	.	.	RASH (?FOLLICULITIS)
	RESPIRATORY	Actifed	15, .	13SEP95	14SEP95		RUNNY NOSE, COUGH
		Robitussin	19, .	17SEP95	19SEP95		COUGH
			55, .	23OCT95	23OCT95		COUGH
329.005.00253	ANTIINFECTIVES,SYSTEMIC	Amoxicillin	-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
		Doxycycline	26, .	04MAR96	12MAR96	200 MG BID	CHLAMYDIA
	CENTRAL NERVOUS SYSTEM	Aspirin	-6, .	02FEB96	14FEB96	650 MG	HEADACHE
		Tylenol	19, .	26FEB96	26FEB96	650 MG	HEADACHE
	MUSCULO-SKELETAL	Advil	20, .	27FEB96	27FEB96		HEADACHE
		Aleve	45, .	23MAR96	23MAR96	1 TAB	HEADACHE
	RESPIRATORY	Promethazine With Codeine	-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
			-10, .	29JAN96	31JAN96#		BRONCHITIS
		Proventil Inhaler	-10, .	29JAN96	08FEB96	3 PUFFS	BRONCHITIS
329.005.00254	CENTRAL NERVOUS SYSTEM	Bayer Aspirin	104, 49	28MAY96	28MAY96	UNKNOWN	MENSTRUAL CRAMPS
		Tylenol	-13, -68	02FEB96	06FEB96#	500MG	HEADACHE
			-4, -59	11FEB96	11FEB96#	500MG	HEADACHE
			23, -33	08MAR96	08MAR96	500MG	HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

483

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication	
329.005.00254	CENTRAL NERVOUS SYSTEM	Tylenol	53, -3	07APR96	07APR96	500MG	HEADACHE	
			201, 146	02SEP96	02SEP96	500 MG	HEADACHE	
	MUSCULO-SKELETAL	Ibuprofen	202, 147	03SEP96	03SEP96	500 MG	HEADACHE	
			24, -32	09MAR96	09MAR96		MENSTRUAL CRAMPS	
329.005.00293	ANTINEOPLASTIC & IMMUNOSUP	Depo-Provera	21, .	01APR97	01APR97		BIRTH CONTROL	
	CENTRAL NERVOUS SYSTEM	Tylenol	-23, .	17FEB97	18FEB97#	1 GM	POST PARTUM PAIN	
			26, .	06APR97	06APR97	500 MG	HEADACHE	
				39, .	19APR97	19APR97	2 TABS	HEADACHE
	GU SYSTEM/SEX HORMONES	Depo-Provera	21, .	01APR97	01APR97		BIRTH CONTROL	
RESPIRATORY	Humibid	7, .	18MAR97	18MAR97	2 PUFFS	RESPIRATORY CONGESTION		
329.005.00298	CENTRAL NERVOUS SYSTEM	Midol (Teen) Pamprin	231, 175	07JAN97	09JAN97	4 TABS	MENSTRUAL CRAMPS	
			-7, -63	15MAY96	15MAY96#	PRN	MENSTRUAL CRAMPS	
			46, -11	06JUL96	07JUL96	1X DAILY TAB	MENSTRUAL CRAMPS	
			167, 111	04NOV96	04NOV96	2 TABS	MENSTRUAL CRAMPS	
			200, 144	07DEC96	09DEC96	1 TAB	MENSTRUAL CRAMPS	
		Sudafed Cold And Cough	204, 148	11DEC96	12DEC96	4 TABS	COLD SX	
		Sudafed Sinus	202, 146	09DEC96	10DEC96	2 TABS	COLD SX.	
		Tylenol Cold	39, -18	29JUN96	29JUN96	2X DAILY TABS	STIFF NECK	
		Tylenol Sinus	12, -45	02JUN96	05JUN96	2X DAILY TABS	SINUS H/A AND CONGESTION	
	MUSCULO-SKELETAL	Advil	26, -31	16JUN96	16JUN96	2X DAILY TABS	RIGHT LEG PAIN	
			33, -24	23JUN96	23JUN96	2X DAILY TABS	BACK PAIN	
			56, -1	16JUL96	16JUL96	1X DAILY TAB	KNEE INJURY	
			133, 77	01OCT96	04OCT96	800 MG	CHARLIE HORSE	
		Advil Cold And Sinus	-22, -78	30APR96	30APR96#	1 DAILY PRN	ALLERGIES	
		Ibuprofen	149, 93	17OCT96	17OCT96	300 MG	PULLED MUSCLE	
RESPIRATORY	Advil Cold And Sinus	-22, -78	30APR96	30APR96#	1 DAILY PRN	ALLERGIES		
		40, -17	30JUN96	01JUL96	2X DAILY TABS	SINUS CONGESTION		
			Sudafed Cold And Cough	204, 148	11DEC96	12DEC96	4 TABS	COLD SX

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

484

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.005.00298	RESPIRATORY	Sudafed Sinus	202, 146	09DEC96	10DEC96	2 TABS	COLD SX.
		Tylenol Allergy And Sinus	-26, -82	26APR96	26APR96#	2 DAILY PRN	ALLERGIES
		Tylenol Cold	39, -18	29JUN96	29JUN96	2X DAILY TABS	STIFF NECK
		Tylenol Sinus	12, -45	02JUN96	05JUN96	2X DAILY TABS	SINUS H/A AND CONGESTION
329.005.00331	ANTIINFECTIVES, SYSTEMIC	Augmentin	27, .	17DEC96	27DEC96	2 CAPS	SINUS INFECTION
		Zithromax	-22, .	30OCT96	06NOV96#		EAR INFECTION
	CENTRAL NERVOUS SYSTEM	Tylenol	1, .	21NOV96	21NOV96	500 MG	HEADACHE
			36, .	26DEC96	26DEC96	500 MG	HEADACHE
	MUSCULO-SKELETAL	Advil	3, .	23NOV96	23NOV96	4 CAPS	HEADACHE
		Robitussin	23, .	13DEC96	17DEC96	2 TSP.	SINUS INFECTION
RESPIRATORY	Unknown Decongestant {Nos}	-14, .	07NOV96	17NOV96#		SINUS INFECTION	
329.005.00334	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	7, .	06FEB97	16FEB97	750 MG	SORE THROAT
		Tylenol	-50, .	12DEC96	19DEC96#	1 GM	POST-OP FOOT SURGERY
	CENTRAL NERVOUS SYSTEM		32, .	03MAR97	03MAR97	500 MG	HEADACHE
			41, .	12MAR97	12MAR97	500 MG	HEADACHE
			48, .	19MAR97	20MAR97	1000 MG	FEVER
			48, .	19MAR97	20MAR97	800 MG	BACKACHE
MUSCULO-SKELETAL	Advil	48, .	19MAR97	20MAR97	800 MG	BACKACHE	
329.006.00037	ANTIINFECTIVES, SYSTEMIC GU SYSTEM/SEX HORMONES	Doxycycline	10, .	06FEB95	13FEB95	UNKNOWN	BRONCHITIS
		Ovcon 35	-119, .	01OCT94	.	1 TAB	BIRTH CONTROL
329.006.00042	ALIMENTARY TRACT/METAB	Pepto Bismol	32, -26	07JAN96	07JAN96	2/3C.	STOMACH UPSET
		Acetaminophen	140, 83	24APR96	24APR96	200 MG	HEADACHE
	CENTRAL NERVOUS SYSTEM	Aleve	211, 154	04JUL96	04JUL96	220 MG	DENTAL PAIN
		Ibuprofen	108, 51	23MAR96	23MAR96	600 MG	HEADACHE
	MUSCULO-SKELETAL		209, 152	02JUL96	02JUL96	400 MG	ORTHODONTAL/DENTAL PAIN
			210, 153	03JUL96	03JUL96	800 MG	DENTAL PAIN
			211, 154	04JUL96	04JUL96	200 MG	DENTAL PAIN
			212, 155	05JUL96	05JUL96	600 MG	DENTAL PAIN
			213, 156	06JUL96	06JUL96	400 MG	DENTAL PAIN
			216, 159	09JUL96	09JUL96	200 MG	HEADACHE
		218, 161	11JUL96	11JUL96	200 MG	HEADACHE	

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

485

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.006.00042	MUSCULO-SKELETAL	Ibuprofen	220, 163	13JUL96	13JUL96	200 MG	HEADACHE
329.006.00259	ANTIINFECTIVES,SYSTEMIC	Minocin	-540, .	01DEC94	.	50MG	ACNE
329.007.00141	DERMATOLOGICALS RESPIRATORY	Benadryl Benadryl	-23, . -23, .	29AUG95 29AUG95	30AUG95# 30AUG95#	25MG 25MG	SLEEP ONSET INSOMNIA SLEEP ONSET INSOMNIA
329.007.00144	CENTRAL NERVOUS SYSTEM	Tylenol	39, -18	14JAN96	15JAN96	1,500MG	HEADACHE
329.007.00266	ANTIINFECTIVES,SYSTEMIC	Keflex	52, .	27APR96	10MAY96	1,000MG	SORE THROAT
329.007.00267	CENTRAL NERVOUS SYSTEM	Tylenol Gelcaps	10, . 31, .	16MAR96 06APR96	16MAR96 06APR96	1000MG 1000MG	HEADACHE HEADACHE
	MUSCULO-SKELETAL	Advil	26, .	01APR96	01APR96	400MG	HEADACHE
329.007.00311	ALIMENTARY TRACT/METAB	Dulcolax Pepto Bismol	7, -54 113, 53	09OCT96 23JAN97	09OCT96 24JAN97	1 TAB 2TSP	ABDOMINAL PAIN VOMITING AND DIARRHEA DUE TO FLU SYMPTOM
	ANTIINFECTIVES,SYSTEMIC	Bactrim	-27, -87 21, -40 28, -33	06SEP96 23OCT96 30OCT96	20SEP96# 24OCT96 02NOV96	2 TAB 2 TABS 2 TABS	BRONCHITIS BRONCHITIS SYMPTOMS BRONCHITIS
	CENTRAL NERVOUS SYSTEM	Sulfatrim Effexor	166, 106 -155, -215	17MAR97 01MAY96	31MAR97 27SEP96#	1,000 MG 1 TAB PRN	BRONCHITIS PRIOR PRESCRIPTION FOR DEPRESSION
	DERMATOLOGICALS	Flonase	21, -40	23OCT96	23NOV96	2 SPRAYS	SINUSITIS
	MUSCULO-SKELETAL	Naprosyn	47, -14	18NOV96	22NOV96	1000 MG	KNEE PAIN
	RESPIRATORY	Albuterol Entex La	166, 106 21, -40	17MAR97 23OCT96	24MAR97 24OCT96	1 TSP. 2 TABS	BRONCHITIS BRONCHITIS SYMPTOMS
		Entex La	28, -33	30OCT96	02NOV96	2 TABS	BRONCHITIS
		Flonase	21, -40	23OCT96	23NOV96	2 SPRAYS	SINUSITIS
		Proventil	-27, -87	06SEP96	13SEP96#	2 TSP	BRONCHITIS
		Sudafed	85, 25	26DEC96	26DEC96	1TAB	SINUS CONGESTION
		Unknown Cough Syrup	166, 106	17MAR97	24MAR97	1 TSP	BRONCHITIS
329.008.00162	ANTIINFECTIVES,SYSTEMIC	Antibiotic {Nos}	29, -37 37, -29	29NOV95 07DEC95	09DEC95 17DEC95		BRONCHITIS EYE INFECTION
329.008.00191	ANTIINFECTIVES,SYSTEMIC	Tetracycline	-51, -112	12DEC95	.	500MG	ACNE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

486

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.008.00191	DERMATOLOGICALS SENSORY ORGANS	Tetracycline	-51, -112	12DEC95	.	500MG	ACNE
		Tetracycline	-51, -112	12DEC95	.	500MG	ACNE
329.009.00128	RESPIRATORY	Dimetapp	-830, .	01JAN93	.	4TABS PRN	SEASONAL ALLERGIES
329.009.00135	CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL SYSTEMIC HORMONAL	Elavil	-9, .	23SEP95	24SEP95#	25MG	DEPRESSION
		Paxil	36, .	06NOV95	.	10MG	DEPRESSION
		Aleve	-274, .	01JAN95	.	220MG PRN	HEADACHES
		Synthroid	-1370, .	01JAN92	.	150MG	HYPOTHYROID
329.009.00136	CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL RESPIRATORY	Midol	-1005, .	01JAN93	.	2 TABS PRN	MENSTRUAL CRAMPS
		Dxivil	-275, .	01JAN95	.	750 MG PRN	OCCASSIONAL HEADACHE
		Drixoral	-275, .	01JAN95	.	500 PRN	SINUS CONGESTION
329.009.00169	DERMATOLOGICALS	Elimite	36, -30	05DEC95	05DEC95	5 %	SCABIES
329.009.00174	ALIMENTARY TRACT/METAB CENTRAL NERVOUS SYSTEM MUSCULO-SKELETAL RESPIRATORY	Pepto Bismol	13, -45	03DEC95	07DEC95	2TBS.PRN	FLU
		Excedrin	-689, -746	01JAN94	.	500 MG PRN	HEADACHES
		Daypro	13, -45	03DEC95	07DEC95	500MG	FLU
		Drixoral	-13, -70	08NOV95	.	600MG PRN	TMJ
329.009.00197	ALIMENTARY TRACT/METAB ANTIINFECTIVES,SYSTEMIC MUSCULO-SKELETAL	Pepcid	-58, -112	01NOV95	.	20MG PRN	STOMACH PAIN
		Augmentin	174, 120	19JUN96	23JUN96	1000 MG	SCALP LACERATIONS
		Advil	-362, -416	01JAN95	.	200MG PRN	HEADACHE
329.009.00198	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM GU SYSTEM/SEX HORMONES RESPIRATORY	Tetanus {Toxoid}	48, .	18FEB96	18FEB96	1CC	VACCINATION (FACIAL CUTS)
		Tylenol	-366, .	01JAN95	.	650MG PRN	HEADACHE
		Triphasil	-1096, .	01JAN93	.	1PILL	BIRTH CONTROL
		Robitussin	-366, .	01JAN95	.	2TBLS	FLU SYMPTOMS
329.009.00200	CENTRAL NERVOUS SYSTEM RESPIRATORY	Benadryl Cold	-22, .	01JAN96	05JAN96#	2TAB PRN	COLD
		Tylenol	-752, .	01JAN94	.	500MG	HEADACHE
		Benadryl Cold	-22, .	01JAN96	05JAN96#	2TAB PRN	COLD
329.009.00202	ANTIINFECTIVES,SYSTEMIC CENTRAL NERVOUS SYSTEM	Metacycline	-415, .	01JAN95	.	1TAB	SEASONAL ALLERGY
		Midol	-50, .	01JAN96	.	2TABS PRN	MENSTRUAL CRAMPS
		Tylenol	-415, .	01JAN95	.	650 PRN	HEADACHES

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.009.00202	GU SYSTEM/SEX HORMONES	Ortho Novum	-50,	01JAN96	.	1PILL	BIRTH CONTROL
329.009.00237	DERMATOLOGICALS	Accutane	.	.	.	.	ACNE
329.009.00238	CENTRAL NERVOUS SYSTEM	Tylenol	-681,	01JAN95	.	325MG PRN	HEADACHES
	RESPIRATORY	Sudafed	50,	31DEC96	.	250 MG	HEADACHE
			38,	19DEC96	31DEC96	60 MG	CONGESTION
329.009.00276	ALIMENTARY TRACT/METAB	Imodium	70,	31MAR97	31MAR97	1 TAB PRN	STOMACH VIRUS
	CENTRAL NERVOUS SYSTEM	Tylenol	-386,	01JAN96	.	500 MG PRN	OCCASIONAL HEADACHE
			-314,	13MAR96	.	500 MG PRN	SORE THROAT
	MUSCULO-SKELETAL	Aleve	53,	14MAR97	14MAR97	440 MG	SORE THROAT
	RESPIRATORY	Robitussin	51,	12MAR97	18MAR97	1 TSP PRN	SORE THROAT
329.009.00302	MUSCULO-SKELETAL	Advil	-86,	01JAN96	20MAR96#	500MG	TENDONITIS
329.009.00306	BLOOD/BLOOD FORM ORGANS	Feosol Liquid	44,	24JUL96	.	4 TSP.	ANEMIA
329.009.00312	ALIMENTARY TRACT/METAB	Zantac	-308,	01JAN96	.	300 MG PRN	STOMACH ULCER
	GU SYSTEM/SEX HORMONES	Tri-Levlen	-1038,	01JAN94	.	1 TAB DAILY	BIRTH CONTROL
	MUSCULO-SKELETAL	Ibuprofen	-673,	01JAN95	.	400 MG PRN	OCCASIONAL HEADACHE
	RESPIRATORY	Claritin	-308,	01JAN96	.	10 MG	SINUS ALLERGIES
		Entex	-308,	01JAN96	.	4 TABS	SINUS ALLERGIES
329.009.00327	ALIMENTARY TRACT/METAB	Dicyclomine	-624,	01JAN95	.	20 MG PRN	STOMACH ACHE
		Mylanta Double Strength	-624,	01JAN95	.	800 MG PRN	STOMACHE
		Zantac	-624,	01JAN95	.	150 MG PRN	STOMACH ACHE
	CENTRAL NERVOUS SYSTEM	Tylenol	-989,	01JAN94	.	1000 MG PRN	OCCASIONAL HEADACHE
	DERMATOLOGICALS	Benadryl	-259,	01JAN96	.	25 MG PRN	INSECT BITES
	MUSCULO-SKELETAL	Midol Ib	-989,	01JAN94	.	400 MG PRN	MENSTRUAL CRAMPS
	RESPIRATORY	Benadryl	-259,	01JAN96	.	25 MG PRN	INSECT BITES
		Codimal La	-259,	01JAN96	.	24 MG PRN	SINUS ALLERGIES
							CONGESTION
329.009.00330	ANTIINFECTIVES, SYSTEMIC	Augmentin	-20,	01OCT96	.	750 MG	BROKEN EAR DRUM
	CENTRAL NERVOUS SYSTEM	Cylert	-13,	08OCT96	08OCT96#	37.5 MG	ADHD
329.010.00263	CENTRAL NERVOUS SYSTEM	Tylenol	6,	14AUG96	14AUG96	375 MG	HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

488

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.010.00263	CENTRAL NERVOUS SYSTEM	Tylenol	9, .	17AUG96	17AUG96	500 MG	HEADACHE
	MUSCULO-SKELETAL	Ibuprofen	33, .	10SEP96	10SEP96	400 MG	ACHE IN SIDE
	RESPIRATORY	Entex	45, .	22SEP96	23SEP96	250 MG	CONGESTION
329.010.00277	CENTRAL NERVOUS SYSTEM	Aspirin	., .	.	.	PRN	HEADACHE
	MUSCULO-SKELETAL	Aleve	159, 103	06AUG96	06AUG96	220 MG	HEADACHE
329.010.00282	ANTIINFECTIVES, SYSTEMIC	Amoxicillin	-17, .	09JUL96	14JUL96#	750 MG	BRONCHITIS
	CENTRAL NERVOUS SYSTEM	Tylenol	21, .	15AUG96	15AUG96	1000 MG	BACKACHE
			39, .	02SEP96	02SEP96	1000 MG	HEADACHE
	MUSCULO-SKELETAL	Motrin	56, .	19SEP96	19SEP96	800 MG	MENSTRUAL CRAMPS
329.011.00164	MUSCULO-SKELETAL	Advil	19, .	09JAN96	.	400MG	HEADACHE BACKACHE
329.011.00210	CENTRAL NERVOUS SYSTEM	Tylenol	., .	.	.	650MG	HEADACHE
329.011.00285	CENTRAL NERVOUS SYSTEM	Tylenol	-503, .	01JAN95	.	500MG	HEADACHE
	MUSCULO-SKELETAL	Motrin	18, .	04JUN96	.	400 MG	TOOTHACHE
329.012.00027	ANTIINFECTIVES, SYSTEMIC	Erythromycin	-8, .	28NOV95	08DEC95	1000MG	OTITIS MEDIA
	CENTRAL NERVOUS SYSTEM	Entrophen	19, .	24DEC95	.	2TABS BID	"NECK SPASM"
		Lorazepam	16, .	21DEC95	26DEC95	0.5MGX1DAY	ANXIETY
		Tylenol	-1069, .	01JAN93	.	975MG PRN	HEADACHE
			-15, .	21NOV95	07DEC95	975MG PRN	OTITIS MEDIA
	DERMATOLOGICALS	Erythromycin	-8, .	28NOV95	08DEC95	1000MG	OTITIS MEDIA
	MUSCULO-SKELETAL	Anaprox	-25, .	11NOV95	17NOV95#	550MG PRN	HEADACHES
	RESPIRATORY	Becloforte	-127, .	01AUG95	20NOV95#	4MCG/PRN	ASTHMA
		Intal	-96, .	01SEP95	.	40MG	ASTHMA
		Neo-Citran	10, .	15DEC95	17DEC95	1TAB	COLD
		Sudafed	10, .	15DEC95	17DEC95	1TAB	COLD
		Ventolin	-461, .	01SEP94	17NOV95#	200MCG/PRN	ASTHMA
			10, .	15DEC95	.	200MCG/PRN	ASTHMA
	SENSORY ORGANS	Erythromycin	-8, .	28NOV95	08DEC95	1000MG	OTITIS MEDIA
		Garasone	-9, .	27NOV95	08DEC95	4GTTS 4XDAY	OTITIS MEDIA
	Intal	-96, .	01SEP95	.	40MG	ASTHMA	
329.012.00217	ALIMENTARY TRACT/METAB	Pepto Bismol	29, .	18JUN96	19JUN96	PRN	FLU
	CENTRAL NERVOUS SYSTEM	Sinutab	16, .	05JUN96	05JUN96	1DOSE	COLD
		Tylenol	-81, .	01MAR96	.	PRN 500MG	HEADACHE

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

489

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.14

Listing of Prior and Concomitant Medications  
by Treatment Group and by Patient  
Intent-to-Treat Population

-----  
----- Treatment Group=PLACEBO -----

Patient ID	ATC Level I	Drug Name	Relative Days *	Start Date	Stop Date	Total Daily Dose	Indication
329.012.00217	CENTRAL NERVOUS SYSTEM	Zoloft	30, .	19JUN96	.	100 MG	DEPRESSION
	DERMATOLOGICALS	Pulmicort	29, .	18JUN96	19JUN96	400 MG	ASTHMA
	RESPIRATORY	Pulmicort	29, .	18JUN96	19JUN96	400 MG	ASTHMA
		Robitussin	21, .	10JUN96	12JUN96	2TBSP/DAY	COLD
329.012.00218	CENTRAL NERVOUS SYSTEM	Clonazepam	-34, -92	13MAY96	16MAY96#	1MG	ANXIETY
		Tylenol	-8, -66	08JUN96	08JUN96#	500 MG	HEADACHE
			26, -33	11JUL96	11JUL96	500 MG	HEADACHE
329.012.00224	ANTIINFECTIVES, SYSTEMIC	Amoxil	87, 21	11DEC96	18DEC96	750 MG	STREP THROAT
	CENTRAL NERVOUS SYSTEM	Tylenol	16, -51	01OCT96	01OCT96	325 MG PRN	TOOTHACHE (ORTHODONTIST APPT)
	RESPIRATORY	Gravol	25, -42	10OCT96	.	650 MG PRN	MENSTRUAL CRAMPS
329.012.00225			108, 42	01JAN97	01JAN97	1 1/2 TAB	DIFFICULTY FALLING ASLEEP
	ANTIINFECTIVES, SYSTEMIC	Pediazole	124, 60	29MAR97	07APR97	40 CC	EAR INFECTION
	MUSCULO-SKELETAL	Ibuprofen	237, 173	20JUL97	23JUL97	300 MG	PREVENT PAIN FROM SPRAINED WRIST
	RESPIRATORY	Bricanyl Inhaler	130, 66	04APR97	08APR97	1 MG Q4H PRN	BRONCHOSPASM
		Prednisone	130, 66	04APR97	09APR97	50 MG	BRONCHOSPASM
		Ventolin	130, 66	04APR97	04APR97	5 MG	BRONCHOSPASM
	SYSTEMIC HORMONAL	Prednisone	130, 66	04APR97	09APR97	50 MG	BRONCHOSPASM

\* days relative to start of acute phase, days relative to start of continuation phase  
# stop date earlier than start of study medication

490

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.001.00063	100.0	WEEK 1	15NOV94	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	22NOV94	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	29NOV94	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	06DEC94	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	13DEC94	40	12	28	7.0	4	100.0	100.0		
329.001.00065	100.0	WEEK 1	21NOV94	20	8	12	6.0	2	100.0	100.0		
		WEEK 2	.	20	.	.	.	2	.	.		
329.001.00068	100.0	WEEK 1	15FEB95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	22FEB95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	01MAR95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	08MAR95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	15MAR95	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	22MAR95	60	18	42	7.0	6	100.0	100.0		
		WEEK 7	29MAR95	60	18	42	7.0	6	100.0	100.0		
		WEEK 8	05APR95	60	18	42	7.0	6	100.0	100.0		
329.001.00072	100.0	WEEK 1	27MAR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	03APR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	10APR95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	13APR95	40	28	12	3.0	4	100.0	100.0		
329.001.00121	99.5	WEEK 1	11APR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	18APR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	26APR95	30	7	23	8.0	3	96.0	95.8		
		WEEK 4	02MAY95	40	16	24	6.0	4	100.0	100.0		
		WEEK 5	09MAY95	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	16MAY95	50	15	35	7.0	5	100.0	100.0		
		WEEK 7	23MAY95	50	15	35	7.0	5	100.0	100.0		
		WEEK 8	30MAY95	50	15	35	7.0	5	100.0	100.0		
		WEEK 12	27JUN95	200	70	130	28.0	5	93.0	92.9		
		WEEK 16	24JUL95	200	67	133	27.0	5	99.0	98.5		
		WEEK 20	21AUG95	200	66	134	28.0	5	96.0	95.7		
		DOWN TITRATION	05SEP95	34	0	34	15.0	5	100.0	45.3		
		329.001.00205	87.5	WEEK 1	14FEB96	20	6	14	7.0	2	100.0	100.0
		329.001.00206	98.7	WEEK 1	28FEB96	20	6	14	7.0	2	100.0	100.0

491

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.001.00206	98.7	WEEK 2	06MAR96	20	5	15	7.0	2	100.0	107.1
		WEEK 3	13MAR96	30	11	19	7.0	3	90.0	90.5
		WEEK 4	20MAR96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	26MAR96	50	20	30	6.0	5	100.0	100.0
		WEEK 6	03APR96	60	12	48	8.0	6	100.0	100.0
		WEEK 7	10APR96	60	18	42	7.0	6	100.0	100.0
		WEEK 8	17APR96	60	18	42	7.0	6	100.0	100.0
		329.002.00055	98.4	WEEK 1	30JUN94	20	7	13	6.5	2
WEEK 2	07JUL94			20	6	14	7.0	2	100.0	100.0
WEEK 3	14JUL94			30	7	23	7.0	3	100.0	109.5
WEEK 4	21JUL94			40	12	28	7.0	5	100.0	80.0
WEEK 5	28JUL94			50	15	35	7.0	5	100.0	100.0
WEEK 6	04AUG94			60	18	42	7.0	6	100.0	100.0
WEEK 7	11AUG94			60	18	42	7.0	6	100.0	100.0
WEEK 8	18AUG94			60	18	42	7.0	6	100.0	100.0
WEEK 12	15SEP94			240	72	168	28.0	6	100.0	100.0
WEEK 16	13OCT94			240	72	168	28.0	6	100.0	100.0
WEEK 20	10NOV94			240	.	.	.	6	.	.
DOWN	15NOV94			44	0	44	16.0	5	100.0	100.0
TITRATION				44	0	44	16.0	4	100.0	100.0
				44	0	44	16.0	3	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
329.002.00058	97.9			WEEK 1	29SEP94	20	2	18	9.0	2
		WEEK 2	07OCT94	20	4	16	8.0	2	100.0	100.0
		WEEK 3	13OCT94	30	12	18	6.0	3	100.0	100.0
		WEEK 4	20OCT94	40	17	23	7.0	4	82.0	82.1
		WEEK 5	27OCT94	50	15	35	7.0	5	100.0	100.0
		WEEK 6	03NOV94	60	18	42	7.0	6	100.0	100.0
		WEEK 7	10NOV94	60	18	42	7.0	6	100.0	100.0
		WEEK 8	17NOV94	60	18	42	7.0	6	100.0	100.0
		WEEK 12	15DEC94	240	48	192	28.0	6	122.0	114.3
		WEEK 16	13JAN95	240	60	180	28.0	6	107.0	6.0
	27JAN95	240	219	21	14.0	6	25.0	6.0		
329.002.00099	88.9	WEEK 1	07MAR95	20	12	8	5.0	2	80.0	80.0
		WEEK 2	14MAR95	20	7	13	7.0	2	93.0	92.9

492

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.002.00099	88.9	WEEK 3	21MAR95	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	28MAR95	40	15	25	7.0	4	89.0	89.3	
		WEEK 5	04APR95	40	15	25	7.0	4	89.0	89.3	
		WEEK 6	11APR95	50	21	29	7.0	5	82.0	82.9	
		WEEK 7	18APR95	60	20	40	7.0	6	95.0	95.2	
		WEEK 8	25APR95	60	21	39	6.0	6	108.0	108.3	
		WEEK 12	23MAY95	240	81	159	28.0	6	95.0	94.6	
		WEEK 16	27JUN95	240	63	177	35.0	6	84.0	84.3	
		WEEK 20	01AUG95	240	61	179	34.0	6	87.0	87.7	
		WEEK 24	31AUG95	240	108	132	30.0	6	73.3	73.3	
		WEEK 28	28SEP95	240	114	126	28.0	6	75.0	75.0	
		WEEK 32	26OCT95	240	132	108	28.0	6	64.0	64.3	
		DOWN	10JAN96	44	5	39	15.0	5	89.0	88.6	
		TITRATION			44	5	39	15.0	4	89.0	88.6
					44	5	39	15.0	3	89.0	88.6
					44	5	39	15.0	2	89.0	88.6
					44	5	39	15.0	2	89.0	88.6
329.002.00102	94.0	WEEK 1	18APR95	20	8	12	6.0	2	100.0	100.0	
		WEEK 2	25APR95	20	8	12	7.0	2	85.7	85.7	
		WEEK 3	02MAY95	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	09MAY95	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	16MAY95	50	20	30	7.0	5	85.7	85.7	
		WEEK 6	23MAY95	60	18	42	7.0	6	100.0	100.0	
		WEEK 7	30MAY95	60	18	42	7.0	6	100.0	100.0	
		WEEK 8	06JUN95	60	27	33	7.0	6	78.6	78.6	
		WEEK 12	13JUL95	240	38	202	37.0	6	91.0	91.0	
		WEEK 16	10AUG95	240	87	153	28.0	6	91.0	91.1	
		WEEK 20	12SEP95	240	75	165	33.0	6	83.3	83.3	
		WEEK 24	10OCT95	240	90	150	28.0	6	89.0	89.3	
		WEEK 28	09NOV95	240	78	162	30.0	6	90.0	90.0	
		WEEK 32	05DEC95	240	138	102	25.0	6	68.0	68.0	
		DOWN	05DEC95	44	12	32	15.0	5	73.0	76.2	
		TITRATION			44	12	32	15.0	4	73.0	76.2
					44	12	32	15.0	3	73.0	76.2
			44	12	32	15.0	2	73.0	76.2		
			44	12	32	15.0	1	73.0	76.2		

493

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.002.00105	100.0	WEEK 1	03AUG95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	10AUG95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	17AUG95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	.	40	.	.	.	.	.	.
329.002.00106	100.6	WEEK 1	03AUG95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	08AUG95	20	10	10	5.0	2	100.0	100.0
		WEEK 3	17AUG95	30	2	28	9.0	3	103.0	103.7
		WEEK 4	24AUG95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	31AUG95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	05SEP95	50	25	25	5.0	5	100.0	100.0
		WEEK 7	12SEP95	60	18	42	7.0	6	100.0	100.0
		WEEK 8	.	60	.	.	.	6	.	.
329.002.00242	99.6	WEEK 1	14FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	21FEB96	20	7	13	7.0	2	93.0	92.9
		WEEK 3	29FEB96	30	12	18	7.0	3	85.7	85.7
		WEEK 4	06MAR96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	14MAR96	50	12	38	8.0	5	95.0	95.0
		WEEK 6	20MAR96	50	10	40	7.0	5	114.0	114.3
		WEEK 7	28MAR96	60	12	48	7.0	6	110.0	114.3
		WEEK 8	05APR96	60	18	42	7.0	6	100.0	100.0
		WEEK 12	08MAY96	240	42	198	33.0	6	100.0	100.0
		WEEK 16	05JUN96	240	93	147	28.0	6	87.0	87.5
329.002.00245	103.8	WEEK 1	04APR96	20	7	13	7.0	2	92.0	92.9
		WEEK 2	.	20	6	14	.	2	.	.
329.002.00319	99.1	WEEK 1	07MAY96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14MAY96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	21MAY96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	28MAY96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	04JUN96	50	17	33	7.0	5	94.0	94.3
		WEEK 6	11JUN96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	18JUN96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	25JUN96	50	15	35	7.0	5	100.0	100.0
		WEEK 12	23JUL96	200	60	140	28.0	5	100.0	100.0
		WEEK 16	15AUG96	200	85	115	23.0	5	100.0	100.0
		WEEK 20	24SEP96	200	2	198	40.0	5	99.0	99.0
		WEEK 24	22OCT96	200	60	140	28.0	5	100.0	100.0

494

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.002.00319	99.1	WEEK 28	19NOV96	200	60	140	28.0	5	100.0	100.0
		WEEK 32	17DEC96	200	60	140	28.0	5	100.0	100.0
		DOWN	30DEC96	44	0	20	14.0	5	100.0	64.5
		TITRATION		44	0	20	14.0	4	100.0	64.5
				44	0	20	14.0	3	100.0	64.5
				44	0	20	14.0	2	100.0	64.5
				44	0	20	14.0	1	100.0	64.5
329.003.00075	88.8	WEEK 1	01FEB95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	08FEB95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	15FEB95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	21FEB95	40	16	24	7.0	4	84.0	85.7
		WEEK 5	01MAR95	50	10	40	8.0	5	100.0	100.0
		WEEK 6	08MAR95	40	19	21	7.0	4	100.0	75.0
		WEEK 7	15MAR95	40	27	13	7.0	4	92.0	46.4
		WEEK 8	22MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 12	19APR95	160	54	106	28.0	4	94.0	94.6
		WEEK 16	17MAY95	160	56	104	28.0	4	107.0	92.9
		WEEK 20	14JUN95	160	62	98	28.0	4	87.0	87.5
		WEEK 24	12JUL95	160	74	86	28.0	4	76.0	76.8
		WEEK 28	09AUG95	160	98	62	29.0	4	108.0	53.4
		WEEK 32	13SEP95	160	86	74	35.0	4	53.0	52.9
		DOWN	01NOV95	26	12	14	.	3	.	70.0
			TITRATION			26	12	14	.	2
				26	12	14	.	2	.	70.0
329.003.00077	86.5	WEEK 1	13MAR95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	20MAR95	20	8	12	7.0	2	86.0	85.7
		WEEK 3	27MAR95	30	12	18	7.0	3	86.0	85.7
		WEEK 4	05APR95	40	10	30	9.0	4	83.0	83.3
		WEEK 5	12APR95	50	15	35	7.0	5	100.0	100.0
		WEEK 6	19APR95	50	18	32	7.0	5	91.0	91.4
		WEEK 7	26APR95	50	21	29	7.0	5	83.0	82.9
		WEEK 8	03MAY95	50	21	29	7.0	5	83.0	82.9
		WEEK 12	07JUN95	200	94	106	34.0	5	62.0	62.4
		WEEK 16	.	200	.	.	.	5	.	.
		329.003.00081	90.3	WEEK 1	18DEC95	20	7	13	7.0	2

495

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.003.00081	90.3	WEEK 2	28DEC95	20	1	19	10.0	2	95.0	95.0	
		WEEK 3	03JAN96	30	13	17	6.0	3	94.0	94.4	
		WEEK 4	10JAN96	40	14	26	7.0	4	93.0	92.9	
		WEEK 5	17JAN96	50	17	33	7.0	5	94.0	94.3	
		WEEK 6	24JAN96	50	22	28	7.0	5	80.0	80.0	
		WEEK 7	31JAN96	50	19	31	7.0	5	89.0	88.6	
		WEEK 8	07FEB96	60	.	.	.	6	.	.	
		329.003.00087	.	WEEK 1	03FEB95	20	.	.	.	2	.
329.003.00089	96.3	WEEK 1	14MAR95	20	7	13	7.0	2	93.0	92.9	
		WEEK 2	21MAR95	20	5	15	7.0	2	110.0	107.1	
		WEEK 3	28MAR95	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	04APR95	40	11	29	7.0	4	100.0	103.6	
		WEEK 5	11APR95	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	18APR95	40	12	28	7.0	4	100.0	100.0	
		WEEK 7	25APR95	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	02MAY95	40	21	19	7.0	4	90.0	67.9	
329.003.00091	102.6	WEEK 1	28MAR95	20	10	10	4.0	2	120.0	125.0	
		WEEK 2	04APR95	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	11APR95	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	18APR95	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	25APR95	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	02MAY95	60	18	42	7.0	6	100.0	100.0	
		WEEK 7	09MAY95	60	12	48	7.0	6	100.0	114.3	
		WEEK 8	16MAY95	60	18	42	7.0	6	100.0	100.0	
		WEEK 12	16JUN95	240	57	183	30.0	6	102.0	101.7	
		WEEK 16	14JUL95	240	78	162	28.0	6	96.0	96.4	
		WEEK 20	10AUG95	240	0	.	26.0	6	.	.	
		WEEK 24	05SEP95	240	72	168	28.0	6	100.0	100.0	
		WEEK 28	03OCT95	240	72	168	27.0	6	104.0	103.7	
		WEEK 32	07NOV95	240	72	168	31.0	6	90.0	90.3	
		DOWN	02JAN96	44	0	44	55.0	5	100.0	100.0	
		TITRATION			44	0	44	55.0	4	100.0	100.0
					44	0	44	55.0	3	100.0	100.0
					44	0	44	55.0	2	100.0	100.0
					44	0	44	55.0	2	100.0	100.0

496

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.003.00248	87.1	WEEK 1	05MAR96	20	12	8	4.0	2	100.0	100.0		
		WEEK 2	12MAR96	20	7	13	7.0	2	100.0	92.9		
		WEEK 3	19MAR96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	26MAR96	40	16	24	7.0	4	85.0	85.7		
		WEEK 5	02APR96	50	19	31	8.0	5	75.0	77.5		
		WEEK 6	11APR96	60	24	36	9.0	6	67.0	66.7		
		WEEK 7	16APR96	60	33	27	6.0	6	75.0	75.0		
		WEEK 8	23APR96	60	18	42	7.0	6	100.0	100.0		
329.003.00250	112.3	WEEK 1	19MAR96	20	9	11	6.0	2	91.6	91.7		
		WEEK 2	26MAR96	20	8	12	8.0	2	85.0	75.0		
		WEEK 3	02APR96	30	12	18	7.0	3	85.0	85.7		
		WEEK 4	12APR96	40	6	34	10.0	4	85.0	85.0		
		WEEK 5	16APR96	50	0	50	7.0	5	142.8	142.9		
		WEEK 6	23APR96	60	30	30	5.0	6	100.0	100.0		
		WEEK 7	30APR96	60	0	60	7.0	6	142.0	142.9		
		WEEK 8	09MAY96	50	0	50	9.0	5	111.0	111.1		
		WEEK 12	28MAY96	80	0	80	.	6	.	86.0		
				80	0	80	.	5	.	86.0		
		329.003.00292	77.2	WEEK 1	16AUG96	20	5	16	10.0	2	80.0	80.0
				WEEK 2	21AUG96	20	14	6	5.0	2	60.0	60.0
WEEK 3	30AUG96			30	9	21	9.0	3	78.0	77.8		
WEEK 4	04SEP96			40	26	14	5.0	4	70.0	70.0		
WEEK 6	18SEP96			40	0	40	14.0	4	71.4	71.4		
WEEK 7	25SEP96			40	18	22	8.0	4	69.0	68.8		
WEEK 8	04OCT96			40	10	30	9.0	4	83.0	83.3		
WEEK 12	.			120	0	.	.	4	.	.		
329.003.00313	112.5			WEEK 1	21MAY96	20	11	9	5.0	2	90.0	90.0
		WEEK 2	28MAY96	20	.	.	.	2	.	.		
329.004.00015	97.9	WEEK 1	14DEC94	20	7	13	7.0	2	100.0	92.9		
		WEEK 2	21DEC94	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	28DEC94	30	10	20	8.0	3	95.0	83.3		
		WEEK 4	04JAN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	11JAN95	40	14	26	7.0	4	93.0	92.9		
		WEEK 6	18JAN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 7	25JAN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 8	03FEB95	40	6	34	9.0	4	94.0	94.4		

497

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.004.00015	97.9	WEEK 12	27FEB95	160	64	96	24.0	4	100.0	100.0	
		WEEK 16	22MAR95	160	70	90	23.0	4	98.0	97.8	
		WEEK 20	19APR95	160	50	110	27.0	4	100.0	101.9	
		WEEK 24	17MAY95	160	48	112	28.0	4	100.0	100.0	
		DOWN	29JUN95	44	18	26	15.0	4	100.0	81.3	
		TITRATION									
					44	18	26	15.0	2	100.0	81.3
					44	18	26	15.0	2	100.0	81.3
					44	18	26	15.0	2	100.0	81.3
329.004.00017	98.5	WEEK 1	30MAR95	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	06APR95	20	7	13	7.0	2	93.0	92.9	
		WEEK 3	13APR95	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	20APR95	40	14	26	7.0	4	98.0	92.9	
		WEEK 5	26APR95	40	14	26	6.0	4	100.0	108.3	
		WEEK 6	03MAY95	50	17	33	7.0	5	98.0	94.3	
		WEEK 7	10MAY95	50	15	35	7.0	5	100.0	100.0	
		WEEK 8	17MAY95	50	15	35	7.0	5	100.0	100.0	
		WEEK 12	14JUN95	200	65	135	29.0	5	100.0	93.1	
		WEEK 16	13JUL95	200	58	142	29.0	5	100.0	97.9	
		WEEK 20	10AUG95	200	60	140	29.0	5	100.0	96.6	
		WEEK 24	06SEP95	200	77	123	28.0	5	98.0	87.9	
		WEEK 28	04OCT95	200	69	131	29.0	5	100.0	90.3	
		WEEK 32	01NOV95	200	68	132	29.0	5	100.0	91.0	
		DOWN	14NOV95	44	14	30	13.0	4	100.0	88.2	
		TITRATION									
					44	14	30	13.0	3	100.0	88.2
					44	14	30	13.0	2	100.0	88.2
					44	14	30	13.0	2	100.0	88.2
329.004.00019	100.0	WEEK 1	07JUN95	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	14JUN95	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	.	30	.	.	.	.	.	.	
329.004.00212	88.2	WEEK 1	10JUN96	20	7	13	7.0	2	100.0	92.9	
		WEEK 2	21JUN96	20	0	20	11.0	2	100.0	90.9	
		WEEK 3	28JUN96	30	18	12	7.0	3	57.0	57.1	
329.004.00214	91.1	WEEK 1	09OCT96	20	10	10	5.0	2	100.0	100.0	
		WEEK 2	15OCT96	20	8	12	7.0	2	86.0	85.7	

498

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.004.00214	91.1	WEEK 3	21OCT96	30	13	17	7.0	3	81.0	81.0		
		WEEK 4	01NOV96	40	2	38	11.0	4	95.0	86.4		
		WEEK 5	11NOV96	50	4	46	10.0	5	100.0	92.0		
		WEEK 6	18NOV96	50	22	28	8.0	5	70.0	70.0		
		WEEK 7	25NOV96	40	14	26	8.0	4	93.0	81.3		
		WEEK 8	03DEC96	40	12	28	8.0	4	93.0	87.5		
		WEEK 12	30DEC96	160	70	90	27.0	4	83.0	83.3		
329.005.00002	99.6	WEEK 1	01JUN94	20	5	15	7.0	2	107.0	107.1		
		WEEK 2	08JUN94	20	7	13	7.0	2	93.0	92.9		
		WEEK 3	15JUN94	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	23JUN94	40	10	30	8.0	4	94.0	93.8		
		WEEK 5	30JUN94	50	13	37	8.0	5	92.5	92.5		
		WEEK 6	07JUL94	60	18	42	7.0	6	100.0	100.0		
		WEEK 7	14JUL94	60	27	33	6.0	6	91.0	91.7		
		WEEK 8	20JUL94	60	15	45	7.0	6	107.0	107.1		
		WEEK 12	17AUG94	240	54	186	31.0	6	100.0	100.0		
		WEEK 16	15SEP94	240	63	177	29.5	6	100.0	100.0		
		WEEK 20	18OCT94	240	39	201	33.0	6	101.0	101.5		
		WEEK 24	.	240	.	.	.	6	.	.		
		329.005.00004	92.2	WEEK 1	20OCT94	20	1	19	10.0	2	95.0	95.0
WEEK 2	27OCT94			20	6	14	7.0	2	100.0	100.0		
WEEK 3	03NOV94			30	9	21	7.0	3	100.0	100.0		
WEEK 4	10NOV94			40	12	28	7.0	4	100.0	100.0		
WEEK 5	17NOV94			50	15	35	7.0	5	100.0	100.0		
WEEK 6	23NOV94			60	24	36	6.0	6	100.0	100.0		
WEEK 7	01DEC94			60	12	48	8.0	6	100.0	100.0		
WEEK 8	08DEC94			60	36	24	7.0	6	57.0	57.1		
WEEK 12	05JAN95			240	84	156	28.0	6	92.0	92.9		
DOWN	26JAN95			44	2	42	21.0	5	100.0	40.0		
TITRATION												
329.005.00008	98.7			WEEK 1	23NOV94	20	7	13	7.0	2	93.0	92.9
				WEEK 2	30NOV94	20	8	12	7.0	2	85.0	85.7
		WEEK 3	07DEC94	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	14DEC94	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	21DEC94	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	28DEC94	60	18	42	7.0	6	100.0	100.0		
		WEEK 7	03JAN95	60	18	42	7.0	6	100.0	100.0		

499

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.005.00008	98.7	WEEK 8	10JAN95	60	24	36	6.0	6	100.0	100.0		
		WEEK 12	06FEB95	200	50	150	30.0	5	100.0	100.0		
		WEEK 16	08MAR95	200	50	150	30.0	5	100.0	100.0		
		WEEK 20	10MAY95	200	53	147	63.0	5	0.5	46.7		
329.005.00011	98.7	WEEK 1	20DEC94	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	27DEC94	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	03JAN95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	09JAN95	40	16	24	6.0	4	100.0	100.0		
		WEEK 5	17JAN95	50	10	40	8.0	5	100.0	100.0		
		WEEK 6	23JAN95	60	24	36	6.0	6	100.0	100.0		
		WEEK 7	31JAN95	60	15	45	7.5	6	100.0	100.0		
		WEEK 8	07FEB95	60	18	42	7.0	6	100.0	100.0		
		WEEK 12	09MAR95	240	57	183	30.5	6	100.0	100.0		
		WEEK 16	06APR95	240	99	141	27.0	6	87.0	87.0		
		WEEK 20	03MAY95	240	96	144	26.0	6	92.0	92.3		
		WEEK 24	.	200	.	.	.	5	.	.		
		329.005.00109	100.0	WEEK 1	05JAN95	20	8	12	6.0	2	100.0	100.0
WEEK 2	12JAN95			20	6	14	7.0	2	100.0	100.0		
WEEK 3	19JAN95			30	9	21	7.0	3	100.0	100.0		
WEEK 4	26JAN95			40	12	28	7.0	4	100.0	100.0		
WEEK 5	02FEB95			40	12	28	7.0	4	100.0	100.0		
WEEK 6	08FEB95			40	16	24	6.0	4	100.0	100.0		
WEEK 7	16FEB95			40	8	32	8.0	4	100.0	100.0		
WEEK 8	21FEB95			40	20	20	5.0	4	100.0	100.0		
WEEK 12	23MAR95			160	42	118	29.5	4	100.0	100.0		
WEEK 16	24APR95			160	38	122	32.0	4	95.0	95.3		
WEEK 20	25MAY95			160	72	.	30.0	4	.	.		
329.005.00112	93.6			WEEK 1	01FEB95	20	8	12	6.0	2	100.0	100.0
				WEEK 2	08FEB95	20	5	15	7.0	2	100.0	107.1
		WEEK 3	15FEB95	30	11	19	7.0	3	90.0	90.5		
		WEEK 4	23FEB95	40	12	28	8.0	4	87.0	87.5		
		WEEK 5	01MAR95	40	15	25	6.0	4	100.0	104.2		
		WEEK 6	08MAR95	40	14	26	7.0	4	93.0	92.9		
		WEEK 7	15MAR95	40	16	24	7.0	4	86.0	85.7		
		WEEK 8	22MAR95	40	14	26	7.0	4	93.0	92.9		
		WEEK 12	19APR95	160	99	61	28.0	4	54.0	54.5		

500

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.005.00112	93.6	DOWN TITRATION	21JUN95	20	3	17	60.0	2	85.0	85.0
				20	3	17	60.0	2	85.0	85.0
329.005.00116	98.0	WEEK 1	13FEB95	20	8	12	6.0	2	100.0	100.0
		WEEK 2	20FEB95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	27FEB95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	09MAR95	40	2	38	10.0	4	95.0	95.0
		WEEK 5	16MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	23MAR95	40	14	26	7.0	4	93.0	92.9
		WEEK 7	30MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 8	06APR95	40	12	28	7.0	4	100.0	100.0
		WEEK 12	04MAY95	160	46	114	28.5	4	100.0	100.0
		WEEK 16	31MAY95	160	50	110	27.5	4	100.0	100.0
		WEEK 20	28JUN95	200	60	140	28.0	5	100.0	100.0
		DOWN TITRATION	26JUL95	44	12	32	28.0	4	100.0	118.5
				44	12	32	28.0	3	100.0	118.5
				44	12	32	28.0	2	100.0	118.5
		44	12	32	28.0	1	100.0	118.5		
329.005.00119	89.0	WEEK 1	18JUL95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	26JUL95	20	6	14	8.0	2	87.5	87.5
		WEEK 3	02AUG95	30	11	19	7.0	3	90.0	90.5
		WEEK 4	08AUG95	40	16	24	6.0	4	100.0	100.0
		WEEK 5	15AUG95	50	15	35	6.0	5	116.0	116.7
		WEEK 6	23AUG95	60	6	45	8.0	6	94.0	93.8
		WEEK 7	29AUG95	60	51	18	6.0	6	50.0	50.0
		WEEK 8	08SEP95	60	3	57	10.0	6	95.0	95.0
		WEEK 12	03OCT95	240	99	141	25.0	6	94.0	94.0
		WEEK 16	30OCT95	240	78	162	27.0	6	100.0	100.0
		WEEK 20	28NOV95	240	77	.	28.0	6	.	.
		DOWN TITRATION	02JAN96	44	.	.	.	.	.	.
		329.005.00151	94.8	WEEK 1	14SEP95	20	4	16	8.0	2
WEEK 2	20SEP95			20	8	12	6.0	2	100.0	100.0
WEEK 3	28SEP95			30	6	24	8.0	3	100.0	100.0
WEEK 4	03OCT95			40	20	20	5.0	4	100.0	100.0
WEEK 5	11OCT95			40	12	28	8.0	4	87.5	87.5

501

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.005.00151	94.8	WEEK 6	19OCT95	40	10	30	8.0	4	93.8	93.8		
		WEEK 7	26OCT95	40	12	28	7.0	4	100.0	100.0		
		WEEK 8	02NOV95	40	16	24	7.0	4	85.7	85.7		
		WEEK 12	28NOV95	160	78	82	28.0	4	73.0	73.2		
		WEEK 16	02JAN96	160	34	126	35.0	4	90.0	90.0		
		WEEK 20	31JAN96	200	88	112	27.0	5	83.0	83.0		
		WEEK 24	27FEB96	200	86	114	27.0	5	84.0	84.4		
		WEEK 28	27MAR96	200	69	131	28.0	5	94.0	93.6		
		WEEK 32	01MAY96	200	50	150	35.0	5	86.0	85.7		
		DOWN TITRATION	21MAY96	44	.	.	.	4	.	.		
329.005.00152	.	WEEK 1	02NOV95	20	.	.	.	2	.	.		
329.005.00257	97.0	WEEK 1	18MAR96	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	25MAR96	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	01APR96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	08APR96	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	15APR96	40	16	24	7.0	4	86.0	85.7		
		WEEK 6	22APR96	40	14	26	7.0	4	93.0	92.9		
		WEEK 7	29APR96	50	15	35	7.0	5	100.0	100.0		
		WEEK 8	06MAY96	50	15	35	7.0	5	100.0	100.0		
		WEEK 12	03JUN96	200	63	137	28.0	5	98.0	97.9		
		WEEK 16	08JUL96	200	33	167	35.0	5	95.0	95.4		
		WEEK 20	07AUG96	200	61	139	30.0	5	93.0	92.7		
		WEEK 24	27AUG96	200	110	90	20.0	5	90.0	90.0		
		WEEK 28	01OCT96	200	35	165	34.0	5	97.0	97.1		
		WEEK 32	21OCT96	150	50	100	20.0	5	100.0	100.0		
		DOWN TITRATION	05NOV96	44	11	33	14.0	4	79.0	97.1		
						44	11	33	14.0	3	79.0	97.1
						44	11	33	14.0	2	79.0	97.1
				44	11	33	14.0	2	79.0	97.1		
329.005.00258	100.8	WEEK 1	19MAR96	20	7	13	7.0	2	93.0	92.9		
		WEEK 2	26MAR96	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	02APR96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	09APR96	40	10	28	7.0	4	100.0	100.0		
		WEEK 5	18APR96	50	5	45	9.0	5	100.0	100.0		
		WEEK 6	23APR96	60	33	27	5.0	6	90.0	90.0		

502

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.005.00258	100.8	WEEK 7	30APR96	60	12	48	7.0	6	100.0	114.3		
		WEEK 8	07MAY96	60	18	42	7.0	6	100.0	100.0		
329.005.00299	99.0	WEEK 1	18JUN96	20	0	20	10.0	2	100.0	100.0		
		WEEK 2	25JUN96	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	02JUL96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	10JUL96	40	8	32	8.0	4	100.0	100.0		
		WEEK 6	22JUL96	48	2	46	12.0	4	96.0	95.8		
		WEEK 7	31JUL96	40	4	36	9.0	4	100.0	100.0		
		WEEK 8	07AUG96	40	12	28	7.0	4	100.0	100.0		
		WEEK 12	03SEP96	160	48	112	27.0	4	103.0	103.7		
		WEEK 16	01OCT96	160	50	110	28.0	4	98.0	98.2		
		WEEK 20	29OCT96	200	71	129	27.0	5	96.0	95.6		
		WEEK 24	05NOV96	200	165	35	7.0	5	100.0	100.0		
		DOWN	19NOV96	34	2	32	13.0	4	100.0	118.5		
		TITRATION				34	2	32	13.0	3	100.0	118.5
						34	2	32	13.0	2	100.0	118.5
				34	2	32	13.0	1	100.0	118.5		
329.005.00300	94.2	WEEK 1	26SEP96	20	9	11	14.0	2	79.0	39.3		
		WEEK 2	03OCT96	20	6	13	7.0	2	93.0	92.9		
		WEEK 3	10OCT96	30	8	22	7.0	3	104.0	104.8		
		WEEK 4	17OCT96	40	13	27	7.0	4	96.0	96.4		
		WEEK 5	24OCT96	40	14	26	7.0	4	95.0	92.9		
		WEEK 6	31OCT96	40	15	25	7.0	4	89.0	89.3		
		WEEK 7	07NOV96	40	12	28	7.0	4	100.0	100.0		
		WEEK 8	14NOV96	40	14	26	7.0	4	93.0	92.9		
329.005.00333	93.8	WEEK 1	31JAN97	20	4	16	8.0	2	100.0	100.0		
		WEEK 2	06FEB97	20	8	12	6.0	2	100.0	100.0		
		WEEK 3	13FEB97	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	20FEB97	40	14	26	7.0	4	93.0	92.9		
		WEEK 5	26FEB97	40	24	16	6.0	4	66.0	66.7		
329.005.00336	94.9	WEEK 1	12MAR97	20	4	16	8.0	2	100.0	100.0		
		WEEK 2	19MAR97	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	25MAR97	30	12	18	6.0	3	100.0	100.0		
		WEEK 4	02APR97	40	8	32	8.0	4	100.0	100.0		
		WEEK 5	09APR97	40	12	28	7.0	4	100.0	100.0		

503

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.005.00336	94.9	WEEK 6	16APR97	40	16	24	28.0	4	86.0	21.4
		WEEK 7	23APR97	40	12	28	7.0	4	100.0	100.0
		WEEK 8	30APR97	40	14	26	6.5	4	100.0	100.0
329.006.00038	103.1	WEEK 1	22FEB95	20	7	13	6.5	2	100.0	100.0
		WEEK 2	03MAR95	20	2	18	9.0	2	100.0	100.0
		WEEK 3	08MAR95	30	14	16	5.0	3	100.0	106.7
		WEEK 4	15MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	22MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	29MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 7	05APR95	40	14	26	6.5	4	100.0	100.0
		WEEK 8	12APR95	40	0	40	7.0	4	143.0	142.9
329.006.00039	96.9	WEEK 1	13FEB95	20	9	11	5.0	2	100.0	110.0
		WEEK 2	22FEB95	20	2	18	9.0	2	100.0	100.0
		WEEK 3	01MAR95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	08MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	17MAR95	40	4	36	9.0	4	100.0	100.0
		WEEK 6	22MAR95	40	16	24	6.0	4	100.0	100.0
		WEEK 7	29MAR95	50	20	30	6.0	5	100.0	100.0
		WEEK 8	05APR95	50	0	50	10.0	5	100.0	100.0
		WEEK 12	01MAY95	150	52	98	20.5	5	95.0	95.6
		DOWN TITRATION	01MAY95	34	0	34	10.0	4	100.0	113.3
				34	0	34	10.0	3	100.0	113.3
				34	0	34	10.0	2	100.0	113.3
				34	0	34	10.0	1	100.0	113.3
		329.006.00260	87.3	WEEK 1	26JUL96	20	7	13	8.0	2
WEEK 2	01AUG96			20	9	11	6.0	2	100.0	91.7
WEEK 3	07AUG96			30	12	18	6.0	3	100.0	100.0
WEEK 4	14AUG96			40	14	26	7.0	4	93.0	92.9
WEEK 5	21AUG96			50	17	33	7.0	5	94.0	94.3
WEEK 6	28AUG96			50	22	28	7.0	5	80.0	80.0
WEEK 7	04SEP96			50	19	31	7.0	5	89.0	88.6
WEEK 8	18SEP96			50	10	40	10.0	5	80.0	80.0
WEEK 12	09OCT96			200	77	123	25.0	5	98.0	98.4
WEEK 16	06NOV96			200	45	155	31.0	5	100.0	100.0
WEEK 20	05DEC96			200	77	123	26.0	5	95.0	94.6

504

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.006.00260	87.3	DOWN TITRATION	17DEC96	34	2	32	13.0	4	100.0	94.1
				34	2	32	13.0	3	100.0	94.1
				34	2	32	13.0	2	100.0	94.1
				34	2	32	13.0	1	100.0	94.1
329.006.00261	94.3	WEEK 1	03DEC96	20	8	12	7.0	2	86.0	85.7
		WEEK 2	10DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	17DEC96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	24DEC96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	02JAN97	50	5	45	9.0	5	100.0	100.0
		WEEK 6	09JAN97	50	17	33	7.0	5	94.0	94.3
		WEEK 7	15JAN97	50	20	30	6.0	5	100.0	100.0
		WEEK 8	23JAN97	50	17	33	8.0	5	83.0	82.5
		WEEK 12	20FEB97	200	116	84	28.0	5	60.0	60.0
		WEEK 16	02APR97	200	125	75	41.0	5	37.0	36.6
		DOWN TITRATION	30APR97	44	14	30	28.0	5	.	61.2
				44	14	30	28.0	4	.	61.2
				44	14	30	28.0	3	.	61.2
				44	14	30	28.0	2	.	61.2
		44	14	30	28.0	1	.	61.2		
329.007.00140	100.5	WEEK 1	21SEP95	20	7	13	6.5	2	100.0	100.0
		WEEK 2	28SEP95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	05OCT95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	12OCT95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	18OCT95	40	16	24	6.0	4	100.0	100.0
		WEEK 6	26OCT95	40	8	32	8.0	4	100.0	100.0
		WEEK 7	02NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 8	09NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 12	22NOV95	160	110	50	13.0	4	96.0	96.2
		DOWN TITRATION	.	44	.	.	.	4	.	.
		329.007.00142	88.8	WEEK 1	26OCT95	20	4	16	8.0	2
WEEK 2	02NOV95			20	6	14	7.0	2	100.0	100.0
WEEK 3	09NOV95			30	9	21	7.0	3	100.0	100.0
WEEK 4	16NOV95			40	14	26	7.0	4	93.0	92.9
WEEK 5	22NOV95			50	20	30	6.0	5	100.0	100.0

505

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.007.00142	88.8	WEEK 6	30NOV95	50	10	40	8.0	5	100.0	100.0		
		WEEK 7	21DEC95	60	48	12	21.0	6	20.0	9.5		
329.007.00145	100.0	WEEK 1	18JAN96	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	25JAN96	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	01FEB96	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	08FEB96	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	12FEB96	50	31	19	4.0	5	95.0	95.0		
		WEEK 6	21FEB96	50	3	47	9.0	5	104.0	104.4		
		WEEK 7	26FEB96	50	25	25	5.0	5	100.0	100.0		
		WEEK 8	07MAR96	60	0	60	10.0	6	100.0	100.0		
		WEEK 12	04APR96	240	72	168	28.0	6	100.0	100.0		
		WEEK 16	02MAY96	240	72	168	28.0	6	100.0	100.0		
		WEEK 20	30MAY96	320	197	123	28.0	5	98.1	99.2		
						320	197	123	28.0	4	98.1	99.2
		WEEK 24	27JUN96	160	48	112	28.0	4	100.0	100.0		
		WEEK 28	25JUL96	160	46	114	28.0	4	102.0	101.8		
		WEEK 32	23AUG96	160	44	116	29.0	4	96.0	100.0		
	DOWN	.	25	0	.	.	3	.	.			
	TITRATION											
329.007.00265	.	WEEK 1	15FEB96	20	.	.	.	2	.	.		
		WEEK 2	.	20	.	.	.	2	.	.		
329.007.00268	97.1	WEEK 1	11APR96	20	0	20	10.0	2	100.0	100.0		
		WEEK 2	18APR96	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	25APR96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	02MAY96	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	09MAY96	40	18	22	7.0	4	79.0	78.6		
		WEEK 6	16MAY96	40	12	28	7.0	4	100.0	100.0		
		WEEK 7	.	50	10	40	8.0	5	100.0	100.0		
		WEEK 8	30MAY96	50	20	30	6.0	5	100.0	100.0		
		WEEK 12	27JUN96	200	60	140	28.0	5	100.0	100.0		
		WEEK 16	01AUG96	200	26	174	35.0	5	99.0	99.4		
		WEEK 20	30AUG96	240	63	177	29.0	6	102.0	101.7		
		WEEK 24	30SEP96	240	54	186	31.0	6	100.0	100.0		
		WEEK 28	07NOV96	200	11	189	38.0	5	99.0	99.5		
		WEEK 32	05DEC96	200	59	141	28.0	5	101.0	100.7		
			DOWN	02JAN97	32	0	32	13.5	4	100.0	59.3	
	TITRATION											

506

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.007.00294	90.5	WEEK 1	10MAR97	20	0	20	10.5	2	95.0	95.2
		WEEK 2	17MAR97	20	7	13	7.0	2	93.0	92.9
		WEEK 3	28MAR97	30	1	29	11.0	3	88.0	87.9
		WEEK 4	03APR97	40	16	24	6.0	4	100.0	100.0
		WEEK 5	10APR97	50	22	28	7.0	5	80.0	80.0
		DOWN	.	44	.	.	.	4	.	.
TITRATION										
329.007.00309	96.7	WEEK 1	18JUL96	20	14	6	3.0	2	100.0	100.0
		WEEK 2	25JUL96	20	8	12	7.0	2	86.0	85.7
		WEEK 3	01AUG96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	08AUG96	40	16	24	7.0	4	86.0	85.7
		WEEK 5	15AUG96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	23AUG96	40	8	32	8.0	4	100.0	100.0
		WEEK 7	30AUG96	40	12	28	7.0	4	100.0	100.0
		WEEK 8	05SEP96	40	16	24	6.0	4	100.0	100.0
		WEEK 12	03OCT96	160	44	116	28.0	4	104.0	103.6
		WEEK 16	31OCT96	160	36	112	28.0	4	100.0	100.0
		WEEK 20	13DEC96	160	2	170	43.0	4	97.0	98.8
		WEEK 24	09JAN97	160	55	105	27.0	4	97.0	97.2
		WEEK 28	10FEB97	160	48	112	32.0	4	87.0	87.5
		WEEK 32	13MAR97	200	48	152	31.0	5	98.0	98.1
		DOWN	26MAR97	32	0	32	13.0	4	100.0	61.5
		TITRATION								
329.007.00310	83.4	WEEK 1	03OCT96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	10OCT96	20	8	12	7.0	2	86.0	85.7
		WEEK 3	17OCT96	30	11	19	7.0	3	90.0	90.5
		WEEK 4	28OCT96	40	2	38	11.0	4	86.0	86.4
		WEEK 5	31OCT96	40	28	12	3.0	4	100.0	100.0
		WEEK 6	08NOV96	40	12	28	8.0	4	88.0	87.5
		WEEK 7	18NOV96	40	20	20	10.0	4	50.0	50.0
		WEEK 8	25NOV96	40	12	28	7.0	4	100.0	100.0
		WEEK 12	02JAN97	160	12	148	38.0	4	97.0	97.4
		WEEK 16	14FEB97	160	0	160	43.0	4	93.0	93.0
		WEEK 20	13MAR97	160	58	102	27.0	4	94.0	94.4
		WEEK 24	17APR97	160	40	120	35.0	4	86.0	85.7
		WEEK 28	15MAY97	160	60	100	28.0	4	89.0	89.3
		WEEK 32	12JUN97	160	51	109	28.0	4	97.0	97.3

507

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.007.00310	83.4	DOWN TITRATION	26JUN97	25	0	25	11.5	3	100.0	72.5
329.007.00318	.	WEEK 1	.	20	0	.	.	2	.	.
329.008.00157	76.8	WEEK 1	05SEP95	20	8	12	7.0	2	92.0	85.7
		WEEK 2	12SEP95	20	7	13	7.0	2	93.0	92.9
		WEEK 3	20SEP95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	26SEP95	40	20	20	6.0	4	83.0	83.3
		WEEK 5	04OCT95	40	16	24	7.0	4	86.0	85.7
		WEEK 6	10OCT95	40	22	18	6.0	4	92.0	75.0
		WEEK 7	16OCT95	40	30	10	6.0	4	42.0	41.7
		WEEK 8	24OCT95	40	16	24	7.0	4	86.0	85.7
		WEEK 12	23NOV95	160	32	128	29.0	4	110.0	110.3
		WEEK 16	15DEC95	160	114	46	22.0	4	52.0	52.3
		WEEK 20	23JAN96	160	44	116	38.0	4	76.0	76.3
		WEEK 24	20FEB96	160	120	40	28.0	4	35.0	35.7
329.008.00160	96.7	WEEK 1	10NOV95	20	2	18	9.0	2	100.0	100.0
		WEEK 2	20NOV95	20	2	18	10.0	2	90.0	90.0
		WEEK 3	27NOV95	30	10	20	7.0	3	95.0	95.2
		WEEK 4	05DEC95	40	.	.	.	4	.	.
		WEEK 5	13DEC95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	20DEC95	50	10	40	7.0	5	114.0	114.3
		WEEK 7	27DEC95	50	15	35	7.0	5	100.0	100.0
		WEEK 8	05JAN96	50	5	45	9.0	5	100.0	100.0
		WEEK 12	31JAN96	200	70	130	26.0	5	100.0	100.0
		WEEK 16	05MAR96	200	43	157	34.0	5	92.0	92.4
		WEEK 20	09APR96	200	28	172	34.0	5	101.0	101.2
		WEEK 24	16MAY96	200	20	180	36.0	5	100.0	100.0
		WEEK 28	18JUN96	200	60	140	34.0	5	82.0	82.4
		WEEK 32	23JUL96	200	57	143	35.0	5	81.0	81.7
		DOWN TITRATION	23JUL96	.	.	.	.	5	.	.
				.	.	.	.	4	.	.
				.	.	.	.	3	.	.
				.	.	.	.	2	.	.
				.	.	.	.	1	.	.
329.008.00188	92.4	WEEK 1	10JAN96	20	7	13	6.0	2	108.0	108.3

508

CONFIDENTIAL

BRL-029060-329-  
individual-data



PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.008.00188	92.4	WEEK 2	17JAN96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	24JAN96	30	12	18	7.0	3	85.0	85.7	
		WEEK 4	31JAN96	40	10	30	7.0	4	107.0	107.1	
		WEEK 5	07FEB96	50	33	17	7.0	5	48.0	48.6	
		WEEK 6	14FEB96	60	21	39	7.0	6	93.0	92.9	
		WEEK 7	21FEB96	60	27	33	7.0	6	78.0	78.6	
		WEEK 8	27FEB96	60	6	54	7.0	6	128.0	128.6	
		329.008.00271	83.5	WEEK 1	18MAR96	20	7	13	8.0	2	81.0
WEEK 2	25MAR96			20	6	14	7.0	2	100.0	100.0	
WEEK 3	01APR96			30	9	21	7.0	3	100.0	100.0	
WEEK 4	08APR96			40	14	26	8.0	4	81.0	81.3	
WEEK 5	15APR96			40	16	24	7.0	4	85.0	85.7	
WEEK 6	22APR96			50	20	30	7.0	5	86.0	85.7	
WEEK 7	02MAY96			60	3	57	10.0	6	95.0	95.0	
WEEK 8	14MAY96			60	18	42	10.0	6	70.0	70.0	
WEEK 12	10JUN96			240	129	111	27.0	6	102.0	68.5	
WEEK 16	12JUL96			240	81	99	31.0	6	53.0	53.2	
WEEK 20	09AUG96			240	.	.	.	6	.	.	
WEEK 24	06SEP96			240	.	.	.	6	.	.	
WEEK 28	07OCT96			240	75	165	28.0	6	98.0	98.2	
WEEK 32	05NOV96			240	.	.	.	6	.	.	
DOWN TITRATION	05NOV96			44	.	.	.	5	.	.	
					44	.	.	.	4	.	.
					44	.	.	.	3	.	.
					44	.	.	.	2	.	.
			44	.	.	.	1	.	.		
329.008.00275	98.7	WEEK 1	15MAY96	20	5	15	7.0	2	107.0	107.1	
		WEEK 2	21MAY96	20	8	12	6.0	2	100.0	100.0	
		WEEK 3	28MAY96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	04JUN96	40	14	26	8.0	4	81.0	81.3	
		WEEK 5	11JUN96	40	.	.	7.0	5	.	.	
		WEEK 6	25JUN96	50	.	.	.	5	.	.	
		WEEK 8	02JUL96	60	.	.	.	6	.	.	
		WEEK 12	23JUL96	200	136	64	21.0	5	60.0	61.0	
		WEEK 16	20AUG96	200	60	140	28.0	5	100.0	100.0	
		WEEK 20	16SEP96	200	76	124	27.0	5	91.0	91.9	
WEEK 24	21OCT96	200	.	.	.	5	.	.			

509

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.008.00275	98.7	WEEK 28	25NOV96	200	32	168	35.0	5	96.0	96.0		
		WEEK 32	16DEC96	240	152	48	21.0	5	45.0	45.7		
329.009.00130	87.3	WEEK 1	25APR95	20	11	9	7.0	2	64.0	64.3		
		WEEK 2	02MAY95	20	8	12	7.0	2	86.0	85.7		
		WEEK 3	09MAY95	30	13	17	7.0	3	81.0	81.0		
		WEEK 4	16MAY95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	23MAY95	40	14	26	7.0	4	93.0	92.9		
		WEEK 6	30MAY95	40	18	22	7.0	4	79.0	78.6		
		WEEK 7	06JUN95	40	14	26	7.0	4	93.0	92.9		
		WEEK 8	13JUN95	40	15	25	7.0	4	89.0	89.3		
		WEEK 16	07AUG95	160	6	154	54.0	4	71.0	71.3		
		WEEK 20	19SEP95	160	38	122	43.0	4	71.0	70.9		
		WEEK 24	03OCT95	160	128	32	14.0	4	57.0	57.1		
		DOWN	31OCT95	32	0	32	13.0	4	100.0	94.1		
		TITRATION										
						32	0	32	13.0	3	100.0	94.1
				32	0	32	13.0	2	100.0	94.1		
				32	0	32	13.0	2	100.0	94.1		
329.009.00131	92.6	WEEK 1	09MAY95	20	9	11	7.0	2	79.0	78.6		
		WEEK 2	16MAY95	20	11	9	7.0	2	64.0	64.3		
		WEEK 3	23MAY95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	30MAY95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	06JUN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	13JUN95	40	14	26	7.0	4	93.0	92.9		
		WEEK 7	20JUN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 8	27JUN95	40	16	24	7.0	4	86.0	85.7		
		WEEK 12	25JUL95	162	66	96	29.0	4	83.0	82.8		
		WEEK 16	24AUG95	160	54	106	30.0	4	88.0	88.3		
		WEEK 20	26SEP95	160	150	10	3.0	4	83.0	83.3		
		329.009.00133	91.2	WEEK 1	20JUN95	20	6	14	7.0	2	100.0	100.0
				WEEK 2	27JUN95	20	6	14	7.0	2	100.0	100.0
WEEK 3	05JUL95			30	6	24	8.0	3	100.0	100.0		
WEEK 4	11JUL95			40	16	24	6.0	4	100.0	100.0		
WEEK 5	18JUL95			50	15	35	7.0	5	100.0	100.0		
WEEK 6	27JUL95			120	75	45	9.0	6	83.0	83.3		
329.009.00138	50.0	WEEK 1	17OCT95	20	16	4	7.0	2	29.0	28.6		

510

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.009.00170	97.5	WEEK 1	14NOV95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	21NOV95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	28NOV95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	05DEC95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	12DEC95	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	21DEC95	60	6	54	9.0	6	100.0	100.0		
		WEEK 7	29DEC95	60	15	45	8.0	6	94.0	93.8		
		WEEK 8	03JAN96	50	28	22	5.0	5	88.0	88.0		
		WEEK 12	29JAN96	200	89	111	26.0	5	85.0	85.4		
		WEEK 16	26FEB96	200	84	116	28.0	5	82.9	82.9		
		WEEK 20	01APR96	200	35	165	35.0	5	94.0	94.3		
		WEEK 24	22APR96	200	152	48	21.0	5	46.0	45.7		
		WEEK 28	23MAY96	200	66	134	31.0	5	86.0	86.5		
		WEEK 32	24JUN96	200	78	122	33.0	5	74.0	73.9		
		DOWN	10JUL96	44	16	28	15.0	4	76.0	82.4		
		TITRATION				44	16	28	15.0	3	76.0	82.4
						44	16	28	15.0	2	76.0	82.4
				44	16	28	15.0	2	76.0	82.4		
329.009.00173	94.1	WEEK 1	27NOV95	20	13	7	7.0	2	50.0	50.0		
		WEEK 2	04DEC95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	11DEC95	30	12	18	7.0	3	86.0	85.7		
		WEEK 4	18DEC95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	29DEC95	50	1	49	11.0	5	89.0	89.1		
		WEEK 6	08JAN96	50	0	50	10.0	5	100.0	100.0		
		WEEK 7	15JAN96	40	10	30	7.0	4	100.0	107.1		
		WEEK 8	22JAN96	40	12	28	7.0	4	100.0	100.0		
		WEEK 12	26FEB96	160	46	114	35.0	4	81.0	81.4		
		DOWN	25MAR96	44	.	.	.	4	.	.		
		TITRATION										
329.009.00193	100.0	WEEK 1	05DEC95	20	4	14	7.0	2	100.0	100.0		
		WEEK 2	12DEC95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	19DEC95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	27DEC95	40	8	32	8.0	4	100.0	100.0		
		WEEK 5	05JAN96	50	5	45	9.0	5	100.0	100.0		
		WEEK 6	09JAN96	50	30	20	4.0	5	100.0	100.0		
		WEEK 7	16JAN96	50	15	35	7.0	5	100.0	100.0		
		WEEK 8	24JAN96	50	10	40	8.0	5	100.0	100.0		

511

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.009.00196	96.8	WEEK 1	27DEC95	20	3	17	9.0	2	94.0	94.4
		WEEK 2	02JAN96	20	8	12	6.0	2	100.0	100.0
		WEEK 3	08JAN96	30	12	18	6.0	3	100.0	100.0
		WEEK 4	15JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	22JAN96	50	18	32	7.0	5	91.0	91.4
		WEEK 6	29JAN96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	05FEB96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	12FEB96	50	18	32	7.0	5	91.0	91.4
		DOWN	26FEB96	44	12	32	14.0	4	100.0	57.1
		TITRATION								
329.009.00201	95.9	WEEK 1	13FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	20FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	28FEB96	30	6	24	8.0	3	100.0	100.0
		WEEK 4	05MAR96	40	16	24	6.0	4	100.0	100.0
		WEEK 5	12MAR96	40	16	24	7.0	4	86.0	85.7
		WEEK 6	19MAR96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	26MAR96	40	14	26	7.0	4	93.0	92.9
		WEEK 8	02APR96	50	17	33	7.0	5	94.0	94.3
329.009.00204	91.0	WEEK 1	26MAR96	20	7	13	7.0	2	93.0	92.9
		WEEK 2	02APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	09APR96	30	11	19	7.0	3	91.0	90.5
		WEEK 4	16APR96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	23APR96	40	14	26	7.0	4	93.0	92.9
		WEEK 6	30APR96	40	16	24	7.0	4	86.0	85.7
		WEEK 7	07MAY96	40	14	26	7.0	4	93.0	92.9
		WEEK 8	14MAY96	40	16	24	7.0	4	86.0	85.7
		WEEK 12	11JUN96	160	86	74	28.0	4	66.0	66.1
		WEEK 16	09JUL96	160	62	98	28.0	4	88.0	87.5
		WEEK 20	13AUG96	160	38	122	35.0	4	87.0	87.1
		WEEK 24	10SEP96	160	74	86	28.0	4	77.0	76.8
		WEEK 28	14OCT96	160	44	116	34.0	4	85.0	85.3
329.009.00235	97.3	WEEK 1	23DEC96	20	11	9	5.0	2	90.0	90.0
		WEEK 2	30DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	06JAN97	30	9	21	7.0	3	100.0	100.0
		WEEK 4	15JAN97	40	8	32	9.0	4	89.0	88.9
		WEEK 5	20JAN97	40	20	20	5.0	4	100.0	100.0
		WEEK 6	27JAN97	40	12	28	7.0	4	100.0	100.0

512

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.009.00235	97.3	WEEK 7	03FEB97	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	10FEB97	40	12	28	7.0	4	100.0	100.0	
		WEEK 12	17MAR97	160	19	141	35.0	4	100.0	100.7	
		WEEK 16	14APR97	160	50	110	28.0	4	98.0	98.2	
		DOWN	28APR97	44	16	28	14.0	4	100.0	93.3	
		TITRATION		44	16	28	14.0	3	100.0	93.3	
				44	16	28	14.0	2	100.0	93.3	
				44	16	28	14.0	2	100.0	93.3	
329.009.00240	86.7	WEEK 1	21JAN97	20	7	13	7.0	2	93.0	92.9	
		WEEK 2	28JAN97	20	7	13	7.0	2	93.0	92.9	
		WEEK 3	04FEB97	30	12	18	7.0	3	86.0	85.7	
		WEEK 4	11FEB97	40	14	26	7.0	4	93.0	92.9	
		WEEK 5	18FEB97	40	14	22	7.0	4	79.0	78.6	
		WEEK 6	25FEB97	50	17	33	7.0	5	94.0	94.3	
		WEEK 7	04MAR97	50	19	31	7.0	5	89.0	88.6	
329.009.00303	98.9	WEEK 1	09APR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	16APR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	23APR96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	30APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	07MAY96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	14MAY96	40	12	28	7.0	4	100.0	100.0	
		WEEK 7	22MAY96	40	8	32	8.0	4	100.0	100.0	
		WEEK 8	28MAY96	40	18	22	6.0	4	92.0	91.7	
		WEEK 12	25JUN96	160	50	110	29.0	4	95.0	94.8	
		WEEK 16	30JUL96	160	24	136	34.0	4	100.0	100.0	
		WEEK 20	27AUG96	160	50	110	28.0	4	98.0	98.2	
		WEEK 24	25SEP96	160	46	114	29.0	4	98.0	98.3	
		WEEK 28	30OCT96	160	22	138	35.0	4	99.0	98.6	
		WEEK 32	10DEC96	160	0	160	41.0	4	98.0	97.6	
		DOWN	15JAN97	44	16	28	36.0	4	100.0	93.3	
		TITRATION		44	16	28	36.0	3	100.0	93.3	
				44	16	28	36.0	2	100.0	93.3	
				44	16	28	36.0	2	100.0	93.3	
		329.009.00304	100.0	WEEK 1	16APR96	20	6	14	7.0	2	100.0
WEEK 2	23APR96			20	6	14	7.0	2	100.0	100.0	

513

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.009.00304	100.0	WEEK 3	30APR96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	07MAY96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	14MAY96	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	21MAY96	50	15	35	7.0	5	100.0	100.0	
		WEEK 7	28MAY96	50	15	35	7.0	5	100.0	100.0	
		WEEK 8	04JUN96	50	15	35	7.0	5	100.0	100.0	
		WEEK 12	02JUL96	200	62	138	28.0	5	99.0	98.6	
		WEEK 16	30JUL96	200	121	79	28.0	5	56.0	56.4	
		WEEK 20	27AUG96	200	62	138	28.0	5	99.0	98.6	
		WEEK 24	23SEP96	200	74	126	27.0	5	93.0	93.3	
		WEEK 28	21OCT96	200	103	97	28.0	5	69.0	69.3	
		DOWN	04NOV96	44	23	21	14.0	4	57.0	63.6	
		TITRATION									
						44	23	21	14.0	3	57.0
				44	23	21	14.0	2	57.0	63.6	
				44	23	21	14.0	2	57.0	63.6	
329.009.00324	97.1	WEEK 1	04NOV96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	11NOV96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	18NOV96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	25NOV96	40	14	26	7.0	4	93.0	92.9	
		WEEK 5	02DEC96	40	14	26	7.0	4	93.0	92.9	
		WEEK 6	09DEC96	40	10	30	7.0	4	107.0	107.1	
		WEEK 7	16DEC96	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	27DEC96	40	0	40	11.0	4	91.0	90.9	
329.009.00328	.	WEEK 1	.	20	.	.	.	2	.	.	
329.009.00329	87.0	WEEK 1	16OCT96	20	10	10	7.0	2	71.0	71.4	
		WEEK 2	23OCT96	20	7	13	7.0	2	93.0	92.9	
		WEEK 3	29OCT96	30	15	15	6.0	3	83.0	83.3	
		WEEK 4	05NOV96	40	14	26	7.0	4	93.0	92.9	
		WEEK 5	12NOV96	40	14	26	7.0	4	93.0	92.9	
		WEEK 6	19NOV96	40	16	24	7.0	4	86.0	85.7	
		WEEK 7	26NOV96	50	15	35	7.0	5	100.0	100.0	
		WEEK 8	03DEC96	50	25	25	7.0	5	71.0	71.4	
329.010.00182	101.0	WEEK 3	12JAN96	70	9	61	25.0	3	81.3	81.3	
		WEEK 4	19JAN96	40	0	40	10.0	4	100.0	100.0	
		WEEK 5	.	40	.	.	.	4	.	.	

514

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.010.00278	89.5	WEEK 1	16FEB96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	23FEB96	20	6	14	7.0	4	100.0	50.0	
		WEEK 3	01MAR96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	08MAR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	15MAR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	22MAR96	50	20	30	7.0	5	86.0	85.7	
		WEEK 7	29MAR96	60	24	36	7.0	6	86.0	85.7	
		WEEK 8	05APR96	60	18	42	7.0	6	100.0	100.0	
		WEEK 12	03MAY96	258	114	144	28.0	6	86.0	85.7	
		WEEK 16	31MAY96	240	102	138	28.0	6	82.0	82.1	
		WEEK 20	27JUN96	240	84	156	27.0	6	96.0	96.3	
		WEEK 24	25JUL96	240	87	153	27.0	6	95.0	94.4	
		WEEK 28	22AUG96	240	78	162	28.0	6	96.0	96.4	
		WEEK 32	19SEP96	240	96	144	28.0	6	86.0	85.7	
		DOWN	09OCT96	44	0	44	16.0	5	100.0	100.0	
		TITRATION									
						44	0	44	16.0	4	100.0
				44	0	44	16.0	3	100.0	100.0	
				44	0	44	16.0	2	100.0	100.0	
				44	0	44	16.0	2	100.0	100.0	
329.010.00280	94.5	WEEK 1	24MAY96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	31MAY96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	07JUN96	30	12	18	7.0	3	86.0	85.7	
		WEEK 4	14JUN96	40	16	24	7.0	4	86.0	85.7	
		WEEK 5	21JUN96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	27JUN96	50	25	25	6.0	5	83.0	83.3	
		WEEK 7	03JUL96	60	24	36	6.0	6	100.0	100.0	
		WEEK 8	11JUL96	60	12	48	8.0	6	100.0	100.0	
		WEEK 12	21AUG96	273	168	105	42.0	6	97.0	41.7	
		329.011.00283	93.2	WEEK 1	14FEB96	20	7	13	7.0	2	93.0
WEEK 2	21FEB96			20	7	13	7.0	2	93.0	92.9	
WEEK 3	29FEB96			30	9	21	7.0	3	100.0	100.0	
WEEK 4	07MAR96			40	16	24	7.0	4	86.0	85.7	
WEEK 5	15MAR96			40	12	28	8.0	4	87.5	87.5	
WEEK 6	22MAR96			40	12	28	7.0	4	100.0	100.0	
WEEK 7	28MAR96			40	16	24	6.0	4	100.0	100.0	
WEEK 8	04APR96			40	12	28	7.0	4	100.0	100.0	
WEEK 12	.			160	.	.	.	4	.	.	

515

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.011.00288	90.9	WEEK 1	01AUG96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	09AUG96	20	5	15	8.0	2	94.0	93.8
		WEEK 3	19AUG96	30	0	30	10.0	3	100.0	100.0
		WEEK 4	29AUG96	40	2	38	10.0	4	95.0	95.0
		WEEK 5	04SEP96	40	17	23	7.0	4	82.0	82.1
329.012.00025	99.1	WEEK 1	31OCT95	20	5	15	7.5	2	100.0	100.0
		WEEK 2	07NOV95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	14NOV95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	21NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	28NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	05DEC95	50	15	35	7.0	5	100.0	100.0
		WEEK 7	12DEC95	60	18	42	7.0	6	100.0	100.0
		WEEK 8	19DEC95	60	15	45	7.5	6	100.0	100.0
329.012.00220	94.3	WEEK 1	22JUN96	20	11	9	5.0	2	90.0	90.0
		WEEK 2	28JUN96	20	8	12	6.0	2	100.0	100.0
		WEEK 3	05JUL96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	12JUL96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	19JUL96	50	17	33	7.0	5	94.0	94.3
		WEEK 6	29JUL96	50	6	44	9.5	5	93.0	92.6
		WEEK 7	06AUG96	50	13	37	8.5	5	87.0	87.1
		WEEK 8	16AUG96	50	0	50	9.5	5	105.0	105.3
		WEEK 12	13SEP96	200	96	104	28.0	5	74.0	74.3
		WEEK 16	11OCT96	200	54	146	29.0	5	101.0	100.7
		WEEK 20	08NOV96	200	60	140	28.0	5	100.0	100.0
		WEEK 24	06DEC96	200	135	65	14.0	5	93.0	92.9
		DOWN	.	34	.	.	.	5	.	.
		TITRATION								
		329.012.00222	94.6	WEEK 1	05JUL96	20	6	14	7.0	2
WEEK 2	12JUL96			20	6	14	7.0	2	100.0	100.0
WEEK 3	19JUL96			30	11	19	7.0	3	90.0	90.5
WEEK 4	29JUL96			40	4	36	9.0	4	100.0	100.0
WEEK 5	06AUG96			40	8	32	8.5	4	94.0	94.1
WEEK 6	13AUG96			50	18	32	7.0	5	91.0	91.4
WEEK 7	20AUG96			50	14	36	7.0	5	103.0	102.9
WEEK 8	30AUG96			50	5	45	9.5	5	95.0	94.7
WEEK 12	27SEP96			200	107	93	29.0	5	74.0	64.1

516

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PAROXETINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.012.00226	100.0	WEEK 1	10DEC96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	20DEC96	20	0	20	10.0	2	100.0	100.0	
		WEEK 3	23DEC96	30	30	0	3.0	0	.	.	
329.012.00228	87.5	WEEK 1	27MAR97	20	13	7	8.0	2	44.0	43.8	
329.012.00231	102.8	WEEK 1	17MAR97	20	0	20	10.0	2	100.0	100.0	
		WEEK 2	24MAR97	20	5	15	7.5	2	100.0	100.0	
		WEEK 3	02APR97	30	2	28	9.0	3	104.0	103.7	
		WEEK 4	09APR97	40	10	30	7.0	4	107.0	107.1	
		WEEK 5	17APR97	40	8	32	8.0	4	100.0	100.0	
		WEEK 6	25APR97	40	8	32	8.0	4	100.0	100.0	
		WEEK 7	01MAY97	50	18	32	6.0	5	107.0	106.7	
		WEEK 8	07MAY97	50	20	30	6.0	5	100.0	100.0	
		WEEK 12	04JUN97	200	63	137	28.0	5	98.0	97.9	
		WEEK 16	30JUN97	200	104	96	76.0	5	74.0	25.3	
		WEEK 20	05AUG97	200	52	148	36.0	5	.	82.2	
		DOWN	19AUG97	34	9	25	13.0	4	83.0	73.5	
		TITRATION									
						34	9	25	13.0	3	83.0
				34	9	25	13.0	2	83.0	73.5	
				34	9	25	13.0	2	83.0	73.5	

517

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.001.00061	100.0	WEEK 1	04AUG94	20	8	12	6.0	2	100.0	100.0		
		WEEK 2	11AUG94	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	18AUG94	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	25AUG94	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	01SEP94	40	12	28	7.0	4	100.0	100.0		
329.001.00066	100.0	WEEK 1	28NOV94	20	8	12	6.0	2	100.0	100.0		
		WEEK 2	05DEC94	20	6	14	7.0	2	100.0	100.0		
329.001.00067	100.0	WEEK 1	29NOV94	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	06DEC94	20	6	14	7.0	2	100.0	100.0		
329.001.00070	100.0	WEEK 1	28FEB95	20	8	12	6.0	2	100.0	100.0		
		WEEK 2	08MAR95	20	4	16	8.0	2	100.0	100.0		
		WEEK 3	15MAR95	30	9	21	7.0	3	100.0	100.0		
329.001.00122	100.0	WEEK 1	27JUN95	20	5	15	7.0	2	100.0	107.1		
		WEEK 2	05JUL95	20	5	15	8.0	2	94.0	93.8		
		WEEK 3	11JUL95	30	12	18	6.0	3	100.0	100.0		
		WEEK 4	18JUL95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	25JUL95	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	01AUG95	40	12	28	7.0	4	100.0	100.0		
		WEEK 7	08AUG95	40	10	30	7.5	4	100.0	100.0		
		WEEK 8	16AUG95	40	10	30	7.5	4	100.0	100.0		
		WEEK 12	12SEP95	160	52	108	27.0	4	100.0	100.0		
		WEEK 16	10OCT95	160	48	112	28.0	4	100.0	100.0		
		WEEK 20	07NOV95	160	48	112	28.0	4	100.0	100.0		
		WEEK 24	05DEC95	160	48	112	28.0	4	100.0	100.0		
		329.002.00050	89.8	WEEK 1	29MAR95	20	9	11	7.0	2	78.6	78.6
				WEEK 2	05APR95	20	6	14	7.0	2	100.0	100.0
WEEK 3	12APR95			30	11	19	7.0	3	90.5	90.5		
329.002.00056	95.1	WEEK 1	26JUL94	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	02AUG94	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	09AUG94	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	16AUG94	40	12	28	7.0	4	100.0	100.0		
329.002.00057	97.5	WEEK 1	15SEP94	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	22SEP94	20	5	15	7.0	2	100.0	107.1		

518

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.002.00057	97.5	WEEK 3	29SEP94	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	06OCT94	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	13OCT94	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	20OCT94	60	18	42	7.0	6	100.0	100.0		
		WEEK 7	27OCT94	60	18	42	7.0	6	100.0	100.0		
		WEEK 8	03NOV94	60	18	42	7.0	6	100.0	100.0		
		WEEK 12	01DEC94	240	72	168	28.0	6	100.0	100.0		
		WEEK 16	29DEC94	240	75	165	28.0	6	98.0	98.2		
		DOWN	11JAN95	44	0	44	16.0	5	100.0	100.0		
		TITRATION										
						44	0	44	16.0	4	100.0	100.0
						44	0	44	16.0	3	100.0	100.0
						44	0	44	16.0	2	100.0	100.0
				44	0	44	16.0	2	100.0	100.0		
329.002.00098	95.1	WEEK 1	10JAN95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	18JAN95	20	4	16	8.0	2	100.0	100.0		
		WEEK 3	24JAN95	30	12	18	6.0	3	100.0	100.0		
		WEEK 4	31JAN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	07FEB95	50	18	32	7.0	5	91.0	91.4		
		WEEK 6	14FEB95	60	20	40	7.0	6	95.0	95.2		
		WEEK 7	21FEB95	50	18	32	7.0	5	91.0	91.4		
		WEEK 8	02MAR95	90	55	35	8.0	5	100.0	92.1		
						90	55	35	8.0	4	100.0	92.1
329.002.00100	98.6	WEEK 1	14MAR95	20	7	13	7.0	2	92.0	92.9		
		WEEK 2	21MAR95	20	7	13	7.0	2	93.0	92.9		
		WEEK 3	28MAR95	30	11	19	7.0	3	85.0	90.5		
		WEEK 4	04APR95	40	8	32	7.0	4	114.0	114.3		
		WEEK 5	11APR95	40	14	26	7.0	4	93.0	92.9		
		WEEK 6	18APR95	50	15	35	7.0	5	100.0	100.0		
		WEEK 7	25APR95	50	18	32	7.0	5	91.0	91.4		
		WEEK 8	04MAY95	50	3	47	9.0	5	104.0	104.4		
		WEEK 12	30MAY95	200	73	127	26.0	5	93.0	97.7		
		WEEK 16	27JUN95	200	.	.	.	5	.	.		
		329.002.00103	98.6	WEEK 1	27APR95	20	6	14	7.0	2	100.0	100.0
WEEK 2	02MAY95			20	10	10	5.0	2	100.0	100.0		
WEEK 3	09MAY95			30	9	21	7.0	3	100.0	100.0		
WEEK 4	16MAY95			40	12	28	7.0	4	100.0	100.0		

519

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.002.00103	98.6	WEEK 5	25MAY95	40	6	34	9.0	4	94.0	94.4		
		WEEK 6	30MAY95	40	20	20	5.0	4	100.0	100.0		
		WEEK 7	06JUN95	50	15	35	7.0	5	100.0	100.0		
		WEEK 8	15JUN95	50	6	44	9.0	5	98.0	97.8		
		WEEK 12	13JUL95	200	66	134	28.0	5	95.0	95.7		
		WEEK 16	10AUG95	240	86	154	28.0	5	110.0	110.0		
		DOWN	25AUG95	44	4	40	15.0	5	91.0	108.1		
		TITRATION		44	4	40	15.0	4	91.0	108.1		
				44	4	40	15.0	3	91.0	108.1		
				44	4	40	15.0	2	91.0	108.1		
				44	4	40	15.0	1	91.0	108.1		
		329.002.00104	100.4	WEEK 1	11MAY95	20	5	15	7.0	2	107.0	107.1
				WEEK 2	18MAY95	20	6	14	7.0	2	100.0	100.0
WEEK 3	25MAY95			30	9	21	7.0	3	100.0	100.0		
WEEK 4	01JUN95			40	12	28	7.0	4	100.0	100.0		
WEEK 5	09JUN95			50	10	40	8.0	5	100.0	100.0		
WEEK 6	16JUN95			60	18	42	7.0	6	100.0	100.0		
WEEK 7	22JUN95			60	24	36	6.0	6	100.0	100.0		
WEEK 8	29JUN95			60	18	42	7.0	6	100.0	100.0		
WEEK 12	25JUL95			240	93	147	26.0	6	94.0	94.2		
WEEK 16	29AUG95			240	36	204	35.0	6	97.0	97.1		
WEEK 20	03OCT95			240	42	198	35.0	6	94.0	94.3		
WEEK 24	06NOV95			240	51	189	34.0	6	92.0	92.6		
WEEK 28	06DEC95			240	36	204	30.0	6	94.0	113.3		
WEEK 32	02JAN96			240	87	153	27.0	6	94.0	94.4		
DOWN	17JAN96			44	0	44	16.0	5	100.0	118.9		
TITRATION				44	0	44	16.0	4	100.0	118.9		
				44	0	44	16.0	3	100.0	118.9		
				44	0	44	16.0	2	100.0	118.9		
				44	0	44	16.0	1	100.0	118.9		
329.002.00243	96.2			WEEK 1	21MAR96	20	5	15	7.0	2	107.0	107.1
		WEEK 2	28MAR96	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	04APR96	30	9	21	7.0	3	100.0	100.0		
		DOWN	.	44	.	.	.	3	.	.		
		TITRATION										

520

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.002.00244	93.7	WEEK 1	28MAR96	20	7	13	7.0	2	92.0	92.9
		WEEK 2	04APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	11APR96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	18APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	25APR96	40	12	28	7.0	5	100.0	80.0
		WEEK 6	02MAY96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	09MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	16MAY96	60	18	42	7.0	6	100.0	100.0
		WEEK 12	23MAY96	300	227	73	7.0	6	103.0	109.0
				300	227	73	7.0	5	103.0	109.0
		DOWN TITRATION	12JUN96	44	10	34	15.0	4	100.0	89.5
				44	10	34	15.0	3	100.0	89.5
				44	10	34	15.0	2	100.0	89.5
				44	10	34	15.0	2	100.0	89.5
329.002.00321	58.3	WEEK 1	30MAY96	20	6	14	7.0	2	100.0	100.0
329.002.00322	94.5	WEEK 1	16JAN97	20	7	13	7.0	2	92.0	92.9
		WEEK 2	23JAN97	20	7	13	7.0	2	93.0	92.9
		WEEK 3	30JAN97	30	9	21	7.0	3	100.0	100.0
		WEEK 4	04FEB97	40	20	20	5.0	4	100.0	100.0
		WEEK 5	13FEB97	40	4	36	9.0	4	100.0	100.0
329.003.00073	92.0	WEEK 1	25JAN95	20	6	14	6.0	2	110.0	116.7
		WEEK 2	03FEB95	20	2	18	9.0	2	100.0	100.0
		WEEK 3	07FEB95	30	18	12	4.0	3	108.0	100.0
		WEEK 4	14FEB95	40	19	21	7.0	3	100.0	100.0
		WEEK 5	22FEB95	40	8	32	8.0	4	100.0	100.0
		WEEK 6	01MAR95	50	22	28	7.0	5	80.0	80.0
		WEEK 7	08MAR95	50	37	13	3.0	5	87.0	86.7
329.003.00076	99.5	WEEK 1	07FEB95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14FEB95	20	7	13	7.0	2	93.0	92.9
		WEEK 3	21FEB95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	27FEB95	40	16	24	6.0	4	100.0	100.0
		WEEK 5	06MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	13MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 7	20MAR95	40	12	28	7.0	4	100.0	100.0
		WEEK 8	27MAR95	40	12	28	7.0	4	100.0	100.0

521

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.003.00076	99.5	WEEK 12	03MAY95	160	26	134	37.0	4	101.0	90.5
		WEEK 16	31MAY95	160	52	108	28.0	4	96.0	96.4
		WEEK 20	28JUN95	160	62	98	28.0	4	88.0	87.5
		WEEK 24	02AUG95	160	38	122	34.0	4	88.0	89.7
		WEEK 28	06SEP95	160	.	.	35.0	4	47.0	.
		WEEK 32	11OCT95	160	.	.	.	4	.	.
329.003.00079	100.0	WEEK 1	10MAY95	20	.	.	7.0	2	.	.
		WEEK 2	19MAY95	20	2	18	9.0	2	100.0	100.0
		WEEK 3	.	30	.	.	.	3	.	.
329.003.00082	80.9	WEEK 1	28DEC95	20	2	18	17.0	2	53.0	52.9
		WEEK 2	03JAN96	20	9	11	6.0	2	92.0	91.7
		WEEK 3	11JAN96	30	7	23	8.0	3	96.0	95.8
		WEEK 4	17JAN96	40	16	24	7.0	4	86.0	85.7
		WEEK 5	.	50	.	.	.	5	.	.
329.003.00088	89.8	WEEK 1	09MAR95	20	2	18	18.0	2	100.0	50.0
		WEEK 2	14MAR95	20	10	10	5.0	2	100.0	100.0
		WEEK 3	21MAR95	30	8	22	7.0	3	110.0	104.8
		WEEK 4	30MAR95	40	6	34	9.0	4	94.0	94.4
		WEEK 5	04APR95	40	32	8	5.0	2	80.0	80.0
		WEEK 6	11APR95	40	26	14	7.0	4	62.0	50.0
329.003.00090	100.0	WEEK 1	28MAR95	20	2	18	14.0	2	64.0	64.3
		WEEK 2	04APR95	20	7	13	7.0	2	93.0	92.9
		WEEK 3	11APR95	30	8	22	7.0	3	104.0	104.8
		WEEK 4	18APR95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	25APR95	40	18	22	7.0	4	78.0	78.6
		WEEK 6	02MAY95	50	4	46	7.0	5	130.0	131.4
		WEEK 7	09MAY95	40	14	26	7.0	4	92.0	92.9
		WEEK 8	16MAY95	40	16	24	7.0	4	86.0	85.7
329.003.00092	82.0	WEEK 1	11MAY95	20	2	18	9.0	2	100.0	100.0
		WEEK 2	16MAY95	20	10	10	5.0	2	100.0	100.0
		WEEK 3	26MAY95	30	2	28	10.0	3	93.0	93.3
		WEEK 4	02JUN95	40	15	25	7.0	4	89.0	89.3
		WEEK 5	06JUN95	40	30	10	4.0	4	63.0	62.5
		WEEK 6	13JUN95	40	20	20	7.0	4	71.0	71.4
		WEEK 7	20JUN95	40	.	.	.	4	.	.

522

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.003.00092	82.0	WEEK 8	30JUN95	40	14	26	10.0	4	65.0	65.0
		WEEK 12	08AUG95	160	16	144	39.0	4	92.0	92.3
		WEEK 16	05SEP95	160	62	98	27.0	4	91.0	90.7
		WEEK 20	26SEP95	160	84	76	21.0	4	90.0	90.5
		WEEK 24	07NOV95	160	32	128	37.0	4	100.0	80.0
				160	32	128	37.0	0	100.0	80.0
				160	32	128	37.0	4	100.0	80.0
		WEEK 28	05DEC95	160	60	100	28.0	4	80.0	89.3
		WEEK 32	02JAN96	160	68	92	27.0	4	71.0	85.2
		DOWN	18JAN96	44	0	44	16.0	5	100.0	100.0
		TITRATION		44	0	44	16.0	4	100.0	100.0
				44	0	44	16.0	3	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
		329.003.00093	80.7	WEEK 1	27JUN95	20	8	12	7.0	2
WEEK 2	06JUL95			20	12	8	10.0	2	40.0	40.0
WEEK 3	21JUL95			30	1	29	14.0	3	69.0	69.0
WEEK 4	25JUL95			40	28	12	4.0	4	75.0	75.0
WEEK 5	01AUG95			50	23	27	7.0	5	77.0	77.1
WEEK 6	10AUG95			60	12	48	9.0	6	89.0	88.9
WEEK 7	.			60	27	33	6.0	6	92.0	91.7
WEEK 8	22AUG95			60	24	36	6.0	6	100.0	100.0
WEEK 12	03OCT95			291	222	69	17.0	6	68.0	67.6
329.003.00247	90.2	WEEK 1	06FEB96	20	9	11	5.0	2	110.0	110.0
		WEEK 2	13FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	20FEB96	30	6	24	7.0	3	110.0	114.3
		WEEK 4	27FEB96	40	14	26	7.0	4	101.0	92.9
		WEEK 5	07MAR96	40	8	32	8.0	4	100.0	100.0
		WEEK 6	12MAR96	40	24	16	4.0	4	100.0	100.0
		WEEK 7	21MAR96	40	24	16	9.0	4	44.0	44.4
		WEEK 8	26MAR96	40	13	27	5.0	4	108.0	135.0
		WEEK 12	30APR96	160	109	.	.	4	.	.
		WEEK 16	21MAY96	160	56	104	21.0	4	124.0	123.8
		WEEK 20	.	160	.	.	.	4	.	.
		329.003.00249	102.1	WEEK 1	12MAR96	20	10	10	5.0	2
WEEK 2	19MAR96			20	7	13	8.0	2	81.3	81.3

523

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.003.00249	102.1	WEEK 3	26MAR96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	02APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	09APR96	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	16APR96	60	18	42	7.0	6	100.0	100.0	
		WEEK 7	23APR96	60	12	48	7.0	6	114.0	114.3	
		WEEK 8	30APR96	60	18	42	7.0	6	100.0	100.0	
329.003.00289	100.0	WEEK 1	06MAR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	13MAR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	20MAR96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	27MAR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	03APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	10APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 7	17APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	24APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 12	22MAY96	160	48	112	28.0	4	100.0	100.0	
		WEEK 16	20JUN96	160	42	118	29.0	4	101.0	101.7	
		WEEK 20	19JUL96	160	44	116	29.0	4	100.0	100.0	
		WEEK 24	16AUG96	160	52	108	28.0	4	96.0	96.4	
		WEEK 28	13SEP96	160	48	112	28.0	4	100.0	100.0	
		WEEK 32	11OCT96	160	48	112	28.0	4	100.0	100.0	
		DOWN	23OCT96	26	0	26	12.0	3	100.0	100.0	
		TITRATION			26	0	26	12.0	2	100.0	100.0
					26	0	26	12.0	2	100.0	100.0
		329.003.00290	91.7	WEEK 1	20MAR96	20	2	18	9.0	2	100.0
WEEK 2	22MAR96			20	16	4	2.0	2	100.0	100.0	
329.003.00314	79.4	WEEK 1	29OCT96	20	8	12	8.0	2	85.7	75.0	
		WEEK 2	05NOV96	20	14	6	7.0	2	42.8	42.9	
		WEEK 3	14NOV96	30	5	25	10.0	3	83.0	83.3	
		WEEK 4	26NOV96	40	.	.	13.0	4	.	.	
		WEEK 5	03DEC96	40	14	26	8.0	4	75.0	81.3	
		WEEK 6	10DEC96	40	18	22	7.0	4	78.0	78.6	
		WEEK 7	17DEC96	40	10	30	8.0	4	94.0	93.8	
		WEEK 8	23DEC96	120	48	72	14.0	5	103.0	72.0	
			120	48	72	14.0	5	103.0	72.0		
329.003.00317	99.1	WEEK 1	23DEC96	20	12	8	5.0	2	80.0	80.0	

524

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.003.00317	99.1	WEEK 2	.	20	7	13	7.0	2	93.0	92.9		
		WEEK 3	07JAN97	30	5	25	8.0	3	104.0	104.2		
		WEEK 4	14JAN97	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	21JAN97	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	28JAN97	50	15	35	7.0	5	100.0	100.0		
		WEEK 7	04FEB97	60	18	42	7.0	6	100.0	100.0		
		WEEK 8	11FEB97	60	18	42	7.0	6	100.0	100.0		
		329.004.00013	99.5	WEEK 1	26JUL94	20	6	14	7.0	2	100.0	100.0
WEEK 2	02AUG94			20	6	14	7.0	2	100.0	100.0		
WEEK 3	09AUG94			30	9	21	7.0	3	100.0	100.0		
WEEK 4	15AUG94			40	18	22	6.0	4	92.0	91.7		
WEEK 5	23AUG94			40	5	35	8.0	4	109.0	109.4		
WEEK 6	31AUG94			40	8	32	8.0	4	100.0	100.0		
WEEK 7	08SEP94			40	8	32	8.0	4	100.0	100.0		
WEEK 8	16SEP94			40	10	30	8.0	4	94.0	93.8		
WEEK 12	11OCT94			160	62	98	25.0	4	98.0	98.0		
WEEK 16	08NOV94			260	138	122	29.0	4	100.0	98.4		
				260	138	122	29.0	5	100.0	98.4		
WEEK 20	06DEC94			200	61	139	29.0	5	96.0	95.9		
WEEK 24	10JAN95			200	25	175	34.0	5	100.0	102.9		
WEEK 28	07FEB95			200	62	138	28.0	5	99.0	98.6		
WEEK 32	10MAR95			200	45	155	31.0	5	100.0	100.0		
DOWN	31MAR95			44	10	34	21.0	4	100.0	100.0		
TITRATION						44	10	34	21.0	3	100.0	100.0
						44	10	34	21.0	2	100.0	100.0
						44	10	34	21.0	2	100.0	100.0
329.004.00014	56.7			WEEK 1	05DEC94	20	9	11	6.0	2	100.0	91.7
		WEEK 2	13DEC94	20	14	6	8.0	2	37.5	37.5		
329.004.00211	93.2	WEEK 1	08FEB96	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	16FEB96	20	5	15	8.0	2	100.0	93.8		
		WEEK 3	23FEB96	30	9	21	8.0	3	100.0	87.5		
		WEEK 4	29FEB96	40	16	24	7.0	4	100.0	85.7		
		WEEK 5	07MAR96	40	14	26	8.0	4	100.0	81.3		
		WEEK 6	14MAR96	40	14	26	7.0	4	100.0	92.9		
		WEEK 7	25MAR96	40	16	24	12.0	4	72.0	50.0		

525

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.004.00215	93.6	WEEK 1	27MAR97	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	03APR97	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	10APR97	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	15APR97	40	20	20	5.0	4	100.0	100.0	
		WEEK 5	24APR97	40	6	34	9.0	4	94.0	94.4	
		WEEK 6	29APR97	40	26	14	5.0	4	70.0	70.0	
329.005.00003	92.3	WEEK 1	27SEP94	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	04OCT94	20	10	10	7.0	2	71.0	83.3	
				20	10	10	7.0	1	71.0	83.3	
329.005.00006	100.4	WEEK 1	14NOV94	20	0	20	10.0	2	100.0	100.0	
		WEEK 2	21NOV94	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	28NOV94	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	05DEC94	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	12DEC94	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	19DEC94	60	17	43	7.0	6	100.0	102.4	
		WEEK 7	27DEC94	60	12	48	8.0	6	100.0	100.0	
		WEEK 8	03JAN95	60	18	42	7.0	6	100.0	100.0	
		WEEK 12	02FEB95	240	60	180	30.0	6	100.0	100.0	
		WEEK 16	27FEB95	240	90	150	25.0	6	100.0	100.0	
		WEEK 20	05APR95	240	21	219	37.0	6	98.0	98.6	
		WEEK 24	12APR95	240	198	42	7.0	6	100.0	100.0	
		DOWN	28APR95	44	2	42	16.0	5	100.0	113.5	
		TITRATION			44	2	42	16.0	4	100.0	113.5
					44	2	42	16.0	3	100.0	113.5
					44	2	42	16.0	2	100.0	113.5
			44	2	42	16.0	1	100.0	113.5		
329.005.00007	95.6	WEEK 1	23NOV94	20	4	16	15.0	2	100.0	53.3	
		WEEK 2	30NOV94	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	07DEC94	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	14DEC94	40	22	18	7.0	4	64.0	64.3	
		WEEK 5	21DEC94	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	28DEC94	60	18	42	7.0	6	100.0	100.0	
		WEEK 7	04JAN95	50	15	35	7.0	5	100.0	100.0	
		WEEK 8	11JAN95	50	15	35	7.0	5	100.0	100.0	
		WEEK 12	15FEB95	200	25	175	35.0	5	100.0	100.0	
		WEEK 16	22MAR95	200	25	175	35.0	5	100.0	100.0	

526

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.005.00007	95.6	WEEK 20	19APR95	200	60	140	28.0	5	100.0	100.0
		WEEK 24	17MAY95	200	55	145	37.0	5	78.0	78.4
		WEEK 28	09AUG95	200	185	15	3.0	5	100.0	100.0
329.005.00009	100.0	WEEK 1	19DEC94	20	6	14	7.0	2	100.0	100.0
		WEEK 2	27DEC94	20	4	16	8.0	2	100.0	100.0
		WEEK 3	03JAN95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	11JAN95	40	8	32	8.0	4	100.0	100.0
		WEEK 5	18JAN95	50	15	35	7.0	5	100.0	100.0
		WEEK 6	25JAN95	60	18	42	7.0	6	100.0	100.0
		WEEK 7	31JAN95	50	20	30	6.0	5	100.0	100.0
		WEEK 8	07FEB95	50	15	35	7.0	5	100.0	100.0
329.005.00110	88.9	WEEK 1	18JAN95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	25JAN95	20	18	2	7.0	2	14.3	14.3
329.005.00113	73.6	WEEK 1	08FEB95	20	3	17	9.0	2	95.0	94.4
		WEEK 2	16FEB95	20	5	15	8.0	2	94.0	93.8
		WEEK 3	23FEB95	30	12	18	7.0	3	85.0	85.7
		WEEK 4	02MAR95	40	26	14	7.0	4	43.0	50.0
329.005.00117	93.3	WEEK 1	27MAR95	20	2	18	9.0	2	100.0	100.0
		WEEK 2	03APR95	20	5	15	7.0	2	107.0	107.1
		WEEK 3	10APR95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	17APR95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	24APR95	40	16	24	7.0	4	85.0	85.7
		WEEK 6	01MAY95	40	14	26	7.0	4	92.0	92.9
		WEEK 7	08MAY95	40	20	20	7.0	4	71.0	71.4
		WEEK 8	15MAY95	40	12	28	7.0	4	100.0	100.0
329.005.00118	105.3	WEEK 1	24MAY95	20	5	15	7.5	2	100.0	100.0
		WEEK 2	30MAY95	20	9	11	6.0	2	92.0	91.7
		WEEK 3	06JUN95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	14JUN95	40	7	33	8.0	4	103.0	103.1
		WEEK 5	20JUN95	50	19	31	7.0	5	88.0	88.6
		WEEK 6	27JUN95	60	12	48	7.0	6	114.0	114.3
329.005.00153	98.6	WEEK 1	01FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	08FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	15FEB96	30	10	20	7.0	3	95.2	95.2

527

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.005.00153	98.6	WEEK 4	22FEB96	40	14	26	7.0	4	92.8	92.9	
		WEEK 5	29FEB96	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	06MAR96	50	20	30	6.0	5	100.0	100.0	
		WEEK 7	14MAR96	50	10	40	8.0	5	100.0	100.0	
		WEEK 8	21MAR96	50	15	35	7.0	5	100.0	100.0	
		WEEK 12	17APR96	200	65	135	27.0	5	100.0	100.0	
		WEEK 16	15MAY96	240	72	168	28.0	6	100.0	100.0	
		WEEK 20	12JUN96	240	72	168	28.0	6	100.0	100.0	
		WEEK 24	10JUL96	240	75	165	28.0	6	98.0	98.2	
		WEEK 28	05AUG96	240	90	150	26.0	6	96.0	96.2	
		WEEK 32	04SEP96	240	78	162	30.0	6	90.0	90.0	
		DOWN	25SEP96	44	13	31	16.0	5	65.0	81.6	
		TITRATION			44	13	31	16.0	4	65.0	81.6
					44	13	31	16.0	3	65.0	81.6
			44	13	31	16.0	2	65.0	81.6		
			44	13	31	16.0	2	65.0	81.6		
329.005.00255	99.1	WEEK 1	11MAR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	18MAR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	25MAR96	30	11	19	7.0	3	90.0	90.5	
		WEEK 4	01APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	08APR96	50	15	35	7.0	5	100.0	100.0	
		WEEK 6	15APR96	60	18	42	7.0	6	100.0	100.0	
		WEEK 7	23APR96	50	10	40	8.0	5	100.0	100.0	
		WEEK 8	29APR96	50	20	30	6.0	5	100.0	100.0	
329.005.00256	94.1	WEEK 1	12MAR96	20	7	13	7.0	2	93.0	92.9	
		WEEK 2	21MAR96	20	3	17	9.0	2	94.0	94.4	
		WEEK 3	26MAR96	30	15	15	5.0	3	100.0	100.0	
		WEEK 4	02APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	11APR96	50	8	42	9.0	5	93.0	93.3	
		WEEK 6	16APR96	50	27	23	5.0	5	92.0	92.0	
		WEEK 7	23APR96	50	18	29	7.0	5	82.0	82.9	
		WEEK 8	30APR96	60	18	42	7.0	6	100.0	100.0	
		WEEK 12	28MAY96	240	81	156	28.0	6	93.0	92.9	
		WEEK 16	02JUL96	240	90	150	34.0	6	74.0	73.5	
		DOWN	18JUL96	44	10	34	15.0	5	77.0	77.3	
		TITRATION			44	10	34	15.0	4	77.0	77.3

528

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.005.00256	94.1	DOWN TITRATION	18JUL96	44	10	34	15.0	3	77.0	77.3
				44	10	34	15.0	2	77.0	77.3
				44	10	34	15.0	2	77.0	77.3
329.005.00295	90.4	WEEK 1	04APR96	20	7	13	7.0	2	93.0	92.9
		WEEK 2	11APR96	20	8	12	7.0	2	86.0	85.7
		WEEK 3	18APR96	30	7	23	7.0	3	100.0	109.5
		WEEK 4	24APR96	40	16	24	6.0	4	100.0	100.0
		WEEK 5	06MAY96	40	0	40	10.0	4	100.0	100.0
		WEEK 6	09MAY96	40	28	12	3.0	4	100.0	100.0
		WEEK 7	16MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	22MAY96	50	39	11	4.0	5	55.0	55.0
329.005.00297	90.3	WEEK 1	26APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	02MAY96	20	8	12	6.0	2	100.0	100.0
		WEEK 3	14MAY96	30	0	30	12.0	3	84.0	83.3
329.005.00332	100.0	WEEK 1	19DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	26DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	02JAN97	30	9	21	7.0	3	100.0	100.0
		WEEK 4	09JAN97	40	12	28	7.0	4	100.0	100.0
		WEEK 5	16JAN97	50	15	35	7.0	5	100.0	100.0
		WEEK 6	23JAN97	60	18	42	7.0	6	100.0	100.0
		WEEK 7	30JAN97	60	18	42	7.0	6	100.0	100.0
		WEEK 8	06FEB97	60	18	42	7.0	6	100.0	100.0
329.005.00335	93.9	WEEK 1	07MAR97	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14MAR97	20	6	14	7.0	2	100.0	100.0
		WEEK 3	21MAR97	30	9	21	7.0	3	100.0	100.0
		WEEK 4	27MAR97	40	16	24	6.0	4	100.0	100.0
		WEEK 5	03APR97	50	15	35	7.0	5	100.0	100.0
		WEEK 6	10APR97	40	14	26	7.0	4	93.0	92.9
		WEEK 7	17APR97	40	14	26	7.0	4	95.0	92.9
		WEEK 8	24APR97	40	16	24	7.0	4	86.0	85.7
329.006.00040	96.2	WEEK 1	22FEB95	20	7	13	7.0	2	100.0	92.9
		WEEK 2	01MAR95	20	8	12	7.0	2	83.0	85.7
329.006.00041	99.6	WEEK 1	10APR95	20	11	9	5.0	2	90.0	90.0

529

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.006.00041	99.6	WEEK 2	19APR95	20	2	18	9.0	2	100.0	100.0		
		WEEK 3	24APR95	30	15	15	5.0	3	100.0	100.0		
		WEEK 4	01MAY95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	08MAY95	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	15MAY95	40	12	28	7.0	4	100.0	100.0		
		WEEK 7	24MAY95	40	4	36	9.0	4	100.0	100.0		
		WEEK 8	31MAY95	110	30	80	15.0	5	100.0	100.0		
				110	30	80	15.0	6	100.0	100.0		
		WEEK 12	05JUL95	240	81	159	27.0	6	98.0	98.1		
		WEEK 16	31JUL95	240	113	127	26.0	6	81.0	81.4		
		WEEK 20	24AUG95	240	118	122	24.0	6	85.0	84.7		
		WEEK 24	21SEP95	240	90	150	28.0	6	89.0	89.3		
		WEEK 28	24OCT95	240	60	180	31.0	6	94.0	96.8		
		WEEK 32	21NOV95	240	90	150	168	6	89.0	14.9		
		DOWN	05DEC95	44	3	41	15.0	5	91.0	113.9		
		TITRATION				44	3	41	15.0	4	91.0	113.9
						44	3	41	15.0	3	91.0	113.9
						44	3	41	15.0	2	91.0	113.9
						44	3	41	15.0	1	91.0	113.9
		329.007.00139	77.8	WEEK 1	18MAY95	20	5	15	9.5	2	79.0	78.9
WEEK 2	25MAY95			20	7	13	7.0	2	93.0	92.9		
329.007.00143	96.2	WEEK 1	16NOV95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	22NOV95	20	9	11	6.0	2	92.0	91.7		
		DOWN	07DEC95	20	0	20	10.0	2	100.0	100.0		
TITRATION												
329.007.00146	100.0	WEEK 1	01FEB96	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	05FEB96	20	12	8	4.0	2	100.0	100.0		
		WEEK 3	12FEB96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	19FEB96	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	26FEB96	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	04MAR96	50	15	35	7.0	5	100.0	100.0		
		WEEK 7	11MAR96	50	15	35	7.0	5	100.0	100.0		
		WEEK 8	18MAR96	40	12	28	7.0	4	100.0	100.0		
		WEEK 12	15APR96	160	47	112	28.0	4	100.0	100.0		
		WEEK 16	13MAY96	320	198	122	28.0	5	100.0	100.0		
				320	198	122	28.0	4	100.0	100.0		

530

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.007.00146	100.0	WEEK 20	06JUN96	160	64	96	24.0	4	100.0	100.0
		WEEK 24	08JUL96	160	30	130	32.0	4	102.0	101.6
		WEEK 28	05AUG96	160	48	112	28.0	4	100.0	100.0
		WEEK 32	09SEP96	160	22	138	35.0	4	99.0	98.6
		DOWN	23SEP96	28	0	28	12.5	4	100.0	93.3
		TITRATION		28	0	28	12.5	3	100.0	93.3
				28	0	28	12.5	2	100.0	93.3
		28	0	28	12.5	2	100.0	93.3		
329.007.00269	93.3	WEEK 1	18APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	25APR96	20	6	14	7.0	2	100.0	100.0
329.007.00270	93.4	WEEK 1	16MAY96	20	7	13	7.0	2	93.0	92.9
		WEEK 2	23MAY96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	30MAY96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	06JUN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	13JUN96	40	14	26	7.0	4	93.0	92.9
		WEEK 6	20JUN96	40	14	26	7.0	4	95.0	92.9
329.007.00307	93.6	WEEK 1	23MAY96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	30MAY96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	06JUN96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	13JUN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	20JUN96	40	15	25	7.0	4	89.0	89.3
329.007.00308	.	WEEK 1	11JUL96	20	.	.	.	1	.	.
329.008.00159	89.8	WEEK 1	19SEP95	20	7	13	6.0	2	108.0	108.3
		WEEK 2	27SEP95	20	7	13	8.0	2	81.0	81.3
		WEEK 3	03OCT95	30	12	18	6.0	3	100.0	100.0
		WEEK 4	10OCT95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	16OCT95	50	22	28	6.0	5	93.0	93.3
		WEEK 6	24OCT95	50	10	40	8.0	5	100.0	100.0
		WEEK 7	31OCT95	50	19	31	7.0	5	89.0	88.6
		WEEK 8	14NOV95	40	0	40	13.0	4	77.0	76.9
		WEEK 12	26DEC95	160	20	140	42.0	4	83.0	83.3
		WEEK 16	23JAN96	160	.	.	27.0	4	.	.
		WEEK 20	.	160	.	.	.	.	.	.

531

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.008.00161	90.9	WEEK 1	22NOV95	20	9	11	5.0	2	110.0	110.0
		WEEK 2	29NOV95	20	7	13	7.0	2	93.0	92.9
		WEEK 3	07DEC95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	15DEC95	40	8	32	8.0	4	100.0	100.0
		WEEK 5	27DEC95	40	8	32	12.0	4	67.0	66.7
		WEEK 7	03JAN96	40	12	28	8.0	4	87.0	87.5
		WEEK 8	10JAN96	40	8	32	8.0	4	100.0	100.0
		WEEK 12	10JAN96	160	.	.	.	4	.	.
329.008.00187	95.5	WEEK 1	07DEC95	20	5	15	8.0	2	93.0	93.8
		WEEK 2	14DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	21DEC95	30	9	21	6.0	3	117.0	116.7
		WEEK 4	28DEC95	40	12	28	6.0	4	117.0	116.7
		WEEK 5	04JAN96	40	16	24	6.0	4	100.0	100.0
		WEEK 6	11JAN96	40	13	27	7.0	4	96.0	96.4
		WEEK 7	18JAN96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	26JAN96	40	12	28	8.0	4	88.0	87.5
329.008.00192	59.0	WEEK 1	11MAR96	20	8	12	7.0	2	85.0	85.7
		WEEK 2	18MAR96	20	9	11	6.0	2	92.0	91.7
		WEEK 3	25MAR96	30	25	5	6.0	3	28.0	27.8
		WEEK 4	03APR96	40	.	.	9.0	4	.	.
		WEEK 5	12APR96	40	22	18	6.0	4	75.0	75.0
329.008.00272	98.4	WEEK 1	10APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	17APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	26APR96	30	3	27	8.0	3	112.0	112.5
		WEEK 4	01MAY96	40	25	15	4.0	4	93.0	93.8
		WEEK 5	07MAY96	40	16	24	7.0	4	85.0	85.7
		WEEK 6	.	40	2	38	8.0	4	118.0	118.8
		WEEK 7	22MAY96	40	18	22	7.0	4	78.0	78.6
		WEEK 8	29MAY96	40	12	28	6.0	4	116.0	116.7
		WEEK 12	26JUN96	160	46	114	28.0	4	101.0	101.8
		WEEK 16	24JUL96	160	48	112	28.0	4	100.0	100.0
		WEEK 20	21AUG96	160	.	.	.	4	.	.
		WEEK 24	18SEP96	160	.	.	.	4	.	.
		329.008.00273	97.3	WEEK 1	24MAY96	20	6	14	7.0	2
WEEK 2	31MAY96			20	6	14	7.0	2	100.0	100.0
WEEK 3	10JUN96			30	0	30	12.0	3	83.0	83.3

532

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.008.00273	97.3	WEEK 4	17JUN96	40	14	26	8.0	4	81.0	81.3		
		WEEK 5	24JUN96	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	01JUL96	50	.	.	7.0	5	.	.		
		WEEK 7	11JUL96	60	0	60	11.0	6	100.0	90.9		
		WEEK 8	19JUL96	60	15	45	11.0	6	68.0	68.2		
		WEEK 12	04SEP96	240	.	.	.	6	.	.		
		WEEK 16	.	240	.	.	.	6	.	.		
329.009.00127	75.2	WEEK 1	17APR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	24APR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	01MAY95	30	11	19	7.0	3	91.0	90.5		
		WEEK 4	08MAY95	40	28	12	7.0	4	43.0	42.9		
		WEEK 5	15MAY95	40	20	20	7.0	4	71.5	71.4		
329.009.00132	94.8	WEEK 1	30MAY95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	06JUN95	20	7	13	7.0	2	93.0	92.9		
		WEEK 3	13JUN95	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	20JUN95	40	16	24	7.0	4	86.0	85.7		
		WEEK 5	27JUN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	05JUL95	40	8	32	8.0	4	100.0	100.0		
		WEEK 7	11JUL95	40	16	24	6.0	4	100.0	100.0		
		WEEK 8	19JUL95	40	12	28	8.0	4	88.0	87.5		
		WEEK 12	24AUG95	160	24	136	36.0	4	94.0	94.4		
		WEEK 16	15SEP95	160	84	76	22.0	4	86.0	86.4		
		WEEK 20	24OCT95	160	46	114	30.0	4	97.0	95.0		
		DOWN	08DEC95	58	19	25	12.0	4	89.0	83.3		
		TITRATION										
						58	19	25	12.0	3	89.0	83.3
						58	19	25	12.0	2	89.0	83.3
						58	19	25	12.0	2	89.0	83.3
		329.009.00134	99.5	WEEK 1	14JUL95	20	5	15	8.0	2	97.0	93.8
WEEK 2	19JUL95			20	10	10	5.0	2	100.0	100.0		
WEEK 3	26JUL95			30	9	21	7.0	3	100.0	100.0		
WEEK 4	03AUG95			40	8	32	8.0	4	100.0	100.0		
WEEK 5	08AUG95			40	20	20	5.0	4	100.0	100.0		
WEEK 6	15AUG95			40	12	28	7.0	4	100.0	100.0		
WEEK 7	24AUG95			40	4	36	9.0	4	100.0	100.0		
WEEK 8	29AUG95			40	20	20	5.0	4	100.0	100.0		

533

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.009.00134	99.5	DOWN TITRATION	12SEP95	44	18	26	11.0	3	100.0	78.8
329.009.00137	99.5	WEEK 1	17OCT95	20	7	13	7.0	2	100.0	92.9
		WEEK 2	24OCT95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	31OCT95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	07NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	14NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 6	21NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 7	28NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 8	05DEC95	40	12	28	7.0	4	100.0	100.0
329.009.00171	50.0	WEEK 1	14NOV95	20	12	8	7.0	2	57.0	57.1
329.009.00172	97.9	WEEK 1	20NOV95	20	8	12	7.0	2	86.0	85.7
		WEEK 2	27NOV95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	04DEC95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	11DEC95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	21DEC95	40	2	38	10.0	4	95.0	95.0
		WEEK 6	27DEC95	40	16	24	6.0	4	100.0	100.0
		WEEK 7	03JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 8	09JAN96	40	16	24	6.0	4	100.0	100.0
		WEEK 12	07FEB96	160	46	114	29.0	4	98.0	98.3
		WEEK 16	04MAR96	160	70	90	26.0	4	87.0	86.5
		WEEK 20	01APR96	160	62	98	28.0	4	88.0	87.5
		WEEK 24	29APR96	160	67	93	28.0	4	83.0	83.0
		WEEK 28	10JUN96	160	27	133	42.0	4	79.0	79.2
		WEEK 32	08JUL96	160	66	94	28.0	4	84.0	83.9
		DOWN TITRATION	22JUL96	44	16	28	14.0	4	100.0	93.3
				44	16	28	14.0	3	100.0	93.3
				44	16	28	14.0	2	100.0	93.3
				44	16	28	14.0	2	100.0	93.3
329.009.00194	100.0	WEEK 1	12DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	19DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	27DEC95	30	6	24	8.0	3	100.0	100.0
		WEEK 4	02JAN96	40	16	24	6.0	4	100.0	100.0
		WEEK 5	09JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	16JAN96	40	12	28	7.0	4	100.0	100.0

534

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.009.00194	100.0	WEEK 7	23JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 8	30JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 12	27FEB96	160	56	104	28.0	4	93.0	92.9
		WEEK 16	02APR96	160	20	140	35.0	4	100.0	100.0
		WEEK 20	30APR96	160	63	97	28.0	4	87.0	86.6
		WEEK 24	04JUN96	160	26	134	35.0	4	96.0	95.7
		DOWN TITRATION	.	44	.	.	.	4	.	.
329.009.00195	98.5	WEEK 1	19DEC95	20	12	8	4.0	2	100.0	100.0
		WEEK 2	27DEC95	20	4	16	8.0	2	100.0	100.0
		WEEK 3	02JAN96	30	13	17	6.0	3	94.0	94.4
		WEEK 4	08JAN96	40	16	24	6.0	4	100.0	100.0
329.009.00199	82.7	WEEK 1	23JAN96	20	7	13	7.0	2	93.0	92.9
		WEEK 2	29JAN96	20	11	9	6.0	2	75.0	75.0
		WEEK 3	07FEB96	30	6	24	9.0	3	89.0	88.9
		WEEK 4	14FEB96	40	16	24	7.0	4	86.0	85.7
		WEEK 5	21FEB96	40	14	26	7.0	4	93.0	92.9
		WEEK 6	28FEB96	50	21	29	7.0	5	83.0	82.9
		WEEK 7	06MAR96	50	23	27	7.0	5	77.0	77.1
		WEEK 8	13MAR96	50	25	25	7.0	5	71.0	71.4
329.009.00203	90.7	WEEK 1	11MAR96	20	5	14	7.0	2	100.0	100.0
		WEEK 2	19MAR96	20	5	15	8.0	2	94.0	93.8
		WEEK 3	26MAR96	30	10	20	7.0	3	95.0	95.2
329.009.00236	88.0	WEEK 1	06JAN97	20	7	13	7.0	2	93.0	92.9
		WEEK 2	15JAN97	20	4	16	9.0	2	89.0	88.9
		WEEK 3	20JAN97	30	15	15	5.0	3	100.0	100.0
		WEEK 4	27JAN97	40	18	22	7.0	4	79.0	78.6
329.009.00239	91.3	WEEK 1	25NOV96	20	8	12	6.0	2	100.0	100.0
		WEEK 2	02DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	09DEC96	30	10	20	7.0	3	95.0	95.2
		WEEK 4	16DEC96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	23DEC96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	30DEC96	40	24	16	7.0	4	57.0	57.1
		WEEK 7	06JAN97	40	16	24	7.0	4	86.0	85.7
		WEEK 8	15JAN97	40	4	36	9.0	4	100.0	100.0

535

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.009.00239	91.3	WEEK 12	18FEB97	160	28	132	34.0	4	97.0	97.1	
		WEEK 16	17MAR97	160	72	88	27.0	4	81.0	81.5	
		WEEK 20	14APR97	160	64	96	28.0	4	86.0	85.7	
		WEEK 24	12MAY97	160	48	.	28.0	4	.	.	
329.009.00262	94.9	WEEK 1	24FEB97	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	03MAR97	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	07MAR97	30	20	10	4.0	3	83.0	83.3	
		WEEK 4	17MAR97	40	0	40	10.0	4	100.0	100.0	
		WEEK 5	24MAR97	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	31MAR97	40	12	28	7.0	4	100.0	100.0	
		WEEK 7	07APR97	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	14APR97	40	16	24	7.0	4	86.0	85.7	
329.009.00264	93.4	WEEK 1	08NOV96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	11NOV96	20	15	5	3.0	2	83.0	83.3	
		WEEK 3	18NOV96	30	10	20	7.0	3	95.0	95.2	
		WEEK 4	25NOV96	40	14	26	7.0	4	93.0	92.9	
		WEEK 5	02DEC96	40	14	26	7.0	4	93.0	92.9	
		WEEK 6	11DEC96	40	10	30	9.0	4	83.0	83.3	
		WEEK 7	16DEC96	40	20	20	5.0	4	100.0	100.0	
		WEEK 8	23DEC96	40	12	28	7.0	4	100.0	100.0	
329.009.00301	100.0	WEEK 1	26MAR96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	05APR96	20	1	19	10.0	2	95.0	95.0	
		WEEK 3	12APR96	30	8	22	7.0	3	105.0	104.8	
		WEEK 4	16APR96	40	24	16	4.0	4	100.0	100.0	
		WEEK 5	23APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	30APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 7	07MAY96	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	14MAY96	40	12	28	7.0	4	100.0	100.0	
		WEEK 12	11JUN96	160	94	66	28.0	4	59.0	58.9	
		DOWN	25JUN96	44	16	28	15.0	4	100.0	93.3	
		TITRATION			44	16	28	15.0	3	100.0	93.3
					44	16	28	15.0	2	100.0	93.3
					44	16	28	15.0	2	100.0	93.3
329.009.00305	92.7	WEEK 1	14MAY96	20	7	13	7.0	2	93.0	92.9	
		WEEK 2	21MAY96	20	6	14	7.0	2	100.0	100.0	

536

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.009.00305	92.7	WEEK 3	28MAY96	30	12	18	7.0	3	86.0	85.7	
		WEEK 4	04JUN96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	11JUN96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	19JUN96	40	12	28	8.0	4	88.0	87.5	
		WEEK 7	25JUN96	40	18	22	6.0	4	92.0	91.7	
		WEEK 8	03JUL96	40	12	28	8.0	4	88.0	87.5	
		WEEK 12	06AUG96	160	49	111	35.0	4	79.0	79.3	
		WEEK 16	27AUG96	160	93	67	21.0	4	80.0	79.8	
		WEEK 20	24SEP96	160	64	96	28.0	4	86.0	85.7	
		WEEK 24	29OCT96	160	40	120	35.0	4	86.0	85.7	
		WEEK 28	03DEC96	160	38	122	35.0	4	87.0	87.1	
		WEEK 32	10JAN97	160	30	130	38.0	4	86.0	85.5	
		DOWN	28JAN97	44	20	24	18.0	4	86.0	80.0	
		TITRATION			44	20	24	18.0	3	86.0	80.0
					44	20	24	18.0	2	86.0	80.0
					44	20	24	18.0	2	86.0	80.0
		329.009.00325	98.9	WEEK 1	03SEP96	20	6	14	7.0	2	100.0
WEEK 2	09SEP96			20	8	12	6.0	2	100.0	100.0	
WEEK 3	16SEP96			30	9	21	7.0	3	100.0	100.0	
WEEK 4	23SEP96			40	12	28	7.0	4	100.0	100.0	
WEEK 5	30SEP96			40	12	28	7.0	4	100.0	100.0	
WEEK 6	10OCT96			40	2	38	10.0	4	95.0	95.0	
WEEK 7	14OCT96			40	24	16	4.0	4	100.0	100.0	
WEEK 8	21OCT96			40	12	28	7.0	4	100.0	100.0	
WEEK 12	18NOV96			160	52	108	28.0	4	96.0	96.4	
WEEK 16	16DEC96			160	60	100	28.0	4	89.0	89.3	
DOWN	30DEC96			44	16	28	12.0	4	100.0	93.3	
TITRATION					44	16	28	12.0	3	100.0	93.3
					44	16	28	12.0	2	100.0	93.3
					44	16	28	12.0	2	100.0	93.3
329.009.00326	93.4	WEEK 1	09SEP96	20	12	8	4.0	2	100.0	100.0	
		WEEK 2	16SEP96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	23SEP96	30	8	21	7.0	3	100.0	100.0	
		WEEK 4	30SEP96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	07OCT96	40	12	28	7.0	4	100.0	100.0	
		WEEK 6	17OCT96	40	12	28	10.0	4	70.0	70.0	

537

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.009.00326	93.4	WEEK 7	24OCT96	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	28OCT96	40	24	16	4.0	4	100.0	100.0	
		WEEK 12	25NOV96	160	48	112	28.0	4	100.0	100.0	
		WEEK 16	16DEC96	160	76	84	21.0	4	100.0	100.0	
		DOWN	28DEC96	44	16	28	12.0	4	100.0	93.3	
		TITRATION									
					44	16	28	12.0	3	100.0	93.3
					44	16	28	12.0	2	100.0	93.3
					44	16	28	12.0	2	100.0	93.3
329.010.00279	100.4	WEEK 1	29MAR96	20	3	17	7.0	2	120.0	121.4	
		WEEK 2	05APR96	20	8	12	7.0	2	86.0	85.7	
		WEEK 3	12APR96	30	9	21	7.0	3	100.0	100.0	
		WEEK 4	19APR96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	25APR96	50	20	30	6.0	5	100.0	100.0	
		WEEK 6	03MAY96	60	12	48	8.0	6	100.0	100.0	
		WEEK 7	10MAY96	60	18	42	7.0	6	100.0	100.0	
		WEEK 8	17MAY96	60	18	42	7.0	6	100.0	100.0	
		WEEK 12	14JUN96	276	111	165	28.0	6	98.0	98.2	
		WEEK 16	11JUL96	240	78	162	27.0	6	100.0	100.0	
		WEEK 20	08AUG96	240	72	168	28.0	6	100.0	100.0	
		WEEK 24	05SEP96	240	70	170	28.0	6	101.0	101.2	
		WEEK 28	02OCT96	240	78	162	27.0	6	100.0	100.0	
		WEEK 32	06NOV96	240	85	155	34.0	6	90.0	84.7	
					240	85	155	34.0	5	90.0	84.7
		DOWN	22NOV96	44	0	44	16.0	5	100.0	100.0	
		TITRATION									
					44	0	44	16.0	4	100.0	100.0
					44	0	44	16.0	3	100.0	100.0
					44	0	44	16.0	2	100.0	100.0
			44	0	44	16.0	2	100.0	100.0		
329.010.00281	100.8	WEEK 1	02AUG96	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	09AUG96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	19AUG96	30	0	30	10.0	3	100.0	100.0	
		WEEK 4	26AUG96	40	12	28	7.0	4	100.0	100.0	
		WEEK 5	04SEP96	50	3	47	10.0	5	94.0	94.0	
		WEEK 6	09SEP96	60	30	30	6.0	6	83.3	83.3	
		WEEK 7	18SEP96	60	6	54	9.0	6	100.0	100.0	
		WEEK 8	25SEP96	60	18	42	7.0	6	100.0	100.0	

538

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.010.00281	100.8	WEEK 12	25OCT96	240	60	180	30.0	6	100.0	100.0
		WEEK 16	20NOV96	240	93	147	26.0	6	94.0	94.2
		WEEK 20	20DEC96	240	78	162	30.0	6	90.0	90.0
		WEEK 24	03JAN97	240	156	84	14.0	6	100.0	100.0
		DOWN	29JAN97	44	0	44	16.0	5	100.0	100.0
		TITRATION		44	0	44	16.0	4	100.0	100.0
				44	0	44	16.0	3	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
				44	0	44	16.0	2	100.0	100.0
329.011.00163	97.2	WEEK 1	01DEC95	20	8	12	7.0	2	85.7	85.7
		WEEK 2	11DEC95	20	0	20	10.0	2	100.0	100.0
		WEEK 3	18DEC95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	27DEC95	40	24	16	9.0	4	44.4	44.4
329.011.00208	100.0	WEEK 1	11SEP96	20	8	12	6.0	2	100.0	100.0
		WEEK 2	17SEP96	20	8	12	6.0	2	100.0	100.0
		WEEK 3	26SEP96	30	3	27	9.0	3	100.0	100.0
		WEEK 4	03OCT96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	10OCT96	50	15	35	7.0	5	100.0	100.0
		WEEK 6	17OCT96	60	18	42	7.0	6	100.0	100.0
		WEEK 7	24OCT96	60	18	42	7.0	6	100.0	100.0
		WEEK 8	03NOV96	60	0	60	10.0	6	100.0	100.0
		WEEK 12	08NOV96	240	213	27	5.0	6	100.0	90.0
		DOWN	23NOV96	44	16	28	.	5	.	75.7
		TITRATION		44	16	28	.	4	.	75.7
				44	16	28	.	3	.	75.7
				44	16	28	.	2	.	75.7
				44	16	28	.	1	.	75.7
329.011.00209	98.6	WEEK 1	19SEP96	20	2	18	9.0	2	100.0	100.0
		WEEK 2	26SEP96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	03OCT96	30	11	19	7.0	3	90.0	90.5
		WEEK 4	11OCT96	40	8	32	8.0	4	100.0	100.0
		WEEK 5	17OCT96	40	16	24	6.0	4	100.0	100.0
		WEEK 6	24OCT96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	01NOV96	40	8	32	8.0	4	100.0	100.0
		WEEK 8	11NOV96	50	1	49	10.0	5	98.0	98.0

539

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.011.00209	98.6	WEEK 12	18DEC96	200	25	175	37.0	5	95.0	94.6
		DOWN TITRATION	18DEC96	44	.	.	.	5	.	.
329.011.00284	100.0	WEEK 1	28MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	05APR96	20	4	16	8.0	2	100.0	100.0
		WEEK 3	11APR96	30	12	18	6.0	3	100.0	100.0
		WEEK 4	19APR96	40	8	32	8.0	4	100.0	100.0
		WEEK 5	25APR96	40	16	24	6.0	4	100.0	100.0
		WEEK 6	02MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	09MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	16MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 12	10JUN96	200	85	115	25.0	5	92.0	92.0
		WEEK 16	08JUL96	200	73	127	28.0	5	90.7	90.7
		WEEK 20	05AUG96	200	60	140	28.0	5	100.0	100.0
WEEK 24	.	200	.	.	.	5	.	.		
329.011.00286	95.1	WEEK 1	14JUN96	20	2	18	9.0	2	100.0	100.0
		WEEK 2	21JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	28JUN96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	08JUL96	40	2	38	10.0	4	95.0	95.0
		WEEK 5	17JUL96	50	8	42	9.0	5	93.0	93.3
		WEEK 6	24JUL96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	02AUG96	60	15	45	9.0	6	83.0	83.3
		WEEK 8	09AUG96	60	0	60	10.0	6	100.0	100.0
		WEEK 12	17SEP96	240	54	186	36.0	6	86.0	86.1
		WEEK 16	24OCT96	240	87	153	37.0	6	69.0	68.9
		WEEK 20	25NOV96	240	84	156	32.0	6	81.0	81.3
		WEEK 24	30DEC96	240	69	171	35.0	6	81.4	81.4
		WEEK 28	30DEC96	240	.	.	.	6	.	.
329.012.00026	.	WEEK 1	05DEC95	20	.	.	.	2	.	.
		WEEK 2	05DEC95	20	.	.	.	2	.	.
329.012.00219	99.0	WEEK 1	07JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	24JUN96	30	0	30	10.0	3	100.0	100.0
		WEEK 4	02JUL96	40	8	32	8.0	4	100.0	100.0
		WEEK 5	09JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	16JUL96	40	12	28	7.0	4	100.0	100.0

540

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.012.00219	99.0	WEEK 7	23JUL96	40	14	26	7.0	4	93.0	92.9
		WEEK 8	30JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 12	30AUG96	160	42	118	32.0	4	92.0	92.2
		WEEK 16	26SEP96	160	70	90	28.0	4	80.0	80.4
		WEEK 20	25OCT96	160	70	90	29.0	4	78.0	77.6
		WEEK 24	22NOV96	160	66	94	27.0	4	87.0	87.0
		WEEK 28	20DEC96	160	62	98	27.0	4	91.0	90.7
		WEEK 32	24JAN97	160	76	84	29.0	4	72.0	72.4
329.012.00221	100.0	WEEK 1	02JUL96	20	5	15	7.0	2	107.0	107.1
		WEEK 2	09JUL96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	16JUL96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	23JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	30JUL96	50	10	40	8.5	5	94.0	94.1
		WEEK 6	09AUG96	40	2	38	9.5	4	100.0	100.0
		WEEK 7	19AUG96	40	4	36	9.5	4	95.0	94.7
		WEEK 8	27AUG96	40	6	34	8.5	4	100.0	100.0
		WEEK 12	23SEP96	160	55	105	28.0	4	94.0	93.8
		WEEK 16	21OCT96	160	54	106	28.0	4	95.0	94.6
		WEEK 20	04NOV96	160	108	52	13.0	4	100.0	100.0
329.012.00223	98.5	WEEK 1	06SEP96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	16SEP96	20	.	.	.	2	.	.
		WEEK 3	23SEP96	30	8	22	7.5	3	98.0	97.8
		WEEK 4	01OCT96	40	10	30	8.0	4	94.0	93.8
329.012.00227	91.7	WEEK 1	27DEC96	20	3	17	9.0	2	94.0	94.4
		WEEK 2	06JAN97	20	16	4	10.0	2	80.0	20.0
		WEEK 3	15JAN97	30	4	26	9.0	3	96.0	96.3
		WEEK 4	24JAN97	40	4	36	9.0	4	100.0	100.0
		WEEK 5	04FEB97	44	0	44	11.0	4	100.0	100.0
		WEEK 6	14FEB97	40	2	38	10.0	4	95.0	95.0
		WEEK 7	20FEB97	50	20	30	6.0	5	100.0	100.0
		WEEK 8	25FEB97	50	25	25	5.0	5	100.0	100.0
		WEEK 12	27MAR97	240	72	168	30.0	6	93.0	93.3
		WEEK 16	25APR97	240	72	168	29.0	6	97.0	96.6
		WEEK 20	26MAY97	240	72	168	31.0	6	90.0	90.3
		WEEK 24	25JUN97	240	69	171	29.0	6	98.0	98.3
		WEEK 28	21JUL97	240	93	147	26.0	6	94.0	94.2
		WEEK 32	19AUG97	240	111	129	29.0	6	74.0	74.1

541

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=IMIPRAMINE -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.012.00227	91.7	DOWN TITRATION	24SEP97	42	10	32	16.0	5	76.0	72.7
				42	10	32	16.0	4	76.0	72.7
				42	10	32	16.0	3	76.0	72.7
				42	10	32	16.0	2	76.0	72.7
				42	10	32	16.0	2	76.0	72.7
329.012.00230	91.4	WEEK 1	07MAR97	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14MAR97	20	7	13	7.0	2	93.0	92.9
		WEEK 3	24MAR97	30	4	26	10.0	3	86.0	86.7
		WEEK 4	03APR97	40	0	40	10.0	4	100.0	100.0
		WEEK 5	11APR97	40	12	28	8.0	4	88.0	87.5
		WEEK 6	23APR97	40	0	40	10.0	4	100.0	100.0
		WEEK 7	02MAY97	40	8	32	11.0	4	73.0	72.7
		WEEK 8	08MAY97	50	20	30	6.0	5	100.0	100.0
		WEEK 12	16MAY97	200	181	19	5.0	5	76.0	76.0
		DOWN TITRATION	26MAY97	48	22	26	13.0	4	81.2	83.9
				48	22	26	13.0	3	81.2	83.9
				48	22	26	13.0	2	81.2	83.9
				48	22	26	13.0	2	81.2	83.9

542

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.001.00062	84.9	WEEK 1	27OCT94	20	8	12	7.0	2	86.0	85.7		
		WEEK 2	03NOV94	20	10	10	7.0	2	71.0	71.4		
		WEEK 3	10NOV94	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	15NOV94	40	20	20	5.0	4	100.0	100.0		
329.001.00064	100.0	WEEK 1	16NOV94	20	8	12	6.0	2	100.0	100.0		
		WEEK 2	22NOV94	20	8	12	6.0	2	100.0	100.0		
		WEEK 3	29NOV94	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	06DEC94	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	13DEC94	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	20DEC94	40	12	28	7.0	4	100.0	100.0		
		WEEK 7	27DEC94	40	12	28	7.0	4	100.0	100.0		
		WEEK 8	03JAN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 12	31JAN95	160	48	112	28.0	4	100.0	100.0		
		WEEK 16	28FEB95	160	48	112	28.0	4	100.0	100.0		
		WEEK 20	28MAR95	160	48	112	28.0	4	100.0	100.0		
		DOWN	14APR95	25	0	25	17.0	4	100.0	36.8		
				TITRATION								
		329.001.00069	100.0	WEEK 1	23FEB95	20	6	14	7.0	2	100.0	100.0
WEEK 2	02MAR95			20	6	14	7.0	2	100.0	100.0		
WEEK 3	09MAR95			30	9	21	7.0	3	100.0	100.0		
WEEK 4	16MAR95			40	12	28	7.0	4	100.0	100.0		
WEEK 5	23MAR95			40	12	28	7.0	4	100.0	100.0		
WEEK 6	30MAR95			40	12	28	7.0	4	100.0	100.0		
WEEK 7	06APR95			50	15	35	7.0	5	100.0	100.0		
WEEK 8	13APR95			60	18	42	7.0	6	100.0	100.0		
329.001.00071	100.0	WEEK 1	02MAR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	09MAR95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	16MAR95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	23MAR95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	30MAR95	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	06APR95	50	8	42	7.0	6	100.0	100.0		
		WEEK 7	13APR95	60	18	42	7.0	6	100.0	100.0		
		WEEK 8	20APR95	60	18	42	7.0	6	100.0	100.0		
329.001.00123	97.5	WEEK 1	12JAN96	20	4	16	8.0	2	100.0	100.0		
		WEEK 2	18JAN96	20	8	12	6.0	2	100.0	100.0		
		WEEK 3	25JAN96	30	9	21	7.0	3	100.0	100.0		

543

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.001.00123	97.5	WEEK 4	01FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	08FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	15FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	22FEB96	40	16	24	7.0	4	86.0	85.7
329.001.00207	100.0	WEEK 1	06MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	13MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	20MAR96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	26MAR96	40	16	24	6.0	4	100.0	100.0
		WEEK 5	03APR96	40	8	32	8.0	4	100.0	100.0
		WEEK 6	10APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	17APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 8	24APR96	40	12	28	7.0	4	100.0	100.0
329.002.00049	97.6	WEEK 1	15MAR95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	22MAR95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	29MAR95	30	10	20	7.0	3	95.0	95.2
		WEEK 4	05APR95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	12APR95	50	15	35	7.0	5	100.0	100.0
		WEEK 6	19APR95	60	18	42	7.0	6	100.0	100.0
		WEEK 7	27APR95	60	17	43	7.5	6	93.0	95.6
		WEEK 8	05MAY95	60	12	48	7.5	6	94.0	106.7
329.002.00059	96.3	WEEK 1	17NOV94	20	5	15	7.0	2	107.0	107.1
		WEEK 2	23NOV94	20	8	12	6.0	2	100.0	100.0
		WEEK 3	01DEC94	30	6	24	8.0	3	100.0	100.0
		WEEK 4	08DEC94	40	16	24	7.0	4	86.0	85.7
		WEEK 5	15DEC94	50	15	35	7.0	5	100.0	100.0
		WEEK 6	22DEC94	60	18	42	7.0	6	100.0	100.0
		WEEK 7	29DEC94	60	18	42	7.0	6	100.0	100.0
		WEEK 8	05JAN95	60	18	42	7.0	6	100.0	100.0
329.002.00060	99.2	WEEK 1	07FEB95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14FEB95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	21FEB95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	28FEB95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	07MAR95	50	15	35	7.0	5	100.0	100.0
		WEEK 6	14MAR95	60	17	43	7.0	6	102.0	102.4
		WEEK 7	21MAR95	60	21	39	7.0	6	92.8	92.9
		WEEK 8	28MAR95	60	18	42	7.0	6	100.0	100.0

544

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.002.00060	99.2	WEEK 12	25APR95	240	120	120	28.0	6	71.0	71.4
329.002.00097	96.4	WEEK 1	10JAN95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	18JAN95	20	7	13	8.0	2	81.0	81.3
		WEEK 3	24JAN95	30	12	18	6.0	3	100.0	100.0
		WEEK 4	31JAN95	40	14	26	6.0	4	108.0	108.3
		WEEK 5	07FEB95	50	18	32	7.0	5	91.0	91.4
		WEEK 6	14FEB95	60	18	42	7.0	6	100.0	100.0
		WEEK 7	21FEB95	60	18	42	7.0	6	100.0	100.0
		WEEK 8	02MAR95	60	9	51	9.0	6	94.0	94.4
		WEEK 12	30MAR95	240	117	123	28.0	6	73.0	73.2
		WEEK 16	27APR95	240	51	189	28.0	6	112.0	112.5
		WEEK 20	23MAY95	240	90	150	26.0	6	96.0	96.2
		WEEK 24	29JUN95	240	104	136	37.0	6	61.0	61.3
		WEEK 28	01AUG95	240	87	153	32.0	6	80.0	79.7
		WEEK 32	05SEP95	240	57	183	34.0	6	89.0	89.7
		DOWN	01NOV95	44	0	44	15.0	5	116.0	118.9
		TITRATION								
				44	0	44	15.0	4	116.0	118.9
				44	0	44	15.0	3	116.0	118.9
				44	0	44	15.0	2	116.0	118.9
				44	0	44	15.0	1	116.0	118.9
329.002.00101	94.2	WEEK 1	04APR95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	13APR95	20	7	13	8.0	2	81.0	81.3
		WEEK 3	20APR95	30	13	17	7.0	3	80.9	81.0
		WEEK 4	27APR95	40	14	26	7.0	4	92.8	92.9
		WEEK 5	04MAY95	50	15	35	7.0	5	100.0	100.0
		WEEK 6	11MAY95	60	18	42	7.0	6	100.0	100.0
		WEEK 7	18MAY95	60	21	39	7.0	6	92.8	92.9
		WEEK 8	25MAY95	60	18	42	7.0	6	100.0	100.0
		WEEK 12	22JUN95	.	.	.	28.0	6	94.0	.
		WEEK 16	27JUN95	.	3	12	5.0	6	100.0	40.0
		DOWN	11JUL95	44	0	44	14.0	5	100.0	137.5
		TITRATION								
				44	0	44	14.0	4	100.0	137.5
				44	0	44	14.0	3	100.0	137.5
				44	0	44	14.0	2	100.0	137.5
				44	0	44	14.0	1	100.0	137.5

545

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.002.00107	96.2	WEEK 1	01FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	08FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	13FEB96	30	15	15	5.0	3	100.0	100.0
		WEEK 4	20FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	27FEB96	40	16	24	7.0	4	86.0	85.7
		WEEK 6	05MAR96	40	14	26	7.0	4	93.0	92.9
		WEEK 7	15MAR96	50	2	48	10.0	5	96.0	96.0
		WEEK 8	21MAR96	60	24	36	6.0	6	100.0	100.0
		WEEK 12	23APR96	240	120	120	33.0	6	60.0	60.6
		WEEK 16	21MAY96	240	82	158	28.0	6	94.0	94.0
		WEEK 20	20JUN96	240	39	201	30.0	6	111.0	111.7
		WEEK 24	18JUL96	240	39	201	35.0	6	95.0	95.7
		WEEK 28	29AUG96	240	30	210	35.0	6	100.0	100.0
		WEEK 32	26SEP96	240	66	174	29.0	6	100.0	100.0
		DOWN TITRATION	09OCT96	44	0	44	16.0	5	100.0	55.0
329.002.00241	98.6	WEEK 1	13FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	22FEB96	20	2	18	9.0	2	100.0	100.0
		WEEK 3	27FEB96	30	18	12	5.0	3	80.0	80.0
		WEEK 4	05MAR96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	12MAR96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	19MAR96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	26MAR96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	02APR96	60	18	42	7.0	6	100.0	100.0
		WEEK 12	30APR96	240	75	165	28.0	6	98.0	98.2
		WEEK 16	.	240	.	.	.	6	.	.
329.002.00246	95.7	WEEK 1	25APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	02MAY96	20	7	13	7.0	2	93.0	92.9
		WEEK 3	09MAY96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	16MAY96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	23MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 6	30MAY96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	04JUN96	50	25	25	5.0	5	100.0	100.0
		WEEK 8	18JUN96	120	46	74	14.0	6	88.0	88.1
329.002.00320	99.2	WEEK 1	23MAY96	20	5	15	7.0	2	107.0	107.1
		WEEK 2	30MAY96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	04JUN96	30	13	17	5.0	3	113.0	113.3

546

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.002.00320	99.2	WEEK 4	18JUN96	80	25	54	14.0	4	96.0	96.4		
		WEEK 5	25JUN96	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	02JUL96	50	15	35	7.0	5	100.0	100.0		
		WEEK 7	09JUL96	60	18	42	7.0	6	100.0	100.0		
		WEEK 8	16JUL96	60	21	39	7.0	6	92.0	92.9		
		WEEK 12	13AUG96	240	74	166	28.0	6	99.0	98.8		
		WEEK 16	17SEP96	240	47	193	34.0	6	95.0	94.6		
		WEEK 20	.	240	195	45	8.0	6	94.0	93.8		
		DOWN	08OCT96	44	0	44	12.0	5	100.0	73.3		
		TITRATION										
329.002.00323	92.3	WEEK 1	19NOV96	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	26NOV96	20	6	14	7.0	4	100.0	50.0		
		WEEK 3	05DEC96	30	3	27	9.0	3	100.0	100.0		
		WEEK 4	10DEC96	40	20	20	5.0	4	100.0	100.0		
		WEEK 5	17DEC96	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	26DEC96	40	6	34	9.0	4	94.0	94.4		
		WEEK 7	02JAN97	40	12	28	7.0	4	100.0	100.0		
		WEEK 8	09JAN97	40	12	28	7.0	4	100.0	100.0		
		WEEK 12	04FEB97	160	57	103	26.0	4	99.0	99.0		
		WEEK 16	04MAR97	160	50	110	28.0	4	99.0	98.2		
		WEEK 20	03APR97	200	50	150	30.0	5	100.0	100.0		
		WEEK 24	30APR97	200	67	133	27.0	5	98.0	98.5		
		WEEK 28	27MAY97	200	67	133	29.0	5	91.0	91.7		
		WEEK 32	12JUN97	200	120	80	16.0	5	100.0	100.0		
		DOWN	26JUN97	34	0	34	14.0	5	100.0	87.2		
		TITRATION										
						34	0	34	14.0	4	100.0	87.2
						34	0	34	14.0	3	100.0	87.2
						34	0	34	14.0	2	100.0	87.2
						34	0	34	14.0	1	100.0	87.2
329.003.00074	85.4	WEEK 1	01FEB95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	08FEB95	20	7	13	7.0	2	93.0	92.9		
		WEEK 3	15FEB95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	21FEB95	40	18	22	6.0	4	92.0	91.7		
		WEEK 5	01MAR95	50	12	38	8.0	5	95.0	95.0		
		WEEK 6	15MAR95	60	3	57	15.0	6	63.0	63.3		
		WEEK 8	22MAR95	60	21	39	7.0	6	93.0	92.9		
		WEEK 12	19APR95	240	66	174	28.0	6	103.5	103.6		

547

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.003.00074	85.4	WEEK 16	17MAY95	240	78	162	27.0	6	100.0	100.0
		WEEK 20	19JUN95	240	73	167	34.0	6	68.0	81.9
		WEEK 24	24JUL95	240	61	179	35.0	6	85.0	85.2
		WEEK 28	30AUG95	240	51	189	37.0	6	85.0	85.1
		WEEK 32	11OCT95	240	0	240	42.0	6	95.0	95.2
		DOWN TITRATION	.	44	.	.	.	5	.	.
329.003.00078	100.0	WEEK 1	02MAY95	20	8	12	6.0	2	100.0	100.0
		WEEK 2	10MAY95	20	4	16	8.0	2	100.0	100.0
		WEEK 3	17MAY95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	24MAY95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	30MAY95	50	20	30	6.0	5	100.0	100.0
		WEEK 6	07JUN95	60	12	48	8.0	6	100.0	100.0
		WEEK 7	15JUN95	60	12	48	8.0	6	100.0	100.0
		WEEK 8	21JUN95	60	18	42	6.0	6	116.0	116.7
329.003.00080	96.1	WEEK 1	04DEC95	20	7	13	7.0	2	92.0	92.9
		WEEK 2	07DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	18DEC95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	29DEC95	40	4	36	11.0	4	80.0	81.8
		WEEK 5	04JAN96	40	14	26	6.0	4	108.0	108.3
		WEEK 6	10JAN96	50	19	31	6.0	5	103.0	103.3
		WEEK 7	17JAN96	60	18	42	7.0	6	100.0	100.0
		WEEK 8	24JAN96	60	21	39	7.0	6	93.0	92.9
329.003.00085	87.4	WEEK 1	14NOV94	20	8	12	7.0	2	86.0	85.7
		WEEK 2	21NOV94	20	6	14	7.0	2	100.0	100.0
		WEEK 3	28NOV94	30	9	21	7.0	3	100.0	100.0
		WEEK 4	05DEC94	40	11	29	7.0	4	100.0	103.6
		WEEK 5	12DEC94	50	29	21	7.0	5	60.0	60.0
		WEEK 6	19DEC94	60	18	42	7.0	6	100.0	100.0
		WEEK 7	27DEC94	60	17	43	8.0	6	90.0	89.6
		WEEK 8	03JAN95	60	27	33	7.0	6	78.0	78.6
329.003.00086	103.8	WEEK 1	05DEC94	20	4	16	7.0	2	100.0	114.3
		WEEK 2	12DEC94	20	7	13	7.0	2	93.0	92.9
		WEEK 3	19DEC94	30	9	21	7.0	3	100.0	100.0
		WEEK 4	27DEC94	40	8	32	8.0	4	100.0	100.0
		WEEK 5	03JAN95	50	15	35	7.0	5	100.0	100.0

548

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.003.00086	103.8	WEEK 6	09JAN95	60	14	46	6.0	6	128.0	127.8
		WEEK 7	17JAN95	60	12	48	7.0	6	120.0	114.3
		WEEK 8	23JAN95	60	24	36	6.0	6	100.0	100.0
		WEEK 12	13FEB95	240	87	153	28.0	6	91.0	91.1
		WEEK 16	28MAR95	240	45	195	35.0	6	93.0	92.9
		WEEK 20	25APR95	240	87	153	28.0	6	91.0	91.1
		WEEK 24	30MAY95	240	39	201	35.0	6	96.0	95.7
		WEEK 28	11JUL95	240	18	222	41.0	6	90.0	90.2
		WEEK 32	17AUG95	240	78	162	36.0	6	75.0	75.0
		DOWN	02SEP95	44	3	41	19.0	5	72.0	107.9
		TITRATION		44	3	41	19.0	4	72.0	107.9
				44	3	41	19.0	3	72.0	107.9
				44	3	41	19.0	2	72.0	107.9
				44	3	41	19.0	1	72.0	107.9
329.003.00094	95.5	WEEK 1	31OCT95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	07NOV95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	14NOV95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	21NOV95	40	14	26	7.0	4	92.0	92.9
		WEEK 5	28NOV95	50	15	35	7.0	5	100.0	100.0
		WEEK 6	05DEC95	60	18	42	7.0	6	100.0	100.0
		WEEK 7	12DEC95	60	21	39	7.0	6	90.0	92.9
		WEEK 8	19DEC95	60	18	42	7.0	6	100.0	100.0
329.003.00251	.	WEEK 1	04APR96	20	.	.	.	2	.	.
		WEEK 2	09APR96	20	.	.	.	2	.	.
		WEEK 3	.	30	.	.	.	3	.	.
329.003.00252	97.3	WEEK 1	16APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	23APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	30APR96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	09MAY96	40	6	34	9.0	4	94.0	94.4
		WEEK 5	14MAY96	40	20	20	5.0	4	100.0	100.0
		WEEK 6	21MAY96	50	20	30	7.0	5	85.0	85.7
		WEEK 7	28MAY96	40	0	40	8.0	4	125.0	125.0
		WEEK 8	04JUN96	40	0	40	8.0	4	125.0	125.0
329.003.00291	100.0	WEEK 1	15JUL96	20	.	.	.	2	.	.
		WEEK 2	24JUL96	20	.	.	15.0	2	.	.

549

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.003.00291	100.0	WEEK 3	31JUL96	30	9	21	8.0	3	87.5	87.5
		WEEK 4	07AUG96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	14AUG96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	21AUG96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	28AUG96	40	12	28	8.0	4	88.0	87.5
		WEEK 8	04SEP96	50	5	45	8.0	5	112.0	112.5
		WEEK 12	02OCT96	200	58	142	27.0	5	105.0	105.2
		WEEK 16	30OCT96	200	.	.	29.0	5	.	.
WEEK 20	.	200	.	.	29.0	5	.	.		
329.003.00315	94.2	WEEK 1	21NOV96	20	3	17	10.0	2	85.0	85.0
		WEEK 2	26NOV96	20	11	9	5.0	2	90.0	90.0
		WEEK 3	03DEC96	30	8	22	8.0	3	91.6	91.7
		WEEK 4	12DEC96	40	6	34	10.0	4	85.0	85.0
		WEEK 5	17DEC96	40	20	20	6.0	4	83.0	83.3
		WEEK 6	23DEC96	40	18	22	6.0	4	92.0	91.7
		WEEK 7	.	40	14	26	8.0	4	100.0	81.3
		WEEK 8	07JAN97	40	12	28	7.0	4	100.0	100.0
329.003.00316	110.0	WEEK 1	23DEC96	20	8	12	7.0	2	86.0	85.7
		WEEK 2	30DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	07JAN97	30	24	6	8.0	3	25.0	25.0
		WEEK 4	14JAN97	40	12	28	7.0	4	100.0	100.0
		WEEK 5	21JAN97	50	19	31	7.0	5	89.0	88.6
		WEEK 6	28JAN97	60	21	39	7.0	6	93.0	92.9
		WEEK 7	04FEB97	60	24	36	6.0	6	100.0	100.0
		WEEK 8	11FEB97	104	18	86	16.0	6	100.0	89.6
329.004.00016	98.2	WEEK 1	20MAR95	20	4	16	7.0	2	107.0	114.3
		WEEK 2	29MAR95	20	2	18	9.0	2	100.0	100.0
		WEEK 3	05APR95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	12APR95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	19APR95	40	12	28	7.0	4	100.0	100.0
329.004.00018	102.6	WEEK 1	11MAY95	20	7	13	7.0	2	98.0	92.9
		WEEK 2	18MAY95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	25MAY95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	01JUN95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	08JUN95	50	7	43	7.0	5	100.0	122.9
		WEEK 6	19JUN95	50	0	50	11.0	5	100.0	90.9

550

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.004.00018	102.6	WEEK 7	22JUN95	60	36	24	6.0	6	100.0	66.7		
		WEEK 8	29JUN95	60	18	42	7.0	6	100.0	100.0		
		DOWN	13JUL95	44	1	42	15.0	5	100.0	56.0		
		TITRATION										
329.004.00020	56.3	WEEK 1	16NOV95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	24NOV95	20	16	4	8.0	2	10.0	25.0		
329.004.00213	97.3	WEEK 1	08AUG96	20	9	11	7.0	2	79.0	78.6		
		WEEK 2	15AUG96	20	8	12	7.0	2	86.0	85.7		
		WEEK 3	21AUG96	30	12	18	7.0	3	100.0	85.7		
		WEEK 4	29AUG96	40	10	30	8.0	4	100.0	93.8		
		WEEK 5	03SEP96	40	20	20	5.0	4	91.0	100.0		
		WEEK 6	10SEP96	40	12	28	7.0	4	93.0	100.0		
		WEEK 7	17SEP96	40	12	28	7.0	4	93.0	100.0		
		WEEK 8	24SEP96	40	8	32	9.0	4	89.0	88.9		
		WEEK 12	22OCT96	160	56	104	28.0	4	93.0	92.9		
		WEEK 16	19NOV96	160	48	112	29.0	4	97.0	96.6		
		WEEK 20	20DEC96	160	40	120	32.0	4	94.0	93.8		
		WEEK 24	21JAN97	160	36	124	32.0	4	97.0	96.9		
		WEEK 28	18FEB97	160	50	110	28.0	4	98.0	98.2		
		WEEK 32	19MAR97	160	44	116	29.0	4	100.0	100.0		
		DOWN	01APR97	44	18	26	15.0	3	100.0	100.0		
						44	18	26	15.0	2	100.0	100.0
						44	18	26	15.0	2	100.0	100.0
329.005.00001	102.1	WEEK 1	27APR94	20	8	12	7.0	2	85.0	85.7		
		WEEK 2	04MAY94	20	5	15	7.0	2	100.0	107.1		
		WEEK 3	11MAY94	30	8	22	7.0	3	100.0	104.8		
		WEEK 4	18MAY94	40	10	30	7.0	4	100.0	107.1		
		WEEK 5	25MAY94	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	01JUN94	60	21	39	7.0	6	100.0	92.9		
		WEEK 7	08JUN94	60	15	45	7.0	6	100.0	107.1		
		WEEK 8	15JUN94	60	15	45	7.0	6	100.0	107.1		
329.005.00005	83.3	WEEK 1	08NOV94	20	5	15	7.0	2	100.0	107.1		
329.005.00010	99.6	WEEK 1	20DEC94	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	27DEC94	20	7	13	7.0	2	93.0	92.9		

551

CONFIDENTIAL  
BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.005.00010	99.6	WEEK 3	04JAN95	30	6	24	8.0	3	100.0	100.0		
		WEEK 4	11JAN95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	18JAN95	50	15	35	7.0	5	100.0	100.0		
		WEEK 6	25JAN95	60	18	42	7.0	6	100.0	100.0		
		WEEK 7	02FEB95	60	12	48	8.0	6	100.0	100.0		
		WEEK 8	08FEB95	60	24	36	6.0	6	100.0	100.0		
		WEEK 12	10MAR95	240	.	.	30.0	6	100.0	.		
		WEEK 16	13APR95	240	36	204	34.0	6	100.0	100.0		
		WEEK 20	10MAY95	240	78	162	28.0	6	96.0	96.4		
		WEEK 24	06JUN95	240	72	168	27.0	6	104.0	103.7		
		WEEK 28	12JUL95	240	21	219	36.5	6	100.0	100.0		
		WEEK 32	09AUG95	240	75	165	27.5	6	100.0	100.0		
		DOWN	06SEP95	44	0	44	28.0	5	100.0	100.0		
		TITRATION										
						44	0	44	28.0	4	100.0	100.0
						44	0	44	28.0	3	100.0	100.0
						44	0	44	28.0	2	100.0	100.0
				44	0	44	28.0	2	100.0	100.0		
329.005.00012	96.7	WEEK 1	27DEC94	20	5	15	7.5	2	100.0	100.0		
		WEEK 2	05JAN95	20	3	17	9.0	2	94.0	94.4		
		WEEK 3	12JAN95	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	18JAN95	40	16	24	7.0	4	86.0	85.7		
		WEEK 5	25JAN95	50	20	30	7.0	5	85.0	85.7		
		WEEK 6	31JAN95	60	24	36	6.0	6	100.0	100.0		
		WEEK 7	08FEB95	60	12	48	8.0	6	100.0	100.0		
		WEEK 8	16FEB95	60	12	48	8.0	6	100.0	100.0		
		WEEK 12	27MAR95	240	27	213	37.0	6	96.0	95.9		
		WEEK 16	04MAY95	240	18	222	37.0	6	100.0	100.0		
		WEEK 20	31MAY95	240	18	222	37.0	6	100.0	100.0		
		WEEK 24	.	240	.	.	.	6	.	.		
		329.005.00111	97.9	WEEK 1	18JAN95	20	6	14	7.0	2	100.0	100.0
WEEK 2	25JAN95			20	6	14	7.0	2	100.0	100.0		
WEEK 3	01FEB95			30	9	21	7.0	3	100.0	100.0		
WEEK 4	08FEB95			40	12	28	7.0	4	100.0	100.0		
WEEK 5	15FEB95			40	14	26	7.0	4	93.0	92.9		
WEEK 6	22FEB95			40	12	28	7.0	4	100.0	100.0		
WEEK 7	01MAR95			40	12	28	7.0	4	100.0	100.0		
WEEK 8	08MAR95			40	14	26	7.0	4	93.0	92.9		

552

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.005.00111	97.9	WEEK 12	05APR95	160	50	110	28.0	4	98.0	98.2		
		WEEK 16	19APR95	160	106	54	13.5	4	100.0	100.0		
		DOWN	03MAY95	26	2	24	11.5	3	100.0	126.3		
		TITRATION		26	2	24	11.5	2	100.0	126.3		
				26	2	24	11.5	1	100.0	126.3		
329.005.00114	95.9	WEEK 1	07FEB95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	14FEB95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	21FEB95	30	11	19	7.0	3	90.0	90.5		
		WEEK 4	28FEB95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	09MAR95	40	4	36	9.0	4	100.0	100.0		
		WEEK 6	15MAR95	40	16	24	6.0	4	100.0	100.0		
		WEEK 7	22MAR95	40	14	26	7.0	4	93.0	92.9		
		WEEK 8	29MAR95	40	16	24	7.0	4	86.0	85.7		
		WEEK 12	26APR95	160	62	98	24.5	4	100.0	100.0		
		DOWN	17MAY95	30	10	20	13.0	4	100.0	87.0		
		TITRATION		30	10	20	13.0	3	100.0	87.0		
				30	10	20	13.0	2	100.0	87.0		
				30	10	20	13.0	1	100.0	87.0		
329.005.00115	92.3	WEEK 1	13FEB95	20	7	13	7.0	2	92.0	92.9		
		WEEK 2	20FEB95	20	8	12	7.0	2	86.0	85.7		
		WEEK 3	02MAR95	30	0	30	10.0	3	100.0	100.0		
		WEEK 4	10MAR95	40	10	30	8.0	4	94.0	93.8		
		WEEK 5	17MAR95	40	10	30	7.5	4	100.0	100.0		
		WEEK 6	28MAR95	40	0	40	10.0	4	100.0	100.0		
		WEEK 7	10APR95	40	0	40	12.0	4	83.3	83.3		
		WEEK 8	18APR95	40	8	32	8.0	4	100.0	100.0		
		WEEK 12	27APR95	160	154	6	9.0	4	13.0	16.7		
		329.005.00120	92.5	WEEK 1	07SEP95	20	4	16	8.0	2	100.0	100.0
				WEEK 2	14SEP95	20	5	14	7.0	2	100.0	100.0
WEEK 3	21SEP95			30	11	19	7.0	3	90.4	90.5		
WEEK 4	28SEP95			40	16	24	7.0	4	85.7	85.7		
WEEK 5	05OCT95			50	15	35	7.0	5	100.0	100.0		
WEEK 6	12OCT95			50	18	32	7.0	5	91.4	91.4		
WEEK 7	19OCT95			60	18	42	7.0	6	100.0	100.0		
WEEK 8	26OCT95			60	21	39	7.0	6	92.8	92.9		

553

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.005.00253	86.0	WEEK 1	14FEB96	20	10	10	6.0	2	83.3	83.3		
		WEEK 2	21FEB96	20	8	12	7.0	2	85.7	85.7		
		WEEK 3	28FEB96	30	11	19	7.0	3	90.4	90.5		
		WEEK 4	06MAR96	40	16	24	7.0	4	85.7	85.7		
		WEEK 5	14MAR96	50	15	35	8.0	5	87.5	87.5		
		WEEK 6	20MAR96	60	30	30	6.0	6	83.3	83.3		
		WEEK 7	28MAR96	60	24	36	8.0	6	75.0	75.0		
		WEEK 8	03APR96	60	.	.	.	6	.	.		
329.005.00254	96.8	WEEK 1	21FEB96	20	7	13	6.5	2	100.0	100.0		
		WEEK 2	28FEB96	20	8	12	7.0	2	86.0	85.7		
		WEEK 3	06MAR96	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	13MAR96	40	11	29	7.0	4	100.0	103.6		
		WEEK 5	20MAR96	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	27MAR96	40	14	26	7.0	4	93.0	92.9		
		WEEK 7	03APR96	40	11	28	7.0	4	100.0	100.0		
		WEEK 8	10APR96	40	16	24	7.0	4	85.0	85.7		
		WEEK 12	22MAY96	160	48	112	28.0	4	100.0	100.0		
		WEEK 16	12JUN96	160	36	124	34.0	4	91.0	91.2		
		WEEK 20	10JUL96	160	48	112	28.0	4	100.0	100.0		
		WEEK 24	07AUG96	160	58	102	28.0	4	91.0	91.1		
		WEEK 28	12SEP96	160	32	128	35.0	4	91.0	91.4		
		WEEK 32	16OCT96	160	36	124	34.0	4	92.0	91.2		
		DOWN	30OCT96	44	12	32	14.0	4	100.0	94.1		
		TITRATION		44	12	32	14.0	3	100.0	94.1		
				44	12	32	14.0	2	100.0	94.1		
				44	12	32	14.0	2	100.0	94.1		
		329.005.00293	91.0	WEEK 1	19MAR97	20	8	12	7.0	2	86.0	85.7
				WEEK 2	25MAR97	20	8	12	6.0	2	100.0	100.0
WEEK 3	02APR97			30	5	25	8.0	3	100.0	104.2		
WEEK 4	09APR97			40	18	22	7.0	4	79.0	78.6		
WEEK 5	16APR97			50	15	35	7.0	5	100.0	100.0		
WEEK 6	23APR97			60	21	39	7.0	6	93.0	92.9		
WEEK 7	30APR97			60	18	42	7.0	6	100.0	100.0		
WEEK 8	07MAY97			60	24	36	7.0	6	86.0	85.7		
329.005.00298	95.7	WEEK 1	30MAY96	20	4	16	8.0	2	100.0	100.0		
		WEEK 2	06JUN96	20	6	14	7.0	2	100.0	100.0		

554

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----											
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)	
329.005.00298	95.7	WEEK 3	12JUN96	30	14	16	6.0	3	89.0	88.9	
		WEEK 4	19JUN96	40	14	26	7.0	4	95.0	92.9	
		WEEK 5	26JUN96	40	14	26	7.0	4	93.0	92.9	
		WEEK 6	03JUL96	40	14	26	7.0	4	93.0	92.9	
		WEEK 7	10JUL96	40	12	28	7.0	4	100.0	100.0	
		WEEK 8	17JUL96	40	12	28	7.0	4	100.0	100.0	
		WEEK 12	07AUG96	160	44	116	28.0	4	97.0	103.6	
		WEEK 16	19SEP96	160	42	118	27.0	4	100.0	109.3	
		WEEK 20	17OCT96	160	62	98	28.0	4	88.0	87.5	
		WEEK 24	14NOV96	160	62	98	28.0	4	88.0	87.5	
		WEEK 28	12DEC96	160	58	102	28.0	4	91.0	91.1	
		WEEK 32	13JAN97	160	52	108	32.0	4	85.0	84.4	
		DOWN	27JAN97	26	1	25	14.0	3	95.0	96.2	
		TITRATION			26	1	25	14.0	2	95.0	96.2
					26	1	25	14.0	2	95.0	96.2
329.005.00331	89.2	WEEK 1	27NOV96	20	9	11	6.0	2	92.0	91.7	
		WEEK 2	04DEC96	20	6	14	7.0	2	100.0	100.0	
		WEEK 3	12DEC96	30	8	22	8.0	3	92.0	91.7	
		WEEK 4	19DEC96	40	14	26	7.0	4	93.0	92.9	
		WEEK 5	26DEC96	40	16	24	7.0	4	95.0	85.7	
		WEEK 6	02JAN97	40	16	24	7.0	4	86.0	85.7	
		WEEK 7	10JAN97	40	10	30	8.0	4	94.0	93.8	
		WEEK 8	16JAN97	40	18	22	6.0	4	92.0	91.7	
329.005.00334	96.7	WEEK 1	06FEB97	20	7	13	6.5	2	100.0	100.0	
		WEEK 2	13FEB97	20	5	15	7.5	2	100.0	100.0	
		WEEK 3	21FEB97	30	8	22	7.5	3	100.0	97.8	
		WEEK 4	26FEB97	40	20	20	5.0	4	100.0	100.0	
		WEEK 5	06MAR97	40	6	34	8.5	4	100.0	100.0	
		WEEK 6	13MAR97	50	15	35	7.0	5	100.0	100.0	
		WEEK 7	21MAR97	50	12	38	8.0	5	95.0	95.0	
		WEEK 8	27MAR97	50	23	27	6.0	5	94.0	90.0	
329.006.00037	98.3	WEEK 1	03FEB95	20	6	14	7.0	2	100.0	100.0	
		WEEK 2	13FEB95	20	0	20	10.0	2	100.0	100.0	
		WEEK 3	22FEB95	30	6	24	8.0	3	100.0	100.0	
329.006.00042	100.4	WEEK 1	13DEC95	20	7	13	7.0	2	100.0	92.9	

555

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.006.00042	100.4	WEEK 2	20DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	27DEC95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	03JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	10JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	17JAN96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	23JAN96	50	20	30	6.0	5	100.0	100.0
		WEEK 8	02FEB96	60	0	60	10.0	6	100.0	100.0
		WEEK 12	29FEB96	240	78	162	27.0	6	100.0	100.0
		WEEK 16	26MAR96	240	84	156	26.5	6	100.0	98.1
		WEEK 20	23APR96	240	72	168	28.0	6	100.0	100.0
		WEEK 24	21MAY96	240	72	168	28.0	6	100.0	100.0
		WEEK 28	18JUN96	240	72	168	28.0	6	100.0	100.0
		WEEK 32	16JUL96	240	69	171	28.0	6	100.0	101.8
		DOWN TITRATION	31JUL96	44	3	41	15.0	5	100.0	113.9
					44	3	41	15.0	4	100.0
			44	3	41	15.0	3	100.0	113.9	
			44	3	41	15.0	2	100.0	113.9	
			44	3	41	15.0	1	100.0	113.9	
329.006.00259	90.2	WEEK 1	30MAY96	20	.	2	4.0	2	50.0	25.0
		WEEK 2	06JUN96	16	1	15	7.0	2	100.0	107.1
		WEEK 3	13JUN96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	20JUN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	27JUN96	50	15	35	8.0	5	90.0	87.5
		WEEK 6	03JUL96	60	12	48	8.0	6	100.0	100.0
		WEEK 7	10JUL96	30	0	30	5.0	6	100.0	100.0
		WEEK 8	17JUL96	60	27	33	6.0	6	100.0	91.7
329.007.00141	96.2	WEEK 1	28SEP95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	05OCT95	20	5	15	7.0	2	107.0	107.1
		WEEK 3	12OCT95	30	9	21	7.0	3	100.0	100.0
329.007.00144	96.7	WEEK 1	14DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	21DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	28DEC95	30	11	19	7.0	3	90.0	90.5
		WEEK 4	04JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	11JAN96	40	14	26	7.0	4	93.0	92.9
		WEEK 6	18JAN96	50	15	35	7.0	5	100.0	100.0
		WEEK 7	25JAN96	50	18	32	7.0	5	91.0	91.4

556

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.007.00144	96.7	WEEK 8	01FEB96	50	15	35	7.0	5	100.0	100.0
		WEEK 12	01FEB96	200	0	.	.	5	.	.
329.007.00266	89.4	WEEK 1	14MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	25MAR96	20	3	17	11.0	2	77.0	77.3
		WEEK 3	28MAR96	30	21	9	3.0	3	100.0	100.0
		WEEK 4	04APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	11APR96	50	17	33	7.0	5	94.0	94.3
		WEEK 6	18APR96	50	19	31	7.0	5	89.0	88.6
		WEEK 7	29APR96	50	0	50	11.0	5	91.0	90.9
		WEEK 8	02MAY96	50	37	13	3.0	5	87.0	86.7
329.007.00267	100.0	WEEK 1	14MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	21MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	28MAR96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	04APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	11APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	18APR96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	25APR96	50	15	35	7.0	5	100.0	100.0
		WEEK 8	02MAY96	50	15	35	7.0	5	100.0	100.0
329.007.00311	94.8	WEEK 1	10OCT96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	17OCT96	20	7	13	7.0	2	93.0	92.9
		WEEK 3	28OCT96	30	0	30	11.0	3	91.0	90.9
		WEEK 4	31OCT96	40	28	12	3.0	4	100.0	100.0
		WEEK 5	07NOV96	40	14	26	7.0	4	93.0	92.9
		WEEK 6	14NOV96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	22NOV96	40	10	30	8.0	4	94.0	93.8
		WEEK 8	02DEC96	50	3	47	10.0	5	94.0	94.0
		WEEK 12	02JAN97	200	61	139	31.0	5	90.0	89.7
		WEEK 16	30JAN97	200	60	140	28.0	5	100.0	100.0
		WEEK 20	13MAR97	200	44	156	42.0	5	74.0	74.3
		WEEK 24	11APR97	200	.	.	.	5	.	.
		DOWN	09MAY97	32	0	32	13.5	4	100.0	59.3
		TITRATION								
329.008.00158	85.6	WEEK 1	19SEP95	20	7	13	6.0	2	108.0	108.3
		WEEK 2	27SEP95	20	5	15	8.0	2	94.0	93.8
		WEEK 3	03OCT95	30	12	18	6.0	3	100.0	100.0
		WEEK 4	10OCT95	40	12	28	7.0	4	100.0	100.0

557

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.008.00158	85.6	WEEK 5	16OCT95	40	18	22	6.0	4	92.0	91.7		
		WEEK 6	24OCT95	50	10	40	8.0	5	100.0	100.0		
		WEEK 7	31OCT95	60	24	36	7.0	6	86.0	85.7		
		WEEK 8	14NOV95	60	6	54	13.0	6	69.0	69.2		
		WEEK 12	26DEC95	240	.	.	.	6	.	.		
		WEEK 16	23JAN96	240	.	.	.	6	.	.		
329.008.00162	107.0	WEEK 1	10NOV95	20	1	19	9.0	2	105.0	105.6		
		WEEK 2	20NOV95	20	0	20	10.0	2	100.0	100.0		
		WEEK 3	29NOV95	30	3	27	9.0	3	100.0	100.0		
		WEEK 4	07DEC95	40	4	36	8.0	4	112.0	112.5		
		WEEK 5	14DEC95	50	10	40	7.0	5	114.0	114.3		
		WEEK 6	20DEC95	.	.	.	.	5	.	.		
		WEEK 7	27DEC95	60	15	45	7.0	6	107.0	107.1		
		WEEK 8	05JAN96	60	3	57	9.0	6	105.0	105.6		
		WEEK 12	09FEB96	240	24	216	35.0	6	97.0	102.9		
		WEEK 16	08MAR96	240	0	240	26.0	6	115.0	153.8		
		WEEK 20	11APR96	240	6	234	33.0	6	118.0	118.2		
		WEEK 24	01MAY96	60	.	.	.	6	.	.		
		WEEK 28	05JUN96	240	6	234	35.0	6	111.0	111.4		
		WEEK 32	02JUL96	240	60	180	26.0	6	115.0	115.4		
		DOWN	02JUL96	44	.	.	.	5	.	.		
		TITRATION										
						44	.	.	.	4	.	.
						44	.	.	.	3	.	.
						44	.	.	.	2	.	.
						44	.	.	.	1	.	.
329.008.00191	98.0	WEEK 1	12FEB96	20	0	20	11.0	2	90.0	90.9		
		WEEK 2	20FEB96	20	3	17	8.0	2	94.0	106.3		
		WEEK 3	27FEB96	30	10	20	7.0	3	95.0	95.2		
		WEEK 4	05MAR96	40	14	26	7.0	4	72.0	92.9		
		WEEK 5	12MAR96	40	12	28	7.0	4	100.0	100.0		
		WEEK 6	18MAR96	40	8	32	6.0	4	130.0	133.3		
		WEEK 7	26MAR96	40	16	24	7.0	4	85.0	85.7		
		WEEK 8	02APR96	40	12	28	6.0	4	116.0	116.7		
		WEEK 12	01MAY96	160	40	120	30.0	4	100.0	100.0		
		WEEK 16	05JUN96	160	28	132	39.0	4	103.0	84.6		
		WEEK 20	12JUN96	40	12	28	7.0	4	100.0	100.0		

558

CONFIDENTIAL

BRL-029060-329-  
individual-data

PAROXETINE - PROTOCOL 329

Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----

Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.008.00191	98.0	DOWN TITRATION	.	44	.	.	.	4	.	.
329.009.00128	87.1	WEEK 1	18APR95	20	8	12	7.0	2	85.0	85.7
		WEEK 2	25APR95	20	9	11	7.0	2	79.0	78.6
		WEEK 3	26APR95	30	26	4	1.0	3	99.0	133.3
329.009.00129	90.6	WEEK 1	18APR95	20	9	11	7.0	2	79.0	78.6
		WEEK 2	25APR95	20	7	13	7.0	2	93.0	92.9
		WEEK 3	02MAY95	30	11	19	7.0	3	91.0	90.5
		WEEK 4	09MAY95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	16MAY95	50	15	35	7.0	5	100.0	100.0
329.009.00135	100.0	WEEK 1	09OCT95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	16OCT95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	23OCT95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	30OCT95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	06NOV95	50	15	35	7.0	5	100.0	100.0
329.009.00136	92.5	WEEK 1	10OCT95	20	14	6	7.0	2	43.0	42.9
		WEEK 2	17OCT95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	24OCT95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	03NOV95	40	0	40	10.0	4	100.0	100.0
		WEEK 5	07NOV95	50	30	20	4.0	5	100.0	100.0
		WEEK 6	14NOV95	50	17	33	7.0	5	94.0	94.3
		WEEK 7	21NOV95	50	18	32	7.0	5	91.0	91.4
		WEEK 8	28NOV95	50	18	32	7.0	5	91.0	91.4
329.009.00169	95.9	WEEK 1	07NOV95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	14NOV95	20	6	14	7.0	2	100.0	100.0
		WEEK 3	21NOV95	30	9	21	7.0	3	100.0	100.0
		WEEK 4	28NOV95	40	12	28	7.0	4	100.0	100.0
		WEEK 5	05DEC95	40	16	24	7.0	4	86.0	85.7
		WEEK 6	12DEC95	40	12	28	7.0	4	100.0	100.0
		WEEK 7	19DEC95	40	12	28	7.0	4	100.0	100.0
		WEEK 8	27DEC95	40	8	32	8.0	4	100.0	100.0
		WEEK 12	23JAN96	160	86	74	19.0	4	97.0	97.4
		DOWN TITRATION	13FEB96	28	0	28	21.0	4	100.0	93.3
				28	0	28	21.0	3	100.0	93.3

559

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----												
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)		
329.009.00169	95.9	DOWN TITRATION	13FEB96	28	0	28	21.0	2	100.0	93.3		
				28	0	28	21.0	2	100.0	93.3		
329.009.00174	97.7	WEEK 1	28NOV95	20	6	14	7.0	2	100.0	100.0		
		WEEK 2	05DEC95	20	6	14	7.0	2	100.0	100.0		
		WEEK 3	12DEC95	30	9	21	7.0	3	100.0	100.0		
		WEEK 4	19DEC95	40	12	28	7.0	4	100.0	100.0		
		WEEK 5	27DEC95	50	10	40	8.0	5	100.0	100.0		
		WEEK 6	02JAN96	50	20	30	6.0	5	100.0	100.0		
		WEEK 7	09JAN96	50	15	35	7.0	5	100.0	100.0		
		WEEK 8	17JAN96	50	15	35	8.0	5	88.0	87.5		
		WEEK 12	31JAN96	200	128	72	15.0	5	103.0	96.0		
		DOWN TITRATION	16FEB96	32	0	32	16.0	4	100.0	86.5		
						32	0	32	16.0	3	100.0	86.5
						32	0	32	16.0	3	100.0	86.5
				32	0	32	16.0	2	100.0	86.5		
329.009.00197	88.3	WEEK 1	02JAN96	20	12	8	4.0	2	100.0	100.0		
		WEEK 2	08JAN96	20	9	11	6.0	2	92.0	91.7		
		WEEK 3	16JAN96	30	10	20	8.0	3	83.0	83.3		
		WEEK 4	23JAN96	40	15	25	7.0	4	89.0	89.3		
		WEEK 5	30JAN96	40	14	26	7.0	4	93.0	92.9		
		WEEK 6	06FEB96	40	18	22	7.0	4	79.0	78.6		
		WEEK 7	13FEB96	40	14	26	7.0	4	93.0	92.9		
		WEEK 8	20FEB96	40	12	28	7.0	4	100.0	100.0		
		WEEK 12	19MAR96	184	94	90	28.0	4	80.0	80.4		
		WEEK 16	23APR96	160	68	92	35.0	4	66.0	65.7		
		WEEK 20	21MAY96	160	60	100	28.0	4	89.0	89.3		
		WEEK 24	25JUN96	160	32	128	36.0	4	89.0	88.9		
		WEEK 28	16JUL96	160	88	72	21.0	4	86.0	85.7		
		WEEK 32	20AUG96	160	55	105	35.0	4	75.0	75.0		
		DOWN TITRATION	03SEP96	44	23	21	14.0	4	75.0	70.0		
						44	23	21	14.0	3	75.0	70.0
						44	23	21	14.0	2	75.0	70.0
						44	23	21	14.0	2	75.0	70.0
329.009.00198	96.3	WEEK 1	08JAN96	20	11	9	6.0	2	75.0	75.0		

560

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.009.00198	96.3	WEEK 2	16JAN96	20	7	13	8.0	2	81.0	81.3
		WEEK 3	23JAN96	30	10	20	7.0	3	95.0	95.2
		WEEK 4	30JAN96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	06FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	13FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	20FEB96	40	12	28	7.0	4	100.0	100.0
		WEEK 8	27FEB96	40	12	28	7.0	4	100.0	100.0
		329.009.00200	91.0	WEEK 1	02FEB96	20	3	17	10.0	2
WEEK 2	06FEB96			20	13	7	4.0	2	88.0	87.5
WEEK 3	13FEB96			30	12	18	7.0	3	86.0	85.7
WEEK 4	20FEB96			40	12	28	7.0	4	100.0	100.0
WEEK 5	28FEB96			40	8	32	8.0	4	100.0	100.0
WEEK 6	08MAR96			40	10	30	9.0	4	83.0	83.3
DOWN	19MAR96			25	19	6	11.0	3	24.0	18.2
TITRATION										
329.009.00202	87.9	WEEK 1	27FEB96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	08MAR96	20	1	19	10.0	2	95.0	95.0
		WEEK 3	19MAR96	30	4	26	11.0	3	79.0	78.8
		WEEK 4	26MAR96	40	12	28	7.0	4	100.0	100.0
329.009.00237	61.1	WEEK 1	18NOV96	20	9	11	8.0	2	69.0	68.8
329.009.00238	94.2	WEEK 1	19NOV96	20	8	12	7.0	2	86.0	85.7
		WEEK 2	26NOV96	20	5	15	7.0	2	101.0	107.1
		WEEK 3	03DEC96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	10DEC96	40	16	24	7.0	4	86.0	85.7
		WEEK 5	17DEC96	40	18	22	7.0	4	79.0	78.6
		WEEK 6	23DEC96	40	16	24	6.0	4	100.0	100.0
		WEEK 7	31DEC96	40	8	32	8.0	4	100.0	100.0
		WEEK 8	07JAN97	40	12	28	7.0	4	100.0	100.0
329.009.00276	88.7	WEEK 1	28JAN97	20	5	15	7.0	2	107.0	107.1
		WEEK 2	04FEB97	20	6	14	7.0	2	100.0	100.0
		WEEK 3	11FEB97	30	9	21	7.0	3	100.0	100.0
		WEEK 4	18FEB97	40	13	27	7.0	4	96.0	96.4
		WEEK 5	25FEB97	50	44	6	7.0	5	16.0	17.1
		WEEK 6	04MAR97	50	12	38	7.0	5	109.0	108.6
		WEEK 7	13MAR97	60	6	54	9.0	6	100.0	100.0

561

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.009.00276	88.7	WEEK 8	18MAR97	60	30	30	5.0	6	100.0	100.0
329.009.00302	90.0	WEEK 1	03APR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	10APR96	20	7	13	7.0	2	93.0	92.9
329.009.00306	100.0	WEEK 1	18JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	25JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	02JUL96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	09JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	16JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	23JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 7	30JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 8	06AUG96	50	15	35	7.0	5	100.0	100.0
329.009.00312	84.2	WEEK 1	15NOV96	20	3	17	11.0	2	77.0	77.3
		WEEK 2	18NOV96	20	14	6	3.0	2	100.0	100.0
		WEEK 3	02DEC96	30	2	28	14.0	3	67.0	66.7
		WEEK 4	09DEC96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	16DEC96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	27DEC96	40	2	38	11.0	4	86.0	86.4
		WEEK 7	30DEC96	40	28	12	3.0	4	100.0	100.0
		WEEK 8	06JAN97	50	20	30	7.0	5	86.0	85.7
329.009.00327	100.0	WEEK 1	23SEP96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	30SEP96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	07OCT96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	14OCT96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	21OCT96	50	15	35	7.0	5	100.0	100.0
329.009.00330	46.7	WEEK 1	28OCT96	20	13	7	7.0	2	50.0	50.0
		WEEK 2	04NOV96	20	13	7	7.0	2	50.0	50.0
329.010.00183	66.7	WEEK 1	05DEC95	33	21	12	11.0	2	55.0	54.5
		WEEK 2	19DEC95	20	0	.	.	2	.	.
329.010.00263	98.0	WEEK 1	14AUG96	20	10	10	5.0	2	100.0	100.0
		WEEK 2	21AUG96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	28AUG96	30	10	20	7.0	3	95.0	95.2
		WEEK 4	04SEP96	40	16	24	7.0	4	86.0	85.7
		WEEK 5	11SEP96	50	18	32	7.0	5	91.0	91.4

562

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.010.00263	98.0	WEEK 6	18SEP96	60	24	36	7.0	6	86.0	85.7
		WEEK 7	25SEP96	60	24	36	7.0	6	86.0	85.7
		WEEK 8	09OCT96	104	35	69	15.0	6	80.0	76.7
329.010.00277	78.1	WEEK 1	08MAR96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	18MAR96	20	10	10	6.0	2	83.0	83.3
		WEEK 3	22MAR96	30	10	20	7.0	3	95.0	95.2
		WEEK 4	29MAR96	40	16	24	6.0	4	100.0	100.0
		WEEK 5	.	50	15	35	7.0	5	100.0	100.0
		WEEK 6	15APR96	50	20	30	10.0	5	60.0	60.0
		WEEK 7	19APR96	60	36	24	4.0	6	100.0	100.0
		WEEK 8	26APR96	60	39	21	7.0	6	50.0	50.0
		WEEK 12	24MAY96	240	113	127	28.0	6	76.0	75.6
		WEEK 16	21JUN96	240	240	0	28.0	6	0.0	0.0
329.010.00282	90.1	WEEK 1	02AUG96	20	5	15	7.0	2	107.0	107.1
		WEEK 2	09AUG96	20	7	13	7.0	2	93.0	92.9
		WEEK 3	16AUG96	30	10	20	7.0	3	95.0	95.2
		WEEK 4	26AUG96	40	8	32	9.0	4	89.0	88.9
		WEEK 5	03SEP96	50	13	37	8.0	5	93.0	92.5
		WEEK 6	13SEP96	60	12	48	9.0	6	89.0	88.9
		WEEK 7	19SEP96	60	27	33	6.0	6	92.0	91.7
		WEEK 8	27SEP96	60	12	48	8.0	6	100.0	100.0
329.011.00164	98.2	WEEK 1	28DEC95	20	6	14	7.0	2	100.0	100.0
		WEEK 2	04JAN96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	11JAN96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	18JAN96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	25JAN96	50	15	35	7.0	5	100.0	100.0
329.011.00210	96.9	WEEK 1	03OCT96	20	9	11	6.0	2	92.0	91.7
		WEEK 2	09OCT96	20	8	12	6.0	2	100.0	100.0
		WEEK 3	17OCT96	30	6	24	8.0	3	100.0	100.0
		WEEK 4	24OCT96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	04NOV96	40	0	40	10.0	4	100.0	100.0
		WEEK 6	12NOV96	50	7	43	9.0	5	96.0	95.6
		WEEK 7	22NOV96	50	3	47	10.0	5	94.0	94.0
		WEEK 8	02DEC96	50	2	48	10.0	5	96.0	96.0
		WEEK 12	02DEC96	200	.	.	.	5	.	.

563

CONFIDENTIAL

BRL-029060-329-  
individual-data

## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.011.00285	97.9	WEEK 1	27MAY96	20	1	19	10.0	2	95.0	95.0
		WEEK 2	03JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	10JUN96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	21JUN96	40	0	40	10.0	4	100.0	100.0
		WEEK 5	28JUN96	50	15	35	7.0	5	100.0	100.0
		WEEK 6	08JUL96	60	0	60	10.0	6	100.0	100.0
		WEEK 7	18JUL96	60	0	60	10.0	6	100.0	100.0
		WEEK 8	24JUL96	60	24	36	6.0	6	100.0	100.0
329.011.00287	96.6	WEEK 1	09JUL96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	17JUL96	20	4	16	8.0	2	100.0	100.0
		WEEK 3	23JUL96	30	12	18	6.0	3	100.0	100.0
		WEEK 4	30JUL96	40	14	26	7.0	4	93.0	92.9
		WEEK 5	06AUG96	50	15	35	7.0	5	100.0	100.0
		WEEK 6	13AUG96	60	18	42	7.0	6	100.0	100.0
		WEEK 7	20AUG96	60	24	36	7.0	6	86.0	85.7
		WEEK 8	27AUG96	60	18	42	7.0	6	100.0	100.0
329.012.00027	100.0	WEEK 1	12DEC95	20	7	13	6.5	2	100.0	100.0
		WEEK 2	19DEC95	20	5	15	7.0	2	107.0	107.1
		WEEK 3	27DEC95	30	6	24	8.0	3	100.0	100.0
		WEEK 4	02JAN96	40	14	26	6.5	4	100.0	100.0
329.012.00217	88.1	WEEK 1	31MAY96	20	4	16	9.5	2	84.0	84.2
		WEEK 2	19JUN96	20	5	15	7.0	2	107.0	107.1
		WEEK 3	14JUN96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	19JUN96	40	40	0	6.0	4	0.0	0.0
329.012.00218	100.5	WEEK 2	28JUN96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	05JUL96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	12JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	19JUL96	40	12	28	7.0	4	100.0	100.0
		WEEK 6	29JUL96	40	2	38	9.5	4	100.0	100.0
		WEEK 7	06AUG96	40	6	34	8.5	4	100.0	100.0
		WEEK 8	13AUG96	40	11	29	7.0	4	104.0	103.6
		WEEK 12	18SEP96	160	.	.	.	4	.	.
		DOWN	.	44	0	.	13.0	4	.	.
		TITRATION	.	44	0	.	13.0	3	.	.
			.	44	0	.	13.0	2	.	.

564

CONFIDENTIAL

BRL-029060-329-  
individual-data



## PAROXETINE - PROTOCOL 329

## Appendix B.15

Listing of Drug Dispensing Data by Treatment Group and Patient  
Intent-to-Treat Population

----- Treatment Group=PLACEBO -----										
Patient ID	Overall Compliance (%)	Visit	Date Returned	# Capsules Dispensed	# Capsules Returned	# Capsules Taken	Days Since Last Visit	# Capsules Daily	Recorded Compliance (%)	Calculated Compliance (%)
329.012.00218	100.5	DOWN TITRATION	.	44	0	.	13.0	2	.	.
329.012.00224	96.9	WEEK 1	24SEP96	20	4	16	8.0	2	100.0	100.0
		WEEK 2	03OCT96	20	3	17	9.0	2	94.0	94.4
		WEEK 3	10OCT96	30	9	21	7.0	3	100.0	100.0
		WEEK 4	17OCT96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	25OCT96	40	10	30	8.0	4	94.0	93.8
		WEEK 6	04NOV96	40	4	36	9.5	4	95.0	94.7
		WEEK 7	12NOV96	40	9	31	8.0	4	97.0	96.9
		WEEK 8	20NOV96	40	3	37	9.0	4	103.0	102.8
		WEEK 12	19DEC96	160	66	94	28.0	4	84.0	83.9
		WEEK 16	20JAN97	160	60	100	32.0	4	78.0	78.1
		WEEK 20	18FEB97	160	88	72	29.0	4	62.0	62.1
		DOWN TITRATION	14MAR97	26	4	22	11.5	3	96.0	84.6
				26	4	22	11.5	2	96.0	84.6
329.012.00225	97.2	WEEK 1	03DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 2	10DEC96	20	6	14	7.0	2	100.0	100.0
		WEEK 3	20DEC96	30	2	28	10.0	3	93.0	93.3
		WEEK 4	27DEC96	40	12	28	7.0	4	100.0	100.0
		WEEK 5	06JAN97	40	0	40	10.0	4	100.0	100.0
		WEEK 6	13JAN97	40	12	28	7.0	4	100.0	100.0
		WEEK 7	21JAN97	40	12	28	8.0	4	88.0	87.5
		WEEK 8	29JAN97	40	8	32	8.0	4	100.0	100.0
		WEEK 12	24FEB97	160	60	100	26.0	4	96.0	96.2
		WEEK 16	20MAR97	160	74	86	25.0	4	86.0	86.0
		WEEK 20	21APR97	160	50	110	32.0	4	86.0	85.9
		WEEK 24	26MAY97	160	34	126	35.0	4	90.0	90.0
		WEEK 28	30JUN97	160	42	118	34.0	4	87.0	86.8
		WEEK 32	30JUL97	160	78	82	30.0	4	68.0	68.3
		DOWN TITRATION	30SEP97	26	0	26	11.5	3	100.0	136.8
				26	0	26	11.5	2	100.0	136.8
				26	0	26	11.5	1	100.0	136.8

565

CONFIDENTIAL

BRL-029060-329-  
individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.001.00063		Oral	1	20 MG	08NOV94	1	14NOV94	7	7
	00063	Oral	2	20 MG	15NOV94	8	21NOV94	14	7
	00063	Oral	3	20 MG	22NOV94	15	28NOV94	21	7
	00063	Oral	4	20 MG	29NOV94	22	05DEC94	28	7
	00063	Oral	4	20 MG	06DEC94	29	12DEC94	35	7
		Oral	4	20 MG	13DEC94	36	25DEC94	48	13
329.001.00065		Oral	1	20 MG	17NOV94	1	22NOV94	6	6
	00065	Oral	2	20 MG	23NOV94	7	30NOV94	14	8
329.001.00068		Oral	1	20 MG	08FEB95	1	14FEB95	7	7
	00068	Oral	2	20 MG	15FEB95	8	21FEB95	14	7
	00068	Oral	3	20 MG	22FEB95	15	28FEB95	21	7
	00068	Oral	4	20 MG	01MAR95	22	07MAR95	28	7
	00068	Oral	5	30 MG	08MAR95	29	14MAR95	35	7
	00068	Oral	6	40 MG	15MAR95	36	22MAR95	43	8
	00068	Oral	6	40 MG	23MAR95	44	28MAR95	49	6
	00068	Oral	6	40 MG	29MAR95	50	04APR95	56	7
		Oral	6	40 MG	05APR95	57	20APR95	72	16
329.001.00072		Oral	1	20 MG	20MAR95	1	26MAR95	7	7
	00072	Oral	2	20 MG	27MAR95	8	02APR95	14	7
	00072	Oral	3	20 MG	03APR95	15	09APR95	21	7
	00072	Oral	4	20 MG	10APR95	22	12APR95	24	3
		Oral	3	20 MG	13APR95	25	20APR95	32	8
329.001.00121		Oral	1	20 MG	04APR95	1	10APR95	7	7
	00121	Oral	2	20 MG	11APR95	8	17APR95	14	7
	00121	Oral	3	20 MG	18APR95	15	25APR95	22	8
	00121	Oral	4	20 MG	26APR95	23	01MAY95	28	6
	00121	Oral	5	30 MG	02MAY95	29	08MAY95	35	7
	00121	Oral	5	30 MG	09MAY95	36	15MAY95	42	7
	00121	Oral	5	30 MG	16MAY95	43	22MAY95	49	7
	00121	Oral	5	30 MG	23MAY95	50	29MAY95	56	7
	00051	Oral	5	30 MG	30MAY95	57	26JUN95	84	28
	00051	Oral	5	30 MG	27JUN95	85	23JUL95	111	27
	00051	Oral	5	30 MG	24JUL95	112	20AUG95	139	28
	00121	Oral	5	30 MG	21AUG95	140	04SEP95	154	15
329.001.00205		Oral	1	20 MG	07FEB96	1	14FEB96	8	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

566

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.001.00206		Oral	1	20 MG	21FEB96	1	27FEB96	7	7
	00206	Oral	2	20 MG	28FEB96	8	05MAR96	14	7
	00206	Oral	3	20 MG	06MAR96	15	12MAR96	21	7
	00206	Oral	4	20 MG	13MAR96	22	19MAR96	28	7
	00206	Oral	5	30 MG	20MAR96	29	25MAR96	34	6
	00206	Oral	6	40 MG	26MAR96	35	02APR96	42	8
	00206	Oral	6	40 MG	03APR96	43	09APR96	49	7
	00206	Oral	6	40 MG	10APR96	50	16APR96	56	7
		Oral	5	30 MG	17APR96	57	18APR96	58	2
329.002.00055		Oral	1	20 MG	24JUN94	1	29JUN94	6	6
	00055	Oral	2	20 MG	30JUN94	7	06JUL94	13	7
	00055	Oral	3	20 MG	07JUL94	14	13JUL94	20	7
	00055	Oral	4	20 MG	14JUL94	21	20JUL94	27	7
	00055	Oral	5	30 MG	21JUL94	28	27JUL94	34	7
	00055	Oral	6	40 MG	28JUL94	35	03AUG94	41	7
	00055	Oral	6	40 MG	04AUG94	42	10AUG94	48	7
	00055	Oral	6	40 MG	11AUG94	49	17AUG94	55	7
	00068	Oral	6	40 MG	18AUG94	56	14SEP94	83	28
	00068	Oral	6	40 MG	15SEP94	84	13OCT94	112	29
	00068	Oral	6	40 MG	14OCT94	113	10NOV94	140	28
	00055	Oral	5	30 MG	11NOV94	141	12NOV94	142	2
	00055	Oral	4	20 MG	13NOV94	143	14NOV94	144	2
	00055	Oral	3	20 MG	15NOV94	145	16NOV94	146	2
	00055	Oral	2	20 MG	17NOV94	147	19NOV94	149	3
	00055	Oral	1	20 MG	20NOV94	150	26NOV94	156	7
329.002.00058		Oral	1	20 MG	20SEP94	1	28SEP94	9	9
	00058	Oral	2	20 MG	29SEP94	10	06OCT94	17	8
	00058	Oral	3	20 MG	07OCT94	18	12OCT94	23	6
	00058	Oral	4	20 MG	13OCT94	24	19OCT94	30	7
	00058	Oral	5	30 MG	20OCT94	31	26OCT94	37	7
	00058	Oral	6	40 MG	27OCT94	38	02NOV94	44	7
	00058	Oral	6	40 MG	03NOV94	45	09NOV94	51	7
	00058	Oral	6	40 MG	10NOV94	52	16NOV94	58	7
	00070	Oral	6	40 MG	17NOV94	59	14DEC94	86	28
	00070	Oral	6	40 MG	15DEC94	87	12JAN95	115	29
	00070	Oral	6	40 MG	13JAN95	116	16JAN95	119	4
329.002.00099		Oral	1	20 MG	02MAR95	1	06MAR95	5	5

\* DAYS RELATIVE TO START OF STUDY MEDICATION

567

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00099	00099	Oral	2	20 MG	07MAR95	6	13MAR95	12	7
	00099	Oral	3	20 MG	14MAR95	13	20MAR95	19	7
	00099	Oral	4	20 MG	21MAR95	20	27MAR95	26	7
	00099	Oral	4	20 MG	28MAR95	27	03APR95	33	7
	00099	Oral	5	30 MG	04APR95	34	11APR95	41	8
	00099	Oral	6	40 MG	12APR95	42	18APR95	48	7
	00099	Oral	6	40 MG	19APR95	49	25APR95	55	7
	00025	Oral	6	40 MG	26APR95	56	22MAY95	82	27
	00025	Oral	6	40 MG	23MAY95	83	26JUN95	117	35
	00025	Oral	6	40 MG	27JUN95	118	31JUL95	152	35
	00025	Oral	6	40 MG	01AUG95	153	30AUG95	182	30
	00025	Oral	6	40 MG	31AUG95	183	27SEP95	210	28
	00025	Oral	6	40 MG	28SEP95	211	26OCT95	239	29
	00099	Oral	5	30 MG	27OCT95	240	28OCT95	241	2
	00099	Oral	4	20 MG	29OCT95	242	30OCT95	243	2
	00099	Oral	3	20 MG	31OCT95	244	01NOV95	245	2
	00099	Oral	2	20 MG	02NOV95	246	04NOV95	248	3
	00099	Oral	1	20 MG	05NOV95	249	11NOV95	255	7
329.002.00102		Oral	1	20 MG	13APR95	1	17APR95	5	5
	00102	Oral	2	20 MG	18APR95	6	24APR95	12	7
	00102	Oral	3	20 MG	25APR95	13	01MAY95	19	7
	00102	Oral	4	20 MG	02MAY95	20	08MAY95	26	7
	00102	Oral	5	30 MG	09MAY95	27	15MAY95	33	7
	00102	Oral	6	40 MG	16MAY95	34	22MAY95	40	7
	00102	Oral	6	40 MG	23MAY95	41	29MAY95	47	7
	00102	Oral	6	40 MG	30MAY95	48	05JUN95	54	7
	00071	Oral	6	40 MG	06JUN95	55	12JUL95	91	37
	00071	Oral	6	40 MG	13JUL95	92	09AUG95	119	28
	00071	Oral	6	40 MG	10AUG95	120	11SEP95	152	33
	00071	Oral	6	40 MG	12SEP95	153	09OCT95	180	28
	00071	Oral	6	40 MG	10OCT95	181	08NOV95	210	30
	00071	Oral	6	40 MG	09NOV95	211	04DEC95	236	26
	00102	Oral	5	30 MG	05DEC95	237	06DEC95	238	2
	00102	Oral	4	20 MG	07DEC95	239	08DEC95	240	2
	00102	Oral	3	20 MG	09DEC95	241	12DEC95	244	4
	00102	Oral	2	20 MG	13DEC95	245	16DEC95	248	4
	00102	Oral	1	20 MG	17DEC95	249	20DEC95	252	4
329.002.00105		Oral	1	20 MG	27JUL95	1	02AUG95	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

568

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00105	00105	Oral	2	20 MG	03AUG95	8	09AUG95	14	7
	00105	Oral	3	20 MG	10AUG95	15	16AUG95	21	7
	00105	Oral	4	20 MG	17AUG95	22	.	.	.
329.002.00106		Oral	1	20 MG	27JUL95	1	02AUG95	7	7
	00106	Oral	2	20 MG	03AUG95	8	07AUG95	12	5
	00106	Oral	3	20 MG	08AUG95	13	16AUG95	21	9
	00106	Oral	4	20 MG	17AUG95	22	23AUG95	28	7
	00106	Oral	4	20 MG	24AUG95	29	30AUG95	35	7
		Oral	5	30 MG	31AUG95	36	04SEP95	40	5
	00106	Oral	6	40 MG	05SEP95	41	11SEP95	47	7
	00106	Oral	6	40 MG	12SEP95	48	12SEP95	48	1
329.002.00242		Oral	1	20 MG	07FEB96	1	14FEB96	8	8
	00242	Oral	2	20 MG	15FEB96	9	21FEB96	15	7
	00242	Oral	3	20 MG	22FEB96	16	28FEB96	22	7
	00242	Oral	4	20 MG	29FEB96	23	05MAR96	28	6
	00242	Oral	5	30 MG	06MAR96	29	13MAR96	36	8
	00242	Oral	5	30 MG	14MAR96	37	20MAR96	43	7
	00242	Oral	6	40 MG	21MAR96	44	28MAR96	51	8
	00242	Oral	6	40 MG	29MAR96	52	04APR96	58	7
		Oral	6	40 MG	05APR96	59	07MAY96	91	33
	00136	Oral	6	40 MG	08MAY96	92	05JUN96	120	29
	00242	Oral	.		06JUN96	121	.	.	.
	329.002.00245		Oral	1	20 MG	28MAR96	1	04APR96	8
00245		Oral	1	20 MG	05APR96	9	09APR96	13	5
		Oral	1	20 MG	10APR96	14	14APR96	18	5
329.002.00319		Oral	1	20 MG	30APR96	1	06MAY96	7	7
	00319	Oral	2	20 MG	07MAY96	8	13MAY96	14	7
	00319	Oral	3	20 MG	14MAY96	15	20MAY96	21	7
	00319	Oral	4	20 MG	21MAY96	22	27MAY96	28	7
	00319	Oral	5	30 MG	28MAY96	29	03JUN96	35	7
	00319	Oral	5	30 MG	04JUN96	36	10JUN96	42	7
	00319	Oral	5	30 MG	11JUN96	43	17JUN96	49	7
	00319	Oral	5	30 MG	18JUN96	50	24JUN96	56	7
	00162	Oral	5	30 MG	25JUN96	57	22JUL96	84	28
	00162	Oral	5	30 MG	23JUL96	85	14AUG96	107	23
	00162	Oral	5	30 MG	15AUG96	108	23SEP96	147	40

\* DAYS RELATIVE TO START OF STUDY MEDICATION

569

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00319	00162	Oral	5	30 MG	24SEP96	148	21OCT96	175	28
	00162	Oral	5	30 MG	22OCT96	176	18NOV96	203	28
	00162	Oral	5	30 MG	19NOV96	204	16DEC96	231	28
	00319	Oral	5	30 MG	17DEC96	232	17DEC96	232	1
	00319	Oral	4	20 MG	18DEC96	233	19DEC96	234	2
	00319	Oral	3	20 MG	20DEC96	235	21DEC96	236	2
	00319	Oral	2	20 MG	22DEC96	237	24DEC96	239	3
	00319	Oral	1	20 MG	25DEC96	240	30DEC96	245	6
329.003.00075		Oral	1	20 MG	25JAN95	1	31JAN95	7	7
	00075	Oral	2	20 MG	01FEB95	8	07FEB95	14	7
	00075	Oral	3	20 MG	08FEB95	15	14FEB95	21	7
	00075	Oral	4	20 MG	15FEB95	22	20FEB95	27	6
	00075	Oral	5	30 MG	21FEB95	28	28FEB95	35	8
	00075	Oral	3	20 MG	01MAR95	36	07MAR95	42	7
	00075	Oral	2	20 MG	08MAR95	43	14MAR95	49	7
	00075	Oral	4	20 MG	15MAR95	50	21MAR95	56	7
	00041	Oral	4	20 MG	22MAR95	57	18APR95	84	28
	00041	Oral	4	20 MG	19APR95	85	16MAY95	112	28
	00041	Oral	4	20 MG	17MAY95	113	13JUN95	140	28
	00041	Oral	4	20 MG	14JUN95	141	11JUL95	168	28
	00041	Oral	4	20 MG	12JUL95	169	09AUG95	197	29
	00041	Oral	4	20 MG	10AUG95	198	12SEP95	231	34
	00075	Oral	3	20 MG	13SEP95	232	14SEP95	233	2
	00075	Oral	2	20 MG	15SEP95	234	17SEP95	236	3
	00075	Oral	1	20 MG	18SEP95	237	21SEP95	240	4
329.003.00077		Oral	1	20 MG	06MAR95	1	12MAR95	7	7
	00077	Oral	2	20 MG	13MAR95	8	19MAR95	14	7
	00077	Oral	3	20 MG	20MAR95	15	26MAR95	21	7
	00077	Oral	4	20 MG	27MAR95	22	04APR95	30	9
	00077	Oral	5	30 MG	05APR95	31	11APR95	37	7
	00077	Oral	5	30 MG	12APR95	38	18APR95	44	7
	00077	Oral	5	30 MG	19APR95	45	26APR95	52	8
	00077	Oral	5	30 MG	27APR95	53	03MAY95	59	7
	00042	Oral	5	30 MG	04MAY95	60	06JUN95	93	34
	00042	Oral	5	30 MG	07JUN95	94	.	.	.
329.003.00081		Oral	1	20 MG	11DEC95	1	17DEC95	7	7
	00081	Oral	2	20 MG	18DEC95	8	27DEC95	17	10

\* DAYS RELATIVE TO START OF STUDY MEDICATION

570

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00081	00081	Oral	3	20 MG	28DEC95	18	02JAN96	23	6
	00081	Oral	4	20 MG	03JAN96	24	09JAN96	30	7
	00081	Oral	5	30 MG	10JAN96	31	16JAN96	37	7
	00081	Oral	5	30 MG	17JAN96	38	23JAN96	44	7
	00081	Oral	5	30 MG	24JAN96	45	30JAN96	51	7
	00081	Oral	6	40 MG	31JAN96	52	06FEB96	58	7
		Oral	6	40 MG	07FEB96	59	.	.	.
329.003.00087		Oral	1	20 MG	31JAN95	1	03FEB95	4	4
329.003.00089		Oral	1	20 MG	07MAR95	1	13MAR95	7	7
	00089	Oral	2	20 MG	14MAR95	8	21MAR95	15	8
	00089	Oral	3	20 MG	22MAR95	16	27MAR95	21	6
	00089	Oral	4	20 MG	28MAR95	22	04APR95	29	8
	00089	Oral	4	20 MG	05APR95	30	11APR95	36	7
	00089	Oral	4	20 MG	12APR95	37	18APR95	43	7
	00089	Oral	4	20 MG	19APR95	44	25APR95	50	7
	00089	Oral	4	20 MG	26APR95	51	01MAY95	56	6
		Oral	3	20 MG	02MAY95	57	05MAY95	60	4
329.003.00091		Oral	1	20 MG	24MAR95	1	28MAR95	5	5
	00091	Oral	2	20 MG	29MAR95	6	04APR95	12	7
	00091	Oral	3	20 MG	05APR95	13	11APR95	19	7
	00091	Oral	4	20 MG	12APR95	20	18APR95	26	7
	00091	Oral	5	30 MG	19APR95	27	25APR95	33	7
	00091	Oral	6	40 MG	26APR95	34	01MAY95	39	6
	00091	Oral	6	40 MG	02MAY95	40	09MAY95	47	8
	00091	Oral	6	40 MG	10MAY95	48	16MAY95	54	7
	00033	Oral	6	40 MG	17MAY95	55	16JUN95	85	31
	00033	Oral	6	40 MG	17JUN95	86	14JUL95	113	28
	00033	Oral	6	40 MG	15JUL95	114	10AUG95	140	27
	00033	Oral	6	40 MG	11AUG95	141	05SEP95	166	26
	00033	Oral	6	40 MG	06SEP95	167	02OCT95	193	27
	00033	Oral	6	40 MG	03OCT95	194	07NOV95	229	36
	00091	Oral	5	30 MG	08NOV95	230	09NOV95	231	2
	00091	Oral	4	20 MG	10NOV95	232	11NOV95	233	2
	00091	Oral	3	20 MG	12NOV95	234	13NOV95	235	2
	00091	Oral	2	20 MG	14NOV95	236	16NOV95	238	3
	00091	Oral	1	20 MG	17NOV95	239	23NOV95	245	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

571

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00248		Oral	1	20 MG	01MAR96	1	05MAR96	5	5
	00248	Oral	2	20 MG	06MAR96	6	11MAR96	11	6
	00248	Oral	3	20 MG	12MAR96	12	18MAR96	18	7
	00248	Oral	4	20 MG	19MAR96	19	25MAR96	25	7
	00248	Oral	5	30 MG	26MAR96	26	01APR96	32	7
	00248	Oral	6	40 MG	02APR96	33	10APR96	41	9
	00248	Oral	6	40 MG	11APR96	42	15APR96	46	5
	00248	Oral	6	40 MG	16APR96	47	22APR96	53	7
		Oral	5	30 MG	23APR96	54	02MAY96	63	10
329.003.00250		Oral	1	20 MG	14MAR96	1	18MAR96	5	5
	00250	Oral	2	20 MG	19MAR96	6	25MAR96	12	7
	00250	Oral	3	20 MG	26MAR96	13	01APR96	19	7
	00250	Oral	4	20 MG	02APR96	20	11APR96	29	10
	00250	Oral	5	30 MG	12APR96	30	18APR96	36	7
	00250	Oral	6	40 MG	19APR96	37	22APR96	40	4
	00250	Oral	6	40 MG	23APR96	41	29APR96	47	7
	00250	Oral	5	30 MG	30APR96	48	09MAY96	57	10
	00250	Oral	6	40 MG	10MAY96	58	12MAY96	60	3
	00250	Oral	5	30 MG	13MAY96	61	27MAY96	75	15
329.003.00292		Oral	1	20 MG	07AUG96	1	16AUG96	10	10
	00292	Oral	2	20 MG	17AUG96	11	21AUG96	15	5
	00292	Oral	3	20 MG	22AUG96	16	30AUG96	24	9
	00292	Oral	4	20 MG	31AUG96	25	04SEP96	29	5
	00292	Oral	4	20 MG	05SEP96	30	17SEP96	42	13
	00292	Oral	4	20 MG	18SEP96	43	25SEP96	50	8
	00292	Oral	4	20 MG	26SEP96	51	03OCT96	58	8
	00179	Oral	4	20 MG	04OCT96	59	.	.	.
329.003.00313		Oral	1	20 MG	17MAY96	1	20MAY96	4	4
	00313	Oral	2	20 MG	21MAY96	5	28MAY96	12	8
329.004.00015		Oral	1	20 MG	08DEC94	1	13DEC94	6	6
	00015	Oral	2	20 MG	14DEC94	7	20DEC94	13	7
	00015	Oral	3	20 MG	21DEC94	14	27DEC94	20	7
	00015	Oral	4	20 MG	28DEC94	21	03JAN95	27	7
	00015	Oral	4	20 MG	04JAN95	28	10JAN95	34	7
	00015	Oral	4	20 MG	11JAN95	35	17JAN95	41	7
	00015	Oral	4	20 MG	18JAN95	42	24JAN95	48	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

572

CONFIDENTIAL

BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.004.00015	00015	Oral	4	20 MG	25JAN95	49	02FEB95	57	9
	00073	Oral	4	20 MG	03FEB95	58	27FEB95	82	25
	00073	Oral	4	20 MG	28FEB95	83	21MAR95	104	22
	00073	Oral	4	20 MG	22MAR95	105	18APR95	132	28
	00073	Oral	4	20 MG	19APR95	133	16MAY95	160	28
	00073	Oral	4	20 MG	17MAY95	161	13JUN95	188	28
	00015	Oral	4	20 MG	14JUN95	189	14JUN95	189	1
	00015	Oral	3	20 MG	15JUN95	190	15JUN95	190	1
	00015	Oral	2	20 MG	16JUN95	191	18JUN95	193	3
	00015	Oral	1	20 MG	19JUN95	194	28JUN95	203	10
329.004.00017		Oral	1	20 MG	22MAR95	1	26MAR95	5	5
	00017	Oral	0	0 MG	27MAR95	6	27MAR95	6	1
	00017	Oral	1	20 MG	28MAR95	7	29MAR95	8	2
	00017	Oral	2	20 MG	30MAR95	9	05APR95	15	7
	00017	Oral	3	20 MG	06APR95	16	12APR95	22	7
	00017	Oral	4	20 MG	13APR95	23	19APR95	29	7
	00017	Oral	4	20 MG	20APR95	30	25APR95	35	6
		Oral	5	30 MG	26APR95	36	02MAY95	42	7
	00017	Oral	5	30 MG	03MAY95	43	09MAY95	49	7
	00017	Oral	5	30 MG	10MAY95	50	16MAY95	56	7
	00075	Oral	5	30 MG	17MAY95	57	13JUN95	84	28
	00075	Oral	5	30 MG	14JUN95	85	12JUL95	113	29
	00075	Oral	5	30 MG	13JUL95	114	09AUG95	141	28
	00075	Oral	5	30 MG	10AUG95	142	05SEP95	168	27
	00075	Oral	5	30 MG	06SEP95	169	03OCT95	196	28
	00075	Oral	5	30 MG	04OCT95	197	31OCT95	224	28
	00017	Oral	4	20 MG	01NOV95	225	02NOV95	226	2
	00017	Oral	3	20 MG	03NOV95	227	04NOV95	228	2
	00017	Oral	2	20 MG	05NOV95	229	07NOV95	231	3
	00017	Oral	1	20 MG	08NOV95	232	14NOV95	238	7
329.004.00019		Oral	1	20 MG	31MAY95	1	06JUN95	7	7
	00019	Oral	2	20 MG	07JUN95	8	13JUN95	14	7
	00019	Oral	3	20 MG	14JUN95	15	.	.	.
329.004.00212		Oral	1	20 MG	03JUN96	1	09JUN96	7	7
	00212	Oral	2	20 MG	10JUN96	8	20JUN96	18	11
	00212	Oral	3	20 MG	21JUN96	19	25JUN96	23	5

\* DAYS RELATIVE TO START OF STUDY MEDICATION

573

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.004.00214		Oral	1	20 MG	04OCT96	1	08OCT96	5	5
	00214	Oral	2	20 MG	09OCT96	6	14OCT96	11	6
	00214	Oral	3	20 MG	15OCT96	12	20OCT96	17	6
	00214	Oral	4	20 MG	21OCT96	18	30OCT96	27	10
	00214	Oral	5	30 MG	01NOV96	29	10NOV96	38	10
	00214	Oral	5	30 MG	11NOV96	39	17NOV96	45	7
	00214	Oral	4	20 MG	18NOV96	46	24NOV96	52	7
	00214	Oral	4	20 MG	25NOV96	53	02DEC96	60	8
	00119	Oral	4	20 MG	03DEC96	61	30DEC96	88	28
329.005.00002		Oral	1	20 MG	25MAY94	1	31MAY94	7	7
	00002	Oral	2	20 MG	01JUN94	8	07JUN94	14	7
	00002	Oral	3	20 MG	08JUN94	15	14JUN94	21	7
	00002	Oral	4	20 MG	15JUN94	22	22JUN94	29	8
	00002	Oral	5	30 MG	23JUN94	30	29JUN94	36	7
	00002	Oral	6	40 MG	30JUN94	37	06JUL94	43	7
	00002	Oral	6	40 MG	07JUL94	44	12JUL94	49	6
	00002	Oral	6	40 MG	13JUL94	50	19JUL94	56	7
	00091	Oral	6	40 MG	20JUL94	57	16AUG94	84	28
	00091	Oral	6	40 MG	17AUG94	85	14SEP94	113	29
	00091	Oral	6	40 MG	15SEP94	114	17OCT94	146	33
	00091	Oral	6	40 MG	18OCT94	147	.	.	.
329.005.00004		Oral	1	20 MG	10OCT94	1	19OCT94	10	10
	00004	Oral	2	20 MG	20OCT94	11	26OCT94	17	7
	00004	Oral	3	20 MG	27OCT94	18	02NOV94	24	7
	00004	Oral	4	20 MG	03NOV94	25	09NOV94	31	7
	00004	Oral	5	30 MG	10NOV94	32	16NOV94	38	7
	00004	Oral	6	40 MG	17NOV94	39	22NOV94	44	6
	00004	Oral	6	40 MG	23NOV94	45	30NOV94	52	8
	00004	Oral	6	40 MG	01DEC94	53	07DEC94	59	7
	00093	Oral	6	40 MG	08DEC94	60	04JAN95	87	28
	00004	Oral	5	30 MG	05JAN95	88	20JAN95	103	16
329.005.00008		Oral	1	20 MG	16NOV94	1	22NOV94	7	7
	00008	Oral	2	20 MG	23NOV94	8	29NOV94	14	7
	00008	Oral	3	20 MG	30NOV94	15	06DEC94	21	7
	00008	Oral	4	20 MG	07DEC94	22	13DEC94	28	7
	00008	Oral	5	30 MG	14DEC94	29	20DEC94	35	7
	00008	Oral	6	40 MG	21DEC94	36	27DEC94	42	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

574

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00008	00008	Oral	6	40 MG	28DEC94	43	03JAN95	49	7
	00008	Oral	6	40 MG	04JAN95	50	09JAN95	55	6
	00095	Oral	5	30 MG	10JAN95	56	05FEB95	82	27
	00095	Oral	5	30 MG	06FEB95	83	07MAR95	112	30
	00095	Oral	5	30 MG	08MAR95	113	06APR95	142	30
329.005.00011		Oral	1	20 MG	13DEC94	1	19DEC94	7	7
	00011	Oral	2	20 MG	20DEC94	8	26DEC94	14	7
	00011	Oral	3	20 MG	27DEC94	15	02JAN95	21	7
	00011	Oral	4	20 MG	03JAN95	22	08JAN95	27	6
	00011	Oral	5	30 MG	09JAN95	28	16JAN95	35	8
	00011	Oral	6	40 MG	17JAN95	36	22JAN95	41	6
	00011	Oral	6	40 MG	23JAN95	42	30JAN95	49	8
	00011	Oral	6	40 MG	31JAN95	50	06FEB95	56	7
	00021	Oral	6	40 MG	07FEB95	57	08MAR95	86	30
	00021	Oral	6	40 MG	09MAR95	87	05APR95	114	28
	00021	Oral	6	40 MG	06APR95	115	02MAY95	141	27
	00021	Oral	5	30 MG	03MAY95	142	17MAY95	156	15
	329.005.00109		Oral	1	20 MG	30DEC94	1	04JAN95	6
00109		Oral	2	20 MG	05JAN95	7	11JAN95	13	7
00109		Oral	3	20 MG	12JAN95	14	18JAN95	20	7
00109		Oral	4	20 MG	19JAN95	21	25JAN95	27	7
00109		Oral	4	20 MG	26JAN95	28	01FEB95	34	7
00109		Oral	4	20 MG	02FEB95	35	07FEB95	40	6
00109		Oral	4	20 MG	08FEB95	41	15FEB95	48	8
00109		Oral	4	20 MG	16FEB95	49	20FEB95	53	5
00023		Oral	4	20 MG	21FEB95	54	22MAR95	83	30
00023		Oral	4	20 MG	23MAR95	84	23APR95	115	32
00023		Oral	4	20 MG	24APR95	116	16MAY95	138	23
329.005.00112		Oral	1	20 MG	26JAN95	1	31JAN95	6	6
	00112	Oral	2	20 MG	01FEB95	7	07FEB95	13	7
	00112	Oral	3	20 MG	08FEB95	14	14FEB95	20	7
	00112	Oral	4	20 MG	15FEB95	21	22FEB95	28	8
	00112	Oral	4	20 MG	23FEB95	29	28FEB95	34	6
	00112	Oral	4	20 MG	01MAR95	35	07MAR95	41	7
	00112	Oral	4	20 MG	08MAR95	42	14MAR95	48	7
	00112	Oral	4	20 MG	15MAR95	49	21MAR95	55	7
	00024	Oral	4	20 MG	22MAR95	56	18APR95	83	28

\* DAYS RELATIVE TO START OF STUDY MEDICATION

575

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00112	00112	Oral	2	20 MG	19APR95	84	21APR95	86	3
	00112	Oral	1	20 MG	22APR95	87	28APR95	93	7
329.005.00116		Oral	1	20 MG	07FEB95	1	12FEB95	6	6
	00116	Oral	2	20 MG	13FEB95	7	19FEB95	13	7
	00116	Oral	3	20 MG	20FEB95	14	26FEB95	20	7
	00116	Oral	4	20 MG	27FEB95	21	08MAR95	30	10
		Oral	4	20 MG	09MAR95	31	15MAR95	37	7
	00116	Oral	4	20 MG	16MAR95	38	22MAR95	44	7
	00116	Oral	4	20 MG	23MAR95	45	29MAR95	51	7
	00116	Oral	4	20 MG	30MAR95	52	05APR95	58	7
	00002	Oral	4	20 MG	06APR95	59	03MAY95	86	28
	00002	Oral	4	20 MG	04MAY95	87	30MAY95	113	27
	00002	Oral	5	30 MG	31MAY95	114	27JUN95	141	28
	00116	Oral	4	20 MG	28JUN95	142	29JUN95	143	2
	00116	Oral	3	20 MG	30JUN95	144	01JUL95	145	2
	00116	Oral	2	20 MG	02JUL95	146	04JUL95	148	3
00116	Oral	1	20 MG	05JUL95	149	11JUL95	155	7	
329.005.00119		Oral	1	20 MG	11JUL95	1	17JUL95	7	7
	00119	Oral	2	20 MG	18JUL95	8	25JUL95	15	8
	00119	Oral	3	20 MG	26JUL95	16	01AUG95	22	7
	00119	Oral	4	20 MG	02AUG95	23	07AUG95	28	6
	00119	Oral	5	30 MG	08AUG95	29	14AUG95	35	7
	00119	Oral	6	40 MG	15AUG95	36	22AUG95	43	8
	00119	Oral	6	40 MG	23AUG95	44	28AUG95	49	6
	00119	Oral	6	40 MG	29AUG95	50	07SEP95	59	10
	00056	Oral	6	40 MG	08SEP95	60	02OCT95	84	25
	00056	Oral	6	40 MG	03OCT95	85	29OCT95	111	27
	00056	Oral	6	40 MG	30OCT95	112	27NOV95	140	29
	00119	Oral	5	30 MG	28NOV95	141	.	.	.
	329.005.00151		Oral	1	20 MG	06SEP95	1	13SEP95	8
00151		Oral	2	20 MG	14SEP95	9	19SEP95	14	6
00151		Oral	3	20 MG	20SEP95	15	27SEP95	22	8
00151		Oral	4	20 MG	28SEP95	23	02OCT95	27	5
00151		Oral	4	20 MG	03OCT95	28	10OCT95	35	8
00151		Oral	4	20 MG	11OCT95	36	18OCT95	43	8
00151		Oral	4	20 MG	19OCT95	44	25OCT95	50	7
00151		Oral	4	20 MG	26OCT95	51	01NOV95	57	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

576

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00151	00030	Oral	4	20 MG	02NOV95	58	27NOV95	83	26
	00030	Oral	4	20 MG	28NOV95	84	03JAN96	120	37
	00030	Oral	5	30 MG	04JAN96	121	30JAN96	147	27
	00030	Oral	5	30 MG	31JAN96	148	26FEB96	174	27
	00192	Oral	5	30 MG	27FEB96	175	26MAR96	203	29
	00192	Oral	5	30 MG	27MAR96	204	30APR96	238	35
	00350	Oral	4	20 MG	01MAY96	239	.	.	.
329.005.00152		Oral	1	20 MG	26OCT95	1	30OCT95	5	5
329.005.00257		Oral	1	20 MG	11MAR96	1	17MAR96	7	7
	00257	Oral	2	20 MG	18MAR96	8	24MAR96	14	7
	00257	Oral	3	20 MG	25MAR96	15	31MAR96	21	7
	00257	Oral	4	20 MG	01APR96	22	07APR96	28	7
	00257	Oral	4	20 MG	08APR96	29	14APR96	35	7
	00257	Oral	4	20 MG	15APR96	36	21APR96	42	7
	00257	Oral	5	30 MG	22APR96	43	28APR96	49	7
	00257	Oral	5	30 MG	29APR96	50	05MAY96	56	7
	00144	Oral	5	30 MG	06MAY96	57	02JUN96	84	28
	00144	Oral	5	30 MG	03JUN96	85	07JUL96	119	35
	00144	Oral	5	30 MG	08JUL96	120	06AUG96	149	30
	00144	Oral	5	30 MG	07AUG96	150	26AUG96	169	20
	00144	Oral	5	30 MG	27AUG96	170	30SEP96	204	35
	00144	Oral	5	30 MG	01OCT96	205	21OCT96	225	21
	00257	Oral	4	20 MG	22OCT96	226	23OCT96	227	2
	00257	Oral	3	20 MG	24OCT96	228	25OCT96	229	2
	00257	Oral	2	20 MG	26OCT96	230	28OCT96	232	3
	00257	Oral	1	20 MG	29OCT96	233	04NOV96	239	7
329.005.00258		Oral	1	20 MG	12MAR96	1	18MAR96	7	7
	00258	Oral	2	20 MG	19MAR96	8	25MAR96	14	7
	00258	Oral	3	20 MG	26MAR96	15	01APR96	21	7
	00258	Oral	4	20 MG	02APR96	22	08APR96	28	7
	00258	Oral	5	30 MG	09APR96	29	17APR96	37	9
	00258	Oral	6	40 MG	18APR96	38	22APR96	42	5
	00258	Oral	6	40 MG	23APR96	43	29APR96	49	7
	00258	Oral	6	40 MG	30APR96	50	06MAY96	56	7
		Oral	5	30 MG	07MAY96	57	.	.	.
329.005.00299		Oral	1	20 MG	08JUN96	1	17JUN96	10	10

\* DAYS RELATIVE TO START OF STUDY MEDICATION

577

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00299	00299	Oral	2	20 MG	18JUN96	11	24JUN96	17	7
	00299	Oral	3	20 MG	25JUN96	18	01JUL96	24	7
	00299	Oral	4	20 MG	02JUL96	25	09JUL96	32	8
	00299	Oral	4	20 MG	10JUL96	33	21JUL96	44	12
		Oral	4	20 MG	22JUL96	45	30JUL96	53	9
	00299	Oral	4	20 MG	31JUL96	54	06AUG96	60	7
	00169	Oral	4	20 MG	07AUG96	61	02SEP96	87	27
	00169	Oral	4	20 MG	03SEP96	88	01OCT96	116	29
	00169	Oral	5	30 MG	02OCT96	117	28OCT96	143	27
	00169	Oral	5	30 MG	29OCT96	144	04NOV96	150	7
	00299	Oral	4	20 MG	05NOV96	151	06NOV96	152	2
	00299	Oral	3	20 MG	07NOV96	153	08NOV96	154	2
	00299	Oral	2	20 MG	09NOV96	155	11NOV96	157	3
	00299	Oral	1	20 MG	12NOV96	158	18NOV96	164	7
	329.005.00300		Oral	1	20 MG	19SEP96	1	25SEP96	7
00300		Oral	2	20 MG	26SEP96	8	02OCT96	14	7
00300		Oral	3	20 MG	03OCT96	15	09OCT96	21	7
00300		Oral	4	20 MG	10OCT96	22	16OCT96	28	7
00300		Oral	4	20 MG	17OCT96	29	23OCT96	35	7
00300		Oral	4	20 MG	24OCT96	36	30OCT96	42	7
00300		Oral	4	20 MG	31OCT96	43	06NOV96	49	7
00300		Oral	4	20 MG	07NOV96	50	13NOV96	56	7
		Oral	3	20 MG	14NOV96	57	.	.	.
329.005.00333			Oral	1	20 MG	23JAN97	1	30JAN97	8
	00333	Oral	2	20 MG	31JAN97	9	05FEB97	14	6
	00333	Oral	3	20 MG	06FEB97	15	12FEB97	21	7
	00333	Oral	4	20 MG	13FEB97	22	19FEB97	28	7
	00333	Oral	4	20 MG	20FEB97	29	24FEB97	33	5
329.005.00336		Oral	1	20 MG	04MAR97	1	11MAR97	8	8
	00336	Oral	2	20 MG	12MAR97	9	18MAR97	15	7
	00336	Oral	3	20 MG	19MAR97	16	24MAR97	21	6
	00336	Oral	4	20 MG	25MAR97	22	01APR97	29	8
	00336	Oral	4	20 MG	02APR97	30	08APR97	36	7
	00336	Oral	4	20 MG	09APR97	37	15APR97	43	7
	00336	Oral	4	20 MG	16APR97	44	22APR97	50	7
	00336	Oral	4	20 MG	23APR97	51	30APR97	58	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

578

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.006.00038		Oral	1	20 MG	15FEB95	1	21FEB95	7	7
	00038	Oral	2	20 MG	22FEB95	8	02MAR95	16	9
	00038	Oral	3	20 MG	03MAR95	17	07MAR95	21	5
	00038	Oral	4	20 MG	08MAR95	22	15MAR95	29	8
	00038	Oral	4	20 MG	16MAR95	30	22MAR95	36	7
	00038	Oral	4	20 MG	23MAR95	37	29MAR95	43	7
	00038	Oral	4	20 MG	30MAR95	44	04APR95	49	6
	00038	Oral	4	20 MG	05APR95	50	12APR95	57	8
329.006.00039		Oral	1	20 MG	08FEB95	1	13FEB95	6	6
	00039	Oral	2	20 MG	14FEB95	7	21FEB95	14	8
	00039	Oral	3	20 MG	22FEB95	15	01MAR95	22	8
	00039	Oral	4	20 MG	02MAR95	23	07MAR95	28	6
	00039	Oral	4	20 MG	08MAR95	29	17MAR95	38	10
	00039	Oral	4	20 MG	18MAR95	39	23MAR95	44	6
	00039	Oral	5	30 MG	24MAR95	45	28MAR95	49	5
	00039	Oral	5	30 MG	29MAR95	50	09APR95	61	12
	00057	Oral	5	30 MG	10APR95	62	30APR95	82	21
	00039	Oral	4	20 MG	01MAY95	83	05MAY95	87	5
	00039	Oral	3	20 MG	06MAY95	88	07MAY95	89	2
	00039	Oral	2	20 MG	08MAY95	90	08MAY95	90	1
	00039	Oral	1	20 MG	09MAY95	91	10MAY95	92	2
329.006.00260		Oral	1	20 MG	18JUL96	1	26JUL96	9	9
	00260	Oral	2	20 MG	27JUL96	10	31JUL96	14	5
	00260	Oral	3	20 MG	01AUG96	15	06AUG96	20	6
	00260	Oral	4	20 MG	07AUG96	21	13AUG96	27	7
	00260	Oral	5	30 MG	14AUG96	28	20AUG96	34	7
	00260	Oral	5	30 MG	21AUG96	35	27AUG96	41	7
	00260	Oral	5	30 MG	28AUG96	42	03SEP96	48	7
	00260	Oral	5	30 MG	04SEP96	49	13SEP96	58	10
	00172	Oral	5	30 MG	14SEP96	59	08OCT96	83	25
	00172	Oral	5	30 MG	09OCT96	84	08NOV96	114	31
	00172	Oral	5	30 MG	09NOV96	115	04DEC96	140	26
	00260	Oral	4	20 MG	05DEC96	141	08DEC96	144	4
	00260	Oral	3	20 MG	09DEC96	145	11DEC96	147	3
	00260	Oral	2	20 MG	12DEC96	148	13DEC96	149	2
	00260	Oral	1	20 MG	14DEC96	150	18DEC96	154	5
329.006.00261		Oral	1	20 MG	26NOV96	1	02DEC96	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

579

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.006.00261	00261	Oral	2	20 MG	03DEC96	8	09DEC96	14	7
	00261	Oral	3	20 MG	10DEC96	15	16DEC96	21	7
	00261	Oral	4	20 MG	17DEC96	22	23DEC96	28	7
	00261	Oral	5	30 MG	24DEC96	29	01JAN97	37	9
	00261	Oral	5	30 MG	02JAN97	38	08JAN97	44	7
	00261	Oral	5	30 MG	09JAN97	45	14JAN97	50	6
	00261	Oral	5	30 MG	15JAN97	51	22JAN97	58	8
	00187	Oral	5	30 MG	23JAN97	59	19FEB97	86	28
	00187	Oral	5	30 MG	20FEB97	87	02APR97	128	42
	00261	Oral	5	30 MG	02APR97	128	03APR97	129	2
	00261	Oral	4	20 MG	04APR97	130	05APR97	131	2
	00261	Oral	3	20 MG	06APR97	132	07APR97	133	2
	00261	Oral	2	20 MG	08APR97	134	10APR97	136	3
	00261	Oral	1	20 MG	11APR97	137	29APR97	155	19
329.007.00140		Oral	1	20 MG	15SEP95	1	20SEP95	6	6
	00140	Oral	2	20 MG	21SEP95	7	27SEP95	13	7
	00140	Oral	3	20 MG	28SEP95	14	04OCT95	20	7
	00140	Oral	4	20 MG	05OCT95	21	11OCT95	27	7
	00140	Oral	4	20 MG	12OCT95	28	17OCT95	33	6
	00140	Oral	4	20 MG	18OCT95	34	25OCT95	41	8
	00140	Oral	4	20 MG	26OCT95	42	01NOV95	48	7
	00140	Oral	4	20 MG	02NOV95	49	08NOV95	55	7
	00005	Oral	4	20 MG	09NOV95	56	21NOV95	68	13
	00140	Oral	4	20 MG	22NOV95	69	.	.	.
329.007.00142		Oral	1	20 MG	18OCT95	1	25OCT95	8	8
	00142	Oral	2	20 MG	26OCT95	9	01NOV95	15	7
	00142	Oral	3	20 MG	02NOV95	16	08NOV95	22	7
	00142	Oral	4	20 MG	09NOV95	23	15NOV95	29	7
	00142	Oral	5	30 MG	16NOV95	30	21NOV95	35	6
	00142	Oral	5	30 MG	22NOV95	36	29NOV95	43	8
	00142	Oral	6	40 MG	30NOV95	44	04DEC95	48	5
329.007.00145		Oral	1	20 MG	11JAN96	1	17JAN96	7	7
	00145	Oral	2	20 MG	18JAN96	8	24JAN96	14	7
	00145	Oral	3	20 MG	25JAN96	15	31JAN96	21	7
		Oral	4	20 MG	01FEB96	22	07FEB96	28	7
	00348	Oral	5	30 MG	08FEB96	29	11FEB96	32	4
	00348	Oral	5	30 MG	12FEB96	33	20FEB96	41	9

\* DAYS RELATIVE TO START OF STUDY MEDICATION

580

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.007.00145	00348	Oral	5	30 MG	21FEB96	42	25FEB96	46	5
	00348	Oral	6	40 MG	26FEB96	47	06MAR96	56	10
	00190	Oral	6	40 MG	07MAR96	57	03APR96	84	28
	00190	Oral	6	40 MG	04APR96	85	01MAY96	112	28
	00190	Oral	5	30 MG	02MAY96	113	13MAY96	124	12
	00190	Oral	4	20 MG	14MAY96	125	29MAY96	140	16
	00190	Oral	4	20 MG	30MAY96	141	26JUN96	168	28
	00190	Oral	4	20 MG	27JUN96	169	24JUL96	196	28
	00190	Oral	4	20 MG	25JUL96	197	22AUG96	225	29
	00348	Oral	3	20 MG	23AUG96	226	.	.	.
329.007.00265		Oral	1	20 MG	01FEB96	1	14FEB96	14	14
	00265	Oral	2	20 MG	15FEB96	15	.	.	.
329.007.00268		Oral	1	20 MG	01APR96	1	10APR96	10	10
	00268	Oral	2	20 MG	11APR96	11	17APR96	17	7
	00268	Oral	3	20 MG	18APR96	18	24APR96	24	7
	00268	Oral	4	20 MG	25APR96	25	01MAY96	31	7
	00268	Oral	4	20 MG	02MAY96	32	08MAY96	38	7
	00268	Oral	4	20 MG	09MAY96	39	15MAY96	45	7
	00268	Oral	5	30 MG	16MAY96	46	23MAY96	53	8
	00268	Oral	5	30 MG	24MAY96	54	29MAY96	59	6
	00157	Oral	5	30 MG	30MAY96	60	26JUN96	87	28
	00157	Oral	5	30 MG	27JUN96	88	31JUL96	122	35
	00157	Oral	6	40 MG	01AUG96	123	29AUG96	151	29
	00157	Oral	6	40 MG	30AUG96	152	29SEP96	182	31
	00157	Oral	5	30 MG	30SEP96	183	06NOV96	220	38
	00157	Oral	5	30 MG	07NOV96	221	04DEC96	248	28
	00268	Oral	4	20 MG	05DEC96	249	18DEC96	262	14
329.007.00294		Oral	1	20 MG	28FEB97	1	09MAR97	10	10
	00294	Oral	2	20 MG	10MAR97	11	16MAR97	17	7
	00294	Oral	3	20 MG	17MAR97	18	27MAR97	28	11
	00294	Oral	4	20 MG	28MAR97	29	02APR97	34	6
	00294	Oral	5	30 MG	03APR97	35	09APR97	41	7
	00294	Oral	4	20 MG	10APR97	42	.	.	.
329.007.00309		Oral	1	20 MG	15JUL96	1	17JUL96	3	3
	00309	Oral	2	20 MG	18JUL96	4	24JUL96	10	7
	00309	Oral	3	20 MG	25JUL96	11	31JUL96	17	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

581

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.007.00309	00309	Oral	4	20 MG	01AUG96	18	07AUG96	24	7
	00309	Oral	4	20 MG	08AUG96	25	14AUG96	31	7
	00309	Oral	4	20 MG	15AUG96	32	22AUG96	39	8
	00309	Oral	4	20 MG	23AUG96	40	29AUG96	46	7
	00309	Oral	4	20 MG	30AUG96	47	04SEP96	52	6
	00170	Oral	4	20 MG	05SEP96	53	02OCT96	80	28
	00170	Oral	4	20 MG	03OCT96	81	30OCT96	108	28
	00170	Oral	4	20 MG	31OCT96	109	12DEC96	151	43
	00170	Oral	4	20 MG	13DEC96	152	08JAN97	178	27
	00170	Oral	4	20 MG	09JAN97	179	09FEB97	210	32
	00170	Oral	5	30 MG	10FEB97	211	12MAR97	241	31
	00309	Oral	4	20 MG	13MAR97	242	26MAR97	255	14
329.007.00310		Oral	1	20 MG	26SEP96	1	02OCT96	7	7
	00310	Oral	2	20 MG	03OCT96	8	09OCT96	14	7
	00310	Oral	3	20 MG	10OCT96	15	16OCT96	21	7
	00310	Oral	4	20 MG	17OCT96	22	27OCT96	32	11
	00310	Oral	4	20 MG	28OCT96	33	30OCT96	35	3
	00310	Oral	4	20 MG	31OCT96	36	07NOV96	43	8
	00310	Oral	4	20 MG	08NOV96	44	17NOV96	53	10
	00310	Oral	4	20 MG	18NOV96	54	24NOV96	60	7
	00180	Oral	4	20 MG	25NOV96	61	01JAN97	98	38
	00180	Oral	4	20 MG	02JAN97	99	13FEB97	141	43
	00180	Oral	4	20 MG	14FEB97	142	12MAR97	168	27
	00180	Oral	4	20 MG	13MAR97	169	16APR97	203	35
	00180	Oral	4	20 MG	17APR97	204	14MAY97	231	28
	00180	Oral	4	20 MG	15MAY97	232	11JUN97	259	28
	00310	Oral	3	20 MG	12JUN97	260	23JUN97	271	12
329.007.00318		Oral	1	20 MG	02DEC96	1	.	.	.
329.008.00157		Oral	1	20 MG	30AUG95	1	04SEP95	6	6
	00157	Oral	2	20 MG	05SEP95	7	12SEP95	14	8
	00157	Oral	3	20 MG	13SEP95	15	19SEP95	21	7
	00157	Oral	4	20 MG	20SEP95	22	26SEP95	28	7
	00157	Oral	4	20 MG	27SEP95	29	03OCT95	35	7
	00157	Oral	4	20 MG	04OCT95	36	09OCT95	41	6
	00157	Oral	4	20 MG	10OCT95	42	15OCT95	47	6
	00157	Oral	4	20 MG	16OCT95	48	23OCT95	55	8
		Oral	4	20 MG	24OCT95	56	22NOV95	85	30

\* DAYS RELATIVE TO START OF STUDY MEDICATION

582

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.008.00157	00100	Oral	4	20 MG	23NOV95	86	14DEC95	107	22
	00100	Oral	4	20 MG	15DEC95	108	22JAN96	146	39
	00100	Oral	4	20 MG	23JAN96	147	19FEB96	174	28
329.008.00160		Oral	1	20 MG	01NOV95	1	09NOV95	9	9
	00160	Oral	2	20 MG	10NOV95	10	19NOV95	19	10
	00160	Oral	3	20 MG	20NOV95	20	26NOV95	26	7
	00160	Oral	4	20 MG	27NOV95	27	04DEC95	34	8
	00160	Oral	4	20 MG	05DEC95	35	12DEC95	42	8
	00160	Oral	5	30 MG	13DEC95	43	19DEC95	49	7
	00160	Oral	5	30 MG	20DEC95	50	26DEC95	56	7
	00160	Oral	5	30 MG	27DEC95	57	05JAN96	66	10
	00104	Oral	5	30 MG	06JAN96	67	30JAN96	91	25
	00104	Oral	5	30 MG	31JAN96	92	04MAR96	125	34
	00104	Oral	5	30 MG	05MAR96	126	08APR96	160	35
	00104	Oral	5	30 MG	09APR96	161	15MAY96	197	37
	00104	Oral	5	30 MG	16MAY96	198	17JUN96	230	33
	00104	Oral	5	30 MG	18JUN96	231	22JUL96	265	35
	00160	Oral	5	30 MG	23JUL96	266	24JUL96	267	2
	00160	Oral	4	20 MG	25JUL96	268	26JUL96	269	2
	00160	Oral	3	20 MG	27JUL96	270	28JUL96	271	2
00160	Oral	2	20 MG	29JUL96	272	31JUL96	274	3	
00160	Oral	1	20 MG	01AUG96	275	07AUG96	281	7	
329.008.00188		Oral	1	20 MG	04JAN96	1	09JAN96	6	6
	00188	Oral	2	20 MG	10JAN96	7	16JAN96	13	7
	00188	Oral	3	20 MG	17JAN96	14	23JAN96	20	7
	00188	Oral	4	20 MG	24JAN96	21	30JAN96	27	7
	00188	Oral	5	30 MG	31JAN96	28	06FEB96	34	7
	00188	Oral	6	40 MG	07FEB96	35	13FEB96	41	7
	00188	Oral	6	40 MG	14FEB96	42	20FEB96	48	7
	00188	Oral	6	40 MG	21FEB96	49	27FEB96	55	7
	329.008.00271		Oral	1	20 MG	11MAR96	1	17MAR96	7
00271		Oral	2	20 MG	18MAR96	8	24MAR96	14	7
00271		Oral	3	20 MG	25MAR96	15	31MAR96	21	7
00271		Oral	4	20 MG	01APR96	22	07APR96	28	7
00271		Oral	4	20 MG	08APR96	29	14APR96	35	7
00271		Oral	5	30 MG	15APR96	36	21APR96	42	7
00271		Oral	6	40 MG	22APR96	43	01MAY96	52	10

\* DAYS RELATIVE TO START OF STUDY MEDICATION

583

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.008.00271	00271	Oral	6	40 MG	02MAY96	53	13MAY96	64	12
	00137	Oral	6	40 MG	14MAY96	65	09JUN96	91	27
	00137	Oral	6	40 MG	10JUN96	92	11JUL96	123	32
	00137	Oral	6	40 MG	12JUL96	124	08AUG96	151	28
	00137	Oral	6	40 MG	09AUG96	152	09SEP96	183	32
	00137	Oral	6	40 MG	10SEP96	184	06OCT96	210	27
	00137	Oral	6	40 MG	07OCT96	211	04NOV96	239	29
	00271	Oral	5	30 MG	05NOV96	240	06NOV96	241	2
	00271	Oral	4	20 MG	07NOV96	242	08NOV96	243	2
	00271	Oral	3	20 MG	09NOV96	244	10NOV96	245	2
	00271	Oral	2	20 MG	11NOV96	246	13NOV96	248	3
	00271	Oral	1	20 MG	14NOV96	249	20NOV96	255	7
329.008.00275		Oral	1	20 MG	08MAY96	1	14MAY96	7	7
	00275	Oral	2	20 MG	15MAY96	8	20MAY96	13	6
	00275	Oral	3	20 MG	21MAY96	14	27MAY96	20	7
	00275	Oral	4	20 MG	28MAY96	21	03JUN96	27	7
	00275	Oral	5	30 MG	04JUN96	28	10JUN96	34	7
	00275	Oral	5	30 MG	11JUN96	35	24JUN96	48	14
	00275	Oral	6	40 MG	25JUN96	49	01JUL96	55	7
	00163	Oral	5	30 MG	02JUL96	56	22JUL96	76	21
	00163	Oral	5	30 MG	23JUL96	77	19AUG96	104	28
	00163	Oral	5	30 MG	20AUG96	105	15SEP96	131	27
	00163	Oral	5	30 MG	16SEP96	132	20OCT96	166	35
	00163	Oral	5	30 MG	21OCT96	167	24NOV96	201	35
	00163	Oral	5	30 MG	25NOV96	202	16DEC96	223	22
329.009.00130		Oral	1	20 MG	18APR95	1	24APR95	7	7
	00130	Oral	2	20 MG	25APR95	8	01MAY95	14	7
	00130	Oral	3	20 MG	02MAY95	15	08MAY95	21	7
	00130	Oral	4	20 MG	09MAY95	22	15MAY95	28	7
	00130	Oral	4	20 MG	16MAY95	29	22MAY95	35	7
	00130	Oral	4	20 MG	23MAY95	36	29MAY95	42	7
	00130	Oral	4	20 MG	30MAY95	43	05JUN95	49	7
	00130	Oral	4	20 MG	06JUN95	50	12JUN95	56	7
	00010	Oral	4	20 MG	13JUN95	57	06AUG95	111	55
	00010	Oral	4	20 MG	07AUG95	112	18SEP95	154	43
	00010	Oral	4	20 MG	19SEP95	155	02OCT95	168	14
	00130	Oral	4	20 MG	03OCT95	169	04OCT95	170	2
	00130	Oral	3	20 MG	05OCT95	171	06OCT95	172	2

\* DAYS RELATIVE TO START OF STUDY MEDICATION

584

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00130	00130	Oral	2	20 MG	07OCT95	173	09OCT95	175	3
	00130	Oral	1	20 MG	10OCT95	176	16OCT95	182	7
329.009.00131		Oral	1	20 MG	02MAY95	1	08MAY95	7	7
	00131	Oral	2	20 MG	09MAY95	8	15MAY95	14	7
	00131	Oral	3	20 MG	16MAY95	15	22MAY95	21	7
	00131	Oral	4	20 MG	23MAY95	22	29MAY95	28	7
	00131	Oral	4	20 MG	30MAY95	29	05JUN95	35	7
	00131	Oral	4	20 MG	06JUN95	36	12JUN95	42	7
	00131	Oral	4	20 MG	13JUN95	43	19JUN95	49	7
	00131	Oral	4	20 MG	20JUN95	50	26JUN95	56	7
	00011	Oral	4	20 MG	27JUN95	57	24JUL95	84	28
	00011	Oral	4	20 MG	25JUL95	85	23AUG95	114	30
	00011	Oral	4	20 MG	24AUG95	115	27AUG95	118	4
329.009.00133		Oral	1	20 MG	13JUN95	1	19JUN95	7	7
	00133	Oral	2	20 MG	20JUN95	8	26JUN95	14	7
	00133	Oral	3	20 MG	27JUN95	15	04JUL95	22	8
	00133	Oral	4	20 MG	05JUL95	23	10JUL95	28	6
	00133	Oral	5	30 MG	11JUL95	29	17JUL95	35	7
	00133	Oral	6	40 MG	18JUL95	36	27JUL95	45	10
329.009.00138		Oral	1	20 MG	10OCT95	1	13OCT95	4	4
329.009.00170		Oral	1	20 MG	07NOV95	1	13NOV95	7	7
	00170	Oral	2	20 MG	14NOV95	8	20NOV95	14	7
	00170	Oral	3	20 MG	21NOV95	15	27NOV95	21	7
	00170	Oral	4	20 MG	28NOV95	22	04DEC95	28	7
	00170	Oral	5	30 MG	05DEC95	29	11DEC95	35	7
	00170	Oral	6	40 MG	12DEC95	36	20DEC95	44	9
	00170	Oral	6	40 MG	21DEC95	45	28DEC95	52	8
	00170	Oral	5	30 MG	29DEC95	53	02JAN96	57	5
	00102	Oral	5	30 MG	03JAN96	58	28JAN96	83	26
	00102	Oral	5	30 MG	29JAN96	84	25FEB96	111	28
	00102	Oral	5	30 MG	26FEB96	112	31MAR96	146	35
	00102	Oral	5	30 MG	01APR96	147	21APR96	167	21
	00102	Oral	5	30 MG	22APR96	168	22MAY96	198	31
	00102	Oral	5	30 MG	23MAY96	199	24JUN96	231	33
	00358	Oral	4	20 MG	25JUN96	232	26JUN96	233	2
00358	Oral	3	20 MG	27JUN96	234	28JUN96	235	2	

\* DAYS RELATIVE TO START OF STUDY MEDICATION

585

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00170	00358	Oral	2	20 MG	29JUN96	236	01JUL96	238	3
	00358	Oral	1	20 MG	02JUL96	239	08JUL96	245	7
329.009.00173		Oral	1	20 MG	20NOV95	1	26NOV95	7	7
	00173	Oral	2	20 MG	27NOV95	8	03DEC95	14	7
	00173	Oral	3	20 MG	04DEC95	15	10DEC95	21	7
	00173	Oral	4	20 MG	11DEC95	22	17DEC95	28	7
	00173	Oral	5	30 MG	18DEC95	29	28DEC95	39	11
	00173	Oral	5	30 MG	29DEC95	40	07JAN96	49	10
	00173	Oral	4	20 MG	08JAN96	50	14JAN96	56	7
	00173	Oral	4	20 MG	15JAN96	57	21JAN96	63	7
	00108	Oral	4	20 MG	22JAN96	64	26FEB96	99	36
	00173	Oral	4	20 MG	27FEB96	100	.	.	.
329.009.00193		Oral	1	20 MG	28NOV95	1	04DEC95	7	7
	00193	Oral	2	20 MG	05DEC95	8	11DEC95	14	7
	00193	Oral	3	20 MG	12DEC95	15	18DEC95	21	7
	00193	Oral	4	20 MG	19DEC95	22	26DEC95	29	8
	00193	Oral	5	30 MG	27DEC95	30	04JAN96	38	9
	00193	Oral	5	30 MG	05JAN96	39	08JAN96	42	4
	00193	Oral	5	30 MG	09JAN96	43	15JAN96	49	7
	00193	Oral	5	30 MG	16JAN96	50	23JAN96	57	8
		Oral	1	20 MG	24JAN96	58	06FEB96	71	14
	329.009.00196		Oral	1	20 MG	18DEC95	1	26DEC95	9
00196		Oral	2	20 MG	27DEC95	10	01JAN96	15	6
00196		Oral	3	20 MG	02JAN96	16	07JAN96	21	6
00196		Oral	4	20 MG	08JAN96	22	14JAN96	28	7
00196		Oral	5	30 MG	15JAN96	29	21JAN96	35	7
00196		Oral	5	30 MG	22JAN96	36	28JAN96	42	7
00196		Oral	5	30 MG	29JAN96	43	04FEB96	49	7
00196		Oral	5	30 MG	05FEB96	50	11FEB96	56	7
00196		Oral	4	20 MG	12FEB96	57	25FEB96	70	14
329.009.00201			Oral	1	20 MG	06FEB96	1	12FEB96	7
	00201	Oral	2	20 MG	13FEB96	8	19FEB96	14	7
	00201	Oral	3	20 MG	20FEB96	15	27FEB96	22	8
	00201	Oral	4	20 MG	28FEB96	23	04MAR96	28	6
	00201	Oral	4	20 MG	05MAR96	29	11MAR96	35	7
	00201	Oral	4	20 MG	12MAR96	36	18MAR96	42	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

586

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00201	00201	Oral	4	20 MG	19MAR96	43	25MAR96	49	7
	00201	Oral	5	30 MG	26MAR96	50	01APR96	56	7
		Oral	4	20 MG	02APR96	57	04APR96	59	3
329.009.00204		Oral	1	20 MG	19MAR96	1	25MAR96	7	7
	00204	Oral	2	20 MG	26MAR96	8	01APR96	14	7
	00204	Oral	3	20 MG	02APR96	15	08APR96	21	7
	00204	Oral	4	20 MG	09APR96	22	15APR96	28	7
	00204	Oral	4	20 MG	16APR96	29	22APR96	35	7
	00204	Oral	4	20 MG	23APR96	36	29APR96	42	7
	00204	Oral	4	20 MG	30APR96	43	06MAY96	49	7
	00204	Oral	4	20 MG	07MAY96	50	13MAY96	56	7
	00149	Oral	4	20 MG	14MAY96	57	10JUN96	84	28
	00149	Oral	4	20 MG	11JUN96	85	08JUL96	112	28
	00149	Oral	4	20 MG	09JUL96	113	12AUG96	147	35
	00149	Oral	4	20 MG	13AUG96	148	09SEP96	175	28
	00149	Oral	4	20 MG	10SEP96	176	14OCT96	210	35
	00149	Oral	4	20 MG	15OCT96	211	.	.	.
329.009.00235		Oral	1	20 MG	18DEC96	1	22DEC96	5	5
	00235	Oral	2	20 MG	23DEC96	6	29DEC96	12	7
	00235	Oral	3	20 MG	30DEC96	13	05JAN97	19	7
	00235	Oral	4	20 MG	06JAN97	20	14JAN97	28	9
	00235	Oral	4	20 MG	15JAN97	29	19JAN97	33	5
	00235	Oral	4	20 MG	20JAN97	34	26JAN97	40	7
	00235	Oral	4	20 MG	27JAN97	41	02FEB97	47	7
	00235	Oral	4	20 MG	03FEB97	48	09FEB97	54	7
	00109	Oral	4	20 MG	10FEB97	55	17MAR97	90	36
	00109	Oral	4	20 MG	17MAR97	90	13APR97	117	28
	00235	Oral	4	20 MG	14APR97	118	14APR97	118	1
	00235	Oral	3	20 MG	15APR97	119	16APR97	120	2
	00235	Oral	2	20 MG	17APR97	121	19APR97	123	3
	00235	Oral	1	20 MG	20APR97	124	26APR97	130	7
329.009.00240		Oral	1	20 MG	14JAN97	1	20JAN97	7	7
	00240	Oral	2	20 MG	21JAN97	8	27JAN97	14	7
	00240	Oral	3	20 MG	28JAN97	15	03FEB97	21	7
	00240	Oral	4	20 MG	04FEB97	22	10FEB97	28	7
	00240	Oral	4	20 MG	11FEB97	29	17FEB97	35	7
	00240	Oral	5	30 MG	18FEB97	36	25FEB97	43	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

587

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS	
329.009.00240	00240	Oral	5	30 MG	25FEB97	43	04MAR97	50	8	
		Oral	5	30 MG	04MAR97	50	05MAR97	51	2	
329.009.00303		Oral	1	20 MG	02APR96	1	08APR96	7	7	
		00303	Oral	2	20 MG	09APR96	8	15APR96	14	7
		00303	Oral	3	20 MG	16APR96	15	22APR96	21	7
		00303	Oral	4	20 MG	23APR96	22	29APR96	28	7
		00303	Oral	4	20 MG	30APR96	29	06MAY96	35	7
		00303	Oral	4	20 MG	07MAY96	36	13MAY96	42	7
		00303	Oral	4	20 MG	14MAY96	43	21MAY96	50	8
		00303	Oral	4	20 MG	22MAY96	51	27MAY96	56	6
		00155	Oral	4	20 MG	28MAY96	57	24JUN96	84	28
		00155	Oral	4	20 MG	25JUN96	85	29JUL96	119	35
		00155	Oral	4	20 MG	30JUL96	120	26AUG96	147	28
		00155	Oral	4	20 MG	27AUG96	148	24SEP96	176	29
		00155	Oral	4	20 MG	25SEP96	177	29OCT96	211	35
		00155	Oral	4	20 MG	30OCT96	212	09DEC96	252	41
		00303	Oral	4	20 MG	10DEC96	253	10DEC96	253	1
		00303	Oral	3	20 MG	11DEC96	254	12DEC96	255	2
		00303	Oral	2	20 MG	13DEC96	256	15DEC96	258	3
00303	Oral	1	20 MG	16DEC96	259	22DEC96	265	7		
329.009.00304		Oral	1	20 MG	09APR96	1	15APR96	7	7	
		00304	Oral	2	20 MG	16APR96	8	22APR96	14	7
		00304	Oral	3	20 MG	23APR96	15	29APR96	21	7
		00304	Oral	4	20 MG	30APR96	22	06MAY96	28	7
		00304	Oral	5	30 MG	07MAY96	29	13MAY96	35	7
		00304	Oral	5	30 MG	14MAY96	36	20MAY96	42	7
		00304	Oral	5	30 MG	21MAY96	43	27MAY96	49	7
		00304	Oral	5	30 MG	28MAY96	50	03JUN96	56	7
		00159	Oral	5	30 MG	04JUN96	57	01JUL96	84	28
		00159	Oral	5	30 MG	02JUL96	85	29JUL96	112	28
		00159	Oral	5	30 MG	30JUL96	113	26AUG96	140	28
		00159	Oral	5	30 MG	27AUG96	141	22SEP96	167	27
		00159	Oral	5	30 MG	23SEP96	168	21OCT96	196	29
		00304	Oral	4	20 MG	22OCT96	197	23OCT96	198	2
		00304	Oral	3	20 MG	24OCT96	199	24OCT96	199	1
		00304	Oral	2	20 MG	25OCT96	200	28OCT96	203	4
		00304	Oral	1	20 MG	29OCT96	204	04NOV96	210	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

588

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00324		Oral	1	20 MG	28OCT96	1	03NOV96	7	7
	00324	Oral	2	20 MG	04NOV96	8	10NOV96	14	7
	00324	Oral	3	20 MG	11NOV96	15	17NOV96	21	7
	00324	Oral	4	20 MG	18NOV96	22	24NOV96	28	7
	00324	Oral	4	20 MG	25NOV96	29	01DEC96	35	7
	00324	Oral	4	20 MG	02DEC96	36	08DEC96	42	7
	00324	Oral	4	20 MG	09DEC96	43	15DEC96	49	7
	00324	Oral	4	20 MG	16DEC96	50	26DEC96	60	11
		Oral	4	20 MG	27DEC96	61	08JAN97	73	13
329.009.00328		Oral	1	20 MG	07OCT96	1	.	.	.
329.009.00329		Oral	1	20 MG	09OCT96	1	15OCT96	7	7
	00329	Oral	2	20 MG	16OCT96	8	22OCT96	14	7
	00329	Oral	3	20 MG	23OCT96	15	28OCT96	20	6
	00329	Oral	4	20 MG	29OCT96	21	04NOV96	27	7
	00329	Oral	4	20 MG	05NOV96	28	11NOV96	34	7
	00329	Oral	4	20 MG	12NOV96	35	18NOV96	41	7
	00329	Oral	5	30 MG	19NOV96	42	25NOV96	48	7
	00329	Oral	5	30 MG	26NOV96	49	02DEC96	55	7
		Oral	5	30 MG	03DEC96	56	17DEC96	70	15
329.010.00182	00182	Oral	3	20 MG	19DEC95	1	11JAN96	24	24
	00182	Oral	4	20 MG	12JAN96	25	18JAN96	31	7
	00182	Oral	4	20 MG	19JAN96	32	.	.	.
329.010.00278		Oral	1	20 MG	09FEB96	1	15FEB96	7	7
	00278	Oral	2	20 MG	16FEB96	8	22FEB96	14	7
	00278	Oral	3	20 MG	23FEB96	15	29FEB96	21	7
	00278	Oral	4	20 MG	01MAR96	22	07MAR96	28	7
	00278	Oral	4	20 MG	08MAR96	29	14MAR96	35	7
	00278	Oral	5	30 MG	15MAR96	36	21MAR96	42	7
	00278	Oral	6	40 MG	22MAR96	43	28MAR96	49	7
	00278	Oral	6	40 MG	29MAR96	50	04APR96	56	7
	00132	Oral	6	40 MG	05APR96	57	02MAY96	84	28
	00132	Oral	6	40 MG	03MAY96	85	30MAY96	112	28
	00132	Oral	6	40 MG	31MAY96	113	26JUN96	139	27
	00132	Oral	6	40 MG	27JUN96	140	24JUL96	167	28
	00132	Oral	6	40 MG	25JUL96	168	21AUG96	195	28
	00132	Oral	6	40 MG	22AUG96	196	19SEP96	224	29

\* DAYS RELATIVE TO START OF STUDY MEDICATION

589

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.010.00278	00278	Oral	5	30 MG	20SEP96	225	21SEP96	226	2
	00278	Oral	4	20 MG	22SEP96	227	23SEP96	228	2
	00278	Oral	3	20 MG	24SEP96	229	25SEP96	230	2
	00278	Oral	2	20 MG	26SEP96	231	28SEP96	233	3
	00278	Oral	1	20 MG	29SEP96	234	05OCT96	240	7
329.010.00280		Oral	1	20 MG	17MAY96	1	23MAY96	7	7
	00280	Oral	2	20 MG	24MAY96	8	30MAY96	14	7
	00280	Oral	3	20 MG	31MAY96	15	06JUN96	21	7
	00280	Oral	4	20 MG	07JUN96	22	13JUN96	28	7
	00280	Oral	4	20 MG	14JUN96	29	20JUN96	35	7
	00280	Oral	5	30 MG	21JUN96	36	26JUN96	41	6
	00280	Oral	6	40 MG	27JUN96	42	02JUL96	47	6
	00280	Oral	6	40 MG	03JUL96	48	10JUL96	55	8
		Oral	6	40 MG	11JUL96	56	29JUL96	74	19
329.011.00283		Oral	1	20 MG	08FEB96	1	14FEB96	7	7
	00283	Oral	2	20 MG	15FEB96	8	21FEB96	14	7
	00283	Oral	3	20 MG	22FEB96	15	29FEB96	22	8
	00283	Oral	4	20 MG	01MAR96	23	07MAR96	29	7
	00283	Oral	4	20 MG	08MAR96	30	15MAR96	37	8
	00283	Oral	4	20 MG	16MAR96	38	22MAR96	44	7
	00283	Oral	4	20 MG	23MAR96	45	28MAR96	50	6
	00283	Oral	4	20 MG	29MAR96	51	04APR96	57	7
	00130	Oral	4	20 MG	05APR96	58	.	.	.
	329.011.00288		Oral	1	20 MG	25JUL96	1	31JUL96	7
00288		Oral	2	20 MG	01AUG96	8	08AUG96	15	8
00288		Oral	3	20 MG	09AUG96	16	18AUG96	25	10
00288		Oral	4	20 MG	19AUG96	26	29AUG96	36	11
00288		Oral	4	20 MG	30AUG96	37	05SEP96	43	7
329.012.00025		Oral	1	20 MG	24OCT95	1	30OCT95	7	7
	00025	Oral	2	20 MG	31OCT95	8	06NOV95	14	7
	00025	Oral	3	20 MG	07NOV95	15	13NOV95	21	7
	00025	Oral	4	20 MG	14NOV95	22	20NOV95	28	7
	00025	Oral	4	20 MG	21NOV95	29	27NOV95	35	7
	00025	Oral	5	30 MG	28NOV95	36	04DEC95	42	7
	00025	Oral	6	40 MG	05DEC95	43	11DEC95	49	7
	00025	Oral	6	40 MG	12DEC95	50	19DEC95	57	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

590

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.012.00025		Oral	5	30 MG	20DEC95	58	04JAN96	73	16
329.012.00220		Oral	1	20 MG	17JUN96	1	21JUN96	5	5
	00220	Oral	2	20 MG	22JUN96	6	27JUN96	11	6
	00220	Oral	3	20 MG	28JUN96	12	04JUL96	18	7
	00220	Oral	4	20 MG	05JUL96	19	11JUL96	25	7
	00220	Oral	5	30 MG	12JUL96	26	18JUL96	32	7
	00220	Oral	5	30 MG	19JUL96	33	28JUL96	42	10
	00220	Oral	5	30 MG	29JUL96	43	05AUG96	50	8
	00220	Oral	5	30 MG	06AUG96	51	15AUG96	60	10
	00110	Oral	5	30 MG	16AUG96	61	12SEP96	88	28
	00110	Oral	5	30 MG	13SEP96	89	10OCT96	116	28
	00110	Oral	5	30 MG	11OCT96	117	07NOV96	144	28
	00110	Oral	5	30 MG	08NOV96	145	21NOV96	158	14
	00220	Oral	5	30 MG	22NOV96	159	.	.	.
329.012.00222		Oral	1	20 MG	28JUN96	1	04JUL96	7	7
	00222	Oral	2	20 MG	05JUL96	8	11JUL96	14	7
	00222	Oral	3	20 MG	12JUL96	15	18JUL96	21	7
	00222	Oral	4	20 MG	19JUL96	22	28JUL96	31	10
	00222	Oral	4	20 MG	29JUL96	32	05AUG96	39	8
	00222	Oral	5	30 MG	06AUG96	40	12AUG96	46	7
	00222	Oral	5	30 MG	13AUG96	47	19AUG96	53	7
	00222	Oral	5	30 MG	20AUG96	54	29AUG96	63	10
	00113	Oral	5	30 MG	30AUG96	64	21SEP96	86	23
329.012.00226		Oral	1	20 MG	03DEC96	1	09DEC96	7	7
	00226	Oral	2	20 MG	10DEC96	8	19DEC96	17	10
	00226	Oral	3	20 MG	20DEC96	18	20DEC96	18	1
329.012.00228		Oral	1	20 MG	19MAR97	1	22MAR97	4	4
329.012.00231		Oral	1	20 MG	07MAR97	1	16MAR97	10	10
	00231	Oral	2	20 MG	17MAR97	11	23MAR97	17	7
	00231	Oral	3	20 MG	24MAR97	18	01APR97	26	9
	00231	Oral	4	20 MG	02APR97	27	08APR97	33	7
	00231	Oral	4	20 MG	09APR97	34	16APR97	41	8
	00231	Oral	4	20 MG	17APR97	42	24APR97	49	8
	00231	Oral	5	30 MG	25APR97	50	30APR97	55	6
	00231	Oral	5	30 MG	01MAY97	56	06MAY97	61	6

\* DAYS RELATIVE TO START OF STUDY MEDICATION

591

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
Intent-to-Treat Population

TREATMENT GROUP: PAROXETINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.012.00231	00118	Oral	5	30 MG	07MAY97	62	03JUN97	89	28
	00118	Oral	5	30 MG	04JUN97	90	29JUN97	115	26
	00118	Oral	5	30 MG	30JUN97	116	05AUG97	152	37
	00231	Oral	4	20 MG	05AUG97	152	06AUG97	153	2
	00231	Oral	3	20 MG	07AUG97	154	08AUG97	155	2
	00231	Oral	2	20 MG	09AUG97	156	11AUG97	158	3
	00231	Oral	1	20 MG	12AUG97	159	18AUG97	165	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.001.00061		Oral	1	50 MG	29JUL94	1	03AUG94	6	6
	00061	Oral	2	100 MG	04AUG94	7	10AUG94	13	7
	00061	Oral	3	150 MG	11AUG94	14	17AUG94	20	7
	00061	Oral	4	200 MG	18AUG94	21	24AUG94	27	7
	00061	Oral	4	200 MG	25AUG94	28	31AUG94	34	7
		Oral	4	200 MG	01SEP94	35	14SEP94	48	14
329.001.00066		Oral	1	50 MG	22NOV94	1	27NOV94	6	6
	00066	Oral	2	100 MG	28NOV94	7	04DEC94	13	7
		Oral	2	100 MG	05DEC94	14	13DEC94	22	9
329.001.00067		Oral	1	50 MG	22NOV94	1	28NOV94	7	7
	00067	Oral	2	100 MG	29NOV94	8	05DEC94	14	7
		Oral	2	100 MG	06DEC94	15	13DEC94	22	8
329.001.00070		Oral	1	50 MG	22FEB95	1	27FEB95	6	6
	00070	Oral	2	100 MG	28FEB95	7	07MAR95	14	8
	00070	Oral	3	150 MG	08MAR95	15	14MAR95	21	7
	00070	Oral	3	150 MG	15MAR95	22	24MAR95	31	10
329.001.00122		Oral	1	50 MG	20JUN95	1	26JUN95	7	7
	00122	Oral	2	100 MG	27JUN95	8	04JUL95	15	8
	00122	Oral	3	150 MG	05JUL95	16	10JUL95	21	6
	00122	Oral	4	200 MG	11JUL95	22	17JUL95	28	7
	00122	Oral	4	200 MG	18JUL95	29	24JUL95	35	7
	00122	Oral	4	200 MG	25JUL95	36	31JUL95	42	7
	00122	Oral	4	200 MG	01AUG95	43	08AUG95	50	8
	00122	Oral	4	200 MG	09AUG95	51	15AUG95	57	7
	00052	Oral	4	200 MG	16AUG95	58	11SEP95	84	27
	00052	Oral	4	200 MG	12SEP95	85	09OCT95	112	28
	00052	Oral	4	200 MG	10OCT95	113	06NOV95	140	28
	00052	Oral	4	200 MG	07NOV95	141	04DEC95	168	28
		Oral	4	200 MG	05DEC95	169	18DEC95	182	14
329.002.00050		Oral	1	50 MG	23MAR95	1	29MAR95	7	7
	00050	Oral	2	100 MG	30MAR95	8	05APR95	14	7
	00050	Oral	3	150 MG	06APR95	15	12APR95	21	7
		Oral	3	150 MG	14APR95	23	26APR95	35	13
329.002.00056		Oral	1	50 MG	19JUL94	1	25JUL94	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

593

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00056	00056	Oral	2	100 MG	26JUL94	8	01AUG94	14	7
	00056	Oral	3	150 MG	02AUG94	15	08AUG94	21	7
	00056	Oral	4	200 MG	09AUG94	22	16AUG94	29	8
		Oral	3	150 MG	17AUG94	30	23AUG94	36	7
329.002.00057		Oral	1	50 MG	08SEP94	1	14SEP94	7	7
	00057	Oral	2	100 MG	15SEP94	8	21SEP94	14	7
	00057	Oral	3	150 MG	22SEP94	15	28SEP94	21	7
	00057	Oral	4	200 MG	29SEP94	22	05OCT94	28	7
	00057	Oral	5	250 MG	06OCT94	29	12OCT94	35	7
	00057	Oral	6	300 MG	13OCT94	36	19OCT94	42	7
	00057	Oral	6	300 MG	20OCT94	43	26OCT94	49	7
	00057	Oral	6	300 MG	27OCT94	50	03NOV94	57	8
	00067	Oral	6	300 MG	04NOV94	58	30NOV94	84	27
	00067	Oral	6	300 MG	01DEC94	85	29DEC94	113	29
	00057	Oral	5	250 MG	30DEC94	114	31DEC94	115	2
	00057	Oral	4	200 MG	01JAN95	116	02JAN95	117	2
	00057	Oral	3	150 MG	03JAN95	118	04JAN95	119	2
	00057	Oral	2	100 MG	05JAN95	120	07JAN95	122	3
00057	Oral	1	50 MG	08JAN95	123	14JAN95	129	7	
329.002.00098		Oral	1	50 MG	03JAN95	1	09JAN95	7	7
	00098	Oral	2	100 MG	10JAN95	8	17JAN95	15	8
	00098	Oral	3	150 MG	18JAN95	16	23JAN95	21	6
	00098	Oral	4	200 MG	24JAN95	22	30JAN95	28	7
	00098	Oral	5	250 MG	31JAN95	29	06FEB95	35	7
	00098	Oral	6	300 MG	07FEB95	36	13FEB95	42	7
	00098	Oral	5	250 MG	14FEB95	43	20FEB95	49	7
	00098	Oral	5	250 MG	21FEB95	50	22FEB95	51	2
	00098	Oral	4	200 MG	23FEB95	52	01MAR95	58	7
		Oral	5	250 MG	02MAR95	59	16MAR95	73	15
329.002.00100		Oral	1	50 MG	07MAR95	1	13MAR95	7	7
	00100	Oral	2	100 MG	14MAR95	8	20MAR95	14	7
	00100	Oral	3	150 MG	21MAR95	15	27MAR95	21	7
	00100	Oral	4	200 MG	28MAR95	22	03APR95	28	7
	00100	Oral	4	200 MG	04APR95	29	10APR95	35	7
	00100	Oral	5	250 MG	11APR95	36	17APR95	42	7
	00100	Oral	5	250 MG	18APR95	43	24APR95	49	7
	00100	Oral	5	250 MG	25APR95	50	03MAY95	58	9

\* DAYS RELATIVE TO START OF STUDY MEDICATION

594

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00100	00069	Oral	5	250 MG	04MAY95	59	29MAY95	84	26
	00069	Oral	5	250 MG	30MAY95	85	.	.	.
329.002.00103		Oral	1	50 MG	20APR95	1	26APR95	7	7
	00103	Oral	2	100 MG	27APR95	8	01MAY95	12	5
	00103	Oral	3	150 MG	02MAY95	13	08MAY95	19	7
	00103	Oral	4	200 MG	09MAY95	20	15MAY95	26	7
	00103	Oral	4	200 MG	16MAY95	27	24MAY95	35	9
	00103	Oral	4	200 MG	25MAY95	36	29MAY95	40	5
	00103	Oral	5	250 MG	30MAY95	41	05JUN95	47	7
	00103	Oral	5	250 MG	06JUN95	48	14JUN95	56	9
	00072	Oral	5	250 MG	15JUN95	57	12JUL95	84	28
	00072	Oral	5	250 MG	13JUL95	85	09AUG95	112	28
	00103	Oral	5	250 MG	10AUG95	113	11AUG95	114	2
	00103	Oral	4	200 MG	12AUG95	115	13AUG95	116	2
	00103	Oral	3	150 MG	14AUG95	117	15AUG95	118	2
	00103	Oral	2	100 MG	16AUG95	119	18AUG95	121	3
	00103	Oral	1	50 MG	19AUG95	122	25AUG95	128	7
329.002.00104		Oral	1	50 MG	04MAY95	1	10MAY95	7	7
	00104	Oral	2	100 MG	11MAY95	8	17MAY95	14	7
	00104	Oral	3	150 MG	18MAY95	15	24MAY95	21	7
	00104	Oral	4	200 MG	25MAY95	22	31MAY95	28	7
	00104	Oral	5	250 MG	01JUN95	29	08JUN95	36	8
	00104	Oral	6	300 MG	09JUN95	37	15JUN95	43	7
	00104	Oral	6	300 MG	16JUN95	44	21JUN95	49	6
	00104	Oral	6	300 MG	22JUN95	50	28JUN95	56	7
	00027	Oral	6	300 MG	29JUN95	57	24JUL95	82	26
	00027	Oral	6	300 MG	25JUL95	83	28AUG95	117	35
	00027	Oral	6	300 MG	29AUG95	118	02OCT95	152	35
	00027	Oral	6	300 MG	03OCT95	153	05NOV95	186	34
	00027	Oral	6	300 MG	06NOV95	187	05DEC95	216	30
	00027	Oral	6	300 MG	06DEC95	217	01JAN96	243	27
	00104	Oral	5	250 MG	02JAN96	244	03JAN96	245	2
	00104	Oral	4	200 MG	04JAN96	246	05JAN96	247	2
	00104	Oral	3	150 MG	06JAN96	248	07JAN96	249	2
	00104	Oral	2	100 MG	08JAN96	250	10JAN96	252	3
	00104	Oral	1	50 MG	11JAN96	253	17JAN96	259	7
329.002.00243		Oral	1	50 MG	14MAR96	1	20MAR96	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

595

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00243	00243	Oral	2	100 MG	21MAR96	8	27MAR96	14	7
	00243	Oral	3	150 MG	28MAR96	15	04APR96	22	8
	00243	Oral	3	150 MG	05APR96	23	.	.	.
329.002.00244		Oral	1	50 MG	21MAR96	1	27MAR96	7	7
	00244	Oral	2	100 MG	28MAR96	8	03APR96	14	7
	00244	Oral	3	150 MG	04APR96	15	10APR96	21	7
	00244	Oral	4	200 MG	11APR96	22	17APR96	28	7
	00244	Oral	5	250 MG	18APR96	29	24APR96	35	7
	00244	Oral	4	200 MG	25APR96	36	01MAY96	42	7
	00244	Oral	5	250 MG	02MAY96	43	08MAY96	49	7
	00244	Oral	6	300 MG	09MAY96	50	16MAY96	57	8
	00138	Oral	6	300 MG	17MAY96	58	23MAY96	64	7
	00138	Oral	5	250 MG	24MAY96	65	28MAY96	69	5
	00244	Oral	4	200 MG	29MAY96	70	31MAY96	72	3
	00244	Oral	3	150 MG	01JUN96	73	02JUN96	74	2
	00244	Oral	2	100 MG	03JUN96	75	05JUN96	77	3
	00244	Oral	1	50 MG	06JUN96	78	12JUN96	84	7
	329.002.00321		Oral	1	50 MG	23MAY96	1	03JUN96	12
329.002.00322		Oral	1	50 MG	09JAN97	1	15JAN97	7	7
	00322	Oral	2	100 MG	16JAN97	8	22JAN97	14	7
	00322	Oral	3	150 MG	23JAN97	15	29JAN97	21	7
	00322	Oral	4	200 MG	30JAN97	22	03FEB97	26	5
	00322	Oral	4	200 MG	04FEB97	27	13FEB97	36	10
	00322	Oral	4	200 MG	14FEB97	37	23FEB97	46	10
329.003.00073		Oral	1	50 MG	19JAN95	1	24JAN95	6	6
	00073	Oral	2	100 MG	25JAN95	7	02FEB95	15	9
	00073	Oral	3	150 MG	03FEB95	16	06FEB95	19	4
	00073	Oral	4	200 MG	07FEB95	20	13FEB95	26	7
	00073	Oral	4	200 MG	14FEB95	27	21FEB95	34	8
	00073	Oral	5	250 MG	22FEB95	35	28FEB95	41	7
	00073	Oral	5	250 MG	01MAR95	42	04MAR95	45	4
329.003.00076		Oral	1	50 MG	31JAN95	1	06FEB95	7	7
	00076	Oral	2	100 MG	07FEB95	8	13FEB95	14	7
	00076	Oral	3	150 MG	14FEB95	15	20FEB95	21	7
	00076	Oral	4	200 MG	21FEB95	22	26FEB95	27	6

\* DAYS RELATIVE TO START OF STUDY MEDICATION

596

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00076	00076	Oral	4	200 MG	27FEB95	28	05MAR95	34	7
	00076	Oral	4	200 MG	06MAR95	35	12MAR95	41	7
	00076	Oral	4	200 MG	13MAR95	42	19MAR95	48	7
	00076	Oral	4	200 MG	20MAR95	49	26MAR95	55	7
	00045	Oral	4	200 MG	27MAR95	56	02MAY95	92	37
	00045	Oral	4	200 MG	03MAY95	93	30MAY95	120	28
	00045	Oral	4	200 MG	31MAY95	121	27JUN95	148	28
	00045	Oral	4	200 MG	28JUN95	149	01AUG95	183	35
	00045	Oral	4	200 MG	02AUG95	184	05SEP95	218	35
	00045	Oral	4	200 MG	06SEP95	219	27SEP95	240	22
	329.003.00079	00079	Oral	1	50 MG	03MAY95	1	09MAY95	7
00079		Oral	2	100 MG	10MAY95	8	18MAY95	16	9
00079		Oral	3	150 MG	19MAY95	17	19MAY95	17	1
329.003.00082	00082	Oral	1	50 MG	11DEC95	1	27DEC95	17	17
	00082	Oral	2	100 MG	28DEC95	18	02JAN96	23	6
	00082	Oral	3	150 MG	03JAN96	24	10JAN96	31	8
	00082	Oral	4	200 MG	11JAN96	32	16JAN96	37	6
	00082	Oral	5	250 MG	17JAN96	38	.	.	.
329.003.00088	00088	Oral	1	50 MG	28FEB95	1	08MAR95	9	9
	00088	Oral	2	100 MG	09MAR95	10	14MAR95	15	6
	00088	Oral	3	150 MG	15MAR95	16	20MAR95	21	6
	00088	Oral	4	200 MG	21MAR95	22	29MAR95	30	9
	00088	Oral	4	200 MG	30MAR95	31	03APR95	35	5
	00088	Oral	4	200 MG	04APR95	36	09APR95	41	6
329.003.00090	00090	Oral	1	50 MG	14MAR95	1	18MAR95	5	5
	00090	Oral	1	50 MG	19MAR95	6	23MAR95	10	5
	00090	Oral	1	50 MG	24MAR95	11	27MAR95	14	4
	00090	Oral	2	100 MG	28MAR95	15	03APR95	21	7
	00090	Oral	3	150 MG	04APR95	22	10APR95	28	7
	00090	Oral	4	200 MG	11APR95	29	17APR95	35	7
	00090	Oral	4	200 MG	18APR95	36	25APR95	43	8
	00090	Oral	5	250 MG	26APR95	44	01MAY95	49	6
	00090	Oral	4	200 MG	02MAY95	50	08MAY95	56	7
	00090	Oral	4	200 MG	09MAY95	57	15MAY95	63	7
	00090	Oral	3	150 MG	16MAY95	64	21MAY95	69	6

\* DAYS RELATIVE TO START OF STUDY MEDICATION

597

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00092		Oral	1	50 MG	03MAY95	1	11MAY95	9	9
	00092	Oral	2	100 MG	12MAY95	10	16MAY95	14	5
	00092	Oral	3	150 MG	17MAY95	15	25MAY95	23	9
	00092	Oral	4	200 MG	26MAY95	24	02JUN95	31	8
	00092	Oral	4	200 MG	03JUN95	32	05JUN95	34	3
	00092	Oral	4	200 MG	06JUN95	35	13JUN95	42	8
	00092	Oral	4	200 MG	14JUN95	43	20JUN95	49	7
	00092	Oral	4	200 MG	21JUN95	50	29JUN95	58	9
	00035	Oral	4	200 MG	30JUN95	59	08AUG95	98	40
	00035	Oral	4	200 MG	09AUG95	99	05SEP95	126	28
	00035	Oral	4	200 MG	06SEP95	127	26SEP95	147	21
	00035	Oral	4	200 MG	27SEP95	148	21OCT95	172	25
	00035	Oral	0	0 MG	22OCT95	173	23OCT95	174	2
	00035	Oral	4	200 MG	24OCT95	175	07NOV95	189	15
	00035	Oral	4	200 MG	08NOV95	190	05DEC95	217	28
	00035	Oral	4	200 MG	06DEC95	218	02JAN96	245	28
	00092	Oral	5	250 MG	03JAN96	246	04JAN96	247	2
	00092	Oral	4	200 MG	05JAN96	248	06JAN96	249	2
	00092	Oral	3	150 MG	07JAN96	250	08JAN96	251	2
	00092	Oral	2	100 MG	09JAN96	252	11JAN96	254	3
	00092	Oral	1	50 MG	12JAN96	255	18JAN96	261	7
329.003.00093		Oral	1	50 MG	21JUN95	1	26JUN95	6	6
	00093	Oral	2	100 MG	27JUN95	7	06JUL95	16	10
	00093	Oral	3	150 MG	07JUL95	17	21JUL95	31	15
	00093	Oral	4	200 MG	22JUL95	32	25JUL95	35	4
	00093	Oral	5	250 MG	26JUL95	36	01AUG95	42	7
	00093	Oral	6	300 MG	02AUG95	43	10AUG95	51	9
	00093	Oral	6	300 MG	11AUG95	52	16AUG95	57	6
	00093	Oral	6	300 MG	17AUG95	58	22AUG95	63	6
	00053	Oral	6	300 MG	23AUG95	64	08SEP95	80	17
329.003.00247		Oral	1	50 MG	01FEB96	1	06FEB96	6	6
	00247	Oral	2	100 MG	07FEB96	7	12FEB96	12	6
	00247	Oral	3	150 MG	13FEB96	13	20FEB96	20	8
	00247	Oral	4	200 MG	21FEB96	21	27FEB96	27	7
	00247	Oral	4	200 MG	28FEB96	28	07MAR96	36	9
	00247	Oral	4	200 MG	08MAR96	37	11MAR96	40	4
	00247	Oral	4	200 MG	12MAR96	41	21MAR96	50	10
	00247	Oral	4	200 MG	22MAR96	51	25MAR96	54	4

\* DAYS RELATIVE TO START OF STUDY MEDICATION

598

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00247	00128	Oral	4	200 MG	26MAR96	55	29APR96	89	35
	00128	Oral	4	200 MG	30APR96	90	20MAY96	110	21
	00128	Oral	4	200 MG	21MAY96	111	.	.	.
329.003.00249		Oral	1	50 MG	07MAR96	1	11MAR96	5	5
	00249	Oral	2	100 MG	12MAR96	6	18MAR96	12	7
	00249	Oral	3	150 MG	19MAR96	13	25MAR96	19	7
	00249	Oral	4	200 MG	26MAR96	20	01APR96	26	7
	00249	Oral	5	250 MG	02APR96	27	08APR96	33	7
	00249	Oral	6	300 MG	09APR96	34	15APR96	40	7
	00249	Oral	6	300 MG	16APR96	41	22APR96	47	7
	00249	Oral	6	300 MG	23APR96	48	29APR96	54	7
	00249	Oral	5	250 MG	30APR96	55	07MAY96	62	8
329.003.00289		Oral	1	50 MG	28FEB96	1	05MAR96	7	7
	00289	Oral	2	100 MG	06MAR96	8	12MAR96	14	7
	00289	Oral	3	150 MG	13MAR96	15	19MAR96	21	7
	00289	Oral	4	200 MG	20MAR96	22	26MAR96	28	7
	00289	Oral	4	200 MG	27MAR96	29	02APR96	35	7
	00289	Oral	4	200 MG	03APR96	36	09APR96	42	7
	00289	Oral	4	200 MG	10APR96	43	16APR96	49	7
	00289	Oral	4	200 MG	17APR96	50	23APR96	56	7
	00131	Oral	4	200 MG	24APR96	57	21MAY96	84	28
	00131	Oral	4	200 MG	22MAY96	85	19JUN96	113	29
	00131	Oral	4	200 MG	20JUN96	114	18JUL96	142	29
	00131	Oral	4	200 MG	19JUL96	143	15AUG96	170	28
	00131	Oral	4	200 MG	16AUG96	171	12SEP96	198	28
	00131	Oral	4	200 MG	13SEP96	199	10OCT96	226	28
	00289	Oral	3	150 MG	11OCT96	227	12OCT96	228	2
	00289	Oral	2	100 MG	13OCT96	229	15OCT96	231	3
	00289	Oral	1	50 MG	16OCT96	232	22OCT96	238	7
	329.003.00290		Oral	1	50 MG	11MAR96	1	19MAR96	9
00290		Oral	2	100 MG	20MAR96	10	22MAR96	12	3
329.003.00314		Oral	1	50 MG	22OCT96	1	28OCT96	7	7
	00314	Oral	2	100 MG	29OCT96	8	04NOV96	14	7
	00314	Oral	3	150 MG	05NOV96	15	13NOV96	23	9
	00314	Oral	4	200 MG	14NOV96	24	25NOV96	35	12
	00314	Oral	4	200 MG	26NOV96	36	02DEC96	42	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

599

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00314	00314	Oral	4	200 MG	03DEC96	43	09DEC96	49	7
	00314	Oral	4	200 MG	10DEC96	50	17DEC96	57	8
	00314	Oral	5	250 MG	18DEC96	58	22DEC96	62	5
	00314	Oral	5	250 MG	23DEC96	63	06JAN97	77	15
329.003.00317		Oral	1	50 MG	19DEC96	1	23DEC96	5	5
	00317	Oral	2	100 MG	24DEC96	6	30DEC96	12	7
	00317	Oral	3	150 MG	31DEC96	13	07JAN97	20	8
	00317	Oral	4	200 MG	08JAN97	21	14JAN97	27	7
	00317	Oral	4	200 MG	15JAN97	28	21JAN97	34	7
	00317	Oral	5	250 MG	22JAN97	35	28JAN97	41	7
	00317	Oral	6	300 MG	29JAN97	42	04FEB97	48	7
	00317	Oral	6	300 MG	05FEB97	49	11FEB97	55	7
	00317	Oral	5	250 MG	11FEB97	55	26FEB97	70	16
329.004.00013		Oral	1	50 MG	19JUL94	1	25JUL94	7	7
	00013	Oral	2	100 MG	26JUL94	8	01AUG94	14	7
	00013	Oral	3	150 MG	02AUG94	15	08AUG94	21	7
	00013	Oral	4	200 MG	09AUG94	22	14AUG94	27	6
	00013	Oral	4	200 MG	15AUG94	28	22AUG94	35	8
	00013	Oral	4	200 MG	23AUG94	36	30AUG94	43	8
	00013	Oral	4	200 MG	31AUG94	44	07SEP94	51	8
	00013	Oral	4	200 MG	08SEP94	52	15SEP94	59	8
	00074	Oral	4	200 MG	16SEP94	60	10OCT94	84	25
	00074	Oral	4	200 MG	11OCT94	85	26OCT94	100	16
	00074	Oral	5	250 MG	27OCT94	101	07NOV94	112	12
	00074	Oral	5	250 MG	08NOV94	113	05DEC94	140	28
	00074	Oral	5	250 MG	06DEC94	141	09JAN95	175	35
	00074	Oral	5	250 MG	10JAN95	176	06FEB95	203	28
	00074	Oral	5	250 MG	07FEB95	204	09MAR95	234	31
	00013	Oral	4	200 MG	10MAR95	235	11MAR95	236	2
	00013	Oral	3	150 MG	12MAR95	237	13MAR95	238	2
	00013	Oral	2	100 MG	14MAR95	239	16MAR95	241	3
	00013	Oral	1	50 MG	17MAR95	242	23MAR95	248	7
329.004.00014		Oral	1	50 MG	29NOV94	1	04DEC94	6	6
	00014	Oral	2	100 MG	05DEC94	7	13DEC94	15	9
329.004.00211		Oral	1	50 MG	02FEB96	1	08FEB96	7	7
	00211	Oral	2	100 MG	09FEB96	8	15FEB96	14	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

600

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.004.00211	00211	Oral	3	150 MG	16FEB96	15	22FEB96	21	7
	00211	Oral	4	200 MG	23FEB96	22	28FEB96	27	6
	00211	Oral	4	200 MG	29FEB96	28	06MAR96	34	7
	00211	Oral	4	200 MG	07MAR96	35	13MAR96	41	7
	00211	Oral	4	200 MG	14MAR96	42	21MAR96	49	8
329.004.00215		Oral	1	50 MG	20MAR97	1	26MAR97	7	7
	00215	Oral	2	100 MG	27MAR97	8	02APR97	14	7
	00215	Oral	3	150 MG	03APR97	15	09APR97	21	7
	00215	Oral	4	200 MG	10APR97	22	14APR97	26	5
	00215	Oral	4	200 MG	15APR97	27	23APR97	35	9
	00215	Oral	4	200 MG	24APR97	36	28APR97	40	5
329.005.00003		Oral	1	50 MG	20SEP94	1	26SEP94	7	7
	00003	Oral	2	100 MG	27SEP94	8	30SEP94	11	4
	00003	Oral	2	100 MG	01OCT94	12	04OCT94	15	4
329.005.00006		Oral	1	50 MG	04NOV94	1	13NOV94	10	10
	00006	Oral	2	100 MG	14NOV94	11	20NOV94	17	7
	00006	Oral	3	150 MG	21NOV94	18	27NOV94	24	7
	00006	Oral	4	200 MG	28NOV94	25	04DEC94	31	7
	00006	Oral	5	250 MG	05DEC94	32	11DEC94	38	7
	00006	Oral	6	300 MG	12DEC94	39	18DEC94	45	7
	00006	Oral	6	300 MG	19DEC94	46	26DEC94	53	8
	00006	Oral	6	300 MG	27DEC94	54	02JAN95	60	7
	00089	Oral	6	300 MG	03JAN95	61	01FEB95	90	30
	00089	Oral	6	300 MG	02FEB95	91	26FEB95	115	25
	00089	Oral	6	300 MG	27FEB95	116	04APR95	152	37
	00089	Oral	6	300 MG	05APR95	153	11APR95	159	7
	00006	Oral	5	250 MG	12APR95	160	13APR95	161	2
	00006	Oral	4	200 MG	14APR95	162	15APR95	163	2
	00006	Oral	3	150 MG	16APR95	164	17APR95	165	2
00006	Oral	2	100 MG	18APR95	166	20APR95	168	3	
00006	Oral	1	50 MG	21APR95	169	27APR95	175	7	
329.005.00007		Oral	1	50 MG	09NOV94	1	09NOV94	1	1
	00007	Oral	1	50 MG	10NOV94	2	15NOV94	7	6
	00007	Oral	1	50 MG	16NOV94	8	22NOV94	14	7
	00007	Oral	2	100 MG	23NOV94	15	29NOV94	21	7
	00007	Oral	3	150 MG	30NOV94	22	06DEC94	28	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

601

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00007	00007	Oral	4	200 MG	07DEC94	29	13DEC94	35	7
	00007	Oral	5	250 MG	14DEC94	36	20DEC94	42	7
	00007	Oral	6	300 MG	21DEC94	43	27DEC94	49	7
	00007	Oral	5	250 MG	28DEC94	50	03JAN95	56	7
	00007	Oral	5	250 MG	04JAN95	57	10JAN95	63	7
	00092	Oral	5	250 MG	11JAN95	64	14FEB95	98	35
	00092	Oral	5	250 MG	15FEB95	99	21MAR95	133	35
	00092	Oral	5	250 MG	22MAR95	134	18APR95	161	28
	00092	Oral	5	250 MG	19APR95	162	16MAY95	189	28
	00092	Oral	5	250 MG	17MAY95	190	19MAY95	192	3
329.005.00009		Oral	1	50 MG	12DEC94	1	18DEC94	7	7
	00009	Oral	2	100 MG	19DEC94	8	26DEC94	15	8
	00009	Oral	3	150 MG	27DEC94	16	02JAN95	22	7
	00009	Oral	4	200 MG	03JAN95	23	10JAN95	30	8
	00009	Oral	5	250 MG	11JAN95	31	17JAN95	37	7
	00009	Oral	6	300 MG	18JAN95	38	24JAN95	44	7
	00009	Oral	5	250 MG	25JAN95	45	30JAN95	50	6
	00009	Oral	5	250 MG	31JAN95	51	06FEB95	57	7
		Oral	5	250 MG	07FEB95	58	22FEB95	73	16
329.005.00110		Oral	1	50 MG	11JAN95	1	17JAN95	7	7
	00110	Oral	2	100 MG	18JAN95	8	19JAN95	9	2
329.005.00113		Oral	1	50 MG	30JAN95	1	07FEB95	9	9
	00113	Oral	2	100 MG	08FEB95	10	15FEB95	17	8
	00113	Oral	3	150 MG	16FEB95	18	22FEB95	24	7
	00113	Oral	4	200 MG	23FEB95	25	02MAR95	32	8
329.005.00117		Oral	1	50 MG	18MAR95	1	26MAR95	9	9
	00117	Oral	2	100 MG	27MAR95	10	02APR95	16	7
	00117	Oral	3	150 MG	03APR95	17	09APR95	23	7
	00117	Oral	4	200 MG	10APR95	24	16APR95	30	7
	00117	Oral	4	200 MG	17APR95	31	23APR95	37	7
	00117	Oral	4	200 MG	24APR95	38	30APR95	44	7
	00117	Oral	4	200 MG	01MAY95	45	07MAY95	51	7
	00117	Oral	4	200 MG	08MAY95	52	14MAY95	58	7
		Oral	4	200 MG	15MAY95	59	26MAY95	70	12
329.005.00118		Oral	1	50 MG	17MAY95	1	23MAY95	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

602

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS	
329.005.00118	00118	Oral	2	100 MG	24MAY95	8	29MAY95	13	6	
	00118	Oral	3	150 MG	30MAY95	14	05JUN95	20	7	
	00118	Oral	4	200 MG	06JUN95	21	13JUN95	28	8	
	00118	Oral	5	250 MG	14JUN95	29	19JUN95	34	6	
	00118	Oral	6	300 MG	20JUN95	35	26JUN95	41	7	
			Oral	5	250 MG	27JUN95	42	05JUL95	50	9
329.005.00153		Oral	1	50 MG	25JAN96	1	31JAN96	7	7	
	00153	Oral	2	100 MG	01FEB96	8	07FEB96	14	7	
	00153	Oral	3	150 MG	08FEB96	15	14FEB96	21	7	
	00153	Oral	4	200 MG	15FEB96	22	21FEB96	28	7	
	00153	Oral	5	250 MG	22FEB96	29	28FEB96	35	7	
	00153	Oral	5	250 MG	29FEB96	36	05MAR96	41	6	
	00153	Oral	5	250 MG	06MAR96	42	13MAR96	49	8	
	00153	Oral	5	250 MG	14MAR96	50	20MAR96	56	7	
	00125	Oral	5	250 MG	21MAR96	57	16APR96	83	27	
	00125	Oral	6	300 MG	17APR96	84	14MAY96	111	28	
	00125	Oral	6	300 MG	15MAY96	112	11JUN96	139	28	
	00125	Oral	6	300 MG	12JUN96	140	09JUL96	167	28	
	00125	Oral	6	300 MG	10JUL96	168	04AUG96	193	26	
	00125	Oral	6	300 MG	05AUG96	194	03SEP96	223	30	
	00153	Oral	5	250 MG	04SEP96	224	05SEP96	225	2	
	00153	Oral	4	200 MG	06SEP96	226	07SEP96	227	2	
	00153	Oral	3	150 MG	08SEP96	228	09SEP96	229	2	
	00153	Oral	2	100 MG	10SEP96	230	13SEP96	233	4	
00153	Oral	1	50 MG	14SEP96	234	16SEP96	236	3		
329.005.00255		Oral	1	50 MG	04MAR96	1	10MAR96	7	7	
	00255	Oral	2	100 MG	11MAR96	8	17MAR96	14	7	
	00255	Oral	3	150 MG	18MAR96	15	24MAR96	21	7	
	00255	Oral	4	200 MG	25MAR96	22	31MAR96	28	7	
	00255	Oral	5	250 MG	01APR96	29	07APR96	35	7	
	00255	Oral	6	300 MG	08APR96	36	14APR96	42	7	
	00255	Oral	5	250 MG	15APR96	43	22APR96	50	8	
	00255	Oral	5	250 MG	23APR96	51	28APR96	56	6	
			Oral	4	200 MG	29APR96	57	13MAY96	71	15
	329.005.00256		Oral	1	50 MG	05MAR96	1	11MAR96	7	7
00256		Oral	2	100 MG	12MAR96	8	20MAR96	16	9	
00256		Oral	3	150 MG	21MAR96	17	25MAR96	21	5	

\* DAYS RELATIVE TO START OF STUDY MEDICATION

603

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00256	00256	Oral	4	200 MG	26MAR96	22	01APR96	28	7
	00256	Oral	5	250 MG	02APR96	29	10APR96	37	9
	00256	Oral	5	250 MG	11APR96	38	15APR96	42	5
	00256	Oral	5	250 MG	16APR96	43	22APR96	49	7
	00256	Oral	6	300 MG	23APR96	50	29APR96	56	7
	00133	Oral	6	300 MG	30APR96	57	27MAY96	84	28
	00133	Oral	6	300 MG	28MAY96	85	01JUL96	119	35
	00256	Oral	5	250 MG	02JUL96	120	03JUL96	121	2
	00256	Oral	4	200 MG	04JUL96	122	05JUL96	123	2
	00256	Oral	3	150 MG	06JUL96	124	07JUL96	125	2
	00256	Oral	2	100 MG	08JUL96	126	10JUL96	128	3
	00256	Oral	1	50 MG	11JUL96	129	17JUL96	135	7
329.005.00295		Oral	1	50 MG	28MAR96	1	03APR96	7	7
	00295	Oral	2	100 MG	04APR96	8	10APR96	14	7
	00295	Oral	3	150 MG	11APR96	15	17APR96	21	7
	00295	Oral	4	200 MG	18APR96	22	23APR96	27	6
	00295	Oral	4	200 MG	24APR96	28	05MAY96	39	12
	00295	Oral	4	200 MG	06MAY96	40	08MAY96	42	3
	00295	Oral	5	250 MG	09MAY96	43	15MAY96	49	7
	00295	Oral	5	250 MG	16MAY96	50	19MAY96	53	4
	00295	Oral	5	250 MG	20MAY96	54	04JUN96	69	16
329.005.00297		Oral	1	50 MG	19APR96	1	25APR96	7	7
	00297	Oral	2	100 MG	26APR96	8	01MAY96	13	6
	00297	Oral	3	150 MG	02MAY96	14	13MAY96	25	12
	00297	Oral	4	200 MG	14MAY96	26	.	.	.
329.005.00332		Oral	1	50 MG	12DEC96	1	18DEC96	7	7
	00332	Oral	2	100 MG	19DEC96	8	25DEC96	14	7
	00332	Oral	3	150 MG	26DEC96	15	01JAN97	21	7
	00332	Oral	4	200 MG	02JAN97	22	08JAN97	28	7
	00332	Oral	5	250 MG	09JAN97	29	15JAN97	35	7
	00332	Oral	6	300 MG	16JAN97	36	22JAN97	42	7
	00332	Oral	6	300 MG	23JAN97	43	29JAN97	49	7
	00332	Oral	6	300 MG	30JAN97	50	05FEB97	56	7
		Oral	5	250 MG	06FEB97	57	21FEB97	72	16
329.005.00335		Oral	1	50 MG	28FEB97	1	06MAR97	7	7
	00335	Oral	2	100 MG	07MAR97	8	13MAR97	14	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

604

CONFIDENTIAL

BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00335	00335	Oral	3	150 MG	14MAR97	15	20MAR97	21	7
	00335	Oral	4	200 MG	21MAR97	22	26MAR97	27	6
	00335	Oral	5	250 MG	27MAR97	28	02APR97	34	7
	00335	Oral	4	200 MG	03APR97	35	09APR97	41	7
	00335	Oral	4	200 MG	10APR97	42	16APR97	48	7
	00335	Oral	4	200 MG	17APR97	49	24APR97	56	8
		Oral	3	150 MG	25APR97	57	06MAY97	68	12
329.006.00040		Oral	1	50 MG	16FEB95	1	22FEB95	7	7
	00040	Oral	2	100 MG	23FEB95	8	28FEB95	13	6
	00040	Oral	1	50 MG	01MAR95	14	.	.	.
329.006.00041		Oral	1	50 MG	05APR95	1	09APR95	5	5
	00041	Oral	2	100 MG	10APR95	6	18APR95	14	9
	00041	Oral	3	150 MG	19APR95	15	23APR95	19	5
	00041	Oral	4	200 MG	24APR95	20	30APR95	26	7
	00041	Oral	4	200 MG	01MAY95	27	07MAY95	33	7
	00041	Oral	4	200 MG	08MAY95	34	14MAY95	40	7
	00041	Oral	4	200 MG	15MAY95	41	23MAY95	49	9
	00041	Oral	5	250 MG	24MAY95	50	02JUN95	59	10
	00041	Oral	6	300 MG	03JUN95	60	07JUN95	64	5
	00059	Oral	6	300 MG	08JUN95	65	04JUL95	91	27
	00059	Oral	6	300 MG	05JUL95	92	30JUL95	117	26
	00059	Oral	6	300 MG	31JUL95	118	23AUG95	141	24
	00059	Oral	6	300 MG	24AUG95	142	20SEP95	169	28
	00059	Oral	6	300 MG	21SEP95	170	23OCT95	202	33
	00059	Oral	6	300 MG	24OCT95	203	20NOV95	230	28
	00041	Oral	5	250 MG	21NOV95	231	22NOV95	232	2
	00041	Oral	4	200 MG	23NOV95	233	24NOV95	234	2
	00041	Oral	3	150 MG	25NOV95	235	26NOV95	236	2
	00041	Oral	2	100 MG	27NOV95	237	29NOV95	239	3
	00041	Oral	1	50 MG	30NOV95	240	05DEC95	245	6
329.007.00139		Oral	1	50 MG	08MAY95	1	17MAY95	10	10
	00139	Oral	2	100 MG	18MAY95	11	25MAY95	18	8
329.007.00143		Oral	1	50 MG	09NOV95	1	15NOV95	7	7
	00143	Oral	2	100 MG	16NOV95	8	21NOV95	13	6
		Oral	2	100 MG	22NOV95	14	01DEC95	23	10

\* DAYS RELATIVE TO START OF STUDY MEDICATION

605

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.007.00146		Oral	1	50 MG	25JAN96	1	31JAN96	7	7
	00347	Oral	2	100 MG	01FEB96	8	04FEB96	11	4
	00347	Oral	3	150 MG	05FEB96	12	11FEB96	18	7
	00347	Oral	4	200 MG	12FEB96	19	18FEB96	25	7
	00347	Oral	5	250 MG	19FEB96	26	25FEB96	32	7
	00347	Oral	5	250 MG	26FEB96	33	03MAR96	39	7
	00347	Oral	5	250 MG	04MAR96	40	10MAR96	46	7
	00347	Oral	4	200 MG	11MAR96	47	17MAR96	53	7
	00188	Oral	4	200 MG	18MAR96	54	14APR96	81	28
	00188	Oral	5	250 MG	15APR96	82	24APR96	91	10
	00188	Oral	4	200 MG	25APR96	92	12MAY96	109	18
	00188	Oral	4	200 MG	13MAY96	110	05JUN96	133	24
	00188	Oral	4	200 MG	06JUN96	134	07JUL96	165	32
	00188	Oral	4	200 MG	08JUL96	166	04AUG96	193	28
	00188	Oral	4	200 MG	05AUG96	194	08SEP96	228	35
	00347	Oral	4	200 MG	09SEP96	229	09SEP96	229	1
	00347	Oral	3	150 MG	10SEP96	230	11SEP96	231	2
	00347	Oral	2	100 MG	12SEP96	232	14SEP96	234	3
	00347	Oral	1	50 MG	15SEP96	235	21SEP96	241	7
329.007.00269		Oral	1	50 MG	11APR96	1	17APR96	7	7
	00269	Oral	2	100 MG	18APR96	8	25APR96	15	8
329.007.00270		Oral	1	50 MG	09MAY96	1	15MAY96	7	7
	00270	Oral	2	100 MG	16MAY96	8	22MAY96	14	7
	00270	Oral	3	150 MG	23MAY96	15	29MAY96	21	7
	00270	Oral	4	200 MG	30MAY96	22	05JUN96	28	7
	00270	Oral	4	200 MG	06JUN96	29	13JUN96	36	8
	00270	Oral	4	200 MG	14JUN96	37	20JUN96	43	7
329.007.00307		Oral	1	50 MG	16MAY96	1	22MAY96	7	7
	00307	Oral	2	100 MG	23MAY96	8	29MAY96	14	7
	00307	Oral	3	150 MG	30MAY96	15	05JUN96	21	7
	00307	Oral	4	200 MG	06JUN96	22	12JUN96	28	7
	00307	Oral	4	200 MG	13JUN96	29	20JUN96	36	8
329.007.00308		Oral	1	50 MG	02JUL96	1	11JUL96	10	10
329.008.00159		Oral	1	50 MG	13SEP95	1	18SEP95	6	6
	00159	Oral	2	100 MG	19SEP95	7	26SEP95	14	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

606

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.008.00159	00159	Oral	3	150 MG	27SEP95	15	02OCT95	20	6
	00159	Oral	4	200 MG	03OCT95	21	09OCT95	27	7
	00159	Oral	5	250 MG	10OCT95	28	15OCT95	33	6
	00159	Oral	5	250 MG	16OCT95	34	23OCT95	41	8
	00159	Oral	5	250 MG	24OCT95	42	30OCT95	48	7
	00159	Oral	4	200 MG	31OCT95	49	13NOV95	62	14
	00022	Oral	4	200 MG	14NOV95	63	25DEC95	104	42
	00022	Oral	4	200 MG	26DEC95	105	23JAN96	133	29
	00191	Oral	4	200 MG	24JAN96	134	.	.	.
329.008.00161		Oral	1	50 MG	16NOV95	1	21NOV95	6	6
	00161	Oral	2	100 MG	22NOV95	7	28NOV95	13	7
	00161	Oral	3	150 MG	29NOV95	14	06DEC95	21	8
	00161	Oral	4	200 MG	07DEC95	22	14DEC95	29	8
	00161	Oral	4	200 MG	15DEC95	30	26DEC95	41	12
	00161	Oral	4	200 MG	27DEC95	42	02JAN96	48	7
	00161	Oral	4	200 MG	03JAN96	49	09JAN96	55	7
	00099	Oral	4	200 MG	10JAN96	56	.	.	.
329.008.00187		Oral	1	50 MG	29NOV95	1	06DEC95	8	8
	00187	Oral	2	100 MG	07DEC95	9	14DEC95	16	8
	00187	Oral	3	150 MG	15DEC95	17	20DEC95	22	6
	00187	Oral	4	200 MG	21DEC95	23	26DEC95	28	6
	00187	Oral	4	200 MG	27DEC95	29	03JAN96	36	8
	00187	Oral	4	200 MG	04JAN96	37	10JAN96	43	7
	00187	Oral	5	250 MG	11JAN96	44	17JAN96	50	7
	00187	Oral	4	200 MG	18JAN96	51	25JAN96	58	8
		Oral	4	200 MG	26JAN96	59	09FEB96	73	15
329.008.00192		Oral	1	50 MG	05MAR96	1	11MAR96	7	7
	00192	Oral	2	100 MG	12MAR96	8	18MAR96	14	7
	00192	Oral	3	150 MG	19MAR96	15	24MAR96	20	6
	00192	Oral	4	200 MG	25MAR96	21	03APR96	30	10
	00192	Oral	4	200 MG	04APR96	31	11APR96	38	8
329.008.00272		Oral	1	50 MG	03APR96	1	10APR96	8	8
	00272	Oral	2	100 MG	11APR96	9	17APR96	15	7
	00272	Oral	3	150 MG	18APR96	16	26APR96	24	9
	00272	Oral	4	200 MG	27APR96	25	30APR96	28	4
	00272	Oral	4	200 MG	01MAY96	29	06MAY96	34	6

\* DAYS RELATIVE TO START OF STUDY MEDICATION

607

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.008.00272	00272	Oral	4	200 MG	07MAY96	35	14MAY96	42	8
	00272	Oral	4	200 MG	15MAY96	43	21MAY96	49	7
	00272	Oral	4	200 MG	22MAY96	50	28MAY96	56	7
	00142	Oral	4	200 MG	29MAY96	57	25JUN96	84	28
	00142	Oral	4	200 MG	26JUN96	85	23JUL96	112	28
	00142	Oral	4	200 MG	24JUL96	113	20AUG96	140	28
	00142	Oral	4	200 MG	21AUG96	141	18SEP96	169	29
329.008.00273		Oral	1	50 MG	17MAY96	1	23MAY96	7	7
	00273	Oral	2	100 MG	24MAY96	8	29MAY96	13	6
	00273	Oral	3	150 MG	30MAY96	14	09JUN96	24	11
	00273	Oral	4	200 MG	10JUN96	25	16JUN96	31	7
	00273	Oral	4	200 MG	17JUN96	32	23JUN96	38	7
	00273	Oral	5	250 MG	24JUN96	39	30JUN96	45	7
	00273	Oral	6	300 MG	01JUL96	46	10JUL96	55	10
	00273	Oral	6	300 MG	11JUL96	56	18JUL96	63	8
	00153	Oral	6	300 MG	19JUL96	64	03SEP96	110	47
	00153	Oral	6	300 MG	04SEP96	111	09SEP96	116	6
329.009.00127		Oral	1	50 MG	10APR95	1	16APR95	7	7
	00127	Oral	2	100 MG	17APR95	8	23APR95	14	7
	00127	Oral	3	150 MG	24APR95	15	30APR95	21	7
	00127	Oral	4	200 MG	01MAY95	22	08MAY95	29	8
	00127	Oral	4	200 MG	09MAY95	30	14MAY95	35	6
	00127	Oral	4	200 MG	15MAY95	36	26MAY95	47	12
329.009.00132		Oral	1	50 MG	23MAY95	1	29MAY95	7	7
	00132	Oral	2	100 MG	30MAY95	8	05JUN95	14	7
	00132	Oral	3	150 MG	06JUN95	15	12JUN95	21	7
	00132	Oral	4	200 MG	13JUN95	22	19JUN95	28	7
	00132	Oral	4	200 MG	20JUN95	29	26JUN95	35	7
	00132	Oral	4	200 MG	27JUN95	36	04JUL95	43	8
	00132	Oral	4	200 MG	05JUL95	44	10JUL95	49	6
	00132	Oral	4	200 MG	11JUL95	50	18JUL95	57	8
	00001	Oral	4	200 MG	19JUL95	58	23AUG95	93	36
	00001	Oral	4	200 MG	24AUG95	94	14SEP95	115	22
	00001	Oral	4	200 MG	15SEP95	116	23OCT95	154	39
	00132	Oral	4	200 MG	24OCT95	155	24OCT95	155	1
	00132	Oral	3	150 MG	25OCT95	156	26OCT95	157	2
	00132	Oral	2	100 MG	27OCT95	158	29OCT95	160	3

\* DAYS RELATIVE TO START OF STUDY MEDICATION

808

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00132	00132	Oral	1	50 MG	30OCT95	161	05NOV95	167	7
329.009.00134		Oral	1	50 MG	06JUL95	1	13JUL95	8	8
	00134	Oral	2	100 MG	14JUL95	9	18JUL95	13	5
	00134	Oral	3	150 MG	19JUL95	14	25JUL95	20	7
	00134	Oral	4	200 MG	26JUL95	21	02AUG95	28	8
	00134	Oral	4	200 MG	03AUG95	29	07AUG95	33	5
	00134	Oral	4	200 MG	08AUG95	34	14AUG95	40	7
	00134	Oral	4	200 MG	15AUG95	41	23AUG95	49	9
	00134	Oral	4	200 MG	24AUG95	50	28AUG95	54	5
	00134	Oral	3	150 MG	29AUG95	55	09SEP95	66	12
329.009.00137		Oral	1	50 MG	10OCT95	1	16OCT95	7	7
	00137	Oral	2	100 MG	17OCT95	8	23OCT95	14	7
	00137	Oral	3	150 MG	24OCT95	15	30OCT95	21	7
	00137	Oral	4	200 MG	31OCT95	22	06NOV95	28	7
	00137	Oral	4	200 MG	07NOV95	29	13NOV95	35	7
	00137	Oral	4	200 MG	14NOV95	36	20NOV95	42	7
	00137	Oral	4	200 MG	21NOV95	43	27NOV95	49	7
	00137	Oral	4	200 MG	28NOV95	50	04DEC95	56	7
		Oral	3	150 MG	05DEC95	57	16DEC95	68	12
329.009.00171		Oral	1	50 MG	07NOV95	1	14NOV95	8	8
329.009.00172		Oral	1	50 MG	13NOV95	1	19NOV95	7	7
	00172	Oral	2	100 MG	20NOV95	8	26NOV95	14	7
	00172	Oral	3	150 MG	27NOV95	15	03DEC95	21	7
	00172	Oral	4	200 MG	04DEC95	22	10DEC95	28	7
	00172	Oral	4	200 MG	11DEC95	29	20DEC95	38	10
	00172	Oral	4	200 MG	21DEC95	39	26DEC95	44	6
	00172	Oral	4	200 MG	27DEC95	45	02JAN96	51	7
	00172	Oral	4	200 MG	03JAN96	52	08JAN96	57	6
	00097	Oral	4	200 MG	09JAN96	58	06FEB96	86	29
	00097	Oral	4	200 MG	07FEB96	87	03MAR96	112	26
	00097	Oral	4	200 MG	04MAR96	113	31MAR96	140	28
	00097	Oral	4	200 MG	01APR96	141	28APR96	168	28
	00097	Oral	4	200 MG	29APR96	169	09JUN96	210	42
	00097	Oral	4	200 MG	10JUN96	211	07JUL96	238	28
	00360	Oral	4	200 MG	08JUL96	239	08JUL96	239	1
	00360	Oral	3	150 MG	09JUL96	240	10JUL96	241	2

\* DAYS RELATIVE TO START OF STUDY MEDICATION

609

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00172	00360	Oral	2	100 MG	11JUL96	242	13JUL96	244	3
	00360	Oral	1	50 MG	14JUL96	245	20JUL96	251	7
329.009.00194		Oral	1	50 MG	05DEC95	1	11DEC95	7	7
	00194	Oral	2	100 MG	12DEC95	8	18DEC95	14	7
	00194	Oral	3	150 MG	19DEC95	15	26DEC95	22	8
	00194	Oral	4	200 MG	27DEC95	23	01JAN96	28	6
	00194	Oral	4	200 MG	02JAN96	29	08JAN96	35	7
	00194	Oral	4	200 MG	09JAN96	36	15JAN96	42	7
	00194	Oral	4	200 MG	16JAN96	43	22JAN96	49	7
	00194	Oral	4	200 MG	23JAN96	50	29JAN96	56	7
	00105	Oral	4	200 MG	30JAN96	57	26FEB96	84	28
	00105	Oral	4	200 MG	27FEB96	85	01APR96	119	35
	00105	Oral	4	200 MG	02APR96	120	29APR96	147	28
	00105	Oral	4	200 MG	30APR96	148	04JUN96	183	36
00194	Oral	4	200 MG	05JUN96	184	.	.	.	
329.009.00195		Oral	1	50 MG	15DEC95	1	18DEC95	4	4
	00195	Oral	2	100 MG	19DEC95	5	26DEC95	12	8
	00195	Oral	3	150 MG	27DEC95	13	01JAN96	18	6
	00195	Oral	4	200 MG	02JAN96	19	07JAN96	24	6
	00195	Oral	3	150 MG	08JAN96	25	19JAN96	36	12
329.009.00199		Oral	1	50 MG	16JAN96	1	22JAN96	7	7
	00199	Oral	2	100 MG	23JAN96	8	28JAN96	13	6
	00199	Oral	3	150 MG	29JAN96	14	06FEB96	22	9
	00199	Oral	4	200 MG	07FEB96	23	13FEB96	29	7
	00199	Oral	4	200 MG	14FEB96	30	20FEB96	36	7
	00199	Oral	5	250 MG	21FEB96	37	27FEB96	43	7
	00199	Oral	5	250 MG	28FEB96	44	05MAR96	50	7
	00199	Oral	5	250 MG	06MAR96	51	12MAR96	57	7
	00199	Oral	4	200 MG	13MAR96	58	26MAR96	71	14
329.009.00203		Oral	1	50 MG	04MAR96	1	10MAR96	7	7
	00203	Oral	2	100 MG	11MAR96	8	18MAR96	15	8
	00203	Oral	3	150 MG	19MAR96	16	26MAR96	23	8
	00203	Oral	2	100 MG	27MAR96	24	05APR96	33	10
329.009.00236		Oral	1	50 MG	30DEC96	1	05JAN97	7	7
	00236	Oral	2	100 MG	06JAN97	8	14JAN97	16	9

\* DAYS RELATIVE TO START OF STUDY MEDICATION

610

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00236	00236	Oral	3	150 MG	15JAN97	17	19JAN97	21	5
	00236	Oral	4	200 MG	20JAN97	22	26JAN97	28	7
		Oral	4	200 MG	27JAN97	29	08FEB97	41	13
329.009.00239		Oral	1	50 MG	19NOV96	1	24NOV96	6	6
	00239	Oral	2	100 MG	25NOV96	7	01DEC96	13	7
	00239	Oral	3	150 MG	02DEC96	14	08DEC96	20	7
	00239	Oral	4	200 MG	09DEC96	21	15DEC96	27	7
	00239	Oral	4	200 MG	16DEC96	28	22DEC96	34	7
	00239	Oral	4	200 MG	23DEC96	35	29DEC96	41	7
	00239	Oral	4	200 MG	30DEC96	42	05JAN97	48	7
	00239	Oral	4	200 MG	06JAN97	49	14JAN97	57	9
	00183	Oral	4	200 MG	15JAN97	58	17FEB97	91	34
	00183	Oral	4	200 MG	18FEB97	92	16MAR97	118	27
	00183	Oral	4	200 MG	17MAR97	119	13APR97	146	28
	00183	Oral	4	200 MG	14APR97	147	.	.	.
329.009.00262		Oral	1	50 MG	17FEB97	1	23FEB97	7	7
	00262	Oral	2	100 MG	24FEB97	8	02MAR97	14	7
	00262	Oral	3	150 MG	03MAR97	15	06MAR97	18	4
	00262	Oral	4	200 MG	07MAR97	19	16MAR97	28	10
	00262	Oral	4	200 MG	17MAR97	29	23MAR97	35	7
	00262	Oral	4	200 MG	24MAR97	36	30MAR97	42	7
	00262	Oral	4	200 MG	31MAR97	43	06APR97	49	7
	00262	Oral	4	200 MG	07APR97	50	14APR97	57	8
	00262	Oral	4	200 MG	14APR97	57	26APR97	69	13
329.009.00264		Oral	1	50 MG	01NOV96	1	07NOV96	7	7
	00264	Oral	2	100 MG	08NOV96	8	10NOV96	10	3
	00264	Oral	3	150 MG	11NOV96	11	17NOV96	17	7
	00264	Oral	4	200 MG	18NOV96	18	24NOV96	24	7
	00264	Oral	4	200 MG	25NOV96	25	01DEC96	31	7
	00264	Oral	4	200 MG	02DEC96	32	10DEC96	40	9
	00264	Oral	4	200 MG	11DEC96	41	15DEC96	45	5
	00264	Oral	4	200 MG	16DEC96	46	22DEC96	52	7
	00264	Oral	4	200 MG	23DEC96	53	04JAN97	65	13
329.009.00301		Oral	1	50 MG	19MAR96	1	25MAR96	7	7
	00301	Oral	2	100 MG	26MAR96	8	04APR96	17	10
	00301	Oral	3	150 MG	05APR96	18	11APR96	24	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

611

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00301	00301	Oral	4	200 MG	12APR96	25	15APR96	28	4
	00301	Oral	4	200 MG	16APR96	29	22APR96	35	7
	00301	Oral	4	200 MG	23APR96	36	29APR96	42	7
	00301	Oral	4	200 MG	30APR96	43	06MAY96	49	7
	00301	Oral	4	200 MG	07MAY96	50	13MAY96	56	7
	00140	Oral	4	200 MG	14MAY96	57	10JUN96	84	28
	00301	Oral	4	200 MG	11JUN96	85	11JUN96	85	1
	00301	Oral	3	150 MG	12JUN96	86	13JUN96	87	2
	00301	Oral	2	100 MG	14JUN96	88	16JUN96	90	3
	00301	Oral	1	50 MG	17JUN96	91	23JUN96	97	7
329.009.00305		Oral	1	50 MG	07MAY96	1	13MAY96	7	7
	00305	Oral	2	100 MG	14MAY96	8	20MAY96	14	7
	00305	Oral	3	150 MG	21MAY96	15	27MAY96	21	7
	00305	Oral	4	200 MG	28MAY96	22	03JUN96	28	7
	00305	Oral	4	200 MG	04JUN96	29	10JUN96	35	7
	00305	Oral	4	200 MG	11JUN96	36	18JUN96	43	8
	00305	Oral	4	200 MG	19JUN96	44	24JUN96	49	6
	00305	Oral	4	200 MG	25JUN96	50	02JUL96	57	8
	00151	Oral	4	200 MG	03JUL96	58	05AUG96	91	34
	00151	Oral	4	200 MG	06AUG96	92	26AUG96	112	21
	00151	Oral	4	200 MG	27AUG96	113	23SEP96	140	28
	00151	Oral	4	200 MG	24SEP96	141	28OCT96	175	35
	00151	Oral	4	200 MG	29OCT96	176	02DEC96	210	35
	00151	Oral	4	200 MG	03DEC96	211	09JAN97	248	38
	00305	Oral	4	200 MG	10JAN97	249	10JAN97	249	1
	00305	Oral	3	150 MG	11JAN97	250	12JAN97	251	2
	00305	Oral	2	100 MG	13JAN97	252	15JAN97	254	3
	00305	Oral	1	50 MG	16JAN97	255	22JAN97	261	7
329.009.00325		Oral	1	50 MG	27AUG96	1	02SEP96	7	7
	00325	Oral	2	100 MG	03SEP96	8	08SEP96	13	6
	00325	Oral	3	150 MG	09SEP96	14	15SEP96	20	7
	00325	Oral	4	200 MG	16SEP96	21	22SEP96	27	7
	00325	Oral	4	200 MG	23SEP96	28	29SEP96	34	7
	00325	Oral	4	200 MG	30SEP96	35	09OCT96	44	10
	00325	Oral	4	200 MG	10OCT96	45	13OCT96	48	4
	00325	Oral	4	200 MG	14OCT96	49	20OCT96	55	7
	00166	Oral	4	200 MG	21OCT96	56	17NOV96	83	28
	00166	Oral	4	200 MG	18NOV96	84	15DEC96	111	28

\* DAYS RELATIVE TO START OF STUDY MEDICATION

612

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00325	00325	Oral	4	200 MG	16DEC96	112	16DEC96	112	1
	00325	Oral	3	150 MG	17DEC96	113	18DEC96	114	2
	00325	Oral	2	100 MG	19DEC96	115	21DEC96	117	3
	00325	Oral	1	50 MG	22DEC96	118	28DEC96	124	7
329.009.00326		Oral	1	50 MG	05SEP96	1	08SEP96	4	4
	00326	Oral	2	100 MG	09SEP96	5	15SEP96	11	7
	00326	Oral	3	150 MG	16SEP96	12	22SEP96	18	7
	00326	Oral	4	200 MG	23SEP96	19	29SEP96	25	7
	00326	Oral	4	200 MG	30SEP96	26	06OCT96	32	7
	00326	Oral	4	200 MG	07OCT96	33	16OCT96	42	10
	00326	Oral	4	200 MG	17OCT96	43	23OCT96	49	7
	00326	Oral	4	200 MG	24OCT96	50	27OCT96	53	4
	00167	Oral	4	200 MG	28OCT96	54	24NOV96	81	28
	00167	Oral	4	200 MG	25NOV96	82	15DEC96	102	21
	00326	Oral	4	200 MG	16DEC96	103	16DEC96	103	1
	00326	Oral	3	150 MG	17DEC96	104	18DEC96	105	2
	00326	Oral	2	100 MG	19DEC96	106	21DEC96	108	3
	00326	Oral	1	50 MG	22DEC96	109	28DEC96	115	7
329.010.00279		Oral	1	50 MG	22MAR96	1	28MAR96	7	7
	00279	Oral	2	100 MG	29MAR96	8	04APR96	14	7
	00279	Oral	3	150 MG	05APR96	15	11APR96	21	7
	00279	Oral	4	200 MG	12APR96	22	18APR96	28	7
	00279	Oral	5	250 MG	19APR96	29	24APR96	34	6
	00279	Oral	6	300 MG	25APR96	35	02MAY96	42	8
	00279	Oral	6	300 MG	03MAY96	43	09MAY96	49	7
	00279	Oral	6	300 MG	10MAY96	50	16MAY96	56	7
	00147	Oral	6	300 MG	17MAY96	57	13JUN96	84	28
	00147	Oral	6	300 MG	14JUN96	85	10JUL96	111	27
	00147	Oral	6	300 MG	11JUL96	112	07AUG96	139	28
	00147	Oral	6	300 MG	08AUG96	140	04SEP96	167	28
	00147	Oral	6	300 MG	05SEP96	168	01OCT96	194	27
	00147	Oral	6	300 MG	02OCT96	195	04OCT96	197	3
	00147	Oral	5	250 MG	05OCT96	198	06NOV96	230	33
	00279	Oral	5	250 MG	07NOV96	231	08NOV96	232	2
	00279	Oral	4	200 MG	09NOV96	233	10NOV96	234	2
	00279	Oral	3	150 MG	11NOV96	235	12NOV96	236	2
00279	Oral	2	100 MG	13NOV96	237	15NOV96	239	3	
00279	Oral	1	50 MG	16NOV96	240	22NOV96	246	7	

\* DAYS RELATIVE TO START OF STUDY MEDICATION

613

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.010.00281		Oral	1	50 MG	26JUL96	1	01AUG96	7	7
	00281	Oral	2	100 MG	02AUG96	8	08AUG96	14	7
	00281	Oral	3	150 MG	09AUG96	15	18AUG96	24	10
	00281	Oral	4	200 MG	19AUG96	25	25AUG96	31	7
	00281	Oral	5	250 MG	26AUG96	32	03SEP96	40	9
	00281	Oral	6	300 MG	04SEP96	41	08SEP96	45	5
	00281	Oral	6	300 MG	09SEP96	46	17SEP96	54	9
	00281	Oral	6	300 MG	18SEP96	55	24SEP96	61	7
	00158	Oral	6	300 MG	25SEP96	62	24OCT96	91	30
	00158	Oral	6	300 MG	25OCT96	92	19NOV96	117	26
	00158	Oral	6	300 MG	20NOV96	118	19DEC96	147	30
	00158	Oral	6	300 MG	20DEC96	148	03JAN97	162	15
	00281	Oral	5	250 MG	04JAN97	163	05JAN97	164	2
	00281	Oral	4	200 MG	06JAN97	165	07JAN97	166	2
	00281	Oral	3	150 MG	08JAN97	167	09JAN97	168	2
	00281	Oral	2	100 MG	10JAN97	169	12JAN97	171	3
	00281	Oral	1	50 MG	13JAN97	172	19JAN97	178	7
329.011.00163		Oral	1	50 MG	25NOV95	1	01DEC95	7	7
	00163	Oral	2	100 MG	02DEC95	8	11DEC95	17	10
	00163	Oral	3	150 MG	12DEC95	18	18DEC95	24	7
	00163	Oral	4	200 MG	19DEC95	25	22DEC95	28	4
329.011.00208		Oral	1	50 MG	06SEP96	1	11SEP96	6	6
	00208	Oral	2	100 MG	12SEP96	7	17SEP96	12	6
	00208	Oral	3	150 MG	18SEP96	13	26SEP96	21	9
	00208	Oral	4	200 MG	27SEP96	22	03OCT96	28	7
	00208	Oral	5	250 MG	04OCT96	29	10OCT96	35	7
	00208	Oral	6	300 MG	11OCT96	36	17OCT96	42	7
	00208	Oral	6	300 MG	18OCT96	43	24OCT96	49	7
	00208	Oral	6	300 MG	25OCT96	50	03NOV96	59	10
	00171	Oral	6	300 MG	04NOV96	60	07NOV96	63	4
	00208	Oral	5	250 MG	08NOV96	64	09NOV96	65	2
	00208	Oral	4	200 MG	10NOV96	66	11NOV96	67	2
	00208	Oral	3	150 MG	12NOV96	68	13NOV96	69	2
	00208	Oral	2	100 MG	14NOV96	70	16NOV96	72	3
	00208	Oral	1	50 MG	17NOV96	73	23NOV96	79	7
329.011.00209		Oral	1	50 MG	11SEP96	1	19SEP96	9	9
	00209	Oral	2	100 MG	20SEP96	10	26SEP96	16	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

614

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.011.00209	00209	Oral	3	150 MG	27SEP96	17	03OCT96	23	7
	00209	Oral	4	200 MG	04OCT96	24	11OCT96	31	8
	00209	Oral	4	200 MG	12OCT96	32	17OCT96	37	6
	00209	Oral	4	200 MG	18OCT96	38	24OCT96	44	7
	00209	Oral	4	200 MG	25OCT96	45	01NOV96	52	8
	00209	Oral	5	250 MG	02NOV96	53	11NOV96	62	10
	00173	Oral	5	250 MG	12NOV96	63	18DEC96	99	37
	00209	Oral	5	250 MG	19DEC96	100	.	.	.
329.011.00284		Oral	1	50 MG	22MAR96	1	28MAR96	7	7
	00284	Oral	2	100 MG	29MAR96	8	05APR96	15	8
	00284	Oral	3	150 MG	06APR96	16	11APR96	21	6
	00284	Oral	4	200 MG	12APR96	22	19APR96	29	8
	00284	Oral	4	200 MG	20APR96	30	25APR96	35	6
	00284	Oral	5	250 MG	26APR96	36	02MAY96	42	7
	00284	Oral	5	250 MG	03MAY96	43	09MAY96	49	7
	00284	Oral	5	250 MG	10MAY96	50	16MAY96	56	7
	00134	Oral	5	250 MG	17MAY96	57	10JUN96	81	25
	00134	Oral	5	250 MG	11JUN96	82	08JUL96	109	28
	00134	Oral	5	250 MG	09JUL96	110	05AUG96	137	28
	00134	Oral	5	250 MG	06AUG96	138	.	.	.
	329.011.00286		Oral	1	50 MG	06JUN96	1	14JUN96	9
00286		Oral	2	100 MG	15JUN96	10	21JUN96	16	7
00286		Oral	3	150 MG	22JUN96	17	28JUN96	23	7
00286		Oral	4	200 MG	29JUN96	24	08JUL96	33	10
00286		Oral	5	250 MG	09JUL96	34	17JUL96	42	9
00286		Oral	5	250 MG	18JUL96	43	24JUL96	49	7
00286		Oral	6	300 MG	25JUL96	50	02AUG96	58	9
00286		Oral	6	300 MG	03AUG96	59	12AUG96	68	10
00154		Oral	6	300 MG	13AUG96	69	17SEP96	104	36
00154		Oral	6	300 MG	18SEP96	105	24OCT96	141	37
00154		Oral	6	300 MG	25OCT96	142	24NOV96	172	31
00154		Oral	6	300 MG	25NOV96	173	30DEC96	208	36
00154		Oral	6	300 MG	31DEC96	209	.	.	.
329.012.00026		Oral	1	50 MG	28NOV95	1	04DEC95	7	7
	00026	Oral	2	100 MG	05DEC95	8	.	.	.
329.012.00219		Oral	1	50 MG	31MAY96	1	06JUN96	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

615

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.012.00219	00219	Oral	2	100 MG	07JUN96	8	13JUN96	14	7
	00219	Oral	3	150 MG	14JUN96	15	23JUN96	24	10
	00219	Oral	4	200 MG	24JUN96	25	01JUL96	32	8
	00219	Oral	4	200 MG	02JUL96	33	08JUL96	39	7
	00219	Oral	4	200 MG	09JUL96	40	15JUL96	46	7
	00219	Oral	4	200 MG	16JUL96	47	22JUL96	53	7
	00219	Oral	4	200 MG	23JUL96	54	29JUL96	60	7
	00106	Oral	4	200 MG	30JUL96	61	29AUG96	91	31
	00106	Oral	4	200 MG	30AUG96	92	25SEP96	118	27
	00106	Oral	4	200 MG	26SEP96	119	24OCT96	147	29
	00106	Oral	4	200 MG	25OCT96	148	21NOV96	175	28
	00106	Oral	4	200 MG	22NOV96	176	19DEC96	203	28
	00106	Oral	4	200 MG	20DEC96	204	18JAN97	233	30
	329.012.00221		Oral	1	50 MG	25JUN96	1	01JUL96	7
00221		Oral	2	100 MG	02JUL96	8	08JUL96	14	7
00221		Oral	3	150 MG	09JUL96	15	15JUL96	21	7
00221		Oral	4	200 MG	16JUL96	22	22JUL96	28	7
00221		Oral	5	250 MG	23JUL96	29	31JUL96	37	9
00221		Oral	4	200 MG	01AUG96	38	08AUG96	45	8
00221		Oral	4	200 MG	09AUG96	46	18AUG96	55	10
00221		Oral	4	200 MG	19AUG96	56	26AUG96	63	8
00112		Oral	4	200 MG	27AUG96	64	22SEP96	90	27
00112		Oral	4	200 MG	23SEP96	91	20OCT96	118	28
00112		Oral	4	200 MG	21OCT96	119	03NOV96	132	14
329.012.00223			Oral	1	50 MG	30AUG96	1	05SEP96	7
	00223	Oral	2	100 MG	06SEP96	8	15SEP96	17	10
	00223	Oral	3	150 MG	16SEP96	18	22SEP96	24	7
	00223	Oral	4	200 MG	23SEP96	25	30SEP96	32	8
		Oral	3	150 MG	01OCT96	33	12OCT96	44	12
329.012.00227		Oral	1	50 MG	18DEC96	1	26DEC96	9	9
	00227	Oral	2	100 MG	27DEC96	10	05JAN97	19	10
	00227	Oral	3	150 MG	06JAN97	20	14JAN97	28	9
	00227	Oral	4	200 MG	15JAN97	29	23JAN97	37	9
	00227	Oral	4	200 MG	24JAN97	38	03FEB97	48	11
	00227	Oral	4	200 MG	04FEB97	49	13FEB97	58	10
	00227	Oral	5	250 MG	14FEB97	59	19FEB97	64	6
	00227	Oral	5	250 MG	20FEB97	65	24FEB97	69	5

\* DAYS RELATIVE TO START OF STUDY MEDICATION

616

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: IMIPRAMINE

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.012.00227	00114	Oral	6	300 MG	25FEB97	70	26MAR97	99	30
	00114	Oral	6	300 MG	27MAR97	100	24APR97	128	29
	00114	Oral	6	300 MG	25APR97	129	25MAY97	159	31
	00114	Oral	6	300 MG	26MAY97	160	24JUN97	189	30
	00114	Oral	6	300 MG	25JUN97	190	20JUL97	215	26
	00114	Oral	6	300 MG	21JUL97	216	18AUG97	244	29
	00227	Oral	5	250 MG	19AUG97	245	20AUG97	246	2
	00227	Oral	4	200 MG	21AUG97	247	22AUG97	248	2
	00227	Oral	3	150 MG	23AUG97	249	24AUG97	250	2
	00227	Oral	2	100 MG	25AUG97	251	27AUG97	253	3
	00227	Oral	1	50 MG	28AUG97	254	03SEP97	260	7
329.012.00230		Oral	1	50 MG	28FEB97	1	06MAR97	7	7
	00230	Oral	2	100 MG	07MAR97	8	13MAR97	14	7
	00230	Oral	3	150 MG	14MAR97	15	23MAR97	24	10
	00230	Oral	4	200 MG	24MAR97	25	02APR97	34	10
	00230	Oral	4	200 MG	03APR97	35	10APR97	42	8
	00230	Oral	4	200 MG	11APR97	43	20APR97	52	10
	00230	Oral	4	200 MG	21APR97	53	01MAY97	63	11
	00230	Oral	5	250 MG	02MAY97	64	07MAY97	69	6
	00116	Oral	5	250 MG	08MAY97	70	12MAY97	74	5
	00230	Oral	4	200 MG	13MAY97	75	13MAY97	75	1
	00230	Oral	3	150 MG	14MAY97	76	14MAY97	76	1
	00230	Oral	2	100 MG	15MAY97	77	16MAY97	78	2
	00230	Oral	1	50 MG	17MAY97	79	26MAY97	88	10

\* DAYS RELATIVE TO START OF STUDY MEDICATION

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.001.00062		Oral	1	0 MG	20OCT94	1	26OCT94	7	7
	00062	Oral	2	0 MG	27OCT94	8	02NOV94	14	7
	00062	Oral	3	0 MG	03NOV94	15	09NOV94	21	7
	00062	Oral	4	0 MG	10NOV94	22	15NOV94	27	6
329.001.00064		Oral	1	0 MG	10NOV94	1	15NOV94	6	6
	00064	Oral	2	0 MG	16NOV94	7	21NOV94	12	6
	00064	Oral	3	0 MG	22NOV94	13	28NOV94	19	7
	00064	Oral	4	0 MG	29NOV94	20	05DEC94	26	7
	00064	Oral	4	0 MG	06DEC94	27	12DEC94	33	7
	00064	Oral	4	0 MG	13DEC94	34	19DEC94	40	7
	00064	Oral	4	0 MG	20DEC94	41	26DEC94	47	7
	00064	Oral	4	0 MG	27DEC94	48	02JAN95	54	7
	00050	Oral	4	0 MG	03JAN95	55	30JAN95	82	28
	00050	Oral	4	0 MG	31JAN95	83	27FEB95	110	28
	00050	Oral	4	0 MG	28FEB95	111	27MAR95	138	28
	00064	Oral	4	0 MG	28MAR95	139	10APR95	152	14
329.001.00069		Oral	1	0 MG	16FEB95	1	22FEB95	7	7
	00069	Oral	2	0 MG	23FEB95	8	01MAR95	14	7
	00069	Oral	3	0 MG	02MAR95	15	08MAR95	21	7
	00069	Oral	4	0 MG	09MAR95	22	15MAR95	28	7
	00069	Oral	4	0 MG	16MAR95	29	22MAR95	35	7
	00069	Oral	4	0 MG	23MAR95	36	29MAR95	42	7
	00069	Oral	5	0 MG	30MAR95	43	05APR95	49	7
	00069	Oral	6	0 MG	06APR95	50	12APR95	56	7
		Oral	5	0 MG	13APR95	57	18APR95	62	6
329.001.00071		Oral	1	0 MG	23FEB95	1	01MAR95	7	7
	00071	Oral	2	0 MG	02MAR95	8	08MAR95	14	7
	00071	Oral	3	0 MG	09MAR95	15	15MAR95	21	7
	00071	Oral	4	0 MG	16MAR95	22	22MAR95	28	7
	00071	Oral	5	0 MG	23MAR95	29	29MAR95	35	7
	00071	Oral	6	0 MG	30MAR95	36	05APR95	42	7
	00071	Oral	6	0 MG	06APR95	43	12APR95	49	7
	00071	Oral	6	0 MG	13APR95	50	19APR95	56	7
		Oral	6	0 MG	20APR95	57	04MAY95	71	15
329.001.00123		Oral	1	0 MG	04JAN96	1	11JAN96	8	8
	00123	Oral	2	0 MG	12JAN96	9	17JAN96	14	6

\* DAYS RELATIVE TO START OF STUDY MEDICATION

618

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.001.00123	00123	Oral	3	0 MG	18JAN96	15	24JAN96	21	7
	00123	Oral	4	0 MG	25JAN96	22	31JAN96	28	7
	00123	Oral	4	0 MG	01FEB96	29	07FEB96	35	7
	00123	Oral	4	0 MG	08FEB96	36	14FEB96	42	7
	00123	Oral	4	0 MG	15FEB96	43	21FEB96	49	7
329.001.00207		Oral	1	0 MG	28FEB96	1	05MAR96	7	7
	00207	Oral	2	0 MG	06MAR96	8	12MAR96	14	7
	00207	Oral	3	0 MG	13MAR96	15	19MAR96	21	7
	00207	Oral	4	0 MG	20MAR96	22	25MAR96	27	6
	00207	Oral	4	0 MG	26MAR96	28	02APR96	35	8
	00207	Oral	4	0 MG	03APR96	36	09APR96	42	7
	00207	Oral	4	0 MG	10APR96	43	16APR96	49	7
	00207	Oral	4	0 MG	17APR96	50	23APR96	56	7
		Oral	3	0 MG	24APR96	57	25APR96	58	2
329.002.00049		Oral	1	0 MG	09MAR95	1	15MAR95	7	7
	00049	Oral	2	0 MG	16MAR95	8	22MAR95	14	7
	00049	Oral	3	0 MG	23MAR95	15	29MAR95	21	7
	00049	Oral	4	0 MG	30MAR95	22	05APR95	28	7
	00049	Oral	5	0 MG	06APR95	29	12APR95	35	7
	00049	Oral	6	0 MG	13APR95	36	19APR95	42	7
	00049	Oral	6	0 MG	20APR95	43	27APR95	50	8
	00049	Oral	6	0 MG	28APR95	51	05MAY95	58	8
		Oral	6	0 MG	06MAY95	59	21MAY95	74	16
329.002.00059		Oral	1	0 MG	10NOV94	1	16NOV94	7	7
	00059	Oral	2	0 MG	17NOV94	8	22NOV94	13	6
	00059	Oral	3	0 MG	23NOV94	14	30NOV94	21	8
	00059	Oral	4	0 MG	01DEC94	22	07DEC94	28	7
	00059	Oral	5	0 MG	08DEC94	29	14DEC94	35	7
	00059	Oral	6	0 MG	15DEC94	36	21DEC94	42	7
	00059	Oral	6	0 MG	22DEC94	43	28DEC94	49	7
	00059	Oral	6	0 MG	29DEC94	50	05JAN95	57	8
		Oral	6	0 MG	06JAN95	58	21JAN95	73	16
329.002.00060		Oral	1	0 MG	31JAN95	1	06FEB95	7	7
	00060	Oral	2	0 MG	07FEB95	8	13FEB95	14	7
	00060	Oral	3	0 MG	14FEB95	15	20FEB95	21	7
	00060	Oral	4	0 MG	21FEB95	22	27FEB95	28	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

619

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00060	00060	Oral	5	0 MG	28FEB95	29	06MAR95	35	7
	00060	Oral	6	0 MG	07MAR95	36	13MAR95	42	7
	00060	Oral	6	0 MG	14MAR95	43	20MAR95	49	7
	00060	Oral	6	0 MG	21MAR95	50	27MAR95	56	7
	00065	Oral	6	0 MG	28MAR95	57	25APR95	85	29
329.002.00097		Oral	1	0 MG	03JAN95	1	09JAN95	7	7
	00097	Oral	2	0 MG	10JAN95	8	17JAN95	15	8
	00097	Oral	3	0 MG	18JAN95	16	24JAN95	22	7
	00097	Oral	4	0 MG	25JAN95	23	31JAN95	29	7
	00097	Oral	5	0 MG	01FEB95	30	06FEB95	35	6
	00097	Oral	6	0 MG	07FEB95	36	13FEB95	42	7
	00097	Oral	6	0 MG	14FEB95	43	20FEB95	49	7
	00097	Oral	6	0 MG	21FEB95	50	01MAR95	58	9
	00026	Oral	6	0 MG	02MAR95	59	29MAR95	86	28
	00026	Oral	6	0 MG	30MAR95	87	26APR95	114	28
	00026	Oral	6	0 MG	27APR95	115	22MAY95	140	26
	00026	Oral	6	0 MG	23MAY95	141	28JUN95	177	37
	00026	Oral	6	0 MG	29JUN95	178	01AUG95	211	34
	00026	Oral	6	0 MG	02AUG95	212	04SEP95	245	34
	00097	Oral	5	0 MG	05SEP95	246	06SEP95	247	2
	00097	Oral	4	0 MG	07SEP95	248	08SEP95	249	2
	00097	Oral	3	0 MG	09SEP95	250	10SEP95	251	2
00097	Oral	2	0 MG	11SEP95	252	13SEP95	254	3	
00097	Oral	1	0 MG	14SEP95	255	20SEP95	261	7	
329.002.00101		Oral	1	0 MG	28MAR95	1	03APR95	7	7
	00101	Oral	2	0 MG	04APR95	8	12APR95	16	9
	00101	Oral	3	0 MG	13APR95	17	19APR95	23	7
	00101	Oral	4	0 MG	20APR95	24	26APR95	30	7
	00101	Oral	5	0 MG	27APR95	31	03MAY95	37	7
	00101	Oral	6	0 MG	04MAY95	38	10MAY95	44	7
	00101	Oral	6	0 MG	11MAY95	45	17MAY95	51	7
	00101	Oral	6	0 MG	18MAY95	52	24MAY95	58	7
	00066	Oral	6	0 MG	25MAY95	59	21JUN95	86	28
		Oral	6	0 MG	22JUN95	87	26JUN95	91	5
	00101	Oral	5	0 MG	27JUN95	92	27JUN95	92	1
	00101	Oral	4	0 MG	28JUN95	93	29JUN95	94	2
	00101	Oral	3	0 MG	30JUN95	95	01JUL95	96	2
	00101	Oral	2	0 MG	02JUL95	97	04JUL95	99	3

\* DAYS RELATIVE TO START OF STUDY MEDICATION

620

CONFIDENTIAL

BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.002.00101	00101	Oral	1	0 MG	05JUL95	100	11JUL95	106	7
329.002.00107		Oral	1	0 MG	25JAN96	1	31JAN96	7	7
	00107	Oral	2	0 MG	01FEB96	8	07FEB96	14	7
	00107	Oral	3	0 MG	08FEB96	15	12FEB96	19	5
	00107	Oral	4	0 MG	13FEB96	20	19FEB96	26	7
	00107	Oral	4	0 MG	20FEB96	27	26FEB96	33	7
	00107	Oral	4	0 MG	27FEB96	34	04MAR96	40	7
	00107	Oral	5	0 MG	05MAR96	41	14MAR96	50	10
	00107	Oral	6	0 MG	15MAR96	51	20MAR96	56	6
	00176	Oral	6	0 MG	21MAR96	57	22APR96	89	33
	00176	Oral	6	0 MG	23APR96	90	20MAY96	117	28
	00176	Oral	6	0 MG	21MAY96	118	19JUN96	147	30
	00176	Oral	6	0 MG	20JUN96	148	24JUL96	182	35
	00176	Oral	6	0 MG	25JUL96	183	28AUG96	217	35
	00176	Oral	6	0 MG	29AUG96	218	25SEP96	245	28
	00176	Oral	5	0 MG	26SEP96	246	08OCT96	258	13
329.002.00241		Oral	1	0 MG	06FEB96	1	12FEB96	7	7
	00241	Oral	2	0 MG	13FEB96	8	21FEB96	16	9
	00241	Oral	3	0 MG	22FEB96	17	26FEB96	21	5
	00241	Oral	4	0 MG	27FEB96	22	04MAR96	28	7
	00241	Oral	4	0 MG	05MAR96	29	11MAR96	35	7
	00241	Oral	5	0 MG	12MAR96	36	18MAR96	42	7
	00241	Oral	5	0 MG	19MAR96	43	25MAR96	49	7
	00241	Oral	6	0 MG	26MAR96	50	01APR96	56	7
	00145	Oral	6	0 MG	02APR96	57	30APR96	85	29
	00145	Oral	6	0 MG	01MAY96	86	23MAY96	108	23
329.002.00246		Oral	1	0 MG	18APR96	1	24APR96	7	7
	00246	Oral	2	0 MG	25APR96	8	01MAY96	14	7
	00246	Oral	3	0 MG	02MAY96	15	08MAY96	21	7
	00246	Oral	4	0 MG	09MAY96	22	15MAY96	28	7
	00246	Oral	5	0 MG	16MAY96	29	22MAY96	35	7
	00246	Oral	5	0 MG	23MAY96	36	29MAY96	42	7
	00246	Oral	5	0 MG	30MAY96	43	03JUN96	47	5
	00246	Oral	6	0 MG	04JUN96	48	17JUN96	61	14
		Oral	6	0 MG	18JUN96	62	28JUN96	72	11
329.002.00320		Oral	1	0 MG	16MAY96	1	22MAY96	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

621

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS	
329.002.00320	00320	Oral	2	0 MG	23MAY96	8	29MAY96	14	7	
	00320	Oral	3	0 MG	30MAY96	15	03JUN96	19	5	
	00320	Oral	4	0 MG	04JUN96	20	17JUN96	33	14	
	00320	Oral	5	0 MG	18JUN96	34	24JUN96	40	7	
	00320	Oral	5	0 MG	25JUN96	41	01JUL96	47	7	
	00320	Oral	6	0 MG	02JUL96	48	08JUL96	54	7	
	00320	Oral	6	0 MG	09JUL96	55	15JUL96	61	7	
	00182	Oral	6	0 MG	16JUL96	62	12AUG96	89	28	
	00182	Oral	6	0 MG	13AUG96	90	16SEP96	124	35	
	00182	Oral	6	0 MG	17SEP96	125	25SEP96	133	9	
	00320	Oral	5	0 MG	26SEP96	134	08OCT96	146	13	
	329.002.00323		Oral	1	0 MG	12NOV96	1	18NOV96	7	7
		00323	Oral	2	0 MG	19NOV96	8	25NOV96	14	7
00323		Oral	3	0 MG	26NOV96	15	04DEC96	23	9	
00323		Oral	4	0 MG	05DEC96	24	09DEC96	28	5	
00323		Oral	4	0 MG	10DEC96	29	16DEC96	35	7	
00323		Oral	4	0 MG	17DEC96	36	25DEC96	44	9	
00323		Oral	4	0 MG	26DEC96	45	01JAN97	51	7	
00323		Oral	4	0 MG	02JAN97	52	08JAN97	58	7	
00175		Oral	4	0 MG	09JAN97	59	03FEB97	84	26	
00175		Oral	4	0 MG	04FEB97	85	03MAR97	112	28	
00175		Oral	5	0 MG	04MAR97	113	02APR97	142	30	
00175		Oral	5	0 MG	03APR97	143	29APR97	169	27	
00175		Oral	5	0 MG	30APR97	170	26MAY97	196	27	
00175		Oral	5	0 MG	27MAY97	197	11JUN97	212	16	
00323		Oral	5	0 MG	12JUN97	213	14JUN97	215	3	
00323		Oral	4	0 MG	15JUN97	216	16JUN97	217	2	
00323		Oral	3	0 MG	17JUN97	218	18JUN97	219	2	
00323	Oral	2	0 MG	19JUN97	220	20JUN97	221	2		
00323	Oral	1	0 MG	21JUN97	222	26JUN97	227	6		
329.003.00074		Oral	1	0 MG	25JAN95	1	31JAN95	7	7	
	00074	Oral	2	0 MG	01FEB95	8	07FEB95	14	7	
	00074	Oral	3	0 MG	08FEB95	15	14FEB95	21	7	
	00074	Oral	4	0 MG	15FEB95	22	20FEB95	27	6	
	00074	Oral	5	0 MG	21FEB95	28	28FEB95	35	8	
	00074	Oral	6	0 MG	01MAR95	36	14MAR95	49	14	
	00074	Oral	6	0 MG	15MAR95	50	21MAR95	56	7	
	00043	Oral	6	0 MG	22MAR95	57	18APR95	84	28	

\* DAYS RELATIVE TO START OF STUDY MEDICATION

622

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00074	00043	Oral	6	0 MG	19APR95	85	16MAY95	112	28
	00043	Oral	6	0 MG	17MAY95	113	18JUN95	145	33
	00043	Oral	6	0 MG	19JUN95	146	23JUL95	180	35
	00043	Oral	6	0 MG	24JUL95	181	29AUG95	217	37
	00043	Oral	6	0 MG	30AUG95	218	11OCT95	260	43
	00074	Oral	5	0 MG	25OCT95	274	.	.	.
329.003.00078		Oral	1	0 MG	26APR95	1	01MAY95	6	6
	00078	Oral	2	0 MG	02MAY95	7	09MAY95	14	8
	00078	Oral	3	0 MG	10MAY95	15	16MAY95	21	7
	00078	Oral	4	0 MG	17MAY95	22	23MAY95	28	7
	00078	Oral	5	0 MG	24MAY95	29	29MAY95	34	6
	00078	Oral	6	0 MG	30MAY95	35	06JUN95	42	8
	00078	Oral	6	0 MG	07JUN95	43	14JUN95	50	8
	00078	Oral	6	0 MG	15JUN95	51	21JUN95	57	7
	00078	Oral	6	0 MG	22JUN95	58	28JUN95	64	7
	329.003.00080		Oral	1	0 MG	27NOV95	1	03DEC95	7
00080		Oral	2	0 MG	04DEC95	8	10DEC95	14	7
00080		Oral	3	0 MG	11DEC95	15	17DEC95	21	7
00080		Oral	4	0 MG	18DEC95	22	28DEC95	32	11
00080		Oral	4	0 MG	29DEC95	33	03JAN96	38	6
00080		Oral	5	0 MG	04JAN96	39	09JAN96	44	6
00080		Oral	6	0 MG	10JAN96	45	16JAN96	51	7
00080		Oral	6	0 MG	17JAN96	52	23JAN96	58	7
00080		Oral	5	0 MG	24JAN96	59	09FEB96	75	17
329.003.00085			Oral	1	0 MG	08NOV94	1	14NOV94	7
	00085	Oral	2	0 MG	15NOV94	8	20NOV94	13	6
	00085	Oral	3	0 MG	21NOV94	14	27NOV94	20	7
	00085	Oral	4	0 MG	28NOV94	21	05DEC94	28	8
	00085	Oral	5	0 MG	06DEC94	29	12DEC94	35	7
	00085	Oral	6	0 MG	13DEC94	36	19DEC94	42	7
	00085	Oral	6	0 MG	20DEC94	43	27DEC94	50	8
	00085	Oral	6	0 MG	28DEC94	51	03JAN95	57	7
	00085	Oral	5	0 MG	04JAN95	58	17JAN95	71	14
	329.003.00086		Oral	1	0 MG	28NOV94	1	04DEC94	7
00086		Oral	2	0 MG	05DEC94	8	12DEC94	15	8
00086		Oral	3	0 MG	13DEC94	16	19DEC94	22	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

623

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00086	00086	Oral	4	0 MG	20DEC94	23	27DEC94	30	8
	00086	Oral	5	0 MG	28DEC94	31	03JAN95	37	7
	00086	Oral	6	0 MG	04JAN95	38	09JAN95	43	6
	00086	Oral	6	0 MG	10JAN95	44	17JAN95	51	8
	00086	Oral	6	0 MG	18JAN95	52	23JAN95	57	6
	00038	Oral	6	0 MG	24JAN95	58	19FEB95	84	27
	00038	Oral	6	0 MG	20FEB95	85	28MAR95	121	37
	00038	Oral	6	0 MG	29MAR95	122	25APR95	149	28
	00038	Oral	6	0 MG	26APR95	150	30MAY95	184	35
	00038	Oral	6	0 MG	31MAY95	185	11JUL95	226	42
	00038	Oral	6	0 MG	12JUL95	227	16AUG95	262	36
	00086	Oral	5	0 MG	17AUG95	263	18AUG95	264	2
	00086	Oral	4	0 MG	19AUG95	265	20AUG95	266	2
	00086	Oral	3	0 MG	21AUG95	267	22AUG95	268	2
	00086	Oral	2	0 MG	23AUG95	269	25AUG95	271	3
	00086	Oral	1	0 MG	26AUG95	272	02SEP95	279	8
329.003.00094		Oral	1	0 MG	24OCT95	1	30OCT95	7	7
	00094	Oral	2	0 MG	31OCT95	8	06NOV95	14	7
	00094	Oral	3	0 MG	07NOV95	15	13NOV95	21	7
	00094	Oral	4	0 MG	14NOV95	22	20NOV95	28	7
	00094	Oral	5	0 MG	21NOV95	29	27NOV95	35	7
	00094	Oral	6	0 MG	28NOV95	36	04DEC95	42	7
	00094	Oral	6	0 MG	05DEC95	43	11DEC95	49	7
	00094	Oral	6	0 MG	12DEC95	50	19DEC95	57	8
		Oral	5	0 MG	20DEC95	58	04JAN96	73	16
329.003.00251		Oral	1	0 MG	28MAR96	1	04APR96	8	8
	00251	Oral	2	0 MG	05APR96	9	08APR96	12	4
	00251	Oral	3	0 MG	09APR96	13	.	.	.
329.003.00252		Oral	1	0 MG	10APR96	1	16APR96	7	7
	00252	Oral	2	0 MG	17APR96	8	23APR96	14	7
	00252	Oral	3	0 MG	24APR96	15	30APR96	21	7
	00252	Oral	4	0 MG	01MAY96	22	09MAY96	30	9
	00252	Oral	4	0 MG	10MAY96	31	14MAY96	35	5
	00252	Oral	5	0 MG	15MAY96	36	20MAY96	41	6
	00252	Oral	4	0 MG	21MAY96	42	27MAY96	48	7
	00252	Oral	4	0 MG	28MAY96	49	10JUN96	62	14
		Oral	3	0 MG	11JUN96	63	18JUN96	70	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

624

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.003.00291		Oral	1	0 MG	03JUL96	1	14JUL96	12	12
	00291	Oral	2	0 MG	15JUL96	13	23JUL96	21	9
	00291	Oral	3	0 MG	24JUL96	22	30JUL96	28	7
	00291	Oral	4	0 MG	31JUL96	29	06AUG96	35	7
	00291	Oral	4	0 MG	07AUG96	36	13AUG96	42	7
	00291	Oral	4	0 MG	14AUG96	43	20AUG96	49	7
	00291	Oral	4	0 MG	21AUG96	50	27AUG96	56	7
	00291	Oral	5	0 MG	28AUG96	57	05SEP96	65	9
	00135	Oral	5	0 MG	06SEP96	66	01OCT96	91	26
	00135	Oral	5	0 MG	02OCT96	92	29OCT96	119	28
	00135	Oral	5	0 MG	30OCT96	120	.	.	.
329.003.00315		Oral	1	0 MG	12NOV96	1	21NOV96	10	10
	00315	Oral	2	0 MG	22NOV96	11	25NOV96	14	4
	00315	Oral	3	0 MG	26NOV96	15	02DEC96	21	7
	00315	Oral	4	0 MG	03DEC96	22	11DEC96	30	9
	00315	Oral	4	0 MG	12DEC96	31	17DEC96	36	6
	00315	Oral	4	0 MG	18DEC96	37	22DEC96	41	5
	00315	Oral	4	0 MG	23DEC96	42	29DEC96	48	7
	00315	Oral	4	0 MG	30DEC96	49	06JAN97	56	8
		Oral	4	0 MG	07JAN97	57	10JAN97	60	4
329.003.00316		Oral	1	0 MG	17DEC96	1	23DEC96	7	7
	00316	Oral	2	0 MG	24DEC96	8	30DEC96	14	7
	00316	Oral	3	0 MG	31DEC96	15	07JAN97	22	8
	00316	Oral	4	0 MG	08JAN97	23	14JAN97	29	7
	00316	Oral	5	0 MG	15JAN97	30	21JAN97	36	7
	00316	Oral	6	0 MG	22JAN97	37	28JAN97	43	7
	00316	Oral	6	0 MG	29JAN97	44	03FEB97	49	6
	00316	Oral	6	0 MG	04FEB97	50	09FEB97	55	6
		Oral	5	0 MG	10FEB97	56	18FEB97	64	9
329.004.00016		Oral	1	0 MG	13MAR95	1	19MAR95	7	7
	00016	Oral	2	0 MG	20MAR95	8	28MAR95	16	9
	00016	Oral	3	0 MG	29MAR95	17	04APR95	23	7
	00016	Oral	4	0 MG	05APR95	24	11APR95	30	7
	00016	Oral	4	0 MG	12APR95	31	19APR95	38	8
329.004.00018		Oral	1	0 MG	03MAY95	1	10MAY95	8	8
	00018	Oral	2	0 MG	11MAY95	9	17MAY95	15	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

625

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.004.00018	00018	Oral	3	0 MG	18MAY95	16	24MAY95	22	7
	00018	Oral	4	0 MG	25MAY95	23	31MAY95	29	7
	00018	Oral	5	0 MG	01JUN95	30	07JUN95	36	7
	00018	Oral	5	0 MG	08JUN95	37	18JUN95	47	11
	00018	Oral	6	0 MG	19JUN95	48	21JUN95	50	3
	00018	Oral	6	0 MG	22JUN95	51	28JUN95	57	7
	00018	Oral	5	0 MG	29JUN95	58	14JUL95	73	16
329.004.00020		Oral	1	0 MG	09NOV95	1	15NOV95	7	7
	00020	Oral	2	0 MG	16NOV95	8	24NOV95	16	9
329.004.00213		Oral	1	0 MG	02AUG96	1	07AUG96	6	6
	00213	Oral	2	0 MG	08AUG96	7	14AUG96	13	7
	00213	Oral	3	0 MG	15AUG96	14	20AUG96	19	6
	00213	Oral	4	0 MG	21AUG96	20	28AUG96	27	8
	00213	Oral	4	0 MG	29AUG96	28	02SEP96	32	5
	00213	Oral	4	0 MG	03SEP96	33	09SEP96	39	7
	00213	Oral	4	0 MG	10SEP96	40	16SEP96	46	7
	00213	Oral	4	0 MG	17SEP96	47	24SEP96	54	8
	00122	Oral	4	0 MG	25SEP96	55	21OCT96	81	27
	00122	Oral	4	0 MG	22OCT96	82	18NOV96	109	28
	00122	Oral	4	0 MG	19NOV96	110	19DEC96	140	31
	00122	Oral	4	0 MG	20DEC96	141	20JAN97	172	32
	00122	Oral	4	0 MG	21JAN97	173	17FEB97	200	28
	00122	Oral	4	0 MG	18FEB97	201	18MAR97	229	29
	00213	Oral	3	0 MG	19MAR97	230	20MAR97	231	2
	00213	Oral	2	0 MG	21MAR97	232	23MAR97	234	3
	00213	Oral	1	0 MG	24MAR97	235	30MAR97	241	7
329.005.00001		Oral	1	0 MG	20APR94	1	26APR94	7	7
	00001	Oral	2	0 MG	27APR94	8	03MAY94	14	7
	00001	Oral	3	0 MG	04MAY94	15	10MAY94	21	7
	00001	Oral	4	0 MG	11MAY94	22	17MAY94	28	7
	00001	Oral	5	0 MG	18MAY94	29	24MAY94	35	7
	00001	Oral	6	0 MG	25MAY94	36	31MAY94	42	7
	00001	Oral	6	0 MG	01JUN94	43	07JUN94	49	7
	00001	Oral	6	0 MG	08JUN94	50	14JUN94	56	7
		Oral	6	0 MG	15JUN94	57	28JUN94	70	14
329.005.00005		Oral	1	0 MG	01NOV94	1	09NOV94	9	9

\* DAYS RELATIVE TO START OF STUDY MEDICATION

626

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00010		Oral	1	0 MG	13DEC94	1	19DEC94	7	7
	00010	Oral	2	0 MG	20DEC94	8	26DEC94	14	7
	00010	Oral	3	0 MG	27DEC94	15	03JAN95	22	8
	00010	Oral	4	0 MG	04JAN95	23	10JAN95	29	7
	00010	Oral	5	0 MG	11JAN95	30	17JAN95	36	7
	00010	Oral	6	0 MG	18JAN95	37	24JAN95	43	7
	00010	Oral	6	0 MG	25JAN95	44	01FEB95	51	8
	00010	Oral	6	0 MG	02FEB95	52	07FEB95	57	6
	00090	Oral	6	0 MG	08FEB95	58	09MAR95	87	30
	00090	Oral	6	0 MG	10MAR95	88	12APR95	121	34
	00090	Oral	6	0 MG	13APR95	122	09MAY95	148	27
	00090	Oral	6	0 MG	10MAY95	149	05JUN95	175	27
	00090	Oral	6	0 MG	06JUN95	176	11JUL95	211	36
	00090	Oral	6	0 MG	12JUL95	212	08AUG95	239	28
	00010	Oral	5	0 MG	09AUG95	240	10AUG95	241	2
	00010	Oral	4	0 MG	11AUG95	242	12AUG95	243	2
	00010	Oral	3	0 MG	13AUG95	244	14AUG95	245	2
	00010	Oral	2	0 MG	15AUG95	246	17AUG95	248	3
	00010	Oral	1	0 MG	18AUG95	249	24AUG95	255	7
329.005.00012		Oral	1	0 MG	19DEC94	1	26DEC94	8	8
	00012	Oral	2	0 MG	27DEC94	9	04JAN95	17	9
	00012	Oral	3	0 MG	05JAN95	18	11JAN95	24	7
	00012	Oral	4	0 MG	12JAN95	25	17JAN95	30	6
	00012	Oral	5	0 MG	18JAN95	31	24JAN95	37	7
	00012	Oral	6	0 MG	25JAN95	38	30JAN95	43	6
	00012	Oral	6	0 MG	31JAN95	44	07FEB95	51	8
	00012	Oral	6	0 MG	08FEB95	52	15FEB95	59	8
	00096	Oral	6	0 MG	16FEB95	60	26MAR95	98	39
	00096	Oral	6	0 MG	27MAR95	99	03MAY95	136	38
	00096	Oral	6	0 MG	04MAY95	137	30MAY95	163	27
	00096	Oral	6	0 MG	31MAY95	164	01JUN95	165	2
329.005.00111		Oral	1	0 MG	11JAN95	1	17JAN95	7	7
	00111	Oral	2	0 MG	18JAN95	8	24JAN95	14	7
	00111	Oral	3	0 MG	25JAN95	15	31JAN95	21	7
	00111	Oral	4	0 MG	01FEB95	22	07FEB95	28	7
	00111	Oral	4	0 MG	08FEB95	29	14FEB95	35	7
	00111	Oral	4	0 MG	15FEB95	36	21FEB95	42	7
	00111	Oral	4	0 MG	22FEB95	43	28FEB95	49	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

627

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00111	00111	Oral	4	0 MG	01MAR95	50	07MAR95	56	7
	00018	Oral	4	0 MG	08MAR95	57	04APR95	84	28
	00018	Oral	4	0 MG	05APR95	85	18APR95	98	14
	00111	Oral	3	0 MG	19APR95	99	20APR95	100	2
	00111	Oral	2	0 MG	21APR95	101	23APR95	103	3
	00111	Oral	1	0 MG	24APR95	104	30APR95	110	7
329.005.00114		Oral	1	0 MG	31JAN95	1	06FEB95	7	7
	00114	Oral	2	0 MG	07FEB95	8	13FEB95	14	7
	00114	Oral	3	0 MG	14FEB95	15	20FEB95	21	7
	00114	Oral	4	0 MG	21FEB95	22	27FEB95	28	7
	00114	Oral	4	0 MG	28FEB95	29	08MAR95	37	9
	00114	Oral	4	0 MG	09MAR95	38	14MAR95	43	6
	00114	Oral	4	0 MG	15MAR95	44	21MAR95	50	7
	00114	Oral	4	0 MG	22MAR95	51	28MAR95	57	7
	00020	Oral	4	0 MG	29MAR95	58	25APR95	85	28
	00114	Oral	4	0 MG	26APR95	86	26APR95	86	1
	00114	Oral	3	0 MG	27APR95	87	28APR95	88	2
	00114	Oral	2	0 MG	29APR95	89	01MAY95	91	3
	00114	Oral	1	0 MG	02MAY95	92	08MAY95	98	7
	329.005.00115		Oral	1	0 MG	06FEB95	1	12FEB95	7
00115		Oral	2	0 MG	13FEB95	8	19FEB95	14	7
00115		Oral	3	0 MG	20FEB95	15	01MAR95	24	10
00115		Oral	4	0 MG	02MAR95	25	09MAR95	32	8
00115		Oral	4	0 MG	10MAR95	33	16MAR95	39	7
00115		Oral	4	0 MG	17MAR95	40	27MAR95	50	11
00115		Oral	4	0 MG	28MAR95	51	09APR95	63	13
00115		Oral	4	0 MG	10APR95	64	17APR95	71	8
00003		Oral	4	0 MG	18APR95	72	21APR95	75	4
329.005.00120			Oral	1	0 MG	30AUG95	1	06SEP95	8
	00120	Oral	2	0 MG	07SEP95	9	13SEP95	15	7
	00120	Oral	3	0 MG	14SEP95	16	20SEP95	22	7
	00120	Oral	4	0 MG	21SEP95	23	27SEP95	29	7
	00120	Oral	5	0 MG	28SEP95	30	04OCT95	36	7
	00120	Oral	5	0 MG	05OCT95	37	11OCT95	43	7
	00120	Oral	6	0 MG	12OCT95	44	18OCT95	50	7
	00120	Oral	6	0 MG	19OCT95	51	26OCT95	58	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

628

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00253		Oral	1	0 MG	08FEB96	1	13FEB96	6	6
	00253	Oral	2	0 MG	14FEB96	7	20FEB96	13	7
	00253	Oral	3	0 MG	21FEB96	14	27FEB96	20	7
	00253	Oral	4	0 MG	28FEB96	21	05MAR96	27	7
	00253	Oral	5	0 MG	06MAR96	28	13MAR96	35	8
	00253	Oral	6	0 MG	14MAR96	36	19MAR96	41	6
	00253	Oral	6	0 MG	20MAR96	42	26MAR96	48	7
	00253	Oral	6	0 MG	27MAR96	49	02APR96	55	7
		Oral	5	0 MG	03APR96	56	.	.	.
329.005.00254		Oral	1	0 MG	15FEB96	1	20FEB96	6	6
	00254	Oral	2	0 MG	21FEB96	7	27FEB96	13	7
	00254	Oral	3	0 MG	28FEB96	14	05MAR96	20	7
	00254	Oral	4	0 MG	06MAR96	21	12MAR96	27	7
	00254	Oral	4	0 MG	13MAR96	28	19MAR96	34	7
	00254	Oral	4	0 MG	20MAR96	35	26MAR96	41	7
	00254	Oral	4	0 MG	27MAR96	42	02APR96	48	7
	00254	Oral	4	0 MG	03APR96	49	09APR96	55	7
	00146	Oral	4	0 MG	10APR96	56	08MAY96	84	29
	00146	Oral	4	0 MG	09MAY96	85	11JUN96	118	34
	00146	Oral	4	0 MG	12JUN96	119	09JUL96	146	28
	00146	Oral	4	0 MG	10JUL96	147	07AUG96	175	29
	00146	Oral	4	0 MG	08AUG96	176	11SEP96	210	35
	00146	Oral	4	0 MG	12SEP96	211	15OCT96	244	34
	00254	Oral	4	0 MG	16OCT96	245	17OCT96	246	2
	00254	Oral	3	0 MG	18OCT96	247	19OCT96	248	2
	00254	Oral	2	0 MG	20OCT96	249	22OCT96	251	3
	00254	Oral	1	0 MG	23OCT96	252	29OCT96	258	7
329.005.00293		Oral	1	0 MG	12MAR97	1	18MAR97	7	7
	00293	Oral	2	0 MG	19MAR97	8	24MAR97	13	6
	00293	Oral	3	0 MG	25MAR97	14	01APR97	21	8
	00293	Oral	4	0 MG	02APR97	22	08APR97	28	7
	00293	Oral	5	0 MG	09APR97	29	15APR97	35	7
	00293	Oral	6	0 MG	16APR97	36	22APR97	42	7
	00293	Oral	6	0 MG	23APR97	43	29APR97	49	7
	00293	Oral	6	0 MG	30APR97	50	07MAY97	57	8
329.005.00298		Oral	1	0 MG	22MAY96	1	29MAY96	8	8
	00298	Oral	2	0 MG	30MAY96	9	05JUN96	15	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

629

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.005.00298	00298	Oral	3	0 MG	06JUN96	16	11JUN96	21	6
	00298	Oral	4	0 MG	12JUN96	22	18JUN96	28	7
	00298	Oral	4	0 MG	19JUN96	29	25JUN96	35	7
	00298	Oral	4	0 MG	26JUN96	36	02JUL96	42	7
	00298	Oral	4	0 MG	03JUL96	43	09JUL96	49	7
	00298	Oral	4	0 MG	10JUL96	50	16JUL96	56	7
	00185	Oral	4	0 MG	17JUL96	57	15AUG96	86	30
	00185	Oral	4	0 MG	16AUG96	87	18SEP96	120	34
	00185	Oral	4	0 MG	19SEP96	121	16OCT96	148	28
	00185	Oral	4	0 MG	17OCT96	149	13NOV96	176	28
	00185	Oral	4	0 MG	14NOV96	177	11DEC96	204	28
	00185	Oral	4	0 MG	12DEC96	205	12JAN97	236	32
	00298	Oral	3	0 MG	13JAN97	237	14JAN97	238	2
	00298	Oral	2	0 MG	15JAN97	239	17JAN97	241	3
	00298	Oral	1	0 MG	18JAN97	242	24JAN97	248	7
329.005.00331		Oral	1	0 MG	21NOV96	1	26NOV96	6	6
	00331	Oral	2	0 MG	27NOV96	7	03DEC96	13	7
	00331	Oral	3	0 MG	04DEC96	14	11DEC96	21	8
	00331	Oral	4	0 MG	12DEC96	22	18DEC96	28	7
	00331	Oral	4	0 MG	19DEC96	29	25DEC96	35	7
	00331	Oral	4	0 MG	26DEC96	36	01JAN97	42	7
	00331	Oral	4	0 MG	02JAN97	43	09JAN97	50	8
	00331	Oral	4	0 MG	10JAN97	51	16JAN97	57	7
329.005.00334		Oral	1	0 MG	31JAN97	1	05FEB97	6	6
	00334	Oral	2	0 MG	06FEB97	7	12FEB97	13	7
	00334	Oral	3	0 MG	13FEB97	14	20FEB97	21	8
	00334	Oral	4	0 MG	21FEB97	22	25FEB97	26	5
	00334	Oral	4	0 MG	26FEB97	27	06MAR97	35	9
	00334	Oral	5	0 MG	07MAR97	36	13MAR97	42	7
	00334	Oral	5	0 MG	14MAR97	43	21MAR97	50	8
	00334	Oral	5	0 MG	22MAR97	51	27MAR97	56	6
329.006.00037		Oral	1	0 MG	28JAN95	1	02FEB95	6	6
	00037	Oral	2	0 MG	03FEB95	7	12FEB95	16	10
	00037	Oral	3	0 MG	13FEB95	17	21FEB95	25	9
329.006.00042		Oral	1	0 MG	07DEC95	1	12DEC95	6	6
	00042	Oral	2	0 MG	13DEC95	7	19DEC95	13	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

630

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.006.00042	00042	Oral	3	0 MG	20DEC95	14	26DEC95	20	7
	00042	Oral	4	0 MG	27DEC95	21	02JAN96	27	7
	00042	Oral	4	0 MG	03JAN96	28	09JAN96	34	7
	00042	Oral	5	0 MG	10JAN96	35	16JAN96	41	7
	00042	Oral	5	0 MG	17JAN96	42	22JAN96	47	6
	00042	Oral	6	0 MG	23JAN96	48	01FEB96	57	10
	00111	Oral	6	0 MG	02FEB96	58	28FEB96	84	27
	00111	Oral	6	0 MG	29FEB96	85	25MAR96	110	26
	00111	Oral	6	0 MG	26MAR96	111	22APR96	138	28
	00111	Oral	6	0 MG	23APR96	139	20MAY96	166	28
	00111	Oral	6	0 MG	21MAY96	167	17JUN96	194	28
	00111	Oral	6	0 MG	18JUN96	195	16JUL96	223	29
	00042	Oral	5	0 MG	17JUL96	224	18JUL96	225	2
	00042	Oral	4	0 MG	19JUL96	226	20JUL96	227	2
	00042	Oral	3	0 MG	21JUL96	228	22JUL96	229	2
	00042	Oral	2	0 MG	23JUL96	230	25JUL96	232	3
	00042	Oral	1	0 MG	26JUL96	233	31JUL96	238	6
329.006.00259		Oral	1	0 MG	24MAY96	1	27MAY96	4	4
	00259	Oral	2	0 MG	28MAY96	5	05JUN96	13	9
	00259	Oral	3	0 MG	06JUN96	14	12JUN96	20	7
	00259	Oral	4	0 MG	13JUN96	21	19JUN96	27	7
	00259	Oral	5	0 MG	20JUN96	28	27JUN96	35	8
	00259	Oral	6	0 MG	28JUN96	36	05JUL96	43	8
	00259	Oral	6	0 MG	06JUL96	44	10JUL96	48	5
	00259	Oral	6	0 MG	11JUL96	49	17JUL96	55	7
		Oral	6	0 MG	18JUL96	56	02AUG96	71	16
329.007.00141		Oral	1	0 MG	21SEP95	1	27SEP95	7	7
	00141	Oral	2	0 MG	28SEP95	8	04OCT95	14	7
	00141	Oral	3	0 MG	05OCT95	15	12OCT95	22	8
329.007.00144		Oral	1	0 MG	07DEC95	1	13DEC95	7	7
	00144	Oral	2	0 MG	14DEC95	8	20DEC95	14	7
	00144	Oral	3	0 MG	21DEC95	15	27DEC95	21	7
	00144	Oral	4	0 MG	28DEC95	22	04JAN96	29	8
	00144	Oral	4	0 MG	05JAN96	30	10JAN96	35	6
	00144	Oral	5	0 MG	11JAN96	36	17JAN96	42	7
	00144	Oral	5	0 MG	18JAN96	43	24JAN96	49	7
	00144	Oral	5	0 MG	25JAN96	50	31JAN96	56	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

631

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.007.00144	00115	Oral	5	0 MG	01FEB96	57	.	.	.
329.007.00266		Oral	1	0 MG	07MAR96	1	13MAR96	7	7
	00266	Oral	2	0 MG	14MAR96	8	24MAR96	18	11
	00266	Oral	3	0 MG	25MAR96	19	27MAR96	21	3
	00266	Oral	4	0 MG	28MAR96	22	03APR96	28	7
	00266	Oral	5	0 MG	04APR96	29	10APR96	35	7
	00266	Oral	5	0 MG	11APR96	36	17APR96	42	7
	00266	Oral	5	0 MG	18APR96	43	28APR96	53	11
	00266	Oral	5	0 MG	29APR96	54	02MAY96	57	4
	00266	Oral	4	0 MG	03MAY96	58	16MAY96	71	14
329.007.00267		Oral	1	0 MG	07MAR96	1	13MAR96	7	7
	00267	Oral	2	0 MG	14MAR96	8	20MAR96	14	7
	00267	Oral	3	0 MG	21MAR96	15	27MAR96	21	7
	00267	Oral	4	0 MG	28MAR96	22	03APR96	28	7
	00267	Oral	4	0 MG	04APR96	29	10APR96	35	7
	00267	Oral	4	0 MG	11APR96	36	17APR96	42	7
	00267	Oral	5	0 MG	18APR96	43	24APR96	49	7
	00267	Oral	5	0 MG	25APR96	50	01MAY96	56	7
		Oral	.		02MAY96	57	.	.	.
329.007.00311		Oral	1	0 MG	03OCT96	1	09OCT96	7	7
	00311	Oral	2	0 MG	10OCT96	8	16OCT96	14	7
	00311	Oral	3	0 MG	17OCT96	15	27OCT96	25	11
	00311	Oral	4	0 MG	28OCT96	26	30OCT96	28	3
	00311	Oral	4	0 MG	31OCT96	29	06NOV96	35	7
	00311	Oral	4	0 MG	07NOV96	36	13NOV96	42	7
	00311	Oral	4	0 MG	14NOV96	43	21NOV96	50	8
	00311	Oral	5	0 MG	22NOV96	51	01DEC96	60	10
	00160	Oral	5	0 MG	02DEC96	61	01JAN97	91	31
	00160	Oral	5	0 MG	02JAN97	92	29JAN97	119	28
	00160	Oral	5	0 MG	30JAN97	120	12MAR97	161	42
	00160	Oral	5	0 MG	13MAR97	162	10APR97	190	29
	00311	Oral	4	0 MG	11APR97	191	24APR97	204	14
329.008.00158		Oral	1	0 MG	13SEP95	1	18SEP95	6	6
	00158	Oral	2	0 MG	19SEP95	7	26SEP95	14	8
	00158	Oral	3	0 MG	27SEP95	15	02OCT95	20	6
	00158	Oral	4	0 MG	03OCT95	21	09OCT95	27	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

632

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.008.00158	00158	Oral	4	0 MG	10OCT95	28	15OCT95	33	6
	00158	Oral	5	0 MG	16OCT95	34	23OCT95	41	8
	00158	Oral	6	0 MG	24OCT95	42	30OCT95	48	7
	00158	Oral	6	0 MG	31OCT95	49	13NOV95	62	14
	00009	Oral	6	0 MG	14NOV95	63	26DEC95	105	43
	00009	Oral	6	0 MG	27DEC95	106	.	.	.
329.008.00162		Oral	1	0 MG	01NOV95	1	09NOV95	9	9
	00162	Oral	2	0 MG	10NOV95	10	19NOV95	19	10
	00162	Oral	3	0 MG	20NOV95	20	28NOV95	28	9
	00162	Oral	4	0 MG	29NOV95	29	06DEC95	36	8
	00162	Oral	5	0 MG	07DEC95	37	13DEC95	43	7
	00162	Oral	5	0 MG	14DEC95	44	19DEC95	49	6
	00162	Oral	6	0 MG	20DEC95	50	26DEC95	56	7
	00162	Oral	6	0 MG	27DEC95	57	04JAN96	65	9
	00101	Oral	6	0 MG	05JAN96	66	08FEB96	100	35
	00101	Oral	6	0 MG	09FEB96	101	07MAR96	128	28
	00101	Oral	6	0 MG	08MAR96	129	10APR96	162	34
		Oral	6	0 MG	11APR96	163	30APR96	182	20
	00101	Oral	6	0 MG	01MAY96	183	04JUN96	217	35
	00101	Oral	6	0 MG	05JUN96	218	01JUL96	244	27
	00162	Oral	5	0 MG	02JUL96	245	03JUL96	246	2
	00162	Oral	4	0 MG	04JUL96	247	05JUL96	248	2
	00162	Oral	3	0 MG	06JUL96	249	07JUL96	250	2
	00162	Oral	2	0 MG	08JUL96	251	10JUL96	253	3
	00162	Oral	1	0 MG	11JUL96	254	17JUL96	260	7
329.008.00191		Oral	1	0 MG	01FEB96	1	11FEB96	11	11
	00191	Oral	2	0 MG	12FEB96	12	19FEB96	19	8
	00191	Oral	3	0 MG	20FEB96	20	26FEB96	26	7
	00191	Oral	4	0 MG	27FEB96	27	04MAR96	33	7
	00191	Oral	4	0 MG	05MAR96	34	11MAR96	40	7
	00191	Oral	4	0 MG	12MAR96	41	17MAR96	46	6
	00191	Oral	4	0 MG	18MAR96	47	25MAR96	54	8
	00191	Oral	4	0 MG	26MAR96	55	01APR96	61	7
	00141	Oral	4	0 MG	02APR96	62	01MAY96	91	30
	00141	Oral	4	0 MG	02MAY96	92	04JUN96	125	34
	00141	Oral	4	0 MG	05JUN96	126	12JUN96	133	8
329.009.00128		Oral	1	0 MG	11APR95	1	17APR95	7	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

633

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00128	00128	Oral	2	0 MG	18APR95	8	24APR95	14	7
	00128	Oral	3	0 MG	25APR95	15	25APR95	15	1
		Oral	4	0 MG	26APR95	16	02MAY95	22	7
329.009.00129		Oral	1	0 MG	11APR95	1	17APR95	7	7
	00129	Oral	2	0 MG	18APR95	8	24APR95	14	7
	00129	Oral	3	0 MG	25APR95	15	01MAY95	21	7
	00129	Oral	4	0 MG	02MAY95	22	08MAY95	28	7
	00129	Oral	5	0 MG	09MAY95	29	16MAY95	36	8
329.009.00135		Oral	1	0 MG	02OCT95	1	08OCT95	7	7
	00135	Oral	2	0 MG	09OCT95	8	15OCT95	14	7
	00135	Oral	3	0 MG	16OCT95	15	22OCT95	21	7
	00135	Oral	4	0 MG	23OCT95	22	29OCT95	28	7
	00135	Oral	5	0 MG	30OCT95	29	05NOV95	35	7
	00135	Oral	4	0 MG	06NOV95	36	19NOV95	49	14
329.009.00136		Oral	1	0 MG	03OCT95	1	09OCT95	7	7
	00136	Oral	2	0 MG	10OCT95	8	16OCT95	14	7
	00136	Oral	3	0 MG	17OCT95	15	23OCT95	21	7
	00136	Oral	4	0 MG	24OCT95	22	02NOV95	31	10
	00136	Oral	5	0 MG	03NOV95	32	06NOV95	35	4
	00136	Oral	5	0 MG	07NOV95	36	13NOV95	42	7
	00136	Oral	5	0 MG	14NOV95	43	20NOV95	49	7
	00136	Oral	5	0 MG	21NOV95	50	27NOV95	56	7
	00136	Oral	4	0 MG	28NOV95	57	11DEC95	70	14
329.009.00169		Oral	1	0 MG	31OCT95	1	06NOV95	7	7
	00169	Oral	2	0 MG	07NOV95	8	13NOV95	14	7
	00169	Oral	3	0 MG	14NOV95	15	20NOV95	21	7
	00169	Oral	4	0 MG	21NOV95	22	27NOV95	28	7
	00169	Oral	4	0 MG	28NOV95	29	04DEC95	35	7
	00169	Oral	4	0 MG	05DEC95	36	11DEC95	42	7
	00169	Oral	4	0 MG	12DEC95	43	18DEC95	49	7
	00169	Oral	4	0 MG	19DEC95	50	27DEC95	58	9
	00098	Oral	4	0 MG	04JAN96	66	22JAN96	84	19
	00169	Oral	4	0 MG	23JAN96	85	23JAN96	85	1
	00169	Oral	3	0 MG	24JAN96	86	25JAN96	87	2
	00169	Oral	2	0 MG	26JAN96	88	28JAN96	90	3
	00169	Oral	1	0 MG	29JAN96	91	04FEB96	97	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

634

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00174		Oral	1	0 MG	21NOV95	1	27NOV95	7	7
	00174	Oral	2	0 MG	28NOV95	8	04DEC95	14	7
	00174	Oral	3	0 MG	05DEC95	15	11DEC95	21	7
	00174	Oral	4	0 MG	12DEC95	22	18DEC95	28	7
	00174	Oral	5	0 MG	19DEC95	29	26DEC95	36	8
	00174	Oral	5	0 MG	27DEC95	37	01JAN96	42	6
	00174	Oral	5	0 MG	02JAN96	43	08JAN96	49	7
	00174	Oral	5	0 MG	09JAN96	50	16JAN96	57	8
	00107	Oral	5	0 MG	17JAN96	58	30JAN96	71	14
	00174	Oral	4	0 MG	31JAN96	72	01FEB96	73	2
	00174	Oral	3	0 MG	02FEB96	74	03FEB96	75	2
	00174	Oral	2	0 MG	04FEB96	76	06FEB96	78	3
	00174	Oral	1	0 MG	07FEB96	79	13FEB96	85	7
329.009.00197		Oral	1	0 MG	29DEC95	1	01JAN96	4	4
	00197	Oral	2	0 MG	02JAN96	5	07JAN96	10	6
	00197	Oral	3	0 MG	08JAN96	11	15JAN96	18	8
	00197	Oral	4	0 MG	16JAN96	19	22JAN96	25	7
	00197	Oral	4	0 MG	23JAN96	26	29JAN96	32	7
	00197	Oral	4	0 MG	30JAN96	33	05FEB96	39	7
	00197	Oral	4	0 MG	06FEB96	40	12FEB96	46	7
	00197	Oral	4	0 MG	13FEB96	47	20FEB96	54	8
	00139	Oral	4	0 MG	21FEB96	55	18MAR96	81	27
	00139	Oral	4	0 MG	19MAR96	82	22APR96	116	35
	00139	Oral	4	0 MG	23APR96	117	20MAY96	144	28
	00139	Oral	4	0 MG	21MAY96	145	24JUN96	179	35
	00139	Oral	4	0 MG	25JUN96	180	15JUL96	200	21
	00139	Oral	4	0 MG	16JUL96	201	19AUG96	235	35
	00197	Oral	4	0 MG	20AUG96	236	20AUG96	236	1
	00197	Oral	3	0 MG	21AUG96	237	22AUG96	238	2
	00197	Oral	2	0 MG	23AUG96	239	25AUG96	241	3
	00197	Oral	1	0 MG	26AUG96	242	01SEP96	248	7
329.009.00198		Oral	1	0 MG	02JAN96	1	07JAN96	6	6
	00198	Oral	2	0 MG	08JAN96	7	15JAN96	14	8
	00198	Oral	3	0 MG	16JAN96	15	22JAN96	21	7
	00198	Oral	4	0 MG	23JAN96	22	29JAN96	28	7
	00198	Oral	4	0 MG	30JAN96	29	05FEB96	35	7
	00198	Oral	4	0 MG	06FEB96	36	12FEB96	42	7
	00198	Oral	4	0 MG	13FEB96	43	19FEB96	49	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

635

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00198	00198	Oral	4	0 MG	20FEB96	50	26FEB96	56	7
		Oral	3	0 MG	27FEB96	57	09MAR96	68	12
329.009.00200	00200	Oral	1	0 MG	23JAN96	1	01FEB96	10	10
		Oral	2	0 MG	02FEB96	11	05FEB96	14	4
		Oral	3	0 MG	06FEB96	15	12FEB96	21	7
		Oral	4	0 MG	13FEB96	22	19FEB96	28	7
		Oral	4	0 MG	20FEB96	29	27FEB96	36	8
		Oral	4	0 MG	28FEB96	37	07MAR96	45	9
		Oral	3	0 MG	08MAR96	46	19MAR96	57	12
329.009.00202	00202	Oral	1	0 MG	20FEB96	1	26FEB96	7	7
		Oral	2	0 MG	27FEB96	8	07MAR96	17	10
		Oral	3	0 MG	08MAR96	18	18MAR96	28	11
		Oral	4	0 MG	19MAR96	29	26MAR96	36	8
329.009.00237		Oral	1	0 MG	11NOV96	1	19NOV96	9	9
329.009.00238	00238	Oral	1	0 MG	12NOV96	1	18NOV96	7	7
		Oral	2	0 MG	19NOV96	8	25NOV96	14	7
		Oral	3	0 MG	26NOV96	15	02DEC96	21	7
		Oral	4	0 MG	03DEC96	22	09DEC96	28	7
		Oral	4	0 MG	10DEC96	29	16DEC96	35	7
		Oral	4	0 MG	17DEC96	36	22DEC96	41	6
		Oral	4	0 MG	23DEC96	42	30DEC96	49	8
		Oral	4	0 MG	31DEC96	50	06JAN97	56	7
		Oral	4	0 MG	07JAN97	57	19JAN97	69	13
329.009.00276	00276	Oral	1	0 MG	21JAN97	1	27JAN97	7	7
		Oral	2	0 MG	28JAN97	8	03FEB97	14	7
		Oral	3	0 MG	04FEB97	15	10FEB97	21	7
		Oral	4	0 MG	11FEB97	22	17FEB97	28	7
		Oral	5	0 MG	18FEB97	29	24FEB97	35	7
		Oral	5	0 MG	25FEB97	36	03MAR97	42	7
		Oral	6	0 MG	04MAR97	43	12MAR97	51	9
		Oral	6	0 MG	13MAR97	52	17MAR97	56	5
329.009.00302	00302	Oral	1	0 MG	27MAR96	1	02APR96	7	7
		Oral	2	0 MG	03APR96	8	10APR96	15	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

636

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data



Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.009.00306		Oral	1	0 MG	11JUN96	1	17JUN96	7	7
	00306	Oral	2	0 MG	18JUN96	8	24JUN96	14	7
	00306	Oral	3	0 MG	25JUN96	15	01JUL96	21	7
	00306	Oral	4	0 MG	02JUL96	22	08JUL96	28	7
	00306	Oral	4	0 MG	09JUL96	29	15JUL96	35	7
	00306	Oral	4	0 MG	16JUL96	36	22JUL96	42	7
	00306	Oral	4	0 MG	23JUL96	43	29JUL96	49	7
	00306	Oral	5	0 MG	30JUL96	50	05AUG96	56	7
		Oral	5	0 MG	06AUG96	57	19AUG96	70	14
329.009.00312		Oral	1	0 MG	04NOV96	1	14NOV96	11	11
	00312	Oral	2	0 MG	15NOV96	12	17NOV96	14	3
	00312	Oral	3	0 MG	18NOV96	15	01DEC96	28	14
	00312	Oral	4	0 MG	02DEC96	29	08DEC96	35	7
	00312	Oral	4	0 MG	09DEC96	36	15DEC96	42	7
	00312	Oral	4	0 MG	16DEC96	43	26DEC96	53	11
	00312	Oral	4	0 MG	27DEC96	54	29DEC96	56	3
	00312	Oral	5	0 MG	30DEC96	57	06JAN97	64	8
		Oral	5	0 MG	06JAN97	64	20JAN97	78	15
329.009.00327		Oral	1	0 MG	16SEP96	1	22SEP96	7	7
	00327	Oral	2	0 MG	23SEP96	8	29SEP96	14	7
	00327	Oral	3	0 MG	30SEP96	15	06OCT96	21	7
	00327	Oral	4	0 MG	07OCT96	22	13OCT96	28	7
	00327	Oral	5	0 MG	14OCT96	29	20OCT96	35	7
		Oral	5	0 MG	21OCT96	36	04NOV96	50	15
329.009.00330		Oral	1	0 MG	21OCT96	1	27OCT96	7	7
	00330	Oral	2	0 MG	28OCT96	8	04NOV96	15	8
329.010.00183		Oral	1	0 MG	03DEC95	1	11DEC95	9	9
	00183	Oral	2	0 MG	12DEC95	10	19DEC95	17	8
	00183	Oral	3	0 MG	20DEC95	18	.	.	.
329.010.00263		Oral	1	0 MG	09AUG96	1	13AUG96	5	5
	00263	Oral	2	0 MG	14AUG96	6	20AUG96	12	7
	00263	Oral	3	0 MG	21AUG96	13	27AUG96	19	7
	00263	Oral	4	0 MG	28AUG96	20	03SEP96	26	7
	00263	Oral	5	0 MG	04SEP96	27	10SEP96	33	7
	00263	Oral	6	0 MG	11SEP96	34	17SEP96	40	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

637

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.010.00263	00263	Oral	6	0 MG	18SEP96	41	24SEP96	47	7
	00263	Oral	6	0 MG	25SEP96	48	03OCT96	56	9
		Oral	5	0 MG	04OCT96	57	19OCT96	72	16
329.010.00277		Oral	1	0 MG	01MAR96	1	07MAR96	7	7
	00277	Oral	2	0 MG	08MAR96	8	14MAR96	14	7
	00277	Oral	3	0 MG	15MAR96	15	21MAR96	21	7
	00277	Oral	4	0 MG	22MAR96	22	28MAR96	28	7
	00277	Oral	5	0 MG	29MAR96	29	04APR96	35	7
	00277	Oral	5	0 MG	05APR96	36	14APR96	45	10
	00277	Oral	6	0 MG	15APR96	46	18APR96	49	4
	00277	Oral	6	0 MG	19APR96	50	25APR96	56	7
	00156	Oral	6	0 MG	26APR96	57	24MAY96	85	29
	00156	Oral	6	0 MG	25MAY96	86	21JUN96	113	28
329.010.00282		Oral	1	0 MG	26JUL96	1	01AUG96	7	7
	00282	Oral	2	0 MG	02AUG96	8	08AUG96	14	7
	00282	Oral	3	0 MG	09AUG96	15	15AUG96	21	7
	00282	Oral	4	0 MG	16AUG96	22	25AUG96	31	10
	00282	Oral	5	0 MG	26AUG96	32	02SEP96	39	8
	00282	Oral	6	0 MG	03SEP96	40	12SEP96	49	10
	00282	Oral	6	0 MG	13SEP96	50	18SEP96	55	6
	00282	Oral	6	0 MG	19SEP96	56	26SEP96	63	8
		Oral	5	0 MG	27SEP96	64	12OCT96	79	16
	329.011.00164		Oral	1	0 MG	22DEC95	1	28DEC95	7
00164		Oral	2	0 MG	29DEC95	8	04JAN96	14	7
00164		Oral	3	0 MG	05JAN96	15	11JAN96	21	7
00164		Oral	4	0 MG	12JAN96	22	18JAN96	28	7
00164		Oral	5	0 MG	19JAN96	29	25JAN96	35	7
00164		Oral	6	0 MG	26JAN96	36	.	.	.
329.011.00210		Oral	1	0 MG	28SEP96	1	03OCT96	6	6
	00210	Oral	2	0 MG	04OCT96	7	09OCT96	12	6
	00210	Oral	3	0 MG	10OCT96	13	17OCT96	20	8
	00210	Oral	4	0 MG	18OCT96	21	24OCT96	27	7
	00210	Oral	4	0 MG	25OCT96	28	03NOV96	37	10
	00210	Oral	5	0 MG	04NOV96	38	12NOV96	46	9
	00210	Oral	5	0 MG	13NOV96	47	22NOV96	56	10
	00210	Oral	5	0 MG	23NOV96	57	02DEC96	66	10

\* DAYS RELATIVE TO START OF STUDY MEDICATION

638

CONFIDENTIAL  
 BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.011.00210	00177	Oral	5	0 MG	03DEC96	67	.	.	.
329.011.00285		Oral	1	0 MG	18MAY96	1	27MAY96	10	10
	00285	Oral	2	0 MG	28MAY96	11	03JUN96	17	7
	00285	Oral	3	0 MG	04JUN96	18	10JUN96	24	7
	00285	Oral	4	0 MG	11JUN96	25	20JUN96	34	10
	00285	Oral	5	0 MG	21JUN96	35	28JUN96	42	8
	00285	Oral	6	0 MG	29JUN96	43	08JUL96	52	10
	00285	Oral	6	0 MG	09JUL96	53	18JUL96	62	10
	00285	Oral	6	0 MG	19JUL96	63	24JUL96	68	6
	00285	Oral	5	0 MG	25JUL96	69	31JUL96	75	7
329.011.00287		Oral	1	0 MG	03JUL96	1	09JUL96	7	7
	00287	Oral	2	0 MG	10JUL96	8	17JUL96	15	8
	00287	Oral	3	0 MG	18JUL96	16	23JUL96	21	6
	00287	Oral	4	0 MG	24JUL96	22	30JUL96	28	7
	00287	Oral	5	0 MG	31JUL96	29	06AUG96	35	7
	00287	Oral	6	0 MG	07AUG96	36	13AUG96	42	7
	00287	Oral	6	0 MG	14AUG96	43	20AUG96	49	7
	00287	Oral	6	0 MG	21AUG96	50	27AUG96	56	7
	00287	Oral	5	0 MG	28AUG96	57	10SEP96	70	14
329.012.00027		Oral	1	0 MG	06DEC95	1	11DEC95	6	6
	00027	Oral	2	0 MG	12DEC95	7	18DEC95	13	7
	00027	Oral	3	0 MG	19DEC95	14	26DEC95	21	8
	00027	Oral	4	0 MG	27DEC95	22	02JAN96	28	7
		Oral	3	0 MG	03JAN96	29	11JAN96	37	9
329.012.00217		Oral	1	0 MG	21MAY96	1	30MAY96	10	10
	00217	Oral	2	0 MG	31MAY96	11	06JUN96	17	7
	00217	Oral	3	0 MG	07JUN96	18	13JUN96	24	7
	00217	Oral	4	0 MG	14JUN96	25	14JUN96	25	1
329.012.00218		Oral	1	0 MG	16JUN96	1	20JUN96	5	5
	00218	Oral	2	0 MG	21JUN96	6	27JUN96	12	7
	00218	Oral	3	0 MG	28JUN96	13	04JUL96	19	7
	00218	Oral	4	0 MG	05JUL96	20	11JUL96	26	7
	00218	Oral	4	0 MG	12JUL96	27	18JUL96	33	7
	00218	Oral	4	0 MG	19JUL96	34	28JUL96	43	10
	00218	Oral	4	0 MG	29JUL96	44	05AUG96	51	8

\* DAYS RELATIVE TO START OF STUDY MEDICATION

639

CONFIDENTIAL

BRL-029060-329-  
 individual-data

Appendix B.16

Listing of Study Medication Data  
 Intent-to-Treat Population

TREATMENT GROUP: PLACEBO

PATIENT NUMBER	BOTLAB	ROUTE	DOSE LEVEL	DOSE	START DATE	RELATIVE* DAYS	STOP DATE	RELATIVE* DAYS	DUR DAYS
329.012.00218	00218	Oral	4	0 MG	06AUG96	52	12AUG96	58	7
	00117	Oral	4	0 MG	13AUG96	59	17SEP96	94	36
	00218	Oral	4	0 MG	18SEP96	95	19SEP96	96	2
	00218	Oral	3	0 MG	20SEP96	97	21SEP96	98	2
	00218	Oral	2	0 MG	22SEP96	99	24SEP96	101	3
	00218	Oral	1	0 MG	25SEP96	102	01OCT96	108	7
329.012.00224		Oral	1	0 MG	16SEP96	1	23SEP96	8	8
	00224	Oral	2	0 MG	24SEP96	9	02OCT96	17	9
	00224	Oral	3	0 MG	03OCT96	18	09OCT96	24	7
	00224	Oral	4	0 MG	10OCT96	25	16OCT96	31	7
	00224	Oral	4	0 MG	17OCT96	32	24OCT96	39	8
	00224	Oral	4	0 MG	25OCT96	40	03NOV96	49	10
	00224	Oral	4	0 MG	04NOV96	50	11NOV96	57	8
	00224	Oral	4	0 MG	12NOV96	58	20NOV96	66	9
	00126	Oral	4	0 MG	21NOV96	67	18DEC96	94	28
	00126	Oral	4	0 MG	19DEC96	95	19JAN97	126	32
	00126	Oral	4	0 MG	20JAN97	127	17FEB97	155	29
	00224	Oral	3	0 MG	18FEB97	156	19FEB97	157	2
	00224	Oral	2	0 MG	20FEB97	158	22FEB97	160	3
	00224	Oral	1	0 MG	23FEB97	161	01MAR97	167	7
329.012.00225		Oral	1	0 MG	26NOV96	1	02DEC96	7	7
	00225	Oral	2	0 MG	03DEC96	8	09DEC96	14	7
	00225	Oral	3	0 MG	10DEC96	15	19DEC96	24	10
	00225	Oral	4	0 MG	20DEC96	25	26DEC96	31	7
	00225	Oral	4	0 MG	27DEC96	32	05JAN97	41	10
	00225	Oral	4	0 MG	06JAN97	42	12JAN97	48	7
	00225	Oral	4	0 MG	13JAN97	49	20JAN97	56	8
	00225	Oral	4	0 MG	21JAN97	57	28JAN97	64	8
	00129	Oral	4	0 MG	29JAN97	65	23FEB97	90	26
	00129	Oral	4	0 MG	24FEB97	91	19MAR97	114	24
	00129	Oral	4	0 MG	20MAR97	115	20APR97	146	32
	00129	Oral	4	0 MG	21APR97	147	25MAY97	181	35
	00129	Oral	4	0 MG	26MAY97	182	29JUN97	216	35
	00129	Oral	4	0 MG	30JUN97	217	29JUL97	246	30
	00225	Oral	3	0 MG	30JUL97	247	31JUL97	248	2
	00225	Oral	2	0 MG	01AUG97	249	03AUG97	251	3
	00225	Oral	1	0 MG	04AUG97	252	10AUG97	258	7

\* DAYS RELATIVE TO START OF STUDY MEDICATION

640

CONFIDENTIAL

BRL-029060-329-  
 individual-data